



# सकलक

Status of National **AIDS** Response

FOURTH EDITION  
2022

© NACO, MoHFW, GoI, 2022

## **All rights reserved**

You may copy, redistribute, and adapt the publication for non-commercial purposes, provided the publication is appropriately cited. In any use of this publication, there should be no suggestion that NACO endorses any specific organization, products, or services. The use of the NACO logo is not permitted. If you adapt the publication, then you must license your work allowing copy, redistribute and adapt the work for non-commercial purposes. If you create a translation of this publication, you should add the following disclaimer: "This translation was not created by the NACO. NACO is not responsible for the content or accuracy of this translation. The original English edition shall be the binding and authentic edition"

## **General disclaimers**

NACO has made every effort to ensure the accuracy of data and verify the information contained in this publication. However, errors and omissions excepted. The publication is being distributed without warranty of any kind, either expressed or implied. Maps (if any), used in this publication, are only to provide visual impressions on the given indicator. These are not for scale and must not be construed or used as a "Legal Description" of any State/UT/district.

## **Suggested citation**

National AIDS Control Organisation (2022). Sankalak: Status of National AIDS Response (Fourth edition, 2022). New Delhi: NACO, Ministry of Health and Family Welfare, Government of India.

## **For additional information about Sankalak: Status of National AIDS Response (Fourth edition, 2022), please contact**

Monitoring & Evaluation - Strategic Information Division  
National AIDS Control Organisation (NACO)  
Ministry of Health and Family Welfare, Government of India  
6<sup>th</sup> and 9<sup>th</sup> Floor  
Chanderlok Building, 36 Janpath, New Delhi, 110001



# संकलक

## Status of National **AIDS** Response

**FOURTH EDITION 2022**







वी. हेकाली झिमोमी, भा.प्र.से.  
अपर सचिव एवं महानिदेशक  
V. Hekali Zhimomi, IAS  
Additional Secretary & Director General

राष्ट्रीय एड्स नियंत्रण संगठन  
स्वास्थ्य और परिवार कल्याण मंत्रालय  
भारत सरकार  
National AIDS Control Organisation  
Ministry of Health & Family Welfare  
Government of India



### FOREWORD

Since the launch of the first phase of NACP Phase-I in 1992, the national AIDS response in the country has come a long way. As a result of strong political leadership, concerted policies and strategic interventions; new infections and AIDS-related mortality have declined significantly in India. Yet, we are still far from ending AIDS as a public health threat and hence, there can be no room for complacency. The vertical transmission rate for HIV is at 24% which is too high given the programme's commitment to achieving zero paediatric new infections.

The use of data has been the hallmark of a very successful national AIDS response in India since its inception. Today, as the country enters the last mile for ending AIDS as a public health threat, the role of Strategic Information (SI) becomes much more relevant than ever for location and population-specific programme designing and implementation particularly for improving the magnitude and direction of the outcomes.

'Sankalak-Status of the national AIDS response is a flagship publication under NACP, reporting not only the progress being made but also the shortfalls indicating areas that need to be prioritised and focussed upon to improve programme directions. The current edition, the fourth in the series, takes the tradition forward and presents the latest evidence on epidemic status and programmatic reach across prevention, testing, treatment, and retention continuum nationally and by State/UT.

The relevance of the fourth edition is further emphasised, as it reports the progress being made in the first year (i.e., 2021-22) of the NACP Phase-V. Much of the progress reported here can become the baseline for setting out evidence-led priority actions by State/UT in their annual action plans. Ending AIDS as a public health threat by 2030 would require data-driven policies and interventions responding to the identified priorities. I am confident that all programme managers and implementers would use the fourth edition of 'Sankalak' to improve the programmes. Especially, I urge State AIDS Control Societies to refer to it extensively while working out priority areas and setting targets for the Annual Action Plan 2023-24.

  
(V. Hekali Zhimomi)

6th Floor, Chandralok Building, 36 Janpath, New Delhi-110001 Tel.: 011-23325331 Fax : 011-23351700  
E-mail : dgoffice@naco.gov.in

**अपनी एचआईवी अवस्था जानें, निकटतम सरकारी अस्पताल में मुफ्त सलाह व जाँच पाएँ**  
**Know your HIV status, go to the nearest Government Hospital for free Voluntary Counselling and Testing**







सत्यमेव जयते

निधि केसरवानी, भा.प्र.से.

निदेशक

**Nidhi Kesarwani, I.A.S.**

Director



राष्ट्रीय एड्स नियंत्रण संगठन  
स्वास्थ्य और परिवार कल्याण मंत्रालय  
भारत सरकार

**National AIDS Control Organisation**  
**Ministry of Health & Family Welfare**  
**Government of India**



### PREFACE

'Sankalak-Status of the National AIDS response' is the flagship publication under the National AIDS and STD Control Programme (NACP) of the Government of India. First published in 2017, this publication details the progress of the national AIDS and STI response towards the attainment of 2025 and 2030 goals by location and population as envisioned under NACP. The current edition, the fourth in the series, analyses and report the robust epidemiological and programmatic data generated/published under NACP during the financial year 2021-22 (i.e., April 2021 to March 2022).

'Sankalak', like its previous edition, has broadly two sections. The narrative section, presented in 12 chapters, first provides an update on the status of the HIV/AIDS epidemic and then follows it with chapters detailing the progress on the prevention of new infections, AIDS-related deaths, elimination of vertical transmission of HIV and AIDS, STI/RTI service uptake and elimination of HIV/AIDS-related stigma and discrimination. In general, the data reflected in the chapter refers to the financial year. The second section, the factsheets, provides data for the reporting year across the programme domains for India and each of the State/Union territories through a standardised template. HIV-TB co-infections management has a dedicated section while the scorecard is a new edition in the current edition factsheet.

One of the guiding principles of NACP Phase-V calls for a gender-sensitive response with a specific focus on gender-disaggregated analysis across the cascade of prevention, testing, treatment, and care. In line with the guidance provided in the NACP Phase-V, the fourth edition of the 'Sankalak' provides data by gender for as many indicators as possible.

We present the fourth edition of the 'Sankalak' showcasing the wealth of actionable evidence informing the priority areas for NACP Phase-V with great pride. We urge the programme managers to carefully peruse the actionable evidence presented here and use them suitably to improve and fast-track the directions of the programme augmenting the country's progress on the 2030 endgame.

(Nidhi Kesarwani)

9th Floor, Chandralok Building, 36 Janpath, New Delhi-110001 Tel. : 011-23325343 Fax : 011-23325335  
E-mail : [dir@naco.gov.in](mailto:dir@naco.gov.in)

**अपनी एचआईवी अवस्था जाने, निकटतम सरकारी अस्पताल में मुफ्त सलाह व जाँच पाएँ**  
**Know your HIV status, go to the nearest Government Hospital for free Voluntary Counselling and Testing**





**Dr. CHINMOYEE DAS**

**Public Health Specialist, Grade-1**

Tel. : +91-11-23736851

Fax : +91-11-23731746

E-mail : c.das@gov.in

drchinmoyee.naco@gmail.com



सत्यमेव जयते



भारत सरकार  
स्वास्थ्य एवं परिवार कल्याण मंत्रालय  
राष्ट्रीय एड्स नियंत्रण विभाग  
6वां तल, चन्द्रलोक बिल्डिंग,  
36, जनपथ, नई दिल्ली-110001

Government of India  
Ministry of Health & Family Welfare  
National AIDS Control Organisation  
6th Floor, Chandralok Building,  
36, Janpath, New Delhi-110001

### ACKNOWLEDGEMENT

'Sankalak: Status of the National AIDS Response' is the in-house publication of the National AIDS Control Organization (NACO). All divisions of NACO collaborate to bring out this flagship publication. We gratefully acknowledge the contributions of NACO's leadership, officers of all divisions of NACO and experts for timely publication of the fourth edition of 'Sankalak'.

Strategic guidance and support for the publication of the document was provided by Ms. V.Hekali Zhimomi (Addl. Secretary & DG, NACO). Day to day progress monitoring and provision of necessary support was anchored by Ms. Nidhi Kesarwani (Director, NACO). We sincerely thank NACO's leadership for the vision, insights and guidance towards strengthening evidence dissemination for effective response to HIV epidemic.

Heads of Divisions at NACO, Dr Anoop Kumar Puri (Care, Support and Treatment and Information, Education and Communication), Dr Uday Bhanu Das (Laboratory Services and Programme Management and Review) and Dr Shobini Rajan (Targeted Interventions and Basic Services Division) provided technical review and inputs on contents. We thank all HoDs for the technical leadership provided for the publication.

Dr Pradeep Kumar (National Consultant, Strategic Information, NACO) and Dr Raveena (Associate Consultant, Strategic Information, NACO) conceptualized and coordinated the development of the fourth edition along with Ms. Nidhi Rawat (National Consultant, Information, Education and Communication, NACO) and Dr Mahesh Mhetre (Technical Expert). The team did in-depth review of the data and chapters, redrafting of chapter wherever required, and coordination with NACO programme divisions & designer. We duly acknowledge the role of the core team.

Deputy Directors along with the officers and Technical Experts from concerned division contributed to development of Chapters and Factsheets. We acknowledge their contribution in drafting the chapters and sharing the data for the factsheets.

**Introduction:** Dr Pradeep Kumar, Dr Raveena from NACO

**Status of the epidemic:** Dr Pradeep Kumar from NACO; Dr Subrata Biswas from ICMR-NICED, Kolkata; Dr Varsha Ranjan from ICMR-NIMS, New Delhi

**Progress on 95-95-95:** Dr Pradeep Kumar from NACO

**Information, Education & Communication, Youth and Mainstreaming:** Dr Bhawna Rao, Ms Nidhi Rawat, Mr Utpal Das, Mr Benjamin Franklin, Ms Parul from NACO

**Prevention among HRG and bridge population:** Dr Bhawani Singh Kushwaha, Dr Shantanu Kumar Purohit, Ms. Suman Sehrawat, Mr Arvind Kumar from NACO; Mr Dew Stanley, Mr Prashant Patra, Ms Jyotsana Pal, Mr Akhilesh Srivastava, Ms Gunjan Pandey as Technical Experts

**Management of Sexually Transmitted Infections/Reproductive Tract Infections:** Dr Srinivas Murthy, Mr Rajiv Sindhu, Mr Shailendra Bhardwaj from NACO; Dr Abhishek Royal, Technical Expert

**Early detection of HIV-infected people:** Dr Bhawani Singh Kushwaha, Dr Vibhavari Deshmukh, Dr P. Sujith, Mr M.Thirunavukkarasu from NACO

**Initiation and retention on ART:** Dr Sai Prasad Bhavsar, Dr Arvind Kumar, Dr Purnima Parmar, Dr Jaswinder Singh from NACO, Dr Mahesh Mhetre, Technical Expert

**HIV-TB Co-infection Management:** Dr Bhawani Singh Kushwaha, Dr Sai Prasad Bhavsar, Dr. Vibhavari Deshmukh, Dr Arvind Kumar, Dr Purnima Parmar, Dr Jaswinder Singh, Dr P. Sujith, Mr M.Thirunavukkarasu from NACO ; Dr Lalit Mehandru & Dr Mahesh Mhetre Technical Experts

**Laboratory Services:** Dr Bhawna Rao, Dr Shivali Kamal, Ms. Smita Mishra, Dr. Kamini Singh from NACO

**Elimination of vertical transmission of HIV and Syphilis:** Dr Pradeep Kumar, Dr. Vibhavari Deshmukh, Dr P. Sujith, Mr M.Thirunavukkarasu from NACO; Dr Abhishek Royal ,Technical Expert

**Scorecard:** Ms Vinita Verma & Mr Sonoo Jha from NACO

External technical experts supported specific aspects during the development of the fourth edition 'Sankalak'. Mr Haresh Patel (PATH India) supported in the development of automated factsheets. Dr Sarvanamurthy (PATH India) reviewed the IEC, Youth and Mainstreaming chapter. Ms Nalini Chandra (UNAIDS India) reviewed the Laboratory Services chapter. Dr Melissa Nyendak and Dr Upma Sharma (CDC India) facilitated the support of technical experts from the implementation partners. We gratefully acknowledge the support.

We specially acknowledge and gratefully thank the Project Directors and Strategic Information team of State AIDS Control Societies, peer educators, outreach workers, counsellors, nurses, laboratory technicians and medical officers at NACP's facilities who have contributed immensely to generating rich volume of evidence under NACP.

This fourth edition of 'Sankalak: Status of National AIDS Response' provides crucial programmatic data by State/UT for the year 2021-2022. We expect that all stakeholders will use it to further strengthen the National AIDS response. We also welcome suggestions from stakeholders for further improvements of this document & the future editions.

  
(Dr Chinmoyee Das)





# Content

Abbreviations	14
Executive Summary	18
1. Introduction	26
1.1 Background	27
1.2 Development of the 4th Edition	27
1.3 Report outline	28
2. Status of the epidemic	30
2.1 Background	31
2.2 Overview	32
2.3 Decline in HIV incidence and AIDS-related mortality	34
2.4 Incidence: prevalence ratio and incidence: mortality ratio	35
2.5 HIV prevalence by risk-groups	41
2.6 Syphilis seropositivity	42
3. Progress on 95-95-95	46
3.1 Background	47
3.2 Method	47
3.3 National Progress	48
3.4 State/UT-wise progress	49
4. Information, Education & Communication, Youth and Mainstreaming	52
4.1 Background	53
4.2 Social Media	54
4.3 National Toll-Free AIDS Helpline 1097	55
4.4 Youth Interventions	56
4.5 Mainstreaming	58
4.6 Strengthening India's response to the elimination of HIV-related stigma and discrimination	59

5.	Prevention among HRG and bridge population	60
5.1	Background	61
5.2	Coverage of key population under TI: An overview	63
5.3	FSW coverage by TI	64
5.4	MSM coverage by TI	66
5.5	H/TG people coverage by TI	68
5.6	IDU coverage by TI	70
5.7	Migrants coverage by TI	72
5.8	Truckers coverage by TI	74
5.9	Opioid Substitution Therapy	76
5.10	Prison Interventions	77
5.11	Link Workers Scheme	78
6.	Management of Sexually Transmitted Infections/Reproductive Tract Infections	80
6.1	Background	81
6.2	Service delivery model	82
6.3	STI/RTI cases managed	82
7.	HIV counseling and testing services	90
7.1	Background	91
7.2	HCT Facilities	92
7.3	HCT services uptake among 'at-risk' population	93
7.4	Spouse/partner testing	96
7.5	Late diagnosis	97
8.	Initiation and retention on ART	98
8.1	Background	99
8.2	Facilities	100
8.3	PLHIV on ART	101
8.4	ART initiation and retention	102
8.5	Differentiated care model	104
9.	HIV-TB Co-infection Management	106
9.1	Background	107
9.2	Intensified TB Case Finding	107
9.3	HIV-TB Co-infection management	108



10.	Laboratory Services	110
10.1	Background	111
10.2	Laboratories under NACP	111
10.3	Quality assurance for HIV testing	112
10.4	Early Infant diagnosis (EID): HIV-1 PCR laboratories tests for children under 18 Months	113
10.5	CD4 testing	114
10.6	National Quality Assurance (NEQA)	115
10.7	HIV-1 Viral Load (VL) testing	115
10.8	Viral Load EQA	118
10.9	Accreditation	118
10.10	Certificate of Excellence to ICTC	119
11.	Elimination of vertical transmission of HIV and Syphilis	120
11.1	Background	121
11.2	Progress at a glance	122
11.4	Pregnancies among known HIV positive women	128
11.5	Early Infant Diagnosis	129
12.	Scorecard	132
12.1	Background	133
12.2	Methodology	133
12.3	Performance of State/UT in Programme Implementation	137
13.	Factsheets	140-349
14.	Indicator Glossary	350-359
15.	References	360-363

# Abbreviations

<b>AAP</b>	Annual Action Plan	<b>DTG</b>	Dolutegravir
<b>ADM</b>	Advance disease management	<b>ELM</b>	Employer-led Model
<b>AEP</b>	Adolescence Education Programme	<b>EQA</b>	External Quality Assurance
<b>AIDS</b>	Acquired Immune Deficiency Syndrome	<b>EVTHS</b>	Elimination of the vertical transmission of HIV and Syphilis
<b>AIIMS</b>	All India Institute Of Medical Science	<b>FI-ICTC</b>	Facility-Integrated-ICTC
<b>AIOCD</b>	Association of Indian Origin Chemist and Distributors	<b>FSW</b>	Female Sex Worker
<b>AIR</b>	All India Radio	<b>GUD</b>	Genital Ulcer Disease
<b>ANI</b>	Annual New HIV Infections	<b>GW</b>	Genital Wart
<b>ARD</b>	Anorectal Discharge	<b>H/TG</b>	Hijra/ Transgender people
<b>ART</b>	Anti-Retroviral Treatment / Anti-Retroviral Therapy	<b>HBV</b>	Hepatitis B Virus
<b>ARV</b>	Anti-Retroviral	<b>HCTS</b>	HIV Counselling and Testing Services
<b>ASHA</b>	Accredited Social Health Activist	<b>HCV</b>	Hepatitis C Virus
<b>ATT</b>	Anti-Tuberculosis treatment	<b>HIV</b>	Human Immunodeficiency Virus
<b>BP</b>	Bridge Population	<b>HRG</b>	High-Risk Group
<b>CARG</b>	Community ART Refill groups	<b>HSS</b>	HIV sentinel surveillance
<b>CBO</b>	Community Based Organisations	<b>HWC</b>	Health & Wellness Centres
<b>CBS</b>	Community-based Screening	<b>IB</b>	Inguinal Bubo
<b>CD4</b>	Clusters of differentiation 4	<b>ICTC</b>	Integrated Counseling and Testing Centers
<b>CDC</b>	Centres for Disease Control	<b>IDU</b>	Injecting Drug User
<b>CHC</b>	Community Health Centres	<b>IEC</b>	Information, Education & Communication
<b>CI</b>	Confidence Interval	<b>IMR</b>	Incidence: mortality ratio
<b>CLHIV</b>	Children Living with HIV	<b>IPR</b>	Incidence: prevalence ratio
<b>CLSI</b>	Clinical & Laboratory Standards Institute	<b>JWG</b>	Joint Working Groups
<b>CMAI</b>	Christian Medical Association of India	<b>LAC</b>	Link ART Centre
<b>COE</b>	Centres of Excellence	<b>LAP</b>	Lower Abdominal Pain
<b>CPT</b>	Co-trimoxazole preventive therapy	<b>LDT</b>	Long-Distance Trucker
<b>CSC</b>	Care & Support Centres	<b>LFU</b>	Loss to Follow-Up
<b>DNA</b>	Deoxyribonucleic Acid	<b>LWS</b>	Link Workers Scheme
<b>DSRC</b>	Designated STI/RTI Clinic		

<b>M(EL)T</b>	Medical Laboratories (Entry Level) training	<b>POC</b>	Point of Care
<b>MCI</b>	Medical Council of India	<b>POCS</b>	Prison and other closed setting intervention
<b>MMD</b>	Multi-month dispensation	<b>PPP</b>	Public-Private Partnership
<b>MOU</b>	Memorandum of Understanding	<b>PPTCT</b>	Prevention of Parent to Child Transmission
<b>MPR</b>	Monthly Progress Report	<b>PPW</b>	Positive Pregnant Women
<b>MSM</b>	Men who have Sex with Men	<b>PT</b>	Presumptive Treatment
<b>MTCT</b>	Mother to Child Transmission	<b>QAS-BC</b>	Quality Assurance Scheme for Basic Composite
<b>NABL</b>	National Accreditation Board for Testing and Calibration Laboratories	<b>RMC</b>	Regular Medical Check-up
<b>NACO</b>	National AIDS Control Organisation	<b>ROT</b>	Route of Transmission
<b>NACP</b>	National AIDS and STD Control Programme	<b>RPR</b>	Rapid Plasma Reagent
<b>NARI</b>	National AIDS Research Institute	<b>RRC</b>	Red Ribbon Club
<b>NBTC</b>	National Blood Transfusion Council	<b>RSTRRL</b>	Regional STI Training, Research and Reference Laboratory
<b>NCERT</b>	National Council of Educational Research and Training	<b>RTI</b>	Reproductive Tract Infection
<b>NGO</b>	Non-Governmental Organizations	<b>SACS</b>	State AIDS Control Society
<b>NHM</b>	National Health Mission	<b>SA-ICTC</b>	Stand-Alone ICTC
<b>NIB</b>	National Institute of Biologicals	<b>SCM</b>	Supply Chain Management.
<b>NICED</b>	National Institute of Cholera and Enteric Diseases	<b>SDG</b>	Sustainable Development Goal
<b>NIMHANS</b>	National Institute of Mental Health and Neuro-Sciences	<b>SI-M&amp;E</b>	Strategic Information : Monitoring & Evaluation
<b>NIRT</b>	National Institute for Research in Tuberculosis	<b>SMM</b>	Single male migrants
<b>NTEP</b>	National Tuberculosis Elimination Programme	<b>SOCH</b>	Strengthening Overall Care for HIV
<b>OI</b>	Opportunistic Infection	<b>SPD</b>	State Prisons Departments
<b>OM</b>	Office Memorandum	<b>SRC</b>	State Reference Centres
<b>ORW</b>	Outreach Workers	<b>SRL</b>	State Reference Laboratory
<b>OST</b>	Opioid Substitution Therapy	<b>SS</b>	Scrotal Swelling
<b>PCR</b>	Polymerase Chain Reaction	<b>SSS</b>	Sampoorna Suraksha Strategy
<b>PEP</b>	Post-exposure prophylaxis	<b>STI</b>	Sexually Transmitted Infection
<b>PHC</b>	Primary Health Centres	<b>TAT</b>	Turn-Around-Time
<b>PLHIV</b>	People Living with HIV	<b>TB</b>	Tuberculosis
<b>PM&amp;SE</b>	Population Mapping & Size Estimates	<b>TI</b>	Targeted Intervention
		<b>TLD</b>	Tenofovir + Lamivudine + Dolutegravir
		<b>TNA-PCR</b>	Total nucleic acid-polymerase chain reaction

TPT	TB preventive treatment
TRG	Technical Resource Group
TSU	Technical Support Unit
UD	Urethral Discharge
UN	United Nations
UNAIDS	The Joint United Nations Programme on HIV/AIDS
UT	Union Territory
VCD	Vaginal/Cervical Discharge
VCTC	Voluntary Counselling Testing Centres
VDRL	Venereal Disease Research Lab
WBFPT	Whole Blood Finger Prick Tests
WCD	Women and Child Development
WLHIV	Women Living with HIV



A thick red ribbon is tied into a loop on the right side of the page, with the tail extending downwards and then curving back towards the bottom right.

# **EXECUTIVE SUMMARY**

# Executive Summary

1. The Government of India is currently implementing Phase-V of the National AIDS and STD Control Programme (NACP) as a fully funded Central Sector Scheme for the period of 1st April 2021 to 31st March 2026 with an outlay of Rs 15471.94 crore. Full attainment of goals envisaged under NACP Phase-V will mean a decline in new HIV infections and AIDS-related mortality by 80%, attainment of universal access to quality STI/RTI services and zero incidences of vertical transmission of HIV and Syphilis and HIV/AIDS-related stigma/discrimination. 'Sankalak', the flagship publication of the National AIDS Control Organization (NACO), presents the progress made in the first year of the NACP Phase-V.
2. Annual new HIV infections and AIDS-related deaths continue to decline nationally. Between 2010 and 2021, new infections declined by 46% and while AIDS-related mortality declined by 76%. Globally, new infections have declined by 32% and AIDS-related mortality by 52% in the same reference period. While the progress in the prevention of new infections is much higher than the global averages, yet national AIDS response is far from the envisioned target of 80% reductions by 2025.
3. While the overall adult prevalence remains low (0.21% in 2021), HIV prevalence among high-risk groups and the bridge population remains very high. HIV prevalence among migrants is 4 times, among truckers is 5 times, among inmates in central jails and female sex workers (FSW) is 9 times, among men who have sex with men (MSM) is 16 times, among hijra/transgender (H/TG) people is 18 times and among injecting drug users (IDU) is 43 times of the overall adult HIV prevalence. HIV prevalence continues to be disproportionately high in the north-eastern region of India with three, Mizoram, Nagaland, and Manipur, continuously having adult HIV prevalence of more than 1%.
4. NACP Phase-V aims to attain 95-95-95 by 2025. In its first year of implementation in 2021-22, the target was to attain 79-84-84 i.e., 79% of people living with HIV (PLHIV) know their status, 84% of PLHIV who know their HIV status are on-ART and 84% of the on-ART PLHIV has viral suppression. As on March 2022, country progress was 77-84-85 i.e., 77% of PLHIV knew their status, 84% of PLHIV who knew their HIV status are on-ART and 85% of the on-ART PLHIV had viral suppression. This translates into 55% of total PLHIV in the country being virally suppressed in 2021-22 against the target of getting 86% of them virally suppressed by 2025-26. The progress among women living with HIV was slightly higher than among men living with HIV.
5. Overall, there were 11 States/UT where at least 80% of PLHIV were aware of their HIV status in March 2022. These included Andhra Pradesh, Chandigarh, Delhi, Goa, Gujarat, Maharashtra, Punjab, Rajasthan, Tamil Nadu, Tripura, and West Bengal. Among all these States/UT PLHIV who knew their status and were on-ART was more than 80% except for Andhra Pradesh and Delhi. Progress of less than 80% on the second 95 is indicative of a significant lost-to-follow-up (LFU) issue and requires urgent attention. Among PLHIV who were on ART, overall, 9 States (Arunachal Pradesh, Chhattisgarh, Haryana, Himachal Pradesh, Jharkhand, Madhya Pradesh, Punjab, Telangana, and Tripura) had viral suppression of less than 80%.

6. NACP Phase-V expanded its reach among the general population for HIV prevention under the New India@75- Azadi ka Amrit Mahotsav campaign. The number of districts covered under the campaign increased from 247 in Phase I to 324 in Phase III reaching out to almost 3 lakh youths during the campaign.
7. Persons across the country continued to use National Toll-Free AIDS Helpline – 1097 for seeking information on HIV/AIDS concerning prevention, testing, treatment, associated stigma & discrimination and mental health issues. Youth (age group 15-24yrs) continued to be benefitted from the helpline with 20% of the calls estimated to be made by them. Overall, 4.88 lakh calls were made to the helpline against the stated target of 5.50 lakh calls in the first year of NACP Phase-V.
8. The HIV and AIDS (Prevention & Control) Act, 2017 provides the overarching framework for the implementation of NACP. In 2021-22, the country made further progress on the implementation of the Act with 15 States already notifying the Act with the Ombudsman in place.
9. The COVID-19 pandemic in 2020-21 halted and reversed the progress being made under NACP. The country regained momentum back in 2021-22 across the spectrum of the prevention-testing-treatment continuum.
10. Around 90.50 lakh FSW, MSM, IDU, H/TG people, migrants and truckers were covered through the 1512 targeted interventions programme. This is almost 40% higher coverage than the persons covered in 2020-21. Not only more persons were covered, but also, per persons covered, more visits to the clinics were made and more HIV tests were done in 2021-22 vis-à-vis previous years indicating improvement in the programme intensity. The number of prisons implementing HIV interventions increased from 1059 in 2020-21 to 1150 in 2021-22. Around 29% of the total inmates were covered in 2021-22 identifying around 2900 positives with 82% linked to ART centres for treatment.
11. Link worker scheme (LWS), to cover the high-risk and vulnerable population in rural areas, increased from 138 in 2020-21 to 146 in 2021-22. The population covered under LWS increased from 16.9 lakh to 19.3 lakh, identifying around 2400 new PLHIV and linking 95% of them to ART centres.
12. Overall, around 1.10 crore HRG, bridge and vulnerable populations were covered through TI/LWS in 2021-22 which is 7% more than the stated coverage target of 1.02 crore in the first year of NACP Phase-V.
13. Management of STI/Reproductive Tract Infections (RTI) is a focus under NACP since its first phase. NACP Phase-V reinforces the focus on STI management by including it as one of the five high-level goals. Goal 4 calls for the promotion of universal access to quality STI/RTI services to at-risk and vulnerable populations through a ten-prong strategy.



14. STI/ RTI services under NACP in the country following a syndromic management approach are delivered through a network of Designated STI/RTI Clinics (DSRC, branded as Suraksha Clinics). NACP Phase-V calls for augmenting the role of DSRC to anchor newer initiatives like the Sampoorna Suraksha Strategy and integrated service delivery tailored to the local contexts. As a cross-cutting facility, the DSRC, in its Sampoorna Suraksha avatar, will evolve into an integrated facility anchoring the country's progress on the prevention of new infections, reduction of AIDS-related mortality, elimination of vertical transmission and promotion of access to STI/RTI services. In the first year of implementation, NACP Phase-V aimed to manage 100.16 lakh patients for STI/RTI and establish 25 Sampoorna Suraksha Centres contacting 22 thousand 'at-risk' population. Overall, 68.50 lakh visits for the management of STI/RTI episodes were made at 1,184 DSRC and 1,512 TI under NACP in 2021-22.
15. The full realization of the ambitious target of 95-95-95 by 2025-26 will require having around 23 lakh PLHIV with known HIV status, around 21.75 lakh PLHIV on anti-retroviral treatment and around 20.50 lakh PLHIV with suppressed viral load. Early detection of infected people through quality HIV counselling and testing (HCT) services becomes the cornerstone for the attainment of envisioned agendas.
16. 'Break the silos, build synergies' is a key guiding principle of the NACP Phase-V. This asks for coordinated actions, through single window delivery systems along with functional and measurable referrals and linkages, within NACP and across national health programmes and related sectors, for efficient service delivery. Stand-alone integrated counselling and testing centres (SA-ICTC) will be central to 'Break the silos, build synergies', offering not only the HCT services but playing a larger role across prevention-testing-treatment care continuum under newer initiatives like Sampoorna Suraksha Strategy (SSS), One Stop Centres etc.
17. NACP Phase-V in 2021-22 aimed to test 2.52 lakh 'at-risk' population (excluding pregnant women) for HIV to boost the country's progress on the first 95. Around 2.35 crore HIV test (93% of the target) was done in the group in 2021-22 with seropositivity of 0.52% (0.59% among male, 0.42% among female and 1.1% among H/TG people).
18. Nationally, there were 17 tests per 1000 population in 2021-22 ranging between 5 to 62 across States/UT. In the high prevalence States of Mizoram and Nagaland, there were more than 40 tests per 1000 population. Manipur, another State with an adult HIV prevalence of more than 1%, had 26 tests for every 1000 population. The lowest number of HIV tests per 1000 population is noted in Bihar and Uttar Pradesh. Uttar Pradesh has the fourth largest size of PLHIV in the country while Bihar has the seventh.
19. Seven States (including four from the northeast India) recorded seropositivity of 1% or more in 2021-22. Mizoram is the only State with HIV seropositivity of more than 2%. Other States with seropositivity of more than 1% included Telangana (1.64%), Meghalaya (1.49%), Nagaland (1.38%), Tripura (1.05%), Punjab (1.05%) and Andhra Pradesh (1.01%).

20. NACP Phase-V calls for augmenting the existing HCT models with efficient approaches for active case findings. Index testing and repeat screening/testing among discordant couples promoting early detection of undiagnosed infections is integral to this strategy. Nationally, spouse/partner testing among HIV-positive cases was reported at around 46% in 2020-21. HIV seropositivity among tested spouses/partners was around 52%, by and large, the same as that noted in the last five years.
21. HCT services aim to diagnose HIV cases as early as possible. Late diagnosis is detrimental to the attainment of NACP Phase-V objectives as people with low CD4 counts are more likely to transmit the virus, thus facilitating new infections. Also, a late diagnosis will result in PLHIV coming into the treatment programme with advanced AIDS-related illness and thus causing a potential scenario of AIDS-related mortality. Overall, in general, around 61% to 65% of PLHIV had a CD4 count of 350 cells per mm<sup>3</sup> or lower in baseline CD4 count at the time of registration at ART centres. In 2021, around 61% of total PLHIV had a CD4 cell count of below 350 cells per mm<sup>3</sup>, with 35% below 200 cells per mm<sup>3</sup>. In general, the late diagnosis was more among males than among females.
22. The 'end of AIDS epidemic as a public health threat' asks for the attainment of viral suppression among 86% of PLHIV. NACP Phase-V aims to attain the same by building upon the gamechanger initiatives of adoption of test and treat, introduction of viral load (VL) testing for monitoring of PLHIV on antiretroviral-treatment (ART), dolutegravir-based regimens for treatment optimization, advance disease management (ADM), implementation of patient-centric differentiated care models including multi-month dispensation (MMD), expansion of Link ART centre (LAC) and Community ART Refill groups (CARG). The aim is to ensure there is universal access to life-saving ART for all PLHIV, along with lifelong retention and sustained viral load suppression.
23. In its first year of implementation, NACP Phase-V aimed to have around 15.30 lakh PLHIV on-ART (including those in the private sector) with 597 ART centres, 1294 Link ART Centres (LAC) and 100 Care Support Centres (CSC). As on March 2022, there were around 15.56 lakh PLHIV on ART with around 14.50 lakh taking lifelong free ART medicines from 664 ART centres supported by NACO. At NACO-supported centres, around 7.36 lakh (51%) of 'Alive and on-ART' PLHIV were males, 7.08 lakh (49%) were females while few (0.05 lakh) were H/TG people.
24. On average, there were 2,184 'Alive and on-ART' PLHIV per ART centre under NACP as on March 2022. Telangana had 3,792 'Alive and on-ART' PLHIV per ART centre, the highest in the country, followed by Andhra Pradesh (3,749). Delhi, Maharashtra, Chandigarh, Punjab, Karnataka, Bihar, West Bengal, and Tamil Nadu were other States with 'Alive and on-ART' PLHIV per ART centre higher than the national average. The average load was less than 1,000 'Alive and on-ART' PLHIV per ART centre in 10 States/UT including that of Tripura, Meghalaya, Mizoram, Nagaland, Himachal Pradesh, Uttarakhand, Sikkim, Dadra and Nagar Haveli and Daman and Diu, Arunachal Pradesh, and Andaman and Nicobar Islands. The average ranged between 143 to 933 in these States.
25. The progress on ART initiation and retention is reflected in initiation on ART per 100 detections in ICTC centres, 12 months retention among PLHIV, and lost-to-follow-up (LFU) per 100 PLHIV 'Alive and on-ART'. As evident, the initiation on ART for every 100 detections in ICTCs under the programme has improved significantly. In 2017-18, the first year of the launch of 'Test and Treat', 78 PLHIV were initiated on ART for every 100 detections made. In comparison, 94 PLHIV were initiated on ART for every 100 detections made in 2021-22. Similarly, 12 months of retention on-ART increased to 80% in comparison to 72% in 2017-18. For every 100 on-ART PLHIV, 25 were LFU in 2017-18 and 2018-19. After assigning definitive outcomes to LFU under 'Mission Sampark' of the government of India, the number of LFU per 100 on-ART PLHIV decreased to 13 in 2019-20. The same level was noted in 2021-22.

26. An integrated package of services keeping beneficiaries and communities in the centre is the first guiding principle of NACP Phase-V. This is being done through institutionalized convergence with the existing schemes of the Central Government including synergy with other National health programmes.
27. Tuberculosis (TB), the commonest opportunistic infection (OI), is the leading cause of hospitalization and death among PLHIV. Given the context, HIV-TB cross-referral is focussed under NACP since 2001. NACP Phase-V aims to maintain and augment programme collaboration with National Tuberculosis Elimination Programme (NTEP) for HIV-TB cross-referrals and single-window delivery at all ART centres.
28. At the ART centres, PLHIV who are attending ARTC is screened for TB on 4S every month. The percentage of PLHIV screened for TB has increased from 94.7% in 2020-21 to 96.5% in 2021-22. In 2021-22, 4S screening of less than 95% was observed in eight States/UT including Nagaland (93.7%), Meghalaya (93.3%), Odisha (92.4%), Bihar (91.9%), Telangana (90.5%), Uttarakhand (90.1%), Goa (89.6%) and Puducherry (87.1%).
29. Elimination of vertical transmission of HIV and Syphilis (EVTHS) is directly related to the attainment of SDG 3.3 of ending of HIV/AIDS epidemic as a public health threat by 2030. Recognising the importance of the EVTHS in context of the SDG 3.3 and the country's progress on EVTHS, NACP Phase-V has included the attainment of the elimination of vertical transmission of HIV and Syphilis as one of the five high-level goals to be attained by 2025. This goal builds upon the significant progress made under the prevention of parent-to-child transmission of HIV, launched as early as in 2002 under the NACP Phase-II, for providing HIV testing to every pregnant woman (universal coverage).
30. National AIDS response has made significant progress on EVTHS but still, a lot needs to be done. While registration of pregnant women for ante-natal care (ANC) services was around 95% in 2021-22, the progress on HIV testing, nationally, was 84% with Syphilis testing coverage among pregnant women being reported much lower. As the new HIV infections declined significantly, the paediatric case rate declined below the target level of <50 per 100,000 live births, but the mother-to-child transmission (MTCT) rate continued to be high (24%) given the progress on testing and treatment coverage.
31. State/UT-wise, in Goa, there were 155 HIV tests among pregnant women (PW) for every 100 pregnant women estimated. This indicates repeat testing. Similarly, Mizoram had 134, Gujarat 123, Puducherry 117, Telangana 116, Chandigarh 114, and Maharashtra 112 tests for every 100 estimated pregnant women. In Uttar Pradesh, there were 81 tests while Bihar had 61 tests for every 100 estimated pregnant women in 2021-22. Overall, there were 14 States/UT with less than 80 tests per 100 estimated pregnant women in 2021-22. These included Chhattisgarh, Nagaland, Jharkhand, Delhi, Madhya Pradesh, Sikkim, Lakshadweep, Bihar, Manipur, Assam, Rajasthan, Arunachal Pradesh and Ladakh.
32. As care, support, and treatment for PLHIV improves, more women with known HIV-positive status choose pregnancy. In 2017-18, only one-third of total HIV-positive pregnant women (PPW) were among known HIV-positive vis-à-vis 51% reported in 2021-22. In States/UT like Puducherry, Kerala, Arunachal Pradesh, Tamil Nadu, Tripura, Sikkim, Manipur, Goa, and DNH&DD; more than 60% of total PPW under the programme were from known positive women.

33. Quality laboratory services have been a critical enabler to the national AIDS and STI-response with a central role across the prevention-detection-treatment cascade. The role of quality laboratory services starts right from diagnosing infection, then informing the decision for determining eligibility for ART and/or prophylaxis and finally continues into lifelong periodic services to monitor the impact of treatment. As NACP Phase-V aims to undertake at least 28 crore tests for HIV, 10 crore tests for Syphilis and 80 lakh tests for viral load in its five-year duration towards the attainment of 80% reductions in new infections and AIDS-related mortality as well as the elimination of vertical transmission of HIV and Syphilis; quality laboratory services continue to be at the forefront of the national AIDS response.
34. NACP Phase-V continues to have a three-tiered external quality assessment system for HIV and Syphilis testing. For HIV serology, there are 13 National Reference Laboratory (NRL), 117 State Reference Laboratory (SRL) & 5000+ Stand-alone Integrated Counselling and Testing Centres (SA-ICTC). For STI, the laboratory network consists of State Reference Centres (SRC), Regional STI Training, Research and Reference Laboratories (RSTRRL) and Apex reference Laboratory. There are 45 SRC and 10 RSTRRL for the STI component of NACP.
35. Among the SRL participating in panel testing for HIV, no discordancy was reported. Discordance was consistently at 0.1% in the reporting years of 2018-19 to 2021-22 among the ICTC participating in panel testing. For ICTC, discordance ranged between 0.03% and 0.10% in re-testing. All six laboratories for early infant diagnosis (EID) participated in the panel testing programme with a score of 100%. Around three-fourth of CD4 laboratories participated in national quality assurance with around 75% having satisfactory results.
36. Having 86% of the total PLHIV virally suppressed is imperative to ending of AIDS epidemic as a public health threat. To ensure that the viral load status of all on-ART PLHIV under the programme is being monitored, routine viral load testing was introduced for PLHIV in NACP in 2018 and then scaled-up in a systematic manner. In addition, given NACP Phase-V endeavours to monitor the progress on the elimination of vertical transmission in terms of viral load suppression, routine viral load testing has been also recommended for all HIV-positive pregnant women during 32 to 36 weeks of pregnancy (regardless of the duration of ART) to inform the suitable prophylaxis administration to eliminate the risk of HIV transmission to the baby. In the first year of NACP Phase-V implementation, the programme aimed to undertake around 11.00 lakh tests among PLHIV on ART.
37. The number of viral load tests under NACP is continuously increasing. In 2018-19, around 2.50 lakh viral load tests were done. In 2021-22, around 10.32 lakh viral load tests were done which is more than 4 times of the tests done in 2018-19. As the utilization of public sector laboratories for viral load tests improved, the number of viral load tests in public sector laboratories increased from 21 thousand in 2017-18 to more than 4 lakh in 2021-22. Overall, around 40% of the total viral load tests in 2021-22 were done in public sector laboratories.
38. In 2021-22, two rounds of proficiency testing (PT) were done among public sector viral load (VL) laboratories as a part of an external quality assurance system. In round 1, 63 VL labs participated of which 59 VL labs scored acceptable results. In round 2, all 64 VL labs participated of which 62 labs scored results within the acceptable range.



39. NACO has developed a Scorecard system for State AIDS Control Societies (SACS) which monitors State/UT-wise performance on 30 indicators. Being implemented as a biannual activity, the Scorecard covers the domains of Information Education & Communication and Mainstreaming, Targeted Intervention, Basic Services, Care Support and Treatment, Laboratory Services, Strategic Information, Finance and Supply Chain Management. Performance on individual indicators is done in 4 categories [Good (Green, 3 Marks), Average (Yellow, 2 Marks), Poor (Red, 1 Mark), Not Applicable (No colour-No score added in denominator)].
40. 'Sankalak-Status of the national AIDS response' is the flagship report under the NACP of the Government of India. Anchored by the Strategic Information-Monitoring and Evaluation (SI-M&E) division of NACO, the report was first published in 2017. The report details the progress of the national AIDS response towards the attainment of 2025 and 2030 goals by location and population as envisioned under NACP. The current edition, the fourth in the series, reports the progress being made in the first year of the NACP Phase-V.

### Progress on output/outcome indicators under NACP Phase-V, 2021-22

S No	Indicator	Target (2021-22)	Achievement (2021-22)
<b>Physical and output targets</b>			
1	No. of calls received at AIDS Helpline (1097) (In lakh)	5.3	4.88
2	No. of Targeted Interventions (TI)	1663	1512
3	No. of districts with the Link Worker Scheme (LWS)	165	146
4	No. of HRG, bridge and the vulnerable population covered through TI/LWS (In lakh)	102.4	112.44
5	No. of OST Centres	400	364
6	No. of IDU on OST (In lakh)	0.38	0.42
7	No. of 'Sampoorna Suraksha' Centres	25	0
8	No. of contacts with 'at-risk' population through 'Sampoorna Suraksha' Centres (In lakh)	0.22	-
9	No. of STI/RTI patients managed (In lakh)	100.16	50
10	No. of 'at-risk' population (excluding pregnant women) tested for HIV (In lakh)	252	235
11	No. of pregnant women tested for HIV (In lakh)	252	248
12	No. of pregnant women tested for Syphilis (In lakh)	176.4	169.4
13	No. of ART Centres	597	664
14	No. of Link ART Centres	1294	1261
15	No. of Care Support Centres	100	319
16	No. of PLHIV on ART (Cumulative)* (in lakh)	15.30	15.56
17	No. of viral load tests conducted among PLHIV on ART (in lakh)	11.0	10.32
<b>Outcome targets</b>			
1	Estimated PLHIV who know their HIV status (%)	79	77
2	PLHIV who know their HIV status and are on ART (%)	84	84
3	PLHIV who are on ART and are virally suppressed (%)	84	85
4	Estimated pregnant women tested for HIV (%)	84	84

\* Including PLHIV on ART in the private sector



# 1. INTRODUCTION

# Introduction

## 1.1 Background

Robust strategic information (SI), through complementary systems of programme monitoring, surveillance & epidemiology, and research & evaluation is the hallmark of extremely successful AIDS response in India since its inception. This system not only provides information on the level, trend, and determinants of HIV, STI and related co-infections among various population at most granular level, but also generate evidence for the programme to take necessary actions improving coverage, quality, and efficiencies, thus facilitating maximal return on investments made. The system also tracks the progress in terms of inputs, outputs, outcomes, and impact suggesting mid-course corrections. This is achieved through in-built mechanisms of data protection-sharing-quality assurance-analysis-interpretation-dissemination

,reporting not only the progresses but also bottlenecks and opportunities for evidence-based decision making.

‘Sankalak-Status of the national AIDS response’ is a flagship SI report under the National AIDS and STD Control Programme (NACP) of the Government of India. Anchored by the SI-Monitoring and Evaluation (SI-M&E) division of National AIDS Control Organisation (NACO), the report was first published in 2017. This flagship report details the progress of national AIDS response towards attainment of 2025 and 2030 goals by location and population as envisioned under NACP. The current edition, fourth in the series, analyses and reports the robust data generated/published under NACP during 2021-22.

## 1.2 Development of the 4<sup>th</sup> Edition

The development of the 4th edition of ‘Sankalak’, like the previous editions, was anchored by SI-M&E with all programme divisions contributing significantly. The process for the development of fourth edition was initiated vide NACO’s office order Z-19014/4/2020-NACO (M&E) dated 24.08.2022. The order identified the author and peer-reviewer for each chapter with specific timelines (Table 1). The

draft of data and chapters shared by programme divisions were reviewed by SI-M&E and inputs were provided to the division. The progress was directly reviewed by the Director (NACO). The agreed draft was finally processed for approval. Same was granted by competent authority on (16 November, 2022).

Table 1. Action plan for 4th edition of 'Sankalak'

S No	Activity	Timeline
1	OM with Activity-timelines responsibility matrix (to be shared with division)	By 24 <sup>th</sup> August 2022
2	<ul style="list-style-type: none"> <li>Meeting with divisions to finalise chapters and factsheet</li> <li>Firming up the technical, info-graphic and language edit support with PATH India</li> </ul>	By 26 <sup>th</sup> August 2022
3	Sharing of the final data for FY 2021-22 y programme divisions for factsheets with SI-M&E	By 2 <sup>nd</sup> September, 2022
4	Sharing of the draft chapters by programme divisions after review	By 15 <sup>th</sup> September, 2022
5	Progress update to Director (NK) during Monthly SI-M&E Review meeting	By 20 <sup>th</sup> September, 2022
6	Review and feedback by SI-M&E to programme divisions concerned	By 30 <sup>th</sup> September, 2022
7	Sharing of the revised draft by programme division	By 10 <sup>th</sup> October, 2022
8	<ul style="list-style-type: none"> <li>Review &amp; finalization by SI-M&amp;E</li> <li>Presentation to the competent authority</li> <li>Approval on e-file</li> <li>Sharing with IEC Division for printing</li> </ul>	By 30 <sup>th</sup> October, 2022
9	Release for the fourth Edition of Sankalak	By 1 <sup>st</sup> December 2022

## 1.3 Report outline

'Sankalak' has broadly two sections. The first section, presented in 12 chapters provides data-driven narratives (Figure 1). The second section is that of factsheet which provides data for the reporting year across the programme domains. There is one factsheet for each of the State/Union Territory (UT) except for UT of Lakshadweep.


Chapter 2 under the narrative section of the report updates the magnitude and directions of the HIV and STI epidemics using recent evidence. Chapter 3 reports the country progress on testing and treatment of 95-95-95 for four years since 2018-19. Chapter 4 details the data from the information, education and communication (IEC) components of NACP including those for national helpline and the progress on the HIV and AIDS (Prevention and Control) Act, 2017. Chapter 5 elaborates the progress made for the high-risk groups, bridge and 'at-risk' population through the strategies of targeted interventions (TI), link worker scheme (LWS), employer-led model (ELM) and prison interventions. Chapter 6 describes the progress made under the

management of sexually transmitted infections (STI) while chapter 7 details the HIV counselling and testing services. Chapter 8 covers the care, support, and treatment services, chapter 9 summarises the progress under HIV-TB co-morbidities management while chapter 10 covers the laboratory services including that on the viral load testing and external quality assurance services. Chapter 11 details the progress made under the elimination of vertical transmission. Chapter 12, a new edition in the 4th edition, provides an overall picture of State/UT-wise performance on NACP implementation across all components.

The domains in factsheet broadly mirror the chapters in narrative section. The factsheet in 2021-22 round of 'Sankalak' evolves from previous rounds by providing data by gender for as many indicators as possible. This is in line of guiding principle number 7 of NACP Phase-V which calls to integrate gender-sensitive response with specific focus on gender-disaggregated analysis across the cascade of prevention, testing, treatment, and care.



Figure 1. Chapters under the 4th edition of 'Sankalak-Status of the national AIDS response'



## 2. STATUS OF THE EPIDEMIC



# Status of the Epidemic

## 2.1 Background

The Government of India is currently implementing NACP Phase-V as a fully funded Central Sector Scheme for the period of 1st April 2021 to 31st March 2026 with an outlay of Rs 15471.94 crore. The NACP Phase-V will anchor the national AIDS and STD response till 2025-26 towards the attainment of the United Nations' Sustainable Development Goals 3.3 of ending the HIV/AIDS epidemic as a public health threat through a comprehensive package of prevention, detection, and treatment services.

The NACP Phase-V aims to reduce annual new HIV infections and AIDS-related mortalities by 80% by 2025-26 from the baseline value of 2010. The NACP Phase-V also aims to attain dual elimination of vertical transmission, elimination of HIV/AIDS related stigma while promoting universal access to quality STI/RTI services to at-risk and vulnerable populations (Figure 2).

Figure 2. Key targets under NACP Phase-V

### HIV/AIDS prevention and control

- ▶ 95% of people who are most at risk of acquiring HIV infection use comprehensive prevention
- ▶ 95% of HIV positive know their status, 95% of those who know their status are on treatment and 95% of those who are on treatment have suppressed viral load
- ▶ 95% of pregnant and breastfeeding women living with HIV have suppressed viral load towards attainment of elimination of vertical transmission of HIV
- ▶ Less than 10% of people living with HIV and key populations experience stigma and discrimination

### STI/RTI prevention and control

- ▶ Universal access to quality STI/RTI services to at-risk and vulnerable populations
- ▶ Attainment of elimination of vertical transmission of syphilis

Robust strategic information, through complementary system of programme monitoring, surveillance & epidemiology and research & evaluation is fundamental to the national AIDS response. The system not only inform the programme on the magnitude and directions of the

epidemic by locations and populations, but also track the progress of national AIDS response on key goals. The section below provides the update on the latest status of the epidemic and progress on response using data from this comprehensive system.


## 2.2 Overview

As per the latest epidemiological data, India is estimated to have around 24.01 lakh (19.92-29.07 lakh) people living with HIV/AIDS (PLHIV) with overall adult prevalence of 0.21% (0.17-0.25%) in 2021<sup>3</sup>. HIV prevalence among males was at 0.22% (0.18-0.28%) while among females was at 0.19% (0.15-0.23).

Around 63 thousand (36.72-104.06 thousand) new

HIV infections were estimated in 2021. Almost ninety-two percent of total new infections were reported to be among population aged 15 years or older, including around 24.55 thousand (14.27-40.69 thousand) among women. Around 42 thousand PLHIV died of AIDS-related mortality in the same reference period (Figure 3).


Figure 3. Overview of HIV/AIDS epidemic in India, 2021 (all figure in lakh)



Overall, around 3% of total PLHIV were estimated to be in the age group of 0-14 years, 7% in the age group of 15-24 years while one third were 50 years or older. In terms of new infections, 8% were in the age

group of 0-14 years, 24% were 15-24 years old while 18% among 50+ years. Almost half of the total new infections were among people in the age group of 25-49 years (Figure 4).


Figure 4. Age and sex-wise proportional distribution (in %) of total PLHIV and new HIV infections, 2021



HIV prevalence continues to be disproportionately high in the north-eastern region with three States,

Mizoram, Nagaland, and Manipur, having an adult prevalence of more than 1% (Figure 5).


Figure 5. Adult HIV prevalence (in %) in India by State, 2021



However, low-to-moderate HIV prevalence but highly populous States in the southern, western, central, and eastern regions of the country are most heavily affected. Eight States from these regions, Maharashtra (3.94 lakh), Andhra Pradesh (3.21 lakh), Karnataka (2.76 lakh), Uttar Pradesh (1.78 lakh), Tamil

Nadu (1.63 lakh), Telangana (1.56 lakh), Bihar (1.43 lakh), and Gujarat (1.14 lakh), account for 72% of the total PLHIV size in the country. The adult prevalence in these eight States ranges from 0.10% in Uttar Pradesh to 0.67% in Andhra Pradesh (Figure 5).

Figure 6. Proportional distribution (in %) of PLHIV in India by State, 2021



## 2.3 Decline in HIV incidence and AIDS-related mortality

'Ending the AIDS epidemic' has not been defined in scientific terms but is being targeted in terms of achieving reduction in incidence and mortality. Based on the modelling results, the 2016 UN high-level meeting adopted a target of 90% reductions in number of new infections and AIDS-related deaths by 2030, against the baseline value of 2010, to track the progress of impact of various components of AIDS response towards attainment of an aspirational goal.


The interim target for the same was set as 75% reductions by 2020 and 80% by 2025. India, being a

signatory to the UNs' resolution, has adopted the same goal under the national AIDS response since 2017.

Between 2010 and 2021, new infections declined by 46% and while AIDS-related mortality declined by 76% (Figure 7). Globally, new infections have declined by 32% and AIDS-related mortality by 52% in the same reference period. While the progress on prevention of new infections is much higher than the global averages, yet national AIDS response is far from envisioned target of 80% reductions by 2025.

<sup>a</sup>ANI refers to Andaman & Nicobar Islands; DNH&DD refers to Dadra and Nagar Haveli and Daman and Diu; J&K refers to Jammu and Kashmir

Figure 7. Decline in new infections and AIDS-related mortality between 2010 and 2021



While annual new HIV infections are declining overall, higher new infection in 2021 vis-à-vis 2010 is noted in Tripura, Meghalaya, Arunachal Pradesh, Assam, Sikkim, Dadra and Nagar Haveli and Daman and Diu (DNH&DD), and Mizoram. The highest decline is noted in Himachal Pradesh (73%), followed by Tamil Nadu (72%), Telangana (71%) and Punjab (70%). Other States/UT where annual new HIV infections have declined from between 50% and 70% are Andhra Pradesh (68%), Kerala (67%), Andaman & Nicobar Islands (67%), Karnataka (63%), Gujarat

(60%), Madhya Pradesh (59%), West Bengal (57%), Maharashtra (56%), and Puducherry (54%) (Table 3).

AIDS-related mortality has declined everywhere except for Arunachal Pradesh, Meghalaya, and Puducherry (Table 3). A decline of more than 80% between 2010 and 2021 was noted in 10 States/UTs including Chandigarh, Telangana, West Bengal, Goa, Punjab, Maharashtra, Kerala, Tamil Nadu, Rajasthan, and Himachal Pradesh.

## 2.4 Incidence: prevalence ratio and incidence: mortality ratio

While decline in new HIV infections and AIDS-related mortality measures the impact of the programme initiatives and their coverage, they do not provide the complete epidemiological context. A country with 90% reduction in incidence/mortality by 2030 may still have higher level of incidence/mortality than noted in 2010 in another country. Recognising the limitations, UNAIDS Science Panel in 2017 recommended to track the epidemic progress through additional indicators namely incidence: prevalence ratio (IPR) and incidence: mortality ratio (IMR). The IPR is the ratio of number of new HIV infections occurring per year in a population to the number of persons living

with HIV in that same population while the IMR is the ratio of the number of people who become HIV infected in a year to the number of PLHIV who die in the same year. As a rule of thumb, if the IPR of 3 is attained, it indicates fewer than one new infection per PLHIV on average in the lifetime. Maintaining the IPR below the threshold for long period will indicate towards attainment of epidemic control. Similarly, attainment of IMR of less than one, will lead to shrinking size of epidemic. Used together, the IPR and IMR, provides a more comprehensive information on directions of the epidemic.



Table 3. State/UT-wise HIV prevalence, incidence, and AIDS-related mortality, 2021

State/UT	Adult HIV Prevalence (%)	PLHIV (In Thousand)	Incidence (per 1000 uninfected population)	New HIV Infections (In Thousand)	Change in New Infections between 2010 and 2021 (%)	AIDS-related deaths (In Thousand)	Change in AIDS-related deaths between 2010 and 2021 (%)
ANI	0.14 (0.06-0.38)	0.43 (0.2-1.15)	0.04 (0.01-0.31)	0.02 (0.01-0.12)	-66.67	0.02 (0-0.06)	-13.04
Andhra Pradesh	0.67 (0.56-0.79)	321.03 (277.88-371.72)	0.08 (0.06-0.12)	4.39 (2.9-6.41)	-68.19	9.19 (6.24-13.46)	-73.75
Arunachal Pradesh	0.07 (0.04-0.1)	0.69 (0.45-1)	0.05 (0.02-0.09)	0.07 (0.03-0.13)	54.55	0.01 (0.01-0.02)	44.44
Assam	0.09 (0.08-0.11)	25.07 (22.14-28.77)	0.06 (0.05-0.08)	2.08 (1.56-2.81)	26.23	0.68 (0.51-0.89)	-7.77
Bihar	0.16 (0.11-0.22)	142.79 (95.81-197.04)	0.07 (0.03-0.13)	8.83 (3.95-15.7)	-7.21	2.47 (1.06-4.93)	-41.25
Chandigarh	0.19 (0.13-0.26)	1.92 (1.42-2.6)	0.06 (0.02-0.11)	0.07 (0.02-0.13)	-42.74	0.01 (0.01-0.01)	-95.83
Chhattisgarh	0.17 (0.14-0.22)	39.63 (33.11-49.18)	0.06 (0.04-0.1)	1.79 (1.15-2.79)	-36.3	1.28 (0.8-1.85)	-65.1
DNH&DD	0.19 (0.13-0.25)	1.54 (1.08-2.09)	0.08 (0.05-0.12)	0.08 (0.05-0.12)	6.76	0.01 (0.01-0.02)	-69.7
Delhi	0.31 (0.25-0.39)	55.8 (45.53-68.59)	0.14 (0.08-0.22)	2.74 (1.68-4.4)	-14.12	0.95 (0.49-1.76)	-25.94
Goa	0.31 (0.24-0.41)	4.6 (3.84-5.66)	0.07 (0.03-0.12)	0.11 (0.05-0.19)	-14.39	0.07 (0.05-0.12)	-86.41
Gujarat	0.19 (0.16-0.23)	113.53 (93.72-138.48)	0.04 (0.02-0.07)	2.51 (1.49-4.87)	-59.68	0.81 (0.5-1.35)	-69.49
Haryana	0.22 (0.18-0.26)	49.98 (42.03-60.67)	0.07 (0.04-0.12)	2.04 (1.23-3.4)	-41.82	0.6 (0.41-0.89)	-76.32
Himachal Pradesh	0.11 (0.08-0.13)	7.14 (5.58-8.65)	0.02 (0.01-0.02)	0.11 (0.08-0.17)	-73.33	0.07 (0.03-0.14)	-80.05
Jammu & Kashmir	0.06 (0.03-0.1)	6.53 (3.8-10.21)	0.02 (0.01-0.06)	0.28 (0.09-0.81)	-35.75	0.14 (0.04-0.32)	-10.13
Ladakh							
Jharkhand	0.08 (0.06-0.11)	24.67 (17.44-33)	0.04 (0.02-0.06)	1.37 (0.75-2.34)	-15.03	0.39 (0.17-0.79)	-51.98
Karnataka	0.46 (0.40-0.56)	275.88 (239.57-323.25)	0.06 (0.04-0.09)	3.79 (2.43-5.84)	-62.87	6.74 (4.2-10.55)	-78.17
Kerala	0.06 (0.04-0.09)	21.21 (15.36-28.03)	0.01 (0.01-0.02)	0.4 (0.25-0.59)	-66.8	0.12 (0.07-0.24)	-81.69
Madhya Pradesh	0.08 (0.07-0.1)	54.77 (47.8-65.55)	0.02 (0.01-0.03)	1.54 (1.1-2.55)	-59.52	1 (0.68-1.53)	-77.83
Maharashtra	0.33 (0.28-0.39)	394.08 (340.74-456.57)	0.04 (0.03-0.07)	5.41 (3.42-8.06)	-55.81	5.83 (3.99-9.31)	-84.83
Manipur	1.05 (0.92-1.22)	27.99 (24.47-31.77)	0.32 (0.2-0.44)	0.98 (0.63-1.36)	-34.89	0.84 (0.63-1.13)	-64.14
Meghalaya	0.42 (0.25-0.69)	8.69 (5.18-14.34)	0.37 (0.15-0.76)	1.19 (0.49-2.46)	221.02	0.07 (0.03-0.27)	30.36
Mizoram	2.7 (2.24-3.25)	23.8 (19.78-28.48)	1.31 (0.87-1.91)	1.55 (1.03-2.24)	3.48	0.19 (0.14-0.55)	-69.52
Nagaland	1.36 (1.08-1.85)	21.73 (17.4-29.07)	0.51 (0.3-0.88)	1.1 (0.65-1.88)	-32.68	0.31 (0.19-2.72)	-65.07
Odisha	0.14 (0.1-0.19)	52.11 (38.71-68.54)	0.05 (0.02-0.08)	2.18 (1.02-3.77)	-45.57	1.63 (0.79-2.72)	-45.51
Puducherry	0.31 (0.18-0.46)	3.96 (2.46-5.76)	0.12 (0.06-0.21)	0.18 (0.09-0.32)	-54.29	0.16 (0.05-0.31)	123.29
Punjab	0.28 (0.23-0.35)	72.95 (60.27-88.68)	0.05 (0.03-0.08)	1.38 (0.99-2.25)	-70.52	0.58 (0.39-0.92)	-85.6
Rajasthan	0.1 (0.09-0.12)	67.19 (56.18-79.84)	0.03 (0.02-0.05)	2.28 (1.27-3.68)	-40.43	0.42 (0.29-0.63)	-80.29
Sikkim	0.09 (0.05-0.14)	0.47 (0.27-0.77)	0.05 (0.01-0.13)	0.03 (0.01-0.09)	13.33	0 (0-0.01)	-40
Tamil Nadu	0.22 (0.18-0.24)	162.86 (137.58-180.87)	0.02 (0.01-0.03)	1.5 (1-2.07)	-72.53	2.08 (1.4-2.92)	-81.11
Telangana	0.47 (0.37-0.6)	155.99 (129.32-194.13)	0.05 (0.03-0.11)	2.01 (0.99-4.03)	-70.95	1.75 (1.12-3.18)	-87.76
Tripura	0.12 (0.08-0.16)	3.61 (2.36-4.73)	0.13 (0.07-0.18)	0.52 (0.27-0.74)	330.58	0.01 (1 (0.01-0.01)	0
Uttar Pradesh	0.1 (0.08-0.14)	178.13 (138.52-235.66)	0.04 (0.02-0.07)	8.45 (4.46-15.15)	-25.51	2.43 (1.35-4.53)	-66.98
Uttarakhand	0.12 (0.1-0.15)	11.33 (9.41-14.06)	0.04 (0.02-0.07)	0.49 (0.28-0.83)	-37.45	0.39 (0.27-0.57)	-45.37
West Bengal	0.08 (0.07-0.09)	69.2 (62.52-77.64)	0.02 (0.01-0.02)	1.53 (1.06-2.27)	-57.47	0.72 (0.54-1)	-87.49
<b>India</b>	<b>0.21 (0.17-0.25)</b>	<b>2401.28 (1992.06-2906.77)</b>	<b>0.05 (0.03-0.08)</b>	<b>62.97 (36.72-104.06)</b>	<b>-46.25</b>	<b>41.97 (26.5-67.45)</b>	<b>-76.54</b>




Application of these two indicators reflect diversity in epidemic transition in India. As revealed by India HIV Estimates 2021, overall new infections peaked around 1995-1997 and then started to decline (Figure 8). The overall PLHIV size peaked almost 5 years later while deaths among PLHIV peaked around 2005. As there were more deaths than new infections from around 2002 onwards, the epidemic started to shrink. However, as treatment coverage improved with almost 65% of total PLHIV on ART by 2020, directions of PLHIV size changed upwardly despite low infections and low mortality. This epidemic transition is fully reflected in IPR and IMR.

The national IPR ratio has been steadily declining. It was at 9.23 (5.38-15.25) in 2000 and reached to 2.62 (1.53-4.33) in 2021 indicating epidemic response is on right track. IMR was less than 1 for most of the years between 2002 and 2019 and in-fact was as low as around 0.50 during 2005-2020. However, this was attained because of high mortality among PLHIV as treatment services under NACP were launched only in 2004.

IMR of less than 1 because of high mortality among PLHIV is neither desirable nor targeted under programme. As treatment services witnessed rapid scaled-up, IMR moved northward towards 1 as mortality started to decline and in-fact reached to 1 or more around 2020. However, with attainment of treatment coverage of around 65% 2020 and continued progress on prevention efforts, is expected to have a downward trend in IMR and expected to attain the IMR of less than one in near future with high treatment coverage.


Figure 9 depicts current level of IPR and IMR for all States/UTs. The data indicates of much lower value of IPR and IMR than the target threshold in erstwhile high prevalence of Tamil Nadu, Telangana, Andhra Pradesh, Maharashtra, and Karnataka. In all these States, at-least two thirds of PLHIV are on treatment. IPR was more than 3 in 22 States in 2021. This included nine States in north-eastern and eastern India with IPR of 5 or more. IMR of 1 or more was noted in 26 States/UTs. IMR value of less than 1 in State/UTs of Manipur, Andaman and Nicobar Islands, and Puducherry needs to be interpreted with caution.

Figure 8. HIV epidemic transition in India



<sup>a</sup>The threshold value of ratio reflected as multiplier of 100

B. Incidence: prevalence ratio



C. Incidence: mortality ratio




Figure 10 depicts trend in IPR and IMR for India and 11 States with adult HIV prevalence of more than 1% or PLHIV size of more than 100,000 in 2021. These includes Andhra Pradesh, Bihar, Gujarat, Karnataka, Maharashtra, Manipur, Mizoram, Nagaland, Tamil Nadu, Telangana and Uttar Pradesh. IPR has a

declining trend in all these States, though with variation in magnitude. Trend in IMR is similar to that of national trend in most of these States having a rising trend first for most of the years and then showing a declining trend in recent past.

Figure 9. State/UT-wise IPR and IMR, 2021






Figure 10. IPR and IMR, India and Select States



Note: IPR (in blue) is represented on the primary 'Y' axis. IMR (in orange) is represented on the secondary 'Y' axis




## 2.5 HIV prevalence by risk-groups

Biennial HIV sentinel surveillance (HSS) is fundamental to track the magnitude and directions of the HIV/AIDS epidemic among various population group across country. In 2021, the 17th round of HSS was implemented across eight population groups comprising pregnant women, single male migrants (SMM), long distance truckers (LDT), prisoners, female sex workers (FSW), men who have sex with men (MSM), hijra/transgender (H/TG) people and injecting drug users (IDU) collecting almost five lakh bio-behavioural samples. Pregnant women are considered as a proxy for general population while SMM and LDT are proxy for bridge population. FSW, inmates, MSM, H/TG people and IDU represents high-risk groups in the disease transmission dynamics in India. For the first time, in the 17th round, biomarkers for Hepatitis B Virus (HBV) and Hepatitis C Virus (HCV) were integrated in HSS. While serum bio-specimen for pregnant women and inmates were subjected to all four biomarkers, the dried blood specimen collected from SMM, LDT, FSW, MSM, IDU and H/TG people were tested for all but Syphilis.

As per the preliminary analysis of data from HSS 2021, HIV prevalence was at 0.22% (95% Confidence Interval (CI): 0.21-0.24) among pregnant women, 0.89% (95% CI: 0.69-1.10) among SMM, 1.00% (95% CI: 0.78-1.21) among LDT, 1.85% (95% CI: 1.75-1.96) among FSW, 1.93% (95% CI: 1.75-2.12) among inmates in central jails, 3.26% (95% CI: 3.03-3.48) among MSM, 3.78% (95% CI: 3.24-4.33) among H/TG people and 9.03% (95% CI: 8.69-9.37) among IDUs (Figure 11). In comparison, observed HIV prevalence among ANC and inmates in 2019 was 0.24% (95% CI: 0.22%-0.26%) and 2.05% (95% CI: 1.9%-2.3%) respectively. The observed HIV prevalence was 0.51% (95%CI: 0.34-0.68) among SMM, 0.86% (95% CI: 0.64-1.07) among LDT, 1.56% (95% CI: 1.46-1.66) among FSW, 2.69% (95% CI: 2.47-2.91) among MSM, 3.14% (95% CI: 2.61-3.66) among H/TG and 6.26% (95% CI: 5.92-6.59) among IDUs in last (2017) round of HSS among group.

Figure 11. HIV Prevalence (in %) by population group, 2017, 2019 and 2021



Note: IPR (in blue) is represented on primary 'Y' axis. IMR (in red) is represented on secondary 'Y' axis

State/UT-wise, highest HIV prevalence among pregnant women was noted in Nagaland (1.61%) followed by that in Mizoram (1.13%), Meghalaya (0.58%), Delhi (0.41%), Chandigarh (0.38%), Tripura (0.38%), Andhra Pradesh (0.37%) and Manipur (0.33%) (Table 4).

Twenty States had HSS sites for SMM while 19 had those for LDT in 2021 round. Among SMM, highest HIV prevalence was noted in Mizoram (4.80%) followed by that in Assam (3.21%), West Bengal (3.20%), Punjab (3.01%) and Odisha (1.60%). Among LDT, HIV prevalence of 2% or more was noted in States of Punjab, Assam, Uttarakhand, West Bengal, Odisha and Chhattisgarh.

Among FSW, highest prevalence was noted in Mizoram (56.10%) followed by that in Meghalaya (10.90%), Punjab (3.38%), Karnataka (3.01%), Tripura (2.90%), Rajasthan (2.75%) and Maharashtra (2.54%). For inmates, highest HIV prevalence was noted in States of Mizoram (26.00%), followed by Punjab (7.49%), Nagaland (4.59%), Chandigarh (3.47%) and Andhra Pradesh (3.25%). Eleven States recorded HIV prevalence of 4% or more among MSM that Included

Mizoram, Punjab, Manipur, Meghalaya, Haryana, Jharkhand, Rajasthan, Gujarat, West Bengal, Maharashtra, and Chhattisgarh.

There were 13 States with HSS sites for H/TG people in 2021 round. Highest HIV prevalence among H/TG people was noted in States of West Bengal followed by that in Maharashtra, Chhattisgarh, Tamil Nadu, and Andhra Pradesh. The prevalence in these States ranged between 4.61% in Andhra Pradesh to 9.15% in West Bengal.

Among all population group covered under HSS 2021, HIV prevalence continues to be highest among IDU like in previous rounds. Among States/UTs, highest HIV prevalence among IDU, three times that of the national average was observed in Mizoram. Four States (Punjab, Maharashtra, Tripura and Delhi) had prevalence ranging between 15% and 20% in the group. HIV prevalence among IDU was around 11% in Meghalaya and Assam while around 9% in Manipur. Uttarakhand, Haryana, West Bengal, Chhattisgarh and Uttar Pradesh were other States with HIV prevalence of more than 5% among IDUs.

## 2.6 Syphilis sero-positivity

Sexually transmitted infections (STI) are key public health issue in view of their association with reproductive health, child health, sexual health and through their role in facilitating sexual transmission of HIV. Given the associations, comprehensive package of prevention, testing and treatment services for high-risk groups and at-risk population is

integral to the NACP. Accordingly, the Phase-V has augmented the focus on STI management. Specifically, two of the five high-level goals of NACP Phase-V refers to the STIs; the third goal includes Syphilis, along with HIV, for the elimination of vertical transmission while the goal four calls for promoting universal access to quality STI/RTI Services.




Table 4. HIV prevalence (in %) among various groups, 2021

State/UT	Pregnant Women	SMM	LDT	FSW	Inmates	H/TG	MSM	IDU
ANI	0.06 (0-0.19)	-	-	-	-	-	-	-
Andhra Pradesh	0.37 (0.27-0.47)	0.93 (0.25-1.62)	0.60 (0.00-1.28)	1.78 (1.32-2.23)	3.25 (2.02-4.48)	4.61 (1.82-7.40)	2.06 (1.26-2.86)	1.32 (0.41-2.23)
Arunachal Pradesh	0 (0-0)	-	-	0.27 (0.00-0.64)	-	-	-	1.60 (0.04-3.16)
Assam	0.11 (0.05-0.17)	3.21 (1.02-5.40)	2.12 (0.82-3.42)	1.65 (1.19-2.11)	2.01 (1.03-2.98)	-	3.61 (2.78-4.95)	11.24 (8.69-13.80)
Bihar	0.24 (0.15-0.32)	-	-	0.62 (0.12-1.11)	0.00 (0.00-0.00)	-	0.41 (0.00-1.20)	2.86 (1.38-4.33)
Chandigarh	0.38 (0-0.8)	0.40 (0.00-0.95)	-	0.80 (0.16-1.44)	3.47 (1.68, 5.25)	-	1.61 (0.04-3.17)	2.80 (0.76-4.84)
Chhattisgarh	0.17 (0.09-0.25)	1.20 (0.00-2.55)	2.00 (0.77-3.23)	1.92 (1.16-2.68)	0.00 (0.00-0.00)	6.00 (3.06-8.94)	4.01 (2.29-5.73)	7.20 (5.35-9.05)
DNH&DD	0.08 (0-0.46)	-	-	-	-	-	-	-
Delhi	0.41 (0.21-0.61)	0.75 (0.00-1.80)	0.80 (0.00-1.90)	0.81 (0.25-1.36)	2.45 (1.33-3.57)	3.60 (1.97-5.23)	2.59 (1.20-3.98)	15.87 (13.25-18.48)
Goa	0.25 (0-0.53)	-	-	0.60 (0.00-1.28)	-	-	2.40 (1.06-3.74)	0.00 (0.00-0.00)
Gujarat	0.27 (0.19-0.36)	0.13 (0.00-0.39)	0.30 (0.00-0.64)	1.34 (0.90-1.77)	0.88 (0.42-1.33)	3.60 (1.29-5.91)	4.61 (3.68-5.53)	2.00 (0.26-3.74)
Haryana	0.11 (0.03-0.18)	-	-	1.33 (0.70-1.96)	1.63 (0.75-2.50)	-	6.89 (5.32-8.46)	9.24 (7.45-11.02)
Himachal Pradesh	0.06 (0-0.13)	0.00 (0.00-0.00)	-	0.55 (0.00-1.18)	0.25 (0.00-0.74)	-	1.56 (0.04-3.07)	4.40 (1.86-6.94)
Jammu & Kashmir	0.02 (0-0.05)	-	-	0.40 (0.19-0.90)	-	-	-	0.50 (0.06-0.93)
Ladakh								
Jharkhand	0.13 (0.06-0.19)	-	0.00 (0.00-0.00)	0.55 (0.19-0.90)	0.00 (0.00-0.00)	-	6.68 (4.29-9.07)	-
Karnataka	0.29 (0.22-0.36)	0.20 (0.00-0.59)	1.20 (0.00-2.55)	3.01 (2.56-3.46)	0.67 (0.21-1.13)	3.20 (1.66-4.74)	2.81 (2.08-3.55)	0.00 (0.00-0.00)
Kerala	0.04 (0-0.1)	0.00 (0.00-0.00)	1.20 (0.00-2.55)	0.44 (0.18-0.70)	0.50 (0.00-1.19)	0.56 (0.01-1.10)	0.35 (0.09-0.61)	0.40 (0.00-0.85)
Madhya Pradesh	0.09 (0.05-0.13)	0.78 (0.00-1.85)	0.00 (0.00-0.00)	0.75 (0.40-1.11)	1.58 (0.88-2.29)	-	1.84 (1.09-2.58)	2.96 (1.92-4.01)
Maharashtra	0.25 (0.2-0.31)	0.13 (0.00-0.39)	0.40 (0.00-0.95)	2.54 (2.10-2.98)	1.13 (0.61-1.64)	6.00 (3.06-8.94)	4.18 (3.05-5.32)	18.41 (13.05-23.77)
Manipur	0.33 (0.19-0.46)	-	-	1.13 (0.60-1.67)	2.26 (0.80-3.72)	-	9.43 (6.68-12.17)	8.84 (7.87-9.82)
Meghalaya	0.58 (0.36-0.8)	-	-	10.92 (8.62-13.22)	-	-	9.09 (3.08-15.10)	11.48 (8.43-14.54)
Mizoram	1.13 (0.79-1.47)	4.80 (2.15-7.45)	-	56.15 (47.62-64.68)	26.00 (21.70-30.30)	-	12.80 (8.66-16.94)	32.08 (29.88-34.28)
Nagaland	1.61 (1.25-1.98)	-	1.20 (0.00-2.56)	2.00 (0.26-3.74)	4.59 (1.66-7.52)	-	3.06 (1.54-4.59)	2.53 (1.93-3.13)
Odisha	0.21 (0.13-0.29)	1.60 (0.04-3.16)	2.00 (0.26-3.74)	0.65 (0.35-0.96)	0.00 (0.00-0.00)	1.49 (0.52-2.46)	1.20 (0.00-2.55)	1.90 (1.05-2.75)
Puducherry	0 (0-0)	0.00 (0.00-0.00)	-	0.50 (0.06-0.94)	-	-	0.00 (0.00-0.00)	-
Punjab	0.18 (0.09-0.27)	3.01 (1.51-4.50)	2.33 (0.49-4.18)	3.38 (2.67-4.09)	7.49 (6.00-8.98)	-	11.62 (9.32-13.91)	19.57 (18.22-20.93)
Rajasthan	0.14 (0.07-0.2)	0.39 (0.00-1.16)	0.00 (0.00-0.00)	2.75 (2.03-3.46)	0.67 (0.21-1.13)	3.60 (1.29-5.91)	6.40 (3.37-9.43)	-
Sikkim	0.05 (0-0.15)	-	-	0.00 (0.00-0.00)	-	-	-	0.20 (0.00-0.59)
Tamil Nadu	0.17 (0.13-0.22)	0.00 (0.00-0.00)	0.60 (0.00-1.28)	1.52 (1.21-1.84)	0.50 (0.10-0.90)	4.80 (2.15-7.45)	2.07 (1.60-2.54)	-
Telangana	0.16 (0.09-0.23)	0.80 (0.00-1.90)	0.80 (0.02-1.58)	1.81 (1.39-2.24)	2.50 (0.97-4.03)	4.00 (0.86-7.14)	2.67 (1.66-3.68)	0.40 (0.00-1.18)
Tripura	0.38 (0.13-0.62)	-	-	2.90 (1.86-3.94)	1.00 (0.02-1.98)	-	-	18.00 (13.24-22.76)
Uttar Pradesh	0.17 (0.13-0.22)	0.67 (0.08-1.25)	0.70 (0.18-1.22)	1.04 (0.62-1.47)	0.13 (0.00-0.37)	3.60 (1.29-5.91)	1.10 (0.56-1.64)	5.45 (4.74-6.16)
Uttaranchal	0.05 (0-0.1)	-	2.10 (0.28-3.92)	0.42 (0.00-0.88)	0.00 (0.00-0.00)	-	2.68 (0.56-4.79)	9.77 (7.09-12.45)
West Bengal	0.08 (0.02-0.14)	3.20 (1.02-5.38)	2.01 (1.00-3.01)	1.27 (0.70-1.84)	0.84 (0.32-1.35)	9.15 (6.60-11.69)	4.36 (3.08-5.63)	7.40 (5.11-9.69)
<b>India</b>	<b>0.22 (0.21-0.24)</b>	<b>0.89 (0.69-1.10)</b>	<b>1.00 (0.78-1.21)</b>	<b>1.85 (1.75-1.96)</b>	<b>1.93 (1.75-2.12)</b>	<b>3.78 (3.24-4.33)</b>	<b>3.26 (3.03-3.48)</b>	<b>9.03 (8.69-9.37)</b>

In HSS 2021, serum samples collected from pregnant women and inmates were tested for Syphilis using non-treponemal Rapid Plasma Reagin (RPR) test. Two test protocol, i.e. first qualitative test and then the quantitative test, was used as in the past. Only samples with first qualitative test with reactive result were subjected to the second quantitative test. Under HSS, RPR quantitative tests are reported as “reactive” at dilution of >1:8.

As per the preliminary analysis of data from HSS 2021, Syphilis sero-positivity was 0.10% (95% CI: 0.09-0.11) among pregnant women and 0.34% (95% CI: 0.26-0.42) among inmates in central prisons (Figure 12). In 2019, Syphilis sero-positivity was at 0.10% (95%CI: 0.08–0.11) among pregnant women and at 0.40% (95% CI: 0.30%-0.50%) among prisoners.

Figure 12. Syphilis seropositivity (in %) by population group, 2017,2019 and 2021



State/UT-wise, in 2021, Syphilis sero-positivity among pregnant women was highest in Meghalaya (0.77%) followed by that in Nagaland (0.71%). Chhattisgarh and Mizoram had Syphilis sero-positivity which was around 3.5 times that of national average. In Sikkim, Manipur and Madhya Pradesh, Syphilis sero-positivity ranged between 0.22% to 0.25% (Table 5).

Among inmates, sero-positivity of more than 1% was noted in three States: Nagaland, Telangana and Madhya Pradesh. In Chandigarh, Chhattisgarh and Punjab, Syphilis sero-positivity ranged between 0.75% and <1%.

Table 5. Syphilis seropositivity (in %) among various groups, 2021

State/UT	Pregnant Women	Inmates
ANI	0.00 (0.00-0.00)	-
Andhra Pradesh	0.02 (0.00-0.04)	0.00 (0.00-0.00)
Arunachal Pradesh	0.00 (0.00-0.00)	-
Assam	0.01 (0.00-0.03)	0.50 (0.01-0.99)
Bihar	0.00 (0.00-0.00)	0.00 (0.00-0.00)
Chandigarh	-	0.99 (0.02-1.96)
Chhattisgarh	0.36 (0.24-0.47)	0.98 (0.26-1.70)
DNH&DD	0.00 (0.00-0.00)	-
Delhi	-	0.41 (0.00-0.87)
Goa	0.00 (0.00-0.00)	-
Gujarat	0.13 (0.05-0.2)	0.00 (0.00-0.00)
Haryana	0.01 (0.00-0.04)	0.00 (0.00-0.00)
Himachal Pradesh	0.06 (0.00-0.13)	0.00 (0.00-0.00)
Jammu & Kashmir	0.00 (0.00-0.00)	-
Ladakh		
Jharkhand	0.1 (0.04-0.16)	0.29 (0.00-0.70)
Karnataka	0.01 (0.00-0.02)	0.00 (0.00-0.00)
Kerala	0.00 (0.00-0.00)	0.00 (0.00-0.00)
Madhya Pradesh	0.22 (0.15-0.28)	1.08 (0.50-1.67)
Maharashtra	0.03 (0.01-0.05)	0.19 (0.00-0.40)
Manipur	0.23 (0.12-0.34)	0.00 (0.00-0.00)
Meghalaya	0.77 (0.52-1.02)	-
Mizoram	0.35 (0.16-0.54)	0.00 (0.00-0.00)
Nagaland	0.71 (0.47-0.95)	3.57 (0.97-6.17)
Odisha	0.1 (0.04-0.15)	0.00 (0.00-0.00)
Puducherry	0.13 (0.00-0.37)	-
Punjab	0.08 (0.02-0.14)	0.75 (0.26-1.24)
Rajasthan	0.03 (0.00-0.06)	0.13 (0.00-0.37)
Sikkim	0.25 (0.03-0.47)	-
Tamil Nadu	0.09 (0.06-0.12)	0.08 (0.00-0.25)
Telangana	0.13 (0.06-0.19)	2.25 (0.80-3.70)
Tripura	0.13 (0.00-0.27)	0.50 (0.00-1.19)
Uttar Pradesh	0.02 (0.01-0.04)	0.25 (0.00-0.60)
Uttaranchal	0.00 (0.00-0.00)	0.00 (0.00-0.00)
West Bengal	0.03 (0.00-0.06)	0.08 (0.00-0.25)
<b>India</b>	<b>0.10 (0.09-0.11)</b>	<b>0.34 (0.26-0.42)</b>

A large, thick red ribbon is tied in a loop, with the tail extending downwards and to the right. The ribbon is set against a yellow background with faint, concentric circles radiating from the center.

# 3.

## PROGRESS ON 95-95-95

# Progress on 95-95-95

## 3.1 Background

Attainment of 95-95-95 by 2025 i.e., 95% of HIV positive know their status, 95% of those who know their status are on treatment and 95% of those who are on treatment have suppressed viral load is vital coverage goals by UNAIDS. Attainment of these coverage goals, inter alia, will lead to 90% reductions in the number of new infections and AIDS-related mortality by 2030, a critical milestone towards attainment of goal of ending AIDS by 2030<sup>6</sup>.

Given the context, NACP Phase-V has included

attainment of 95-95-95 by 2025 as one of key outcome coverage indicators in alignment with global targets. Realization of 95-95-95 in totality would mean that 86% of total PLHIV are virally suppressed, often presented in terms of testing and treatment cascade, a critical programmatic prerequisite for the goal 1 i.e., reduce annual new HIV infections by 80%, goal 2 i.e., reduce AIDS-related mortalities by 80% and goal 3 i.e., eliminate vertical transmission of HIV and Syphilis. This chapter describes the progress on 95-95-95 by State/UTs.

## 3.2 Method

The method for calculating the progress on 95-95-95 has been detailed elsewhere. Table below summarises

the numerator and denominator for calculation of 95-95-95.

**Table 6. Method of calculating progress on 95-95-95**

Indicator	Description	Calculation details	
		Numerator	Denominator
First 95	Percent of all PLHIV who know their HIV status	Number of PLHIV who know their HIV status	Estimated number of PLHIV
Second 95	Percent of PLHIV who are on ART among those who know their HIV status	Number of PLHIV who are on ART	Number of PLHIV who know their HIV status
Third 95	Percent of PLHIV on ART who are virally suppressed	Number of PLHIV on ART who are virally suppressed	Number of PLHIV on ART who are tested for viral load

HIV testing and treatment cascade is another way of measuring progress on the testing-treatment-suppression


aspect of the programme. Here the denominator at each step remains the same i.e., estimated PLHIV.

### 3.3 National Progress

As on March 2022, 77% (around 18.56 lakh) of PLHIV were aware of their HIV status, 84% of those who knew their HIV status received antiretroviral therapy (ART), and 85% of on-ART PLHIV were virally suppressed (Figure 13). Overall, 65% of PLHIV were on ART and 55% of PLHIV achieved HIV viral suppression. The progress among women living with

HIV was slightly higher than among men living with HIV. Globally, 85% of PLHIV knew their HIV status, 75% of PLHIV received ART (representing 88% of those who knew their HIV-positive status), and 68% of PLHIV had viral suppression (representing 92% of people on treatment)<sup>8</sup>. The target is to have 86% of all PLHIV with suppressed viral load.

Figure 13. Gender-wise progress on 95-95-95 and treatment cascade (in %), 2021-22



The number of PLHIV diagnosed, placed on treatment, and virally suppressed is increasing. Number of PLHIV who knew their HIV status, increased from around 17 lakh in March 2019 to 18.56 lakh in March 2022 (around 9% increase). In the same reference period, number of PLHIV on-ART increased from around 14 lakh to 15.56 lakh (around 11% increase). As on March 2022, based on the extrapolation of the viral load suppressions rate among on-ART PLHIV tested for viral load to the

total on-ART PLHIV, around 13.19 lakh PLHIV were estimated to had suppressed viral load (Figure 14).

Overall, proportion of total PLHIV who knew their HIV status increased from 71% in March 2018 to 77% in March 2022. Similarly, proportion of total PLHIV on-ART who knew their HIV status increased from 58% to 65% and proportion of total PLHIV who were virally suppressed increased from 42% to 55% in the same reference period.

### 3.4 State/UT-wise progress

Overall, there were 11 States/UT where at least 80% of PLHIV were aware of their HIV status in March 2022. These included Andhra Pradesh, Chandigarh, Delhi, Goa, Gujarat, Maharashtra, Punjab, Rajasthan, Tamil Nadu, Tripura, and West Bengal. Among all these States/UT PLHIV who knew their status and were on-ART was more than 80% except for Andhra Pradesh and Delhi. Progress of less than 80% on the

second 95 is indicative of a significant lost-to-follow-up (LFU) issue and requires urgent attention. Among PLHIV who were on ART, overall, 9 States (Arunachal Pradesh, Chhattisgarh, Haryana, Himachal Pradesh, Jharkhand, Madhya Pradesh, Punjab, Telangana, and Tripura) had viral suppression of less than 80% (Table 7).



Figure 14. Trend in progress on 95-95-95 and treatment cascade (in %), 2018-19 to 2021-22



There was substantial variation in trends of progress on 95-95-95 by States/UT. For the first 95, the trend is rising across all States/UTs except for Puducherry and Telangana percentage of PLHIV who knew their HIV status in 2021-22 was less than that of 2018-19. This may be because of two reasons. First, the detection and retention of PLHIV under the programme is slower than the rate of epidemic expansion. Second, if death among PLHIV under the programme is higher than the number of new detections for the given year. The exact reason of decline needs to be investigated carefully to inform the suitable responses.

To achieve end of AIDS, detection of PLHIV must be

followed-up by initiation, retention and adherence on ART. In nine States/UT (Assam, Chandigarh, Delhi, Gujarat, Rajasthan, Sikkim, Tripura, Uttarakhand and West Bengal; percentage of PLHIV who knew their HIV status and were on ART decreased between 2018-19 and 2021-22. On a year-to-year basis, in 12 States (Bihar, Chhattisgarh, Gujarat, Himachal Pradesh, Haryana, Jharkhand, Madhya Pradesh, Meghalaya, Nagaland, Odisha, Puducherry, Punjab, Telangana, Tripura and Uttar Pradesh), on-ART PLHIV who were virally suppressed recorded stable to declining trend. These are indicative of less than optimum progress on retention and adherence in these States.

Table 7. State/UT-wise Progress on 95-95-95 (2018-19 to 2021-22)

State/UTs	First 95 (%)				Second 95 (%)				Third 95 (%)			
	2018-19	2019-20	2020-21	2021-22	2018-19	2019-20	2020-21	2021-22	2018-19	2019-20	2020-21	2021-22
ANI	35	31	33	37	69	89	87	91	-	-	-	-
Andhra Pradesh	74	78	80	82	75	76	75	78	60	80	81	86
Arunachal Pradesh	40	45	42	47	63	63	69	67	58	73	74	78
Assam	42	47	48	52	77	76	72	72	77	87	88	89
Bihar	54	56	56	56	79	83	84	85	67	81	85	83
Chandigarh	>=95	>=95	>=95	>=95	81	88	88	82	65	91	93	93
Chhattisgarh	48	54	55	59	76	77	76	77	70	85	86	76
DNH & DD	-	-	-	15	-	-	-	>=95	-	-	-	82
Delhi	87	93	91	92	77	75	73	73	75	87	88	88
Goa	74	77	77	81	84	85	84	84	79	86	86	89
Gujarat	76	80	81	82	87	86	84	84	72	86	85	84
Haryana	36	46	50	58	72	79	73	81	51	63	82	78
Himachal Pradesh	69	72	75	78	87	89	86	87	56	81	84	73
Jammu & Kashmir	55	61	59	59	77	74	77	80	76	84	90	90
Ladakh												
Jharkhand	62	59	62	63	80	88	84	86	74	83	83	77
Karnataka	72	74	77	79	83	85	83	83	68	79	81	81
Kerala	75	76	78	79	>=95	>=95	>=95	>=95	83	89	91	92
Madhya Pradesh	61	71	75	78	77	77	74	78	73	81	81	77
Maharashtra	83	88	89	88	84	83	82	84	74	87	87	88
Manipur	53	52	53	56	86	92	92	90	86	92	93	>=95
Meghalaya	54	53	55	57	72	78	73	74	89	90	92	88
Mizoram	53	56	60	64	80	83	85	85	82	92	90	91
Nagaland	63	57	63	67	65	83	78	76	73	80	87	86
Odisha	43	48	50	52	86	85	84	83	76	84	87	85
Puducherry	47	41	41	42	67	78	78	77	66	86	86	83
Punjab	61	73	79	84	83	80	77	83	70	83	84	79
Rajasthan	78	85	87	89	87	86	84	86	59	82	83	85
Sikkim	53	58	60	65	89	87	84	84	86	87	89	91
Tamil Nadu	86	87	89	91	84	86	85	85	74	85	85	86
Telangana	76	70	68	70	91	>=95	>=95	>=95	66	78	80	77
Tripura	70	75	76	92	88	89	89	86	70	80	85	78
Uttar Pradesh	58	61	63	65	82	84	84	84	78	88	87	85
Uttarakhand	47	53	55	60	78	76	71	67	62	86	86	86
West Bengal	71	78	81	85	89	87	85	84	80	89	90	87
<b>India</b>	<b>71</b>	<b>74</b>	<b>75</b>	<b>77</b>	<b>82</b>	<b>84</b>	<b>83</b>	<b>84</b>	<b>72</b>	<b>84</b>	<b>85</b>	<b>85</b>





4.

INFORMATION,  
EDUCATION &  
COMMUNICATION,  
YOUTH AND  
MAINSTREAMING

# Information, Education & Communication, Youth and Mainstreaming

## 4.1 Background

Being a signatory to the United Nations political declaration on Sustainable Development Goals, the Government of India has a target to end the epidemic of HIV/AIDS by 2030. The progress on the same is monitored through the decline in annual new HIV infections and AIDS-related mortalities. So far, while the country's progress in the reduction of new infections and AIDS-related mortality has been phenomenal, off-late a stagnancy has been noted in the rate of drop in annual new HIV infections as the country enters the last mile of the national AIDS response.

Recognising the relatively slower progress on the decline of new infections, NACP Phase-V calls for

fast-tracking the prevention initiatives not only by augmenting the focus on the high-risk groups, bridge population and youth through existing interventions but also by expanding to the newer population group like at-risk HIV negatives, or the virtual population through comprehensive prevention approaches. It underlines the HIV and AIDS (Prevention and Control) Act, 2017 as the cornerstone to break down barriers, driving delivery of a comprehensive package of services in an ecosystem free of stigma and discrimination with a specific target of less than 10% of PLHIV reporting experiencing stigma and discrimination in healthcare and community settings (Figure 15).

*Figure 15. Information, Education and Communication (IEC) as a critical enabler across NACP Phase-V goals*

### **Goal 1: Reduce annual new HIV infections by 80%**

- ▶ Develop and roll-out new generation communication strategy suitable to current context
- ▶ Develop and scale-up sustainable models for 'at-risk' Virtual Population
- ▶ Maintain and augment the behavior change communications for general population
- ▶ Sustain focus on adolescent and youth population

### **Goal 2: Reduce AIDS-related mortalities by 80%**

- ▶ Develop and roll-out tailored communication campaigns focusing on risk perception and HCTS uptake

### **Goal 3: Eliminate vertical transmission of HIV and Syphilis**

- ▶ Strengthen the primary prevention through coordinated actions
- ▶ Engage with private sector augmenting their role in attainment of dual elimination

### **Goal 4: Promote universal access to quality STI/RTI services to at-risk and vulnerable populations**

- ▶ Develop and implement integrated communication strategies
- ▶ Strengthen and streamline private sector engagement on STI/RTI management

### **Goal 5: Eliminate HIV/AIDS related stigma and discrimination**

- ▶ Undertake bottom-up institutionalized community system strengthening
- ▶ Accelerate the notification of State rules and appointment of Ombudsman in the context of the HIV and AIDS (Prevention and Control) Act, 2017
- ▶ Undertake sensitization of related stakeholders on HIV/AIDS related stigma and discrimination
- ▶ Design and implement communication strategy on elimination of HIV/AIDS-related stigma and discrimination
- ▶ Enhance strategic information on HIV/AIDS related stigma and discrimination
- ▶ Engage with State governments promoting launch and scale-up of social protection scheme

Multi-media-driven communication strategy, focusing on the youth, and multisectoral response through the enabling umbrella of the HIV and AIDS (Prevention and Control) Act, 2017, is central to NACP Phase-V across all goals (Figure 15). The focus is on the development of communication materials tailored to the epidemiological context and programmatic insights. The Social and Behavioural Change

Communication campaigns focus on sustained behaviour change among the High-Risk Groups and Bridge Populations, EVTHS, information on access to services under NACP and strengthening an enabling environment by facilitating appropriate changes in societal norms that reinforce positive attitudes, beliefs, and practices to reduce stigma and discrimination.


## 4.2 Social Media

Digital interventions in present times are the most economic means of communication and certainly the most powerful medium to reaching out to the masses. To optimally utilize this opportunity, NACO is presently active on Facebook, Twitter, Instagram & YouTube as @NACOINDIA (Figure 16). Through all its Social Media Platforms, NACO has been actively developing, uploading, and sharing content around different themes such as safe behaviour, condom usage, stigma and discrimination, myths and misconceptions about HIV and AIDS, important health days observed around the globe, and days of other national and international significance. The idea behind exploring these digital platforms is to bring

upfront the issues related to HIV prevention, promoting services offered under the umbrella of the NACP, augmenting the well-being of people living with HIV and eliminating the stigma and discrimination against people living with and affected by HIV.

In the year 2021-22, NACO focused more on enhancing the performance of the Social Media Platforms of States. Handholding of State Officers and social media teams are regularly being done to get the right message through an inclusive approach.

Figure 16. Social media approaches under NACP





### 4.3 National Toll-Free AIDS Helpline 1097



The outbreak of the COVID-19 pandemic in India in early 2020 and the subsequent waves forced people to reach out to various digital and IT-enabled mediums available for obtaining information on health issues. Capitalizing on the unique features of the National Toll-Free AIDS Helpline – 1097, NACO had taken timely appropriate measures to ensure that the callers seeking information on HIV/AIDS concerning prevention, testing, treatment, associated stigma & discrimination and mental health issues are dealt effectively.


The helpline recorded 4.2 million calls from its inception in 2014 to till 30th September 2022. From April 2021 to March 2022, the helpline recorded 4,88,261 calls on the server. The percentage of actual service-provided calls on the helpline increased to 63% in 2022 from 41% in 2021 of the connected calls which indicates that more callers reaching out to the helpline were offered necessary support. Gender was

disclosed by around half (48%) of the serviced calls. Among the callers who disclosed their gender, 72% were males, 27% were females and a few were transgender. Most (58%) of the callers were in the age group of 25-34 years, followed by 20% of calls by young of age 15-24 years. (Figure 17).

A maximum percentage (48%) of the total calls on the helpline during 2021-22 were received from the West Bengal, Andhra Pradesh & Telangana, Rajasthan, Madhya Pradesh, and Maharashtra telecom circles. Currently, the daily aggregate average of calls recorded on the helpline stands at around 1600 calls per day.

Outbound calls were initiated on the helpline during 2021-22 wherein 2,82,114 calls were made to the PLHIV registered at ART centres to follow up for treatment adherence as a part of the Self-Verified Adherence initiative of NACO in select sites across India.

Figure 17. Age and gender-wise distribution (in %) of the serviced callers, 2021-22



States continue to undertake focused promotion efforts for increasing the utilization of the toll-free helpline service across India. Efforts were being made at the national level to enhance the outbound calling services from the helpline by obtaining prior consent from the clients visiting service facilities

including the youth registered in the Red Ribbon Clubs. This will enable the programme not only to understand the reach but will also provide scope for client follow-up which will be beneficial for the programme to ensure that the services reach the last mile.

## 4.4 Youth Interventions

### Adolescence Education Programme (AEP)


AEP works with one overarching principle of providing age-appropriate knowledge to school-going adolescents and helping them to cope with peer pressure, develop positive behaviour and improve awareness on sexual and reproductive health for preventing HIV infections. AEP is

implemented in government schools in collaboration with NCERT/SCERT. A 16-hour curriculum is imparted to adolescent students of class IX and XI in more than 50,000 schools in the country (Figure 18). The status of the level of functioning of AEP is presented in table 8.

Table 8. The status of the level of functioning of AEP

Current Status	States/UT
Functional	Andaman & Nicobar Islands, Andhra Pradesh, Arunachal Pradesh Assam, Bihar, Chandigarh, Chhattisgarh, DNH&DD, Goa, Gujarat, Haryana, Himachal Pradesh, Jammu and Kashmir, Ladakh, Jharkhand, Karnataka, Kerala, Manipur, Meghalaya, Nagaland, Odisha, Puducherry, Punjab, Rajasthan, Sikkim, Tamil Nadu, Telangana, Tripura, Uttarakhand, West Bengal
Non-Functional	Delhi, Mizoram
Suspended	Madhya Pradesh, Maharashtra, Uttar Pradesh

Figure 18. Figure: Schools with Operational Adolescence Education Programme (AEP) in States/UT



## Red Ribbon Club (RRC)


RRC programme is a promotional and preventive intervention to harness the potential of youth in educational institutions, specifically to mainstream HIV and AIDS prevention, care & support and treatment, impact mitigation, stigma reduction and enhance Voluntary Blood Donation.

It also prepares and promotes youth peer educators within and outside the campuses. Currently, there are

more than 12,000 Red Ribbon Clubs constituted/functional in colleges under the across India. (Figure 19).

RRCs provide a platform to college students for outreach and mobilizing activities for generating age-appropriate and culture-centric awareness, stigma reduction and promoting Voluntary Blood Donation.

Figure 19. Colleges with Operational Red Ribbon Club (RRC) in States/UTs.



## India @75 Campaign Azadi ka Amrit Mahotsav

The New India@75 initiative is to commemorate India's 75th Independence Day as a mega mass mobilization and engagement movement. To mark the occasion, NACO organized three major

awareness campaigns on HIV/AIDS, Tuberculosis and Voluntary Blood Donation in a phased manner throughout the year and fruitfully engaged 75 schools and 75 Red Ribbon Clubs (RRC) (Figure 20).



Figure 20. Celebration of India @75 Campaign Azadi ka Amrit Mahotsav in school



To continue the celebration after every launch event, various activities were conducted in schools and colleges both in physical and online mode by following the COVID-19 protocols in the States. The States conducted various activities like poster competitions, slogan competitions, one-minute video

competitions, RRC Talk, essay writing, face painting, webinars etc. to generate awareness among members of RRCs and school students of 9th & 11th standard. Table 9 depicts the coverage made under three phases of Azadi ka Amrit Mahotsav.

Table 9. Coverage made under three phases of Azadi ka Amrit Mahotsav

Phases	Districts Covered	Schools Covered	Colleges Covered	Youth Reached
Phase I	247	834	889	86150
Phase II	248	877	938	90750
Phase III	324	767	970	97189


## 4.5 Mainstreaming

NACP Phase-V aims to build upon the systematized convergence with the existing programmes of the Central Government as well as State Governments to increase the reach of the and spread awareness on HIV and AIDS. The perspective behind the mainstreaming efforts of NACP Phase- V is based on reaching the last mile of success in terms of prevention of HIV, treatment for those who need it, addressing deprivations rooted in socio-economic imbalances and reducing stigma and discrimination that drive the HIV epidemic. It is an initiative towards 'integrated responses', to deal with susceptibility to HIV infection, as well as mitigating the burden of the disease on affected communities.

NACO has reached out to a large number of individuals and institutions through its mainstreaming efforts with key departments/ministries and the private sector. To take the agenda forward, NACO has signed Memoranda of Understanding (MoU) with 18 key Departments/Ministries (Figure 21). Several activities that are provisioned in the MoU are implemented at the State level for generating awareness of HIV & AIDS, information regarding the services under the National programme, promoting testing and linking with necessary services.

During 2021-22, around 2.70 lakh persons were sensitized across the country through mainstreaming efforts.

Figure 21. MoU under NACP



## 4.6 Strengthening India's response to the elimination of HIV-related stigma and discrimination

The HIV and AIDS (Prevention & Control) Act, 2017 is a central legislation which came into force on September 10, 2018. The objective of the Act is to prevent and control the spread of HIV and AIDS and for reinforcing the legal and human rights of persons infected with and affected by HIV and AIDS. It also seeks to protect the rights of healthcare providers.

One of the key features of the HIV and AIDS (Prevention & Control) Act, 2017 is that it addresses and prohibits HIV-related stigma and discrimination against people infected with and affected by HIV.

The HIV and AIDS (Prevention & Control) Act, 2017 will be instrumental in accelerating the progress of achieving the target under NACP-V (2021-2026) i.e.,


less than 10% of people living with HIV and key populations experience stigma and discrimination.

The provisions of the HIV and AIDS (Prevention & Control) Act, 2017 deal with stigma & discrimination and strives to create an enabling environment for enhancing access to services. It provides diagnostic facilities related to ART and opportunistic infection management for people living with HIV and AIDS. The Act also provides for a robust grievance redressal mechanism in the form of an Ombudsman at the State level and a Complaints Officer at the establishment level aiming to provide speedy redressal. State/UT-wise status of the Act implementation is summarised in Table 10.

Table 10. State/UT-wise status of Rules notification and placement of Ombudsman, March 2022

Status	States
States/UTs where Rules have been notified and Ombudsman has been placed	Chhattisgarh, Punjab, Madhya Pradesh, Jharkhand, Karnataka, Himachal Pradesh, Bihar, Nagaland, Andaman & Nicobar Islands, Gujarat, Manipur, Rajasthan, Uttar Pradesh, Assam, and West Bengal
States/UTs where Rules have been notified	Jammu & Kashmir
States/UTs where Ombudsman have been deputed/designated (Rules are yet to be notified)	Haryana, Puducherry, Sikkim, Tamil Nadu, Odisha, D&D, DNH, Goa, Andhra Pradesh, and Uttarakhand
States/UTs where rules have been formulated and submitted for further approval	Chandigarh, Maharashtra, Delhi, Tripura, Meghalaya, Arunachal Pradesh, Kerala, Telangana, and Mizoram



A large, thick red ribbon is draped across the right side of the page, forming a loop at the top and extending downwards. The background is a solid yellow color with faint, concentric circular lines radiating from the center.

# 5.

PREVENTION  
AMONG HIGH  
RISK GROUP AND  
BRIDGE  
POPULATION

# Prevention among High Risk Group and Bridge Population

## 5.1 Background

NACP Phase-V envisages accelerating reduction in new annual HIV infections through a basket of strategies tailored to the high-risk and at-risk population. In this regard, National AIDS Control Organisation (NACO) continue to implement and evolve with the existing peer-led targeted interventions (TI) and Link Worker Schemes (LWS) strategies for providing services to the population who are at risk of acquiring HIV /STI infections. TI is a flagship programme of NACO that aimed at providing a package of prevention, support, and linkage services to High-Risk Groups (HRG) or Bridge Populations in a defined geography through a peer-led, outreach-based service delivery model in partnership with Non-Governmental Organizations (NGO) and Community Based Organisations (CBO). HRG includes Female Sex Workers (FSW), Men who have Sex with Men (MSM), Injecting Drug Users (IDU), and Hijra/Transgender (H/TG) people. Traditionally, migrants and truckers are covered as a proxy of bridge populations in TI.

The Targeted Interventions have evolved offering a comprehensive package of services across the prevention–testing–treatment spectrum through a revamped model. The changing dynamics of solicitation, locations of outreach and use of technology

by communities have led to revamping the TI strategy in 2019 wherein newer activities were included in the programme. As per the revamped strategy, the focus is given to increasing coverage of the population in TI, spouse, and partner testing of HRGs, identification of a social and sexual network of HRG etc. In addition to this, attempts have been made to build capacities of the communities, the implementing NGO/CBOs, use technology to capture programme data through SOCH etc. Efforts are made to reach out to the other subgroups of the population like those who are incarcerated, informal sector workers, and rural populations through schemes such as the Prison and other closed setting intervention (POCS), Employer Led Model (ELM) and LWS respectively.

NACP Phase –V build upon the time-tested strategy of offering differentiated services meeting the needs of the community. Aligning with the goal of NACP and the demand of the communities, a bouquet of services is provided to the communities through a peer-led approach i.e., by the communities who work as peer educators in the programme. The package of services provided under TIs and the activities conducted are outlined in Table 11.

Table 11. Key components and unique elements of Targeted Interventions

Key components	Unique elements
<p><b>Behaviour Change Communication:</b></p> <ul style="list-style-type: none"> <li>▶ Interpersonal Communication (IPC) by peers and ORW</li> <li>▶ Counselling for behaviour change</li> <li>▶ Field-level events/melas</li> <li>▶ Awareness generation workshops</li> <li>▶ Training on condom usage, negotiation skills, and usage of needles (IDUs only)</li> <li>▶ Multi-media advertisements</li> <li>▶ NACO National Helpline</li> </ul> <p><b>Clinical Services:</b></p> <ul style="list-style-type: none"> <li>▶ Treatment of HIV/AIDS and Sexually Transmitted Infections (STIs)</li> <li>▶ Community-based Screening for HIV</li> <li>▶ Opioid Substitution Therapy (OST)</li> </ul> <p><b>Referrals &amp; Linkages:</b></p> <ul style="list-style-type: none"> <li>▶ HIV-integrated counselling and testing centres</li> <li>▶ Anti-retroviral therapy (ART) centres</li> </ul> <p><b>Provision of Commodities:</b></p> <ul style="list-style-type: none"> <li>▶ Free condom and lubricant distribution</li> <li>▶ Social marketing of condoms</li> <li>▶ Clean needle/syringe exchange (IDUs only)</li> </ul> <p><b>Enabling Environment:</b></p> <ul style="list-style-type: none"> <li>▶ Advocacy and Liaison with key stakeholders such</li> </ul> <p><b>Community Mobilization:</b></p> <ul style="list-style-type: none"> <li>▶ Reach out to the community through Outreach Workers (ORW) and Peer Leaders</li> <li>▶ Capacity building of communities to own the programme</li> </ul>	<p><b>Focussed:</b> TIs target key population (KP) groups based on detailed mapping and surveillance data. Detailed micro mapping and surveillance data of the KP collected in partnership with leading research organizations, technical experts, community-based organizations and peer leaders have been strong components of the TI strategy over the years. These help to better target interventions, resources and to evaluate impact.</p> <p><b>Community-Based Implementation:</b> Working through community-based organizations allows for easier buy-in of target groups as well as programme implementation and monitoring.</p> <ul style="list-style-type: none"> <li>▶ Peer Led Model: Community as an active participant is a distinctive aspect of the TI approach. As peer leaders and outreach workers are identified and nurtured by the community, they help to reach otherwise hard-to-reach/hidden communities, build trust and get active community inputs thereby increasing the effectiveness of TI.</li> <li>▶ Services at the Doorstep: From training to condom supply to HIV/STI screening, all services are provided to the KP within their community itself. The community-based drop-in centres provide a safe and non-judgemental space.</li> </ul> <p><b>Decentralized Implementation:</b> The states are empowered through the SACs to adapt the TIs to their local contexts, thereby increasing the relevance and effectiveness of services provided by a TI to the KP.</p> <p><b>Regular Capacity Building:</b> Regular training programmes are planned and delivered by NACO and states to continuously build and reinforce TI effectiveness.</p> <p><b>Life-cycle Approach:</b> From outreach to the identification of the KP, to prevention, to testing and ART-treatment and regular follow-ups, TIs cover the entire lifecycle of a person at high risk of HIV infection.</p> <p><b>Evidence-Based with Strong Monitoring:</b> TIs have a strong results-focus, with the success of implementing partners (NGOs/CBOs) being measured based on results in reach, testing and reduction in the prevalence of HIV infection in the target communities. Strong checks and balances have been developed through close co-ordination between NACO, SACS and TSU programme officers and NGOs/CBOs.</p>

## 5.2 Coverage of key population under TI: An overview

A total of 1512 TI were on-board during 2021-22 against a total sanctioned of 1586 TI as per the Annual Action Plan (AAP) for the year. Coverage among the HRG and bridge populations has varied

against the estimated population. Coverage among truckers was lowest at 50%, while that of other populations was more than 85% (Table 12).


Table 12. Typology-wise number of TI and population coverage against estimation, 2021-22

Typology	Mapping Estimates (In Lakh) <sup>c</sup>	2021-22				Percentage Coverage against the Mapping Estimates
		Exclusive	Through Composite <sup>d</sup>	Total Unit (Exclusive + Composite) <sup>e</sup>	Coverage (In Lakh)	
FSW	8.68	320	513	833	8.90	≥95
MSM	3.57	95	432	527	3.20	90
IDU	1.77	203	187	390	1.79	≥95
H/TG people	0.7	41	253	294	0.61	88
Migrants	72	209	14	223	66.13	92
Truckers	20	75	21	96	9.93	50
Core Composite	-	569	-	-	-	-
Total	-	1512	-	-	-	-

Overall, the number of TI and coverage of HRG and bridge population has a rising trend over the last five years. The dip in coverage in 2020-21 may be attributed to the impact of the COVID-19 pandemic. The momentum was regained in 2021-22 with around

40% higher coverage. The revamping strategy with a focus on reaching out to new, hard-to-reach populations within the catchment area and beyond has attributed to an increase in coverage of the programme (Figure 22).

Figure 22. Number of TI and population covered, 2017-18 to 2021-22



<sup>c</sup>Last mapping of FSW, MSM, Migrants and Truckers population are conducted in 2008-09. Hijra/TG population mapping was conducted in 2013-14

<sup>d</sup>In composite interventions more than one typology are covered in a TI


<sup>e</sup>Total units are the total number of interventions implemented either through exclusive or composite interventions

## 5.3 FSW coverage by TI

In 2021-22, more FSW were covered under the TI than the previous year as the programme recovered from the impact of COVID-19 (Figure 23). Higher coverage is also reflected in more clinic visits, HIV testing and condom distribution. The increase was noted not only in terms of absolute number but also in terms of service intensity. Average visits by an FSW for clinical services increased from 1.9 visits in

2020-21 to 2.6 visits in 2021-22. Similarly, the average condom distributed per year to an FSW increased from 129 in 2020-21 to 216 in 2021-22. HIV seropositivity continues to have a declining trend. In the last five years, maximum seropositivity was at 0.13%. Overall, 1047 new HIV positive FSW were detected in 2021-22 and 86% of them were linked to anti-retroviral therapy (ART) centres.

Figure 23. Key services among FSW, 2017-18 to 2021-22



Overall, there were 19 States/UT which reported coverage of 95% or more against the estimated population. Bihar reported the lowest coverage of the FSW population at 34%. Mizoram has shown the highest seropositivity (1.37%) among all FSW tested

for HIV with 100% linkage of HIV positives to ART centres. Under the revamped strategy, efforts are made to link all identified HIV-positive HRG to ART centres by way of prioritising the HRGs and linking them through navigation (Table 13).



Table 13. State/UT-wise key service uptake by FSW, 2021-22

State/UT	Total Coverage	Percentage Coverage against the estimated population	Clinical Visits (Lakh)	STI Treated	Condom Distribution (Lakh)	HIV Testing (Lakh)	Total tested positive	Total linked to ART	ART Linkage (%)
Andhra Pradesh	1,44,198	≥95	3.7	1,432	442.9	2.0	109	80	73
Arunachal Pradesh	5,091	≥95	0.1	139	5.0	0.1	1	1	100
Assam	13,760	78.9	0.4	814	27.2	0.2	80	41	51
Bihar	6,419	34.4	0.2	157	13.3	0.1	6	5	83
Chandigarh	4,836	≥95	0.1	158	13.6	0.1	3	2	67
Chhattisgarh	17,895	75.8	0.5	1,990	52.5	0.3	72	54	75
Delhi	50,687	≥95	1.4	2,199	12.8	0.7	79	69	87
Goa	5,180	≥95	0.2	210	16.0	0.1	4	3	75
Gujarat	28,075	75.9	1.0	1,272	116.1	0.5	28	24	86
Haryana	12,107	≥95	0.3	553	28.2	0.2	14	10	71
Himachal Pradesh	5,584	61.86	0.2	528	16.5	0.1	2	1	50
Jammu and Kashmir Ladakh	1,970	≥95	0.1	178	4.6	0.1	2	2	100
Jharkhand	15,029	72.15	0.5	551	26.2	0.3	5	5	100
Karnataka	1,25,686	≥95	3.2	2,644	208.4	1.6	71	70	99
Kerala	21,261	≥95	0.6	916	50.1	0.3	3	3	100
Madhya Pradesh	47,721	≥95	1.3	3,388	80.5	0.7	51	47	92
Maharashtra	84,924	≥95	2.6	3,830	212.6	1.3	175	173	99
Manipur	6,427	≥95	0.2	47	12.3	0.1	10	8	80
Meghalaya	2,023	≥95	0.0	17	2.5	0.0	19	9	47
Mizoram	890	60.8	0.0	28	0.8	0.0	12	13	108
Nagaland	3,705	≥95	0.1	151	5.9	0.0	6	6	100
Odisha	15,547	≥95	0.4	1,296	30.5	0.2	11	9	82
Puducherry	3,512	≥95	0.1	54	6.4	0.0	1	1	100
Punjab	20,850	81.3	0.5	990	44.3	0.3	53	44	83
Rajasthan	15,725	57.1	0.4	849	45.4	0.2	29	29	100
Sikkim	1,018	≥95	0.0	65	1.9	0.0	0	0	0
Tamil Nadu	64,415	90.9	0.9	647	84.6	0.8	28	26	93
Telangana	1,13,874	≥95	2.4	1,417	228.5	1.3	88	80	91
Tripura	4,559	83.3	0.1	156	5.3	0.0	8	8	100
Uttar Pradesh	23,844	≥95	0.6	1,449	64.6	0.3	39	35	90
Uttarakhand	5,023	86.6	0.2	676	11.6	0.1	4	4	100
West Bengal	18,284	84.8	0.5	417	50.9	0.3	34	34	100
<b>India</b>	<b>8,90,119</b>	<b>≥95</b>	<b>22.8</b>	<b>29,218</b>	<b>1,921.8</b>	<b>12.3</b>	<b>12.3</b>	<b>896</b>	<b>86</b>

<sup>†</sup>No interventions in Andaman and Nicobar Island, Dadra and Nagar Haveli and Daman and Diu, and Lakshadweep


<sup>‡</sup>In few States, more positive were linked then the diagnosed which may be because of cases diagnosed in previous year being linked in current year

## 5.4 MSM coverage by TI

Around 3.20 lakh MSM (90% of the estimated size) were covered under TI interventions in 2021-22 (Table 14). Around 6.35 crore condoms were distributed among the group which amounts to 198 condoms distributed per MSM in the year. Around 8.09 lakh clinic visits were made by MSM and 6,000 episodes of STI were treated. A total of 4.36 lakh HIV tests were done in the population group and seropositivity was 0.25%. Around 86% of the identified MSM were linked to ART centres.

Overall, the coverage and uptake of various services by MSM have an increasing trend (Figure 24). Condoms distributed per MSM (198) in 2021-22 was second only to distribution in 2017-18 (204). HIV seropositivity among the tests conducted in the group hovered in the range of 0.24% to 0.29% in the last five years. In 2020-21, 93% of the HIV positives were linked to ART vis-à-vis 86% in 2021-22.

Figure 24. Key services among MSM, 2017-18 to 2021-22



There were 20 States/UT reporting coverage of 95% or more among MSM (Table 14). Bihar reported the lowest coverage (36%). The highest seropositivity

(5.40%) among tests conducted among MSM was noted in Manipur while Maharashtra has 100% linkages of all identified positives to ART centre.

Table 14. State/UT-wise key service uptake by MSM, 2021-22

State/UT	Total Coverage	Percentage Coverage against the estimated population	Clinical Visits (Lakh)	STI Treated	Condom Distribution (Lakh)	HIV Testing (Lakh)	Total tested positive	Total linked to ART	ART Linkage (%)
Andhra Pradesh	27,686	≥95	0.70	156	83.36	0.38	64	46	72
Arunachal Pradesh	611	85.5	0.02	29	1.10	0.01	2	2	100
Assam	4,552	≥95	0.13	93	7.06	0.07	92	51	55
Bihar	1,712	36.1	0.06	87	2.83	0.03	6	6	100
Chandigarh	2,983	≥95	0.08	65	6.68	0.04	12	11	92
Chhattisgarh	3,002	≥95	0.06	93	7.28	0.04	56	50	89
Delhi	19,542	≥95	0.50	173	35.44	0.27	58	48	83
Goa	3,875	≥95	0.13	94	8.55	0.06	5	5	100
Gujarat	27,688	81.4	0.97	982	76.17	0.49	79	71	90
Haryana	4,802	67.4	0.14	167	11.26	0.08	40	23	58
Himachal Pradesh	503	59.2	0.02	38	1.64	0.01	5	5	100
Jammu and Kashmir	1,029	≥95	0.02	65	0.53	0.02	1	1	100
Ladakh									
Jharkhand	1,738	54.0	0.06	44	2.85	0.03	8	6	75
Karnataka	43,287	≥95	0.99	228	84.56	0.51	109	104	95
Kerala	25,132	≥95	0.62	543	33.80	0.26	19	15	79
Madhya Pradesh	16,786	≥95	0.48	597	22.12	0.25	80	74	50
Maharashtra	28,033	83.8	0.94	1056	61.83	0.44	133	130	100
Manipur	1787	≥95	0.05	8	2.35	0.02	5	5	100
Meghalaya	208	92.4	0.01	0	0.21	0.00	2	0	100
Mizoram	794	≥95	0.02	3	0.48	0.01	6	3	0
Nagaland	2,232	≥95	0.05	10	3.91	0.02	3	3	100
Odisha	3,694	87.3	0.10	282	6.99	0.05	8	7	88
Puducherry	2,742	≥95	0.08	21	5.45	0.05	0	0	
Punjab	4,744	80.9	0.16	140	11.28	0.08	66	56	85
Rajasthan	5,549	45.9	0.15	211	12.27	0.08	20	19	95
Tamil Nadu	46,653	≥95	0.61	104	61.34	0.56	64	64	100
Telangana	22,999	≥95	0.49	55	49.99	0.27	42	36	86
Tripura	565	≥95	0.02	9	0.64	0.01	6	5	83
Uttar Pradesh	11,071	≥95	0.31	439	24.39	0.17	68	65	96
Uttarakhand	2,246	≥95	0.08	189	4.68	0.04	19	18	95
West Bengal	1,809	68.9	0.06	15	3.56	0.03	25	23	92
<b>India</b>	<b>3,20,054</b>	<b>89.7</b>	<b>8.09</b>	<b>5996</b>	<b>634.62</b>	<b>4.36</b>	<b>1,103</b>	<b>952</b>	<b>86</b>


<sup>H</sup>No interventions in the States/UT of Andaman and Nicobar Island, Dadra and Nagar Haveli and Daman and Diu, and Lakshadweep

## 5.5 H/TG people coverage by TI

Around 62 thousand H/TG people, around 88% of the estimated size, were covered through 294 TI across 25 States/UT in 2021-22 (Table 15). A total of 1.46 crore condoms were distributed @ 236 condoms per H/TG person. H/TG people covered under TI made around 1.54 lakh visits to the clinics and around 1500 episodes of STI were treated. HIV seropositivity was at 0.38% and 92% of the identified positives were linked to ART centres.

Coverage of H/TG people under TI has an increasing trend by and large with maximum coverage of 66 thousand in 2020-21; 39% higher than the H/TG people covered in the previous year. However, the average number of condoms distributed per H/TG person in 2021-22 was almost twice of the same in 2020-21. Average visits to the clinics in the group was also higher in 2021-22 than in the previous years. ART linkage of identified positives was 90% or higher in the last 4 years (Figure 25).

Figure 25 Key services among H/TG people, 2017-18 to 2021-22



A total of 14 States/UT had a coverage of 95% or more against the estimated size of H/TG people (Table 15). Manipur had the lowest coverage at 17%.

The highest HIV seropositivity (2.31%) was noted in Chhattisgarh. ART linkage among identified positives was 100% in 10 States/UT.

Table 15. State/UT-wise key service uptake by H/TG people, 2021-22

State/UT	Total Coverage	Percentage Coverage against the estimated population	Clinical Visits (Lakh)	STI Treated	Condom Distribution (Lakh)	HIV Testing (Lakh)	Total tested positive	Total linked to ART	ART Linkage (%)
Andhra Pradesh	4224	≥95	0.11	17	15.12	0.06	31	18	58
Assam	495	≥95	0.01	12	0.67	0.01	0	0	-
Bihar	0	0.0	0.00	0	0.00	0.00	0	0	-
Chandigarh	214	≥95	0.00	0	0.46	0.00	1	1	100
Chhattisgarh	1112	≥95	0.02	39	2.94	0.01	30	24	80
Delhi	10780	≥95	0.28	105	19.52	0.16	26	22	85
Goa	92	92	0.00	0	0.24	0.00	0	0	-
Gujarat	1790	58.5	0.07	17	3.59	0.03	10	10	100
Haryana	225	-	0.00	2	0.25	0.00	0	0	-
Jharkhand	356	92.5	0.01	15	0.37	0.01	0	0	-
Karnataka	5949	≥95	0.11	25	12.79	0.07	9	9	100
Kerala	2551	≥95	0.07	43	3.84	0.05	2	1	50
Madhya Pradesh	706	-	0.02	16	0.92	0.01	5	4	80
Maharashtra	9243	≥95	0.31	546	34.90	0.13	65	61	94
Manipur	140	17.5	0.00	0	0.11	0.00	0	0	-
Nagaland	86	≥95	0.00	0	0.23	0.00	0	0	-
Odisha	3883	49.4	0.11	325	9.87	0.05	46	45	98
Puducherry	193	≥95	0.01	1	0.63	0.00	1	1	100
Punjab	830	19.8	0.03	47	2.56	0.01	6	6	100
Rajasthan	967	52.4	0.02	34	1.59	0.01	2	2	100
Tamil Nadu	8466	≥95	0.11	10	14.45	0.11	16	16	100
Telangana	2415	≥95	0.04	6	5.87	0.03	18	21	117
Uttar Pradesh	4993	62.4	0.14	160	10.71	0.07	19	17	89
Uttarakhand	168	≥95	0.01	18	0.31	0.00	5	5	100
West Bengal	2060	≥95	0.05	34	4.09	0.03	32	34	106
<b>India</b>	<b>61938</b>	<b>88.5</b>	<b>1.54</b>	<b>1472</b>	<b>146.03</b>	<b>0.85</b>	<b>324</b>	<b>297</b>	<b>92</b>

<sup>1</sup>No intervention in Andaman and Nicobar Island, Arunachal Pradesh, Dadra and Nagar Haveli and Daman and Diu, Himachal Pradesh, Jammu and Kashmir, Ladakh, Meghalaya, Mizoram, Sikkim, Tripura, and Lakshadweep




## 5.6 IDU coverage by TI

Around 1.79 lakh IDU ( $\geq 95\%$  of the estimated size) were covered in 2021-22 through 390 TI in 31 States/UT (Table 16). Around 3.92 crore needles/syringes (N/S) were distributed @ 219 N/S per IDU under the programme. Around 4.90 lakh visits to the clinics were made by the covered population and around 1150 episodes of STIs were treated. HIV seropositivity in the samples tested from the target group was around 1.05%. Less than three-fourths (71%) of the identified HIV positives were linked to ART centres.

Coverage among the IDU has an increasing trend with maximum coverage in 2021-22 (Figure 26). However, the average N/S distributed per IDU per year declined from 247 in 2017-18 to 185 in 2020-21 and then increased to 219 in 2021-22. HIV seropositivity among samples tested in the group ranged between 0.94% to 1.09%. In 2018-19, 86% of the identified positives were linked to ART centres which declined to 71% in 2021-22.

Figure 26. Key services among IDU, 2017-18 to 2021-22



In 19 States/UT, coverage was 95% or more against the total estimated population. Tamil Nadu reported the lowest coverage (15%). HIV seropositivity in samples

tested from the group was highest in Tripura (9.41%). In 9 States/UT, ART linkage was at 100% (Table 16).

Table 16. State/UT-wise key service uptake by IDU, 2021-22

State/UT	Total Coverage	Percentage Coverage against the estimated population	Clinical Visits (Lakh)	STI Treated	Condom Distribution (Lakh)	HIV Testing (Lakh)	Total tested positive	Total linked to ART	ART Linkage (%)
Andhra Pradesh	1,656	≥95	0.06	7	2.24	0.03	5	5	100
Arunachal Pradesh	2,773	≥95	0.06	34	1.99	0.04	8	5	63
Assam	2,816	89.5	0.07	37	4.19	0.04	332	167	50
Bihar	3,144	39.6	0.11	56	12.31	0.06	16	15	94
Chandigarh	1,951	≥95	0.06	8	3.99	0.03	5	5	100
Chhattisgarh	3,558	≥95	0.11	139	8.24	0.06	38	15	39
Delhi	12,084	≥95	0.33	31	50.75	0.18	150	99	66
Goa	494	≥95	0.01	3	0.84	0.01	0	0	-
Gujarat	898	45.8	0.03	4	1.23	0.02	3	3	100
Haryana	4,464	90.6	0.12	25	10.44	0.07	76	58	76
Himachal Pradesh	833	≥95	0.02	0	0.47	0.01	2	2	100
Jammu and Kashmir	3,782	≥95	0.09	126	12.12	0.08	8	8	100
Ladakh									
Jharkhand	931	65.1	0.03	0	2.98	0.02	1	0	0
Karnataka	987	31.8	0.02	1	1.43	0.01	1	1	100
Kerala	2,583	62.8	0.08	1	2.90	0.04	1	1	100
Madhya Pradesh	10,346	≥95	0.30	48	14.36	0.16	114	81	71
Maharashtra	836	86.7	0.02	1	0.40	0.01	2	2	100
Manipur	25,909	≥95	0.62	26	52.37	0.30	62	49	79
Meghalaya	1,247	65.9	0.04	9	1.85	0.01	23	8	35
Mizoram	13,476	≥95	0.36	15	14.13	0.10	239	150	63
Nagaland	24,401	≥95	0.59	91	16.90	0.26	106	92	87
Odisha	4,287	≥95	0.11	122	3.37	0.05	2	2	100
Punjab	20,712	90.2	0.68	100	35.54	0.31	551	434	79
Rajasthan	1,705	87.3	0.05	3	5.64	0.03	35	34	97
Sikkim	1,691	≥95	0.03	22	4.03	0.02	0	0	-
Tamil Nadu	418	15.1	0.00	0	0.13	0.01	0	0	-
Telangana	1,065	≥95	0.03	17	3.59	0.02	1	0	0
Tripura	3,945	≥95	0.11	2	7.21	0.05	509	395	78
Uttar Pradesh	21,796	≥95	0.62	145	96.56	0.31	229	169	74
Uttarakhand	2,880	≥95	0.09	60	10.73	0.04	33	24	73
West Bengal	1,673	≥95	0.05	0	9.60	0.03	5	1	20
<b>India</b>	<b>1,79,341</b>	<b>≥95</b>	<b>4.90</b>	<b>1133</b>	<b>392.54</b>	<b>2.42</b>	<b>2557</b>	<b>1825</b>	<b>71</b>

<sup>1</sup>No intervention in Andaman and Nicobar Island, Dadra and Nagar Haveli and Daman and Diu, Lakshadweep, and Puducherry

## 5.7 Migrants coverage by TI


Around 66.13 lakh migrants, 92% of the estimated size, were covered through 223 interventions in 30 States/UT in 2021-22 (Table 17). Almost 8.30 lakh HIV testing was done among migrants covered with seropositivity of 0.11%. Around 89% of the total positives detected were linked to ART centres.

Coverage of the migrant population was highest in 2021-22, around 70% higher than the coverage reported in 2017-18 (Figure 27). Overall, HIV testing followed a trend which was similar to that of coverage. However, in terms of HIV testing per 1000

population covered, a different trend was noted. HIV testing per 1000 population ranged between 138 and 150 during 2017-18 to 2020-21 and then dipped to 125 in 2021-22.

HIV seropositivity among the samples tested in the group was also declining; down from 0.19% in 2017-18 to 0.11% in 2021-22. During the last five years, ART linkage of identified positives was in the range of 87-90% except for that in 2018-19 when it was lowest at 69%.

Figure 27. Key services among migrants, 2017-18 to 2021-22.



Overall, 17 States/UT reported having covered more than 95% of the total estimated population. Andhra Pradesh reported the lowest coverage of the migrant population (20%). HIV seropositivity in the tested samples from the group was highest in Assam (1.26%). In 9 States/UT, 100% linkages to ART centres were reported (Table 17).

The population is also covered through Employer Led

Model (ELM). Under ELM, concerted efforts were made to engage major industries and associations to integrate comprehensive HIV/AIDS prevention-to-care programmes within their existing structure. During 2021-22, under ELM, a total of 1,46,557 labourers were tested for HIV and 120 (0.08%) were detected as HIV positive. Similarly, a total of 1,31,210 labourers were provided STI check-ups through health camps organised by the employers.

Table 17. State/UT-wise key service uptake by Migrants, 2021-22

State/UT	Total Coverage	Percentage Coverage against the estimated population	HIV Testing (Lakh)	Total positive detected	Total linked to ART	ART Linkage (%)
Andhra Pradesh	39,850	19.97	0.38	33	16	48
Arunachal Pradesh	55,110	≥95	0.07	1	1	100
Assam	17,445	87.23	0.05	57	47	82
Chandigarh	62,347	≥95	0.09	13	11	85
Chhattisgarh	1,49,062	64.53	0.20	18	15	83
Delhi	6,74,227	≥95	0.52	97	81	84
Goa	63,326	≥95	0.06	3	3	100
Gujarat	8,96,039	68.17	0.74	63	56	89
Haryana	72,180	54.78	0.09	3	2	67
Himachal Pradesh	51,905	35.58	0.03	4	4	100
Jammu and Kashmir	17,967	71.87	0.09	3	3	100
Ladakh						
Jharkhand	66,683	≥95	0.09	1	1	100
Karnataka	3,94,731	≥95	0.43	42	29	69
Kerala	4,54,528	≥95	0.59	45	44	98
Madhya Pradesh	2,55,124	≥95	0.29	11	8	73
Maharashtra	21,54,702	≥95	2.45	377	356	94
Manipur	9,098	56.86	0.01	7	4	57
Mizoram	29,021	57.70	0.04	10	7	70
Nagaland	14,129	≥95	0.02	2	2	100
Odisha	41,432	45.03	0.45	33	32	97
Puducherry	24,162	≥95	0.07	0	0	-
Punjab	1,54,354	≥95	0.25	22	21	95
Rajasthan	1,60,939	≥95	0.16	9	9	100
Tamil Nadu	1,93,576	≥95	0.26	19	18	95
Telangana	93,204	≥95	0.26	12	10	83
Tripura	7,331	20.48	0.05	18	17	94
Uttar Pradesh	1,38,209	42.27	0.19	26	23	88
Uttarakhand	2,70,303	≥95	0.23	15	15	100
West Bengal	52,058	≥95	0.12	4	4	100
<b>India</b>	<b>66,13,042</b>	<b>91.8</b>	<b>8.31</b>	<b>948</b>	<b>839</b>	<b>89</b>

<sup>k</sup>No intervention in Andaman and Nicobar Island, Bihar, Dadra and Nagar Haveli and Daman and Diu, Meghalaya, Lakshadweep, and Sikkim

## 5.8 Truckers coverage by TI


Overall, 9.93 lakh truckers, around 50% of the total estimated population, were covered through 96 interventions in 26 States/UT in 2021-22 (Table 18). Around 2.40 lakh HIV testing was done in the group with seropositivity of 0.12%. Around 80% of the HIV-diagnosed cases were linked to ART centres.

With a total coverage of around 14 lakh, coverage among truckers was highest in 2018-19 (Figure 28). Since then, the coverage among truckers had a declining trend till 2020-21 when around 8.80 lakh truckers were covered. Coverage increased by around 14% between 2020-21 and 2021-22.

In 2018-19, when the overall coverage was highest, there were 98 tests for every 1000 people covered in the group. In comparison, there were 149 tests per 1000 population in 2019-20, 172 in 2020-21 and 240 in 2021-22.

HIV seropositivity among the samples tested in the group had declined from around 0.23% in 2017-18 to around 0.12% in 2021-22. In the last three years, around 80% of the identified positives were linked to ART centres.

Figure 28. Key services among truckers, 2017-18 to 2021-22.



Eight States were reported to have covered more than 95% of the total estimated population in 2021-22 (Table 19). Goa has reported the lowest

coverage at 44%. HIV seropositivity was highest in Nagaland (0.40%). In ten States/UT, ART linkage was 100%.



Table 18. State/UT-wise key service uptake by Truckers, 2021-22<sup>l</sup>

State/UT	Total Coverage	Percentage Coverage against the estimated population	HIV Testing (Lakh)	Total positive detected	Total linked to ART	ART Linkage (%)
Andhra Pradesh	30,000	57.31	0.17	15	3	20
Assam	15,000	60.00	0.05	17	2	12
Bihar	10,000	66.67	0.02	2	2	100
Chandigarh	10,000	65.23	0.04	4	3	75
Chhattisgarh	40,000	64.52	0.11	19	11	58
Delhi	35,000	58.33	0.06	4	4	100
Goa	10,000	43.48	0.02	0	0	0
Gujarat	55,000	45.83	0.08	4	4	100
Haryana	35,000	≥95	0.03	3	3	100
Himachal Pradesh	10,000	71.43	0.02	0	0	0
Jammu and Kashmir	35,000	≥95	0.16	20	18	90
Ladakh						
Jharkhand	24,000	68.57	0.04	1	1	100
Karnataka	80,000	94.12	0.11	10	9	90
Kerala	50,000	≥95	0.08	29	25	86
Madhya Pradesh	57,061	67.13	0.21	18	13	72
Maharashtra	1,65,000	80.49	0.41	43	41	95
Nagaland	10,000	≥95	0.02	6	4	67
Odisha	20,000	≥95	0.08	6	4	67
Punjab	25,000	62.20	0.10	24	22	92
Rajasthan	20,000	52.16	0.04	5	6	120
Tamil Nadu	40,000	85.11	0.11	9	8	89
Telangana	52,900	≥95	0.03	1	2	200
Tripura	5,000	≥95	0.01	5	2	40
Uttar Pradesh	65,000	90.28	0.19	17	17	100
Uttarakhand	40,000	≥95	0.08	10	10	100
West Bengal	55,000	91.67	0.11	7	7	100
<b>India</b>	<b>9,93,961</b>	<b>49.70</b>	<b>2.40</b>	<b>279</b>	<b>221</b>	<b>79.2</b>

<sup>l</sup>No intervention in Andaman and Nicobar Island, Arunachal Pradesh, Dadra and Nagar Haveli and Daman and Diu, Lakshadweep, Manipur, Meghalaya, Mizoram, Puducherry, and Sikkim

<sup>m</sup>In few States, more positive were linked then the diagnosed which may be because of cases diagnosed in previous year being linked in current year


## 5.9 Opioid Substitution Therapy

NACO has adopted Opioid Substitution Therapy (OST) as a harm reduction strategy to prevent HIV infection among the IDU since 2007. OST programme involves treating opioid-dependent IDU with a long-acting opioid agonist medication for a long duration of time through the sublingual route, which effectively minimizes craving and withdrawals, and thereby enables the IDUs to stop injecting drugs. OST has proved to be successful in reducing drug-related harms including HIV transmission. NACP provides OST as a “Directly Observed Treatment” in a clinic-based setting known as OST centre under the supervision of a Medical Officer. There are two different models of OST service delivery – NGO-based OST centres and

Collaborative or Public health facility-based OST centres.

As on March 2022, there were 187 OST centres in public health facilities and another 43 through NGO. As part of the TI Revamped strategy, 126 satellite OST centres have been set up to help de-congest the facilities having high client load and provide accessibility for clients in distant locations from the main centre. Low threshold approaches such as take-home dosing for stable clients and flexible timings have also been incorporated from 2021-22. The coverage of OST clients has been steadily increasing from 29,090 in 2018-19 to 42,586 in 2021-22 (Figure 29).

Figure 29. OST client's coverage, 2018-19 to 2021-22



Total clients on OST, out of the total IDU covered under the TI programme, has increased from 29 thousand (19% of the active population) in 2018-19 to

41 thousand (25% of the active population) in 2020-21 and then declined to around 31 thousand (17% of the active population) in 2021-22 (Table 19).

Table 19. IDU under TI and on-OST, 2018-19 to 2021-22

Year	Number of TI	Active population	On OST
2018-19	349	1,49,726	29,090
2019-20	343	1,67,139	36,445
2020-21	373	1,67,078	41,215
2021-22	390	1,79,341	42,586

There are more than 100 satellite OST centres linked to the main OST centres. After initiation of the OST at the main OST centre, the clients as per their preferences are linked to the nearest satellite OST

centre and are provided OST. Regular follow-ups and check-ups of clients are done periodically at the main OST centre.

## 5.10 Prison Interventions

To achieve the SDG-3 global commitment of eliminating HIV/AIDS by 2030, NACO through respective SACS and in collaboration with State Prisons Departments (SPD) and departments of Women and Child Development (WCD) has been implementing HIV and TB interventions in a phased manner across the country since 2017. Significant progress has been made since Phase-I where HIV counselling and testing services were carried out in a

mission mode approach to saturate the coverage and achieve the First 95. The number of prisons covered has increased from 805 prisons in 2019-20 to 1150 in 2021-22 (Figure 30). Around 7 lakh inmates (29% of the total inmates) were covered in 2021-22. A total number of 2,886 HIV-positive inmates were identified and 82% of them were linked to ART centres in 2021-22 (Table 20).

Figure 30. Number of Prisons implementing HIV intervention, 2018-19 to 2021-22




Table 20. Prison inmates tested for HIV, diagnosed HIV positive and linked to ART, 2018-19 to 2021-22

Indicators	2018-19	2019-20	2020-21	2021-22
Inmates covered	4,12,500	4,13,572	9,06,806	7,08,544
Tested	2,78,705	2,77,015	4,79,880	6,56,749
HIV positive	1,330	1,728	2,122	2,886
Linked to ART	1,050	1,259	1,814	2,362

## 5.11 Link Workers Scheme

The Link Workers Scheme (LWS) is implemented to cover HRG and other vulnerable populations in rural areas. This scheme envisages the creation of demand for various HIV/AIDS-related services, linking the target population to existing services, creation of an enabling and stigma-free environment, and increasing access to information, and services by linking them to other departments/programmes through Accredited Social Health Activist (ASHA) volunteers, Anganwadi workers, Panchayat heads, etc. It may be noted that the scheme itself does not create any service delivery points. Apart from the rural

HRG, other vulnerable populations such as antenatal mothers, spouses, and partners of HRG, migrants & truckers, and youth, persons having TB, and PLHIV are covered under the programme. LWS is placed in high-risk or vulnerable districts considering the presence of HRG, migration pattern, PLHIV burden etc. One LWS districts cover approximately 60-100 villages. In the last five years, there is an increasing trend in the number of districts covered under the programme. This has also led to an increase in the coverage of the total population in the rural villages (Figure 31, Table 21).

Figure 31. LWS districts and population covered by the scheme, 2017-18 to 2021-22




Table 21. Coverage of population under LWS, 2017-18 to 2021-22

Typology	Coverage					Total tested for HIV					The number of positives detected					Number of HIV +ve linked to ART Centre				
	2017-18	2018-19	2019-20	2020-21	2021-22	2017-18	2018-19	2019-20	2020-21	2021-22	2017-18	2018-19	2019-20	2020-21	2021-22	2017-18	2018-19	2019-20	2020-21	2021-22
FSW	67,470	50,311	65,699	69411	78,528	57,454	37,077	51,692	57,292	63652	110	132	113	158	64	103	127	109	148	
IDU	4,106	4,121	4,564	5770	10,412	3,696	3,696	4,234	4,603	7648	107	178	123	598	30	92	163	113	560	
MSM	7,247	5,100	7,611	9850	17,438	5,672	3,373	5,126	7,298	8835	18	43	37	51	15	17	40	35	43	
H/TG	297	226	471	642	1,047	122	139	313	435	634	3	5	7	5	6	2	5	7	5	
Migrant	610,007	501,979	477,812	520985	594,729	310,956	278,341	287,763	276,957	342237	500	494	372	463	442	467	463	347	444	
Trucker	98,547	78,772	97,539	105600	136,551	60,600	53,598	66,036	60,695	74097	88	117	79	116	69	82	110	71	107	
OVP	641,816	644,253	717,973	726303	797,957	320,897	375,968	420,402	363,878	429297	719	915	583	849	469	640	838	541	813	
TB Cases	13,740	12,559	20,241	61132	17,439	9,317	8,935	16,214	41,350	11091	55	51	12	25	21	49	31	11	19	
ANC	154,349	146,981	193,795	151561	182,478	136,134	126,559	174,690	133,853	159010	65	94	89	108	65	63	90	84	106	
PLHIV	23,907	21,637	33,511	42091	41,822	-	-	-	-	-	-	-	-	-	-	-	-	-	-	



A large, stylized red ribbon graphic that loops from the top right, crosses itself, and extends diagonally towards the bottom left, set against a yellow background with faint concentric circles.

6.

MANAGEMENT  
OF SEXUALLY  
TRANSMITTED  
INFECTIONS/  
REPRODUCTIVE  
TRACT  
INFECTIONS

# Management of Sexually Transmitted Infections/ Reproductive Tract Infections


## 6.1 Background

Sexually Transmitted Infections (STI) are indicative of ongoing unprotected high-risk sexual intercourse<sup>9</sup>. For areas where HIV infection is not well established, the high prevalence of STI is an early warning of the epidemic potential of HIV from sexual transmission. Besides, one of the STI, Syphilis is of particular concern for maternal and child health given the commitment toward the elimination of congenital syphilis. Given the association with STI with many of the public health priorities, WHO in its global health sector strategy on STI (2016–2021) has linked STI surveillance to report the progress on four Sustainable Development Goals (SDGs) of neonatal

and under-5 mortality (SDG 3.2), ending of AIDS epidemic (SDG 3.3), universal access to sexual and reproductive health (SDG 3.7) and universal health coverage including vaccines for all (SDG 3.8)<sup>10</sup>.

Management of STI/Reproductive Tract Infections (RTI) is a focus under NACP since its first phase. NACP Phase-V reinforces the focus on STI management by including it as one of the five high-level goals. Goal 4 calls for the promotion of universal access to quality STI/RTI services to at-risk and vulnerable populations through a ten-prong strategy (Figure 31).

*Figure 31. Promote universal access to quality STI/RTI services to at-risk and vulnerable: Strategy at a glance*



## 6.2 Service delivery model

STI/ RTI services under NACP in the country following syndromic management approach are delivered through a network of Designated STI/RTI Clinics (DSRC, branded as Suraksha Clinics), primarily co-located in obstetrics & gynaecology and skin & venereology clinics, at district and sub-district level under NACP. Besides, under the NGO/ CBO-managed targeted interventions, STI/RTI services are provided to high-risk groups and bridge populations through STI clinics and a network of preferred private providers.


The services below the district/sub-district level are provided at Community Health Centres (CHC), Primary Health Centres (PHC) and Health & Wellness Centres (HWC) under National Health Mission (NHM).

NACP Phase-V calls for maintaining the existing DSRC models while augmenting its role to anchor newer initiatives like Sampoorana Suraksha Strategy

and integrated service delivery tailored to the local contexts. As a cross-cutting facility, the DSRC, in its Sampoorana Suraksha avatar, will evolve into an integrated facility anchoring the country's progress on the prevention of new infections, reduction of AIDS-related mortality, elimination of vertical transmission and promotion of access to STI/RTI services.

There were 1,184 DSRC operational under NACP as of March 2022 (Figure 32). Approximately, 86% of these DSRCs are in 19 States/UT – Tamil Nadu (157), Uttar Pradesh (115), Maharashtra (80), Gujarat (66), Madhya Pradesh (66), Andhra Pradesh (55), Karnataka (54), Rajasthan (53), Telangana (50), West Bengal (48), Bihar (44), Odisha (40), Chhattisgarh (31), Haryana (31), Punjab (31), Assam (28), Delhi (28), Jharkhand (28) and Uttarakhand (27). In Uttar Pradesh, 17 new DSRC were opened during 2021-22 taking the total number of operational DSRC to 115 in the State.

Figure 32. States/UT-wise distribution of NACO-supported DSRC, March 2022



## 6.3 STI/RTI cases managed

In 2021-22, around 68.50 lakh visits for the management of STI/RTI episodes were made through

1,184 DSRC and 1,512 TI under NACP.

No DSRC in Lakshadweep


## Visits to DSRC for STI episodes management

A total number of 50.66 lakh visits were reported to seek various STI/RTI services in 2021-22 with a national average of 15 client visits per day per DSRC<sup>a</sup>. More than 60% of these visits were by females while another one-third were reported to be males. The footfall of Hijra & Transgender (H/TG) people in DSRC to access STI/RTI services was reported to be less than 1%<sup>b</sup>.

Overall, around 7% of the total visits were from people in the age group of less than 20 years while another 20% were among 20-24 years<sup>a</sup>. The rest of

the visits were among people aged 25 years or older including 17% among those aged 45 years or higher) (Figure 33). The age-wise distribution varied by gender. While visits by those in the age group of 25-44 years ranged between 56% to 60% across the genders, 20% of the total visits among males was by those 45 years or older in comparison to 10% among H/TG people. Around 30% of the visits among females and H/TG people were by those aged 24 years or younger in comparison to 22% among males.


Figure 33. Age-wise distributions of visits to DSRC, 2021-22



Ten States/UT reported higher or equivalent per day per DSRC visits in comparison to the national average. These states were Telangana (32), Maharashtra (26), Uttar Pradesh (25), Madhya Pradesh (23), Odisha (20), Bihar (19), Punjab (19), Chhattisgarh (18), Haryana (15) and Karnataka (15)

(Figure 34). Less than 5 visits per day per DSRC were reported in 10 States/UTs - Jharkhand, Kerala, Meghalaya, Arunachal Pradesh, Jammu & Kashmir, Nagaland, Manipur, Chandigarh, Dadra & Nagar Haveli Daman & Diu and Sikkim (Figure 34).

Figure 34. Average visits per day per DSRC by State/UT, 2021-22



<sup>a</sup>Total number of working days considered to be 288 in FY 2021-22


<sup>b</sup>The data on gender-wise distribution was not available for the States of UP & Telangana for the reporting period of 2021-22

<sup>c</sup>The data on age-wise distribution was not available from the states of Delhi, Kerala, Madhya Pradesh, Nagaland, Punjab, Telangana, UP

More than 50% of the total client visits were reported from 5 States – Uttar Pradesh (16%), Tamil Nadu

(12%), Maharashtra (11%), Telangana (9%) and Madhya Pradesh (9%). (Figure 35)

Figure 35. Distribution (in %) of total clinic visits made by State/UT, 2021-22




## Syndromic Diagnosis of STI/RTI at DSRC

Syndromic management is an approach to the treatment of symptoms and signs of STI and RTI mostly based on the micro-organisms commonly responsible for these syndromes. The STI/RTI syndromes reported in males are urethral discharge (UD), anorectal discharge (ARD), inguinal bubo (IB), painful scrotal swelling (PSS), genital ulcer disease – non-herpetic (GUD – NH) and genital ulcer disease–herpetic (GUD–H) while STI/RTI syndromes reported in females are vagino-cervical discharge (VCD), anorectal discharge (ARD), inguinal bubo (IB), lower abdominal pain (LAP), genital ulcer disease – non-herpetic (GUD – NH) and genital ulcer disease

–herpetic (GUD – H). The clients accessing services from DSRCs are also screened for genital warts and other local STI & RTI.

More than 2.5 lakh syndromic diagnosis were reported among males in 2021-22. Almost two-thirds (65%) of the total syndromes reported in males were UD followed by GUD – H (13%) and GUD-NH (11%). Around females, around 12.5 lakh STI/RTI syndromes were reported with almost two-thirds (63%) as VCD while another one-third (34%) were diagnosed with LAP (Figure 36).

Figure 36. Distribution of syndromic diagnosis (in %) at DSRC, 2021-22






## Management of Sexually Transmitted Infections/Reproductive Tract Infections

UD remained the predominant diagnosed syndrome among male clients with the highest proportion reported in Punjab and DNH&DD (89%), Tripura (79%), Madhya Pradesh (77%) and Assam (75%). However, Chandigarh (68%), Delhi (42%) and Kerala (35%) reported GUD -H as the predominant

diagnosed syndrome in comparison to UD. Andaman & Nicobar Islands, Puducherry and Jammu & Kashmir reported PSS, GUD-NH & IB as the predominantly diagnosed syndrome respectively (Figure 37, Table 22).

Figure 37. State/UT-wise distribution of STI/RTI syndromes (in percentage) among males, 2021 – 22



VCD remained the predominant diagnosed syndrome among female clients with the highest proportion reported in Mizoram (91%), followed by Tripura (80%), Goa (79%), Maharashtra (77%), Kerala (73%) and Andhra Pradesh (73%). However, Punjab

(94%), Manipur (48%) and Jammu & Kashmir (46%) reported LAP as the predominant diagnosed syndrome in comparison to VCD. (Figure 38, Table 22).

Figure 38. State/UT-wise distribution of STI/RTI syndromes among females (in percentage), 2021–22




Table 22. State/UT-wise distribution of STI/RTI syndromes among males and females (in percentage), 2021-22

State/UT	Male						Female					
	UD	ARD	IB	PSS	GUD-NH	GUD - H	VCD	ARD	IB	LAP	GUD - NH	GUD - H
ANI	11	0%	2%	58%	2%	27%	54%	0%	0%	32%	10%	4%
Andhra Pradesh	48	0%	0%	10%	12%	29%	73%	0%	0%	26%	1%	1%
Arunachal Pradesh	74	1%	0%	3%	12%	9%	60%	1%	0%	27%	7%	5%
Assam	75	1%	0%	8%	8%	7%	68%	0%	0%	30%	1%	1%
Bihar	54	2%	4%	12%	17%	12%	59%	0%	1%	37%	2%	2%
Chandigarh	31	0%	0%	0%	1%	68%	63%	0%	0%	34%	0%	3%
Chhattisgarh	43	3%	3%	15%	24%	12%	51%	0%	1%	41%	4%	2%
DNH&DD	89	0%	0%	0%	1%	10%	68%	0%	0%	31%	0%	1%
Delhi	33	0%	6%	2%	18%	42%	59%	0%	1%	38%	1%	1%
Goa	44	0%	4%	3%	31%	18%	79%	0%	0%	19%	1%	1%
Gujarat	61	2%	3%	5%	10%	19%	69%	0%	0%	27%	1%	2%
Haryana	52	9%	1%	8%	11%	19%	52%	0%	0%	47%	0%	1%
Himachal Pradesh	41	2%	3%	8%	15%	31%	57%	0%	0%	41%	0%	1%
Jammu & Kashmir	28	12%	29%	27%	2%	2%	38%	10%	0%	46%	4%	1%
Ladakh												
Jharkhand	68	1%	22%	2%	4%	4%	65%	1%	0%	29%	3%	2%
Karnataka	60	1%	2%	9%	13%	15%	64%	0%	0%	29%	4%	2%
Kerala	33	0%	2%	8%	22%	35%	73%	0%	0%	24%	0%	2%
Madhya Pradesh	77	2%	0%	5%	11%	5%	66%	0%	0%	30%	2%	1%
Maharashtra	59	2%	1%	2%	14%	22%	77%	0%	0%	21%	1%	1%
Manipur	55	0%	0%	3%	16%	27%	42%	0%	8%	48%	0%	1%
Meghalaya	70	0%	3%	1%	15%	11%	69%	0%	0%	28%	2%	1%
Mizoram	71	1%	3%	2%	11%	12%	91%	0%	0%	7%	1%	1%
Nagaland	60	13%	2%	6%	14%	5%	69%	4%	0%	23%	3%	1%
Odisha	59	3%	2%	13%	11%	13%	63%	0%	1%	29%	3%	3%
Puducherry	14	0%	2%	0%	65%	20%	51%	0%	0%	46%	2%	1%
Punjab	89	2%	3%	5%	0%	0%	5%	0%	0%	94%	0%	0%
Rajasthan	50	4%	1%	4%	18%	23%	59%	0%	0%	39%	1%	1%
Sikkim	53	0%	0%	0%	27%	20%	64%	0%	0%	30%	3%	2%
Tamil Nadu	55	1%	2%	1%	21%	20%	69%	0%	0%	28%	2%	2%
Telangana	74	1%	1%	6%	3%	13%	65%	0%	0%	32%	1%	2%
Tripura	79	0%	1%	15%	4%	1%	80%	0%	0%	18%	1%	1%
Uttar Pradesh	71	4%	1%	9%	8%	7%	56%	0%	0%	41%	1%	1%
Uttarakhand	74	2%	2%	7%	6%	9%	61%	0%	0%	37%	1%	1%
West Bengal	63	3%	1%	1%	11%	22%	66%	0%	0%	32%	1%	1%
<b>India</b>	<b>65</b>	<b>3%</b>	<b>2%</b>	<b>8%</b>	<b>11%</b>	<b>13%</b>	<b>62%</b>	<b>0%</b>	<b>0%</b>	<b>34%</b>	<b>2%</b>	<b>1%</b>

## Laboratory Diagnosis at DSRC

A total number of 30.07 lakhs RPR tests were conducted for syphilis screening at DSRC. The test with a titer value  $\geq 1:8$  is considered reactive. The test positivity (reactivity) was reported to be 1.00% among males and 0.28% among females. It was reported higher in the H/TG population and was around 9%. The overall RPR positivity was reported as 0.60% at the national level (Table 23). The overall

RPR positivity is reported to be increased in comparison to the previous year (an RPR positivity of 0.49% was reported in 2020 -21). Moreover, the RPR positivity was reported to be higher than 1% in the states of Meghalaya, Kerala, Sikkim, Chandigarh, Arunachal Pradesh, Dadar & Nagar Haveli and Daman & Diu, Puducherry, Gujarat, Delhi, Nagaland, West Bengal, and Goa (Table 24).

Table 23. Laboratory Diagnosis of Syphilis, 2021-22

Indicator	Male	Female	H/TG	Total
Total number of RPR tests conducted	10,79,488	19,05,284	22,706	30,07,478
Total number of RPR tested reactive ( $\geq 1:8$ )	10,798	5,273	2,061	18,132
% RPR Positivity	1.00	0.28	9.08	0.60

## Management of Sexually Transmitted Infections/Reproductive Tract Infections

Table 24. RPR Positivity in States & UTs reported in DSRCs, FY 2021-22

Indicator	Male	Female	H/TG*	Total
ANI	0.47%	0.17%	0.00%^	0.31%
Andhra Pradesh	0.54%	0.09%	0.02%^	0.22%
Arunachal Pradesh	5.28%	2.53%	100.00% ^	2.99%
Assam	2.77%	0.28%	0.00%	0.86%
Bihar	0.25%	0.05%	0.00%^	0.08%
Chandigarh	10.48%	1.09%	NA	3.28%
Chhattisgarh	0.80%	0.23%	4.41%	0.48%
DNH & DD	4.96%	1.61%	0.00%^	2.70%
Delhi	3.94%	0.50%	7.89%^	1.52%
Goa	8.82%	0.26%	NA	1.07%
Gujarat	3.02%	0.76%	0.89%	1.75%
Haryana	0.84%	0.12%	0.00%^	0.29%
Himachal Pradesh	0.40%	0.06%	8.57%^	0.19%
J & K	1.03%	0.09%	100.00%^	0.28%
Ladakh				
Jharkhand	0.42%	0.14%	100.00%^	0.26%
Karnataka	0.84%	0.22%	1.51%	0.43%
Kerala	7.80%	1.48%	13.04%	4.03%
Madhya Pradesh	0.80%	0.16%	2.80%	0.33%
Maharashtra	0.79%	0.20%	7.21%	0.44%
Manipur	2.33%	0.15%	5.26%^	0.83%
Meghalaya	7.18%	5.59%	100.00%^	6.37%
Mizoram	0.49%	0.19%	NA	0.24%
Nagaland	1.05%	1.60%	0.00%^	1.32%
Odisha	0.68%	0.25%	1.12%	0.49%
Puducherry	2.61%	0.95%	10.61%	1.79%
Punjab	0.95%	0.18%	0.84%	0.49%
Rajasthan	1.63%	0.44%	0.00%^	0.75%
Sikkim	7.92%	2.07%	NA	3.59%
Tamil Nadu	0.57%	0.14%	27.75%	0.71%
Telangana	1.57%	0.61%	7.14%	0.91%
Tripura	0.32%	0.14%	0.00%^	0.21%
Uttar Pradesh	0.37%	0.19%	4.26%	0.29%
Uttarakhand	1.01%	0.06%	NA	0.29%
West Bengal	2.00%	0.66%	21.35%^	1.10%
<b>India</b>	<b>1.00%</b>	<b>0.28%</b>	<b>9.08%</b>	<b>0.60%</b>

## STI/RTI services uptake in Targeted Intervention

The STI/RTI services to key populations are provided through a network of 1512 NGO/CBO managed Targeted Interventions. The range of services includes safer sexual counselling, assessment of clients and syndromic management of STI/RTI in a community-friendly setting, including referrals and linkages for health services. These services are provided either through static clinics at TI sites or a network of preferred providers engaged under the TI programme.

A total number of 10.69 lakh RPR tests were conducted in FSW in FY 2021-2022 with a test positivity of 0.04% (Table 25). The States/UTs reporting high test positivity were Meghalaya (1.07%) and Arunachal Pradesh (0.51%).

A test positivity of 0.24% was reported in 4.01 lakh

RPR tests conducted among MSM during the reporting period (Table 25). The state of Arunachal Pradesh (1.86%) and Chhattisgarh (1.34%) reported a test positivity greater than 1%.

A total number of 0.78 lakh RPR tests were conducted among TGH persons, and the test positivity was reported to be 0.38% (Table 25). The states reporting a test positivity greater than 1% were Chhattisgarh (1.90%), Manipur (1.42%), Punjab (1.39%), and Odisha (1.32%).

A total number of 2.3 lakh RPR tests were conducted and a test positivity of 0.07% was reported in the reporting period (Table 25). The state of Goa (3.45%) and Chhattisgarh (1.50%) reported a test positivity greater than 1%.

Table 25. Syphilis testing under TI Programme, 2021-22

HRG	Total number of RPR tests conducted	Total positive	% RPR Positivity
FSW	10,69,110	19,05,284	30,07,478
MSM	4,01,779	5,273	18,132
H/TG people	78,290	0.28	0.60
IDU	2,30,086		



A large, thick red ribbon is draped across the right side of the page, forming a loop at the top and extending downwards. The background is a solid yellow color with faint, concentric circles radiating from the center.

# 7.

## HIV COUNSELING AND TESTING SERVICES

# HIV Counseling and Testing Services


## 7.1 Background

Anchoring the national AIDS response towards the attainment of the 2030 goal of ending AIDS as a public health threat, NACP Phase-V has ambitious agendas for reducing annual new HIV infections and AIDS-related mortalities by 80%, dual elimination of vertical transmission, promotion of universal access to quality STI/RTI services to at-risk and vulnerable populations and elimination of HIV/AIDS-related stigma. The full realization of this ambitious agenda will require having around 23 lakh PLHIV with known HIV status, around 21.75 lakh PLHIV on anti-retroviral treatment and around 20.50 lakh PLHIV with suppressed viral load. Early detection of infected

people through quality HIV counselling and testing (HCT) services becomes the cornerstone for the attainment of envisioned agendas.

NACP Phase-V directly calls for six strategies for fast-tracking HCT services (figure 39). While these strategies have been reflected under goal 2 i.e., reducing AIDS-related mortalities by 80%; successful implementation of these strategies will also directly drive the progress on goal 1 of reductions in new infections and goal 3 of elimination of vertical transmission of HIV and Syphilis.

*Figure 39. HCTS-related strategies under NACP Phase-V*



## 7.2 HCT Facilities


NACP Phase-V not only calls for maintaining the existing models of HCT services and expanding through strategic scale-up and efficient approaches but also advocates for adapting evidence-backed newer technologies to supplement existing models. In line with the recommended strategies, the offering of HCT services continues through a mix-model of stand-alone facilities, mobile vans, facility-integrated facilities (in both government and private sectors) and community-based screening (CBS).

Initiated in 1997 as stand-alone Voluntary Counselling Testing Centres (VCTC) and Prevention of Parent to Child transmission of HIV (PPTCT) Centres in 2002, the facilities evolved into ICTC in 2006. Stand-alone ICTC (SA-ICT) facilities are in both public as well as the private health sector. Later, the HCT facilities were expanded through the launch and expansion of facility-integrated ICTC (FI-ICTC). FI-ICTC in public health facilities has

fast-tracked the reach to the most granular level taking HCT services to the doorstep of the target population. From 2018-19 onwards, HCT services were further expanded through community-based HIV screening (CBS) centres (Figure 40).

Breaking the silos, and building synergies is a key guiding principle of the NACP Phase-V. This asks for coordinated actions, through single window delivery systems along with functional and measurable referrals and linkages, within NACP and across national health programmes and related sectors, for efficient service delivery. Stand-alone integrated counselling and testing centres (SA-ICTC) will be central to 'Break the silos, build synergies', offering not only the HCT services but playing a larger role across prevention-testing-treatment care continuum under newer initiatives like Sampoorna Suraksha Strategy (SSS), One Stop Centres.

Figure 40. Scale up of HCTS Facilities (in thousand), 2012-13 to 2021-22



The current model of HCT facilities is broadly categorised into screening and confirmatory facilities. In screening facilities, Whole Blood Finger Prick Tests (WBFPT) are used to screen for HIV infection. FI-ICTC and CBS centres are screening facilities. All reactive cases identified at screening facilities are referred to confirmatory facilities to confirm HIV diagnosis. Confirmatory Facilities, which include all SA-ICTC and mobile ICTC, undertake tests using

three separate kits with different principles to confirm HIV diagnosis. As on March 2022, there were 34,607 HCTS facilities including 5,408 confirmatory facilities.

The sub-populations which are more vulnerable or practice high-risk behaviour or have higher HIV prevalence levels are the target group for HCT services in the country. These sub-populations fall

under the two umbrella categories of 'at-risk clients' and 'pregnant women.' The HCT uptake for 'at-risk clients' is discussed in the current chapter in subse-


quent sections while the details related to pregnant women are covered in chapter ten of elimination of vertical transmission of HIV and Syphilis.

## 7.3 HCT services uptake among 'at-risk' population

Around 2.35 crore (93% of the target) HIV counselling and testing among the 'at-risk' population was done in 2021-22. While this is around 30% higher than the testing done in 2020-21 when the uptake was significantly affected because of the COVID-19 pandemic, still it is lower than the performance in 2019-20 (pre-COVID-19 year) when almost 3 crore testing was done (Figure 41 a).

There were almost 7.51 lakh confirmed HIV-positive test results in the last five years. Though testing was highest in 2019-20, the maximum number of HIV-positive test results were reported in 2017-18. The seropositivity also declined from 0.87% in 2017-18 to 0.52% (0.59% among males, 0.42% among females and 1.1% among H/TG people) in 2021-22 (Figure 41b).

Figure 41. HCT services uptake, 2017-18 to 2021-22



Maharashtra has contributed the most HIV tests in FY 2021-22, accounting for 14% of all tests, followed by Tamil Nadu (13%), Karnataka (10%), West Bengal (7%), Gujarat (6%) and Andhra Pradesh (6%). Rajasthan, Uttar Pradesh, Madhya Pradesh, and Odisha contributed to 5% each in total testing for 2021-22. Nearly 76% of all HIV tests performed on 'at-risk clients' were undertaken in these 10 States (Table 26).


In terms of HIV positive, Maharashtra and Andhra Pradesh had the highest number of HIV positives, accounting for 11% of all HIV sero-positives in 2021-22. Other States with a higher contribution to the national total in terms of HIV-diagnosed cases were Uttar Pradesh (9%), Karnataka (9%), Telangana (7%), Punjab (6%), Bihar (6%), Gujarat (5%), Tamil Nadu (5%) and Rajasthan (4%). The rest of the states contributed 26% in total (Table 26).

Table 26 State/UT-wise HCT facility and service uptake, 2021-22

State/UT	FI-ICTC (Govt & PPP) & CBS	SA-ICTC	Total ICTC	Tested for HIV	HIV Positives	HIV sero-positivity (%)	Spouse/partner testing among positive	HIV sero-positivity (%) among spouse/partner
ANI	26	13	39	20,049	21	0.10	5	1
Andhra Pradesh	1,733	225	1,958	12,94,993	13,054	1.01	8,258	4,208
Arunachal Pradesh	108	39	147	16,492	68	0.41	27	13
Assam	326	109	435	2,22,627	2,156	0.97	830	230
Bihar	647	209	856	7,35,391	7,178	0.98	4,041	2,330
Chandigarh	26	12	38	75,459	472	0.63	165	71
Chhattisgarh	697	147	844	3,84,785	2,086	0.54	899	526
DNH & DD	20	5	25	38,628	44	0.11	26	9
Delhi	528	90	618	4,07,804	4,008	0.98	1,406	576
Goa	53	16	69	61,668	220	0.36	167	85
Gujarat	2,583	321	2,904	14,91,830	6,289	0.42	3,273	1,337
Haryana	626	117	743	5,87,946	3,708	0.63	1,416	766
Himachal Pradesh	126	49	175	2,02,084	354	0.18	218	129
Jammu and Kashmir	611	32	643	2,28,732	285	0.12	94	54
Ladakh	14	3	17	3,188	4	0.13	1	0
Jharkhand	293	66	359	2,39,254	1,172	0.49	584	373
Karnataka	2,901	473	3,374	22,70,566	10,617	0.47	3,679	1,628
Kerala	649	150	799	5,25,116	895	0.17	398	102
Lakshadweep	0	1	1	3,115	-	0.00	-	-
Madhya Pradesh	1,646	199	1,845	11,81,394	3,974	0.34	1,694	964
Maharashtra	4,095	565	4,660	33,97,052	14,082	0.41	7,426	4,047
Manipur	162	64	226	80,911	688	0.85	241	124
Meghalaya	188	34	222	49,331	737	1.49	181	145
Mizoram	120	41	161	55,606	1,564	2.81	777	312
Nagaland	196	73	269	92,297	1,271	1.38	726	398
Odisha	446	214	660	10,79,861	2,195	0.20	587	219
Puducherry	69	12	81	92,278	147	0.16	107	33
Punjab	729	116	845	7,61,435	8,009	1.05	2,003	864
Rajasthan	2,521	184	2,705	12,46,556	5,242	0.42	2,663	1,628
Sikkim	32	13	45	18,622	53	0.28	3	1
Tamil Nadu	2,180	807	2,987	29,78,786	5,921	0.20	2,661	905
Telangana	1,020	164	1,184	5,55,742	9,102	1.64	3,489	1,899
Tripura	163	24	187	1,03,819	1,092	1.05	102	29
Uttar Pradesh	2,832	456	3,288	12,05,876	10,889	0.90	5,034	3,511
Uttarakhand	132	51	183	1,48,219	822	0.55	204	75
West Bengal	701	314	1,015	16,66,056	4,169	0.25	2,497	1,195
<b>India</b>	<b>29,199</b>	<b>5,408</b>	<b>34,607</b>	<b>2,35,23,568</b>	<b>1,22,588</b>	<b>0.52</b>	<b>55,882</b>	<b>28,787</b>




Figure 42. State/UT-wise distribution (in %) of total HCT services uptake and positive test results, 2021-22<sup>r</sup>



Nationally, there were 17 tests per 1000 population in 2021-22 ranging between 5 to 62 across States/UT (Figure 43). In the high prevalence States of Mizoram and Nagaland, there were more than 40 tests per 1000 population. Manipur, another State with an adult HIV prevalence of more than 1%, had 26 tests for every 1000 population. Among the erstwhile high prevalence southern and western States, Tamil Nadu had 39 tests per 1000 population followed by 34 in

Karnataka, 27 in Maharashtra, 25 in Andhra Pradesh and 15 in Telangana. By and large, States with higher HIV prevalence, currently or in the past, has higher tests per 1000 population. The lowest number of HIV tests per 1000 population is noted in Bihar and Uttar Pradesh. Uttar Pradesh has the fourth largest size of PLHIV while Bihar has the seventh. Relatively low HIV tests in these States draw attention to understanding context and implications in totality.


Figure 43. HIV tests per 1000 population by States/UT, 2021-22<sup>s</sup>



<sup>r</sup>AP refers to Andhra Pradesh, MP refers to Madhya Pradesh and UP refers to Uttar Pradesh, ANI refers to Andaman and Nicobar  
<sup>s</sup>Population size informed by HIV Estimations 2021. Lakshadweep not included in HIV Estimations in view of lack of surveillance sites.

While the maximum number of HIV testing and positive results were from States in western, southern, eastern, and central India, the seropositivity had a different picture. Overall, seven States (including four from northeast India) recorded seropositivity of 1% or more in 2021-22. Mizoram is the only State with HIV seropositivity of more than 2%. Other States with seropositivity of more than 1% included Telangana (1.64%), Meghalaya (1.49%), Nagaland (1.38%), Tripura (1.05%), Punjab (1.05%), Andhra Pradesh (1.01%), Delhi (0.98%), Bihar (0.98%), Assam (0.97%), Uttar Pradesh (0.90%), Manipur (0.85%), Haryana (0.63%), Chandigarh (0.63%), Uttarakhand (0.55%), Chhattisgarh (0.54%), India (0.52%), Jharkhand (0.49%), Karnataka (0.47%), Gujarat (0.42%), Rajasthan (0.42%), Maharashtra (0.41%), Arunachal Pradesh (0.41%), Goa (0.36%), Madhya Pradesh (0.34%), Sikkim (0.28%), West Bengal (0.25%), Odisha (0.20%), Tamil Nadu (0.20%), Himachal Pradesh (0.18%), Kerala (0.17%), Puducherry (0.16%), Ladakh (0.13%), Jammu & Kashmir (0.12%), DNH&DD (0.11%), ANI (0.10%), and Andhra Pradesh (1.01%). Sero-positivity in the range of 0.85% to <1% was noted in States/UT of Delhi, Bihar, Assam, Uttar Pradesh, and Manipur. Haryana, Chandigarh, Uttarakhand, and Chhattisgarh were other States/UT with HIV seropositivity among at-risk populations higher than the national average. Erstwhile high prevalence of Maharashtra and Karnataka recorded seropositivity in the range of 0.41% to 0.47% while Tamil Nadu had a seropositivity of 0.20% (Figure 44).

Figure 44. State/UT-wise seropositivity (in %), 2021-22




## 7.4 Spouse/partner testing

NACP Phase-V calls for augmenting the existing HCT models with efficient approaches for active case findings. Index testing and repeat screening/testing among discordant couples promoting early detection of undiagnosed infections is integral to this strategy. Due to the high risk of HIV transmission from index PLHIV to their sexual and sharing spouses/ partner, spouse or partner notification has been included in the essential packages under NACP.

Nationally, spouse /partner testing among HIV-positive cases was reported at around 46% in 2020-21. HIV seropositivity among tested spouses/partners was around 52%, by and large, the same as that noted in the last five years.

Wide variation was noted by States/UT in terms of proportion tested and ranged between 6% to 76%. Some States/UT such as Goa, Puducherry, Andhra Pradesh, Himachal Pradesh, and West Bengal reported more than 60% spouse/partner testing while few like Jammu & Kashmir (33%), Punjab (28%), Odisha (27%), Ladakh (25%), Uttarakhand (25%), Meghalaya (25%), Andaman & Nicobar Islands (24%), Tripura (9%), and Sikkim (6%) had one third or lower proportion of spouse/partners tested for HIV. HIV seropositivity was at-least 20% among the partners/spouse tested except for that in UT of Ladakh (0 %). In Meghalaya, with only around 25% testing among spouses/partners, seropositivity was as high as 80% (Figure 45).

Figure 45. HIV seropositivity among partners tested




## 7.5 Late diagnosis

HCT services aim to diagnose HIV cases as early as possible. Late diagnosis is detrimental to the attainment of NACP Phase-V objectives as people with low CD4 counts are more likely to transmit the virus, thus facilitating new infections. Also, a late diagnosis will result in PLHIV coming into the treatment programme with advanced AIDS-related illness and thus causing a potential scenario of AIDS-related mortality.

diagnosis as cases presenting for HIV care with a CD4 count below 350 cells per cubic mm<sup>11</sup>. Overall, in general, around 61% to 65% of PLHIV had a CD4 count of 350 cells per mm<sup>3</sup> or lower in baseline CD4 count at the time of registration at ART centres<sup>6</sup>. In 2021, around 61% of total PLHIV had a CD4 cell count of below 350 cells per mm<sup>3</sup>, with 35% below 200 cells per mm<sup>3</sup>. In general, the late diagnosis was more among males than among females (Figure 46).

UNAIDS Global AIDS Monitoring defines late

Figure 46. Late HIV diagnosis, 2017-2021



<sup>11</sup>As reported in Global AIDS Monitoring Portal



8.

# INITIATION AND RETENTION ON ART

# Initiation and Retention on ART


## 8.1 Background

The 'end of AIDS epidemic as a public health threat' asks for the attainment of viral suppression among 86% of PLHIV. With around 55% of PLHIV with viral load suppression in 2021-22, the country's progress is on-track, yet far from the envisioned targets. Recognising the need, NACP Phase-V aims to attain the target of 86% viral suppression by 2025 through strategies like (i) maintaining existing care, support, and treatment (CST) services models and expanding further in a sustainable manner, (ii) continued provisions of high-quality ARV through differentiated service delivery models improving access and retention to care, (iii) focus on rapid ART initiation and advanced HIV disease management augmenting quality of care, and (iv) addressing linkage loss at all level. The objective is to attain 95-95-95 HIV testing and treatment targets leading to 80% reductions in AIDS-related mortality by 2025.

Care, support, and treatment have been integral to

the AIDS response in India since the early years of NACP Phase-II. The provision of free Anti-Retroviral Therapy (ART) for People Living with HIV (PLHIV) under the NACP has been a pivotal decision in the fight against HIV/AIDS in the country. The Government of India launched free ART on 1st April 2004 at 8 centres under the second phase of the NACP. The programme has come a long way (Figure 47) and has witnessed several changes including the adoption of test and treat, introduction of viral load (VL) testing for monitoring of PLHIV on ART, dolutegravir-based regimens for treatment optimization, advanced disease management (ADM), implementation of patient-centric differentiated care models including multi-month dispensation (MMD), expansion of Link ART centre (LAC) and Community ART Refill groups (CARG). The aim is to ensure there is universal access to life-saving ART for all PLHIV, along with lifelong retention and sustained viral load suppression.

Figure 47. Evolution of ART under NACP





Under NACP Phase-V, PLHIV continues to have access to free diagnostic facilities; free first-line, second and third-line ART; prevention, diagnosis and management of opportunistic infections including management of Tuberculosis (TB) with daily anti-TB treatment through a single window approach. NACP Phase-V is committed to offering integrated service

delivery packages through establishing referrals and linkages in coordination with related national health programmes. NACO is also engaging with the private sector for setting up ART centres where every teaching college will have an ART centre providing ART services in line with the national guidelines.

## 8.2 Facilities


NACP Phase-V calls for maintaining existing care, support, and treatment (CST) service models along with expansion in a sustainable manner. The objective is to have 703 ART centres, 1400 Link ART Centres (LAC) and 400 Care and Support Centres (CSC) by 2025-26.

Over the years, the Service delivery mechanism for ART services has evolved into a three-tier system (Figure 48). As on March 2022, there were 664 ART centres including 85 ART-plus centres across the country; mostly located at medical colleges and district hospitals. These ART centres are fundamental to this service delivery mechanism. Efforts are also

being taken under NACP Phase-V to expand CST delivery points in a sustainable manner tapping the public and private sectors. In the last two years, more than 100 ART centres have been added. There were 553 ART centres providing ART in March 2020 which have been scaled up to 664 as on March 2022 (Figure 49).

The ART centres are mapped to 18 (11 Adult and 7 Paediatric) Centres of Excellence (CoE). In addition, there are 85 ART Plus centres at select teaching institutions for the timely initiation of the second and third lines of ART.

Figure 48. ART service delivery mechanism, March 2022



The PLHIV enter the CST services models through ART centres and are subsequently linked with LAC and CSC for decentralized dispensation/refilling, counselling and follow-ups. Currently, decentralization of services is provided through the

establishment of 1261 LAC/ LAC plus and 319 CSCs (including 9 funded by the State government) which facilitate access to essential services ultimately increasing treatment adherence and reducing stigma & discrimination.

## 8.3 PLHIV on ART


Overall, as on March 2022, around 14.50 lakh PLHIV were taking lifelong free antiretroviral (ARV) medicines from 664 ART centres supported by NACO. This works out to around 2,184 'Alive and on-ART' per centre. Around 7.36 lakh (51%) of 'Alive and on-ART' PLHIV were males, 7.08 lakh (49%) were females while a few (0.05 lakh) were hijra/ transgender (H/TG) population.

The preferred 1st line regimen is a fixed-dose combination of Tenofovir + Lamivudine + Dolutegravir (TLD) which is also the preferred regimen for post-exposure prophylaxis as per national guidelines on HIV care and treatment (2021). This is in line with the NACP Phase-V goal to reduce mortality by 80% through the continued provision of

high-quality ARVs. Overall, 7.5% (1.09 lakh) were on second-line ART while very few (around three thousand) were on the third line of ART.

The number of 'Alive and on-ART' PLHIV under NACO's supported facilities in March 2022 is almost 40% higher than the number in March 2017. The 'Test and Treat' policy was adopted in 2017. In the first year of the test and treat policy, the number of 'on-ART' PLHIV increased by almost 1.50 lakh on a year-to-year basis. The upward trend continued till 2020-21 which coincided with the COVID-19 pandemic. The momentum was regained in 2021-22 with a net gain of around 70 thousand in terms of 'on-ART' PLHIV.

Figure 49. Scale-up of ART facilities and PLHIV on ART at NACP facilities, 2005 to March 2022



Several PLHIV do avail ARV from private health care providers. To estimate the size of PLHIV availing ARV from the private sector, a study was undertaken in 2018. Under the study, ARV-wise sales data for the period 2013-17 was collected from the Association of Indian Origin Chemist and Distributors Pharma-soft tech. Only 2-drug or 3-drug combinations were considered to calculate the unique number of patients. With a response rate of 54%, it was estimated that PLHIV availing ARV from the private sector may range from 1,05,767 to 1,95,864. Based on this assessment, for all reporting purposes, it has

been assumed that 1,05,767 PLHIV are on ART in the private sector. This number has been considered fixed until better evidence about PLHIV taking ARV from the private sector emerges. To encourage reporting by the private sector, NACO has designed a simple quarterly reporting format for the sites that provide treatment services in the private sector which captures the number of patients accessing ART and VL services. The private practitioners are encouraged to share the details quarterly with SACS. Taking into account almost 1.06 lakh PLHIV taking ARV from the private sector, there were almost 15.56

lakh 'Alive and on-ART' PLHIV in India as of March 2022.

With around 2.58 lakh 'Alive and on-ART' PLHIV, Maharashtra has the highest number of on-ART PLHIV in the country followed by Andhra Pradesh (1.99 lakh), Karnataka (1.72 lakh) and Tamil Nadu (1.22 lakh). Uttar Pradesh, Telangana, Gujarat, Bihar, and Rajasthan were other States with 'Alive and on-ART' in the range of 50,000 to less than one lakh. Together, these 9 States account for more than 75% of the total 'Alive and on-ART' PLHIV in the country (Figure 50 a, Table 27).

On average, Telangana had 3,792 'Alive and on-ART'


PLHIV per ART centre, the highest in the country, followed by Andhra Pradesh (3,749). Delhi, Maharashtra, Chandigarh, Punjab, Karnataka, Bihar, West Bengal, and Tamil Nadu were other States with 'Alive and on-ART' PLHIV per ART centre higher than the national average. The average 'Alive and on-ART' PLHIV per ART centre in these States ranged between 2,217 in Tamil Nadu to 2,861 in Delhi. The average load was less than 1,000 'Alive and on-ART' PLHIV per ART centre in 10 States/UT including that of Tripura, Meghalaya, Mizoram, Nagaland, Himachal Pradesh, Uttarakhand, Sikkim, DNH&DD, Arunachal Pradesh, and ANI. The average ranged between 143 (ANI) to 933 (Tripura) in these States (Figure 50 b, Table 27).


## 8.4 ART initiation and retention

The Government of India launched "Test and Treat" on 28th April 2017. The introduction of the policy aimed for the rapid initiation of ART, including the offer of same-day initiation where there is no clinical contraindication. Besides, retention and adherence on-ART is critical to achieving and maintaining the status of adequate viral suppression for the prevention of opportunistic infections and maintaining a healthy life while also eliminating

chances of further transmission of the virus. Under NACP Phase-V, focus on rapid ART initiation, advanced HIV disease management and focus on adherence and retention on treatment augmenting the quality of care continue to be key priorities. The objective is to improve the survival and quality of life of the HIV-infected person at the individual level and to fast-track the country's response to achieve the "End of AIDS" at the population level.

Figure 50. PLHIV on ART, March 2022






The progress on ART initiation and retention has been demonstrated through indicators of (i) initiation of ART per 100 detections in ICTC centres, (ii) 12 months retention among PLHIV (in %), and (iii) lost-to-follow-up (LFU) per 100 PLHIV 'Alive and on-ART' (Figure 51). As evident, the initiation of ART for every 100 detections in ICTCs under the programme has improved significantly. In 2017-18, the first year of the launch of 'Test and Treat, 78 PLHIV were initiated on ART for every 100 detections made. In comparison, 94 PLHIV were initiated on ART for

every 100 detections made in 2021-22. Similarly, 12 months of retention on-ART increased to 80% in comparison to 72% in 2017-18.

For every 100 on-ART PLHIV, 25 were LFU in 2017-18 and 2018-19. After assigning definitive outcomes to LFU under 'Mission Sampark' of the government of India, the number of LFU per 100 on-ART PLHIV decreased to 13 in 2019-20. The same level was noted in 2021-22.

Figure 51. ART initiation, retention and LFU; 2017-18 to 2021-22



There were State/UT-wise variations on aspects of initiation, retention and LFU (Table 27). In Puducherry, Sikkim, Jammu & Kashmir, Arunachal Pradesh, and Assam there were only 55, 65, 67, 71 and 73 initiations respectively for every 100 detections. Kerala, Chandigarh, Meghalaya, Himachal Pradesh, Telangana, Odisha, Chhattisgarh, Goa, Delhi, and DNH&DD were other States/UTs with ART initiation per 100 detections ranging between 75 to 89. In the remaining states, the ART initiation was > 90%.

Gaps between the detection and initiation on ART in select States may be attributed to duplicate testing or registration in the ART centres of the neighbouring States and data recording reporting issues. In the State of Haryana, there was high number of initiations compared to detections. Earlier, Haryana had one ART centre in Rohtak while currently there are additional 14 ART centres. There are high number of transfer-in to these 14 ART centres from ART centres in neighbouring States/UT like Chandigarh, Punjab, and Rajasthan. Similarly for the State of Bihar, Jharkhand etc, perhaps PLHIV are being initiated on ART who were diagnosed in other States/UT. Another reason may be associated with the fact that those PLHIV diagnosed in the previous FY 2020-21 are being registered and initiated in FY 2021-22. Still, it is worth exploring the reasons for the gaps in these States/UTs to further strengthen the linkage from HIV case detection to ART initiation (Table 27).

Against the national average of 80% for 12 months retention, States/UT with the largest number of PLHIV on ART (Maharashtra, Andhra Pradesh, Karnataka, Tamil Nadu) had 12 months retention

above/equivalent to the national average (Table 27). However, there were 5 States with 12-months retention of less than <75% with the lowest retention rate for Chhattisgarh (65%). States/UT like Arunachal Pradesh, Assam, Chandigarh, Tripura Haryana, Madhya Pradesh, Meghalaya, Punjab, Telangana, and Tripura have shown improvement under this indicator. Though Uttarakhand has shown improvement, the retention is still <70%.

As linkage loss adversely impacts the progress on all three 95s, responding to the issue of the LFU is a key priority under NACP Phase-V. The programme aims to mitigate linkage loss across screening-confirmation-treatment-retention by leveraging technology, strengthening outreach, upskilling field resources, improving counselling and building synergy across service delivery points. These initiatives, in turn, will promote retention and adherence towards rapid viral load suppression.

Mission Sampark, launched on 1st December 2017, was a key initiative NACP to trace those who were LFU and bring them back under ART services. As on March 2022, Kerala had 4 LFU for every 100 PLHIV on ART, followed by Tamil Nadu, Uttar Pradesh, Sikkim, Andhra Pradesh, and Pondicherry. Jharkhand and Rajasthan were other States/UTs with LFU PLHIV lesser than 10 for every 100 on-ART PLHIV. Assam, Uttarakhand, Meghalaya, and Delhi have LFU ranging from 30-40 for every 100 PLHIV on ART. There was 16 States/UT with a much higher number of LFU for every 100 PLHIV on ART than the national average.

## 8.5 Differentiated care model

Differentiated care is a person-centred approach that simplifies and adapts HIV services across the treatment cascade and takes into consideration the preferences and expectations of various groups of PLHIV while reducing unnecessary burdens on the health system. Since each person's specific needs are central, differentiated care aims to improve the experience and treatment outcomes while ensuring that the health system is functioning both in a medically accountable and efficient manner. General considerations for differentiated ART service delivery are based on the three elements such as the clinical characteristics of the patient (e.g. stable, unstable, comorbidity/coinfection), the sub-population (e.g.

adults, children and adolescents, pregnant and breastfeeding women, key populations, men) and the context (e.g. difficult terrains and hard to reach areas). The differentiated care models (MMD, LAC, CARG etc.) helps to improve patient outcomes, motivate, and empowers patients to take responsibility, enhance the quality of care and access to treatment for PLHIV and effective resource management. Under NACP Phase-V, these models are being piloted and scaled up not only to bring services closer to the PLHIV but also to decongest ART centres. This will improve adherence and facilitate the attainment of viral load suppression.



Table 27. State/UT-wise progress on ARV treatment services, 2021-22

State/UT	ART Centres (March 2022)	PLHIV (Alive and on-ART) in NACP-supported facilities (March 2022)	PLHIV (Alive and on-ART) per ART centre	LFU PLHIV (March 2022)	PLHIV initiated on ART per 100 detections	12 months retention among PLHIV (%)	LFU per 100 'Alive and on-ART' PLHIV
ANI	1	143	143	15	≥95	75	10
Andhra Pradesh	53	1,98,698	3749	14,637	98	81	7
Arunachal Pradesh	1	212	212	29	69	88	14
Assam	7	9,055	1294	3,086	73	84	34
Bihar	28	67,601	2414	8,675	≥95	82	13
Chandigarh	2	5,096	2548	646	78	85	13
Chhattisgarh	8	16,700	2088	4,116	83	65	25
DNH&DD	1	235	235	0	89	90	0
Delhi	12	34,330	2861	13,743	88	80	40
Goa	2	3,118	1559	411	83	73	13
Gujarat	44	74,457	1692	10,514	91	79	14
Haryana	15	4,847	323	3,814	≥95	77	17
Himachal Pradesh	6	21,796	3633	537	81	83	11
Jammu & Kashmir	3	3,054	1018	531	66	80	17
Ladakh							
Jharkhand	13	13,174	1013	1,032	≥95	79	8
Karnataka	70	1,71,647	2452	23,218	91	81	14
Kerala	11	14,985	1362	610	75	84	4
Madhya Pradesh	19	32,842	1729	5,705	92	80	17
Maharashtra	95	2,57,846	2714	48,350	95	81	19
Manipur	13	13,627	1048	1,631	≥95	85	12
Meghalaya	4	3,613	903	1,297	81	85	36
Mizoram	14	12,562	897	1,665	≥95	89	13
Nagaland	12	10,617	885	2,907	97	77	27
Odisha	16	22,621	1414	3,586	82	79	16
Puducherry	1	1,265	1265	96	55	78	8
Punjab	19	47,075	2478	8,094	≥95	76	17
Rajasthan	35	50,044	1430	4,798	95	78	10
Sikkim	1	250	250	18	65	75	7
Tamil Nadu	55	1,21,955	2217	5,590	92	80	5
Telangana	23	87,217	3792	19,768	81	77	23
Tripura	3	2,800	933	507	90	81	18
Uttar Pradesh	51	96,205	1886	5,965	92	79	6
Uttaranchal	6	4,541	757	1,622	92	70	36
West Bengal	20	46,031	2302	10,649	92	80	23
<b>India</b>	<b>664</b>	<b>14,50,259</b>	<b>2184</b>	<b>2,07,862</b>	<b>94</b>	<b>80</b>	<b>14</b>

<sup>u</sup>No ART centre in Lakshadweep

A large, stylized red ribbon symbol, representing HIV/AIDS awareness, is positioned diagonally across the right side of the page. The background is a solid yellow color with faint, concentric circular lines radiating from the center.

9.

HIV-TB  
CO-INFECTION  
MANAGEMENT

# HIV-TB Co-infection Management

## 9.1 Background

An integrated package of services keeping beneficiaries and communities in the centre is the first guiding principle of NACP Phase-V. This is being done through institutionalized convergence with the existing schemes of the Central Government including synergy with other National health programmes.

Tuberculosis (TB), the commonest opportunistic infection (OI), is the leading cause of hospitalization and death among PLHIV, accounting for one in five

HIV-related deaths. Given the context, HIV-TB cross-referral is focussed under NACP since 2001. NACP Phase-V aims to maintain and augment programme collaboration with National Tuberculosis Elimination Programme (NTEP) for HIV-TB cross-referrals and single-window delivery at all ART centres. HIV-TB collaborative activities are being implemented in all service delivery centres. The objective is to ensure early detection and prompt linkage of presumptive TB cases as well as notified TB cases for care, support, and treatment.

## 9.2 Intensified TB Case Finding

Intensified case finding (ICF) is the core TB case finding activity under NACP. Under ICF, all ICTC attendees are screened by ICTC counsellors for the presence of any signs/symptoms of TB at the time of pre/post-test counselling. Persons who have symptoms or signs of TB, irrespective of their HIV status, are referred to the NTEP diagnostic and treatment facility located in the nearest/co-located institution.

Table 28 summarizes progress on HIV/TB cross-referral activities for the last five years. In-referrals to ICTC from NTEP was increasing till 2019-20 and then the trend reversed. The HIV positivity among the in-referrals from NTEP was lowest in 2021-22 at 1.29%. Out-referrals to NTEP declined from 14.37 lakh in 2019-20 to 7.74 lakh in 2020-21 and then increased to around 9.57 lakh in 2021-22.


Table 28. HIV-TB cross-referral, 2017-18 to 2021-22

Indicator	2017-18	2018-19	2019-20	2019-20	2021-22
NTEP to ICTC referral	11,57,582	14,51,844	19,27,713	16,61,701	15,31,278
HIV seropositive (%) among in-referrals from NTEP	2.17	2.22	2.40	1.94	1.29
ICTC to NTEP referral	11,70,350	12,59,762	14,37,761	7,74,356	9,56,666

HIV positivity among NTEP's in-referrals was 7% or more in Bihar and Tripura. Telangana, Nagaland, and Mizoram were other States with HIV seropositivity of 5% or more among in-referrals while it was 4.84% in

Uttar Pradesh. HIV seropositivity among in-referrals was zero in UTs of DNH&DD, Puducherry and Ladakh (Figure 52).

Figure 52. State/UT-wise HIV positivity (in %) among in-referral from NTEP, 2021-22




## 9.3 HIV-TB Co-infection management

At the ART centres, PLHIV who are attending ARTC is screened for TB on 4S every month. The percentage of PLHIV screened for TB has increased from 94.7% in 2020-21 to 96.5% in 2021-22. In 2021-22, 4S screening of less than 95% was observed in eight States/UT including Nagaland (93.7%), Meghalaya (93.3%), Odisha (92.4%), Bihar (91.9%), Telangana (90.5%), Uttarakhand (90.1%), Goa (89.6%) and Puducherry (87.1%)

Emphasis is also given to early ART initiation for

co-infected PLHIV. Combined use of ART and anti-TB treatment (ATT) reduces the impact of active TB among PLHIV significantly. The National Guidelines for HIV Care and Treatment (2021) recommends that ART should be started among PLHIV as soon as possible within two weeks of initiating TB treatment, regardless of CD4 cell count (except among PLHIV with TB meningitis). In 2021-22, out of those PLHIV who were enrolled in the HIV-TB register, almost all (99%) were initiated on anti-TB treatment (ATT), 96% on CPT and 94.6% on ART (Figure 53).


Figure 53. Percentage of screening and initiation under single window services, 2021-22



TB preventive treatment (TPT) is offered to PLHIV and CLHIV after ruling out TB. Till March 2022, overall, 95% of PLHIV in active care at NACO's ART centres were initiated on TB preventive treatment since the inception of single window services at ART centres. In the States of Andhra Pradesh, Karnataka,

Tamil Nadu, Telangana, and Uttar Pradesh, TPT has been provided to >95% of PLHIV (Figure 54). However, there are states like Kerala, Delhi, Mizoram, Assam, Manipur, Haryana, and Arunachal Pradesh where the TPT uptake was <70% as on March 2022.

Figure 54. State/UT-wise TPT initiation, as on March 2022







# 10.

## LABORATORY SERVICES

# Laboratory Services


## 10.1 Background

Over the past three decades, since its launch in 1992, NACP has made tremendous progress towards improving access to preventive, diagnostics, and care, support and treatment services at the most granular level across the country. The impact of the national AIDS response has been significant with a decline in new HIV infections as well as AIDS-related morbidity, and mortality as the proportions of people who know their HIV status and are enrolled on antiretroviral treatment (ART) programmes increased.

Quality laboratory services have been a critical enabler to the national AIDS and STI response with a

central role across the prevention-detection-treatment cascade. The role of quality laboratory services starts right from diagnosing infection, then informing the decision for determining eligibility for ART and/or prophylaxis and finally continues into lifelong periodic services to monitor the impact of treatment. As NACP Phase-V aims to undertake at least 28 crore tests for HIV, 10 crore tests for Syphilis and 80 lakh tests for viral load in its five-year duration towards the attainment of 80% reductions in new infections and AIDS-related mortality as well as the elimination of vertical transmission of HIV and Syphilis; quality laboratory services continues to be at the forefront of the national AIDS response (Figure 55)<sup>2</sup>.

Figure 55. Key testing targets under NACP Phase-V, 2021-22 to 2025-26




## 10.2 Laboratories under NACP

The quality assurance of laboratory services under NACP are provided through a three-tiered network. For HIV serology, there are 13 National Reference Laboratory (NRL), 117 State Reference Laboratory (SRL) & 5000+ Stand-alone Integrated Counselling and Testing Centres (SA-ICTC). Besides, there are >400 CD4 labs for CD4 testing and 64 HIV-1 Viral Load labs for Viral load and six EID (Early Infant

Diagnosis) labs for testing of infants under 18 months of age. Indian Council of Medical Research (ICMR) - National AIDS Research Institute (NARI)-Pune is the apex laboratory for providing External Quality Assurance (EQA) to the testing facilities. The EQA panels are indigenously prepared by ICMR-NARI for HIV Serology, CD4 testing labs, and Viral load testing labs (Figure 56).

Figure 56. EQA system for HIV Serology, CD4 and Viral Load Testing laboratories under NACP



For STI, the laboratory network consists of State Reference Centres (SRC), Regional STI Training, Research and Reference Laboratory (RSTRRL) and Apex Reference Laboratory. There are 45 SRC and 10

RSTRRL for the STI component of NACP. VMMC & Safdarjung Hospital, New Delhi is the Apex laboratory for STI. This is also one of the ten RSTRRLs.

### 10.3 Quality assurance for HIV testing

Under NACP Phase-V, maintaining and expanding the laboratory quality assurance system is one of the key strategies for the reduction of AIDS-related mortality by 80%. Delivering correct tests is fundamental to the success of any public health programme. NACP Phase-V continues to have a three-tiered external quality assessment system. The external quality assurance system (EQAS) is being expanded beyond HIV testing to include other related components of the programme like STI/RTI management, especially given the context of laboratory quality assurance as one of the foundational requirements of dual elimination. This includes framing/ upgradation of proficiency testing, inter-lab comparisons, laboratory accreditations etc.

Currently, under NACP, around 5 crore HIV testing is being performed every year which includes around 3 crore testing at stand-alone ICTC. Testing at ICTC is part of the quality assurance programme monitored by NACO. The quality assurance systems aim for delivering accurate results at the exact time on the right specimen from the actual patient with results/interpretation based on the correct reference date at the right place. For NACO, The EQA ensures high reliability and provides evidence of quality under the programme.


Panel testing, and retesting/reverse testing are the two mechanisms being followed to check and ensure quality-assured HIV testing services.

- a. Panel Testing: Well-characterized blinded panels are sent biannually from the Apex lab to NRL (8-member panel), NRL to SRL (8-member panel) and SRL to SA-ICTC (4-member panel). In 2021-20, 100% of NRL participated in panel testing and zero discordance was reported.

Participation of SRL and SA-ICTC in panel testing in the last four years is depicted in Figure 57 below. As evident, ICTC participation has declined in the year 2020-21 and 2021-22 vis-a-vis previous years which may be because of the COVID-19 pandemic. During the pandemic, staff's diversion for Covid-19 testing was noted and that might have resulted in lower participation.

Among the SRL participating in panel testing, no discordance was reported. Among the participating ICTCs, discordance was 0.1% in the reporting years. Corrective and preventive actions are taken for the ICTCs where discordance results are reported.

Figure 57. Participation in panel testing and discordant results, 2018-19 to 2021-22




b. Re-testing/reverse testing is integral to the quality assurance programme for HIV. Twenty per cent of positive samples and 5% of negative samples tested in ICTC in the first seven working days of each quarter (April, July, October, and January) are sent to linked SRLs for re-testing to assess the quality of testing.

Figure 58 shows the participation of ICTC in the re-testing/ reverse testing and the results thereof over

the years. Participation of ICTCs in re-testing has declined by around 10 percentage points between 2019-20 to 2020-21 as Laboratory Technicians (LT) were engaged in COVID-19 response. Participation in re-testing increased during 2021-22 but was still around 5% points below the level of 2018-19 and 2019-20. Discordance was lowest in 2019-20 at 0.03% and has had a rising trend since then with 0.10% in 2020-21 and 2021-22.

Figure 58. Participation of ICTC in re-testing and discordant results, 2018-19 to 2021-22



## 10.4 Early Infant diagnosis (EID): HIV-1 PCR laboratories tests for children under 18 Months

The World Health Organisation (WHO) has recommended the implementation of EID and treatment among Human Immunodeficiency Virus type-1 (HIV-1) exposed infants to achieve the 2030 goal of HIV elimination. The Government of India initiated the implementation of EID services under the NACP in 2010 to diagnose HIV-1 infection in infants and children aged <18 months. HIV-exposed

infants cannot be tested using standard HIV antibody tests due to the presence of maternal antibodies (transferred during pregnancy or breastfeeding) and the absence of self-generated antibodies early in life.

Thus, in infants below 18 months, direct detection tests for the virus must be conducted. The current test of choice is the HIV Total nucleic acid-polymerase

chain reaction (TNA-PCR) for which a network of 6 laboratories has been strengthened for the purpose. The dried blood spots (DBS) are collected and sent to six EID labs for testing

The dried blood spots (DBS) are collected and sent to six EID labs for testing. All six EID laboratories (AIIMS-New Delhi, ICMR-NARI-Pune, NIMHANS-Bengaluru, NIRT-Chennai, Kasturba-Mumbai, and NICED-Kolkata) participate in EQA. This is a bi-annual activity. Dried Blood Spots (DBS) are issued with instructions to all participating labs. The labs

test the results within the defined time and submit the report on the portal. In 2021-22, all six EID labs successfully participated in the panel testing programme with a score of 100%.

The number of EID tests conducted at six EID laboratories over the last four years is represented in Figure 59. The number of EID tests conducted improved in 2019-20 with a drop in 2020-21. However, the number of tests conducted in 2021-22 was almost back to the pre-COVID-19 level.

## 10.5 CD4 testing

CD4 testing and monitoring continue to remain a vital part of the programme considering its importance to understand the baseline immune status of the infected individual and measuring disease progression particularly to monitor the likely emergence of opportunistic infections (OI). Further, it remains a marker of treatment failure, especially in the case of HIV-2.

As per the current testing guidelines, CD4 monitoring can be discontinued for any patient (except children aged <5 yrs.), if the CD4 count is greater than 350 cells/mm<sup>3</sup> and viral load count is less than 1000 copies/mL (when both tests are conducted at the same time). However, CD4 monitoring must be restarted for the patient if the patient has been switched due to treatment failure, that is, virologic failure (Plasma Viral Load  $\geq$  1000 copies/mL) or when deemed necessary for clinical

management by the clinician at any point in time.

To strengthen the implementation of the quality management system, all LT of CD4 laboratories undergo annual training conducted by NACO and SACS. There are 478 CD4 testing machines under NACP which are installed at 465 CD4 testing centres. The machines are both lab-based and Point of Care (POC).

Figure 60 shows the CD4 testing over the last four years. CD4 testing has had a declining trend since 2019-20. This is due to the introduction of routine viral load monitoring as it provides an early and more accurate indication of treatment failure and the need to switch from first-line ART to second-line drugs, which can reduce the accumulation of drug-resistant mutants and thus improve clinical outcomes.

Figure 59. Number of EID tests (in thousand), 2018-19 to 2021-22





Figure 60. Number of CD4 tests (in lakh), 2018-19 to 2021-22





State/UT-wise CD4 testing conducted during 2021-22 is shown in Table 29. The number of CD4 tests conducted remains high for high burden States such as Andhra Pradesh, Maharashtra, Karnataka, and Tamil Nadu. The number of CD4 tests conducted depends on new registrations being made (baseline test) as well as the total number of


PLHIV registered at the ART centre and further for monitoring based on other aspects such as the patient who are switched due to treatment failure. The higher number of CD4 tests noted in Andhra Pradesh, Maharashtra, Karnataka, and Tamil Nadu reflects a large number of new detections and PLHIV registered in ART centres in these States.

## 10.6 National Quality Assurance (NEQA)

NEQA is conducted for CD4 testing services. It is a bi-annual activity and proficiency panels are distributed twice a year. The results are analysed, and performance is assessed by the Apex laboratory (ICMR-NARI-Pune). All the machines are enrolled in NEQA.

By and large, around 75-80% of laboratories having CD4 machines have participated in NEQA over the last 10 years with a maximum of 95% in 2020-21. In 2016-17, only 59% of the laboratories had satisfactory performance under NEQA which improved to 96% in 2020-21. In 2021-22, around three-fourths had satisfactory results Figure 61.

Figure 61. Participation in NEQA and results



## 10.7 HIV-1 Viral Load (VL) testing

Having 86% of the total PLHIV virally suppressed is imperative to ending of AIDS epidemic as a public health threat. To ensure that the viral load status of all on-ART PLHIV under the programme is being monitored, routine viral load testing was introduced for PLHIV in NACP in 2018 and then scaled up systematically. As per the guidelines, for all patients on first-line ART, plasma viral load testing should be done at 6 months and 12 months after ART initiation and thereafter annually while for all patients on second- or third-line ART, plasma viral load testing should be done every 6 months after initiation of

second- or third-line ART.

In addition, given NACP Phase-V endeavours to monitor the progress on the elimination of vertical transmission in terms of viral load suppression, routine viral load testing has been also recommended for all HIV-positive pregnant women during 32 to 36 weeks of pregnancy (regardless of the duration of ART) to inform the suitable prophylaxis administration to eliminate the risk of HIV transmission to the baby. As evident, viral load testing remains an important component under




NACP Phase-V as it is a more accurate indication of treatment failure.

NACP Phase-V calls for the optimum utilization of public sector laboratories for viral load measurements. There are 64 viral load machines in public sector laboratories under NACP. All of these are fully operational (Figure 62). The laboratories were initially testing samples from co-located ART centres but in the Phase-V, the viral load testing at

these laboratories was optimized through systematic mapping and linkages complementing the existing public-private model of viral load testing. Sample transportation agencies have been hired in some of the States for transporting samples from non-Co-located ART centres to the designated viral load laboratories in the cold chain within a defined turn-around time (TAT). Routine viral load testing is also being implemented in a public-private partnership (PPP) in NACP.

Figure 62. Distribution of public sector viral load laboratories under NACP



Overall, around 29 lakh viral load tests have been done between 2017-18 and 2021-22 under NACP. The number of viral load tests is rapidly increasing every year. In 2018-19, around 2.50 lakh viral load tests were done. In 2021-22, around 10.32 lakh viral load tests were done which is more than 4 times the tests done in 2018-19. As the utilization of public

sector laboratories for viral load tests improved, the number of viral load tests in public sector laboratories increased from 21 thousand in 2017-18 to more than 4 lakh in 2021-22. Overall, around 40% of the total viral load tests in 2021-22 were done in public sector VL laboratories.

Figure 63. Viral load tests under NACP, 2017-18 to 2021-22




Table 29. State/UT-wise CD4 and viral load tests done, 2021-22

State/UT	Total number of CD4 tests conducted in FY 2020-21	Number of Viral Load tests conducted at MHL and Public Sector Labs for FY 2021-22		
		PPP Model	Public Sector	Total VL Testing
Andhra Pradesh	140770	73080	104643	177723
Arunachal Pradesh	80	164	0	164
Assam	3962	4189	0	4189
Bihar	28280	28912	121	29033
Chandigarh	2402	199	5308	5507
Chhattisgarh	9901	6521	3962	10483
DNH&DD	-	490	0	490
Delhi	37243	9359	9337	18696
Goa	1002	3161	0	3161
Gujarat	72629	40161	19802	59963
Haryana	8140	6265	1684	7949
Himachal Pradesh	5016	3994	864	4858
Jammu & Kashmir	2460	1838	0	1838
Ladakh	-			
Jharkhand	6470	9017	1027	10044
Karnataka	141784	73546	46715	120261
Kerala	10528	9750	2324	12074
Madhya Pradesh	19868	20383	2333	22716
Maharashtra	195977	104234	105368	209602
Manipur	4178	1490	7883	9373
Meghalaya	1673	2496	0	2496
Mizoram	2299	8343	0	8343
Nagaland	5375	9435	0	9435
Odisha	11932	11309	0	11309
Puducherry	1196	859	0	859
Punjab	38290	20161	3180	23341
Rajasthan	53810	15947	15329	31276
Sikkim	222	325	0	325
Tamil Nadu	131901	43440	42540	85980
Telangana	67666	49377	13744	63121
Tripura	1584	1395	0	1395
Uttar Pradesh	56663	46338	15735	62073
Uttaranchal	3364	4374	0	4374
West Bengal	33300	14018	5795	19813
<b>India</b>	<b>1099965</b>	<b>624570</b>	<b>407694</b>	<b>1032264</b>

\*No ART centre in Lakshadweep. Data not available for Andaman and Nicobar Islands for 2021-22

Out of the total viral load tests conducted in 2021 – 22, almost 20% were done in Maharashtra followed by Andhra Pradesh (17%), Karnataka (12%) and Tamil Nadu (8%) (Table 29). Out of these total tests

conducted in each State, Andhra Pradesh had 59% tested conducted through public sector labs followed by around 50% each in Maharashtra, Delhi, Tamil Nadu, and Rajasthan.

## 10.8 Viral Load EQA

ICMR-NARI-Pune has been identified as an Apex laboratory for executing the countrywide Viral load (VL) Proficiency testing (PT) programme. All 64 VL laboratories are enrolled under the EQA programme. Two rounds are conducted every year and five-member panels are sent to the labs. The labs are required to test the PT samples within the defined time frame and upload the results on NACO's 'Prayogshala' portal for further analysis. In 2020-2021, two rounds of PT were conducted. In round 1, 41 VL labs participated of which 39 labs

scored acceptable results (with z score <3). In round 2, 52 VL labs participated of which 49 labs scored acceptable results (with z score <3).

In 2021-2022 also, two PT rounds were conducted. In round 1 of 2021-22, 63 VL labs participated of which 59 VL labs scored acceptable results (z score <3). In round 2, all 64 VL labs participated of which 62 labs scored results within the acceptable range (z score <3). The percentage of participation has improved to 100% in FY 2021-22 (Table 30).

Table 30. Viral load EQA participation and results, 2020-21 and 2021-22

S No.	Year	Round	Total Labs	Labs Ready for Participation	Labs Participated	Labs with Satisfactory Report	Percentage of Participation	Labs with satisfactory results (%)
1	2020	Round-I	64	41	40	39	97.6	97.5
2		Round-II	64	53	52	49	97.5	94.2
3	2021	Round-I	64	63	63	59	100	93.7
4		Round-II	64	64	64	62	100	96.9

## 10.9 Accreditation


Quality is an integral part of the Lab Services Division and emphasis on quality-assured laboratory service delivery is important to the success of the NACP. In an endeavour to promote quality in the HIV testing laboratories, NACO initiated a quality improvement programme to aid 130 National and State Referral Laboratories across the country. HIV testing reference laboratory under National AIDS Control Organisation (NACO) consists of 13 National Reference laboratories (NRL), 117 State Reference Laboratories (SRL) and more than 5000 standalone Integrated Counselling and Testing Centres (ICTC).

Anticipating the need to maintain and enhance the quality of the laboratory services, NACO launched a National External Quality Assessment Scheme (NEQAS)

in the year 2000. NACO's implementation of Quality Management Systems (QMS) in alignment with ISO 15189 standards has resulted in the accreditation of 72% SRLs and 100% NRLs starting from zero. This is a remarkable achievement and the only one of its kind for public sector laboratories under the Government of India.

Laboratory accreditation is a procedure by which an authoritative body gives formal recognition of technical competence for specific tests, based on third-party assessment, following ISO 15189:2012 international standard. As on March 2022, all 13 NRLs and 84 SRLs have achieved/ applied for accreditation as per ISO 15189. The status of accreditation is shown in figure 64.

Figure 64. Status of NRL &amp; SRL accreditation



## 10.10 Certificate of Excellence to ICTC

ICTC are the first level of testing and to maintain the quality of testing at these centres, mentoring and assessments for these ~5000 ICTC are done by regular onsite visits by a technical officer of linked SRL. To implement QMS in ICTCs, Laboratory Services Division prepared a checklist based on ISO 15189 and CLSI guidelines. NACO issues a Certificate of Excellence to ICTCs that have obtained a score of  $\geq 90\%$  in the final assessment. Currently, 92 SA-ICTCs have been approved by NACO certification of excellence.

Apart from "Certificate of Excellence", NACO's Laboratory Services division has also introduced Quality Assurance Scheme (QAS) for Basic Composite (BC) Medical Laboratories (Entry Level) through NABL under which SA-ICTCs are proposed to apply for M(EL)T certification. The Entry Level QAS-BC certificate is issued to the laboratory with a validity of three years. The scheme was introduced in the year 2020-2021. A total number of 86 ICTCs were awarded M(EL)T certificates from FY 2020-2022, out of which 41 ICTCs are from the state of Kerala.

A large, stylized red ribbon graphic that loops from the top right, crosses itself, and extends diagonally towards the bottom left, set against a yellow background with faint concentric circles.

11.

ELIMINATION OF  
VERTICAL  
TRANSMISSION OF  
HIV AND SYPHILIS



# Elimination of Vertical Transmission of HIV and Syphilis

## 11.1 Background

Elimination of the vertical transmission of HIV and Syphilis (EVTHS) is a public health priority globally<sup>13,14</sup>. Untreated, approximately 15–30% of infants born to women living with HIV (WLHIV) will acquire HIV during gestation and delivery, with a further 5–15% acquiring HIV through breastfeeding<sup>15</sup>. Over half of the pregnancies among women with active syphilis result in stillbirth, early neonatal death, a preterm or low-birth-weight infant or serious neonatal infection like congenital syphilis<sup>16</sup>.

Given the context, EVTHS is directly related to the attainment of SDG 3.3 of ending of HIV/AIDS epidemic as a public health threat by 2030. As untreated syphilis and HIV infections among pregnant and breastfeeding women may lead to adverse outcomes, EVTHS is also associated with

SDG 3.2 of ending preventable deaths of newborns and children<sup>17</sup>.

Recognising the importance of the EVTHS in context of the SDG 3.3 and the country's progress on EVTHS, NACP Phase-V has included the attainment of the elimination of vertical transmission of HIV and Syphilis as one of the five high-level goals to be attained by 2025<sup>2</sup>. This goal builds upon the significant progress made under the prevention of parent-to-child transmission of HIV, launched as early as in 2002 under the NACP Phase-II, for providing HIV testing to every pregnant woman (universal coverage). NACP Phase-V prescribes ten key strategies towards the attainment of EVTHS (Figure 65).

Figure 65. EVTHS under NACP Phase-V, key strategies

- 1 Augement comprehensive synergy with NHM
- 2 Strengthen the primary prevention through coordinated actions
- 3 Introduce and scale-up dual test kits ( HIV & Syphilis)
- 4 Strengthen retention and on-ART adherence among eligible WLHIV
- 5 Prioritize family planning services for eligible PLHIV
- 6 Strengthen the early diagnosis of infants and all children living with HIV (CLHIV)
- 7 Strengthen the strategic information in the context of HIV positive pregnant women/mother
- 8 Prepare strategic roadmap to guide actions towards attainment of validation of elimination of vertical transmission
- 9 Engage with private sector augenting their role in attainment of dual elimination

## 11.2 Progress at a glance

The progress of a country on EVTHS is measured through standard indicators and targets as prescribed by WHO in its periodic global guidance<sup>18</sup>. As evident, the national AIDS response has made significant progress but still, a lot needs to be done (Table 31). While registration of pregnant women for ante-natal care (ANC) services was around 95% in 2021-22, the progress on HIV testing,

nationally, was 84% with Syphilis testing coverage among pregnant women being reported much lower. As the new HIV infections declined significantly, the paediatric case rate declined below the target level of <50 per 100,000 live births, but the mother-to-child transmission (MTCT) rate continued to be high (24%) given the progress on testing and treatment coverage.

Table 31. Progress against impact and process indicators and targets for EVTHS, 2021-22


Infection	Indicator Type	Indicator	Target	Progress (2021-22)
HIV	Impact	HIV MTCT rate,	<5% (breastfeeding populations) OR <2% (non-breast feeding populations)	24.2%
		Case rate of new paediatric HIV infections due to MTCT	<50 per 100,000 live births	21 per 100,000 live births
	Process	ANC-1 coverage (at least one visit)	≥95%	≥95%
		Coverage of HIV testing among pregnant women	≥95%	84%
		ART coverage of pregnant women living with HIV	≥95%	64%
Syphilis	Impact	Case rate of Congenital Syphilis (CS)	≤50 per 100,000 live births	-
	Process	ANC-1 coverage (at least one visit)	≥95%	≥95%
		Coverage of Syphilis testing among pregnant women	≥95%	57%*
		Adequate treatment coverage of Syphilis-seropositive pregnant women	≥95%	78%*

\*Based on the facility-level denominator

Counselling, testing and treatment services are a critical component of EVTHS with the goal of attainment of testing and treatment coverage of 95%. Figure 65 depicts the country's progress on key testing and treatment indicators in the last five years. As evident, significant progress has been made under EVTHS with HIV testing coverage reaching 84% against the around 70% coverage in 2017-18. Similarly, the Syphilis testing coverage among pregnant women is more than twice in 2021-22 vis-à-vis 2017-18. In 2021-22, for the first time in the last five years, the treatment coverage among

known/detected positive pregnant women (PPW) as well as ARV prophylaxis coverage to HIV-exposed babies reached 95%.

Despite the significant progress made, the evidence indicates significant challenges to the attainment of EVTHS. The treatment coverage for HIV against the population-level denominator is still only at 64%. The progress on testing for syphilis, though increasing, is still far from the envisioned level while evidence on treatment coverage is a cause of concern.

Figure 65. Testing and treatment coverage for EVTHS, 2017-18 to 2021-22<sup>w</sup>


With registration, testing and treatment targets of 95%, universalization of required services is key to the attainment of EVTHS. Still, some States need to be put more attention than the rest given the population and high fertility in these States. Uttar Pradesh and Bihar together contribute almost 35% of the total pregnancies in the country. Madhya Pradesh, Maharashtra, Rajasthan, and West Bengal; each with estimated pregnancies in the range of 16.00 lakh to 22.50 lakh; account for almost 27% of the total pregnancies in the country. Karnataka, Tamil Nadu, Gujarat, Odisha, Andhra Pradesh, Jharkhand, and Assam; are estimated to have around 8-12 lakh, pregnant women, accounting for almost 24% of the total pregnancies. Chhattisgarh, Telangana, Haryana, Kerala, and Punjab each are estimated to have pregnancies in the range of 4.5 lakh to 7.25 lakh while each of Delhi, Jammu & Kashmir, Uttarakhand, Himachal Pradesh is estimated to have pregnant women in the range of 1 to 4 lakh. States of Manipur, Mizoram, and Nagaland, each with HIV prevalence of 1% or more, have estimated pregnancies in the range of 18,000 to 55,000. The distribution of pregnancies by States/UT is a critical consideration

for prioritization while working towards universalization (Figure 66).

State/UT-wise, in Goa, there were 155 HIV tests among pregnant women (PW) for every 100 pregnant women estimated (Figure 67). This indicates repeat testing. Similarly, Mizoram had 134, Gujarat 123, Puducherry 117, Telangana 116, Chandigarh 114, and Maharashtra 112 tests for every 100 estimated pregnant women. In the States/UT of Tamil Nadu, Karnataka, Andhra Pradesh, Andaman & Nicobar Islands, Himachal Pradesh, Jammu & Kashmir, West Bengal and Haryana, the number of tests for every 100 estimated pregnant women ranged from 91 in Haryana to 109 in Tamil Nadu. In Uttar Pradesh, there were 81 tests while Bihar had 61 tests for every 100 estimated pregnant women in 2021-22. Overall, there were 14 States/UT with less than 80 tests per 100 estimated pregnant women in 2021-22. These included Chhattisgarh, Nagaland, Jharkhand, Delhi, Madhya Pradesh, Sikkim, Lakshadweep, Bihar, Manipur, Assam, Rajasthan, Arunachal Pradesh and Ladakh.

<sup>w</sup>Data for testing and treatment for Syphilis refers to the calendar year as reported in Global AIDS Monitoring Portal


Figure 66. State/UT-wise distribution (in %) of estimated pregnant women, 2021-22



In Goa, Puducherry, Chandigarh, and Tamil Nadu; there were 105 (Tamil Nadu) to 154 (Goa) Syphilis tests for every 100 pregnant women (Figure 67). There were 94-99 Syphilis tests for every 100 pregnant women in Gujarat, Mizoram, and Andaman & Nicobar Islands. Karnataka had 89, Andhra Pradesh had 81, Tripura 80, Odisha 80, and Telangana 76 tests for every 100 pregnant women. In Uttar Pradesh,

there were 54 tests, In Maharashtra 53 and Bihar, there were only 14 Syphilis tests for every 100 pregnant women (Figure 67). Given the fact that Uttar Pradesh, Maharashtra, and Bihar together account for almost 40% of the total pregnant women, urgent attention on these States would be critical for the country's progress on dual elimination.

Figure 67. HIV and Syphilis testing coverage by State/UT, 2021-22



Overall, the seropositivity of HIV and Syphilis among tested PW was low at 0.03% in 2021-22. However, State/UT-wise distribution of the HIV seropositivity continues to corroborate epidemic heterogeneity as established by biennial sero-surveillance of NACP. HIV Sero-positivity was 0.50% or higher in the States of Nagaland (0.50%) and Mizoram (0.69%).

Meghalaya reported the third highest seropositivity (0.23%) followed by Manipur (0.12%) and Punjab (0.11%). In five States/UT, HIV seropositivity ranged between 0.05% to 0.07%. These included States/UTs of Chandigarh, Andhra Pradesh, Haryana, Delhi, and Telangana (Figure 63 a).




Epidemic heterogeneity was reflected in terms of seropositivity of Syphilis also, but with a slightly different pattern than that of HIV (Figure 68 b). Arunachal Pradesh, one of the States with the lowest HIV prevalence, recorded the highest seropositivity of 1.86% in 2021-22 followed by 1.32% in Chandigarh. North-eastern States of Meghalaya and Sikkim had the third and fourth highest Syphilis seropositivity; 0.95% and 0.45% respectively. All other States/UT had reported Syphilis seropositivity of less than 0.10% with seropositivity in the range of 0.05% to 0.09% in eight States/UT of Sikkim, Haryana, Rajasthan, DNH & DD, West Bengal, Odisha Tripura,

and Mizoram.

With timely treatment, vertical transmission of HIV and Syphilis is largely eliminable. Lifelong maternal ART and infant prophylaxis may reduce the risk of HIV among exposed infants to <5% (or <2% if no breastfeeding). Similarly, Syphilis is completely curable on adequate treatment and even a single dose of injection Benzathine Penicillin G is sufficient to prevent infection to the foetus irrespective of the stage of syphilis in the mother. Timely treatment provision is key for progress on EVTHS as envisaged under NACP Phase-V.

Figure 68. State/UT-wise seropositivity (in %) of HIV and Syphilis, 2021-22



Overall, there were 15 States/UT with ARV treatment coverage of 95% or more among newly diagnosed/known PPW (Figure 69). These included Chandigarh, Assam, Uttar Pradesh, Tripura, Telangana, Tamil Nadu, Andhra Pradesh, Rajasthan, Goa, Puducherry, Karnataka, Mizoram, Madhya Pradesh, Kerala, and Gujarat. ARV coverage of around 80% or less was reported in State/UTs of Bihar (80%), DNH & DD (80%), Odisha (79%), Uttarakhand (73%), Haryana (68%) and Sikkim (33%). For Haryana, it's important to note that many of the PPW avail services from the neighbouring States and hence may be reflected in the coverage of those States. The same may also be true for other States/UT.

Against the estimated need for elimination of vertical transmission of HIV, five States/UT reported coverage of 100% or more (against the point estimate). These included the States/UT of

Chandigarh, Tripura, Arunachal Pradesh, Punjab, Tamil Nadu, and Himachal Pradesh. Chandigarh reported coverage almost 3 times that of estimated need, perhaps because the PPW from the neighbouring State of Haryana avails ARV services in this UT. However, higher coverage against the need in Tripura (168%) and Arunachal Pradesh (133%) is more reflective of the underestimation of epidemic size (Figure 69).

By and large, the difference between the ARV coverage against the facility-level denominator vis-à-vis coverage against the population-level denominator needs to be interpreted with caution, especially in States where population-level coverage is lower than the facility-level coverage. Some of these differences may be explained in terms of testing coverage. Lower testing coverage will in general reflect in lower population-level coverage. In States/UT with high testing coverage

among pregnant women, at least two scenarios are possible. If repeat testing is very high, then the actual testing coverage is perhaps lower which might be a plausible explanation for lower population-level coverage. The other possibility may be of higher estimates emanating from assumptions of age-sex structures or fertility rates differing from that of the actual world. Both scenarios need to be explored carefully as the country strengthens its strategic information on EVTHS as envisaged under the NACP Phase-V strategy document.

Based on the evidence available under NACP, the treatment coverage among pregnant women with

Syphilis ranged between 5% in Haryana and Chandigarh to 100% or more in States/UT of Tripura, Telangana, Andhra Pradesh, Bihar, Goa, Jharkhand, Mizoram, Sikkim, Tamil Nadu, and Puducherry (Figure 70). Overall, 21 States/UT had recorded a treatment coverage of 90% or more. However, the high treatment coverage in the States shall be interpreted against the testing coverage for syphilis. For example, treatment coverage was 90% in Maharashtra. However, as testing coverage for Syphilis was only 53% in Maharashtra, there may be still a lot of PW who didn't receive the treatment for Syphilis despite needing the same.

Figure 69. State/UT-wise ARV coverage (in%) against the facility and population-level denominators, 2021-22




Figure 70. State/UT-wise Syphilis treatment coverage (in%) against the diagnosed cases, 2021-22






Table 32. State/UT-wise key indicators for EVTHS, 2021-22


State/UT	Estimated PW	Estimated PPW	HIV testing coverage	Syphilis testing coverage	New HIV cases detected	PPW among known WLHIV	PPW on ARVs	PW found Syphilis positive	PW treated for Syphilis
ANI	4,660	4 (2-15)	4,797	4,385	2	0	0	0	0
Andhra Pradesh	8,99,900	2,014 (1,700-2,421)	9,53,940	7,27,272	625	810	1,450	37	37
Arunachal Pradesh	29,540	9 (6-13)	13,780	9,980	3	11	12	186	150
Assam	8,16,980	334 (284-399)	4,71,235	2,96,243	107	71	194	38	24
Bihar	34,20,990	2,446 (1,682-3,474)	20,74,460	4,72,699	342	362	566	46	46
Chandigarh	18,190	16 (11-22)	20,751	20,357	14	18	48	268	13
Chhattisgarh	7,17,190	487 (384-641)	5,41,977	3,38,866	192	143	301	111	107
DNH & DD	24,650	17 (12-23)	20,662	18,148	2	3	4	12	6
Delhi	3,53,740	394 (313-500)	2,51,382	1,96,977	137	108	205	37	31
Goa	20,910	35 (26-44)	32,454	32,281	10	16	26	9	9
Gujarat	10,93,130	1,030 (811-1,333)	13,44,671	10,83,748	425	542	932	322	317
Haryana	6,32,900	475 (384-596)	5,76,224	3,90,930	342	50	268	314	15
Himachal Pradesh	1,25,380	40 (31-53)	1,22,929	81,186	29	19	40	20	18
Jammu & Kashmir	2,21,900	58 (34-95)	2,16,851	49,138	17	9	21	4	3
Ladakh		-			0	0	0	0	0
Jharkhand	8,50,800	342 (234-482)	6,23,860	5,52,939	89	102	181	22	22
Karnataka	11,96,210	1,707 (1,448-2,079)	12,74,231	10,62,760	518	743	1,258	98	92
Kerala	5,26,340	114 (78-164)	4,59,255	3,91,811	18	46	62	102	101
Lakshadweep	1,070	-	672	704	0	0	0	0	0
Madhya Pradesh	22,23,030	536 (460-675)	15,77,818	12,71,529	275	233	503	553	546
Maharashtra	20,86,620	2,667 (2,252-3,145)	23,53,557	11,03,775	716	1,017	1,607	202	181
Manipur	52,390	366 (303-430)	31,571	25,017	38	66	87	0	0
Meghalaya	80,690	234 (144-382)	67,289	51,013	152	90	219	483	330
Mizoram	18,760	328 (271-399)	25,201	18,490	174	57	230	9	9
Nagaland	29,830	386 (300-530)	22,104	16,578	111	43	126	75	74
Odisha	9,27,940	534 (381-769)	7,92,116	7,41,889	207	83	230	410	398
Puducherry	22,670	30 (17-49)	26,607	25,473	1	9	10	7	7
Punjab	4,83,520	520 (411-670)	4,14,443	3,09,599	446	201	593	75	70
Rajasthan	20,64,990	788 (624-961)	11,40,211	9,94,417	294	388	688	739	631
Sikkim	11,970	5 (3-9)	7,682	6,957	1	2	1	6	6
Tamil Nadu	11,70,490	774 (661-892)	12,75,399	12,32,598	234	578	823	66	66
Telangana	6,80,790	1,073 (857-1,390)	7,91,512	5,18,643	415	386	813	35	39
Tripura	59,310	47 (33-61)	53,242	47,457	23	54	79	25	28
Uttar Pradesh	67,91,420	2,186 (1,691-2,911)	55,00,861	36,88,156	492	568	1,110	301	292
Uttarakhand	2,18,460	97 (73-120)	1,70,977	1,24,175	32	23	40	7	5
West Bengal	16,24,570	517 (460-599)	15,56,286	10,33,524	237	228	440	609	381
<b>India</b>	<b>2,95,06,840</b>	<b>20,612 (16,379-26,359)</b>	<b>2,48,12,717</b>	<b>1,69,40,091</b>	<b>6,720</b>	<b>7,079</b>	<b>13,167</b>	<b>5,228</b>	<b>4,054</b>

## 11.4 Pregnancies among known HIV positive women

There are two types of HIV cases in pregnancy: those in which women with known HIV-positive status become pregnant, and those in which women are first diagnosed as HIV-positive during pregnancy, labour, or the post-natal period. In India, as PLHIV management improves, more women with known HIV-positive status choose

pregnancy. In 2017-18, only one-third of total PPW were among known HIV positive vis-à-vis 51% reported in 2021-22 (Figure 71). The specifics of these cases are significant because early detection of HIV status and subsequent viral suppression via ART administration plays a critical role in preventing vertical transmission.


Figure 71. Distribution (in %) of total PPW between new diagnosis and known positive, 2017-18 to 2021-22



In 2021-22, in States/UT like Puducherry, Kerala, Arunachal Pradesh, Tamil Nadu, Tripura, Sikkim, Manipur, Goa and DNH&DD; more than 60% of

total PPW under the programme were from known positive women (Figure 72).

Figure 72. Distribution (in %) of total PPW between new diagnosis and known positive by State/UT, 2021-22



## 11.5 Early Infant Diagnosis

Early infant diagnosis (EID) of HIV is an integral component of the EVTHS under NACP, ensuring follow-up care of HIV-exposed children for early

detection of infection and timely access to antiretroviral treatment. The services are offered through all stand-alone ICTC.


### Live birth and ARV prophylaxis initiation

For the elimination of vertical transmission of HIV, all HIV-exposed infants must receive suitable ARV prophylaxis to reduce the risk of HIV transmission. Accordingly, the administration of ARV prophylaxis to the exposed infants, in addition to ARV treatment for the mother, following the extant guidelines is fundamental to EVTHS under NACP.

While overall coverage for administration for ARV

prophylaxis among HIV-exposed babies identified under NACP was 95% in 2021-22, it ranged from 72% in Tripura to 100% in State/UT of Arunachal Pradesh, DNH&DD, Himachal Pradesh, Kerala, Sikkim, and Goa (Figure 73). Overall, 21 States/UT had prophylaxis coverage of 95% or more. However, relatively lower coverage (85% to <90%) in States of high burden States such as Bihar and Uttar Pradesh is a cause of concern (Figure 73).

Figure 73. State/UT-wise coverage (in %) of ARV prophylaxis against the diagnosed HIV-exposed babies, 2021-22



### TNA-PCR Test and HIV Confirmation among infants (6weeks-6months)

As part of the EID programme, all HIV-exposed babies are tested for HIV infection using Total nucleic acid-polymerase chain reaction (TNA-PCR) as early as 6 weeks of age. In 2021-22, approximately 11,864 TNA-PCR tests were done among HIV-exposed babies in the age group of 6 weeks to 6 months with 1.73% positive test results (Table 33). In States/UTs with at-least 50 TNA-PCR tests

among HIV-exposed babies done, Jharkhand had 10% positive results while Telangana and Assam had positive results in the range of 3.30% to 3.40%. Chhattisgarh, Karnataka, Gujarat, Uttar Pradesh and Nagaland were other States with 2.00-2.50% positive results. It is important to note that if ART among a woman is started before pregnancy or if the ART is started during pregnancy and PPW is

one ART for at least 4 weeks before delivery, the perinatal transmission risk reduces to 1.40% or lower<sup>19</sup>. For the States/UT where less than 50 tests

were done in the age group, the results need to be interpreted with caution as they may not be reflecting the situation comprehensively.

## HIV Exposed babies' 18-month Antibody test

The HIV-exposed child's HIV status is confirmed only at 18 months of age or 6 weeks after complete cessation of breastfeeding whichever is later. Nationally, in 2021-22, a total of 7,686 HIV-exposed babies underwent antibody tests at 18 months and 226 (2.94%) of them were confirmed HIV positive. This is much below the target MTCT rate of 5% but must be interpreted with caution given potential biases. First, this positivity is only among a subset of the population and roughly around half of the total PPW under a programme in a year. Besides, these tests are largely among a population group which is usually well connected with the programme. Given these contexts, the positivity rate of 2.9% shall not be viewed as a proxy for MTCT rates.

There was 21 States/UT where at least 50 exposed children were tested for HIV antibodies at 18 months of age (Figure 74, Table 33). In six States, the HIV seropositivity was more than 5% with the highest seropositivity of 7% recorded in Assam. Chhattisgarh, Haryana, Rajasthan, West Bengal, and Meghalaya were other States in this category. HIV seropositivity was around 4% in Madhya Pradesh and Tamil Nadu. Among HIV-exposed babies who were tested for HIV antibodies at 18 months of age in Kerala in 2021-22, not even a single baby was positive. For the States/UT where less than 50 tests were done in the age group, the results need to be interpreted with caution as they may not be reflecting the situation comprehensively.

Figure 74. State/UT-wise HIV seropositivity (in %) among babies aged 6 weeks to 6 months and 18 months, 2021-22




Table 33. State/UT-wise performance on EID including ARV prophylaxis and treatment, 2021-22

State/UT	Live births among PPW	Babies given ARV prophylaxis	Babies tested for HIV (6 weeks- 6 months)	Babies confirmed HIV Positive (6 weeks- 6 months)	HIV-exposed babies tested at 18 months	Babies confirmed HIV positive at 18 months	HIV-positive babies initiated on ART
ANI	0	0	2	0	1	0	0
Andhra Pradesh	926	907	1,053	3	745	6	10
Arunachal Pradesh	6	6	6	0	1	0	0
Assam	147	144	211	7	159	11	90
Bihar	664	590	434	3	538	4	37
Chandigarh	45	40	47	1	29	0	2
Chhattisgarh	272	259	367	9	199	13	29
DNH&DD	3	3	4	1	1	0	0
Delhi	148	144	218	1	280	6	6
Goa	14	14	17	0	11	1	1
Gujarat	692	673	765	17	568	19	43
Haryana	293	290	331	4	137	8	12
Himachal Pradesh	22	22	21	0	6	0	0
Jammu & Kashmir	17	15	20	0	8	0	0
Ladakh	0	0	0	0	0	0	0
Jharkhand	143	129	169	17	100	1	18
Karnataka	966	905	1,037	24	745	20	55
Kerala	45	45	42	2	51	0	0
Lakshadweep	0	0	0	0	0	0	0
Madhya Pradesh	468	467	621	5	438	19	25
Maharashtra	1,631	1,553	2,237	36	1,272	32	66
Manipur	85	82	106	0	41	0	0
Meghalaya	205	199	201	3	153	7	10
Mizoram	220	217	237	4	168	5	7
Nagaland	206	204	181	4	150	3	5
Odisha	203	182	86	1	49	7	8
Puducherry	12	11	13	1	8	0	1
Punjab	367	338	411	5	191	2	8
Rajasthan	570	567	599	5	465	25	23
Sikkim	3	3	0	0	3	0	0
Tamil Nadu	488	470	696	11	448	16	29
Telangana	599	549	560	19	460	7	15
Tripura	18	13	1	0	0	0	0
Uttar Pradesh	674	573	765	17	3	1	10
Uttarakhand	42	33	54	1	17	1	2
West Bengal	362	356	352	4	241	12	25
<b>India</b>	<b>10,556</b>	<b>10,003</b>	<b>11,864</b>	<b>205</b>	<b>7,686</b>	<b>226</b>	<b>537</b>



# 12.

## SCORECARD



# Scorecard

## 12.1 Background

The Scorecard of SACS provides an overall picture of State/UT performance on NACP implementation across all facilities. It also provides big pictures of areas needed for more effort to achieve NACP targets.

A biannual activity in a financial year, the first scorecard for 2021-22 was prepared in December 2021

for a mid-year monitoring based on programme data (2021-22 till Nov.) and other information as of December 2021.

The second scorecard of the financial year 2021-22 was prepared in June 2022 based on the programme data and other information of the entire financial year.

## 12.2 Methodology

A total of 30 indicators across the service categories under NACP have been used in the State/UT scorecard for the year 2021-22. These 30 indicators cover the service categories from Information Education & Communication (IEC) and Mainstreaming

(MS), Targeted Intervention (TI), Basic Services, Care Support and Treatment (CST), Laboratory Services (LS), Strategic Information, Finance and Supply Chain Management. Details of indicators have been given in Table 34.

Table 34. Indicators used for scorecard, 2021-22

Sl. No.	Indicators	Numerator	Denominator
<b>Information Education &amp; Communication and Mainstreaming &amp; Partnership</b>			
1	Frequency of Social Media updates	-	-
2	Status of AEP integration in the state School curriculum	Number of States integrated AEP into their school course curriculum	All states & UTs except MDACS
3	Status of SCA	SCA constituted and meeting held	All states & UTs except MDACS
4	Status of State Rules	Number of States/UTs notified rules	All states & UTs except MDACS
5	Status of Ombudsman	Number of States/UTs designated Ombudsman	All states & UTs except MDACS
<b>Targeted Intervention</b>			
1	Facilities onboarded	No. of Facilities onboarded	No. of facilities approved in AAP (TI, LWS, OST, Satellite OST)
2	Coverage against the target in the contract	No. of HRG & BP covered by TI	Contracted target by the SACS
3	HRG & BP living with HIV on ART	No. of HIV-positive HRG & BP alive and on ART under the TI	No. of HRG & BP living with HIV under the TI

Sl. No.	Indicators	Numerator	Denominator
<b>Basic Services</b>			
1	Percentage of PLHIV who know their status (first 95 Status)	Total PLHIV in Active care	Estimated PLHIV
2	HIV testing against target-GC	No. of HIV tests done among GC in the FY	The target for HIV testing among GC in the FY
3	HIV testing against target-PW	No. of HIV tests done among PW in the FY	The target for HIV testing among PW in the FY
4	Percentage of Pregnant women who initiated ART	No. of HIV Positive pregnant women initiated on ART (MPR data)	Total no of HIV Positive pregnant women reported (incl. Known Positive)
5	Percentage of TB suspected cases referred to NTEP out of that 10% of general clients received the Pretest counselling	Number of TB suspect cases referred to NTEP	10% of general clients excluding pregnant women received the pretest counselling
6	Clients managed at DSRC against the target	No. of Clients managed at DSRC	The target for the FY
7	Percentage of pregnant women tested for Syphilis	Total no. of PW tested for Syphilis reported at HCTS Level	Estimated Pregnant women
<b>Care Support and Treatment</b>			
1	ART Initiation (Current FY)	Out of PLHIV registered at ART centres in the period, a number of PLHIV initiated on ART	PLHIV registered at the ART centre in the period
2	LFU rate among new ART initiation	Out of PLHIV newly initiated on ART are LFU	Number of patients newly initiated on ART during the F.Y
3	Progress on PLHIV alive on ART during the FY	PLHIV alive on ART at the end of the Quarter (MPR + Pvt Sector)	Quarter-wise target of Alive on ART in Output Outcome indicator
4	Status on the establishment of CSC	Number of CSC established in state under AAP	Number of CSC allotted for the establishment to the state under AAP
<b>Lab Services</b>			
1	VL Suppression Rate (Current FY)	No. of PLHIV Virally suppressed	No PLHIV who are tested for VL (F.Y 2020-21)
2	% of SRL accredited	No. of SRL accredited	No. of SRL in the state
3	% Participation of ICTCs in Re-testing	No. of ICTC participated in the state	Total no of ICTC in the state
<b>Strategic Information</b>			
1	% of NACP facilities active in SOCH	No. of NACP facilities active in SOCH during the period	No. of NACP facilities registered in SOCH during the period
2	Status of State Data Management Committee	State Data Management Committee constituted, and meeting held	All States/UT
3	Status of finalized Priority Areas for Operational Research and Evaluation	No. of finalized Priority areas	Priority Areas for Operational Research and Evaluation

Sl. No.	Indicators	Numerator	Denominator
<b>Finance</b>			
1	Expenditure with respect to funds released during FY 2021-22	Expenditure in the FY	Funds released in FY
2	Submission of Audit Report after approval of EC/GB for the preceding year (FY 2020-21)	Date of receipt of requisite report/document	by 30-Jun
3	Submission of Utilization Certificate (in prescribed format GFR 12A) for the previous financial year (FY 2020-21)	Date of receipt of requisite report/document	by 30-Jun
<b>Supply Chain Management</b>			
1	Report Submission (BSD-SCM Report)	No. of formats reported during the period	Total no. of formats to be reported in the period

Performance on individual indicators was divided into 4 categories [Good (Green, 3 Marks), Average (Yellow, 2 Marks), Poor (Red, 1 Mark), Not Applicable (No

colour- No score added in denominator)]. Indicator-wise details of performance categories have been given in table 35.

Table 35. Performance on individual indicators

Sl. No.	Indicator Name	Zone for ranking		
		Green	Yellow	Red
Information Education & Communication and Mainstreaming & Partnership				
	Frequency of Social Media updates	If SACS has been able to cross 60 Social Media updates in total, including indigenous content, repost, retweet, and sharing. 30 updates on each Social Media Platform (best 2) in the last quarter i.e. January to March 2022.	If the social media update number falls between 40-59 including indigenous content, reposting, retweeting, and sharing. 20+ updates on each Social Media Platform (best 2) in the last quarter i.e., January to March 2022.	If the social media update number falls below 40 including indigenous content, repost, retweet, sharing. 10+ updates on each Social Media Platform (best 2) in the last quarter i.e., January to March 2022.
	Status of AEP integration in the State School curriculum	Yes		No
	Status of SCA	Constituted and at least one meeting held since 2017		Not constituted/ Constituted and no meeting held since 2017
	Status of State Rules	Notified		Not notified
	Status of Ombudsman	Appointed/ designated		Not appointed/ designated

Sl. No.	Indicator Name	Zone for ranking		
		Green	Yellow	Red
Targeted Interventions				
1	Facilities onboarded	≥95%	≥90% to <95%	<90%
2	Coverage against the target in contract	≥95%	≥90% to <95%	<90%
3	HRG & BP living with HIV on ART	≥95%	≥90% to <95%	<90%
4	IDU on OST	≥95%	≥90% to <95%	<90%
Basic Services				
1	Percentage of PLHIV who know their status (first 95 Status)	95% or more	≥80% to <95%	<80%
2	HIV testing against target-GC	95% or more	≥80% to <95%	<80%
3	HIV testing against target-PW	95% or more	≥80% to <95%	<80%
4	Percentage of Pregnant women who initiated ART	95% or more	≥80% to <95%	<80%
5	Partner testing among GC	95% or more	≥80% to <95%	<80%
6	Percentage of TB suspected cases referred to NTEP out of that 10% of general clients received pretest counselling	95% or more	≥80% to <95%	<80%
7	Clients managed at DSRC against the target	95% or more	≥80% to <95%	<80%
8	Percentage of pregnant women tested for Syphilis	95% or more	≥80% to <95%	<80%
Care Support and Treatment				
1	ART Initiation (Current FY)	≥95%	≥80% to <95%	<80%
2	LFU rate among new ART initiation	<2%	≥ 2% to <5%	≥5%
3	Progress on PLHIV alive on ART during the FY	≥95%	≥80% to <95%	<80%
4	Status on the establishment of CSC	≥95%	≥80% to <95%	<80%
Lab Services				
1	VL Suppression Rate (Current FY)	≥95%	≥85% to <95%	<85%
2	% of SRL accredited	100%	≥80% to <100%	<80%
3	% Participation of ICTCs in Re-testing	≥95%	≥85% to <95%	<85%
Strategic Information				
1	% of NACP facilities active in SOCH	90% or more	≥75% to <90%	<75%
2	Status of State Data Management Committee	Constituted and at least one meeting held in FY 2021-22	Constituted and no meeting held in FY 2021	Not constituted



Sl. No.	Indicator Name	Zone for ranking		
		Green	Yellow	Red
3	Status of finalized Priority Areas for Operational Research and Evaluation	4	3	<3
Finance				
1	Expenditure with respect to funds released during FY 2021-22	90% or more	≥85% to <90%	<85%
2	Submission of Audit Report after approval of EC/GB for the preceding year (FY 2020-21)	by 30-June 2021	by 30-September 2021	beyond 30-September 2021
SCM				
3	Report Submission (BSD-SCM Report)	90% or more	≥75% to <90%	<75%

## 12.3 Performance of State/UT in Programme Implementation

### A. Comparison of June 2022 and December 2021 Scorecards

Among 34 States/UT, 13 improved their ranking while 5 retained their ranking. State/UT-wise changes in

ranking are given in Table 36 below.

*Table 36. Change in overall performance; from Scorecard FY 2021-22 (December 2021) to Scorecard FY 2021-22 (June 2022)*

Improved Rank	Retained Rank	Deteriorated Rank
West Bengal (20→3), Uttar Pradesh (21→7), Madhya Pradesh (21→8), Mizoram (10→8), Rajasthan (13→11), Meghalaya (16→12), Nagaland (21→12), Maharashtra* (26→14), Haryana (34→17), DNH & DD (30→21), Uttarakhand (24→21), Bihar (33→24) and Delhi (29→28)	Goa (1), Chandigarh (2), Tamil Nadu (5) and Jharkhand (27)	Manipur (3→4), Gujarat (5→6), Karnataka (5→8), Punjab (14→15), Himachal Pradesh (5→16), Assam (5→17), Chhattisgarh (11→19), Tripura (18→20), Kerala (11→21), Puducherry (14→24), Andhra Pradesh (4→26), J&K & Ladakh (27→29), Sikkim (16→30), Andaman and Nicobar Islands (19→31), Telangana (31→32), Arunachal Pradesh (25→33), and Odisha (31→34)

As per the recent Scorecard, out of 34 SACS, the percentage distribution of SACS in green, yellow, and red zones for each indicator is given in Figure 75. The

State/UT were ranked based on their obtained scores calculated based on performance on 30 indicators (Figure 76).

Figure 75. Performance of States/UTs on each indicator, 2021-22





Figure 76. State/UT wise obtained score (in percentage), 2021-22



\*Data on indicators related to Basic Services, facilities active in SOCH includes Mumbai

A thick red ribbon is draped across the page, starting from the bottom left, looping upwards and to the right, and then looping back down towards the right edge. The background is a gradient of yellow and orange with faint, concentric circular lines.

# FACT SHEET

## INDIA

## 1. Status of HIV/AIDS Epidemic

### A. Epidemic Estimates (2021)

Indicator	Male	Female	Total
1. IPR	-	-	2.62
2. IMR	-	-	1.01
3. Adult (15-49 yrs) HIV Prevalence (%)	0.22	0.19	0.21
4. Estimated people living with HIV	13,17,842	10,83,441	24,01,284
5. ART coverage (%)	60.0	71	65
6. Estimated children living with HIV	36,617	33,190	69,808
7. Annual new HIV infections	36,034	26,933	62,967
8. Annual AIDS-related deaths (ARD)	29,513	12,455	41,968
9. Change in annual new HIV infections since 2010 (%)	-72.7	-82.38	-76.54
10. Change in annual ARD since 2010(%)	-46.5	-45.86	-46.25
11. EMTCT need	-	20,612	20,612


### B. High risk population size (2009), safe practices (2015) and prevalence (2021)

Population Group	Estimates Size	Condom Use (%)	New Needle/ Syringe use (%)	HIV Prevalence (%)
1. Female Sex Workers	8,68,000	74.2	48.5	1.85
2. Men who have sex with men	3,57,000	55.3	46.9	3.26
3. Injecting Drug Users	1,77,000	50	85.5	9.03
4. Hijra/Transgender People	70,000	65.2	35.5	3.78
5. Migrants	72,00,000	-	-	0.89
6. Truckers	20,00,000	-	-	1
7. Prison inmates	21,94,364	49.2	39.6	1.93

### C. HIV/AIDS related knowledge, stigma and high-risk behaviour in general population (2019-21)

Indicator	Male	Female	Total
1. Adults (15-49 yrs) with comprehensive knowledge about HIV/AIDS (%)	30.7	21.6	-
2. Youth (15-24 yrs) with comprehensive knowledge about HIV/AIDS (%)	28.5	20.1	-
3. Adults willing to care for a relative with HIV/AIDS in own home (%)	74.3	70.9	-
4. Adults willing to buy fresh vegetables from a shopkeeper or vendor who has HIV/AIDS (%)	69.2	64.3	-
5. Adults (15-49 yrs) who have had higher-risk sexual behaviour in the past 12 months (%)	3.8	0.5	-
5.1 Condom use during last higher-risk intercourse (%)	60	57.4	-
6. Youth (15-24 yrs) who have had higher-risk sexual behaviour in the past 12 months (%)	6.4	0.8	-
6.1 Condom use during last higher-risk intercourse (%)	60.6	62.8	-

## 2. Progress on 95-95-95 (2021-22)



Indicator	Male	Female	Total
1. Estimated PLHIV size (2021)	13,17,842	10,83,441	24,01,284
2. PLHIV who know their HIV Status	9,69,951	8,86,475	18,56,426
3. PLHIV who know their HIV status and are on ART	7,89,931	7,66,095	15,56,026
4. PLHIV who are on ART and tested for their viral load	4,99,543	5,06,077	10,05,620
5. PLHIV who are virally suppressed	4,17,258	4,35,475	8,52,733

### 3. Prevention of new HIV infections among general population

#### A. Information, Education, Communication, Youth and Mainstreaming

Indicator	2021-22
1. Schools with operational Adolescent Education Program (AEP)	51,670
2. Colleges with operational Red Ribbon Clubs (RRC)	12,897
3. Persons trained under mainstreaming	2,69,707
4. No. of calls received at helpline	4,88,261

#### B. Sexually Transmitted Infections (STI)/Reproductive Tract Infections (RTI) Management at DSRCs

Indicator	2021-22			
1. NACO Supported Designated STI/RTI Clinics (DSRC)	1184			
	Male	Female	TG	Total
2. Clients managed	-	-	-	50,66,351
3. RPR Tests conducted	10,79,488	19,05,284	22,706	30,07,478
4. Syphilis seropositivity (%)	1.00	0.28	9.08	0.60

### 4. Prevention of new HIV infections among high-risk group and bridge population

#### A. Targeted Interventions (TI) and Opioid Substitution Therapy (OST)

Indicator	2021-22
1. Targeted Interventions	1,512
2. OST centres	364
3. Employer Led Model Interventions	906

#### B. Female Sex Workers

Indicator	2021-22
1. Estimated size	8,68,000
2. Coverage (%)	>=95
3. Condoms distributed	19,21,80,291
4. Tested for HIV (April 2021 - September 2021)	5,88,793
4.1. HIV sero-positive (%)	0.09
4.1.1. Linked to ART	435
5. Tested for HIV (October 2021 - March 2022)	6,39,516
5.1. HIV sero-positive (%)	0.08
5.1.1. Linked to ART	461
6. Clinic Visits	22,82,847
7. STI/RTI treated	29,218
8. Presumptive treatment	98,110

#### C. Men who have Sex with Men

Indicator	2021-22
1. Estimated size	3,57,000
2. Coverage (%)	90
3. Condoms distributed	6,34,62,546
4. Tested for HIV (April 2021 - September 2021)	2,12,615
4.1. HIV sero-positive (%)	0.25
4.1.1. Linked to ART	445
5. Tested for HIV (October 2021 - March 2022)	2,23,528
5.1. HIV sero-positive (%)	0.26
5.1.1. Linked to ART	507
6. Clinic Visits	8,08,959
7. STI/RTI treated	5,996
8. Presumptive treatment	35,955

### D. Injecting Drug Users

Indicator	2021-22
1. Estimated size	1,77,000
2. Coverage (%)	>=95
3. Needles distributed	3,92,53,718
4. Syringes distributed	2,79,17,942
5. On OST	42,586
6. Tested for HIV (April 2021 - September 2021)	1,15,719
6.1. HIV sero-positive (%)	1.19
6.1.1. Linked to ART	966
7. Tested for HIV (October 2021 - March 2022)	1,26,337
7.1. HIV sero-positive (%)	0.94
7.1.1. Linked to ART	859

### E. Hijra/Transgender people

Indicator	2021-22
1. Estimated size	70,000
2. Coverage (%)	88
3. Condoms distributed	1,46,02,537
4. Tested for HIV (April 2021 - September 2021)	40,339
4.1. HIV sero-positive (%)	0.40
4.1.1. Linked to ART	144
5. Tested for HIV (October 2021 - March 2022)	45,120
5.1. HIV sero-positive (%)	0.36
5.1.1. Put on ART	153
6. Clinic Visits	1,53,516
7. STI / RTI treated	1,472
8. Presumptive treatment	6,289

### F. Migrants

Indicator	2021-22
1. Estimated size	72,00,000
2. Coverage (%)	92
3. Tested for HIV	8,30,604
3.1. HIV sero-positive (%)	0.11
3.2. Linked to ART	839

### G. Truckers

Indicator	2021-22
1. Estimated size	20,00,000
2. Coverage (%)	50
3. Tested for HIV	2,39,824
3.1. HIV sero-positive (%)	0.12
3.2. On ART	221

### H. Prison Inmates

Indicator	2021-22
1. Total prisons	1,350
2. Prisons covered under programme	1,150
3. Total inmates admitted	18,89,531
4. Inmates Covered(%)	38
5. Tested for HIV	6,56,749
5.1. HIV sero-positive (%)	0.44
5.2. On ART (%)	82

### I. Link Worker Scheme

Indicator	2021-22
1. Districts covered under scheme	145
2. Vulnerable population covered	21,85,938
3. Tested for HIV	11,50,297
3.1. HIV sero-positive (%)	0.18
3.2. Linked to ART (%)	94.11



## J. Opioid Substitution Therapy

Indicator	2021-22
1. OST Centres	364
1.1. OSTC in Public Health Settings	197
1.2. OSTC in NGO Settings	41
1.3 No. of Satellite OST Centres	126
2. IDU on OST	42,586

## 5. Early detection of HIV infected people

### A. HIV Counselling and Testing Services (HCTS)

Indicator	2021-22
1. ICTC facilities	34,607
1.1. Stand-alone	5,408
1.2. Facility integrated (Govt)	22,637
1.3. Facility integrated (PPP)	3,733
1.4. CBS	2,829

### B. HIV Testing among Vulnerable Population (Excluding Pregnant Women)

Indicator	2021-22			
	Male	Female	TG	Total
1. Tested for HIV	1,34,11,792	99,97,407	1,14,369	2,35,23,568
2. Found HIV Positive among tested	79,276	42,055	1,257	1,22,588
3. HIV sero-positivity (%) among tested	0.59	0.42	1.10	0.52
4. Spouse/sexual partner testing of HIV positive people identified	28,697	26,800	385	55,882

## 6. Initiation and retention on ART of HIV infected people

### A. Treatment Facilities

Indicator	2021-22
1. ART Centres	664
2. Centre of Excellence	
2.1. Centre of Excellence (Adult)	11
2.2. Centre of Excellence (Paediatric)	7
3. Link ART Centres	1,261
4. Care Support Centres	319

### B. Treatment Uptake

Indicator	2021-22			
	Male	Female	TG	Total
1. HIV positive cases diagnosed (At ICTC)	79,276	48,775	1,257	1,29,308
2. New PLHIV Registered at ART center	78,538	48,432	854	1,27,824
2.1 Initiated on ART	74,039	46,570	802	1,21,411
3. PLHIV alive and on ART	7,90,080	7,60,585	5,361	15,56,026
4. 12 months retention on ART (%)				79.57
5. Lost to follow-up cases	1,24,270	82,309	1,283	2,07,862

## 7. Viral Suppression and laboratories

### A. Laboratory facilities and service uptake

Indicator	2021-22
1. Viral load laboratories	64
1.1 Accredited Viral load laboratories	22
2. Viral load testing conducted	10,32,264
2.1. Virally suppressed (%)	85
3. National reference laboratories (NRL)	13
3.1 Accredited NRL	13
4. State reference laboratories (SRL)	117
4.1 Accredited SRL	85
5. CD4 testing conducted	10,99,964
6. External Quality Assessment of ICTC	
6.1 Average Participation (%)	83.80
6.2. Average Discordance (%)	0.06
7. Quality Assurance Scheme for Basic Composite Medical Laboratories (Entry Level)- M(EL)T	
7.1 No. of ICTCs certified for M(EL)T certification	70.00

## 8. Elimination of mother to child transmission of HIV & Syphilis

### A. HIV

Indicator	2021-22
1. Estimated pregnant women (PW)	2,95,06,840
2. HIV testing among PW	2,48,12,717
3. HIV sero-positivity (%) among tested	0.03
4. HIV Positive PW (old + new detections)	13,799
4.1 On life-long ART	13,167
5. Live births among HIV positive PW	10,556
5.1 Babies given ARV Prophylaxis (%)	94.76
6. Babies tested HIV (6 week- 6 month)	11,864
6.1 Babies confirmed HIV Positive (6 week- 6 month)	205
7. HIV exposed babies at 18 months	
7.1 HIV exposed babies tested at 18 month	7,686
7.2 Babies confirmed HIV positive at 18 months	226
8. HIV positive babies initiated on ART	537

### B. Syphilis

Indicator	2021-22
1. Estimated pregnant women (PW)	2,95,06,840
2. Syphilis testing among PW	1,69,40,091
3. Sero-positivity (%) among tested	0.03
4. Put on treatment	4,054

## 9. Elimination of HIV/AIDS related Stigma and Discrimination

### A. HIV/AIDS Prevention & Control Act (2017)

Indicator	2021-22
1. No of State rules notified for HIV/AIDS Prevention and Control Act (2017)	16
2. No. of State designated/appointed ombudsman for HIV/AIDS Prevention and Control Act (2017)	24

## 10. HIV-TB Co-morbidities

### A. HRG and Bridge Population

Indicator								2021-22
	Quarter	FSW	MSW	IDU	TG	Migrants	Truckers	Total
Screened for TB	Quarter 1	6,77,247	2,16,454	80,884	40,248	3,37,196	1,14,109	14,66,138
	Quarter 2	8,07,156	2,61,729	1,03,632	50,741	4,73,508	1,70,644	18,67,410
	Quarter 3	8,27,210	2,77,306	1,05,836	52,729	5,27,313	1,77,030	19,67,424
	Quarter 4	8,71,833	2,87,137	1,10,001	58,279	5,50,374	1,85,482	20,63,106
Tested for TB	Quarter 1	3,605	1,397	1,126	201	1,967	366	8,662
	Quarter 2	7,088	2,685	1,772	764	3,023	575	15,907
	Quarter 3	7,005	2,939	1,413	902	2,837	786	15,882
	Quarter 4	7,472	2,798	1,694	555	2,202	1,420	16,141
Diagnosed with TB	Quarter 1	49	17	88	3	87	7	251
	Quarter 2	122	34	106	3	92	35	392
	Quarter 3	107	38	35	6	67	10	263
	Quarter 4	165	109	31	8	56	31	400
Initiated on TB treatment	Quarter 1	45	23	34	3	43	7	155
	Quarter 2	81	34	55	3	68	15	256
	Quarter 3	73	24	23	6	68	8	202
	Quarter 4	93	51	30	7	54	21	256

### B. HIV-TB Cross-Referral

Indicator	2021-22
1. In referral from TB program	15,31,278
1.1. HIV sero-positive (%)	1.29
1.2. ICTC clients referred to NTEP	9,56,666

### C. HIV-TB Coinfected at ART Centre

Indicator							2021-22	
	PLHIV attending ART Centre	PLHIV underwent 4S screening	PLHIV with presumptive TB	PLHIV tested for TB	PLHIV diagnosed with TB	PLHIV initiated on IPT	Co-infected enrolled at ARTc	Co-infected initiated on ART
Apr-21	9,27,688	8,96,603	35,405	29,166	1,797	21,586		
May-21	7,74,119	7,37,947	26,068	20,487	1,092	10,358		
Jun-21	7,98,200	7,59,509	32,598	25,712	1,937	13,118		
Jul-21	9,13,722	8,78,473	41,146	33,600	2,466	18,489		
Aug-21	9,27,964	8,95,042	44,367	35,604	2,544	16,786		
Sep-21	9,37,949	9,07,282	46,901	37,835	2,563	16,708		
Oct-21	8,94,812	8,67,762	43,688	34,857	2,526	14,563		
Nov-21	8,48,611	8,21,269	36,065	32,593	2,410	14,176		
Dec-21	8,81,132	8,53,764	40,918	34,182	2,625	14,516		
Jan-22	8,44,701	8,09,745	39,064	32,411	2,268	22,956		
Feb-22	7,87,739	7,68,268	44,835	31,054	2,386	15,971		
Mar-22	8,49,761	8,23,884	43,249	33,651	2,843	16,096		
April 2021- March 2022							34,732	32,849





# FACT SHEET

ANDAMAN &  
NICOBAR  
ISLANDS

# ANDAMAN & NICOBAR ISLANDS

## 1. Status of HIV/AIDS Epidemic

### A. Epidemic Estimates (2021)

Indicator	Male	Female	Total
1. IPR	-	-	3.52
2. IMR	-	-	0.68
3. Adult (15-49 yrs) HIV Prevalence (%)	0.15	0.12	0.14
4. Estimated people living with HIV	255	171	426
5. ART coverage (%)	32.4	41	36
6. Estimated children living with HIV	9	9	18
7. Annual new HIV infections	9	6	15
8. Annual AIDS-related deaths (ARD)	13	7	20
9. Change in annual new HIV infections since 2010 (%)	-67.9	-66.67	-66.67
10. Change in annual ARD since 2010(%)	-13.3	-22.22	-13.04
11. EMTCT need	-	4	4


### B. High risk population size (2009), safe practices (2015) and prevalence (2021)

Population Group	Estimates Size	Condom Use (%)	New Needle/ Syringe use (%)	HIV Prevalence (%)
1. Female Sex Workers	-	-	-	-
2. Men who have sex with men	-	-	-	-
3. Injecting Drug Users	-	-	-	-
4. Hijra/Transgender People	-	-	-	-
5. Migrants	-	-	-	-
6. Truckers	-	-	-	-
7. Prison inmates	619	-	-	-

### C. HIV/AIDS related knowledge, stigma and high-risk behaviour in general population (2019-21)

Indicator	Male	Female	Total
1. Adults (15-49 yrs) with comprehensive knowledge about HIV/AIDS (%)	34.7	14.9	-
2. Youth (15-24 yrs) with comprehensive knowledge about HIV/AIDS (%)	37	14.8	-
3. Adults willing to care for a relative with HIV/AIDS in own home (%)	59.9	66.5	-
4. Adults willing to buy fresh vegetables from a shopkeeper or vendor who has HIV/AIDS (%)	64.4	72.9	-
5. Adults (15-49 yrs) who have had higher-risk sexual behaviour in the past 12 months (%)	3.8	0.1	-
5.1 Condom use during last higher-risk intercourse (%)	84.1	0	-
6. Youth (15-24 yrs) who have had higher-risk sexual behaviour in the past 12 months (%)	5.9	0	-
6.1 Condom use during last higher-risk intercourse (%)	100.0	NA	-

## 2. Progress on 95-95-95 (2021-22)



Indicator	Male	Female	Total
1. Estimated PLHIV size (2021)	255	171	426
2. PLHIV who know their HIV Status	87	71	158
3. PLHIV who know their HIV status and are on ART	77	66	143
4. PLHIV who are on ART and tested for their viral load	-	-	-
5. PLHIV who are virally suppressed	-	-	-

### 3. Prevention of new HIV infections among general population

#### A. Information, Education, Communication, Youth and Mainstreaming

Indicator	2021-22
1. Schools with operational Adolescent Education Program (AEP)	119
2. Colleges with operational Red Ribbon Clubs (RRC)	12
3. Persons trained under mainstreaming	4,173

#### B. Sexually Transmitted Infections (STI)/Reproductive Tract Infections (RTI) Management at DSRCs

Indicator	2021-22			
1. NACO Supported Designated STI/RTI Clinics (DSRC)	1			
	Male	Female	TG	Total
2. Clients managed	-	-	-	3,205
3. RPR Tests conducted	1,477	1,727	1	3,205
4. Syphilis seropositivity (%)	0.47	0.17	0.00	0.31

### 4. Prevention of new HIV infections among high-risk group and bridge population

#### A. Targeted Interventions (TI) and Opioid Substitution Therapy (OST)

Indicator	2021-22
1. Targeted Interventions	-
2. OST centres	-
3. Employer Led Model Interventions	-

#### B. Female Sex Workers

Indicator	2021-22
1. Estimated size	-
2. Coverage (%)	-
3. Condoms distributed	-
4. Tested for HIV (April 2021 - September 2021)	-
4.1. HIV sero-positive (%)	-
4.1.1. Linked to ART	-
5. Tested for HIV (October 2021 - March 2022)	-
5.1. HIV sero-positive (%)	-
5.1.1. Linked to ART	-
6. Clinic Visits	-
7. STI/RTI treated	-
8. Presumptive treatment	-

#### C. Men who have Sex with Men

Indicator	2021-22
1. Estimated size	-
2. Coverage (%)	-
3. Condoms distributed	-
4. Tested for HIV (April 2021 - September 2021)	-
4.1. HIV sero-positive (%)	-
4.1.1. Linked to ART	-
5. Tested for HIV (October 2021 - March 2022)	-
5.1. HIV sero-positive (%)	-
5.1.1. Linked to ART	-
6. Clinic Visits	-
7. STI/RTI treated	-
8. Presumptive treatment	-

#### D. Injecting Drug Users

Indicator	2021-22
1. Estimated size	-
2. Coverage (%)	-
3. Needles distributed	-
4. Syringes distributed	-
5. On OST	-
6. Tested for HIV (April 2021 - September 2021)	-
6.1. HIV sero-positive (%)	-
6.1.1. Linked to ART	-
7. Tested for HIV (October 2021 - March 2022)	-
7.1. HIV sero-positive (%)	-
7.1.1. Linked to ART	-

#### E. Hijra/Transgender people

Indicator	2021-22
1. Estimated size	-
2. Coverage (%)	-
3. Condoms distributed	-
4. Tested for HIV (April 2021 - September 2021)	-
4.1. HIV sero-positive (%)	-
4.1.1. Linked to ART	-
5. Tested for HIV (October 2021 - March 2022)	-
5.1. HIV sero-positive (%)	-
5.1.1. Put on ART	-
6. Clinic Visits	-
7. STI / RTI treated	-
8. Presumptive treatment	-

#### F. Migrants

Indicator	2021-22
1. Estimated size	-
2. Coverage (%)	-
3. Tested for HIV	-
3.1. HIV sero-positive (%)	-
3.2. Linked to ART	-

#### G. Truckers

Indicator	2021-22
1. Estimated size	-
2. Coverage (%)	-
3. Tested for HIV	-
3.1. HIV sero-positive (%)	-
3.2. On ART	-

#### H. Prison Inmates

Indicator	2021-22
1. Total prisons	4
2. Prisons covered under programme	1
3. Total inmates admitted	882
4. Inmates Covered(%)	28
5. Tested for HIV	248
5.1. HIV sero-positive (%)	0.40
5.2. On ART (%)	100

#### I. Link Worker Scheme

Indicator	2021-22
1. Districts covered under scheme	-
2. Vulnerable population covered	-
3. Tested for HIV	-
3.1. HIV sero-positive (%)	-
3.2. Linked to ART (%)	-



## J. Opioid Substitution Therapy

Indicator	2021-22
1. OST Centres	-
1.1. OSTC in Public Health Settings	-
1.2. OSTC in NGO Settings	-
1.3 No. of Satellite OST Centres	-
2. IDU on OST	-

## 5. Early detection of HIV infected people

### A. HIV Counselling and Testing Services (HCTS)

Indicator	2021-22
1. ICTC facilities	39
1.1. Stand-alone	13
1.2. Facility integrated (Govt)	24
1.3. Facility integrated (PPP)	2
1.4. CBS	-

### B. HIV Testing among Vulnerable Population (Excluding Pregnant Women)

Indicator	2021-22			
	Male	Female	TG	Total
1. Tested for HIV	11,872	8,175	2	20,049
2. Found HIV Positive among tested	15	6	-	21
3. HIV sero-positivity (%) among tested	0.13	0.07	-	0.10
4. Spouse/sexual partner testing of HIV positive people identified	1	4	-	5

## 6. Initiation and retention on ART of HIV infected people

### A. Treatment Facilities

Indicator	2021-22
1. ART Centres	1
2. Centre of Excellence	
2.1. Centre of Excellence (Adult)	-
2.2. Centre of Excellence (Paediatric)	-
3. Link ART Centres	-
4. Care Support Centres	-

### B. Treatment Uptake

Indicator	2021-22			
	Male	Female	TG	Total
1. HIV positive cases diagnosed (At ICTC)	15	8	-	23
2. New PLHIV Registered at ART center	14	10	-	24
2.1 Initiated on ART	14	10	-	24
3. PLHIV alive and on ART	82	70	-	153
4. 12 months retention on ART (%)				75.00
5. Lost to follow-up cases	10	5	-	15

## 7. Viral Suppression and laboratories

### A. Laboratory facilities and service uptake

Indicator	2021-22
1. Viral load laboratories	-
1.1 Accredited Viral load laboratories	-
2. Viral load testing conducted	-
2.1. Virally suppressed (%)	-
3. National reference laboratories (NRL)	-
3.1 Accredited NRL	-
4. State reference laboratories (SRL)	1
4.1 Accredited SRL	-
5. CD4 testing conducted	-
6. External Quality Assessment of ICTC	
6.1 Average Participation (%)	100.00
6.2. Average Discordance (%)	0.00
7. Quality Assurance Scheme for Basic Composite Medical Laboratories (Entry Level)- M(EL)T	
7.1 No. of ICTCs certified for M(EL)T certification	1.00

## 8. Elimination of mother to child transmission of HIV & Syphilis

### A. HIV

Indicator	2021-22
1. Estimated pregnant women (PW)	4,660
2. HIV testing among PW	4,797
3. HIV sero-positivity (%) among tested	0.04
4. HIV Positive PW (old + new detections)	2
4.1 On life-long ART	-
5. Live births among HIV positive PW	-
5.1 Babies given ARV Prophylaxis (%)	-
6. Babies tested HIV (6 week- 6 month)	2
6.1 Babies confirmed HIV Positive (6 week- 6 month)	-
7. HIV exposed babies at 18 months	
7.1 HIV exposed babies tested at 18 month	1
7.2 Babies confirmed HIV positive at 18 months	-
8. HIV positive babies initiated on ART	-

### B. Syphilis

Indicator	2021-22
1. Estimated pregnant women (PW)	4,660
2. Syphilis testing among PW	4,385
3. Sero-positivity (%) among tested	0.00
4. Put on treatment	-

## 9. Elimination of HIV/AIDS related Stigma and Discrimination

### A. HIV/AIDS Prevention & Control Act (2017)

Indicator	2021-22
1. State rules notified for HIV/AIDS Prevention and Control Act (2017)	Yes
2. State designated/appointed ombudsman for HIV/AIDS Prevention and Control Act (2017)	Yes

## 10. HIV-TB Co-morbidities

## A. HRG and Bridge Population

Indicator								2021-22
	Quarter	FSW	MSW	IDU	TG	Migrants	Truckers	Total
Screened for TB	Quarter 1	-	-	-	-	-	-	-
	Quarter 2	-	-	-	-	-	-	-
	Quarter 3	-	-	-	-	-	-	-
	Quarter 4	-	-	-	-	-	-	-
Tested for TB	Quarter 1	-	-	-	-	-	-	-
	Quarter 2	-	-	-	-	-	-	-
	Quarter 3	-	-	-	-	-	-	-
	Quarter 4	-	-	-	-	-	-	-
Diagnosed with TB	Quarter 1	-	-	-	-	-	-	-
	Quarter 2	-	-	-	-	-	-	-
	Quarter 3	-	-	-	-	-	-	-
	Quarter 4	-	-	-	-	-	-	-
Initiated on TB treatment	Quarter 1	-	-	-	-	-	-	-
	Quarter 2	-	-	-	-	-	-	-
	Quarter 3	-	-	-	-	-	-	-
	Quarter 4	-	-	-	-	-	-	-

## B. HIV-TB Cross-Referral

Indicator	2021-22
1. In referral from TB program	206
1.1. HIV sero-positive (%)	1.46
1.2. ICTC clients referred to NTEP	648

## C. HIV-TB Coinfected at ART Centre

Indicator							2021-22	
	PLHIV attending ART Centre	PLHIV underwent 4S screening	PLHIV with presumptive TB	PLHIV tested for TB	PLHIV diagnosed with TB	PLHIV initiated on IPT	Co-infected enrolled at ARTc	Co-infected initiated on ART
Apr-21	36	36	-	-	-	1		
May-21	34	34	-	-	-	3		
Jun-21	70	70	-	-	-	2		
Jul-21	71	71	-	-	-	-		
Aug-21	49	49	3	3	-	1		
Sep-21	49	49	3	3	-	1		
Oct-21	79	79	-	-	-	-		
Nov-21	79	79	-	-	-	-		
Dec-21	84	84	-	-	-	2		
Jan-22	81	81	-	-	-	2		
Feb-22	71	71	-	-	-	2		
Mar-22	61	61	1	1	-	2		
April 2021-March 2022							4	4

## 11. Scorecard

State/UT Name		Andaman & Nicobar Islands
Overall Rank		31
IEC & MS	Frequency of Social Media updates (G= ≥60, Y=40-59, R=<40)	
	Status of AEP integration in state School curriculum (G=Yes, R=No)	
	Status of SCA (G= At least one meeting held since 2017, R= other than G)	
	Status of State Rules (G= Notified, R= Not notified)	
	Status of Ombudsman (G= Appointed, R=Not appointed)	
	Rank	15
TI	Facilities onboarded (G=≥95%, Y= 90-94%, R=<90%)	
	Coverage against target in contract (G=≥95%, Y= 90-94%, R=<90%)	NA
	HRG & BP living with HIV on ART (G=≥95%, Y= 90-94%, R=<90%)	NA
	IDU on OST (G=≥95%, Y= 90-94%, R=<90%)	NA
	Rank	33
BSD	Percentage of PLHIV who know their status (G=≥95%, Y= 80-94%, R=<80%)	
	HIV testing against target-GC ((G=≥95%, Y= 80-94%, R=<80%)	
	HIV testing against target-PW (G=≥95%, Y= 80-94%, R=<80%)	
	Percentage of Pregnant women who initiated ART (G=≥95%, Y= 80-94%, R=<80%)	
	Percentage of TB suspected cases referred to NTEP (G=≥95%, Y= 80-94%, R=<80%)	
	Clients managed at DSRC against the target (G=≥95%, Y= 80-94%, R=<80%)	
	Percentage of pregnant women tested for Syphilis (G=≥95%, Y= 80-94%, R=<80%)	
	Rank	34
CST	ART Initiation (Current FY) (G=≥95%, Y= 80-94%, R=<80%)	
	LFU rate among new ART initiation (G=<2%, Y= 2-4%, R=≥5%)	
	PLHIV put on ART during the FY against target (G=≥95%, Y= 80-94%, R=<80%)	
	Status on establishment of CSC (G=≥95%, Y= 80-94%, R=<80%)	NA
	Rank	1
LS	VL Suppression Rate (Current FY) (G=≥95%, Y= 85-94%, R=<85%)	NA
	% of SRL accredited (G=100%, Y= 80-99%, R=<80%)	
	% Participation of ICTCs in Re-testing (G=≥95%, Y= 85-94, R=<85%)	
	Rank	12
SI	% of NACP facilities active in SOCH (G=≥90%, Y= 75-89%, R=<75%)	
	Status of State Data Management Committee (G=one meeting held, Y= no meeting held, R= not constituted)	
	Status of finalized Priority Areas for Operational Research and Evaluation (G= 4, Y= 3, R= <3)	
	Rank	4
Finance	Expenditure with respect to funds released during FY 2021-22 (G=≥90%, Y= 85-89%, R=<85%)	
	Submission of Audit Report after approval of EC/GB for the preceding year (G= by 30th June, Y= 30th Sept, R= beyond 30th Sept 2021)	
	Submission of Utilization Certificate (in prescribed format GFR 12A) for the previous financial year (G= by 30th June, Y= 30th Sept, R= beyond 30th Sept 2021)	
	Rank	18
SCM	Report Submission (BSD-SCM Report) (G=≥90%, Y= 75-89%, R=<75%)	

Green=3 Marks

Yellow=2Marks

Red=1 Mark

No Colour=Not Applicable

A thick red ribbon is draped across the page, starting from the bottom left, looping upwards and to the right, and then looping back down towards the bottom right. The background is a gradient of yellow and orange with faint, concentric circular lines.

# **FACT SHEET**

## **ANDHRA PRADESH**

# ANDHRA PRADESH

## 1. Status of HIV/AIDS Epidemic

### A. Epidemic Estimates (2021)

Indicator	Male	Female	Total
1. IPR	-	-	1.37
2. IMR	-	-	0.36
3. Adult (15-49 yrs) HIV Prevalence (%)	0.69	0.65	0.67
4. Estimated people living with HIV	1,64,661	1,56,367	3,21,028
5. ART coverage (%)	57.5	76	66
6. Estimated children living with HIV	3,434	3,193	6,627
7. Annual new HIV infections	2,468	1,918	4,386
8. Annual AIDS-related deaths (ARD)	6,797	2,389	9,186
9. Change in annual new HIV infections since 2010 (%)	-68.1	-68.25	-68.19
10. Change in annual ARD since 2010(%)	-68.1	-82.55	-73.75
11. EMTCT need	-	2,014	2,014


### B. High risk population size (2009), safe practices (2015) and prevalence (2021)

Population Group	Estimates Size	Condom Use (%)	New Needle/ Syringe use (%)	HIV Prevalence (%)
1. Female Sex Workers	1,17,584	73.1	56.7	1.78
2. Men who have sex with men	17,777	52	77.9	2.06
3. Injecting Drug Users	1,284	72.1	90.3	1.32
4. Hijra/Transgender People	3,565	37.8	-	4.61
5. Migrants	1,99,533	-	-	0.93
6. Truckers	52,345	-	-	0.6
7. Prison inmates	69,761	27	-	3.25

### C. HIV/AIDS related knowledge, stigma and high-risk behaviour in general population (2019-21)

Indicator	Male	Female	Total
1. Adults (15-49 yrs) with comprehensive knowledge about HIV/AIDS (%)	38.6	24.6	-
2. Youth (15-24 yrs) with comprehensive knowledge about HIV/AIDS (%)	38.1	27.2	-
3. Adults willing to care for a relative with HIV/AIDS in own home (%)	66.4	64.1	-
4. Adults willing to buy fresh vegetables from a shopkeeper or vendor who has HIV/AIDS (%)	72.1	64.3	-
5. Adults (15-49 yrs) who have had higher-risk sexual behaviour in the past 12 months (%)	3.8	0.1	-
5.1 Condom use during last higher-risk intercourse (%)	31.3	0	-
6. Youth (15-24 yrs) who have had higher-risk sexual behaviour in the past 12 months (%)	5.2	0	-
6.1 Condom use during last higher-risk intercourse (%)	42.9	NA	-

## 2. Progress on 95-95-95 (2021-22)



Indicator	Male	Female	Total
1. Estimated PLHIV size (2021)	1,64,661	1,56,367	3,21,028
2. PLHIV who know their HIV Status	1,21,158	1,40,979	2,62,137
3. PLHIV who know their HIV status and are on ART	90,624	1,13,457	2,04,081
4. PLHIV who are on ART and tested for their viral load	73,792	94,416	1,68,208
5. PLHIV who are virally suppressed	62,744	82,194	1,44,938

### 3. Prevention of new HIV infections among general population

#### A. Information, Education, Communication, Youth and Mainstreaming

Indicator	2021-22
1. Schools with operational Adolescent Education Program (AEP)	750
2. Colleges with operational Red Ribbon Clubs (RRC)	148
3. Persons trained under mainstreaming	1,921

#### B. Sexually Transmitted Infections (STI)/Reproductive Tract Infections (RTI) Management at DSRCs

Indicator	2021-22			
1. NACO Supported Designated STI/RTI Clinics (DSRC)	55			
	Male	Female	TG	Total
2. Clients managed	-	-	-	1,93,180
3. RPR Tests conducted	32,272	70,168	4,156	1,06,596
4. Syphilis seropositivity (%)	0.54	0.09	0.02	0.22

### 4. Prevention of new HIV infections among high-risk group and bridge population

#### A. Targeted Interventions (TI) and Opioid Substitution Therapy (OST)

Indicator	2021-22
1. Targeted Interventions	96
2. OST centres	2
3. Employer Led Model Interventions	27

#### B. Female Sex Workers

Indicator	2021-22
1. Estimated size	1,17,584
2. Coverage (%)	>=95
3. Condoms distributed	44,29,2828
4. Tested for HIV (April 2021 - September 2021)	90,081
4.1. HIV sero-positive (%)	0.06
4.1.1. Linked to ART	39
5. Tested for HIV (October 2021 - March 2022)	1,07,644
5.1. HIV sero-positive (%)	0.05
5.1.1. Linked to ART	41
6. Clinic Visits	3,71,392
7. STI/RTI treated	1,432
8. Presumptive treatment	16,481

#### C. Men who have Sex with Men

Indicator	2021-22
1. Estimated size	17,777
2. Coverage (%)	>=95
3. Condoms distributed	83,36,143
4. Tested for HIV (April 2021 - September 2021)	17,046
4.1. HIV sero-positive (%)	0.14
4.1.1. Linked to ART	15
5. Tested for HIV (October 2021 - March 2022)	20,751
5.1. HIV sero-positive (%)	0.19
5.1.1. Linked to ART	31
6. Clinic Visits	70,075
7. STI/RTI treated	156
8. Presumptive treatment	3,304

#### D. Injecting Drug Users

Indicator	2021-22
1. Estimated size	1,284
2. Coverage (%)	>=95
3. Needles distributed	2,24,267
4. Syringes distributed	2,24,267
5. On OST	62
6. Tested for HIV (April 2021 - September 2021)	1,261
6.1. HIV sero-positive (%)	0.16
6.1.1. Linked to ART	2
7. Tested for HIV (October 2021 - March 2022)	1,534
7.1. HIV sero-positive (%)	0.20
7.1.1. Linked to ART	3

#### E. Hijra/Transgender people

Indicator	2021-22
1. Estimated size	3,565
2. Coverage (%)	>=95
3. Condoms distributed	15,11,739
4. Tested for HIV (April 2021 - September 2021)	2,653
4.1. HIV sero-positive (%)	0.79
4.1.1. Linked to ART	12
5. Tested for HIV (October 2021 - March 2022)	3,201
5.1. HIV sero-positive (%)	0.31
5.1.1. Put on ART	6
6. Clinic Visits	10,810
7. STI / RTI treated	17
8. Presumptive treatment	514

#### F. Migrants

Indicator	2021-22
1. Estimated size	1,99,533
2. Coverage (%)	20
3. Tested for HIV	38,334
3.1. HIV sero-positive (%)	0.09
3.2. Linked to ART	16

#### G. Truckers

Indicator	2021-22
1. Estimated size	52,345
2. Coverage (%)	57
3. Tested for HIV	17,028
3.1. HIV sero-positive (%)	0.09
3.2. On ART	3

#### H. Prison Inmates

Indicator	2021-22
1. Total prisons	106
2. Prisons covered under programme	81
3. Total inmates admitted	78,369
4. Inmates Covered (%)	7
5. Tested for HIV	2,176
5.1. HIV sero-positive (%)	0.32
5.2. On ART (%)	86

#### I. Link Worker Scheme

Indicator	2021-22
1. Districts covered under scheme	13
2. Vulnerable population covered	1,86,460
3. Tested for HIV	1,64,600
3.1. HIV sero-positive (%)	0.18
3.2. Linked to ART (%)	93.96



## J. Opioid Substitution Therapy

Indicator	2021-22
1. OST Centres	2
1.1. OSTC in Public Health Settings	1
1.2. OSTC in NGO Settings	-
1.3 No. of Satellite OST Centres	1
2. IDU on OST	62

## 5. Early detection of HIV infected people

## A. HIV Counselling and Testing Services (HCTS)

Indicator	2021-22
1. ICTC facilities	1,958
1.1. Stand-alone	225
1.2. Facility integrated (Govt)	1,451
1.3. Facility integrated (PPP)	169
1.4. CBS	113

## B. HIV Testing among Vulnerable Population (Excluding Pregnant Women)

Indicator	2021-22			
	Male	Female	TG	Total
1. Tested for HIV	6,52,714	6,35,468	6,811	12,94,993
2. Found HIV Positive among tested	7,086	5,886	82	13,054
3. HIV sero-positivity (%) among tested	1.09	0.93	1.20	1.01
4. Spouse/sexual partner testing of HIV positive people identified	4,130	4,110	18	8,258

## 6. Initiation and retention on ART of HIV infected people

## A. Treatment Facilities

Indicator	2021-22
1. ART Centres	53
2. Centre of Excellence	
2.1. Centre of Excellence (Adult)	1
2.2. Centre of Excellence (Paediatric)	-
3. Link ART Centres	117
4. Care Support Centres	23

## B. Treatment Uptake

Indicator	2021-22			
	Male	Female	TG	Total
1. HIV positive cases diagnosed (At ICTC)	7,086	6,511	82	13,679
2. New PLHIV Registered at ART center	7,042	6,532	74	13,648
2.1 Initiated on ART	6,901	6,465	74	13,440
3. PLHIV alive and on ART	94,710	1,17,858	622	2,13,191
4. 12 months retention on ART (%)				81.00
5. Lost to follow-up cases	7,841	6,696	100	14,637

## 7. Viral Suppression and laboratories

## A. Laboratory facilities and service uptake

Indicator	2021-22
1. Viral load laboratories	10
1.1 Accredited Viral load laboratories	1
2. Viral load testing conducted	1,77,723
2.1. Virally suppressed (%)	86
3. National reference laboratories (NRL)	-
3.1 Accredited NRL	-
4. State reference laboratories (SRL)	7
4.1 Accredited SRL	2
5. CD4 testing conducted	1,40,770
6. External Quality Assessment of ICTC	
6.1 Average Participation (%)	54.32
6.2. Average Discordance (%)	0.00
7. Quality Assurance Scheme for Basic Composite Medical Laboratories (Entry Level)- M(EL)T	
7.1 No. of ICTCs certified for M(EL)T certification	-

## 8. Elimination of mother to child transmission of HIV &amp; Syphilis

## A. HIV

Indicator	2021-22
1. Estimated pregnant women (PW)	8,99,900
2. HIV testing among PW	9,53,940
3. HIV sero-positivity (%) among tested	0.07
4. HIV Positive PW (old + new detections)	1,435
4.1 On life-long ART	1,450
5. Live births among HIV positive PW	926
5.1 Babies given ARV Prophylaxis (%)	97.95
6. Babies tested HIV (6 week- 6 month)	1,053
6.1 Babies confirmed HIV Positive (6 week- 6 month)	3
7. HIV exposed babies at 18 months	
7.1 HIV exposed babies tested at 18 month	745
7.2 Babies confirmed HIV positive at 18 months	6
8. HIV positive babies initiated on ART	10

## B. Syphilis

Indicator	2021-22
1. Estimated pregnant women (PW)	8,99,900
2. Syphilis testing among PW	7,27,272
3. Sero-positivity (%) among tested	0.01
4. Put on treatment	37

## 9. Elimination of HIV/AIDS related Stigma and Discrimination

## A. HIV/AIDS Prevention &amp; Control Act (2017)

Indicator	2021-22
1. State rules notified for HIV/AIDS Prevention and Control Act (2017)	No
2. State designated/appointed ombudsman for HIV/AIDS Prevention and Control Act (2017)	Yes

## 10. HIV-TB Co-morbidities

## A. HRG and Bridge Population

Indicator								2021-22
	Quarter	FSW	MSW	IDU	TG	Migrants	Truckers	Total
Screened for TB	Quarter 1	76,004	13,691	679	2,012	11,770	1,706	1,05,862
	Quarter 2	89,465	16,208	829	2,419	12,464	3,598	1,24,983
	Quarter 3	95,928	18,527	902	2,645	11,921	1,949	1,31,872
	Quarter 4	1,11,961	23,810	1,219	3,373	14,341	2,827	1,57,531
Tested for TB	Quarter 1	575	77	17	9	23	-	701
	Quarter 2	866	158	19	6	74	-	1,123
	Quarter 3	990	129	25	23	95	7	1,269
	Quarter 4	959	161	25	34	131	20	1,330
Diagnosed with TB	Quarter 1	3	2	-	-	-	-	5
	Quarter 2	-	2	1	-	1	-	4
	Quarter 3	2	2	4	-	-	-	8
	Quarter 4	29	18	-	-	-	-	47
Initiated on TB treatment	Quarter 1	3	2	-	-	-	-	5
	Quarter 2	-	2	1	-	1	-	4
	Quarter 3	2	2	-	-	-	-	4
	Quarter 4	28	18	-	-	-	-	46

## B. HIV-TB Cross-Referral

Indicator	2021-22
1. In referral from TB program	59,787
1.1. HIV sero-positive (%)	2.14
1.2. ICTC clients referred to NTEP	63,046

## C. HIV-TB Coinfected at ART Centre

Indicator								2021-22
	PLHIV attending ART Centre	PLHIV underwent 4S screening	PLHIV with presumptive TB	PLHIV tested for TB	PLHIV diagnosed with TB	PLHIV initiated on IPT	Co-infected enrolled at ARTc	Co-infected initiated on ART
Apr-21	1,49,327	1,45,100	5,210	4,922	218	2,605		
May-21	1,32,447	1,26,328	3,421	3,084	97	911		
Jun-21	94,440	89,024	3,389	3,366	160	853		
Jul-21	1,13,197	1,07,344	4,874	4,832	252	3,105		
Aug-21	1,23,606	1,17,303	5,284	5,218	269	2,165		
Sep-21	1,13,830	1,08,295	5,339	5,282	236	2,386		
Oct-21	92,455	87,686	4,695	4,631	286	1,307		
Nov-21	91,493	87,671	4,462	4,439	295	1,285		
Dec-21	1,00,764	97,000	4,437	4,202	304	1,165		
Jan-22	85,331	81,365	5,307	3,957	241	1,358		
Feb-22	88,297	85,983	4,292	4,271	277	1,240		
Mar-22	98,985	95,291	4,684	4,634	303	1,322		
April 2021- March 2022							4,311	4,201

## 11. Scorecard

State/UT Name		Andhra Pradesh
Overall Rank		26
IEC & MS	Frequency of Social Media updates (G= ≥60, Y=40-59, R=<40)	
	Status of AEP integration in state School curriculum (G=Yes, R=No)	
	Status of SCA (G= At least one meeting held since 2017, R= other than G)	
	Status of State Rules (G= Notified, R= Not notified)	
	Status of Ombudsman (G= Appointed, R=Not appointed)	
	Rank	26
TI	Facilities onboarded (G=≥95%, Y= 90-94%, R=<90%)	
	Coverage against target in contract (G=≥95%, Y= 90-94%, R=<90%)	
	HRG & BP living with HIV on ART (G=≥95%, Y= 90-94%, R=<90%)	
	IDU on OST (G=≥95%, Y= 90-94%, R=<90%)	
	Rank	19
BSD	Percentage of PLHIV who know their status (G=≥95%, Y= 80-94%, R=<80%)	
	HIV testing against target-GC ((G=≥95%, Y= 80-94%, R=<80%)	
	HIV testing against target-PW (G=≥95%, Y= 80-94%, R=<80%)	
	Percentage of Pregnant women who initiated ART (G=≥95%, Y= 80-94%, R=<80%)	
	Percentage of TB suspected cases referred to NTEP (G=≥95%, Y= 80-94%, R=<80%)	
	Clients managed at DSRC against the target (G=≥95%, Y= 80-94%, R=<80%)	
	Percentage of pregnant women tested for Syphilis (G=≥95%, Y= 80-94%, R=<80%)	
	Rank	5
CST	ART Initiation (Current FY) (G=≥95%, Y= 80-94%, R=<80%)	
	LFU rate among new ART initiation (G=<2%, Y= 2-4%, R=≥5%)	
	PLHIV put on ART during the FY against target (G=≥95%, Y= 80-94%, R=<80%)	
	Status on establishment of CSC (G=≥95%, Y= 80-94%, R=<80%)	
	Rank	25
LS	VL Suppression Rate (Current FY) (G=≥95%, Y= 85-94%, R=<85%)	
	% of SRL accredited (G=100%, Y= 80-99%, R=<80%)	
	% Participation of ICTCs in Re-testing (G=≥95%, Y= 85-94, R=<85%)	
	Rank	25
SI	% of NACP facilities active in SOCH (G=≥90%, Y= 75-89%, R=<75%)	
	Status of State Data Management Committee (G=one meeting held, Y= no meeting held, R= not constituted)	
	Status of finalized Priority Areas for Operational Research and Evaluation (G= 4, Y= 3, R= <3)	
	Rank	14
Finance	Expenditure with respect to funds released during FY 2021-22 (G=≥90%, Y= 85-89%, R=<85%)	
	Submission of Audit Report after approval of EC/GB for the preceding year (G= by 30th June, Y= 30th Sept, R= beyond 30th Sept 2021)	
	Submission of Utilization Certificate (in prescribed format GFR 12A) for the previous financial year (G= by 30th June, Y= 30th Sept, R= beyond 30th Sept 2021)	
	Rank	23
SCM	Report Submission (BSD-SCM Report) (G=≥90%, Y= 75-89%, R=<75%)	

Green=3 Marks

Yellow=2Marks

Red=1 Mark

No Colour=Not Applicable



# FACT SHEET

ARUNACHAL  
PRADESH

# ARUNACHAL PRADESH

## 1. Status of HIV/AIDS Epidemic

### A. Epidemic Estimates (2021)

Indicator	Male	Female	Total
1. IPR	-	-	9.91
2. IMR	-	-	4.00
3. Adult (15-49 yrs) HIV Prevalence (%)	0.0	0.06	0.07
4. Estimated people living with HIV	407	280	687
5. ART coverage (%)	32.7	33	33
6. Estimated children living with HIV	13	13	26
7. Annual new HIV infections	41	27	68
8. Annual AIDS-related deaths (ARD)	7	6	13
9. Change in annual new HIV infections since 2010 (%)	51.9	50.00	54.55
10. Change in annual ARD since 2010(%)	40.0	50.00	44.44
11. EMTCT need	-	9	9


### B. High risk population size (2009), safe practices (2015) and prevalence (2021)

Population Group	Estimates Size	Condom Use (%)	New Needle/ Syringe use (%)	HIV Prevalence (%)
1. Female Sex Workers	4,690	48.1	68.6	0.27
2. Men who have sex with men	715	-	-	-
3. Injecting Drug Users	2,565	62.5	87.9	1.6
4. Hijra/Transgender People	-	-	-	-
5. Migrants	40,500	-	-	-
6. Truckers	-	-	-	-
7. Prison inmates	599	-	-	-

### C. HIV/AIDS related knowledge, stigma and high-risk behaviour in general population (2019-21)

Indicator	Male	Female	Total
1. Adults (15-49 yrs) with comprehensive knowledge about HIV/AIDS (%)	33.4	12.3	-
2. Youth (15-24 yrs) with comprehensive knowledge about HIV/AIDS (%)	35.4	15.5	-
3. Adults willing to care for a relative with HIV/AIDS in own home (%)	67.9	56.7	-
4. Adults willing to buy fresh vegetables from a shopkeeper or vendor who has HIV/AIDS (%)	59.3	50.3	-
5. Adults (15-49 yrs) who have had higher-risk sexual behaviour in the past 12 months (%)	7.4	2	-
5.1 Condom use during last higher-risk intercourse (%)	75.8	58.5	-
6. Youth (15-24 yrs) who have had higher-risk sexual behaviour in the past 12 months (%)	12.3	4.0	-
6.1 Condom use during last higher-risk intercourse (%)	80.0	62.2	-

## 2. Progress on 95-95-95 (2021-22)



Indicator	Male	Female	Total
1. Estimated PLHIV size (2021)	407	280	687
2. PLHIV who know their HIV Status	190	133	323
3. PLHIV who know their HIV status and are on ART	129	89	218
4. PLHIV who are on ART and tested for their viral load	93	83	176
5. PLHIV who are virally suppressed	72	65	137

### 3. Prevention of new HIV infections among general population

#### A. Information, Education, Communication, Youth and Mainstreaming

Indicator	2021-22
1. Schools with operational Adolescent Education Program (AEP)	200
2. Colleges with operational Red Ribbon Clubs (RRC)	47
3. Persons trained under mainstreaming	3,700

#### B. Sexually Transmitted Infections (STI)/Reproductive Tract Infections (RTI) Management at DSRCs

Indicator	2021-22			
1. NACO Supported Designated STI/RTI Clinics (DSRC)	18			
	Male	Female	TG	Total
2. Clients managed	-	-	-	7,745
3. RPR Tests conducted	2,215	11,855	4	14,074
4. Syphilis seropositivity (%)	5.28	2.53	100.00	2.99

### 4. Prevention of new HIV infections among high-risk group and bridge population

#### A. Targeted Interventions (TI) and Opioid Substitution Therapy (OST)

Indicator	2021-22
1. Targeted Interventions	20
2. OST centres	3
3. Employer Led Model Interventions	-

#### B. Female Sex Workers

Indicator	2021-22
1. Estimated size	4,690
2. Coverage (%)	>=95
3. Condoms distributed	4,96,101
4. Tested for HIV (April 2021 - September 2021)	4,176
4.1. HIV sero-positive (%)	0.00
4.1.1. Linked to ART	-
5. Tested for HIV (October 2021 - March 2022)	4,320
5.1. HIV sero-positive (%)	0.02
5.1.1. Linked to ART	1
6. Clinic Visits	14,162
7. STI/RTI treated	139
8. Presumptive treatment	675

#### C. Men who have Sex with Men

Indicator	2021-22
1. Estimated size	715
2. Coverage (%)	85
3. Condoms distributed	1,10,211
4. Tested for HIV (April 2021 - September 2021)	613
4.1. HIV sero-positive (%)	0.00
4.1.1. Linked to ART	-
5. Tested for HIV (October 2021 - March 2022)	627
5.1. HIV sero-positive (%)	0.32
5.1.1. Linked to ART	2
6. Clinic Visits	2,155
7. STI/RTI treated	29
8. Presumptive treatment	42

#### D. Injecting Drug Users

Indicator	2021-22
1. Estimated size	2,565
2. Coverage (%)	>=95
3. Needles distributed	1,98,928
4. Syringes distributed	1,99,084
5. On OST	327
6. Tested for HIV (April 2021 - September 2021)	1,955
6.1. HIV sero-positive (%)	0.15
6.1.1. Linked to ART	0
7. Tested for HIV (October 2021 - March 2022)	2,400
7.1. HIV sero-positive (%)	0.21
7.1.1. Linked to ART	5

#### E. Hijra/Transgender people

Indicator	2021-22
1. Estimated size	-
2. Coverage (%)	-
3. Condoms distributed	-
4. Tested for HIV (April 2021 - September 2021)	-
4.1. HIV sero-positive (%)	-
4.1.1. Linked to ART	-
5. Tested for HIV (October 2021 - March 2022)	-
5.1. HIV sero-positive (%)	-
5.1.1. Put on ART	-
6. Clinic Visits	-
7. STI / RTI treated	-
8. Presumptive treatment	-

#### F. Migrants

Indicator	2021-22
1. Estimated size	40,500
2. Coverage (%)	>=95
3. Tested for HIV	6,896
3.1. HIV sero-positive (%)	0.01
3.2. Linked to ART	1

#### G. Truckers

Indicator	2021-22
1. Estimated size	-
2. Coverage (%)	-
3. Tested for HIV	-
3.1. HIV sero-positive (%)	-
3.2. On ART	-

#### H. Prison Inmates

Indicator	2021-22
1. Total prisons	2
2. Prisons covered under programme	-
3. Total inmates admitted	563
4. Inmates Covered(%)	36
5. Tested for HIV	0
5.1. HIV sero-positive (%)	-
5.2. On ART (%)	-

#### I. Link Worker Scheme

Indicator	2021-22
1. Districts covered under scheme	-
2. Vulnerable population covered	-
3. Tested for HIV	-
3.1. HIV sero-positive (%)	-
3.2. Linked to ART (%)	-



## J. Opioid Substitution Therapy

Indicator	2021-22
1. OST Centres	3
1.1. OSTC in Public Health Settings	3
1.2. OSTC in NGO Settings	-
1.3 No. of Satellite OST Centres	-
2. IDU on OST	327

## 5. Early detection of HIV infected people

### A. HIV Counselling and Testing Services (HCTS)

Indicator	2021-22
1. ICTC facilities	147
1.1. Stand-alone	39
1.2. Facility integrated (Govt)	83
1.3. Facility integrated (PPP)	4
1.4. CBS	21

### B. HIV Testing among Vulnerable Population (Excluding Pregnant Women)

Indicator	2021-22			
	Male	Female	TG	Total
1. Tested for HIV	8,225	7,816	451	16,492
2. Found HIV Positive among tested	44	23	1	68
3. HIV sero-positivity (%) among tested	0.53	0.29	0.22	0.41
4. Spouse/sexual partner testing of HIV positive people identified	9	18	-	27

## 6. Initiation and retention on ART of HIV infected people

### A. Treatment Facilities

Indicator	2021-22
1. ART Centres	1
2. Centre of Excellence	
2.1. Centre of Excellence (Adult)	-
2.2. Centre of Excellence (Paediatric)	-
3. Link ART Centres	4
4. Care Support Centres	-

### B. Treatment Uptake

Indicator	2021-22			
	Male	Female	TG	Total
1. HIV positive cases diagnosed (At ICTC)	44	26	1	71
2. New PLHIV Registered at ART center	37	21	-	58
2.1 Initiated on ART	34	15	-	49
3. PLHIV alive and on ART	133	93	-	226
4. 12 months retention on ART (%)				87.50
5. Lost to follow-up cases	18	10	1	29

## 7. Viral Suppression and laboratories

### A. Laboratory facilities and service uptake

Indicator	2021-22
1. Viral load laboratories	-
1.1 Accredited Viral load laboratories	-
2. Viral load testing conducted	164
2.1. Virally suppressed (%)	78
3. National reference laboratories (NRL)	-
3.1 Accredited NRL	-
4. State reference laboratories (SRL)	1
4.1 Accredited SRL	1
5. CD4 testing conducted	80
6. External Quality Assessment of ICTC	
6.1 Average Participation (%)	47.97
6.2. Average Discordance (%)	0.00
7. Quality Assurance Scheme for Basic Composite Medical Laboratories (Entry Level)- M(EL)T	
7.1 No. of ICTCs certified for M(EL)T certification	-

## 8. Elimination of mother to child transmission of HIV & Syphilis

### A. HIV

Indicator	2021-22
1. Estimated pregnant women (PW)	29,540
2. HIV testing among PW	13,780
3. HIV sero-positivity (%) among tested	0.02
4. HIV Positive PW (old + new detections)	14
4.1 On life-long ART	12
5. Live births among HIV positive PW	6
5.1 Babies given ARV Prophylaxis (%)	100.00
6. Babies tested HIV (6 week- 6 month)	6
6.1 Babies confirmed HIV Positive (6 week- 6 month)	-
7. HIV exposed babies at 18 months	
7.1 HIV exposed babies tested at 18 month	1
7.2 Babies confirmed HIV positive at 18 months	-
8. HIV positive babies initiated on ART	-

### B. Syphilis

Indicator	2021-22
1. Estimated pregnant women (PW)	29,540
2. Syphilis testing among PW	9,980
3. Sero-positivity (%) among tested	1.86
4. Put on treatment	150

## 9. Elimination of HIV/AIDS related Stigma and Discrimination

### A. HIV/AIDS Prevention & Control Act (2017)

Indicator	2021-22
1. State rules notified for HIV/AIDS Prevention and Control Act (2017)	No
2. State designated/appointed ombudsman for HIV/AIDS Prevention and Control Act (2017)	No

## 10. HIV-TB Co-morbidities

## A. HRG and Bridge Population

Indicator								2021-22
	Quarter	FSW	MSW	IDU	TG	Migrants	Truckers	Total
Screened for TB	Quarter 1	2,001	476	1,593	-	7,082	-	11,152
	Quarter 2	2,288	476	1,847	-	6,938	-	11,549
	Quarter 3	2,342	491	2,487	-	6,528	-	11,848
	Quarter 4	2,519	506	2,735	-	7,625	-	13,385
Tested for TB	Quarter 1	10	-	4	-	1	-	15
	Quarter 2	23	-	10	-	-	-	33
	Quarter 3	26	-	13	-	-	-	39
	Quarter 4	18	3	4	-	-	-	25
Diagnosed with TB	Quarter 1	2	-	1	-	-	-	3
	Quarter 2	12	-	2	-	-	-	14
	Quarter 3	10	-	3	-	-	-	13
	Quarter 4	3	-	1	-	-	-	4
Initiated on TB treatment	Quarter 1	-	-	-	-	-	-	-
	Quarter 2	-	-	-	-	-	-	-
	Quarter 3	-	-	-	-	-	-	-
	Quarter 4	-	-	-	-	-	-	-

## B. HIV-TB Cross-Referral

Indicator	2021-22
1. In referral from TB program	1,199
1.1. HIV sero-positive (%)	0.17
1.2. ICTC clients referred to NTEP	180

## C. HIV-TB Coinfected at ART Centre

Indicator								2021-22
	PLHIV attending ART Centre	PLHIV underwent 4S screening	PLHIV with presumptive TB	PLHIV tested for TB	PLHIV diagnosed with TB	PLHIV initiated on IPT	Co-infected enrolled at ARTc	Co-infected initiated on ART
Apr-21	86	86	2	2	-	-		
May-21	60	54	-	-	-	-		
Jun-21	58	58	6	6	1	-		
Jul-21	58	58	6	6	1	-		
Aug-21	57	57	-	-	-	11		
Sep-21	62	62	10	10	-	-		
Oct-21	56	56	5	5	-	4		
Nov-21	49	49	3	3	-	2		
Dec-21	58	58	5	5	-	2		
Jan-22	77	77	5	5	-	3		
Feb-22	45	45	6	6	-	8		
Mar-22	52	52	2	2	2	7		
April 2021- March 2022							8	6

## 11. Scorecard

State/UT Name		Arunachal Pradesh
Overall Rank		33
IEC & MS	Frequency of Social Media updates (G= ≥60, Y=40-59, R=<40)	
	Status of AEP integration in state School curriculum (G=Yes, R=No)	
	Status of SCA (G= At least one meeting held since 2017, R= other than G)	
	Status of State Rules (G= Notified, R= Not notified)	
	Status of Ombudsman (G= Appointed, R=Not appointed)	
	Rank	32
TI	Facilities onboarded (G=≥95%, Y= 90-94%, R=<90%)	
	Coverage against target in contract (G=≥95%, Y= 90-94%, R=<90%)	
	HRG & BP living with HIV on ART (G=≥95%, Y= 90-94%, R=<90%)	
	IDU on OST (G=≥95%, Y= 90-94%, R=<90%)	
	Rank	11
BSD	Percentage of PLHIV who know their status (G=≥95%, Y= 80-94%, R=<80%)	
	HIV testing against target-GC ((G=≥95%, Y= 80-94%, R=<80%)	
	HIV testing against target-PW (G=≥95%, Y= 80-94%, R=<80%)	
	Percentage of Pregnant women who initiated ART (G=≥95%, Y= 80-94%, R=<80%)	
	Percentage of TB suspected cases referred to NTEP (G=≥95%, Y= 80-94%, R=<80%)	
	Clients managed at DSRC against the target (G=≥95%, Y= 80-94%, R=<80%)	
	Percentage of pregnant women tested for Syphilis (G=≥95%, Y= 80-94%, R=<80%)	
	Rank	17
CST	ART Initiation (Current FY) (G=≥95%, Y= 80-94%, R=<80%)	
	LFU rate among new ART initiation (G=<2%, Y= 2-4%, R=≥5%)	
	PLHIV put on ART during the FY against target (G=≥95%, Y= 80-94%, R=<80%)	
	Status on establishment of CSC (G=≥95%, Y= 80-94%, R=<80%)	NA
	Rank	17
LS	VL Suppression Rate (Current FY) (G=≥95%, Y= 85-94%, R=<85%)	
	% of SRL accredited (G=100%, Y= 80-99%, R=<80%)	
	% Participation of ICTCs in Re-testing (G=≥95%, Y= 85-94, R=<85%)	
	Rank	19
SI	% of NACP facilities active in SOCH (G=≥90%, Y= 75-89%, R=<75%)	
	Status of State Data Management Committee (G=one meeting held, Y= no meeting held, R= not constituted)	
	Status of finalized Priority Areas for Operational Research and Evaluation (G= 4, Y= 3, R= <3)	
	Rank	25
Finance	Expenditure with respect to funds released during FY 2021-22 (G=≥90%, Y= 85-89%, R=<85%)	
	Submission of Audit Report after approval of EC/GB for the preceding year (G= by 30th June, Y= 30th Sept, R= beyond 30th Sept 2021)	
	Submission of Utilization Certificate (in prescribed format GFR 12A) for the previous financial year (G= by 30th June, Y= 30th Sept, R= beyond 30th Sept 2021)	
	Rank	23
SCM	Report Submission (BSD-SCM Report) (G=≥90%, Y= 75-89%, R=<75%)	

Green=3 Marks

Yellow=2Marks

Red=1 Mark

No Colour=Not Applicable

A thick red ribbon is draped across the page, starting from the bottom left, looping up to the top right, and then extending back down towards the bottom right. The background is a gradient of yellow and orange with faint, concentric circular patterns.

# FACT SHEET

## ASSAM

## 1. Status of HIV/AIDS Epidemic

### A. Epidemic Estimates (2021)

Indicator	Male	Female	Total
1. IPR	-	-	8.29
2. IMR	-	-	2.39
3. Adult (15-49 yrs) HIV Prevalence (%)	0.10	0.09	0.09
4. Estimated people living with HIV	13,766	11,306	25,072
5. ART coverage (%)	42.8	33	39
6. Estimated children living with HIV	467	435	902
7. Annual new HIV infections	1,085	993	2,078
8. Annual AIDS-related deaths (ARD)	349	328	677
9. Change in annual new HIV infections since 2010 (%)	18.2	36.21	26.23
10. Change in annual ARD since 2010(%)	-17.7	5.81	-7.77
11. EMTCT need	-	334	334


### B. High risk population size (2009), safe practices (2015) and prevalence (2021)

Population Group	Estimates Size	Condom Use (%)	New Needle/ Syringe use (%)	HIV Prevalence (%)
1. Female Sex Workers	17,448	75.3	0	1.65
2. Men who have sex with men	2,570	33.8	17.9	3.61
3. Injecting Drug Users	3,146	48.9	87.6	11.24
4. Hijra/Transgender People	466	-	-	-
5. Migrants	20,000	-	-	3.21
6. Truckers	25,000	-	-	2.12
7. Prison inmates	37,621	22.2	68.5	2.01

### C. HIV/AIDS related knowledge, stigma and high-risk behaviour in general population (2019-21)

Indicator	Male	Female	Total
1. Adults (15-49 yrs) with comprehensive knowledge about HIV/AIDS (%)	25.3	19.2	-
2. Youth (15-24 yrs) with comprehensive knowledge about HIV/AIDS (%)	27.4	19	-
3. Adults willing to care for a relative with HIV/AIDS in own home (%)	75.6	76.1	-
4. Adults willing to buy fresh vegetables from a shopkeeper or vendor who has HIV/AIDS (%)	69.1	72.4	-
5. Adults (15-49 yrs) who have had higher-risk sexual behaviour in the past 12 months (%)	1.1	0.3	-
5.1 Condom use during last higher-risk intercourse (%)	62.6	40	-
6. Youth (15-24 yrs) who have had higher-risk sexual behaviour in the past 12 months (%)	1.8	0.5	-
6.1 Condom use during last higher-risk intercourse (%)	69.2	25.0	-

## 2. Progress on 95-95-95 (2021-22)



### 3. Prevention of new HIV infections among general population

#### A. Information, Education, Communication, Youth and Mainstreaming

Indicator	2021-22
1. Schools with operational Adolescent Education Program (AEP)	500
2. Colleges with operational Red Ribbon Clubs (RRC)	239
3. Persons trained under mainstreaming	10,355

#### B. Sexually Transmitted Infections (STI)/Reproductive Tract Infections (RTI) Management at DSRCs

Indicator	2021-22			
1. NACO Supported Designated STI/RTI Clinics (DSRC)	28			
	Male	Female	TG	Total
2. Clients managed	-	-	-	44,784
3. RPR Tests conducted	9,763	31,858	26	41,647
4. Syphilis seropositivity (%)	2.77	0.28	0.00	0.86

### 4. Prevention of new HIV infections among high-risk group and bridge population

#### A. Targeted Interventions (TI) and Opioid Substitution Therapy (OST)

Indicator	2021-22
1. Targeted Interventions	46
2. OST centres	6
3. Employer Led Model Interventions	4

#### B. Female Sex Workers

Indicator	2021-22
1. Estimated size	17,448
2. Coverage (%)	79
3. Condoms distributed	27,19,386
4. Tested for HIV (April 2021 - September 2021)	8,358
4.1. HIV sero-positive (%)	0.50
4.1.1. Linked to ART	24
5. Tested for HIV (October 2021 - March 2022)	10,072
5.1. HIV sero-positive (%)	0.38
5.1.1. Linked to ART	17
6. Clinic Visits	37,596
7. STI/RTI treated	814
8. Presumptive treatment	1,701

#### C. Men who have Sex with Men

Indicator	2021-22
1. Estimated size	2,570
2. Coverage (%)	>=95
3. Condoms distributed	7,05,916
4. Tested for HIV (April 2021 - September 2021)	3,138
4.1. HIV sero-positive (%)	1.21
4.1.1. Linked to ART	22
5. Tested for HIV (October 2021 - March 2022)	3,632
5.1. HIV sero-positive (%)	1.49
5.1.1. Linked to ART	29
6. Clinic Visits	13,167
7. STI/RTI treated	93
8. Presumptive treatment	686

### D. Injecting Drug Users

Indicator	2021-22
1. Estimated size	3,146
2. Coverage (%)	90
3. Needles distributed	4,19,366
4. Syringes distributed	4,19,372
5. On OST	1,391
6. Tested for HIV (April 2021 - September 2021)	1,985
6.1. HIV sero-positive (%)	9.67
6.1.1. Linked to ART	114
7. Tested for HIV (October 2021 - March 2022)	2,240
7.1. HIV sero-positive (%)	6.25
7.1.1. Linked to ART	53

### E. Hijra/Transgender people

Indicator	2021-22
1. Estimated size	466
2. Coverage (%)	>=95
3. Condoms distributed	67,362
4. Tested for HIV (April 2021 - September 2021)	329
4.1. HIV sero-positive (%)	0.00
4.1.1. Linked to ART	0
5. Tested for HIV (October 2021 - March 2022)	316
5.1. HIV sero-positive (%)	0.00
5.1.1. Put on ART	-
6. Clinic Visits	1,294
7. STI / RTI treated	12
8. Presumptive treatment	101

### F. Migrants

Indicator	2021-22
1. Estimated size	20,000
2. Coverage (%)	87
3. Tested for HIV	4,541
3.1. HIV sero-positive (%)	1.26
3.2. Linked to ART	47

### G. Truckers

Indicator	2021-22
1. Estimated size	25,000
2. Coverage (%)	60
3. Tested for HIV	5,123
3.1. HIV sero-positive (%)	0.33
3.2. On ART	2

### H. Prison Inmates

Indicator	2021-22
1. Total prisons	31
2. Prisons covered under programme	28
3. Total inmates admitted	18,090
4. Inmates Covered(%)	42
5. Tested for HIV	7,082
5.1. HIV sero-positive (%)	2.47
5.2. On ART (%)	66

### I. Link Worker Scheme

Indicator	2021-22
1. Districts covered under scheme	-
2. Vulnerable population covered	-
3. Tested for HIV	-
3.1. HIV sero-positive (%)	-
3.2. Linked to ART (%)	-



## J. Opioid Substitution Therapy

Indicator	2021-22
1. OST Centres	6
1.1. OSTC in Public Health Settings	5
1.2. OSTC in NGO Settings	-
1.3 No. of Satellite OST Centres	1
2. IDU on OST	1,391

## 5. Early detection of HIV infected people

### A. HIV Counselling and Testing Services (HCTS)

Indicator	2021-22
1. ICTC facilities	435
1.1. Stand-alone	109
1.2. Facility integrated (Govt)	231
1.3. Facility integrated (PPP)	65
1.4. CBS	30

### B. HIV Testing among Vulnerable Population (Excluding Pregnant Women)

Indicator	2021-22			
	Male	Female	TG	Total
1. Tested for HIV	1,33,566	88,688	373	2,22,627
2. Found HIV Positive among tested	1,793	357	6	2,156
3. HIV sero-positivity (%) among tested	1.34	0.40	1.61	0.97
4. Spouse/sexual partner testing of HIV positive people identified	228	598	4	830

## 6. Initiation and retention on ART of HIV infected people

### A. Treatment Facilities

Indicator	2021-22
1. ART Centres	7
2. Centre of Excellence	
2.1. Centre of Excellence (Adult)	-
2.2. Centre of Excellence (Paediatric)	-
3. Link ART Centres	10
4. Care Support Centres	3

### B. Treatment Uptake

Indicator	2021-22			
	Male	Female	TG	Total
1. HIV positive cases diagnosed (At ICTC)	1,793	464	6	2,263
2. New PLHIV Registered at ART center	1,480	490	7	1,977
2.1 Initiated on ART	1,211	434	6	1,651
3. PLHIV alive and on ART	5,892	3,748	15	9,655
4. 12 months retention on ART (%)				84.04
5. Lost to follow-up cases	1,966	1,106	14	3,086

## 7. Viral Suppression and laboratories

### A. Laboratory facilities and service uptake

Indicator	2021-22
1. Viral load laboratories	-
1.1 Accredited Viral load laboratories	-
2. Viral load testing conducted	4,189
2.1. Virally suppressed (%)	89
3. National reference laboratories (NRL)	-
3.1 Accredited NRL	-
4. State reference laboratories (SRL)	3
4.1 Accredited SRL	3
5. CD4 testing conducted	3,962
6. External Quality Assessment of ICTC	
6.1 Average Participation (%)	86.78
6.2. Average Discordance (%)	0.00
7. Quality Assurance Scheme for Basic Composite Medical Laboratories (Entry Level)- M(EL)T	
7.1 No. of ICTCs certified for M(EL)T certification	-

## 8. Elimination of mother to child transmission of HIV & Syphilis

### A. HIV

Indicator	2021-22
1. Estimated pregnant women (PW)	8,16,980
2. HIV testing among PW	4,71,235
3. HIV sero-positivity (%) among tested	0.02
4. HIV Positive PW (old + new detections)	178
4.1 On life-long ART	194
5. Live births among HIV positive PW	147
5.1 Babies given ARV Prophylaxis (%)	97.96
6. Babies tested HIV (6 week- 6 month)	211
6.1 Babies confirmed HIV Positive (6 week- 6 month)	7
7. HIV exposed babies at 18 months	
7.1 HIV exposed babies tested at 18 month	159
7.2 Babies confirmed HIV positive at 18 months	11
8. HIV positive babies initiated on ART	90

### B. Syphilis

Indicator	2021-22
1. Estimated pregnant women (PW)	8,16,980
2. Syphilis testing among PW	2,96,243
3. Sero-positivity (%) among tested	0.01
4. Put on treatment	24

## 9. Elimination of HIV/AIDS related Stigma and Discrimination

### A. HIV/AIDS Prevention & Control Act (2017)

Indicator	2021-22
1. State rules notified for HIV/AIDS Prevention and Control Act (2017)	Yes
2. State designated/appointed ombudsman for HIV/AIDS Prevention and Control Act (2017)	Yes

## 10. HIV-TB Co-morbidities

### A. HRG and Bridge Population

Indicator								2021-22
	Quarter	FSW	MSW	IDU	TG	Migrants	Truckers	Total
Screened for TB	Quarter 1	9,349	3,756	1,342	524	117	1,762	16,850
	Quarter 2	10,560	3,991	1,710	506	536	1,139	18,442
	Quarter 3	10,147	4,123	1,813	534	506	1,853	18,976
	Quarter 4	10,555	4,399	1,916	518	1,171	1,779	20,338
Tested for TB	Quarter 1	7	8	2	1	6	-	24
	Quarter 2	11	9	27	-	13	-	60
	Quarter 3	6	10	4	-	14	-	34
	Quarter 4	13	4	32	-	12	-	61
Diagnosed with TB	Quarter 1	1	-	1	-	44	-	46
	Quarter 2	2	-	1	-	24	-	27
	Quarter 3	-	-	-	-	-	-	-
	Quarter 4	10	-	-	-	-	-	10
Initiated on TB treatment	Quarter 1	-	-	1	-	1	-	2
	Quarter 2	1	-	1	-	1	-	3
	Quarter 3	-	-	-	-	-	-	-
	Quarter 4	-	-	-	-	-	-	-

### B. HIV-TB Cross-Referral

Indicator	2021-22
1. In referral from TB program	14,224
1.1. HIV sero-positive (%)	0.49
1.2. ICTC clients referred to NTEP	4,057

### C. HIV-TB Coinfected at ART Centre

Indicator							2021-22	
	PLHIV attending ART Centre	PLHIV underwent 4S screening	PLHIV with presumptive TB	PLHIV tested for TB	PLHIV diagnosed with TB	PLHIV initiated on IPT	Co-infected enrolled at ARTc	Co-infected initiated on ART
Apr-21	5,244	5,244	46	29	20	65		
May-21	4,518	4,518	32	18	13	20		
Jun-21	4,029	4,029	26	10	5	19		
Jul-21	4,090	4,090	52	28	22	43		
Aug-21	4,301	4,301	76	17	13	9		
Sep-21	4,427	4,427	68	31	18	19		
Oct-21	4,618	4,618	82	30	12	4		
Nov-21	3,947	3,947	102	48	19	10		
Dec-21	4,213	4,213	64	28	8	48		
Jan-22	4,270	4,270	67	42	13	108		
Feb-22	4,312	4,312	88	54	24	55		
Mar-22	4,584	4,584	82	46	25	68		
April 2021-March 2022							288	242

## 11. Scorecard

State/UT Name		Assam
Overall Rank		17
IEC & MS	Frequency of Social Media updates (G= ≥60, Y=40-59, R=<40)	
	Status of AEP integration in state School curriculum (G=Yes, R=No)	
	Status of SCA (G= At least one meeting held since 2017, R= other than G)	
	Status of State Rules (G= Notified, R= Not notified)	
	Status of Ombudsman (G= Appointed, R=Not appointed)	
	Rank	1
TI	Facilities onboarded (G=≥95%, Y= 90-94%, R=<90%)	
	Coverage against target in contract (G=≥95%, Y= 90-94%, R=<90%)	
	HRG & BP living with HIV on ART (G=≥95%, Y= 90-94%, R=<90%)	
	IDU on OST (G=≥95%, Y= 90-94%, R=<90%)	
	Rank	28
BSD	Percentage of PLHIV who know their status (G=≥95%, Y= 80-94%, R=<80%)	
	HIV testing against target-GC ((G=≥95%, Y= 80-94%, R=<80%)	
	HIV testing against target-PW (G=≥95%, Y= 80-94%, R=<80%)	
	Percentage of Pregnant women who initiated ART (G=≥95%, Y= 80-94%, R=<80%)	
	Percentage of TB suspected cases referred to NTEP (G=≥95%, Y= 80-94%, R=<80%)	
	Clients managed at DSRC against the target (G=≥95%, Y= 80-94%, R=<80%)	
	Percentage of pregnant women tested for Syphilis (G=≥95%, Y= 80-94%, R=<80%)	
	Rank	26
CST	ART Initiation (Current FY) (G=≥95%, Y= 80-94%, R=<80%)	
	LFU rate among new ART initiation (G=<2%, Y= 2-4%, R=≥5%)	
	PLHIV put on ART during the FY against target (G=≥95%, Y= 80-94%, R=<80%)	
	Status on establishment of CSC (G=≥95%, Y= 80-94%, R=<80%)	NA
	Rank	17
LS	VL Suppression Rate (Current FY) (G=≥95%, Y= 85-94%, R=<85%)	
	% of SRL accredited (G=100%, Y= 80-99%, R=<80%)	
	% Participation of ICTCs in Re-testing (G=≥95%, Y= 85-94, R=<85%)	
	Rank	19
SI	% of NACP facilities active in SOCH (G=≥90%, Y= 75-89%, R=<75%)	
	Status of State Data Management Committee (G=one meeting held, Y= no meeting held, R= not constituted)	
	Status of finalized Priority Areas for Operational Research and Evaluation (G= 4, Y= 3, R= <3)	
	Rank	1
Finance	Expenditure with respect to funds released during FY 2021-22 (G=≥90%, Y= 85-89%, R=<85%)	
	Submission of Audit Report after approval of EC/GB for the preceding year (G= by 30th June, Y= 30th Sept, R= beyond 30th Sept 2021)	
	Submission of Utilization Certificate (in prescribed format GFR 12A) for the previous financial year (G= by 30th June, Y= 30th Sept, R= beyond 30th Sept 2021)	
	Rank	23
SCM	Report Submission (BSD-SCM Report) (G=≥90%, Y= 75-89%, R=<75%)	

Green=3 Marks

Yellow=2Marks

Red=1 Mark

No Colour=Not Applicable

A thick red ribbon is draped across the page, starting from the bottom left, looping upwards and to the right, and then looping back down towards the bottom right. The background is a gradient of yellow and orange with faint, concentric circular patterns.

# FACT SHEET

## BIHAR

## 1. Status of HIV/AIDS Epidemic

### A. Epidemic Estimates (2021)

Indicator	Male	Female	Total
1. IPR	-	-	6.18
2. IMR	-	-	2.50
3. Adult (15-49 yrs) HIV Prevalence (%)	0.18	0.14	0.16
4. Estimated people living with HIV	82,804	59,988	1,42,792
5. ART coverage (%)	47.2	56	51
6. Estimated children living with HIV	3,929	3,602	7,531
7. Annual new HIV infections	5,206	3,621	8,827
8. Annual AIDS-related deaths (ARD)	1,722	749	2,471
9. Change in annual new HIV infections since 2010 (%)	-7.3	-7.11	-7.21
10. Change in annual ARD since 2010(%)	-26.2	-59.99	-41.25
11. EMTCT need	-	2,446	2,446


### B. High risk population size (2009), safe practices (2015) and prevalence (2021)

Population Group	Estimates Size	Condom Use (%)	New Needle/ Syringe use (%)	HIV Prevalence (%)
1. Female Sex Workers	18,682	-	-	0.62
2. Men who have sex with men	4,739	-	-	0.41
3. Injecting Drug Users	7,938	35.4	96.6	2.86
4. Hijra/Transgender People	1,053	-	-	-
5. Migrants	-	-	-	-
6. Truckers	15,000	-	-	-
7. Prison inmates	2,45,503	-	-	0.00

### C. HIV/AIDS related knowledge, stigma and high-risk behaviour in general population (2019-21)

Indicator	Male	Female	Total
1. Adults (15-49 yrs) with comprehensive knowledge about HIV/AIDS (%)	25.1	10.3	-
2. Youth (15-24 yrs) with comprehensive knowledge about HIV/AIDS (%)	25.3	10.1	-
3. Adults willing to care for a relative with HIV/AIDS in own home (%)	81.5	76.7	-
4. Adults willing to buy fresh vegetables from a shopkeeper or vendor who has HIV/AIDS (%)	65.2	68.6	-
5. Adults (15-49 yrs) who have had higher-risk sexual behaviour in the past 12 months (%)	5	0.4	-
5.1 Condom use during last higher-risk intercourse (%)	50.9	23.4	-
6. Youth (15-24 yrs) who have had higher-risk sexual behaviour in the past 12 months (%)	9.0	0.6	-
6.1 Condom use during last higher-risk intercourse (%)	51.4	33.3	-

## 2. Progress on 95-95-95 (2021-22)



Indicator	Male	Female	Total
1. Estimated PLHIV size (2021)	82,804	59,988	1,42,792
2. PLHIV who know their HIV Status	43,992	36,479	80,471
3. PLHIV who know their HIV status and are on ART	36,920	31,550	68,470
4. PLHIV who are on ART and tested for their viral load	17,007	14,743	31,750
5. PLHIV who are virally suppressed	13,955	12,397	26,352

### 3. Prevention of new HIV infections among general population

#### A. Information, Education, Communication, Youth and Mainstreaming

Indicator	2021-22
1. Schools with operational Adolescent Education Program (AEP)	360
2. Colleges with operational Red Ribbon Clubs (RRC)	396
3. Persons trained under mainstreaming	2,929

#### B. Sexually Transmitted Infections (STI)/Reproductive Tract Infections (RTI) Management at DSRCs

Indicator	2021-22			
1. NACO Supported Designated STI/RTI Clinics (DSRC)	44			
	Male	Female	TG	Total
2. Clients managed	-	-	-	2,37,075
3. RPR Tests conducted	20,357	88,498	100	1,08,955
4. Syphilis seropositivity (%)	0.25	0.05	0.00	0.08

### 4. Prevention of new HIV infections among high-risk group and bridge population

#### A. Targeted Interventions (TI) and Opioid Substitution Therapy (OST)

Indicator	2021-22
1. Targeted Interventions	17
2. OST centres	2
3. Employer Led Model Interventions	19

#### B. Female Sex Workers

Indicator	2021-22
1. Estimated size	18,682
2. Coverage (%)	34
3. Condoms distributed	13,27,185
4. Tested for HIV (April 2021 - September 2021)	5,484
4.1. HIV sero-positive (%)	0.05
4.1.1. Linked to ART	3
5. Tested for HIV (October 2021 - March 2022)	5,650
5.1. HIV sero-positive (%)	0.05
5.1.1. Linked to ART	2
6. Clinic Visits	22,581
7. STI/RTI treated	157
8. Presumptive treatment	251

#### C. Men who have Sex with Men

Indicator	2021-22
1. Estimated size	4,739
2. Coverage (%)	36
3. Condoms distributed	2,83,318
4. Tested for HIV (April 2021 - September 2021)	1,524
4.1. HIV sero-positive (%)	0.26
4.1.1. Linked to ART	4
5. Tested for HIV (October 2021 - March 2022)	1,537
5.1. HIV sero-positive (%)	0.13
5.1.1. Linked to ART	2
6. Clinic Visits	5,706
7. STI/RTI treated	87
8. Presumptive treatment	74

### D. Injecting Drug Users

Indicator	2021-22
1. Estimated size	7,938
2. Coverage (%)	40
3. Needles distributed	12,31,085
4. Syringes distributed	8,30,856
5. On OST	175
6. Tested for HIV (April 2021 - September 2021)	2,774
6.1. HIV sero-positive (%)	0.36
6.1.1. Linked to ART	9
7. Tested for HIV (October 2021 - March 2022)	2,833
7.1. HIV sero-positive (%)	0.21
7.1.1. Linked to ART	6

### E. Hijra/Transgender people

Indicator	2021-22
1. Estimated size	1,053
2. Coverage (%)	-
3. Condoms distributed	-
4. Tested for HIV (April 2021 - September 2021)	-
4.1. HIV sero-positive (%)	-
4.1.1. Linked to ART	-
5. Tested for HIV (October 2021 - March 2022)	-
5.1. HIV sero-positive (%)	-
5.1.1. Put on ART	-
6. Clinic Visits	-
7. STI / RTI treated	-
8. Presumptive treatment	-

### F. Migrants

Indicator	2021-22
1. Estimated size	-
2. Coverage (%)	-
3. Tested for HIV	-
3.1. HIV sero-positive (%)	-
3.2. Linked to ART	-

### G. Truckers

Indicator	2021-22
1. Estimated size	15,000
2. Coverage (%)	67
3. Tested for HIV	1,616
3.1. HIV sero-positive (%)	0.12
3.2. On ART	2

### H. Prison Inmates

Indicator	2021-22
1. Total prisons	59
2. Prisons covered under programme	59
3. Total inmates admitted	1,93,184
4. Inmates Covered(%)	63
5. Tested for HIV	1,21,626
5.1. HIV sero-positive (%)	0.36
5.2. On ART (%)	59

### I. Link Worker Scheme

Indicator	2021-22
1. Districts covered under scheme	4
2. Vulnerable population covered	1,69,891
3. Tested for HIV	54,208
3.1. HIV sero-positive (%)	0.08
3.2. Linked to ART (%)	83.33



## J. Opioid Substitution Therapy

Indicator	2021-22
1. OST Centres	2
1.1. OSTC in Public Health Settings	2
1.2. OSTC in NGO Settings	-
1.3 No. of Satellite OST Centres	-
2. IDU on OST	175

## 5. Early detection of HIV infected people

### A. HIV Counselling and Testing Services (HCTS)

Indicator	2021-22
1. ICTC facilities	856
1.1. Stand-alone	209
1.2. Facility integrated (Govt)	543
1.3. Facility integrated (PPP)	45
1.4. CBS	59

### B. HIV Testing among Vulnerable Population (Excluding Pregnant Women)

Indicator	2021-22			
	Male	Female	TG	Total
1. Tested for HIV	3,68,707	3,56,673	10,011	7,35,391
2. Found HIV Positive among tested	4,551	2,605	22	7,178
3. HIV sero-positivity (%) among tested	1.23	0.73	0.22	0.98
4. Spouse/sexual partner testing of HIV positive people identified	2,442	1,583	16	4,041

## 6. Initiation and retention on ART of HIV infected people

### A. Treatment Facilities

Indicator	2021-22
1. ART Centres	28
2. Centre of Excellence	
2.1. Centre of Excellence (Adult)	-
2.2. Centre of Excellence (Paediatric)	-
3. Link ART Centres	13
4. Care Support Centres	15

### B. Treatment Uptake

Indicator	2021-22			
	Male	Female	TG	Total
1. HIV positive cases diagnosed (At ICTC)	4,551	2,947	22	7,520
2. New PLHIV Registered at ART center	5,128	3,469	16	8,613
2.1 Initiated on ART	4,710	3,260	12	7,982
3. PLHIV alive and on ART	39,048	33,295	92	72,434
4. 12 months retention on ART (%)				82.07
5. Lost to follow-up cases	5,189	3,473	13	8,675

## 7. Viral Suppression and laboratories

### A. Laboratory facilities and service uptake

Indicator	2021-22
1. Viral load laboratories	1
1.1 Accredited Viral load laboratories	-
2. Viral load testing conducted	29,033
2.1. Virally suppressed (%)	83
3. National reference laboratories (NRL)	-
3.1 Accredited NRL	-
4. State reference laboratories (SRL)	2
4.1 Accredited SRL	-
5. CD4 testing conducted	28,280
6. External Quality Assessment of ICTC	
6.1 Average Participation (%)	48.91
6.2. Average Discordance (%)	0.00
7. Quality Assurance Scheme for Basic Composite Medical Laboratories (Entry Level)- M(EL)T	
7.1 No. of ICTCs certified for M(EL)T certification	-

## 8. Elimination of mother to child transmission of HIV & Syphilis

### A. HIV

Indicator	2021-22
1. Estimated pregnant women (PW)	34,20,990
2. HIV testing among PW	20,74,460
3. HIV sero-positivity (%) among tested	0.02
4. HIV Positive PW (old + new detections)	704
4.1 On life-long ART	566
5. Live births among HIV positive PW	664
5.1 Babies given ARV Prophylaxis (%)	88.86
6. Babies tested HIV (6 week- 6 month)	434
6.1 Babies confirmed HIV Positive (6 week- 6 month)	3
7. HIV exposed babies at 18 months	
7.1 HIV exposed babies tested at 18 month	538
7.2 Babies confirmed HIV positive at 18 months	4
8. HIV positive babies initiated on ART	37

### B. Syphilis

Indicator	2021-22
1. Estimated pregnant women (PW)	34,20,990
2. Syphilis testing among PW	4,72,699
3. Sero-positivity (%) among tested	0.01
4. Put on treatment	46

## 9. Elimination of HIV/AIDS related Stigma and Discrimination

### A. HIV/AIDS Prevention & Control Act (2017)

Indicator	2021-22
1. State rules notified for HIV/AIDS Prevention and Control Act (2017)	Yes
2. State designated/appointed ombudsman for HIV/AIDS Prevention and Control Act (2017)	Yes

## 10. HIV-TB Co-morbidities

### A. HRG and Bridge Population

Indicator								2021-22
	Quarter	FSW	MSW	IDU	TG	Migrants	Truckers	Total
Screened for TB	Quarter 1	2,683	754	1,112	-	-	2	4,551
	Quarter 2	5,451	1,484	2,636	-	-	-	9,571
	Quarter 3	5,300	1,408	3,177	-	-	304	10,189
	Quarter 4	6,175	1,623	3,384	-	-	494	11,676
Tested for TB	Quarter 1	4	2	1	-	-	2	9
	Quarter 2	20	1	20	-	-	-	41
	Quarter 3	3	1	32	-	-	-	36
	Quarter 4	10	-	32	-	-	-	42
Diagnosed with TB	Quarter 1	-	-	1	-	-	-	1
	Quarter 2	-	1	-	-	-	-	1
	Quarter 3	-	-	-	-	-	-	-
	Quarter 4	1	-	2	-	-	-	3
Initiated on TB treatment	Quarter 1	-	-	1	-	-	-	1
	Quarter 2	-	1	-	-	-	-	1
	Quarter 3	-	-	-	-	-	-	-
	Quarter 4	1	-	2	-	-	-	3

### B. HIV-TB Cross-Referral

Indicator	2021-22
1. In referral from TB program	16,860
1.1. HIV sero-positive (%)	7.19
1.2. ICTC clients referred to NTEP	19,322

### C. HIV-TB Coinfected at ART Centre

Indicator								2021-22
	PLHIV attending ART Centre	PLHIV underwent 4S screening	PLHIV with presumptive TB	PLHIV tested for TB	PLHIV diagnosed with TB	PLHIV initiated on IPT	Co-infected enrolled at ARTc	Co-infected initiated on ART
Apr-21	41,633	39,074	618	415	103	319		
May-21	35,872	31,136	625	406	62	276		
Jun-21	35,829	33,159	656	403	90	347		
Jul-21	34,507	30,628	689	469	109	595		
Aug-21	36,307	32,672	745	429	138	306		
Sep-21	30,990	30,069	854	381	157	306		
Oct-21	34,362	31,882	931	391	117	366		
Nov-21	34,634	31,122	676	373	120	335		
Dec-21	33,342	32,283	791	423	130	405		
Jan-22	36,961	34,164	1,077	722	105	343		
Feb-22	34,173	33,294	1,088	723	105	343		
Mar-22	34,766	29,768	1,132	623	157	354		
April 2021-March 2022							1,495	1,358

## 11. Scorecard

State/UT Name		Bihar
Overall Rank		24
IEC & MS	Frequency of Social Media updates (G= ≥60, Y=40-59, R=<40)	
	Status of AEP integration in state School curriculum (G=Yes, R=No)	
	Status of SCA (G= At least one meeting held since 2017, R= other than G)	
	Status of State Rules (G= Notified, R= Not notified)	
	Status of Ombudsman (G= Appointed, R=Not appointed)	
	Rank	12
TI	Facilities onboarded (G=≥95%, Y= 90-94%, R=<90%)	
	Coverage against target in contract (G=≥95%, Y= 90-94%, R=<90%)	
	HRG & BP living with HIV on ART (G=≥95%, Y= 90-94%, R=<90%)	
	IDU on OST (G=≥95%, Y= 90-94%, R=<90%)	
	Rank	19
BSD	Percentage of PLHIV who know their status (G=≥95%, Y= 80-94%, R=<80%)	
	HIV testing against target-GC ((G=≥95%, Y= 80-94%, R=<80%)	
	HIV testing against target-PW (G=≥95%, Y= 80-94%, R=<80%)	
	Percentage of Pregnant women who initiated ART (G=≥95%, Y= 80-94%, R=<80%)	
	Percentage of TB suspected cases referred to NTEP (G=≥95%, Y= 80-94%, R=<80%)	
	Clients managed at DSRC against the target (G=≥95%, Y= 80-94%, R=<80%)	
	Percentage of pregnant women tested for Syphilis (G=≥95%, Y= 80-94%, R=<80%)	
	Rank	11
CST	ART Initiation (Current FY) (G=≥95%, Y= 80-94%, R=<80%)	
	LFU rate among new ART initiation (G=<2%, Y= 2-4%, R=≥5%)	
	PLHIV put on ART during the FY against target (G=≥95%, Y= 80-94%, R=<80%)	
	Status on establishment of CSC (G=≥95%, Y= 80-94%, R=<80%)	NA
	Rank	6
LS	VL Suppression Rate (Current FY) (G=≥95%, Y= 85-94%, R=<85%)	
	% of SRL accredited (G=100%, Y= 80-99%, R=<80%)	
	% Participation of ICTCs in Re-testing (G=≥95%, Y= 85-94, R=<85%)	
	Rank	31
SI	% of NACP facilities active in SOCH (G=≥90%, Y= 75-89%, R=<75%)	
	Status of State Data Management Committee (G=one meeting held, Y= no meeting held, R= not constituted)	
	Status of finalized Priority Areas for Operational Research and Evaluation (G= 4, Y= 3, R= <3)	
	Rank	32
Finance	Expenditure with respect to funds released during FY 2021-22 (G=≥90%, Y= 85-89%, R=<85%)	
	Submission of Audit Report after approval of EC/GB for the preceding year (G= by 30th June, Y= 30th Sept, R= beyond 30th Sept 2021)	
	Submission of Utilization Certificate (in prescribed format GFR 12A) for the previous financial year (G= by 30th June, Y= 30th Sept, R= beyond 30th Sept 2021)	
	Rank	23
SCM	Report Submission (BSD-SCM Report) (G=≥90%, Y= 75-89%, R=<75%)	

Green=3 Marks

Yellow=2Marks

Red=1 Mark

No Colour=Not Applicable

A thick red ribbon is tied in a loop, with the ends trailing off to the right and bottom. The background is a gradient of yellow and orange, with faint concentric circles centered behind the text.

# FACT SHEET

## CHANDIGARH

## 1. Status of HIV/AIDS Epidemic

### A. Epidemic Estimates (2021)

Indicator	Male	Female	Total
1. IPR	-	-	3.49
2. IMR	-	-	3.72
3. Adult (15-49 yrs) HIV Prevalence (%)	0.23	0.14	0.19
4. Estimated people living with HIV	1,269	652	1,921
5. ART coverage (%)	>=95	>=95	>=95
6. Estimated children living with HIV	26	22	48
7. Annual new HIV infections	46	21	67
8. Annual AIDS-related deaths (ARD)	4	2	6
9. Change in annual new HIV infections since 2010 (%)	-42.5	-43.24	-42.74
10. Change in annual ARD since 2010(%)	-96.0	-95.45	-95.83
11. EMTCT need	-	16	16


### B. High risk population size (2009), safe practices (2015) and prevalence (2021)

Population Group	Estimates Size	Condom Use (%)	New Needle/ Syringe use (%)	HIV Prevalence (%)
1. Female Sex Workers	3,644	87.4	61.4	0.8
2. Men who have sex with men	2,262	68.7	1.9	1.61
3. Injecting Drug Users	1,262	64.5	94.8	2.8
4. Hijra/Transgender People	100	-	-	-
5. Migrants	25,000	-	-	0.4
6. Truckers	15,330	-	-	-
7. Prison inmates	3,706	72.7	26.7	3.47

### C. HIV/AIDS related knowledge, stigma and high-risk behaviour in general population (2019-21)

Indicator	Male	Female	Total
1. Adults (15-49 yrs) with comprehensive knowledge about HIV/AIDS (%)	54.1	20.3	-
2. Youth (15-24 yrs) with comprehensive knowledge about HIV/AIDS (%)	43.2	21	-
3. Adults willing to care for a relative with HIV/AIDS in own home (%)	88.4	65.8	-
4. Adults willing to buy fresh vegetables from a shopkeeper or vendor who has HIV/AIDS (%)	76	48.4	-
5. Adults (15-49 yrs) who have had higher-risk sexual behaviour in the past 12 months (%)	1.8	0	-
5.1 Condom use during last higher-risk intercourse (%)	46.5	NA	-
6. Youth (15-24 yrs) who have had higher-risk sexual behaviour in the past 12 months (%)	5.0	0	-
6.1 Condom use during last higher-risk intercourse (%)	50.0	NA	-

## 2. Progress on 95-95-95 (2021-22)



Indicator	Male	Female	Total
1. Estimated PLHIV size (2021)	1,269	652	1,921
2. PLHIV who know their HIV Status	4,087	2,118	6,205
3. PLHIV who know their HIV status and are on ART	3,293	1,803	5,096
4. PLHIV who are on ART and tested for their viral load	2,735	1,532	4,267
5. PLHIV who are virally suppressed	2,507	1,442	3,949

### 3. Prevention of new HIV infections among general population

#### A. Information, Education, Communication, Youth and Mainstreaming

Indicator	2021-22
1. Schools with operational Adolescent Education Program (AEP)	150
2. Colleges with operational Red Ribbon Clubs (RRC)	25
3. Persons trained under mainstreaming	4,121

#### B. Sexually Transmitted Infections (STI)/Reproductive Tract Infections (RTI) Management at DSRCs

Indicator	2021-22			
1. NACO Supported Designated STI/RTI Clinics (DSRC)	5			
	Male	Female	TG	Total
2. Clients managed	-	-	-	4,607
3. RPR Tests conducted	1,069	3,501	0	4,570
4. Syphilis seropositivity (%)	10.48	1.09	-	3.28

### 4. Prevention of new HIV infections among high-risk group and bridge population

#### A. Targeted Interventions (TI) and Opioid Substitution Therapy (OST)

Indicator	2021-22
1. Targeted Interventions	12
2. OST centres	4
3. Employer Led Model Interventions	0

#### B. Female Sex Workers

Indicator	2021-22
1. Estimated size	3,644
2. Coverage (%)	>=95
3. Condoms distributed	13,55,819
4. Tested for HIV (April 2021 - September 2021)	3,050
4.1. HIV sero-positive (%)	0.03
4.1.1. Linked to ART	1
5. Tested for HIV (October 2021 - March 2022)	3,058
5.1. HIV sero-positive (%)	0.07
5.1.1. Linked to ART	1
6. Clinic Visits	11,701
7. STI/RTI treated	158
8. Presumptive treatment	409

#### C. Men who have Sex with Men

Indicator	2021-22
1. Estimated size	2,262
2. Coverage (%)	>=95
3. Condoms distributed	6,67,834
4. Tested for HIV (April 2021 - September 2021)	1,970
4.1. HIV sero-positive (%)	0.20
4.1.1. Linked to ART	4
5. Tested for HIV (October 2021 - March 2022)	1,910
5.1. HIV sero-positive (%)	0.42
5.1.1. Linked to ART	7
6. Clinic Visits	7,760
7. STI/RTI treated	65
8. Presumptive treatment	414

#### D. Injecting Drug Users

Indicator	2021-22
1. Estimated size	1,262
2. Coverage (%)	>=95
3. Needles distributed	3,98,645
4. Syringes distributed	2,47,263
5. On OST	732
6. Tested for HIV (April 2021 - September 2021)	1,488
6.1. HIV sero-positive (%)	0.07
6.1.1. Linked to ART	1
7. Tested for HIV (October 2021 - March 2022)	1,621
7.1. HIV sero-positive (%)	0.25
7.1.1. Linked to ART	4

#### E. Hijra/Transgender people

Indicator	2021-22
1. Estimated size	100
2. Coverage (%)	>=95
3. Condoms distributed	45,980
4. Tested for HIV (April 2021 - September 2021)	102
4.1. HIV sero-positive (%)	0.98
4.1.1. Linked to ART	0
5. Tested for HIV (October 2021 - March 2022)	118
5.1. HIV sero-positive (%)	0.00
5.1.1. Put on ART	1
6. Clinic Visits	423
7. STI / RTI treated	0
8. Presumptive treatment	26

#### F. Migrants

Indicator	2021-22
1. Estimated size	25,000
2. Coverage (%)	>=95
3. Tested for HIV	8,925
3.1. HIV sero-positive (%)	0.15
3.2. Linked to ART	11

#### G. Truckers

Indicator	2021-22
1. Estimated size	15,330
2. Coverage (%)	65
3. Tested for HIV	4,227
3.1. HIV sero-positive (%)	0.09
3.2. On ART	3

#### H. Prison Inmates

Indicator	2021-22
1. Total prisons	1
2. Prisons covered under programme	1
3. Total inmates admitted	2,627
4. Inmates Covered(%)	38
5. Tested for HIV	835
5.1. HIV sero-positive (%)	0.36
5.2. On ART (%)	100

#### I. Link Worker Scheme

Indicator	2021-22
1. Districts covered under scheme	-
2. Vulnerable population covered	-
3. Tested for HIV	-
3.1. HIV sero-positive (%)	-
3.2. Linked to ART (%)	-



## J. Opioid Substitution Therapy

Indicator	2021-22
1. OST Centres	4
1.1. OSTC in Public Health Settings	-
1.2. OSTC in NGO Settings	4
1.3 No. of Satellite OST Centres	-
2. IDU on OST	732

## 5. Early detection of HIV infected people

### A. HIV Counselling and Testing Services (HCTS)

Indicator	2021-22
1. ICTC facilities	38
1.1. Stand-alone	12
1.2. Facility integrated (Govt)	11
1.3. Facility integrated (PPP)	2
1.4. CBS	13

### B. HIV Testing among Vulnerable Population (Excluding Pregnant Women)

Indicator	2021-22			
	Male	Female	TG	Total
1. Tested for HIV	48,933	26,161	365	75,459
2. Found HIV Positive among tested	375	94	3	472
3. HIV sero-positivity (%) among tested	0.77	0.36	0.82	0.63
4. Spouse/sexual partner testing of HIV positive people identified	46	118	1	165

## 6. Initiation and retention on ART of HIV infected people

### A. Treatment Facilities

Indicator	2021-22
1. ART Centres	2
2. Centre of Excellence	
2.1. Centre of Excellence (Adult)	1
2.2. Centre of Excellence (Paediatric)	-
3. Link ART Centres	4
4. Care Support Centres	1

### B. Treatment Uptake

Indicator	2021-22			
	Male	Female	TG	Total
1. HIV positive cases diagnosed (At ICTC)	375	108	3	486
2. New PLHIV Registered at ART center	328	102	1	431
2.1 Initiated on ART	282	96	1	379
3. PLHIV alive and on ART	3,608	1,957	24	5,589
4. 12 months retention on ART (%)				85.20
5. Lost to follow-up cases	466	176	4	646

## 7. Viral Suppression and laboratories

### A. Laboratory facilities and service uptake

Indicator	2021-22
1. Viral load laboratories	1
1.1 Accredited Viral load laboratories	1
2. Viral load testing conducted	5,507
2.1. Virally suppressed (%)	93
3. National reference laboratories (NRL)	-
3.1 Accredited NRL	-
4. State reference laboratories (SRL)	1
4.1 Accredited SRL	1
5. CD4 testing conducted	2,402
6. External Quality Assessment of ICTC	
6.1 Average Participation (%)	98.08
6.2. Average Discordance (%)	0.00
7. Quality Assurance Scheme for Basic Composite Medical Laboratories (Entry Level)- M(EL)T	
7.1 No. of ICTCs certified for M(EL)T certification	-

## 8. Elimination of mother to child transmission of HIV & Syphilis

### A. HIV

Indicator	2021-22
1. Estimated pregnant women (PW)	18,190
2. HIV testing among PW	20,751
3. HIV sero-positivity (%) among tested	0.07
4. HIV Positive PW (old + new detections)	32
4.1 On life-long ART	48
5. Live births among HIV positive PW	45
5.1 Babies given ARV Prophylaxis (%)	88.89
6. Babies tested HIV (6 week- 6 month)	47
6.1 Babies confirmed HIV Positive (6 week- 6 month)	1
7. HIV exposed babies at 18 months	
7.1 HIV exposed babies tested at 18 month	29
7.2 Babies confirmed HIV positive at 18 months	-
8. HIV positive babies initiated on ART	2

### B. Syphilis

Indicator	2021-22
1. Estimated pregnant women (PW)	18,190
2. Syphilis testing among PW	20,357
3. Sero-positivity (%) among tested	1.32
4. Put on treatment	13

## 9. Elimination of HIV/AIDS related Stigma and Discrimination

### A. HIV/AIDS Prevention & Control Act (2017)

Indicator	2021-22
1. State rules notified for HIV/AIDS Prevention and Control Act (2017)	No
2. State designated/appointed ombudsman for HIV/AIDS Prevention and Control Act (2017)	No

## 10. HIV-TB Co-morbidities

### A. HRG and Bridge Population

Indicator								2021-22
	Quarter	FSW	MSW	IDU	TG	Migrants	Truckers	Total
Screened for TB	Quarter 1	3,164	1,979	1,572	107	1,997	2,347	11,166
	Quarter 2	2,893	1,893	1,526	85	2,381	2,544	11,322
	Quarter 3	2,915	1,942	1,459	105	2,392	2,388	11,201
	Quarter 4	2,988	1,948	1,639	123	2,992	2,483	12,173
Tested for TB	Quarter 1	8	9	4	2	14	15	52
	Quarter 2	6	10	1	-	16	7	40
	Quarter 3	5	19	-	1	10	3	38
	Quarter 4	6	7	-	3	16	57	89
Diagnosed with TB	Quarter 1	-	1	3	-	1	-	5
	Quarter 2	-	-	-	-	1	2	3
	Quarter 3	-	1	-	-	-	-	1
	Quarter 4	-	2	-	-	2	-	4
Initiated on TB treatment	Quarter 1	-	1	3	-	1	-	5
	Quarter 2	-	-	-	-	1	2	3
	Quarter 3	-	1	-	-	-	-	1
	Quarter 4	-	2	-	-	2	-	4

### B. HIV-TB Cross-Referral

Indicator	2021-22
1. In referral from TB program	3,581
1.1. HIV sero-positive (%)	0.64
1.2. ICTC clients referred to NTEP	134

### C. HIV-TB Coinfected at ART Centre

Indicator								2021-22
	PLHIV attending ART Centre	PLHIV underwent 4S screening	PLHIV with presumptive TB	PLHIV tested for TB	PLHIV diagnosed with TB	PLHIV initiated on IPT	Co-infected enrolled at ARTc	Co-infected initiated on ART
Apr-21	2,315	2,315	9	7	2	80		
May-21	1,590	1,590	7	6	4	22		
Jun-21	2,657	2,657	16	11	3	98		
Jul-21	2,286	2,286	18	14	10	72		
Aug-21	2,743	2,743	22	17	5	97		
Sep-21	2,621	2,621	22	19	10	34		
Oct-21	2,534	2,534	19	17	5	42		
Nov-21	2,700	2,700	18	14	3	61		
Dec-21	3,259	3,259	26	22	11	55		
Jan-22	3,029	3,029	23	19	6	68		
Feb-22	2,641	2,641	23	22	7	61		
Mar-22	2,786	2,786	37	37	16	25		
April 2021-March 2022							194	175

## 11. Scorecard

State/UT Name		Chandigarh
Overall Rank		2
IEC & MS	Frequency of Social Media updates (G= ≥60, Y=40-59, R=<40)	
	Status of AEP integration in state School curriculum (G=Yes, R=No)	
	Status of SCA (G= At least one meeting held since 2017, R= other than G)	
	Status of State Rules (G= Notified, R= Not notified)	
	Status of Ombudsman (G= Appointed, R=Not appointed)	
	Rank	5
TI	Facilities onboarded (G=≥95%, Y= 90-94%, R=<90%)	
	Coverage against target in contract (G=≥95%, Y= 90-94%, R=<90%)	
	HRG & BP living with HIV on ART (G=≥95%, Y= 90-94%, R=<90%)	
	IDU on OST (G=≥95%, Y= 90-94%, R=<90%)	
	Rank	3
BSD	Percentage of PLHIV who know their status (G=≥95%, Y= 80-94%, R=<80%)	
	HIV testing against target-GC ((G=≥95%, Y= 80-94%, R=<80%)	
	HIV testing against target-PW (G=≥95%, Y= 80-94%, R=<80%)	
	Percentage of Pregnant women who initiated ART (G=≥95%, Y= 80-94%, R=<80%)	
	Percentage of TB suspected cases referred to NTEP (G=≥95%, Y= 80-94%, R=<80%)	
	Clients managed at DSRC against the target (G=≥95%, Y= 80-94%, R=<80%)	
	Percentage of pregnant women tested for Syphilis (G=≥95%, Y= 80-94%, R=<80%)	
	Rank	17
CST	ART Initiation (Current FY) (G=≥95%, Y= 80-94%, R=<80%)	
	LFU rate among new ART initiation (G=<2%, Y= 2-4%, R=≥5%)	
	PLHIV put on ART during the FY against target (G=≥95%, Y= 80-94%, R=<80%)	
	Status on establishment of CSC (G=≥95%, Y= 80-94%, R=<80%)	
	Rank	25
LS	VL Suppression Rate (Current FY) (G=≥95%, Y= 85-94%, R=<85%)	
	% of SRL accredited (G=100%, Y= 80-99%, R=<80%)	
	% Participation of ICTCs in Re-testing (G=≥95%, Y= 85-94, R=<85%)	
	Rank	2
SI	% of NACP facilities active in SOCH (G=≥90%, Y= 75-89%, R=<75%)	
	Status of State Data Management Committee (G=one meeting held, Y= no meeting held, R= not constituted)	
	Status of finalized Priority Areas for Operational Research and Evaluation (G= 4, Y= 3, R= <3)	
	Rank	1
Finance	Expenditure with respect to funds released during FY 2021-22 (G=≥90%, Y= 85-89%, R=<85%)	
	Submission of Audit Report after approval of EC/GB for the preceding year (G= by 30th June, Y= 30th Sept, R= beyond 30th Sept 2021)	
	Submission of Utilization Certificate (in prescribed format GFR 12A) for the previous financial year (G= by 30th June, Y= 30th Sept, R= beyond 30th Sept 2021)	
	Rank	2
SCM	Report Submission (BSD-SCM Report) (G=≥90%, Y= 75-89%, R=<75%)	

Green=3 Marks

Yellow=2Marks

Red=1 Mark

No Colour=Not Applicable

A thick red ribbon is draped across the page, starting from the bottom left, looping upwards and to the right, and then looping back down towards the right edge. The background is a gradient of yellow and orange with faint, concentric circular lines.

# **FACT SHEET**

## **CHHATTISGARH**

# CHHATTISGARH

## 1. Status of HIV/AIDS Epidemic

### A. Epidemic Estimates (2021)

Indicator	Male	Female	Total
1. IPR	-	-	4.51
2. IMR	-	-	1.11
3. Adult (15-49 yrs) HIV Prevalence (%)	0.18	0.16	0.17
4. Estimated people living with HIV	21,103	18,523	39,626
5. ART coverage (%)	46.2	44	45
6. Estimated children living with HIV	972	926	1,898
7. Annual new HIV infections	896	892	1,788
8. Annual AIDS-related deaths (ARD)	696	585	1,281
9. Change in annual new HIV infections since 2010 (%)	-39.7	-32.42	-36.30
10. Change in annual ARD since 2010(%)	-66.6	-63.07	-65.10
11. EMTCT need	-	487	487


### B. High risk population size (2009), safe practices (2015) and prevalence (2021)

Population Group	Estimates Size	Condom Use (%)	New Needle/ Syringe use (%)	HIV Prevalence (%)
1. Female Sex Workers	23,603	72.8	46.9	1.92
2. Men who have sex with men	2,786	29	6.5	4.01
3. Injecting Drug Users	3,397	67.1	92.3	7.2
4. Hijra/Transgender People	910	-	-	6
5. Migrants	2,31,000	-	-	1.2
6. Truckers	62,000	-	-	2
7. Prison inmates	66,388	39.4	0	0.00

### C. HIV/AIDS related knowledge, stigma and high-risk behaviour in general population (2019-21)

Indicator	Male	Female	Total
1. Adults (15-49 yrs) with comprehensive knowledge about HIV/AIDS (%)	30.7	23	-
2. Youth (15-24 yrs) with comprehensive knowledge about HIV/AIDS (%)	29.9	22	-
3. Adults willing to care for a relative with HIV/AIDS in own home (%)	77.7	79.4	-
4. Adults willing to buy fresh vegetables from a shopkeeper or vendor who has HIV/AIDS (%)	74.5	72.4	-
5. Adults (15-49 yrs) who have had higher-risk sexual behaviour in the past 12 months (%)	5	0.5	-
5.1 Condom use during last higher-risk intercourse (%)	56	21.2	-
6. Youth (15-24 yrs) who have had higher-risk sexual behaviour in the past 12 months (%)	9.1	0.4	-
6.1 Condom use during last higher-risk intercourse (%)	54.8	16.7	-

## 2. Progress on 95-95-95 (2021-22)



Indicator	Male	Female	Total
1. Estimated PLHIV size (2021)	21,103	18,523	39,626
2. PLHIV who know their HIV Status	13,072	10,303	23,375
3. PLHIV who know their HIV status and are on ART	9,850	8,177	18,027
4. PLHIV who are on ART and tested for their viral load	4,309	3,819	8,128
5. PLHIV who are virally suppressed	3,083	3,056	6,139

### 3. Prevention of new HIV infections among general population

#### A. Information, Education, Communication, Youth and Mainstreaming

Indicator	2021-22
1. Schools with operational Adolescent Education Program (AEP)	220
2. Colleges with operational Red Ribbon Clubs (RRC)	152
3. Persons trained under mainstreaming	2,843

#### B. Sexually Transmitted Infections (STI)/Reproductive Tract Infections (RTI) Management at DSRCs

Indicator	2021-22				
1. NACO Supported Designated STI/RTI Clinics (DSRC)	31				
	Male	Female	TG	Total	
2. Clients managed	-	-	-	1,54,249	
3. RPR Tests conducted	41,908	62,945	476	1,05,329	
4. Syphilis seropositivity (%)	0.80	0.23	4.41	0.48	

### 4. Prevention of new HIV infections among high-risk group and bridge population

#### A. Targeted Interventions (TI) and Opioid Substitution Therapy (OST)

Indicator	2021-22
1. Targeted Interventions	44
2. OST centres	6
3. Employer Led Model Interventions	21

#### B. Female Sex Workers

Indicator	2021-22
1. Estimated size	23,603
2. Coverage (%)	76
3. Condoms distributed	52,51,617
4. Tested for HIV (April 2021 - September 2021)	11,568
4.1. HIV sero-positive (%)	0.23
4.1.1. Linked to ART	18
5. Tested for HIV (October 2021 - March 2022)	15,402
5.1. HIV sero-positive (%)	0.29
5.1.1. Linked to ART	36
6. Clinic Visits	46,935
7. STI/RTI treated	1,990
8. Presumptive treatment	3,919

#### C. Men who have Sex with Men

Indicator	2021-22
1. Estimated size	2,786
2. Coverage (%)	>=95
3. Condoms distributed	7,28,359
4. Tested for HIV (April 2021 - September 2021)	1,503
4.1. HIV sero-positive (%)	1.00
4.1.1. Linked to ART	12
5. Tested for HIV (October 2021 - March 2022)	2,044
5.1. HIV sero-positive (%)	2.01
5.1.1. Linked to ART	38
6. Clinic Visits	6,248
7. STI/RTI treated	93
8. Presumptive treatment	1,016

### D. Injecting Drug Users

Indicator	2021-22
1. Estimated size	3,397
2. Coverage (%)	>=95
3. Needles distributed	8,23,798
4. Syringes distributed	5,50,732
5. On OST	795
6. Tested for HIV (April 2021 - September 2021)	2,619
6.1. HIV sero-positive (%)	0.65
6.1.1. Linked to ART	7
7. Tested for HIV (October 2021 - March 2022)	3,043
7.1. HIV sero-positive (%)	0.69
7.1.1. Linked to ART	8

### E. Hijra/Transgender people

Indicator	2021-22
1. Estimated size	910
2. Coverage (%)	>=95
3. Condoms distributed	2,93,536
4. Tested for HIV (April 2021 - September 2021)	529
4.1. HIV sero-positive (%)	1.32
4.1.1. Linked to ART	6
5. Tested for HIV (October 2021 - March 2022)	767
5.1. HIV sero-positive (%)	3.00
5.1.1. Put on ART	18
6. Clinic Visits	2,308
7. STI / RTI treated	39
8. Presumptive treatment	316

### F. Migrants

Indicator	2021-22
1. Estimated size	2,31,000
2. Coverage (%)	65
3. Tested for HIV	19,883
3.1. HIV sero-positive (%)	0.09
3.2. Linked to ART	15

### G. Truckers

Indicator	2021-22
1. Estimated size	62,000
2. Coverage (%)	65
3. Tested for HIV	10,824
3.1. HIV sero-positive (%)	0.18
3.2. On ART	11

### H. Prison Inmates

Indicator	2021-22
1. Total prisons	33
2. Prisons covered under programme	33
3. Total inmates admitted	53,735
4. Inmates Covered(%)	19
5. Tested for HIV	17,906
5.1. HIV sero-positive (%)	0.49
5.2. On ART (%)	69

### I. Link Worker Scheme

Indicator	2021-22
1. Districts covered under scheme	6
2. Vulnerable population covered	45,373
3. Tested for HIV	36,438
3.1. HIV sero-positive (%)	0.15
3.2. Linked to ART (%)	91.07



## J. Opioid Substitution Therapy

Indicator	2021-22
1. OST Centres	6
1.1. OSTC in Public Health Settings	6
1.2. OSTC in NGO Settings	-
1.3 No. of Satellite OST Centres	-
2. IDU on OST	795

## 5. Early detection of HIV infected people

### A. HIV Counselling and Testing Services (HCTS)

Indicator	2021-22
1. ICTC facilities	844
1.1. Stand-alone	147
1.2. Facility integrated (Govt)	643
1.3. Facility integrated (PPP)	11
1.4. CBS	43

### B. HIV Testing among Vulnerable Population (Excluding Pregnant Women)

Indicator	2021-22			
	Male	Female	TG	Total
1. Tested for HIV	1,80,701	2,02,899	1,185	3,84,785
2. Found HIV Positive among tested	1,366	688	32	2,086
3. HIV sero-positivity (%) among tested	0.76	0.34	2.70	0.54
4. Spouse/sexual partner testing of HIV positive people identified	459	434	6	899

## 6. Initiation and retention on ART of HIV infected people

### A. Treatment Facilities

Indicator	2021-22
1. ART Centres	8
2. Centre of Excellence	
2.1. Centre of Excellence (Adult)	-
2.2. Centre of Excellence (Paediatric)	-
3. Link ART Centres	22
4. Care Support Centres	3

### B. Treatment Uptake

Indicator	2021-22			
	Male	Female	TG	Total
1. HIV positive cases diagnosed (At ICTC)	1,366	688	32	2,278
2. New PLHIV Registered at ART center	1,273	788	19	2,080
2.1 Initiated on ART	1,134	732	18	1,884
3. PLHIV alive and on ART	9,753	7,988	118	17,859
4. 12 months retention on ART (%)				64.97
5. Lost to follow-up cases	2,356	1,746	14	4,116

## 7. Viral Suppression and laboratories

### A. Laboratory facilities and service uptake

Indicator	2021-22
1. Viral load laboratories	1
1.1 Accredited Viral load laboratories	0
2. Viral load testing conducted	10,483
2.1. Virally suppressed (%)	76
3. National reference laboratories (NRL)	0
3.1 Accredited NRL	0
4. State reference laboratories (SRL)	1
4.1 Accredited SRL	0
5. CD4 testing conducted	9,901
6. External Quality Assessment of ICTC	
6.1 Average Participation (%)	49.27
6.2. Average Discordance (%)	0.00
7. Quality Assurance Scheme for Basic Composite Medical Laboratories (Entry Level)- M(EL)T	
7.1 No. of ICTCs certified for M(EL)T certification	1.00

## 8. Elimination of mother to child transmission of HIV & Syphilis

### A. HIV

Indicator	2021-22
1. Estimated pregnant women (PW)	7,17,190
2. HIV testing among PW	5,41,977
3. HIV sero-positivity (%) among tested	0.04
4. HIV Positive PW (old + new detections)	335
4.1 On life-long ART	301
5. Live births among HIV positive PW	272
5.1 Babies given ARV Prophylaxis (%)	95.22
6. Babies tested HIV (6 week- 6 month)	367
6.1 Babies confirmed HIV Positive (6 week- 6 month)	9
7. HIV exposed babies at 18 months	
7.1 HIV exposed babies tested at 18 month	199
7.2 Babies confirmed HIV positive at 18 months	13
8. HIV positive babies initiated on ART	29

### B. Syphilis

Indicator	2021-22
1. Estimated pregnant women (PW)	7,17,190
2. Syphilis testing among PW	3,38,866
3. Sero-positivity (%) among tested	0.03
4. Put on treatment	107

## 9. Elimination of HIV/AIDS related Stigma and Discrimination

### A. HIV/AIDS Prevention & Control Act (2017)

Indicator	2021-22
1. State rules notified for HIV/AIDS Prevention and Control Act (2017)	Yes
2. State designated/appointed ombudsman for HIV/AIDS Prevention and Control Act (2017)	Yes

## 10. HIV-TB Co-morbidities

## A. HRG and Bridge Population

Indicator								2021-22
	Quarter	FSW	MSW	IDU	TG	Migrants	Truckers	Total
Screened for TB	Quarter 1	3,790	560	1,229	277	1,509	1,204	8,569
	Quarter 2	6,601	1,310	2,023	523	5,243	2,088	17,788
	Quarter 3	7,475	1,440	2,241	576	5,138	2,773	19,643
	Quarter 4	9,170	1,833	2,601	751	6,133	4,457	24,945
Tested for TB	Quarter 1	57	3	21	1	24	4	110
	Quarter 2	172	23	25	24	126	20	390
	Quarter 3	194	11	48	7	40	19	319
	Quarter 4	166	32	39	20	98	63	418
Diagnosed with TB	Quarter 1	5	-	-	-	-	-	5
	Quarter 2	14	-	-	-	1	-	15
	Quarter 3	11	-	-	-	-	-	11
	Quarter 4	20	-	-	-	-	3	23
Initiated on TB treatment	Quarter 1	3	-	-	-	-	-	3
	Quarter 2	6	-	-	-	1	-	7
	Quarter 3	11	-	-	-	-	-	11
	Quarter 4	17	-	-	-	-	3	20

## B. HIV-TB Cross-Referral

Indicator	2021-22
1. In referral from TB program	15,847
1.1. HIV sero-positive (%)	1.71
1.2. ICTC clients referred to NTEP	14,499

## C. HIV-TB Coinfected at ART Centre

Indicator								2021-22
	PLHIV attending ART Centre	PLHIV underwent 4S screening	PLHIV with presumptive TB	PLHIV tested for TB	PLHIV diagnosed with TB	PLHIV initiated on IPT	Co-infected enrolled at ARTc	Co-infected initiated on ART
Apr-21	9,720	9,585	129	129	12	24		
May-21	8,932	8,698	135	135	12	194		
Jun-21	10,738	10,353	257	257	28	146		
Jul-21	11,741	11,498	222	222	25	137		
Aug-21	11,551	11,098	301	301	40	210		
Sep-21	11,727	11,215	253	253	28	87		
Oct-21	10,994	10,520	361	285	36	50		
Nov-21	9,025	8,349	329	223	35	74		
Dec-21	10,539	10,155	344	213	32	59		
Jan-22	10,290	9,834	318	230	31	63		
Feb-22	9,161	8,868	284	248	27	77		
Mar-22	7,568	7,328	266	266	30	103		
April 2021-March 2022							403	338

## 11. Scorecard

State/UT Name		Chhattisgarh
Overall Rank		19
IEC & MS	Frequency of Social Media updates (G= ≥60, Y=40-59, R=<40)	
	Status of AEP integration in state School curriculum (G=Yes, R=No)	
	Status of SCA (G= At least one meeting held since 2017, R= other than G)	
	Status of State Rules (G= Notified, R= Not notified)	
	Status of Ombudsman (G= Appointed, R=Not appointed)	
	Rank	1
TI	Facilities onboarded (G=≥95%, Y= 90-94%, R=<90%)	
	Coverage against target in contract (G=≥95%, Y= 90-94%, R=<90%)	
	HRG & BP living with HIV on ART (G=≥95%, Y= 90-94%, R=<90%)	
	IDU on OST (G=≥95%, Y= 90-94%, R=<90%)	
	Rank	11
BSD	Percentage of PLHIV who know their status (G=≥95%, Y= 80-94%, R=<80%)	
	HIV testing against target-GC ((G=≥95%, Y= 80-94%, R=<80%)	
	HIV testing against target-PW (G=≥95%, Y= 80-94%, R=<80%)	
	Percentage of Pregnant women who initiated ART (G=≥95%, Y= 80-94%, R=<80%)	
	Percentage of TB suspected cases referred to NTEP (G=≥95%, Y= 80-94%, R=<80%)	
	Clients managed at DSRC against the target (G=≥95%, Y= 80-94%, R=<80%)	
	Percentage of pregnant women tested for Syphilis (G=≥95%, Y= 80-94%, R=<80%)	
	Rank	26
CST	ART Initiation (Current FY) (G=≥95%, Y= 80-94%, R=<80%)	
	LFU rate among new ART initiation (G=<2%, Y= 2-4%, R=≥5%)	
	PLHIV put on ART during the FY against target (G=≥95%, Y= 80-94%, R=<80%)	
	Status on establishment of CSC (G=≥95%, Y= 80-94%, R=<80%)	
	Rank	11
LS	VL Suppression Rate (Current FY) (G=≥95%, Y= 85-94%, R=<85%)	
	% of SRL accredited (G=100%, Y= 80-99%, R=<80%)	
	% Participation of ICTCs in Re-testing (G=≥95%, Y= 85-94%, R=<85%)	
	Rank	31
SI	% of NACP facilities active in SOCH (G=≥90%, Y= 75-89%, R=<75%)	
	Status of State Data Management Committee (G=one meeting held, Y= no meeting held, R= not constituted)	
	Status of finalized Priority Areas for Operational Research and Evaluation (G= 4, Y= 3, R= <3)	
	Rank	14
Finance	Expenditure with respect to funds released during FY 2021-22 (G=≥90%, Y= 85-89%, R=<85%)	
	Submission of Audit Report after approval of EC/GB for the preceding year (G= by 30th June, Y= 30th Sept, R= beyond 30th Sept 2021)	
	Submission of Utilization Certificate (in prescribed format GFR 12A) for the previous financial year (G= by 30th June, Y= 30th Sept, R= beyond 30th Sept 2021)	
	Rank	18
SCM	Report Submission (BSD-SCM Report) (G=≥90%, Y= 75-89%, R=<75%)	

Green=3 Marks

Yellow=2Marks

Red=1 Mark

No Colour=Not Applicable



# **FACT SHEET**

**DADRA & NAGAR  
HAVELI AND  
DAMAN DIU**

# DADRA & NAGAR HAVELI AND DAMAN DIU

## 1. Status of HIV/AIDS Epidemic

### A. Epidemic Estimates (2021)

Indicator	Male	Female	Total
1. IPR	-	-	5.12
2. IMR	-	-	5.27
3. Adult (15-49 yrs) HIV Prevalence (%)	0.20	0.16	0.19
4. Estimated people living with HIV	1,101	442	1,543
5. ART coverage (%)	13.2	20	15
6. Estimated children living with HIV	26	21	47
7. Annual new HIV infections	56	22	78
8. Annual AIDS-related deaths (ARD)	6	4	10
9. Change in annual new HIV infections since 2010 (%)	12.0	-12.00	6.76
10. Change in annual ARD since 2010(%)	-71.4	-63.64	-69.70
11. EMTCT need	-	17	17


### B. High risk population size (2009), safe practices (2015) and prevalence (2021)

Population Group	Estimates Size	Condom Use (%)	New Needle/ Syringe use (%)	HIV Prevalence (%)
1. Female Sex Workers	850	-	-	-
2. Men who have sex with men	769	-	-	-
3. Injecting Drug Users	-	-	-	-
4. Hijra/Transgender People	-	-	-	-
5. Migrants	1,34,800	-	-	-
6. Truckers	81,640	-	-	-
7. Prison inmates	485	-	-	-

### C. HIV/AIDS related knowledge, stigma and high-risk behaviour in general population (2019-21)

Indicator	Male	Female	Total
1. Adults (15-49 yrs) with comprehensive knowledge about HIV/AIDS (%)	28.1	25.3	-
2. Youth (15-24 yrs) with comprehensive knowledge about HIV/AIDS (%)	31.1	24.6	-
3. Adults willing to care for a relative with HIV/AIDS in own home (%)	55.7	82.3	-
4. Adults willing to buy fresh vegetables from a shopkeeper or vendor who has HIV/AIDS (%)	77.4	73.5	-
5. Adults (15-49 yrs) who have had higher-risk sexual behaviour in the past 12 months (%)	7.3	0	-
5.1 Condom use during last higher-risk intercourse (%)	84	NA	-
6. Youth (15-24 yrs) who have had higher-risk sexual behaviour in the past 12 months (%)	6.5	0	-
6.1 Condom use during last higher-risk intercourse (%)	100.0	NA	-

## 2. Progress on 95-95-95 (2021-22)



### 3. Prevention of new HIV infections among general population

#### A. Information, Education, Communication, Youth and Mainstreaming

Indicator	2021-22
1. Schools with operational Adolescent Education Program (AEP)	90
2. Colleges with operational Red Ribbon Clubs (RRC)	18
3. Persons trained under mainstreaming	2,250

#### B. Sexually Transmitted Infections (STI)/Reproductive Tract Infections (RTI) Management at DSRCs

Indicator	2021-22			
1. NACO Supported Designated STI/RTI Clinics (DSRC)	4			
	Male	Female	TG	Total
2. Clients managed	-	-	-	2,816
3. RPR Tests conducted	908	1,868	1	2,777
4. Syphilis seropositivity (%)	4.96	1.61	0.00	2.70

### 4. Prevention of new HIV infections among high-risk group and bridge population

#### A. Targeted Interventions (TI) and Opioid Substitution Therapy (OST)

Indicator	2021-22
1. Targeted Interventions	-
2. OST centres	-
3. Employer Led Model Interventions	-

#### B. Female Sex Workers

Indicator	2021-22
1. Estimated size	850
2. Coverage (%)	-
3. Condoms distributed	-
4. Tested for HIV (April 2021 - September 2021)	-
4.1. HIV sero-positive (%)	-
4.1.1. Linked to ART	-
5. Tested for HIV (October 2021 - March 2022)	-
5.1. HIV sero-positive (%)	-
5.1.1. Linked to ART	-
6. Clinic Visits	-
7. STI/RTI treated	-
8. Presumptive treatment	-

#### C. Men who have Sex with Men

Indicator	2021-22
1. Estimated size	769
2. Coverage (%)	-
3. Condoms distributed	-
4. Tested for HIV (April 2021 - September 2021)	-
4.1. HIV sero-positive (%)	-
4.1.1. Linked to ART	-
5. Tested for HIV (October 2021 - March 2022)	-
5.1. HIV sero-positive (%)	-
5.1.1. Linked to ART	-
6. Clinic Visits	-
7. STI/RTI treated	-
8. Presumptive treatment	-

#### D. Injecting Drug Users

Indicator	2021-22
1. Estimated size	-
2. Coverage (%)	-
3. Needles distributed	-
4. Syringes distributed	-
5. On OST	-
6. Tested for HIV (April 2021 - September 2021)	-
6.1. HIV sero-positive (%)	-
6.1.1. Linked to ART	-
7. Tested for HIV (October 2021 - March 2022)	-
7.1. HIV sero-positive (%)	-
7.1.1. Linked to ART	-

#### E. Hijra/Transgender people

Indicator	2021-22
1. Estimated size	-
2. Coverage (%)	-
3. Condoms distributed	-
4. Tested for HIV (April 2021 - September 2021)	-
4.1. HIV sero-positive (%)	-
4.1.1. Linked to ART	-
5. Tested for HIV (October 2021 - March 2022)	-
5.1. HIV sero-positive (%)	-
5.1.1. Put on ART	-
6. Clinic Visits	-
7. STI / RTI treated	-
8. Presumptive treatment	-

#### F. Migrants

Indicator	2021-22
1. Estimated size	1,34,800
2. Coverage (%)	-
3. Tested for HIV	-
3.1. HIV sero-positive (%)	-
3.2. Linked to ART	-

#### G. Truckers

Indicator	2021-22
1. Estimated size	81,640
2. Coverage (%)	-
3. Tested for HIV	-
3.1. HIV sero-positive (%)	-
3.2. On ART	-

#### H. Prison Inmates

Indicator	2021-22
1. Total prisons	2
2. Prisons covered under programme	2
3. Total inmates admitted	379
4. Inmates Covered(%)	51
5. Tested for HIV	173
5.1. HIV sero-positive (%)	0.58
5.2. On ART (%)	100

#### I. Link Worker Scheme

Indicator	2021-22
1. Districts covered under scheme	-
2. Vulnerable population covered	-
3. Tested for HIV	-
3.1. HIV sero-positive (%)	-
3.2. Linked to ART (%)	-



## J. Opioid Substitution Therapy

Indicator	2021-22
1. OST Centres	-
1.1. OSTC in Public Health Settings	-
1.2. OSTC in NGO Settings	-
1.3 No. of Satellite OST Centres	-
2. IDU on OST	-

## 5. Early detection of HIV infected people

### A. HIV Counselling and Testing Services (HCTS)

Indicator	2021-22
1. ICTC facilities	25
1.1. Stand-alone	5
1.2. Facility integrated (Govt)	14
1.3. Facility integrated (PPP)	4
1.4. CBS	2

### B. HIV Testing among Vulnerable Population (Excluding Pregnant Women)

Indicator	2021-22			
	Male	Female	TG	Total
1. Tested for HIV	22,667	15,960	1	38,628
2. Found HIV Positive among tested	31	13	-	44
3. HIV sero-positivity (%) among tested	0.14	0.08	0.00	0.11
4. Spouse/sexual partner testing of HIV positive people identified	8	18	-	26

## 6. Initiation and retention on ART of HIV infected people

### A. Treatment Facilities

Indicator	2021-22
1. ART Centres	1
2. Centre of Excellence	
2.1. Centre of Excellence (Adult)	-
2.2. Centre of Excellence (Paediatric)	-
3. Link ART Centres	-
4. Care Support Centres	-

### B. Treatment Uptake

Indicator	2021-22			
	Male	Female	TG	Total
1. HIV positive cases diagnosed (At ICTC)	31	15	-	46
2. New PLHIV Registered at ART center	25	16	-	41
2.1 Initiated on ART	25	16	-	41
3. PLHIV alive and on ART	145	90	-	235
4. 12 months retention on ART (%)				90.48
5. Lost to follow-up cases	-	-	-	-

## 7. Viral Suppression and laboratories

### A. Laboratory facilities and service uptake

Indicator	2021-22
1. Viral load laboratories	-
1.1 Accredited Viral load laboratories	-
2. Viral load testing conducted	490
2.1. Virally suppressed (%)	82
3. National reference laboratories (NRL)	-
3.1 Accredited NRL	-
4. State reference laboratories (SRL)	-
4.1 Accredited SRL	-
5. CD4 testing conducted	-
6. External Quality Assessment of ICTC	
6.1 Average Participation (%)	0.00
6.2. Average Discordance (%)	0.00
7. Quality Assurance Scheme for Basic Composite Medical Laboratories (Entry Level)- M(EL)T	
7.1 No. of ICTCs certified for M(EL)T certification	0.00

## 8. Elimination of mother to child transmission of HIV & Syphilis

### A. HIV

Indicator	2021-22
1. Estimated pregnant women (PW)	24,650
2. HIV testing among PW	20,662
3. HIV sero-positivity (%) among tested	0.01
4. HIV Positive PW (old + new detections)	5
4.1 On life-long ART	4
5. Live births among HIV positive PW	3
5.1 Babies given ARV Prophylaxis (%)	100.00
6. Babies tested HIV (6 week- 6 month)	4
6.1 Babies confirmed HIV Positive (6 week- 6 month)	1
7. HIV exposed babies at 18 months	
7.1 HIV exposed babies tested at 18 month	1
7.2 Babies confirmed HIV positive at 18 months	-
8. HIV positive babies initiated on ART	-

### B. Syphilis

Indicator	2021-22
1. Estimated pregnant women (PW)	24,650
2. Syphilis testing among PW	18,148
3. Sero-positivity (%) among tested	0.07
4. Put on treatment	6

## 9. Elimination of HIV/AIDS related Stigma and Discrimination

### A. HIV/AIDS Prevention & Control Act (2017)

Indicator	2021-22
1. State rules notified for HIV/AIDS Prevention and Control Act (2017)	No
2. State designated/appointed ombudsman for HIV/AIDS Prevention and Control Act (2017)	Yes

## 10. HIV-TB Co-morbidities

## A. HRG and Bridge Population

Indicator								2021-22
	Quarter	FSW	MSW	IDU	TG	Migrants	Truckers	Total
Screened for TB	Quarter 1	-	-	-	-	-	-	-
	Quarter 2	-	-	-	-	-	-	-
	Quarter 3	-	-	-	-	-	-	-
	Quarter 4	-	-	-	-	-	-	-
Tested for TB	Quarter 1	-	-	-	-	-	-	-
	Quarter 2	-	-	-	-	-	-	-
	Quarter 3	-	-	-	-	-	-	-
	Quarter 4	-	-	-	-	-	-	-
Diagnosed with TB	Quarter 1	-	-	-	-	-	-	-
	Quarter 2	-	-	-	-	-	-	-
	Quarter 3	-	-	-	-	-	-	-
	Quarter 4	-	-	-	-	-	-	-
Initiated on TB treatment	Quarter 1	-	-	-	-	-	-	-
	Quarter 2	-	-	-	-	-	-	-
	Quarter 3	-	-	-	-	-	-	-
	Quarter 4	-	-	-	-	-	-	-

## B. HIV-TB Cross-Referral

Indicator	2021-22
1. In referral from TB program	1,952
1.1. HIV sero-positive (%)	-
1.2. ICTC clients referred to NTEP	231

## C. HIV-TB Coinfected at ART Centre

Indicator							2021-22	
	PLHIV attending ART Centre	PLHIV underwent 4S screening	PLHIV with presumptive TB	PLHIV tested for TB	PLHIV diagnosed with TB	PLHIV initiated on IPT	Co-infected enrolled at ARTc	Co-infected initiated on ART
Apr-21	-	-	-	-	-	-		
May-21	-	-	-	-	-	-		
Jun-21	-	-	-	-	-	-		
Jul-21	-	-	-	-	-	-		
Aug-21	-	-	-	-	-	-		
Sep-21	-	-	-	-	-	-		
Oct-21	-	-	-	-	-	-		
Nov-21	-	-	-	-	-	-		
Dec-21	-	-	-	-	-	-		
Jan-22	199	199	1	1	1	1		
Feb-22	181	181	-	-	-	-		
Mar-22	208	208	-	-	-	4		
April 2021-March 2022							10	10

## 11. Scorecard

State/UT Name		DNH & DD
Overall Rank		21
IEC & MS	Frequency of Social Media updates (G= ≥60, Y=40-59, R=<40)	
	Status of AEP integration in state School curriculum (G=Yes, R=No)	
	Status of SCA (G= At least one meeting held since 2017, R= other than G)	
	Status of State Rules (G= Notified, R= Not notified)	
	Status of Ombudsman (G= Appointed, R=Not appointed)	
	Rank	15
TI	Facilities onboarded (G=≥95%, Y= 90-94%, R=<90%)	
	Coverage against target in contract (G=≥95%, Y= 90-94%, R=<90%)	NA
	HRG & BP living with HIV on ART (G=≥95%, Y= 90-94%, R=<90%)	NA
	IDU on OST (G=≥95%, Y= 90-94%, R=<90%)	NA
	Rank	33
BSD	Percentage of PLHIV who know their status (G=≥95%, Y= 80-94%, R=<80%)	
	HIV testing against target-GC ((G=≥95%, Y= 80-94%, R=<80%)	
	HIV testing against target-PW (G=≥95%, Y= 80-94%, R=<80%)	
	Percentage of Pregnant women who initiated ART (G=≥95%, Y= 80-94%, R=<80%)	
	Percentage of TB suspected cases referred to NTEP (G=≥95%, Y= 80-94%, R=<80%)	
	Clients managed at DSRC against the target (G=≥95%, Y= 80-94%, R=<80%)	
	Percentage of pregnant women tested for Syphilis (G=≥95%, Y= 80-94%, R=<80%)	
	Rank	22
CST	ART Initiation (Current FY) (G=≥95%, Y= 80-94%, R=<80%)	
	LFU rate among new ART initiation (G=<2%, Y= 2-4%, R=≥5%)	
	PLHIV put on ART during the FY against target (G=≥95%, Y= 80-94%, R=<80%)	
	Status on establishment of CSC (G=≥95%, Y= 80-94%, R=<80%)	NA
	Rank	1
LS	VL Suppression Rate (Current FY) (G=≥95%, Y= 85-94%, R=<85%)	
	% of SRL accredited (G=100%, Y= 80-99%, R=<80%)	NA
	% Participation of ICTCs in Re-testing (G=≥95%, Y= 85-94, R=<85%)	NA
	Rank	31
SI	% of NACP facilities active in SOCH (G=≥90%, Y= 75-89%, R=<75%)	
	Status of State Data Management Committee (G=one meeting held, Y= no meeting held, R= not constituted)	
	Status of finalized Priority Areas for Operational Research and Evaluation (G= 4, Y= 3, R= <3)	
	Rank	14
Finance	Expenditure with respect to funds released during FY 2021-22 (G=≥90%, Y= 85-89%, R=<85%)	
	Submission of Audit Report after approval of EC/GB for the preceding year (G= by 30th June, Y= 30th Sept, R= beyond 30th Sept 2021)	
	Submission of Utilization Certificate (in prescribed format GFR 12A) for the previous financial year (G= by 30th June, Y= 30th Sept, R= beyond 30th Sept 2021)	
	Rank	23
SCM	Report Submission (BSD-SCM Report) (G=≥90%, Y= 75-89%, R=<75%)	

Green=3 Marks

Yellow=2Marks

Red=1 Mark

No Colour=Not Applicable

# FACT SHEET

DELHI



## 1. Status of HIV/AIDS Epidemic

### A. Epidemic Estimates (2021)

Indicator	Male	Female	Total
1. IPR	-	-	4.90
2. IMR	-	-	2.24
3. Adult (15-49 yrs) HIV Prevalence (%)	0.37	0.25	0.31
4. Estimated people living with HIV	34,888	20,913	55,801
5. ART coverage (%)	67.2	64	66
6. Estimated children living with HIV	736	622	1,358
7. Annual new HIV infections	1,638	1,098	2,736
8. Annual AIDS-related deaths (ARD)	576	372	948
9. Change in annual new HIV infections since 2010 (%)	-18.3	-7.11	-14.12
10. Change in annual ARD since 2010(%)	-30.9	-16.59	-25.94
11. EMTCT need	-	394	394


### B. High risk population size (2009), safe practices (2015) and prevalence (2021)

Population Group	Estimates Size	Condom Use (%)	New Needle/ Syringe use (%)	HIV Prevalence (%)
1. Female Sex Workers	45,466	58.6	68.3	0.81
2. Men who have sex with men	18,145	42.2	37	2.59
3. Injecting Drug Users	12,698	35	90.8	15.87
4. Hijra/Transgender People	7,173	48.9	-	3.6
5. Migrants	2,77,822	-	-	0.75
6. Truckers	60,000	-	-	0.8
7. Prison inmates	75,472	40.9	28.6	2.45

### C. HIV/AIDS related knowledge, stigma and high-risk behaviour in general population (2019-21)

Indicator	Male	Female	Total
1. Adults (15-49 yrs) with comprehensive knowledge about HIV/AIDS (%)	43.8	29.5	-
2. Youth (15-24 yrs) with comprehensive knowledge about HIV/AIDS (%)	36.3	25.1	-
3. Adults willing to care for a relative with HIV/AIDS in own home (%)	85.9	80	-
4. Adults willing to buy fresh vegetables from a shopkeeper or vendor who has HIV/AIDS (%)	80.3	73.2	-
5. Adults (15-49 yrs) who have had higher-risk sexual behaviour in the past 12 months (%)	7.2	0.6	-
5.1 Condom use during last higher-risk intercourse (%)	72.8	86.5	-
6. Youth (15-24 yrs) who have had higher-risk sexual behaviour in the past 12 months (%)	11.4	0.8	-
6.1 Condom use during last higher-risk intercourse (%)	70.0	100.0	-

## 2. Progress on 95-95-95 (2021-22)



Indicator	Male	Female	Total
1. Estimated PLHIV size (2021)	34,888	20,913	55,801
2. PLHIV who know their HIV Status	34,312	17,180	51,492
3. PLHIV who know their HIV status and are on ART	23,888	13,610	37,498
4. PLHIV who are on ART and tested for their viral load	11,235	6,907	18,142
5. PLHIV who are virally suppressed	9,711	6,167	15,878

### 3. Prevention of new HIV infections among general population

#### A. Information, Education, Communication, Youth and Mainstreaming

Indicator	2021-22
1. Schools with operational Adolescent Education Program (AEP)	-
2. Colleges with operational Red Ribbon Clubs (RRC)	86
3. Persons trained under mainstreaming	2,744
	-

#### B. Sexually Transmitted Infections (STI)/Reproductive Tract Infections (RTI) Management at DSRCs

Indicator	2021-22			
1. NACO Supported Designated STI/RTI Clinics (DSRC)	28			
	Male	Female	TG	Total
2. Clients managed	-	-	-	65,589
3. RPR Tests conducted	10,313	24,742	76	35,131
4. Syphilis seropositivity (%)	3.94	0.50	7.89	1.52

### 4. Prevention of new HIV infections among high-risk group and bridge population

#### A. Targeted Interventions (TI) and Opioid Substitution Therapy (OST)

Indicator	2021-22
1. Targeted Interventions	73
2. OST centres	8
3. Employer Led Model Interventions	36

#### B. Female Sex Workers

Indicator	2021-22
1. Estimated size	45,466
2. Coverage (%)	>=95
3. Condoms distributed	12,82,419
4. Tested for HIV (April 2021 - September 2021)	35,669
4.1. HIV sero-positive (%)	0.08
4.1.1. Linked to ART	24
5. Tested for HIV (October 2021 - March 2022)	38,834
5.1. HIV sero-positive (%)	0.13
5.1.1. Linked to ART	45
6. Clinic Visits	1,38,599
7. STI/RTI treated	2,199
8. Presumptive treatment	1,196

#### C. Men who have Sex with Men

Indicator	2021-22
1. Estimated size	18,145
2. Coverage (%)	>=95
3. Condoms distributed	35,44,116
4. Tested for HIV (April 2021 - September 2021)	12,496
4.1. HIV sero-positive (%)	0.22
4.1.1. Linked to ART	26
5. Tested for HIV (October 2021 - March 2022)	14,397
5.1. HIV sero-positive (%)	0.21
5.1.1. Linked to ART	22
6. Clinic Visits	50,083
7. STI/RTI treated	173
8. Presumptive treatment	144

### D. Injecting Drug Users

Indicator	2021-22
1. Estimated size	12,698
2. Coverage (%)	95
3. Needles distributed	50,75,133
4. Syringes distributed	26,39,462
5. On OST	1,571
6. Tested for HIV (April 2021 - September 2021)	8,379
6.1. HIV sero-positive (%)	0.75
6.1.1. Linked to ART	32
7. Tested for HIV (October 2021 - March 2022)	9,583
7.1. HIV sero-positive (%)	0.91
7.1.1. Linked to ART	67

### E. Hijra/Transgender people

Indicator	2021-22
1. Estimated size	7,173
2. Coverage (%)	>=95
3. Condoms distributed	19,52,354
4. Tested for HIV (April 2021 - September 2021)	7,300
4.1. HIV sero-positive (%)	0.16
4.1.1. Linked to ART	9
5. Tested for HIV (October 2021 - March 2022)	8,382
5.1. HIV sero-positive (%)	0.17
5.1.1. Put on ART	13
6. Clinic Visits	27,861
7. STI / RTI treated	105
8. Presumptive treatment	158

### F. Migrants

Indicator	2021-22
1. Estimated size	2,77,822
2. Coverage (%)	>=95
3. Tested for HIV	52,189
3.1. HIV sero-positive (%)	0.19
3.2. Linked to ART	81

### G. Truckers

Indicator	2021-22
1. Estimated size	60,000
2. Coverage (%)	58
3. Tested for HIV	6,213
3.1. HIV sero-positive (%)	0.06
3.2. On ART	4

### H. Prison Inmates

Indicator	2021-22
1. Total prisons	16
2. Prisons covered under programme	16
3. Total inmates admitted	50,362
4. Inmates Covered(%)	38
5. Tested for HIV	8,107
5.1. HIV sero-positive (%)	1.70
5.2. On ART (%)	84

### I. Link Worker Scheme

Indicator	2021-22
1. Districts covered under scheme	-
2. Vulnerable population covered	-
3. Tested for HIV	-
3.1. HIV sero-positive (%)	-
3.2. Linked to ART (%)	-



## J. Opioid Substitution Therapy

Indicator	2021-22
1. OST Centres	8
1.1. OSTC in Public Health Settings	8
1.2. OSTC in NGO Settings	-
1.3 No. of Satellite OST Centres	-
2. IDU on OST	1,571

## 5. Early detection of HIV infected people

### A. HIV Counselling and Testing Services (HCTS)

Indicator	2021-22
1. ICTC facilities	618
1.1. Stand-alone	90
1.2. Facility integrated (Govt)	416
1.3. Facility integrated (PPP)	30
1.4. CBS	82

### B. HIV Testing among Vulnerable Population (Excluding Pregnant Women)

Indicator	2021-22			
	Male	Female	TG	Total
1. Tested for HIV	2,31,760	1,67,132	8,912	4,07,804
2. Found HIV Positive among tested	2,983	977	48	4,008
3. HIV sero-positivity (%) among tested	1.29	0.58	0.54	0.98
4. Spouse/sexual partner testing of HIV positive people identified	637	748	21	1,406

## 6. Initiation and retention on ART of HIV infected people

### A. Treatment Facilities

Indicator	2021-22
1. ART Centres	12
2. Centre of Excellence	
2.1. Centre of Excellence (Adult)	1
2.2. Centre of Excellence (Paediatric)	1
3. Link ART Centres	-
4. Care Support Centres	5

### B. Treatment Uptake

Indicator	2021-22			
	Male	Female	TG	Total
1. HIV positive cases diagnosed (At ICTC)	2,983	1,114	48	4,145
2. New PLHIV Registered at ART center	2,958	1,019	57	4,034
2.1 Initiated on ART	2,674	931	53	3,658
3. PLHIV alive and on ART	23,445	12,956	417	36,818
4. 12 months retention on ART (%)				79.76
5. Lost to follow-up cases	10,120	3,416	207	13,743

## 7. Viral Suppression and laboratories

### A. Laboratory facilities and service uptake

Indicator	2021-22
1. Viral load laboratories	2
1.1 Accredited Viral load laboratories	1
2. Viral load testing conducted	18,696
2.1. Virally suppressed (%)	88
3. National reference laboratories (NRL)	2
3.1 Accredited NRL	2
4. State reference laboratories (SRL)	4
4.1 Accredited SRL	4
5. CD4 testing conducted	37,243
6. External Quality Assessment of ICTC	
6.1 Average Participation (%)	96.47
6.2. Average Discordance (%)	0.00
7. Quality Assurance Scheme for Basic Composite Medical Laboratories (Entry Level)- M(EL)T	
7.1 No. of ICTCs certified for M(EL)T certification	3.00

## 8. Elimination of mother to child transmission of HIV & Syphilis

### A. HIV

Indicator	2021-22
1. Estimated pregnant women (PW)	3,53,740
2. HIV testing among PW	2,51,382
3. HIV sero-positivity (%) among tested	0.05
4. HIV Positive PW (old + new detections)	245
4.1 On life-long ART	205
5. Live births among HIV positive PW	148
5.1 Babies given ARV Prophylaxis (%)	97.30
6. Babies tested HIV (6 week- 6 month)	218
6.1 Babies confirmed HIV Positive (6 week- 6 month)	1
7. HIV exposed babies at 18 months	
7.1 HIV exposed babies tested at 18 month	280
7.2 Babies confirmed HIV positive at 18 months	6
8. HIV positive babies initiated on ART	6

### B. Syphilis

Indicator	2021-22
1. Estimated pregnant women (PW)	3,53,740
2. Syphilis testing among PW	1,96,977
3. Sero-positivity (%) among tested	0.02
4. Put on treatment	31

## 9. Elimination of HIV/AIDS related Stigma and Discrimination

### A. HIV/AIDS Prevention & Control Act (2017)

Indicator	2021-22
1. State rules notified for HIV/AIDS Prevention and Control Act (2017)	No
2. State designated/appointed ombudsman for HIV/AIDS Prevention and Control Act (2017)	No

## 10. HIV-TB Co-morbidities

### A. HRG and Bridge Population

Indicator								2021-22
	Quarter	FSW	MSW	IDU	TG	Migrants	Truckers	Total
Screened for TB	Quarter 1	27,630	9,611	6,077	5,117	19,590	3,288	71,313
	Quarter 2	42,554	14,304	10,392	7,714	32,792	5,676	1,13,432
	Quarter 3	41,593	14,684	10,542	8,532	34,111	4,604	1,14,066
	Quarter 4	41,557	13,918	9,794	8,330	30,828	4,210	1,08,637
Tested for TB	Quarter 1	48	35	11	2	38	20	154
	Quarter 2	92	23	23	1	105	37	281
	Quarter 3	187	35	22	2	131	32	409
	Quarter 4	178	26	18	6	94	44	366
Diagnosed with TB	Quarter 1	8	-	5	1	3	-	17
	Quarter 2	13	1	1	1	6	-	22
	Quarter 3	34	2	1	-	3	-	40
	Quarter 4	12	1	1	4	1	-	19
Initiated on TB treatment	Quarter 1	11	-	5	1	3	-	20
	Quarter 2	10	1	1	1	6	-	19
	Quarter 3	26	2	1	-	2	-	31
	Quarter 4	12	1	1	3	-	-	17

### B. HIV-TB Cross-Referral

Indicator	2021-22
1. In referral from TB program	52,728
1.1. HIV sero-positive (%)	1.37
1.2. ICTC clients referred to NTEP	10,952

### C. HIV-TB Coinfected at ART Centre

Indicator								2021-22
	PLHIV attending ART Centre	PLHIV underwent 4S screening	PLHIV with presumptive TB	PLHIV tested for TB	PLHIV diagnosed with TB	PLHIV initiated on IPT	Co-infected enrolled at ARTc	Co-infected initiated on ART
Apr-21	22,298	21,822	167	113	62	434		
May-21	19,186	18,719	129	77	30	288		
Jun-21	19,664	19,320	189	114	63	365		
Jul-21	18,789	18,308	218	150	85	153		
Aug-21	21,384	20,467	208	147	67	673		
Sep-21	23,382	22,768	297	195	84	658		
Oct-21	22,056	21,861	306	173	70	582		
Nov-21	22,305	21,908	302	179	74	377		
Dec-21	22,914	22,592	355	193	66	139		
Jan-22	20,192	19,760	261	142	49	256		
Feb-22	17,487	17,034	251	153	80	289		
Mar-22	20,596	20,180	292	173	85	317		
April 2021-March 2022							1,053	966

## 11. Scorecard

State/UT Name		Delhi
Overall Rank		28
IEC & MS	Frequency of Social Media updates (G= ≥60, Y=40-59, R=<40)	
	Status of AEP integration in state School curriculum (G=Yes, R=No)	
	Status of SCA (G= At least one meeting held since 2017, R= other than G)	
	Status of State Rules (G= Notified, R= Not notified)	
	Status of Ombudsman (G= Appointed, R=Not appointed)	
	Rank	31
TI	Facilities onboarded (G=≥95%, Y= 90-94%, R=<90%)	
	Coverage against target in contract (G=≥95%, Y= 90-94%, R=<90%)	
	HRG & BP living with HIV on ART (G=≥95%, Y= 90-94%, R=<90%)	
	IDU on OST (G=≥95%, Y= 90-94%, R=<90%)	
	Rank	28
BSD	Percentage of PLHIV who know their status (G=≥95%, Y= 80-94%, R=<80%)	
	HIV testing against target-GC ((G=≥95%, Y= 80-94%, R=<80%)	
	HIV testing against target-PW (G=≥95%, Y= 80-94%, R=<80%)	
	Percentage of Pregnant women who initiated ART (G=≥95%, Y= 80-94%, R=<80%)	
	Percentage of TB suspected cases referred to NTEP (G=≥95%, Y= 80-94%, R=<80%)	
	Clients managed at DSRC against the target (G=≥95%, Y= 80-94%, R=<80%)	
	Percentage of pregnant women tested for Syphilis (G=≥95%, Y= 80-94%, R=<80%)	
	Rank	17
CST	ART Initiation (Current FY) (G=≥95%, Y= 80-94%, R=<80%)	
	LFU rate among new ART initiation (G=<2%, Y= 2-4%, R=≥5%)	
	PLHIV put on ART during the FY against target (G=≥95%, Y= 80-94%, R=<80%)	
	Status on establishment of CSC (G=≥95%, Y= 80-94%, R=<80%)	NA
	Rank	17
LS	VL Suppression Rate (Current FY) (G=≥95%, Y= 85-94%, R=<85%)	
	% of SRL accredited (G=100%, Y= 80-99%, R=<80%)	
	% Participation of ICTCs in Re-testing (G=≥95%, Y= 85-94, R=<85%)	
	Rank	2
SI	% of NACP facilities active in SOCH (G=≥90%, Y= 75-89%, R=<75%)	
	Status of State Data Management Committee (G=one meeting held, Y= no meeting held, R= not constituted)	
	Status of finalized Priority Areas for Operational Research and Evaluation (G= 4, Y= 3, R= <3)	
	Rank	32
Finance	Expenditure with respect to funds released during FY 2021-22 (G=≥90%, Y= 85-89%, R=<85%)	
	Submission of Audit Report after approval of EC/GB for the preceding year (G= by 30th June, Y= 30th Sept, R= beyond 30th Sept 2021)	
	Submission of Utilization Certificate (in prescribed format GFR 12A) for the previous financial year (G= by 30th June, Y= 30th Sept, R= beyond 30th Sept 2021)	
	Rank	5
SCM	Report Submission (BSD-SCM Report) (G=≥90%, Y= 75-89%, R=<75%)	

Green=3 Marks

Yellow=2Marks

Red=1 Mark

No Colour=Not Applicable

A thick red ribbon is tied in a loop, with the ends trailing off to the right and bottom. It is set against a yellow background with faint, concentric circles.

# FACT SHEET

## GOA

## 1. Status of HIV/AIDS Epidemic

### A. Epidemic Estimates (2021)

Indicator	Male	Female	Total
1. IPR	-	-	2.46
2. IMR	-	-	1.18
3. Adult (15-49 yrs) HIV Prevalence (%)	0.33	0.30	0.31
4. Estimated people living with HIV	2,462	2,134	4,596
5. ART coverage (%)	68.9	78	73
6. Estimated children living with HIV	54	51	105
7. Annual new HIV infections	58	55	113
8. Annual AIDS-related deaths (ARD)	53	17	70
9. Change in annual new HIV infections since 2010 (%)	-20.5	-6.78	-14.39
10. Change in annual ARD since 2010(%)	-83.6	-91.10	-86.41
11. EMTCT need	-	35	35


### B. High risk population size (2009), safe practices (2015) and prevalence (2021)

Population Group	Estimates Size	Condom Use (%)	New Needle/ Syringe use (%)	HIV Prevalence (%)
1. Female Sex Workers	4,000	81.8	10.5	0.6
2. Men who have sex with men	2,924	73.4	51.8	2.4
3. Injecting Drug Users	400	48.3	62.7	0
4. Hijra/Transgender People	100	-	-	-
5. Migrants	35,000	-	-	-
6. Truckers	23,000	-	-	-
7. Prison inmates	1,647	-	-	-

### C. HIV/AIDS related knowledge, stigma and high-risk behaviour in general population (2019-21)

Indicator	Male	Female	Total
1. Adults (15-49 yrs) with comprehensive knowledge about HIV/AIDS (%)	67.2	49	-
2. Youth (15-24 yrs) with comprehensive knowledge about HIV/AIDS (%)	72.8	52.9	-
3. Adults willing to care for a relative with HIV/AIDS in own home (%)	79.8	80.1	-
4. Adults willing to buy fresh vegetables from a shopkeeper or vendor who has HIV/AIDS (%)	83	79.8	-
5. Adults (15-49 yrs) who have had higher-risk sexual behaviour in the past 12 months (%)	8.8	5.2	-
5.1 Condom use during last higher-risk intercourse (%)	96.6	100	-
6. Youth (15-24 yrs) who have had higher-risk sexual behaviour in the past 12 months (%)	15.1	2.8	-
6.1 Condom use during last higher-risk intercourse (%)	92.3	100.0	-

## 2. Progress on 95-95-95 (2021-22)



Indicator	Male	Female	Total
1. Estimated PLHIV size (2021)	2,462	2,134	4,596
2. PLHIV who know their HIV Status	1,941	1,783	3,724
3. PLHIV who know their HIV status and are on ART	1,580	1,538	3,118
4. PLHIV who are on ART and tested for their viral load	1,530	1,555	3,085
5. PLHIV who are virally suppressed	1,342	1,393	2,735

### 3. Prevention of new HIV infections among general population

#### A. Information, Education, Communication, Youth and Mainstreaming

Indicator	2021-22
1. Schools with operational Adolescent Education Program (AEP)	520
2. Colleges with operational Red Ribbon Clubs (RRC)	166
3. Persons trained under mainstreaming	770

#### B. Sexually Transmitted Infections (STI)/Reproductive Tract Infections (RTI) Management at DSRCs

Indicator	2021-22			
1. NACO Supported Designated STI/RTI Clinics (DSRC)	4			
	Male	Female	TG	Total
2. Clients managed	-	-	-	7,409
3. RPR Tests conducted	850	8,139	0	8,989
4. Syphilis seropositivity (%)	8.82	0.26	-	1.07

### 4. Prevention of new HIV infections among high-risk group and bridge population

#### A. Targeted Interventions (TI) and Opioid Substitution Therapy (OST)

Indicator	2021-22
1. Targeted Interventions	16
2. OST centres	1
3. Employer Led Model Interventions	33

#### B. Female Sex Workers

Indicator	2021-22
1. Estimated size	4,000
2. Coverage (%)	>=95
3. Condoms distributed	16,01,776
4. Tested for HIV (April 2021 - September 2021)	4,315
4.1. HIV sero-positive (%)	0.05
4.1.1. Linked to ART	1
5. Tested for HIV (October 2021 - March 2022)	4,464
5.1. HIV sero-positive (%)	0.04
5.1.1. Linked to ART	2
6. Clinic Visits	16,436
7. STI/RTI treated	210
8. Presumptive treatment	383

#### C. Men who have Sex with Men

Indicator	2021-22
1. Estimated size	2,924
2. Coverage (%)	>=95
3. Condoms distributed	8,54,610
4. Tested for HIV (April 2021 - September 2021)	2,766
4.1. HIV sero-positive (%)	0.07
4.1.1. Linked to ART	2
5. Tested for HIV (October 2021 - March 2022)	3,147
5.1. HIV sero-positive (%)	0.10
5.1.1. Linked to ART	3
6. Clinic Visits	12,994
7. STI/RTI treated	94
8. Presumptive treatment	19

### D. Injecting Drug Users

Indicator	2021-22
1. Estimated size	400
2. Coverage (%)	>=95
3. Needles distributed	83,756
4. Syringes distributed	83,757
5. On OST	32
6. Tested for HIV (April 2021 - September 2021)	384
6.1. HIV sero-positive (%)	0.00
6.1.1. Linked to ART	0
7. Tested for HIV (October 2021 - March 2022)	381
7.1. HIV sero-positive (%)	0.00
7.1.1. Linked to ART	0

### E. Hijra/Transgender people

Indicator	2021-22
1. Estimated size	100
2. Coverage (%)	92
3. Condoms distributed	24,012
4. Tested for HIV (April 2021 - September 2021)	44
4.1. HIV sero-positive (%)	0.00
4.1.1. Linked to ART	-
5. Tested for HIV (October 2021 - March 2022)	45
5.1. HIV sero-positive (%)	0.00
5.1.1. Put on ART	-
6. Clinic Visits	236
7. STI / RTI treated	0
8. Presumptive treatment	0

### F. Migrants

Indicator	2021-22
1. Estimated size	35,000
2. Coverage (%)	>=95
3. Tested for HIV	6,279
3.1. HIV sero-positive (%)	0.05
3.2. Linked to ART	3

### G. Truckers

Indicator	2021-22
1. Estimated size	23,000
2. Coverage (%)	43
3. Tested for HIV	1,667
3.1. HIV sero-positive (%)	0.00
3.2. On ART	-

### H. Prison Inmates

Indicator	2021-22
1. Total prisons	1
2. Prisons covered under programme	1
3. Total inmates admitted	1,406
4. Inmates Covered(%)	-
5. Tested for HIV	-
5.1. HIV sero-positive (%)	-
5.2. On ART (%)	-

### I. Link Worker Scheme

Indicator	2021-22
1. Districts covered under scheme	-
2. Vulnerable population covered	-
3. Tested for HIV	-
3.1. HIV sero-positive (%)	-
3.2. Linked to ART (%)	-



## J. Opioid Substitution Therapy

Indicator	2021-22
1. OST Centres	1
1.1. OSTC in Public Health Settings	-
1.2. OSTC in NGO Settings	1
1.3 No. of Satellite OST Centres	-
2. IDU on OST	32

## 5. Early detection of HIV infected people

### A. HIV Counselling and Testing Services (HCTS)

Indicator	2021-22
1. ICTC facilities	69
1.1. Stand-alone	16
1.2. Facility integrated (Govt)	25
1.3. Facility integrated (PPP)	12
1.4. CBS	16

### B. HIV Testing among Vulnerable Population (Excluding Pregnant Women)

Indicator	2021-22			
	Male	Female	TG	Total
1. Tested for HIV	38,069	23,577	22	61,668
2. Found HIV Positive among tested	154	66	-	220
3. HIV sero-positivity (%) among tested	0.40	0.28	0.00	0.36
4. Spouse/sexual partner testing of HIV positive people identified	80	85	2	167

## 6. Initiation and retention on ART of HIV infected people

### A. Treatment Facilities

Indicator	2021-22
1. ART Centres	2
2. Centre of Excellence	
2.1. Centre of Excellence (Adult)	-
2.2. Centre of Excellence (Paediatric)	-
3. Link ART Centres	3
4. Care Support Centres	1

### B. Treatment Uptake

Indicator	2021-22			
	Male	Female	TG	Total
1. HIV positive cases diagnosed (At ICTC)	154	66	-	230
2. New PLHIV Registered at ART center	133	71	-	204
2.1 Initiated on ART	124	68	-	192
3. PLHIV alive and on ART	1,695	1,651	2	3,349
4. 12 months retention on ART (%)				73.47
5. Lost to follow-up cases	247	162	2	411

## 7. Viral Suppression and laboratories

### A. Laboratory facilities and service uptake

Indicator	2021-22
1. Viral load laboratories	-
1.1 Accredited Viral load laboratories	-
2. Viral load testing conducted	3,161
2.1. Virally suppressed (%)	89
3. National reference laboratories (NRL)	0
3.1 Accredited NRL	0
4. State reference laboratories (SRL)	1
4.1 Accredited SRL	1
5. CD4 testing conducted	1,002
6. External Quality Assessment of ICTC	
6.1 Average Participation (%)	100.00
6.2. Average Discordance (%)	0.00
7. Quality Assurance Scheme for Basic Composite Medical Laboratories (Entry Level)- M(EL)T	
7.1 No. of ICTCs certified for M(EL)T certification	0.00

## 8. Elimination of mother to child transmission of HIV & Syphilis

### A. HIV

Indicator	2021-22
1. Estimated pregnant women (PW)	20,910
2. HIV testing among PW	32,454
3. HIV sero-positivity (%) among tested	0.03
4. HIV Positive PW (old + new detections)	26
4.1 On life-long ART	26
5. Live births among HIV positive PW	14
5.1 Babies given ARV Prophylaxis (%)	100.00
6. Babies tested HIV (6 week- 6 month)	17
6.1 Babies confirmed HIV Positive (6 week- 6 month)	-
7. HIV exposed babies at 18 months	
7.1 HIV exposed babies tested at 18 month	11
7.2 Babies confirmed HIV positive at 18 months	1
8. HIV positive babies initiated on ART	1

### B. Syphilis

Indicator	2021-22
1. Estimated pregnant women (PW)	20,910
2. Syphilis testing among PW	32,281
3. Sero-positivity (%) among tested	0.03
4. Put on treatment	9

## 9. Elimination of HIV/AIDS related Stigma and Discrimination

### A. HIV/AIDS Prevention & Control Act (2017)

Indicator	2021-22
1. State rules notified for HIV/AIDS Prevention and Control Act (2017)	No
2. State designated/appointed ombudsman for HIV/AIDS Prevention and Control Act (2017)	Yes

## 10. HIV-TB Co-morbidities

### A. HRG and Bridge Population

Indicator								2021-22
	Quarter	FSW	MSW	IDU	TG	Migrants	Truckers	Total
Screened for TB	Quarter 1	2,869	2,548	406	41	2,181	1,939	9,984
	Quarter 2	3,837	2,595	375	39	2,570	2,169	11,585
	Quarter 3	4,040	2,914	377	45	2,340	2,187	11,903
	Quarter 4	4,138	2,791	341	59	1,910	2,401	11,640
Tested for TB	Quarter 1	2	-	-	-	2	-	4
	Quarter 2	6	-	-	-	3	-	9
	Quarter 3	2	-	-	-	1	-	3
	Quarter 4	-	-	-	-	-	-	-
Diagnosed with TB	Quarter 1	-	-	-	-	1	-	1
	Quarter 2	1	-	-	-	1	-	2
	Quarter 3	-	-	-	-	-	-	-
	Quarter 4	-	-	-	-	-	-	-
Initiated on TB treatment	Quarter 1	-	-	-	-	1	-	1
	Quarter 2	1	-	-	-	1	-	2
	Quarter 3	-	-	-	-	-	-	-
	Quarter 4	-	-	-	-	-	-	-

### B. HIV-TB Cross-Referral

Indicator		2021-22
1. In referral from TB program		2,164
1.1. HIV sero-positive (%)		0.92
1.2. ICTC clients referred to NTEP		1,525

### C. HIV-TB Coinfected at ART Centre

Indicator								2021-22
	PLHIV attending ART Centre	PLHIV underwent 4S screening	PLHIV with presumptive TB	PLHIV tested for TB	PLHIV diagnosed with TB	PLHIV initiated on IPT	Co-infected enrolled at ARTc	Co-infected initiated on ART
Apr-21	2,405	2,125	25	20	2	13		
May-21	1,723	1,475	8	6	-	7		
Jun-21	1,862	1,591	7	6	1	25		
Jul-21	2,172	1,900	11	10	1	12		
Aug-21	2,503	2,419	38	38	2	20		
Sep-21	2,656	2,396	59	54	-	6		
Oct-21	2,777	2,504	16	15	-	12		
Nov-21	2,459	2,225	26	24	1	7		
Dec-21	2,373	2,102	19	19	1	29		
Jan-22	2,359	2,091	23	16	2	14		
Feb-22	2,468	2,228	12	9	-	13		
Mar-22	2,566	2,320	6	3	-	13		
April 2021-March 2022							53	49

## 11. Scorecard

State/UT Name		Goa
Overall Rank		1
IEC & MS	Frequency of Social Media updates (G= ≥60, Y=40-59, R=<40)	
	Status of AEP integration in state School curriculum (G=Yes, R=No)	
	Status of SCA (G= At least one meeting held since 2017, R= other than G)	
	Status of State Rules (G= Notified, R= Not notified)	
	Status of Ombudsman (G= Appointed, R=Not appointed)	
	Rank	15
TI	Facilities onboarded (G=≥95%, Y= 90-94%, R=<90%)	
	Coverage against target in contract (G=≥95%, Y= 90-94%, R=<90%)	
	HRG & BP living with HIV on ART (G=≥95%, Y= 90-94%, R=<90%)	
	IDU on OST (G=≥95%, Y= 90-94%, R=<90%)	
	Rank	3
BSD	Percentage of PLHIV who know their status (G=≥95%, Y= 80-94%, R=<80%)	
	HIV testing against target-GC ((G=≥95%, Y= 80-94%, R=<80%)	
	HIV testing against target-PW (G=≥95%, Y= 80-94%, R=<80%)	
	Percentage of Pregnant women who initiated ART (G=≥95%, Y= 80-94%, R=<80%)	
	Percentage of TB suspected cases referred to NTEP (G=≥95%, Y= 80-94%, R=<80%)	
	Clients managed at DSRC against the target (G=≥95%, Y= 80-94%, R=<80%)	
	Percentage of pregnant women tested for Syphilis (G=≥95%, Y= 80-94%, R=<80%)	
	Rank	1
CST	ART Initiation (Current FY) (G=≥95%, Y= 80-94%, R=<80%)	
	LFU rate among new ART initiation (G=<2%, Y= 2-4%, R=≥5%)	
	PLHIV put on ART during the FY against target (G=≥95%, Y= 80-94%, R=<80%)	
	Status on establishment of CSC (G=≥95%, Y= 80-94%, R=<80%)	
	Rank	11
LS	VL Suppression Rate (Current FY) (G=≥95%, Y= 85-94%, R=<85%)	
	% of SRL accredited (G=100%, Y= 80-99%, R=<80%)	
	% Participation of ICTCs in Re-testing (G=≥95%, Y= 85-94, R=<85%)	
	Rank	2
SI	% of NACP facilities active in SOCH (G=≥90%, Y= 75-89%, R=<75%)	
	Status of State Data Management Committee (G=one meeting held, Y= no meeting held, R= not constituted)	
	Status of finalized Priority Areas for Operational Research and Evaluation (G= 4, Y= 3, R= <3)	
	Rank	1
Finance	Expenditure with respect to funds released during FY 2021-22 (G=≥90%, Y= 85-89%, R=<85%)	
	Submission of Audit Report after approval of EC/GB for the preceding year (G= by 30th June, Y= 30th Sept, R= beyond 30th Sept 2021)	
	Submission of Utilization Certificate (in prescribed format GFR 12A) for the previous financial year (G= by 30th June, Y= 30th Sept, R= beyond 30th Sept 2021)	
	Rank	1
SCM	Report Submission (BSD-SCM Report) (G=≥90%, Y= 75-89%, R=<75%)	

Green=3 Marks

Yellow=2Marks

Red=1 Mark

No Colour=Not Applicable

A thick red ribbon is draped across the page, starting from the bottom left, looping upwards and to the right, and then looping back down towards the right edge. The background is a gradient of yellow and orange with faint, concentric circular patterns.

# FACT SHEET

## GUJARAT

## 1. Status of HIV/AIDS Epidemic

### A. Epidemic Estimates (2021)

Indicator	Male	Female	Total
1. IPR	-	-	2.21
2. IMR	-	-	1.41
3. Adult (15-49 yrs) HIV Prevalence (%)	0.21	0.17	0.19
4. Estimated people living with HIV	65,260	48,272	1,13,532
5. ART coverage (%)	72.1	68	70
6. Estimated children living with HIV	1,820	1,552	3,372
7. Annual new HIV infections	1,348	1,159	2,507
8. Annual AIDS-related deaths (ARD)	393	417	810
9. Change in annual new HIV infections since 2010 (%)	-60.7	-58.38	-59.68
10. Change in annual ARD since 2010(%)	-72.3	-66.32	-69.49
11. EMTCT need	-	1,030	1,030


### B. High risk population size (2009), safe practices (2015) and prevalence (2021)

Population Group	Estimates Size	Condom Use (%)	New Needle/ Syringe use (%)	HIV Prevalence (%)
1. Female Sex Workers	36,995	69.6	67.7	1.34
2. Men who have sex with men	34,032	79.1	41.2	4.61
3. Injecting Drug Users	1,961	74.6	79.4	2
4. Hijra/Transgender People	3,058	67.6	-	3.6
5. Migrants	13,14,462	-	-	0.13
6. Truckers	1,20,000	-	-	0.3
7. Prison inmates	92,697	61.5	14.3	0.88

### C. HIV/AIDS related knowledge, stigma and high-risk behaviour in general population (2019-21)

Indicator	Male	Female	Total
1. Adults (15-49 yrs) with comprehensive knowledge about HIV/AIDS (%)	35.7	28.5	-
2. Youth (15-24 yrs) with comprehensive knowledge about HIV/AIDS (%)	33.4	27.2	-
3. Adults willing to care for a relative with HIV/AIDS in own home (%)	87.9	86.3	-
4. Adults willing to buy fresh vegetables from a shopkeeper or vendor who has HIV/AIDS (%)	72.4	70.4	-
5. Adults (15-49 yrs) who have had higher-risk sexual behaviour in the past 12 months (%)	5.5	0.7	-
5.1 Condom use during last higher-risk intercourse (%)	42.9	51.2	-
6. Youth (15-24 yrs) who have had higher-risk sexual behaviour in the past 12 months (%)	8.7	1.5	-
6.1 Condom use during last higher-risk intercourse (%)	45.5	52.2	-

## 2. Progress on 95-95-95 (2021-22)



Indicator	Male	Female	Total
1. Estimated PLHIV size (2021)	65,260	48,272	1,13,532
2. PLHIV who know their HIV Status	55,471	37,955	93,426
3. PLHIV who know their HIV status and are on ART	46,403	32,397	78,800
4. PLHIV who are on ART and tested for their viral load	37,060	25,306	62,366
5. PLHIV who are virally suppressed	31,017	21,215	52,232

### 3. Prevention of new HIV infections among general population

#### A. Information, Education, Communication, Youth and Mainstreaming

Indicator	2021-22
1. Schools with operational Adolescent Education Program (AEP)	10,266
2. Colleges with operational Red Ribbon Clubs (RRC)	213
3. Persons trained under mainstreaming	40,126

#### B. Sexually Transmitted Infections (STI)/Reproductive Tract Infections (RTI) Management at DSRCs

Indicator	2021-22			
1. NACO Supported Designated STI/RTI Clinics (DSRC)	66			
	Male	Female	TG	Total
2. Clients managed	-	-	-	1,02,874
3. RPR Tests conducted	42,748	52,863	2,597	98,208
4. Syphilis seropositivity (%)	3.02	0.76	0.89	1.75

### 4. Prevention of new HIV infections among high-risk group and bridge population

#### A. Targeted Interventions (TI) and Opioid Substitution Therapy (OST)

Indicator	2021-22
1. Targeted Interventions	93
2. OST centres	2
3. Employer Led Model Interventions	14

#### B. Female Sex Workers

Indicator	2021-22
1. Estimated size	36,995
2. Coverage (%)	76
3. Condoms distributed	11,61,0391
4. Tested for HIV (April 2021 - September 2021)	24,465
4.1. HIV sero-positive (%)	0.05
4.1.1. Linked to ART	12
5. Tested for HIV (October 2021 - March 2022)	25,553
5.1. HIV sero-positive (%)	0.06
5.1.1. Linked to ART	12
6. Clinic Visits	96,675
7. STI/RTI treated	1,272
8. Presumptive treatment	4,234

#### C. Men who have Sex with Men

Indicator	2021-22
1. Estimated size	34,032
2. Coverage (%)	81
3. Condoms distributed	76,17,341
4. Tested for HIV (April 2021 - September 2021)	24,039
4.1. HIV sero-positive (%)	0.15
4.1.1. Linked to ART	31
5. Tested for HIV (October 2021 - March 2022)	24,546
5.1. HIV sero-positive (%)	0.18
5.1.1. Linked to ART	40
6. Clinic Visits	97,326
7. STI/RTI treated	982
8. Presumptive treatment	3,217

### D. Injecting Drug Users

Indicator	2021-22
1. Estimated size	1,961
2. Coverage (%)	46
3. Needles distributed	1,22,958
4. Syringes distributed	1,22,967
5. On OST	93
6. Tested for HIV (April 2021 - September 2021)	719
6.1. HIV sero-positive (%)	0.28
6.1.1. Linked to ART	2
7. Tested for HIV (October 2021 - March 2022)	793
7.1. HIV sero-positive (%)	0.13
7.1.1. Linked to ART	1

### E. Hijra/Transgender people

Indicator	2021-22
1. Estimated size	3,058
2. Coverage (%)	59
3. Condoms distributed	3,59,326
4. Tested for HIV (April 2021 - September 2021)	1,565
4.1. HIV sero-positive (%)	0.13
4.1.1. Linked to ART	2
5. Tested for HIV (October 2021 - March 2022)	1,494
5.1. HIV sero-positive (%)	0.54
5.1.1. Put on ART	8
6. Clinic Visits	6,526
7. STI / RTI treated	17
8. Presumptive treatment	232

### F. Migrants

Indicator	2021-22
1. Estimated size	13,14,462
2. Coverage (%)	68
3. Tested for HIV	74,121
3.1. HIV sero-positive (%)	0.08
3.2. Linked to ART	56

### G. Truckers

Indicator	2021-22
1. Estimated size	1,20,000
2. Coverage (%)	46
3. Tested for HIV	7,665
3.1. HIV sero-positive (%)	0.05
3.2. On ART	4

### H. Prison Inmates

Indicator	2021-22
1. Total prisons	30
2. Prisons covered under programme	29
3. Total inmates admitted	61,916
4. Inmates Covered(%)	63
5. Tested for HIV	16,778
5.1. HIV sero-positive (%)	0.29
5.2. On ART (%)	94

### I. Link Worker Scheme

Indicator	2021-22
1. Districts covered under scheme	11
2. Vulnerable population covered	1,95,819
3. Tested for HIV	54,346
3.1. HIV sero-positive (%)	0.11
3.2. Linked to ART (%)	84.75



## J. Opioid Substitution Therapy

Indicator	2021-22
1. OST Centres	2
1.1. OSTC in Public Health Settings	2
1.2. OSTC in NGO Settings	-
1.3 No. of Satellite OST Centres	-
2. IDU on OST	93

## 5. Early detection of HIV infected people

### A. HIV Counselling and Testing Services (HCTS)

Indicator	2021-22
1. ICTC facilities	2,904
1.1. Stand-alone	321
1.2. Facility integrated (Govt)	2,139
1.3. Facility integrated (PPP)	315
1.4. CBS	129

### B. HIV Testing among Vulnerable Population (Excluding Pregnant Women)

Indicator	2021-22			
	Male	Female	TG	Total
1. Tested for HIV	8,32,545	6,55,461	3,824	14,91,830
2. Found HIV Positive among tested	4,357	1,893	39	6,289
3. HIV sero-positivity (%) among tested	0.52	0.29	1.02	0.42
4. Spouse/sexual partner testing of HIV positive people identified	1,208	2,054	11	3,273

## 6. Initiation and retention on ART of HIV infected people

### A. Treatment Facilities

Indicator	2021-22
1. ART Centres	44
2. Centre of Excellence	
2.1. Centre of Excellence (Adult)	1
2.2. Centre of Excellence (Paediatric)	-
3. Link ART Centres	66
4. Care Support Centres	25

### B. Treatment Uptake

Indicator	2021-22			
	Male	Female	TG	Total
1. HIV positive cases diagnosed (At ICTC)	4,357	2,318	39	6,714
2. New PLHIV Registered at ART center	4,237	2,284	46	6,567
2.1 Initiated on ART	3,907	2,178	44	6,129
3. PLHIV alive and on ART	47,065	32,524	331	79,920
4. 12 months retention on ART (%)				78.73
5. Lost to follow-up cases	6,602	3,832	80	10,514

## 7. Viral Suppression and laboratories

### A. Laboratory facilities and service uptake

Indicator	2021-22
1. Viral load laboratories	4
1.1 Accredited Viral load laboratories	4
2. Viral load testing conducted	59,963
2.1. Virally suppressed (%)	84
3. National reference laboratories (NRL)	0
3.1 Accredited NRL	0
4. State reference laboratories (SRL)	5
4.1 Accredited SRL	5
5. CD4 testing conducted	72,629
6. External Quality Assessment of ICTC	
6.1 Average Participation (%)	92.63
6.2. Average Discordance (%)	0.30
7. Quality Assurance Scheme for Basic Composite Medical Laboratories (Entry Level)- M(EL)T	
7.1 No. of ICTCs certified for M(EL)T certification	0.00

## 8. Elimination of mother to child transmission of HIV & Syphilis

### A. HIV

Indicator	2021-22
1. Estimated pregnant women (PW)	10,93,130
2. HIV testing among PW	13,44,671
3. HIV sero-positivity (%) among tested	0.03
4. HIV Positive PW (old + new detections)	967
4.1 On life-long ART	932
5. Live births among HIV positive PW	692
5.1 Babies given ARV Prophylaxis (%)	97.25
6. Babies tested HIV (6 week- 6 month)	765
6.1 Babies confirmed HIV Positive (6 week- 6 month)	17
7. HIV exposed babies at 18 months	
7.1 HIV exposed babies tested at 18 month	568
7.2 Babies confirmed HIV positive at 18 months	19
8. HIV positive babies initiated on ART	43

### B. Syphilis

Indicator	2021-22
1. Estimated pregnant women (PW)	10,93,130
2. Syphilis testing among PW	10,83,748
3. Sero-positivity (%) among tested	0.03
4. Put on treatment	317

## 9. Elimination of HIV/AIDS related Stigma and Discrimination

### A. HIV/AIDS Prevention & Control Act (2017)

Indicator	2021-22
1. State rules notified for HIV/AIDS Prevention and Control Act (2017)	Yes
2. State designated/appointed ombudsman for HIV/AIDS Prevention and Control Act (2017)	Yes

## 10. HIV-TB Co-morbidities

### A. HRG and Bridge Population

Indicator								2021-22
	Quarter	FSW	MSW	IDU	TG	Migrants	Truckers	Total
Screened for TB	Quarter 1	27,075	22,092	564	981	32,908	11,643	95,263
	Quarter 2	21,986	22,737	518	1,224	41,060	11,814	99,339
	Quarter 3	20,933	22,551	538	1,034	35,060	12,269	92,385
	Quarter 4	19,300	21,366	873	1,482	32,868	12,830	88,719
Tested for TB	Quarter 1	354	345	15	5	125	33	877
	Quarter 2	691	840	20	59	294	83	1,987
	Quarter 3	540	804	9	59	253	78	1,743
	Quarter 4	515	765	16	54	249	81	1,680
Diagnosed with TB	Quarter 1	2	2	-	-	10	-	14
	Quarter 2	8	6	-	-	14	-	28
	Quarter 3	3	4	-	2	20	-	29
	Quarter 4	2	10	1	-	12	-	25
Initiated on TB treatment	Quarter 1	2	2	-	-	10	-	14
	Quarter 2	8	6	-	-	14	-	28
	Quarter 3	3	4	-	2	20	-	29
	Quarter 4	2	10	1	-	11	-	24

### B. HIV-TB Cross-Referral

Indicator		2021-22
1. In referral from TB program		1,50,763
1.1. HIV sero-positive (%)		2.37
1.2. ICTC clients referred to NTEP		85,676

### C. HIV-TB Coinfected at ART Centre

Indicator								2021-22
	PLHIV attending ART Centre	PLHIV underwent 4S screening	PLHIV with presumptive TB	PLHIV tested for TB	PLHIV diagnosed with TB	PLHIV initiated on IPT	Co-infected enrolled at ARTc	Co-infected initiated on ART
Apr-21	49,663	49,453	2,590	2,580	127	550		
May-21	36,795	36,791	2,079	2,060	114	459		
Jun-21	42,691	42,464	2,944	2,876	218	586		
Jul-21	45,167	44,929	3,281	3,246	247	630		
Aug-21	46,929	46,188	3,524	3,455	261	655		
Sep-21	46,202	45,317	3,482	3,479	259	594		
Oct-21	48,008	47,673	3,449	3,324	211	909		
Nov-21	39,316	38,162	3,907	2,804	228	762		
Dec-21	44,549	44,246	4,944	3,266	211	696		
Jan-22	43,360	43,019	4,244	3,093	190	546		
Feb-22	40,791	40,467	3,956	3,130	207	515		
Mar-22	45,179	45,140	3,360	3,353	256	530		
April 2021-March 2022							2,888	2,765

## 11. Scorecard

State/UT Name		Gujarat
Overall Rank		6
IEC & MS	Frequency of Social Media updates (G= ≥60, Y=40-59, R=<40)	
	Status of AEP integration in state School curriculum (G=Yes, R=No)	
	Status of SCA (G= At least one meeting held since 2017, R= other than G)	
	Status of State Rules (G= Notified, R= Not notified)	
	Status of Ombudsman (G= Appointed, R=Not appointed)	
	Rank	5
TI	Facilities onboarded (G=≥95%, Y= 90-94%, R=<90%)	
	Coverage against target in contract (G=≥95%, Y= 90-94%, R=<90%)	
	HRG & BP living with HIV on ART (G=≥95%, Y= 90-94%, R=<90%)	
	IDU on OST (G=≥95%, Y= 90-94%, R=<90%)	
	Rank	19
BSD	Percentage of PLHIV who know their status (G=≥95%, Y= 80-94%, R=<80%)	
	HIV testing against target-GC ((G=≥95%, Y= 80-94%, R=<80%)	
	HIV testing against target-PW (G=≥95%, Y= 80-94%, R=<80%)	
	Percentage of Pregnant women who initiated ART (G=≥95%, Y= 80-94%, R=<80%)	
	Percentage of TB suspected cases referred to NTEP (G=≥95%, Y= 80-94%, R=<80%)	
	Clients managed at DSRC against the target (G=≥95%, Y= 80-94%, R=<80%)	
	Percentage of pregnant women tested for Syphilis (G=≥95%, Y= 80-94%, R=<80%)	
	Rank	5
CST	ART Initiation (Current FY) (G=≥95%, Y= 80-94%, R=<80%)	
	LFU rate among new ART initiation (G=<2%, Y= 2-4%, R=≥5%)	
	PLHIV put on ART during the FY against target (G=≥95%, Y= 80-94%, R=<80%)	
	Status on establishment of CSC (G=≥95%, Y= 80-94%, R=<80%)	NA
	Rank	17
LS	VL Suppression Rate (Current FY) (G=≥95%, Y= 85-94%, R=<85%)	
	% of SRL accredited (G=100%, Y= 80-99%, R=<80%)	
	% Participation of ICTCs in Re-testing (G=≥95%, Y= 85-94, R=<85%)	
	Rank	12
SI	% of NACP facilities active in SOCH (G=≥90%, Y= 75-89%, R=<75%)	
	Status of State Data Management Committee (G=one meeting held, Y= no meeting held, R= not constituted)	
	Status of finalized Priority Areas for Operational Research and Evaluation (G= 4, Y= 3, R= <3)	
	Rank	4
Finance	Expenditure with respect to funds released during FY 2021-22 (G=≥90%, Y= 85-89%, R=<85%)	
	Submission of Audit Report after approval of EC/GB for the preceding year (G= by 30th June, Y= 30th Sept, R= beyond 30th Sept 2021)	
	Submission of Utilization Certificate (in prescribed format GFR 12A) for the previous financial year (G= by 30th June, Y= 30th Sept, R= beyond 30th Sept 2021)	
	Rank	18
SCM	Report Submission (BSD-SCM Report) (G=≥90%, Y= 75-89%, R=<75%)	

Green=3 Marks

Yellow=2Marks

Red=1 Mark

No Colour=Not Applicable

A thick red ribbon is tied in a loop on the right side of the page, with the tail extending downwards and then curving back towards the left. The background is a gradient of yellow and orange with faint concentric circles.

# FACT SHEET

## HARYANA

## 1. Status of HIV/AIDS Epidemic

### A. Epidemic Estimates (2021)

Indicator	Male	Female	Total
1. IPR	-	-	4.08
2. IMR	-	-	2.12
3. Adult (15-49 yrs) HIV Prevalence (%)	0.26	0.16	0.22
4. Estimated people living with HIV	32,033	17,942	49,975
5. ART coverage (%)	61.4	90	73
6. Estimated children living with HIV	764	635	1,399
7. Annual new HIV infections	1,349	688	2,037
8. Annual AIDS-related deaths (ARD)	466	129	595
9. Change in annual new HIV infections since 2010 (%)	-41.8	-42.04	-41.82
10. Change in annual ARD since 2010(%)	-72.7	-84.03	-76.32
11. EMTCT need	-	475	475


### B. High risk population size (2009), safe practices (2015) and prevalence (2021)

Population Group	Estimates Size	Condom Use (%)	New Needle/ Syringe use (%)	HIV Prevalence (%)
1. Female Sex Workers	11,552	66.2	37.8	1.33
2. Men who have sex with men	7,126	48.9	29.9	6.89
3. Injecting Drug Users	4,925	53.6	90.7	9.24
4. Hijra/Transgender People	-	-	-	-
5. Migrants	1,31,755	-	-	-
6. Truckers	15,000	-	-	-
7. Prison inmates	78,049	64.3	57.6	1.63

### C. HIV/AIDS related knowledge, stigma and high-risk behaviour in general population (2019-21)

Indicator	Male	Female	Total
1. Adults (15-49 yrs) with comprehensive knowledge about HIV/AIDS (%)	36.4	19.7	-
2. Youth (15-24 yrs) with comprehensive knowledge about HIV/AIDS (%)	31.7	17.5	-
3. Adults willing to care for a relative with HIV/AIDS in own home (%)	84.5	75.2	-
4. Adults willing to buy fresh vegetables from a shopkeeper or vendor who has HIV/AIDS (%)	78.9	64.3	-
5. Adults (15-49 yrs) who have had higher-risk sexual behaviour in the past 12 months (%)	6.7	0.2	-
5.1 Condom use during last higher-risk intercourse (%)	70.1	35	-
6. Youth (15-24 yrs) who have had higher-risk sexual behaviour in the past 12 months (%)	10.9	0.4	-
6.1 Condom use during last higher-risk intercourse (%)	65.3	20.0	-

## 2. Progress on 95-95-95 (2021-22)



Indicator	Male	Female	Total
1. Estimated PLHIV size (2021)	32,033	17,942	49,975
2. PLHIV who know their HIV Status	17,190	11,716	28,906
3. PLHIV who know their HIV status and are on ART	13,578	9,831	23,409
4. PLHIV who are on ART and tested for their viral load	5,372	4,107	9,479
5. PLHIV who are virally suppressed	4,097	3,283	7,380

### 3. Prevention of new HIV infections among general population

#### A. Information, Education, Communication, Youth and Mainstreaming

Indicator	2021-22
1. Schools with operational Adolescent Education Program (AEP)	3,322
2. Colleges with operational Red Ribbon Clubs (RRC)	369
3. Persons trained under mainstreaming	24,215

#### B. Sexually Transmitted Infections (STI)/Reproductive Tract Infections (RTI) Management at DSRCs

Indicator	2021-22			
1. NACO Supported Designated STI/RTI Clinics (DSRC)	31			
	Male	Female	TG	Total
2. Clients managed	-	-	-	1,29,651
3. RPR Tests conducted	24,473	80,874	22	1,05,369
4. Syphilis seropositivity (%)	0.84	0.12	0.00	0.29

### 4. Prevention of new HIV infections among high-risk group and bridge population

#### A. Targeted Interventions (TI) and Opioid Substitution Therapy (OST)

Indicator	2021-22
1. Targeted Interventions	32
2. OST centres	9
3. Employer Led Model Interventions	-

#### B. Female Sex Workers

Indicator	2021-22
1. Estimated size	11,552
2. Coverage (%)	>=95
3. Condoms distributed	28,20,442
4. Tested for HIV (April 2021 - September 2021)	8,531
4.1. HIV sero-positive (%)	0.07
4.1.1. Linked to ART	6
5. Tested for HIV (October 2021 - March 2022)	9,288
5.1. HIV sero-positive (%)	0.09
5.1.1. Linked to ART	4
6. Clinic Visits	30,199
7. STI/RTI treated	553
8. Presumptive treatment	1,546

#### C. Men who have Sex with Men

Indicator	2021-22
1. Estimated size	7,126
2. Coverage (%)	67
3. Condoms distributed	11,26,407
4. Tested for HIV (April 2021 - September 2021)	3,734
4.1. HIV sero-positive (%)	0.43
4.1.1. Linked to ART	8
5. Tested for HIV (October 2021 - March 2022)	3,796
5.1. HIV sero-positive (%)	0.63
5.1.1. Linked to ART	15
6. Clinic Visits	13,945
7. STI/RTI treated	167
8. Presumptive treatment	485

### D. Injecting Drug Users

Indicator	2021-22
1. Estimated size	4,925
2. Coverage (%)	91
3. Needles distributed	10,44,104
4. Syringes distributed	6,56,387
5. On OST	1,099
6. Tested for HIV (April 2021 - September 2021)	3,102
6.1. HIV sero-positive (%)	1.19
6.1.1. Linked to ART	30
7. Tested for HIV (October 2021 - March 2022)	3,868
7.1. HIV sero-positive (%)	1.01
7.1.1. Linked to ART	28

### E. Hijra/Transgender people

Indicator	2021-22
1. Estimated size	-
2. Coverage (%)	-
3. Condoms distributed	25,272
4. Tested for HIV (April 2021 - September 2021)	67
4.1. HIV sero-positive (%)	0.00
4.1.1. Linked to ART	-
5. Tested for HIV (October 2021 - March 2022)	219
5.1. HIV sero-positive (%)	0.00
5.1.1. Put on ART	-
6. Clinic Visits	376
7. STI / RTI treated	2
8. Presumptive treatment	87

### F. Migrants

Indicator	2021-22
1. Estimated size	1,31,755
2. Coverage (%)	55
3. Tested for HIV	9,451
3.1. HIV sero-positive (%)	0.03
3.2. Linked to ART	2

### G. Truckers

Indicator	2021-22
1. Estimated size	15,000
2. Coverage (%)	>=95
3. Tested for HIV	3,485
3.1. HIV sero-positive (%)	0.09
3.2. On ART	3

### H. Prison Inmates

Indicator	2021-22
1. Total prisons	19
2. Prisons covered under programme	19
3. Total inmates admitted	59,089
4. Inmates Covered(%)	28
5. Tested for HIV	16,081
5.1. HIV sero-positive (%)	0.58
5.2. On ART (%)	84

### I. Link Worker Scheme

Indicator	2021-22
1. Districts covered under scheme	-
2. Vulnerable population covered	-
3. Tested for HIV	-
3.1. HIV sero-positive (%)	-
3.2. Linked to ART (%)	-



## J. Opioid Substitution Therapy

Indicator	2021-22
1. OST Centres	9
1.1. OSTC in Public Health Settings	9
1.2. OSTC in NGO Settings	-
1.3 No. of Satellite OST Centres	-
2. IDU on OST	1,099

## 5. Early detection of HIV infected people

### A. HIV Counselling and Testing Services (HCTS)

Indicator	2021-22
1. ICTC facilities	743
1.1. Stand-alone	117
1.2. Facility integrated (Govt)	533
1.3. Facility integrated (PPP)	30
1.4. CBS	63

### B. HIV Testing among Vulnerable Population (Excluding Pregnant Women)

Indicator	2021-22			
	Male	Female	TG	Total
1. Tested for HIV	3,38,958	2,48,260	728	5,87,946
2. Found HIV Positive among tested	2,682	1,000	26	3,708
3. HIV sero-positivity (%) among tested	0.79	0.40	3.57	0.63
4. Spouse/sexual partner testing of HIV positive people identified	687	711	18	1,416

## 6. Initiation and retention on ART of HIV infected people

### A. Treatment Facilities

Indicator	2021-22
1. ART Centres	15
2. Centre of Excellence	
2.1. Centre of Excellence (Adult)	-
2.2. Centre of Excellence (Paediatric)	-
3. Link ART Centres	11
4. Care Support Centres	1

### B. Treatment Uptake

Indicator	2021-22			
	Male	Female	TG	Total
1. HIV positive cases diagnosed (At ICTC)	2,682	1,342	26	4,050
2. New PLHIV Registered at ART center	3,299	1,623	24	4,946
2.1 Initiated on ART	3,191	1,594	22	4,807
3. PLHIV alive and on ART	13,466	9,484	72	23,021
4. 12 months retention on ART (%)				77.33
5. Lost to follow-up cases	2,513	1,295	6	3,814

## 7. Viral Suppression and laboratories

### A. Laboratory facilities and service uptake

Indicator	2021-22
1. Viral load laboratories	1
1.1 Accredited Viral load laboratories	-
2. Viral load testing conducted	7,949
2.1. Virally suppressed (%)	78
3. National reference laboratories (NRL)	-
3.1 Accredited NRL	-
4. State reference laboratories (SRL)	1
4.1 Accredited SRL	-
5. CD4 testing conducted	8,140
6. External Quality Assessment of ICTC	
6.1 Average Participation (%)	86.40
6.2. Average Discordance (%)	0.00
7. Quality Assurance Scheme for Basic Composite Medical Laboratories (Entry Level)- M(EL)T	
7.1 No. of ICTCs certified for M(EL)T certification	-

## 8. Elimination of mother to child transmission of HIV & Syphilis

### A. HIV

Indicator	2021-22
1. Estimated pregnant women (PW)	6,32,900
2. HIV testing among PW	5,76,224
3. HIV sero-positivity (%) among tested	0.06
4. HIV Positive PW (old + new detections)	392
4.1 On life-long ART	268
5. Live births among HIV positive PW	293
5.1 Babies given ARV Prophylaxis (%)	98.98
6. Babies tested HIV (6 week- 6 month)	331
6.1 Babies confirmed HIV Positive (6 week- 6 month)	4
7. HIV exposed babies at 18 months	
7.1 HIV exposed babies tested at 18 month	137
7.2 Babies confirmed HIV positive at 18 months	8
8. HIV positive babies initiated on ART	12

### B. Syphilis

Indicator	2021-22
1. Estimated pregnant women (PW)	6,32,900
2. Syphilis testing among PW	3,90,930
3. Sero-positivity (%) among tested	0.08
4. Put on treatment	15

## 9. Elimination of HIV/AIDS related Stigma and Discrimination

### A. HIV/AIDS Prevention & Control Act (2017)

Indicator	2021-22
1. State rules notified for HIV/AIDS Prevention and Control Act (2017)	No
2. State designated/appointed ombudsman for HIV/AIDS Prevention and Control Act (2017)	Yes

## 10. HIV-TB Co-morbidities

## A. HRG and Bridge Population

Indicator								2021-22
	Quarter	FSW	MSW	IDU	TG	Migrants	Truckers	Total
Screened for TB	Quarter 1	6,735	3,104	2,271	3	2,119	188	14,420
	Quarter 2	7,589	3,602	2,627	110	1,982	1,414	17,324
	Quarter 3	6,476	3,204	3,002	122	3,429	3,248	19,481
	Quarter 4	8,631	3,743	3,507	173	5,530	3,868	25,452
Tested for TB	Quarter 1	8	-	5	-	-	-	13
	Quarter 2	10	1	1	-	-	2	14
	Quarter 3	4	6	8	-	3	-	21
	Quarter 4	4	7	14	-	1	1	27
Diagnosed with TB	Quarter 1	-	-	1	-	-	-	1
	Quarter 2	2	-	-	-	-	2	4
	Quarter 3	-	-	2	-	3	-	5
	Quarter 4	1	2	4	-	-	1	8
Initiated on TB treatment	Quarter 1	-	-	1	-	-	-	1
	Quarter 2	2	-	-	-	-	2	4
	Quarter 3	-	-	2	-	3	-	5
	Quarter 4	1	1	4	-	-	1	7

## B. HIV-TB Cross-Referral

Indicator		2021-22
1. In referral from TB program		41,993
1.1. HIV sero-positive (%)		1.24
1.2. ICTC clients referred to NTEP		8,899

## C. HIV-TB Coinfected at ART Centre

Indicator								2021-22
	PLHIV attending ART Centre	PLHIV underwent 4S screening	PLHIV with presumptive TB	PLHIV tested for TB	PLHIV diagnosed with TB	PLHIV initiated on IPT	Co-infected enrolled at ARTc	Co-infected initiated on ART
Apr-21	9,424	9,424	121	99	38	225		
May-21	9,123	9,123	107	66	25	154		
Jun-21	8,292	8,292	107	85	38	179		
Jul-21	7,519	7,519	121	101	36	224		
Aug-21	6,539	6,539	132	109	39	151		
Sep-21	6,771	6,771	158	130	25	237		
Oct-21	6,460	6,460	142	116	38	223		
Nov-21	5,520	5,520	151	114	31	159		
Dec-21	6,296	5,108	201	146	49	195		
Jan-22	6,296	5,108	201	146	49	195		
Feb-22	8,049	8,049	149	75	29	362		
Mar-22	10,171	10,171	206	133	51	282		
April 2021-March 2022							475	449

## 11. Scorecard

State/UT Name		Haryana
Overall Rank		17
IEC & MS	Frequency of Social Media updates (G= ≥60, Y=40-59, R=<40)	
	Status of AEP integration in state School curriculum (G=Yes, R=No)	
	Status of SCA (G= At least one meeting held since 2017, R= other than G)	
	Status of State Rules (G= Notified, R= Not notified)	
	Status of Ombudsman (G= Appointed, R=Not appointed)	
	Rank	15
TI	Facilities onboarded (G=≥95%, Y= 90-94%, R=<90%)	
	Coverage against target in contract (G=≥95%, Y= 90-94%, R=<90%)	
	HRG & BP living with HIV on ART (G=≥95%, Y= 90-94%, R=<90%)	
	IDU on OST (G=≥95%, Y= 90-94%, R=<90%)	
	Rank	19
BSD	Percentage of PLHIV who know their status (G=≥95%, Y= 80-94%, R=<80%)	
	HIV testing against target-GC ((G=≥95%, Y= 80-94%, R=<80%)	
	HIV testing against target-PW (G=≥95%, Y= 80-94%, R=<80%)	
	Percentage of Pregnant women who initiated ART (G=≥95%, Y= 80-94%, R=<80%)	
	Percentage of TB suspected cases referred to NTEP (G=≥95%, Y= 80-94%, R=<80%)	
	Clients managed at DSRC against the target (G=≥95%, Y= 80-94%, R=<80%)	
	Percentage of pregnant women tested for Syphilis (G=≥95%, Y= 80-94%, R=<80%)	
	Rank	5
CST	ART Initiation (Current FY) (G=≥95%, Y= 80-94%, R=<80%)	
	LFU rate among new ART initiation (G=<2%, Y= 2-4%, R=≥5%)	
	PLHIV put on ART during the FY against target (G=≥95%, Y= 80-94%, R=<80%)	
	Status on establishment of CSC (G=≥95%, Y= 80-94%, R=<80%)	NA
	Rank	17
LS	VL Suppression Rate (Current FY) (G=≥95%, Y= 85-94%, R=<85%)	
	% of SRL accredited (G=100%, Y= 80-99%, R=<80%)	
	% Participation of ICTCs in Re-testing (G=≥95%, Y= 85-94, R=<85%)	
	Rank	25
SI	% of NACP facilities active in SOCH (G=≥90%, Y= 75-89%, R=<75%)	
	Status of State Data Management Committee (G=one meeting held, Y= no meeting held, R= not constituted)	
	Status of finalized Priority Areas for Operational Research and Evaluation (G= 4, Y= 3, R= <3)	
	Rank	14
Finance	Expenditure with respect to funds released during FY 2021-22 (G=≥90%, Y= 85-89%, R=<85%)	
	Submission of Audit Report after approval of EC/GB for the preceding year (G= by 30th June, Y= 30th Sept, R= beyond 30th Sept 2021)	
	Submission of Utilization Certificate (in prescribed format GFR 12A) for the previous financial year (G= by 30th June, Y= 30th Sept, R= beyond 30th Sept 2021)	
	Rank	5
SCM	Report Submission (BSD-SCM Report) (G=≥90%, Y= 75-89%, R=<75%)	

Green=3 Marks

Yellow=2Marks

Red=1 Mark

No Colour=Not Applicable



# FACT SHEET

HIMACHAL  
PRADESH

# HIMACHAL PRADESH

## 1. Status of HIV/AIDS Epidemic

### A. Epidemic Estimates (2021)

Indicator	Male	Female	Total
1. IPR	-	-	1.57
2. IMR	-	-	0.82
3. Adult (15-49 yrs) HIV Prevalence (%)	0.13	0.08	0.11
4. Estimated people living with HIV	4,288	2,851	7,139
5. ART coverage (%)	42.0	53	46
6. Estimated children living with HIV	85	76	161
7. Annual new HIV infections	63	49	112
8. Annual AIDS-related deaths (ARD)	65	8	73
9. Change in annual new HIV infections since 2010 (%)	-75.8	-69.38	-73.33
10. Change in annual ARD since 2010(%)	-77.0	-90.48	-80.05
11. EMTCT need	-	40	40


### B. High risk population size (2009), safe practices (2015) and prevalence (2021)

Population Group	Estimates Size	Condom Use (%)	New Needle/ Syringe use (%)	HIV Prevalence (%)
1. Female Sex Workers	9,027	59.3	0	0.55
2. Men who have sex with men	849	61	8.5	1.56
3. Injecting Drug Users	648	36.3	92.8	4.4
4. Hijra/Transgender People	-	-	-	-
5. Migrants	1,45,880	-	-	0
6. Truckers	14,000	-	-	-
7. Prison inmates	6,439	54.5	25	0.25

### C. HIV/AIDS related knowledge, stigma and high-risk behaviour in general population (2019-21)

Indicator	Male	Female	Total
1. Adults (15-49 yrs) with comprehensive knowledge about HIV/AIDS (%)	40.8	36.2	-
2. Youth (15-24 yrs) with comprehensive knowledge about HIV/AIDS (%)	37.3	34	-
3. Adults willing to care for a relative with HIV/AIDS in own home (%)	87.1	89.7	-
4. Adults willing to buy fresh vegetables from a shopkeeper or vendor who has HIV/AIDS (%)	85.2	80.7	-
5. Adults (15-49 yrs) who have had higher-risk sexual behaviour in the past 12 months (%)	5.9	0.2	-
5.1 Condom use during last higher-risk intercourse (%)	76.2	28.8	-
6. Youth (15-24 yrs) who have had higher-risk sexual behaviour in the past 12 months (%)	8.1	0.7	-
6.1 Condom use during last higher-risk intercourse (%)	66.7	33.3	-

## 2. Progress on 95-95-95 (2021-22)



### 3. Prevention of new HIV infections among general population

#### A. Information, Education, Communication, Youth and Mainstreaming

Indicator	2021-22
1. Schools with operational Adolescent Education Program (AEP)	1,000
2. Colleges with operational Red Ribbon Clubs (RRC)	268
3. Persons trained under mainstreaming	7,050

#### B. Sexually Transmitted Infections (STI)/Reproductive Tract Infections (RTI) Management at DSRCs

Indicator	2021-22			
1. NACO Supported Designated STI/RTI Clinics (DSRC)	20			
	Male	Female	TG	Total
2. Clients managed	-	-	-	58,665
3. RPR Tests conducted	21,113	36,820	35	57,968
4. Syphilis seropositivity (%)	0.40	0.06	8.57	0.19

### 4. Prevention of new HIV infections among high-risk group and bridge population

#### A. Targeted Interventions (TI) and Opioid Substitution Therapy (OST)

Indicator	2021-22
1. Targeted Interventions	17
2. OST centres	2
3. Employer Led Model Interventions	-

#### B. Female Sex Workers

Indicator	2021-22
1. Estimated size	9,027
2. Coverage (%)	62
3. Condoms distributed	16,49,196
4. Tested for HIV (April 2021 - September 2021)	4,495
4.1. HIV sero-positive (%)	0.02
4.1.1. Linked to ART	1
5. Tested for HIV (October 2021 - March 2022)	4,740
5.1. HIV sero-positive (%)	0.02
5.1.1. Linked to ART	0
6. Clinic Visits	18,299
7. STI/RTI treated	528
8. Presumptive treatment	180

#### C. Men who have Sex with Men

Indicator	2021-22
1. Estimated size	849
2. Coverage (%)	59
3. Condoms distributed	1,63,747
4. Tested for HIV (April 2021 - September 2021)	434
4.1. HIV sero-positive (%)	0.69
4.1.1. Linked to ART	3
5. Tested for HIV (October 2021 - March 2022)	472
5.1. HIV sero-positive (%)	0.42
5.1.1. Linked to ART	2
6. Clinic Visits	1,500
7. STI/RTI treated	38
8. Presumptive treatment	3

#### D. Injecting Drug Users

Indicator	2021-22
1. Estimated size	648
2. Coverage (%)	>=95
3. Needles distributed	47,008
4. Syringes distributed	90,970
5. On OST	95
6. Tested for HIV (April 2021 - September 2021)	359
6.1. HIV sero-positive (%)	0.28
6.1.1. Linked to ART	1
7. Tested for HIV (October 2021 - March 2022)	636
7.1. HIV sero-positive (%)	0.16
7.1.1. Linked to ART	1

#### E. Hijra/Transgender people

Indicator	2021-22
1. Estimated size	-
2. Coverage (%)	-
3. Condoms distributed	-
4. Tested for HIV (April 2021 - September 2021)	-
4.1. HIV sero-positive (%)	-
4.1.1. Linked to ART	-
5. Tested for HIV (October 2021 - March 2022)	-
5.1. HIV sero-positive (%)	-
5.1.1. Put on ART	-
6. Clinic Visits	-
7. STI / RTI treated	-
8. Presumptive treatment	-

#### F. Migrants

Indicator	2021-22
1. Estimated size	1,45,880
2. Coverage (%)	36
3. Tested for HIV	3,156
3.1. HIV sero-positive (%)	0.13
3.2. Linked to ART	4

#### G. Truckers

Indicator	2021-22
1. Estimated size	14,000
2. Coverage (%)	71
3. Tested for HIV	1,930
3.1. HIV sero-positive (%)	0.00
3.2. On ART	-

#### H. Prison Inmates

Indicator	2021-22
1. Total prisons	14
2. Prisons covered under programme	13
3. Total inmates admitted	5,997
4. Inmates Covered(%)	27
5. Tested for HIV	1,132
5.1. HIV sero-positive (%)	0.44
5.2. On ART (%)	100

#### I. Link Worker Scheme

Indicator	2021-22
1. Districts covered under scheme	-
2. Vulnerable population covered	-
3. Tested for HIV	-
3.1. HIV sero-positive (%)	-
3.2. Linked to ART (%)	-



## J. Opioid Substitution Therapy

Indicator	2021-22
1. OST Centres	2
1.1. OSTC in Public Health Settings	-
1.2. OSTC in NGO Settings	-
1.3 No. of Satellite OST Centres	2
2. IDU on OST	95

## 5. Early detection of HIV infected people

### A. HIV Counselling and Testing Services (HCTS)

Indicator	2021-22
1. ICTC facilities	175
1.1. Stand-alone	49
1.2. Facility integrated (Govt)	77
1.3. Facility integrated (PPP)	19
1.4. CBS	30

### B. HIV Testing among Vulnerable Population (Excluding Pregnant Women)

Indicator	2021-22			
	Male	Female	TG	Total
1. Tested for HIV	1,27,628	74,413	43	2,02,084
2. Found HIV Positive among tested	241	112	1	354
3. HIV sero-positivity (%) among tested	0.19	0.15	2.33	0.18
4. Spouse/sexual partner testing of HIV positive people identified	114	103	1	218

## 6. Initiation and retention on ART of HIV infected people

### A. Treatment Facilities

Indicator	2021-22
1. ART Centres	6
2. Centre of Excellence	
2.1. Centre of Excellence (Adult)	-
2.2. Centre of Excellence (Paediatric)	-
3. Link ART Centres	5
4. Care Support Centres	2

### B. Treatment Uptake

Indicator	2021-22			
	Male	Female	TG	Total
1. HIV positive cases diagnosed (At ICTC)	241	141	1	383
2. New PLHIV Registered at ART center	217	123	-	340
2.1 Initiated on ART	195	116	-	311
3. PLHIV alive and on ART	2,634	2,561	3	5,198
4. 12 months retention on ART (%)				83.27
5. Lost to follow-up cases	357	180	-	537

## 7. Viral Suppression and laboratories

### A. Laboratory facilities and service uptake

Indicator	2021-22
1. Viral load laboratories	1
1.1 Accredited Viral load laboratories	-
2. Viral load testing conducted	4,858
2.1. Virally suppressed (%)	73
3. National reference laboratories (NRL)	-
3.1 Accredited NRL	-
4. State reference laboratories (SRL)	1
4.1 Accredited SRL	-
5. CD4 testing conducted	5,016
6. External Quality Assessment of ICTC	
6.1 Average Participation (%)	93.65
6.2. Average Discordance (%)	0.00
7. Quality Assurance Scheme for Basic Composite Medical Laboratories (Entry Level)- M(EL)T	
7.1 No. of ICTCs certified for M(EL)T certification	-

## 8. Elimination of mother to child transmission of HIV & Syphilis

### A. HIV

Indicator	2021-22
1. Estimated pregnant women (PW)	1,25,380
2. HIV testing among PW	1,22,929
3. HIV sero-positivity (%) among tested	0.02
4. HIV Positive PW (old + new detections)	48
4.1 On life-long ART	40
5. Live births among HIV positive PW	22
5.1 Babies given ARV Prophylaxis (%)	100.00
6. Babies tested HIV (6 week- 6 month)	21
6.1 Babies confirmed HIV Positive (6 week- 6 month)	-
7. HIV exposed babies at 18 months	
7.1 HIV exposed babies tested at 18 month	6
7.2 Babies confirmed HIV positive at 18 months	-
8. HIV positive babies initiated on ART	-

### B. Syphilis

Indicator	2021-22
1. Estimated pregnant women (PW)	1,25,380
2. Syphilis testing among PW	81,186
3. Sero-positivity (%) among tested	0.02
4. Put on treatment	18

## 9. Elimination of HIV/AIDS related Stigma and Discrimination

### A. HIV/AIDS Prevention & Control Act (2017)

Indicator	2021-22
1. State rules notified for HIV/AIDS Prevention and Control Act (2017)	Yes
2. State designated/appointed ombudsman for HIV/AIDS Prevention and Control Act (2017)	Yes

## 10. HIV-TB Co-morbidities

## A. HRG and Bridge Population

Indicator								2021-22
	Quarter	FSW	MSW	IDU	TG	Migrants	Truckers	Total
Screened for TB	Quarter 1	4,376	548	27	-	3,034	-	7,985
	Quarter 2	5,546	551	126	-	7,722	1,317	15,262
	Quarter 3	5,350	595	270	-	6,021	2,085	14,321
	Quarter 4	5,373	587	314	-	4,668	2,429	13,371
Tested for TB	Quarter 1	8	-	21	-	9	-	38
	Quarter 2	26	-	42	-	41	-	109
	Quarter 3	17	-	21	-	16	-	54
	Quarter 4	63	-	8	-	-	-	71
Diagnosed with TB	Quarter 1	-	-	-	-	1	-	1
	Quarter 2	1	-	-	-	1	-	2
	Quarter 3	2	-	-	-	1	-	3
	Quarter 4	-	-	-	-	-	-	-
Initiated on TB treatment	Quarter 1	-	-	-	-	1	-	1
	Quarter 2	1	-	-	-	1	-	2
	Quarter 3	2	-	-	-	1	-	3
	Quarter 4	-	-	-	-	-	-	-

## B. HIV-TB Cross-Referral

Indicator		2021-22
1. In referral from TB program		9,995
1.1. HIV sero-positive (%)		0.75
1.2. ICTC clients referred to NTEP		3,834

## C. HIV-TB Coinfected at ART Centre

Indicator								2021-22
	PLHIV attending ART Centre	PLHIV underwent 4S screening	PLHIV with presumptive TB	PLHIV tested for TB	PLHIV diagnosed with TB	PLHIV initiated on IPT	Co-infected enrolled at ARTc	Co-infected initiated on ART
Apr-21	3,136	3,116	18	18	6	21		
May-21	2,706	2,665	14	14	3	7		
Jun-21	2,879	2,825	24	24	3	16		
Jul-21	3,365	3,316	19	19	4	26		
Aug-21	3,088	3,039	108	108	6	25		
Sep-21	2,967	2,760	43	43	4	30		
Oct-21	3,030	3,022	32	25	6	32		
Nov-21	2,128	2,119	25	25	4	30		
Dec-21	2,558	2,546	35	35	1	18		
Jan-22	2,059	2,050	32	27	3	27		
Feb-22	2,114	2,105	39	39	4	28		
Mar-22	2,431	2,419	37	37	5	36		
April 2021-March 2022							81	77

## 11. Scorecard

State/UT Name		Himachal Pradesh
Overall Rank		16
IEC & MS	Frequency of Social Media updates (G= ≥60, Y=40-59, R=<40)	
	Status of AEP integration in state School curriculum (G=Yes, R=No)	
	Status of SCA (G= At least one meeting held since 2017, R= other than G)	
	Status of State Rules (G= Notified, R= Not notified)	
	Status of Ombudsman (G= Appointed, R=Not appointed)	
	Rank	12
TI	Facilities onboarded (G=≥95%, Y= 90-94%, R=<90%)	
	Coverage against target in contract (G=≥95%, Y= 90-94%, R=<90%)	
	HRG & BP living with HIV on ART (G=≥95%, Y= 90-94%, R=<90%)	
	IDU on OST (G=≥95%, Y= 90-94%, R=<90%)	
	Rank	3
BSD	Percentage of PLHIV who know their status (G=≥95%, Y= 80-94%, R=<80%)	
	HIV testing against target-GC ((G=≥95%, Y= 80-94%, R=<80%)	
	HIV testing against target-PW (G=≥95%, Y= 80-94%, R=<80%)	
	Percentage of Pregnant women who initiated ART (G=≥95%, Y= 80-94%, R=<80%)	
	Percentage of TB suspected cases referred to NTEP (G=≥95%, Y= 80-94%, R=<80%)	
	Clients managed at DSRC against the target (G=≥95%, Y= 80-94%, R=<80%)	
	Percentage of pregnant women tested for Syphilis (G=≥95%, Y= 80-94%, R=<80%)	
	Rank	2
CST	ART Initiation (Current FY) (G=≥95%, Y= 80-94%, R=<80%)	
	LFU rate among new ART initiation (G=<2%, Y= 2-4%, R=≥5%)	
	PLHIV put on ART during the FY against target (G=≥95%, Y= 80-94%, R=<80%)	
	Status on establishment of CSC (G=≥95%, Y= 80-94%, R=<80%)	
	Rank	29
LS	VL Suppression Rate (Current FY) (G=≥95%, Y= 85-94%, R=<85%)	
	% of SRL accredited (G=100%, Y= 80-99%, R=<80%)	
	% Participation of ICTCs in Re-testing (G=≥95%, Y= 85-94%, R=<85%)	
	Rank	25
SI	% of NACP facilities active in SOCH (G=≥90%, Y= 75-89%, R=<75%)	
	Status of State Data Management Committee (G=one meeting held, Y= no meeting held, R= not constituted)	
	Status of finalized Priority Areas for Operational Research and Evaluation (G= 4, Y= 3, R= <3)	
	Rank	4
Finance	Expenditure with respect to funds released during FY 2021-22 (G=≥90%, Y= 85-89%, R=<85%)	
	Submission of Audit Report after approval of EC/GB for the preceding year (G= by 30th June, Y= 30th Sept, R= beyond 30th Sept 2021)	
	Submission of Utilization Certificate (in prescribed format GFR 12A) for the previous financial year (G= by 30th June, Y= 30th Sept, R= beyond 30th Sept 2021)	
	Rank	23
SCM	Report Submission (BSD-SCM Report) (G=≥90%, Y= 75-89%, R=<75%)	

Green=3 Marks

Yellow=2Marks

Red=1 Mark

No Colour=Not Applicable



# **FACT SHEET**

JAMMU & KASHMIR  
AND LADAKH

# JAMMU & KASHMIR AND LADAKH

## 1. Status of HIV/AIDS Epidemic

### A. Epidemic Estimates (2021)

Indicator	Male	Female	Total
1. IPR	-	-	4.35
2. IMR	-	-	1.57
3. Adult (15-49 yrs) HIV Prevalence (%)	0.07	0.05	0.06
4. Estimated people living with HIV	3,962	2,565	6,527
5. ART coverage (%)	47.6	54	50
6. Estimated children living with HIV	94	84	178
7. Annual new HIV infections	166	118	284
8. Annual AIDS-related deaths (ARD)	107	36	143
9. Change in annual new HIV infections since 2010 (%)	-42.6	-22.88	-35.75
10. Change in annual ARD since 2010(%)	-13.0	2.86	-10.13
11. EMTCT need	-	58	58

### B. High risk population size (2009), safe practices (2015) and prevalence (2021)


Population Group	Estimates Size	Condom Use (%)	New Needle/ Syringe use (%)	HIV Prevalence (%)
1. Female Sex Workers	2,020	-	-	0.4
2. Men who have sex with men	727	-	-	-
3. Injecting Drug Users	1,522	25.9	90.9	0.5
4. Hijra/Transgender People	-	-	-	-
5. Migrants	25,000	-	-	-
6. Truckers	20,000	-	-	-
7. Prison inmates	11,297	-	-	-

### C. HIV/AIDS related knowledge, stigma and high-risk behaviour in general population (2019-21)

Indicator*	Male	Female	Total
1. Adults (15-49 yrs) with comprehensive knowledge about HIV/AIDS (%)	33.6	15.8	-
2. Youth (15-24 yrs) with comprehensive knowledge about HIV/AIDS (%)	33.8	17.2	-
3. Adults willing to care for a relative with HIV/AIDS in own home (%)	66.2	59.8	-
4. Adults willing to buy fresh vegetables from a shopkeeper or vendor who has HIV/AIDS (%)	74.6	65	-
5. Adults (15-49 yrs) who have had higher-risk sexual behaviour in the past 12 months (%)	0.6	0	-
5.1 Condom use during last higher-risk intercourse (%)	66.1	NA	-
6. Youth (15-24 yrs) who have had higher-risk sexual behaviour in the past 12 months (%)	0.5	0	-
6.1 Condom use during last higher-risk intercourse (%)	66.7	NA	-

\*Data includes J&K Data only

## 2. Progress on 95-95-95 (2021-22)



### 3. Prevention of new HIV infections among general population

#### A. Information, Education, Communication, Youth and Mainstreaming

Indicator	2021-22
1. Schools with operational Adolescent Education Program (AEP)	850
2. Colleges with operational Red Ribbon Clubs (RRC)	282
3. Persons trained under mainstreaming	1,680

#### B. Sexually Transmitted Infections (STI)/Reproductive Tract Infections (RTI) Management at DSRCs

Indicator	2021-22			
1. NACO Supported Designated STI/RTI Clinics (DSRC)	6			
	Male	Female	TG	Total
2. Clients managed	-	-	-	6,065
3. RPR Tests conducted	2,035	8,806	1	10,842
4. Syphilis seropositivity (%)	1.03	0.09	100.00	0.28

### 4. Prevention of new HIV infections among high-risk group and bridge population

#### A. Targeted Interventions (TI) and Opioid Substitution Therapy (OST)

Indicator	2021-22
1. Targeted Interventions	19
2. OST centres	2
3. Employer Led Model Interventions	-

#### B. Female Sex Workers

Indicator	2021-22
1. Estimated size	2,020
2. Coverage (%)	98
3. Condoms distributed	4,61,963
4. Tested for HIV (April 2021 - September 2021)	2,583
4.1. HIV sero-positive (%)	0.08
4.1.1. Linked to ART	2
5. Tested for HIV (October 2021 - March 2022)	2,862
5.1. HIV sero-positive (%)	0.00
5.1.1. Linked to ART	0
6. Clinic Visits	5,585
7. STI/RTI treated	178
8. Presumptive treatment	698

#### C. Men who have Sex with Men

Indicator	2021-22
1. Estimated size	727
2. Coverage (%)	>=95
3. Condoms distributed	53,204
4. Tested for HIV (April 2021 - September 2021)	654
4.1. HIV sero-positive (%)	0.15
4.1.1. Linked to ART	1
5. Tested for HIV (October 2021 - March 2022)	907
5.1. HIV sero-positive (%)	0.00
5.1.1. Linked to ART	-
6. Clinic Visits	1,891
7. STI/RTI treated	65
8. Presumptive treatment	301

#### D. Injecting Drug Users

Indicator	2021-22
1. Estimated size	1,522
2. Coverage (%)	>=95
3. Needles distributed	12,12,489
4. Syringes distributed	5,86,785
5. On OST	1,046
6. Tested for HIV (April 2021 - September 2021)	3,818
6.1. HIV sero-positive (%)	0.18
6.1.1. Linked to ART	7
7. Tested for HIV (October 2021 - March 2022)	3,777
7.1. HIV sero-positive (%)	0.03
7.1.1. Linked to ART	1

#### E. Hijra/Transgender people

Indicator	2021-22
1. Estimated size	-
2. Coverage (%)	-
3. Condoms distributed	-
4. Tested for HIV (April 2021 - September 2021)	-
4.1. HIV sero-positive (%)	-
4.1.1. Linked to ART	-
5. Tested for HIV (October 2021 - March 2022)	-
5.1. HIV sero-positive (%)	-
5.1.1. Put on ART	-
6. Clinic Visits	-
7. STI / RTI treated	-
8. Presumptive treatment	-

#### F. Migrants

Indicator	2021-22
1. Estimated size	25,000
2. Coverage (%)	72
3. Tested for HIV	9,037
3.1. HIV sero-positive (%)	0.03
3.2. Linked to ART	3

#### G. Truckers

Indicator	2021-22
1. Estimated size	20,000
2. Coverage (%)	>=95
3. Tested for HIV	16,242
3.1. HIV sero-positive (%)	0.12
3.2. On ART	18

#### H. Prison Inmates

Indicator	2021-22
1. Total prisons	15
2. Prisons covered under programme	15
3. Total inmates admitted	9,337
4. Inmates Covered(%)	38
5. Tested for HIV	3,036
5.1. HIV sero-positive (%)	0.03
5.2. On ART (%)	100

#### I. Link Worker Scheme

Indicator	2021-22
1. Districts covered under scheme	-
2. Vulnerable population covered	-
3. Tested for HIV	-
3.1. HIV sero-positive (%)	-
3.2. Linked to ART (%)	-



## J. Opioid Substitution Therapy

Indicator	2021-22
1. OST Centres	2
1.1. OSTC in Public Health Settings	2
1.2. OSTC in NGO Settings	-
1.3 No. of Satellite OST Centres	-
2. IDU on OST	1,046

## 5. Early detection of HIV infected people

## A. HIV Counselling and Testing Services (HCTS)

Indicator	2021-22
1. ICTC facilities	660
1.1. Stand-alone	35
1.2. Facility integrated (Govt)	593
1.3. Facility integrated (PPP)	22
1.4. CBS	10

## B. HIV Testing among Vulnerable Population (Excluding Pregnant Women)

Indicator	2021-22			
	Male	Female	TG	Total
1. Tested for HIV	1,77,036	54,883	1	2,31,920
2. Found HIV Positive among tested	210	78	1	289
3. HIV sero-positivity (%) among tested	0.12	0.14	100.00	0.12
4. Spouse/sexual partner testing of HIV positive people identified	26	67	2	95

## 6. Initiation and retention on ART of HIV infected people

## A. Treatment Facilities

Indicator	2021-22
1. ART Centres	3
2. Centre of Excellence	
2.1. Centre of Excellence (Adult)	-
2.2. Centre of Excellence (Paediatric)	-
3. Link ART Centres	4
4. Care Support Centres	1

## B. Treatment Uptake

Indicator	2021-22			
	Male	Female	TG	Total
1. HIV positive cases diagnosed (At ICTC)	210	95	1	306
2. New PLHIV Registered at ART center	143	73	1	217
2.1 Initiated on ART	132	68	1	201
3. PLHIV alive and on ART	1,886	1,378	13	3,277
4. 12 months retention on ART (%)				80.12
5. Lost to follow-up cases	361	168	2	531

## 7. Viral Suppression and laboratories

## A. Laboratory facilities and service uptake

Indicator	2021-22
1. Viral load laboratories	-
1.1 Accredited Viral load laboratories	-
2. Viral load testing conducted	1,838
2.1. Virally suppressed (%)	90
3. National reference laboratories (NRL)	-
3.1 Accredited NRL	-
4. State reference laboratories (SRL)	2
4.1 Accredited SRL	1
5. CD4 testing conducted	2,460
6. External Quality Assessment of ICTC	
6.1 Average Participation (%)	82.14
6.2. Average Discordance (%)	0.00
7. Quality Assurance Scheme for Basic Composite Medical Laboratories (Entry Level)- M(EL)T	
7.1 No. of ICTCs certified for M(EL)T certification	-

## 8. Elimination of mother to child transmission of HIV &amp; Syphilis

## A. HIV

Indicator	2021-22
1. Estimated pregnant women (PW)	2,26,810
2. HIV testing among PW	2,18,561
3. HIV sero-positivity (%) among tested	0.01
4. HIV Positive PW (old + new detections)	26
4.1 On life-long ART	21
5. Live births among HIV positive PW	17
5.1 Babies given ARV Prophylaxis (%)	88.24
6. Babies tested HIV (6 week- 6 month)	20
6.1 Babies confirmed HIV Positive (6 week- 6 month)	-
7. HIV exposed babies at 18 months	
7.1 HIV exposed babies tested at 18 month	8
7.2 Babies confirmed HIV positive at 18 months	-
8. HIV positive babies initiated on ART	-

## B. Syphilis

Indicator	2021-22
1. Estimated pregnant women (PW)	2,26,810
2. Syphilis testing among PW	49,515
3. Sero-positivity (%) among tested	0.01
4. Put on treatment	3

## 9. Elimination of HIV/AIDS related Stigma and Discrimination

## A. HIV/AIDS Prevention &amp; Control Act (2017)

Indicator	2021-22
1. State rules notified for HIV/AIDS Prevention and Control Act (2017)	Yes
2. State designated/appointed ombudsman for HIV/AIDS Prevention and Control Act (2017)	No

## 10. HIV-TB Co-morbidities

## A. HRG and Bridge Population

Indicator								2021-22
	Quarter	FSW	MSW	IDU	TG	Migrants	Truckers	Total
Screened for TB	Quarter 1	1,255	306	1,288	-	780	1,381	5,010
	Quarter 2	1,549	345	1,786	-	1,065	2,218	6,963
	Quarter 3	1,282	224	1,380	-	1,094	1,783	5,763
	Quarter 4	747	107	1,810	-	1,347	953	4,964
Tested for TB	Quarter 1	78	54	269	-	256	33	690
	Quarter 2	88	64	276	-	374	59	861
	Quarter 3	131	88	257	-	229	134	839
	Quarter 4	275	36	349	-	151	151	962
Diagnosed with TB	Quarter 1	1	-	-	-	1	-	2
	Quarter 2	-	-	-	-	-	-	-
	Quarter 3	-	-	1	-	-	-	1
	Quarter 4	-	-	-	-	-	1	1
Initiated on TB treatment	Quarter 1	1	-	-	-	1	-	2
	Quarter 2	-	-	-	-	-	-	-
	Quarter 3	-	-	1	-	-	-	1
	Quarter 4	-	-	-	-	-	1	1

## B. HIV-TB Cross-Referral

Indicator	2021-22
1. In referral from TB program	1,090
1.1. HIV sero-positive (%)	1.56
1.2. ICTC clients referred to NTEP	390

## C. HIV-TB Coinfected at ART Centre

Indicator							2021-22	
	PLHIV attending ART Centre	PLHIV underwent 4S screening	PLHIV with presumptive TB	PLHIV tested for TB	PLHIV diagnosed with TB	PLHIV initiated on IPT	Co-infected enrolled at ARTc	Co-infected initiated on ART
Apr-21	2,980	2,980	12	12	7	14		
May-21	1,888	1,888	4	4	3	12		
Jun-21	2,442	2,442	6	6	2	13		
Jul-21	2,444	2,444	11	11	9	12		
Aug-21	2,448	2,448	11	11	6	5		
Sep-21	2,469	2,451	3	1	1	6		
Oct-21	2,514	2,514	8	2	2	8		
Nov-21	2,432	2,432	4	4	2	28		
Dec-21	2,477	2,477	9	9	3	28		
Jan-22	2,460	2,460	15	11	5	15		
Feb-22	2,404	2,404	8	4	-	8		
Mar-22	2,460	2,460	15	11	5	15		
April 2021-March 2022							42	32

## 11. Scorecard

State/UT Name		J&K & Ladakh
Overall Rank		29
IEC & MS	Frequency of Social Media updates (G= ≥60, Y=40-59, R=<40)	
	Status of AEP integration in state School curriculum (G=Yes, R=No)	
	Status of SCA (G= At least one meeting held since 2017, R= other than G)	
	Status of State Rules (G= Notified, R= Not notified)	
	Status of Ombudsman (G= Appointed, R=Not appointed)	
	Rank	25
TI	Facilities onboarded (G=≥95%, Y= 90-94%, R=<90%)	
	Coverage against target in contract (G=≥95%, Y= 90-94%, R=<90%)	
	HRG & BP living with HIV on ART (G=≥95%, Y= 90-94%, R=<90%)	
	IDU on OST (G=≥95%, Y= 90-94%, R=<90%)	
	Rank	31
BSD	Percentage of PLHIV who know their status (G=≥95%, Y= 80-94%, R=<80%)	
	HIV testing against target-GC ((G=≥95%, Y= 80-94%, R=<80%)	
	HIV testing against target-PW (G=≥95%, Y= 80-94%, R=<80%)	
	Percentage of Pregnant women who initiated ART (G=≥95%, Y= 80-94%, R=<80%)	
	Percentage of TB suspected cases referred to NTEP (G=≥95%, Y= 80-94%, R=<80%)	
	Clients managed at DSRC against the target (G=≥95%, Y= 80-94%, R=<80%)	
	Percentage of pregnant women tested for Syphilis (G=≥95%, Y= 80-94%, R=<80%)	
	Rank	5
CST	ART Initiation (Current FY) (G=≥95%, Y= 80-94%, R=<80%)	
	LFU rate among new ART initiation (G=<2%, Y= 2-4%, R=≥5%)	
	PLHIV put on ART during the FY against target (G=≥95%, Y= 80-94%, R=<80%)	
	Status on establishment of CSC (G=≥95%, Y= 80-94%, R=<80%)	
	Rank	25
LS	VL Suppression Rate (Current FY) (G=≥95%, Y= 85-94%, R=<85%)	
	% of SRL accredited (G=100%, Y= 80-99%, R=<80%)	
	% Participation of ICTCs in Re-testing (G=≥95%, Y= 85-94, R=<85%)	
	Rank	25
SI	% of NACP facilities active in SOCH (G=≥90%, Y= 75-89%, R=<75%)	
	Status of State Data Management Committee (G=one meeting held, Y= no meeting held, R= not constituted)	
	Status of finalized Priority Areas for Operational Research and Evaluation (G= 4, Y= 3, R= <3)	
	Rank	25
Finance	Expenditure with respect to funds released during FY 2021-22 (G=≥90%, Y= 85-89%, R=<85%)	
	Submission of Audit Report after approval of EC/GB for the preceding year (G= by 30th June, Y= 30th Sept, R= beyond 30th Sept 2021)	
	Submission of Utilization Certificate (in prescribed format GFR 12A) for the previous financial year (G= by 30th June, Y= 30th Sept, R= beyond 30th Sept 2021)	
	Rank	18
SCM	Report Submission (BSD-SCM Report) (G=≥90%, Y= 75-89%, R=<75%)	

Green=3 Marks

Yellow=2Marks

Red=1 Mark

No Colour=Not Applicable

A thick red ribbon is draped across the page, starting from the bottom left, looping up to the top right, and then coming back down towards the bottom right. The background is a gradient of yellow and orange with faint, concentric circular lines.

# FACT SHEET

## JHARKHAND

## 1. Status of HIV/AIDS Epidemic

### A. Epidemic Estimates (2021)

Indicator	Male	Female	Total
1. IPR	-	-	5.54
2. IMR	-	-	2.34
3. Adult (15-49 yrs) HIV Prevalence (%)	0.09	0.08	0.08
4. Estimated people living with HIV	13,456	11,214	24,670
5. ART coverage (%)	54.3	61	57
6. Estimated children living with HIV	601	561	1,162
7. Annual new HIV infections	722	646	1,368
8. Annual AIDS-related deaths (ARD)	270	118	388
9. Change in annual new HIV infections since 2010 (%)	-19.7	-9.14	-15.09
10. Change in annual ARD since 2010(%)	-41.2	-66.19	-51.98
11. EMTCT need	-	342	342


### B. High risk population size (2009), safe practices (2015) and prevalence (2021)

Population Group	Estimates Size	Condom Use (%)	New Needle/ Syringe use (%)	HIV Prevalence (%)
1. Female Sex Workers	20,830	46.2	39.1	0.55
2. Men who have sex with men	3,220	32.9	19.3	6.68
3. Injecting Drug Users	1,430	75.1	95	-
4. Hijra/Transgender People	385	-	-	-
5. Migrants	20,000	-	-	-
6. Truckers	35,000	-	-	0
7. Prison inmates	67,153	0	0	0.00

### C. HIV/AIDS related knowledge, stigma and high-risk behaviour in general population (2019-21)

Indicator	Male	Female	Total
1. Adults (15-49 yrs) with comprehensive knowledge about HIV/AIDS (%)	31.1	13.8	-
2. Youth (15-24 yrs) with comprehensive knowledge about HIV/AIDS (%)	28.4	15.2	-
3. Adults willing to care for a relative with HIV/AIDS in own home (%)	86.2	77.2	-
4. Adults willing to buy fresh vegetables from a shopkeeper or vendor who has HIV/AIDS (%)	75.3	67.5	-
5. Adults (15-49 yrs) who have had higher-risk sexual behaviour in the past 12 months (%)	3.6	0.4	-
5.1 Condom use during last higher-risk intercourse (%)	38.3	23.1	-
6. Youth (15-24 yrs) who have had higher-risk sexual behaviour in the past 12 months (%)	5.7	0.7	-
6.1 Condom use during last higher-risk intercourse (%)	35.6	30.0	-

## 2. Progress on 95-95-95 (2021-22)



### 3. Prevention of new HIV infections among general population

#### A. Information, Education, Communication, Youth and Mainstreaming

Indicator	2021-22
1. Schools with operational Adolescent Education Program (AEP)	2,108
2. Colleges with operational Red Ribbon Clubs (RRC)	321
3. Persons trained under mainstreaming	2,106

#### B. Sexually Transmitted Infections (STI)/Reproductive Tract Infections (RTI) Management at DSRCs

Indicator	2021-22			
1. NACO Supported Designated STI/RTI Clinics (DSRC)	28			
	Male	Female	TG	Total
2. Clients managed	-	-	-	32,907
3. RPR Tests conducted	8,097	10,865	1	18,963
4. Syphilis seropositivity (%)	0.42	0.14	100.00	0.26

### 4. Prevention of new HIV infections among high-risk group and bridge population

#### A. Targeted Interventions (TI) and Opioid Substitution Therapy (OST)

Indicator	2021-22
1. Targeted Interventions	28
2. OST centres	2
3. Employer Led Model Interventions	22

#### B. Female Sex Workers

Indicator	2021-22
1. Estimated size	20,830
2. Coverage (%)	72
3. Condoms distributed	26,15,213
4. Tested for HIV (April 2021 - September 2021)	12,417
4.1. HIV sero-positive (%)	0.02
4.1.1. Linked to ART	2
5. Tested for HIV (October 2021 - March 2022)	13,584
5.1. HIV sero-positive (%)	0.02
5.1.1. Linked to ART	3
6. Clinic Visits	46,731
7. STI/RTI treated	551
8. Presumptive treatment	2,471

#### C. Men who have Sex with Men

Indicator	2021-22
1. Estimated size	3,220
2. Coverage (%)	54
3. Condoms distributed	2,84,529
4. Tested for HIV (April 2021 - September 2021)	1,521
4.1. HIV sero-positive (%)	0.33
4.1.1. Linked to ART	3
5. Tested for HIV (October 2021 - March 2022)	1,525
5.1. HIV sero-positive (%)	0.20
5.1.1. Linked to ART	3
6. Clinic Visits	5,775
7. STI/RTI treated	44
8. Presumptive treatment	265

### D. Injecting Drug Users

Indicator	2021-22
1. Estimated size	1,430
2. Coverage (%)	65
3. Needles distributed	2,98,379
4. Syringes distributed	2,35,547
5. On OST	117
6. Tested for HIV (April 2021 - September 2021)	768
6.1. HIV sero-positive (%)	0.13
6.1.1. Linked to ART	0
7. Tested for HIV (October 2021 - March 2022)	836
7.1. HIV sero-positive (%)	0.00
7.1.1. Linked to ART	-

### E. Hijra/Transgender people

Indicator	2021-22
1. Estimated size	385
2. Coverage (%)	92
3. Condoms distributed	36,676
4. Tested for HIV (April 2021 - September 2021)	314
4.1. HIV sero-positive (%)	0.00
4.1.1. Linked to ART	-
5. Tested for HIV (October 2021 - March 2022)	285
5.1. HIV sero-positive (%)	-
5.1.1. Put on ART	-
6. Clinic Visits	1,154
7. STI / RTI treated	15
8. Presumptive treatment	43

### F. Migrants

Indicator	2021-22
1. Estimated size	20,000
2. Coverage (%)	>=95
3. Tested for HIV	9,323
3.1. HIV sero-positive (%)	0.01
3.2. Linked to ART	1

### G. Truckers

Indicator	2021-22
1. Estimated size	35,000
2. Coverage (%)	69
3. Tested for HIV	4,308
3.1. HIV sero-positive (%)	0.02
3.2. On ART	1

### H. Prison Inmates

Indicator	2021-22
1. Total prisons	30
2. Prisons covered under programme	29
3. Total inmates admitted	54,447
4. Inmates Covered(%)	18
5. Tested for HIV	9,468
5.1. HIV sero-positive (%)	0.18
5.2. On ART (%)	94

### I. Link Worker Scheme

Indicator	2021-22
1. Districts covered under scheme	-
2. Vulnerable population covered	-
3. Tested for HIV	-
3.1. HIV sero-positive (%)	-
3.2. Linked to ART (%)	-



## J. Opioid Substitution Therapy

Indicator	2021-22
1. OST Centres	2
1.1. OSTC in Public Health Settings	2
1.2. OSTC in NGO Settings	-
1.3 No. of Satellite OST Centres	-
2. IDU on OST	117

## 5. Early detection of HIV infected people

### A. HIV Counselling and Testing Services (HCTS)

Indicator	2021-22
1. ICTC facilities	359
1.1. Stand-alone	66
1.2. Facility integrated (Govt)	211
1.3. Facility integrated (PPP)	24
1.4. CBS	58

### B. HIV Testing among Vulnerable Population (Excluding Pregnant Women)

Indicator	2021-22			
	Male	Female	TG	Total
1. Tested for HIV	1,33,872	1,04,651	731	2,39,254
2. Found HIV Positive among tested	761	409	2	1,172
3. HIV sero-positivity (%) among tested	0.57	0.39	0.27	0.49
4. Spouse/sexual partner testing of HIV positive people identified	268	308	8	584

## 6. Initiation and retention on ART of HIV infected people

### A. Treatment Facilities

Indicator	2021-22
1. ART Centres	13
2. Centre of Excellence	
2.1. Centre of Excellence (Adult)	-
2.2. Centre of Excellence (Paediatric)	-
3. Link ART Centres	11
4. Care Support Centres	5

### B. Treatment Uptake

Indicator	2021-22			
	Male	Female	TG	Total
1. HIV positive cases diagnosed (At ICTC)	761	498	2	1,261
2. New PLHIV Registered at ART center	864	582	3	1,449
2.1 Initiated on ART	792	561	3	1,356
3. PLHIV alive and on ART	7,309	6,763	25	14,098
4. 12 months retention on ART (%)				79.26
5. Lost to follow-up cases	612	418	2	1,032

## 7. Viral Suppression and laboratories

### A. Laboratory facilities and service uptake

Indicator	2021-22
1. Viral load laboratories	1
1.1 Accredited Viral load laboratories	-
2. Viral load testing conducted	10,044
2.1. Virally suppressed (%)	77
3. National reference laboratories (NRL)	-
3.1 Accredited NRL	-
4. State reference laboratories (SRL)	3
4.1 Accredited SRL	-
5. CD4 testing conducted	6,470
6. External Quality Assessment of ICTC	
6.1 Average Participation (%)	92.69
6.2. Average Discordance (%)	0.00
7. Quality Assurance Scheme for Basic Composite Medical Laboratories (Entry Level)- M(EL)T	
7.1 No. of ICTCs certified for M(EL)T certification	-

## 8. Elimination of mother to child transmission of HIV & Syphilis

### A. HIV

Indicator	2021-22
1. Estimated pregnant women (PW)	8,50,800
2. HIV testing among PW	6,23,860
3. HIV sero-positivity (%) among tested	0.01
4. HIV Positive PW (old + new detections)	191
4.1 On life-long ART	181
5. Live births among HIV positive PW	143
5.1 Babies given ARV Prophylaxis (%)	90.21
6. Babies tested HIV (6 week- 6 month)	169
6.1 Babies confirmed HIV Positive (6 week- 6 month)	17
7. HIV exposed babies at 18 months	
7.1 HIV exposed babies tested at 18 month	100
7.2 Babies confirmed HIV positive at 18 months	1
8. HIV positive babies initiated on ART	18

### B. Syphilis

Indicator	2021-22
1. Estimated pregnant women (PW)	8,50,800
2. Syphilis testing among PW	5,52,939
3. Sero-positivity (%) among tested	0.00
4. Put on treatment	22

## 9. Elimination of HIV/AIDS related Stigma and Discrimination

### A. HIV/AIDS Prevention & Control Act (2017)

Indicator	2021-22
1. State rules notified for HIV/AIDS Prevention and Control Act (2017)	Yes
2. State designated/appointed ombudsman for HIV/AIDS Prevention and Control Act (2017)	Yes

## 10. HIV-TB Co-morbidities

### A. HRG and Bridge Population

Indicator								2021-22
	Quarter	FSW	MSW	IDU	TG	Migrants	Truckers	Total
Screened for TB	Quarter 1	9,235	1,346	708	249	3,011	3,365	17,914
	Quarter 2	10,957	1,484	851	320	3,681	3,731	21,024
	Quarter 3	11,896	1,583	773	332	4,467	3,684	22,735
	Quarter 4	12,273	1,426	812	265	6,265	3,389	24,430
Tested for TB	Quarter 1	7	2	1	-	-	-	10
	Quarter 2	26	2	-	-	-	-	28
	Quarter 3	59	1	-	-	8	-	68
	Quarter 4	46	1	-	-	-	-	47
Diagnosed with TB	Quarter 1	-	-	1	-	-	-	1
	Quarter 2	1	-	-	-	-	-	1
	Quarter 3	-	1	-	-	-	-	1
	Quarter 4	1	-	-	-	-	-	1
Initiated on TB treatment	Quarter 1	-	-	1	-	-	-	1
	Quarter 2	1	-	-	-	-	-	1
	Quarter 3	-	1	-	-	-	-	1
	Quarter 4	1	-	-	-	-	-	1

### B. HIV-TB Cross-Referral

Indicator		2021-22
1. In referral from TB program		8,481
1.1. HIV sero-positive (%)		1.44
1.2. ICTC clients referred to NTEP		10,936

### C. HIV-TB Coinfected at ART Centre

Indicator								2021-22
	PLHIV attending ART Centre	PLHIV underwent 4S screening	PLHIV with presumptive TB	PLHIV tested for TB	PLHIV diagnosed with TB	PLHIV initiated on IPT	Co-infected enrolled at ARTc	Co-infected initiated on ART
Apr-21	9,443	9,278	206	206	16	423		
May-21	7,037	6,933	94	94	3	246		
Jun-21	7,491	7,342	183	115	18	129		
Jul-21	8,311	8,144	162	162	31	392		
Aug-21	8,867	8,684	193	177	41	169		
Sep-21	8,693	8,579	192	189	38	130		
Oct-21	8,649	8,473	163	162	32	180		
Nov-21	8,725	8,340	223	171	19	150		
Dec-21	8,978	8,307	197	147	27	173		
Jan-22	7,731	7,160	143	103	21	100		
Feb-22	7,205	6,782	178	149	26	254		
Mar-22	8,149	7,627	164	133	40	279		
April 2021-March 2022							334	280

## 11. Scorecard

State/UT Name		Jharkhand
Overall Rank		27
IEC & MS	Frequency of Social Media updates (G= ≥60, Y=40-59, R=<40)	
	Status of AEP integration in state School curriculum (G=Yes, R=No)	
	Status of SCA (G= At least one meeting held since 2017, R= other than G)	
	Status of State Rules (G= Notified, R= Not notified)	
	Status of Ombudsman (G= Appointed, R=Not appointed)	
	Rank	15
TI	Facilities onboarded (G=≥95%, Y= 90-94%, R=<90%)	
	Coverage against target in contract (G=≥95%, Y= 90-94%, R=<90%)	
	HRG & BP living with HIV on ART (G=≥95%, Y= 90-94%, R=<90%)	
	IDU on OST (G=≥95%, Y= 90-94%, R=<90%)	
	Rank	19
BSD	Percentage of PLHIV who know their status (G=≥95%, Y= 80-94%, R=<80%)	
	HIV testing against target-GC ((G=≥95%, Y= 80-94%, R=<80%)	
	HIV testing against target-PW (G=≥95%, Y= 80-94%, R=<80%)	
	Percentage of Pregnant women who initiated ART (G=≥95%, Y= 80-94%, R=<80%)	
	Percentage of TB suspected cases referred to NTEP (G=≥95%, Y= 80-94%, R=<80%)	
	Clients managed at DSRC against the target (G=≥95%, Y= 80-94%, R=<80%)	
	Percentage of pregnant women tested for Syphilis (G=≥95%, Y= 80-94%, R=<80%)	
	Rank	26
CST	ART Initiation (Current FY) (G=≥95%, Y= 80-94%, R=<80%)	
	LFU rate among new ART initiation (G=<2%, Y= 2-4%, R=≥5%)	
	PLHIV put on ART during the FY against target (G=≥95%, Y= 80-94%, R=<80%)	
	Status on establishment of CSC (G=≥95%, Y= 80-94%, R=<80%)	
	Rank	25
LS	VL Suppression Rate (Current FY) (G=≥95%, Y= 85-94%, R=<85%)	
	% of SRL accredited (G=100%, Y= 80-99%, R=<80%)	
	% Participation of ICTCs in Re-testing (G=≥95%, Y= 85-94%, R=<85%)	
	Rank	25
SI	% of NACP facilities active in SOCH (G=≥90%, Y= 75-89%, R=<75%)	
	Status of State Data Management Committee (G=one meeting held, Y= no meeting held, R= not constituted)	
	Status of finalized Priority Areas for Operational Research and Evaluation (G= 4, Y= 3, R= <3)	
	Rank	4
Finance	Expenditure with respect to funds released during FY 2021-22 (G=≥90%, Y= 85-89%, R=<85%)	
	Submission of Audit Report after approval of EC/GB for the preceding year (G= by 30th June, Y= 30th Sept, R= beyond 30th Sept 2021)	
	Submission of Utilization Certificate (in prescribed format GFR 12A) for the previous financial year (G= by 30th June, Y= 30th Sept, R= beyond 30th Sept 2021)	
	Rank	34
SCM	Report Submission (BSD-SCM Report) (G=≥90%, Y= 75-89%, R=<75%)	

Green=3 Marks

Yellow=2Marks

Red=1 Mark

No Colour=Not Applicable

A thick red ribbon is tied in a loop on the right side of the page, with the tail extending downwards and to the left. The background is a gradient of yellow and orange with faint concentric circles.

# FACT SHEET

## KARNATAKA

## 1. Status of HIV/AIDS Epidemic

### A. Epidemic Estimates (2021)

Indicator	Male	Female	Total
1. IPR	-	-	1.37
2. IMR	-	-	0.41
3. Adult (15-49 yrs) HIV Prevalence (%)	0.44	0.48	0.46
4. Estimated people living with HIV	1,32,478	1,43,402	2,75,880
5. ART coverage (%)	61.7	72	67
6. Estimated children living with HIV	3,527	3,277	6,804
7. Annual new HIV infections	1,920	1,872	3,792
8. Annual AIDS-related deaths (ARD)	4,213	2,529	6,742
9. Change in annual new HIV infections since 2010 (%)	-62.9	-62.86	-62.87
10. Change in annual ARD since 2010(%)	-73.9	-82.85	-78.17
11. EMTCT need	-	1,707	1,707


### B. High risk population size (2009), safe practices (2015) and prevalence (2021)

Population Group	Estimates Size	Condom Use (%)	New Needle/ Syringe use (%)	HIV Prevalence (%)
1. Female Sex Workers	1,05,310	85.2	32.5	3.01
2. Men who have sex with men	25,555	67.4	61.4	2.81
3. Injecting Drug Users	3,107	27.8	69.6	0
4. Hijra/Transgender People	2,254	73.4	-	3.2
5. Migrants	2,10,000	-	-	0.2
6. Truckers	85,000	-	-	1.2
7. Prison inmates	85,576	65.5	11.8	0.67

### C. HIV/AIDS related knowledge, stigma and high-risk behaviour in general population (2019-21)

Indicator	Male	Female	Total
1. Adults (15-49 yrs) with comprehensive knowledge about HIV/AIDS (%)	26.6	24.5	-
2. Youth (15-24 yrs) with comprehensive knowledge about HIV/AIDS (%)	24.4	26.8	-
3. Adults willing to care for a relative with HIV/AIDS in own home (%)	78.8	73.7	-
4. Adults willing to buy fresh vegetables from a shopkeeper or vendor who has HIV/AIDS (%)	74.8	69.5	-
5. Adults (15-49 yrs) who have had higher-risk sexual behaviour in the past 12 months (%)	2.8	0.4	-
5.1 Condom use during last higher-risk intercourse (%)	59.2	74.6	-
6. Youth (15-24 yrs) who have had higher-risk sexual behaviour in the past 12 months (%)	4.2	0.1	-
6.1 Condom use during last higher-risk intercourse (%)	56.9	100.0	-

## 2. Progress on 95-95-95 (2021-22)



Indicator	Male	Female	Total
1. Estimated PLHIV size (2021)	1,32,478	1,43,402	2,75,880
2. PLHIV who know their HIV Status	1,00,343	1,18,271	2,18,614
3. PLHIV who know their HIV status and are on ART	79,881	1,00,609	1,80,490
4. PLHIV who are on ART and tested for their viral load	49,344	62,910	1,12,254
5. PLHIV who are virally suppressed	38,708	52,578	91,286

### 3. Prevention of new HIV infections among general population

#### A. Information, Education, Communication, Youth and Mainstreaming

Indicator	2021-22
1. Schools with operational Adolescent Education Program (AEP)	7,200
2. Colleges with operational Red Ribbon Clubs (RRC)	1,536
3. Persons trained under mainstreaming	56,752

#### B. Sexually Transmitted Infections (STI)/Reproductive Tract Infections (RTI) Management at DSRCs

Indicator	2021-22			
1. NACO Supported Designated STI/RTI Clinics (DSRC)	54			
	Male	Female	TG	Total
2. Clients managed	-	-	-	2,31,732
3. RPR Tests conducted	41,610	88,167	1,128	1,30,905
4. Syphilis seropositivity (%)	0.84	0.22	1.51	0.43

### 4. Prevention of new HIV infections among high-risk group and bridge population

#### A. Targeted Interventions (TI) and Opioid Substitution Therapy (OST)

Indicator	2021-22
1. Targeted Interventions	76
2. OST centres	2
3. Employer Led Model Interventions	72

#### B. Female Sex Workers

Indicator	2021-22
1. Estimated size	1,05,310
2. Coverage (%)	>=95
3. Condoms distributed	20,838,493
4. Tested for HIV (April 2021 - September 2021)	75,862
4.1. HIV sero-positive (%)	0.04
4.1.1. Linked to ART	29
5. Tested for HIV (October 2021 - March 2022)	80,296
5.1. HIV sero-positive (%)	0.05
5.1.1. Linked to ART	41
6. Clinic Visits	3,20,322
7. STI/RTI treated	2,644
8. Presumptive treatment	15,587

#### C. Men who have Sex with Men

Indicator	2021-22
1. Estimated size	25,555
2. Coverage (%)	>=95
3. Condoms distributed	84,55,984
4. Tested for HIV (April 2021 - September 2021)	24,300
4.1. HIV sero-positive (%)	0.26
4.1.1. Linked to ART	55
5. Tested for HIV (October 2021 - March 2022)	27,079
5.1. HIV sero-positive (%)	0.17
5.1.1. Linked to ART	49
6. Clinic Visits	99,234
7. STI/RTI treated	228
8. Presumptive treatment	5,362

### D. Injecting Drug Users

Indicator	2021-22
1. Estimated size	3,107
2. Coverage (%)	32
3. Needles distributed	1,43,330
4. Syringes distributed	71,665
5. On OST	149
6. Tested for HIV (April 2021 - September 2021)	655
6.1. HIV sero-positive (%)	0.00
6.1.1. Linked to ART	-
7. Tested for HIV (October 2021 - March 2022)	728
7.1. HIV sero-positive (%)	0.14
7.1.1. Linked to ART	1

### E. Hijra/Transgender people

Indicator	2021-22
1. Estimated size	2,254
2. Coverage (%)	>=95
3. Condoms distributed	12,79,354
4. Tested for HIV (April 2021 - September 2021)	2,807
4.1. HIV sero-positive (%)	0.11
4.1.1. Linked to ART	3
5. Tested for HIV (October 2021 - March 2022)	3,927
5.1. HIV sero-positive (%)	0.15
5.1.1. Put on ART	6
6. Clinic Visits	11,114
7. STI / RTI treated	25
8. Presumptive treatment	707

### F. Migrants

Indicator	2021-22
1. Estimated size	2,10,000
2. Coverage (%)	>=95
3. Tested for HIV	43,336
3.1. HIV sero-positive (%)	0.10
3.2. Linked to ART	29

### G. Truckers

Indicator	2021-22
1. Estimated size	85,000
2. Coverage (%)	94
3. Tested for HIV	10,869
3.1. HIV sero-positive (%)	0.09
3.2. On ART	9

### H. Prison Inmates

Indicator	2021-22
1. Total prisons	104
2. Prisons covered under programme	55
3. Total inmates admitted	52,738
4. Inmates Covered(%)	43
5. Tested for HIV	26,660
5.1. HIV sero-positive (%)	0.33
5.2. On ART (%)	83

### I. Link Worker Scheme

Indicator	2021-22
1. Districts covered under scheme	5
2. Vulnerable population covered	1,44,466
3. Tested for HIV	91,534
3.1. HIV sero-positive (%)	0.29
3.2. Linked to ART (%)	95.19



## J. Opioid Substitution Therapy

Indicator	2021-22
1. OST Centres	2
1.1. OSTC in Public Health Settings	2
1.2. OSTC in NGO Settings	-
1.3 No. of Satellite OST Centres	-
2. IDU on OST	149

## 5. Early detection of HIV infected people

### A. HIV Counselling and Testing Services (HCTS)

Indicator	2021-22
1. ICTC facilities	3,374
1.1. Stand-alone	473
1.2. Facility integrated (Govt)	2,436
1.3. Facility integrated (PPP)	407
1.4. CBS	58

### B. HIV Testing among Vulnerable Population (Excluding Pregnant Women)

Indicator	2021-22			
	Male	Female	TG	Total
1. Tested for HIV	12,13,796	10,40,310	16,460	22,70,566
2. Found HIV Positive among tested	6,082	4,457	78	10,617
3. HIV sero-positivity (%) among tested	0.50	0.43	0.47	0.47
4. Spouse/sexual partner testing of HIV positive people identified	1,740	1,936	3	3,679

## 6. Initiation and retention on ART of HIV infected people

### A. Treatment Facilities

Indicator	2021-22
1. ART Centres	70
2. Centre of Excellence	
2.1. Centre of Excellence (Adult)	1
2.2. Centre of Excellence (Paediatric)	1
3. Link ART Centres	305
4. Care Support Centres	36

### B. Treatment Uptake

Indicator	2021-22			
	Male	Female	TG	Total
1. HIV positive cases diagnosed (At ICTC)	6,082	4,975	78	11,135
2. New PLHIV Registered at ART center	5,691	4,796	81	10,568
2.1 Initiated on ART	5,439	4,620	79	10,138
3. PLHIV alive and on ART	81,775	1,02,291	519	1,84,585
4. 12 months retention on ART (%)				80.69
5. Lost to follow-up cases	12,303	10,780	135	23,218

## 7. Viral Suppression and laboratories

### A. Laboratory facilities and service uptake

Indicator	2021-22
1. Viral load laboratories	7
1.1 Accredited Viral load laboratories	4
2. Viral load testing conducted	1,20,261
2.1. Virally suppressed (%)	81
3. National reference laboratories (NRL)	1
3.1 Accredited NRL	1
4. State reference laboratories (SRL)	10
4.1 Accredited SRL	10
5. CD4 testing conducted	1,41,784
6. External Quality Assessment of ICTC	
6.1 Average Participation (%)	74.89
6.2. Average Discordance (%)	0.00
7. Quality Assurance Scheme for Basic Composite Medical Laboratories (Entry Level)- M(EL)T	
7.1 No. of ICTCs certified for M(EL)T certification	-

## 8. Elimination of mother to child transmission of HIV & Syphilis

### A. HIV

Indicator	2021-22
1. Estimated pregnant women (PW)	11,96,210
2. HIV testing among PW	12,74,231
3. HIV sero-positivity (%) among tested	0.04
4. HIV Positive PW (old + new detections)	1,261
4.1 On life-long ART	1,258
5. Live births among HIV positive PW	966
5.1 Babies given ARV Prophylaxis (%)	93.69
6. Babies tested HIV (6 week- 6 month)	1,037
6.1 Babies confirmed HIV Positive (6 week- 6 month)	24
7. HIV exposed babies at 18 months	
7.1 HIV exposed babies tested at 18 month	745
7.2 Babies confirmed HIV positive at 18 months	20
8. HIV positive babies initiated on ART	55

### B. Syphilis

Indicator	2021-22
1. Estimated pregnant women (PW)	11,96,210
2. Syphilis testing among PW	10,62,760
3. Sero-positivity (%) among tested	0.01
4. Put on treatment	92

## 9. Elimination of HIV/AIDS related Stigma and Discrimination

### A. HIV/AIDS Prevention & Control Act (2017)

Indicator	2021-22
1. State rules notified for HIV/AIDS Prevention and Control Act (2017)	Yes
2. State designated/appointed ombudsman for HIV/AIDS Prevention and Control Act (2017)	Yes

## 10. HIV-TB Co-morbidities

### A. HRG and Bridge Population

Indicator								2021-22
	Quarter	FSW	MSW	IDU	TG	Migrants	Truckers	Total
Screened for TB	Quarter 1	1,51,106	41,942	1,810	6,532	40,644	14,743	2,56,777
	Quarter 2	1,76,475	52,601	1,969	8,738	56,182	29,123	3,25,088
	Quarter 3	1,81,839	59,917	2,065	9,222	87,835	27,147	3,68,025
	Quarter 4	1,94,718	63,014	2,172	11,360	82,506	24,536	3,78,306
Tested for TB	Quarter 1	422	140	-	-	24	1	587
	Quarter 2	1,187	194	-	3	76	2	1,462
	Quarter 3	1,478	427	3	6	101	24	2,039
	Quarter 4	1,322	362	8	-	69	15	1,776
Diagnosed with TB	Quarter 1	4	2	-	-	2	-	8
	Quarter 2	7	1	-	-	1	-	9
	Quarter 3	9	6	3	-	1	1	20
	Quarter 4	6	2	-	-	4	-	12
Initiated on TB treatment	Quarter 1	4	2	-	-	2	-	8
	Quarter 2	6	1	-	-	1	-	8
	Quarter 3	11	6	-	-	1	-	18
	Quarter 4	7	2	-	-	4	-	13

### B. HIV-TB Cross-Referral

Indicator		2021-22
1. In referral from TB program		85,222
1.1. HIV sero-positive (%)		1.41
1.2. ICTC clients referred to NTEP		1,05,132

### C. HIV-TB Coinfected at ART Centre

Indicator								2021-22
	PLHIV attending ART Centre	PLHIV underwent 4S screening	PLHIV with presumptive TB	PLHIV tested for TB	PLHIV diagnosed with TB	PLHIV initiated on IPT	Co-infected enrolled at ARTc	Co-infected initiated on ART
Apr-21	1,00,013	95,881	4,133	3,814	195	1,340		
May-21	71,114	66,717	2,633	2,013	84	657		
Jun-21	79,536	75,141	3,502	3,240	200	1,186		
Jul-21	1,07,915	1,04,556	6,301	4,855	247	2,130		
Aug-21	1,17,725	1,14,472	6,323	5,453	261	1,896		
Sep-21	1,22,280	1,18,085	6,400	5,576	274	1,200		
Oct-21	1,11,193	1,08,735	6,121	5,019	299	1,039		
Nov-21	1,05,747	1,03,254	5,453	4,568	316	1,003		
Dec-21	1,06,659	1,03,963	5,653	4,775	329	1,749		
Jan-22	1,03,759	1,01,478	5,729	4,674	270	2,051		
Feb-22	94,231	92,183	6,446	4,264	286	1,731		
Mar-22	1,03,139	1,00,660	4,808	4,668	304	1,950		
April 2021-March 2022							3,697	3,551

## 11. Scorecard

State/UT Name		Karnataka
Overall Rank		8
IEC & MS	Frequency of Social Media updates (G= ≥60, Y=40-59, R=<40)	
	Status of AEP integration in state School curriculum (G=Yes, R=No)	
	Status of SCA (G= At least one meeting held since 2017, R= other than G)	
	Status of State Rules (G= Notified, R= Not notified)	
	Status of Ombudsman (G= Appointed, R=Not appointed)	
	Rank	5
TI	Facilities onboarded (G=≥95%, Y= 90-94%, R=<90%)	
	Coverage against target in contract (G=≥95%, Y= 90-94%, R=<90%)	
	HRG & BP living with HIV on ART (G=≥95%, Y= 90-94%, R=<90%)	
	IDU on OST (G=≥95%, Y= 90-94%, R=<90%)	
	Rank	3
BSD	Percentage of PLHIV who know their status (G=≥95%, Y= 80-94%, R=<80%)	
	HIV testing against target-GC ((G=≥95%, Y= 80-94%, R=<80%)	
	HIV testing against target-PW (G=≥95%, Y= 80-94%, R=<80%)	
	Percentage of Pregnant women who initiated ART (G=≥95%, Y= 80-94%, R=<80%)	
	Percentage of TB suspected cases referred to NTEP (G=≥95%, Y= 80-94%, R=<80%)	
	Clients managed at DSRC against the target (G=≥95%, Y= 80-94%, R=<80%)	
	Percentage of pregnant women tested for Syphilis (G=≥95%, Y= 80-94%, R=<80%)	
	Rank	11
CST	ART Initiation (Current FY) (G=≥95%, Y= 80-94%, R=<80%)	
	LFU rate among new ART initiation (G=<2%, Y= 2-4%, R=≥5%)	
	PLHIV put on ART during the FY against target (G=≥95%, Y= 80-94%, R=<80%)	
	Status on establishment of CSC (G=≥95%, Y= 80-94%, R=<80%)	NA
	Rank	6
LS	VL Suppression Rate (Current FY) (G=≥95%, Y= 85-94%, R=<85%)	
	% of SRL accredited (G=100%, Y= 80-99%, R=<80%)	
	% Participation of ICTCs in Re-testing (G=≥95%, Y= 85-94, R=<85%)	
	Rank	19
SI	% of NACP facilities active in SOCH (G=≥90%, Y= 75-89%, R=<75%)	
	Status of State Data Management Committee (G=one meeting held, Y= no meeting held, R= not constituted)	
	Status of finalized Priority Areas for Operational Research and Evaluation (G= 4, Y= 3, R= <3)	
	Rank	25
Finance	Expenditure with respect to funds released during FY 2021-22 (G=≥90%, Y= 85-89%, R=<85%)	
	Submission of Audit Report after approval of EC/GB for the preceding year (G= by 30th June, Y= 30th Sept, R= beyond 30th Sept 2021)	
	Submission of Utilization Certificate (in prescribed format GFR 12A) for the previous financial year (G= by 30th June, Y= 30th Sept, R= beyond 30th Sept 2021)	
	Rank	5
SCM	Report Submission (BSD-SCM Report) (G=≥90%, Y= 75-89%, R=<75%)	

Green=3 Marks

Yellow=2Marks

Red=1 Mark

No Colour=Not Applicable

A thick red ribbon is tied in a loop, with the ends trailing off to the right and bottom. The background is a gradient of yellow and orange, with faint concentric circles centered behind the text.

# FACT SHEET

## KERALA

## 1. Status of HIV/AIDS Epidemic

### A. Epidemic Estimates (2021)

Indicator	Male	Female	Total
1. IPR	-	-	1.90
2. IMR	-	-	1.34
3. Adult (15-49 yrs) HIV Prevalence (%)	0.07	0.06	0.06
4. Estimated people living with HIV	11,323	9,887	21,210
5. ART coverage (%)	76.7	75	76
6. Estimated children living with HIV	298	285	583
7. Annual new HIV infections	212	191	403
8. Annual AIDS-related deaths (ARD)	61	60	121
9. Change in annual new HIV infections since 2010 (%)	-66.7	-66.96	-66.80
10. Change in annual ARD since 2010(%)	-79.7	-83.33	-81.69
11. EMTCT need	-	114	114


### B. High risk population size (2009), safe practices (2015) and prevalence (2021)

Population Group	Estimates Size	Condom Use (%)	New Needle/ Syringe use (%)	HIV Prevalence (%)
1. Female Sex Workers	21,698	67.3	50	0.44
2. Men who have sex with men	14,281	33.5	60.3	0.35
3. Injecting Drug Users	4,116	35.2	88.7	0.4
4. Hijra/Transgender People	2,540	51.3	-	0.56
5. Migrants	1,50,000	-	-	0
6. Truckers	20,000	-	-	1.2
7. Prison inmates	26,545	41.8	15.4	0.50

### C. HIV/AIDS related knowledge, stigma and high-risk behaviour in general population (2019-21)

Indicator	Male	Female	Total
1. Adults (15-49 yrs) with comprehensive knowledge about HIV/AIDS (%)	45.2	34.8	-
2. Youth (15-24 yrs) with comprehensive knowledge about HIV/AIDS (%)	40.6	30.2	-
3. Adults willing to care for a relative with HIV/AIDS in own home (%)	65.3	71	-
4. Adults willing to buy fresh vegetables from a shopkeeper or vendor who has HIV/AIDS (%)	78.9	71.7	-
5. Adults (15-49 yrs) who have had higher-risk sexual behaviour in the past 12 months (%)	0.5	0	-
5.1 Condom use during last higher-risk intercourse (%)	47.9	NA	-
6. Youth (15-24 yrs) who have had higher-risk sexual behaviour in the past 12 months (%)	0.5	0	-
6.1 Condom use during last higher-risk intercourse (%)	0.0	NA	-

## 2. Progress on 95-95-95 (2021-22)



### 3. Prevention of new HIV infections among general population

#### A. Information, Education, Communication, Youth and Mainstreaming

Indicator	2021-22
1. Schools with operational Adolescent Education Program (AEP)	2,150
2. Colleges with operational Red Ribbon Clubs (RRC)	271
3. Persons trained under mainstreaming	3,650

#### B. Sexually Transmitted Infections (STI)/Reproductive Tract Infections (RTI) Management at DSRCs

Indicator	2021-22			
1. NACO Supported Designated STI/RTI Clinics (DSRC)	23			
	Male	Female	TG	Total
2. Clients managed	-	-	-	28,665
3. RPR Tests conducted	7,804	12,213	184	20,201
4. Syphilis seropositivity (%)	7.80	1.48	13.04	4.03

### 4. Prevention of new HIV infections among high-risk group and bridge population

#### A. Targeted Interventions (TI) and Opioid Substitution Therapy (OST)

Indicator	2021-22
1. Targeted Interventions	64
2. OST centres	11
3. Employer Led Model Interventions	51

#### B. Female Sex Workers

Indicator	2021-22
1. Estimated size	21,698
2. Coverage (%)	98
3. Condoms distributed	50,06,755
4. Tested for HIV (April 2021 - September 2021)	15,795
4.1. HIV sero-positive (%)	0.01
4.1.1. Linked to ART	1
5. Tested for HIV (October 2021 - March 2022)	16,721
5.1. HIV sero-positive (%)	0.01
5.1.1. Linked to ART	2
6. Clinic Visits	63,476
7. STI/RTI treated	916
8. Presumptive treatment	3,381

#### C. Men who have Sex with Men

Indicator	2021-22
1. Estimated size	14,281
2. Coverage (%)	>=95
3. Condoms distributed	33,80,308
4. Tested for HIV (April 2021 - September 2021)	13,060
4.1. HIV sero-positive (%)	0.05
4.1.1. Linked to ART	7
5. Tested for HIV (October 2021 - March 2022)	12,875
5.1. HIV sero-positive (%)	0.09
5.1.1. Linked to ART	8
6. Clinic Visits	62,447
7. STI/RTI treated	543
8. Presumptive treatment	3,345

### D. Injecting Drug Users

Indicator	2021-22
1. Estimated size	4,116
2. Coverage (%)	63
3. Needles distributed	2,89,581
4. Syringes distributed	1,75,408
5. On OST	421
6. Tested for HIV (April 2021 - September 2021)	2,105
6.1. HIV sero-positive (%)	0.00
6.1.1. Linked to ART	-
7. Tested for HIV (October 2021 - March 2022)	2,151
7.1. HIV sero-positive (%)	0.05
7.1.1. Linked to ART	1

### E. Hijra/Transgender people

Indicator	2021-22
1. Estimated size	2,540
2. Coverage (%)	>=95
3. Condoms distributed	3,84,047
4. Tested for HIV (April 2021 - September 2021)	2,224
4.1. HIV sero-positive (%)	0.04
4.1.1. Linked to ART	0
5. Tested for HIV (October 2021 - March 2022)	2,278
5.1. HIV sero-positive (%)	0.04
5.1.1. Put on ART	1
6. Clinic Visits	7,115
7. STI / RTI treated	43
8. Presumptive treatment	239

### F. Migrants

Indicator	2021-22
1. Estimated size	1,50,000
2. Coverage (%)	>=95
3. Tested for HIV	59,366
3.1. HIV sero-positive (%)	0.08
3.2. Linked to ART	44

### G. Truckers

Indicator	2021-22
1. Estimated size	20,000
2. Coverage (%)	>=95
3. Tested for HIV	8,092
3.1. HIV sero-positive (%)	0.36
3.2. On ART	25

### H. Prison Inmates

Indicator	2021-22
1. Total prisons	55
2. Prisons covered under programme	54
3. Total inmates admitted	38,248
4. Inmates Covered(%)	37
5. Tested for HIV	13,346
5.1. HIV sero-positive (%)	0.04
5.2. On ART (%)	100

### I. Link Worker Scheme

Indicator	2021-22
1. Districts covered under scheme	-
2. Vulnerable population covered	-
3. Tested for HIV	-
3.1. HIV sero-positive (%)	-
3.2. Linked to ART (%)	-

## J. Opioid Substitution Therapy

Indicator	2021-22
1. OST Centres	11
1.1. OSTC in Public Health Settings	7
1.2. OSTC in NGO Settings	3
1.3 No. of Satellite OST Centres	1
2. IDU on OST	421

## 5. Early detection of HIV infected people

### A. HIV Counselling and Testing Services (HCTS)

Indicator	2021-22
1. ICTC facilities	799
1.1. Stand-alone	150
1.2. Facility integrated (Govt)	479
1.3. Facility integrated (PPP)	109
1.4. CBS	61

### B. HIV Testing among Vulnerable Population (Excluding Pregnant Women)

Indicator	2021-22			
	Male	Female	TG	Total
1. Tested for HIV	3,00,847	2,20,229	4,040	5,25,116
2. Found HIV Positive among tested	637	251	7	895
3. HIV sero-positivity (%) among tested	0.2	0.11	0.17	0.17
4. Spouse/sexual partner testing of HIV positive people identified	118	277	3	398

## 6. Initiation and retention on ART of HIV infected people

### A. Treatment Facilities

Indicator	2021-22
1. ART Centres	11
2. Centre of Excellence	
2.1. Centre of Excellence (Adult)	-
2.2. Centre of Excellence (Paediatric)	-
3. Link ART Centres	14
4. Care Support Centres	7

### B. Treatment Uptake

Indicator	2021-22			
	Male	Female	TG	Total
1. HIV positive cases diagnosed (At ICTC)	637	269	7	913
2. New PLHIV Registered at ART center	576	246	3	825
2.1 Initiated on ART	482	200	3	685
3. PLHIV alive and on ART	8,687	7,404	15	16,106
4. 12 months retention on ART (%)				83.80
5. Lost to follow-up cases	471	138	1	610

## 7. Viral Suppression and laboratories

### A. Laboratory facilities and service uptake

Indicator	2021-22
1. Viral load laboratories	1
1.1 Accredited Viral load laboratories	-
2. Viral load testing conducted	12,074
2.1. Virally suppressed (%)	92
3. National reference laboratories (NRL)	1
3.1 Accredited NRL	1
4. State reference laboratories (SRL)	5
4.1 Accredited SRL	5
5. CD4 testing conducted	10,528
6. External Quality Assessment of ICTC	
6.1 Average Participation (%)	93.33
6.2. Average Discordance (%)	0.00
7. Quality Assurance Scheme for Basic Composite Medical Laboratories (Entry Level)- M(EL)T	
7.1 No. of ICTCs certified for M(EL)T certification	28.00

## 8. Elimination of mother to child transmission of HIV & Syphilis

### A. HIV

Indicator	2021-22
1. Estimated pregnant women (PW)	5,26,340
2. HIV testing among PW	4,59,255
3. HIV sero-positivity (%) among tested	0.00
4. HIV Positive PW (old + new detections)	64
4.1 On life-long ART	62
5. Live births among HIV positive PW	45
5.1 Babies given ARV Prophylaxis (%)	100.00
6. Babies tested HIV (6 week- 6 month)	42
6.1 Babies confirmed HIV Positive (6 week- 6 month)	2
7. HIV exposed babies at 18 months	
7.1 HIV exposed babies tested at 18 month	51
7.2 Babies confirmed HIV positive at 18 months	-
8. HIV positive babies initiated on ART	-

### B. Syphilis

Indicator	2021-22
1. Estimated pregnant women (PW)	5,26,340
2. Syphilis testing among PW	3,91,811
3. Sero-positivity (%) among tested	0.03
4. Put on treatment	101

## 9. Elimination of HIV/AIDS related Stigma and Discrimination

### A. HIV/AIDS Prevention & Control Act (2017)

Indicator	2021-22
1. State rules notified for HIV/AIDS Prevention and Control Act (2017)	No
2. State designated/appointed ombudsman for HIV/AIDS Prevention and Control Act (2017)	No



## 10. HIV-TB Co-morbidities

### A. HRG and Bridge Population

Indicator								2021-22
	Quarter	FSW	MSW	IDU	TG	Migrants	Truckers	Total
Screened for TB	Quarter 1	8,659	5,950	1,699	1,573	17,947	1,497	37,325
	Quarter 2	14,025	10,571	1,930	1,817	26,541	2,224	57,108
	Quarter 3	13,320	12,248	2,279	1,648	29,511	2,504	61,510
	Quarter 4	12,138	10,333	2,254	1,694	24,154	2,964	53,537
Tested for TB	Quarter 1	4	11	-	-	302	-	317
	Quarter 2	21	9	-	1	124	-	155
	Quarter 3	24	65	45	24	378	-	536
	Quarter 4	28	6	1	12	14	-	61
Diagnosed with TB	Quarter 1	-	-	-	-	-	-	-
	Quarter 2	-	1	-	-	1	-	2
	Quarter 3	1	-	1	-	7	-	9
	Quarter 4	1	1	-	-	-	-	2
Initiated on TB treatment	Quarter 1	-	-	-	-	-	-	-
	Quarter 2	-	1	-	-	1	-	2
	Quarter 3	1	-	1	-	7	-	9
	Quarter 4	1	1	-	-	-	-	2

### B. HIV-TB Cross-Referral

Indicator	2021-22
1. In referral from TB program	7,644
1.1. HIV sero-positive (%)	0.99
1.2. ICTC clients referred to NTEP	17,854

### C. HIV-TB Coinfected at ART Centre

Indicator								2021-22
	PLHIV attending ART Centre	PLHIV underwent 4S screening	PLHIV with presumptive TB	PLHIV tested for TB	PLHIV diagnosed with TB	PLHIV initiated on IPT	Co-infected enrolled at ARTc	Co-infected initiated on ART
Apr-21	10,606	10,606	183	167	16	89		
May-21	8,867	8,867	136	119	13	17		
Jun-21	9,118	9,118	148	138	14	43		
Jul-21	10,929	10,909	172	165	17	71		
Aug-21	9,569	9,569	157	153	14	48		
Sep-21	10,793	10,793	207	201	22	76		
Oct-21	10,537	10,537	201	194	21	57		
Nov-21	10,161	10,161	218	209	18	82		
Dec-21	10,329	10,329	198	194	9	87		
Jan-22	10,013	10,013	210	191	12	66		
Feb-22	9,346	9,346	192	182	13	52		
Mar-22	9,592	9,592	224	207	19	75		
April 2021-March 2022							220	189

## 11. Scorecard

State/UT Name		Kerala
Overall Rank		21
IEC & MS	Frequency of Social Media updates (G= ≥60, Y=40-59, R=<40)	
	Status of AEP integration in state School curriculum (G=Yes, R=No)	
	Status of SCA (G= At least one meeting held since 2017, R= other than G)	
	Status of State Rules (G= Notified, R= Not notified)	
	Status of Ombudsman (G= Appointed, R=Not appointed)	
	Rank	26
TI	Facilities onboarded (G=≥95%, Y= 90-94%, R=<90%)	
	Coverage against target in contract (G=≥95%, Y= 90-94%, R=<90%)	
	HRG & BP living with HIV on ART (G=≥95%, Y= 90-94%, R=<90%)	
	IDU on OST (G=≥95%, Y= 90-94%, R=<90%)	
	Rank	19
BSD	Percentage of PLHIV who know their status (G=≥95%, Y= 80-94%, R=<80%)	
	HIV testing against target-GC ((G=≥95%, Y= 80-94%, R=<80%)	
	HIV testing against target-PW (G=≥95%, Y= 80-94%, R=<80%)	
	Percentage of Pregnant women who initiated ART (G=≥95%, Y= 80-94%, R=<80%)	
	Percentage of TB suspected cases referred to NTEP (G=≥95%, Y= 80-94%, R=<80%)	
	Clients managed at DSRC against the target (G=≥95%, Y= 80-94%, R=<80%)	
	Percentage of pregnant women tested for Syphilis (G=≥95%, Y= 80-94%, R=<80%)	
	Rank	31
CST	ART Initiation (Current FY) (G=≥95%, Y= 80-94%, R=<80%)	
	LFU rate among new ART initiation (G=<2%, Y= 2-4%, R=≥5%)	
	PLHIV put on ART during the FY against target (G=≥95%, Y= 80-94%, R=<80%)	
	Status on establishment of CSC (G=≥95%, Y= 80-94%, R=<80%)	
	Rank	11
LS	VL Suppression Rate (Current FY) (G=≥95%, Y= 85-94%, R=<85%)	
	% of SRL accredited (G=100%, Y= 80-99%, R=<80%)	
	% Participation of ICTCs in Re-testing (G=≥95%, Y= 85-94%, R=<85%)	
	Rank	6
SI	% of NACP facilities active in SOCH (G=≥90%, Y= 75-89%, R=<75%)	
	Status of State Data Management Committee (G=one meeting held, Y= no meeting held, R= not constituted)	
	Status of finalized Priority Areas for Operational Research and Evaluation (G= 4, Y= 3, R= <3)	
	Rank	4
Finance	Expenditure with respect to funds released during FY 2021-22 (G=≥90%, Y= 85-89%, R=<85%)	
	Submission of Audit Report after approval of EC/GB for the preceding year (G= by 30th June, Y= 30th Sept, R= beyond 30th Sept 2021)	
	Submission of Utilization Certificate (in prescribed format GFR 12A) for the previous financial year (G= by 30th June, Y= 30th Sept, R= beyond 30th Sept 2021)	
	Rank	5
SCM	Report Submission (BSD-SCM Report) (G=≥90%, Y= 75-89%, R=<75%)	

Green=3 Marks

Yellow=2Marks

Red=1 Mark

No Colour=Not Applicable



# FACT SHEET

## MADHYA PRADESH

# MADHYA PRADESH

## 1. Status of HIV/AIDS Epidemic

### A. Epidemic Estimates (2021)

Indicator	Male	Female	Total
1. IPR	-	-	2.81
2. IMR	-	-	1.03
3. Adult (15-49 yrs) HIV Prevalence (%)	0.10	0.06	0.08
4. Estimated people living with HIV	34,068	20,705	54,773
5. ART coverage (%)	57.7	75	64
6. Estimated children living with HIV	951	876	1,827
7. Annual new HIV infections	1,014	526	1,540
8. Annual AIDS-related deaths (ARD)	817	181	998
9. Change in annual new HIV infections since 2010 (%)	-59.0	-60.57	-59.52
10. Change in annual ARD since 2010(%)	-73.0	-87.80	-77.83
11. EMTCT need	-	536	536


### B. High risk population size (2009), safe practices (2015) and prevalence (2021)

Population Group	Estimates Size	Condom Use (%)	New Needle/ Syringe use (%)	HIV Prevalence (%)
1. Female Sex Workers	28,418	67	63.6	0.75
2. Men who have sex with men	13,343	39.6	71.6	1.84
3. Injecting Drug Users	7,021	41.3	85.7	2.96
4. Hijra/Transgender People	-	-	-	-
5. Migrants	1,25,834	-	-	0.78
6. Truckers	85,000	-	-	0
7. Prison inmates	1,90,301	40	30.8	1.58

### C. HIV/AIDS related knowledge, stigma and high-risk behaviour in general population (2019-21)

Indicator	Male	Female	Total
1. Adults (15-49 yrs) with comprehensive knowledge about HIV/AIDS (%)	26.2	18.7	-
2. Youth (15-24 yrs) with comprehensive knowledge about HIV/AIDS (%)	23.7	17.3	-
3. Adults willing to care for a relative with HIV/AIDS in own home (%)	73.9	71.5	-
4. Adults willing to buy fresh vegetables from a shopkeeper or vendor who has HIV/AIDS (%)	60.7	59.6	-
5. Adults (15-49 yrs) who have had higher-risk sexual behaviour in the past 12 months (%)	5.5	0.5	-
5.1 Condom use during last higher-risk intercourse (%)	56.9	40.5	-
6. Youth (15-24 yrs) who have had higher-risk sexual behaviour in the past 12 months (%)	10.2	1.0	-
6.1 Condom use during last higher-risk intercourse (%)	51.6	50.0	-

## 2. Progress on 95-95-95 (2021-22)



### 3. Prevention of new HIV infections among general population

#### A. Information, Education, Communication, Youth and Mainstreaming

Indicator	2021-22
1. Schools with operational Adolescent Education Program (AEP)	-
2. Colleges with operational Red Ribbon Clubs (RRC)	660
3. Persons trained under mainstreaming	24,535

#### B. Sexually Transmitted Infections (STI)/Reproductive Tract Infections (RTI) Management at DSRCs

Indicator	2021-22			
1. NACO Supported Designated STI/RTI Clinics (DSRC)	66			
	Male	Female	TG	Total
2. Clients managed	-	-	-	4,31,442
3. RPR Tests conducted	60,974	1,63,938	107	2,25,019
4. Syphilis seropositivity (%)	0.80	0.16	2.80	0.33

### 4. Prevention of new HIV infections among high-risk group and bridge population

#### A. Targeted Interventions (TI) and Opioid Substitution Therapy (OST)

Indicator	2021-22
1. Targeted Interventions	68
2. OST centres	17
3. Employer Led Model Interventions	91

#### B. Female Sex Workers

Indicator	2021-22
1. Estimated size	28,418
2. Coverage (%)	>=95
3. Condoms distributed	80,48,501
4. Tested for HIV (April 2021 - September 2021)	34,178
4.1. HIV sero-positive (%)	0.09
4.1.1. Linked to ART	25
5. Tested for HIV (October 2021 - March 2022)	36,183
5.1. HIV sero-positive (%)	0.06
5.1.1. Linked to ART	22
6. Clinic Visits	1,30,036
7. STI/RTI treated	3,388
8. Presumptive treatment	3,441

#### C. Men who have Sex with Men

Indicator	2021-22
1. Estimated size	13,343
2. Coverage (%)	>=95
3. Condoms distributed	22,12,356
4. Tested for HIV (April 2021 - September 2021)	12,131
4.1. HIV sero-positive (%)	0.32
4.1.1. Linked to ART	37
5. Tested for HIV (October 2021 - March 2022)	12,959
5.1. HIV sero-positive (%)	0.32
5.1.1. Linked to ART	37
6. Clinic Visits	47,520
7. STI/RTI treated	597
8. Presumptive treatment	599

#### D. Injecting Drug Users

Indicator	2021-22
1. Estimated size	7,021
2. Coverage (%)	>=95
3. Needles distributed	14,35,619
4. Syringes distributed	14,20,682
5. On OST	1,591
6. Tested for HIV (April 2021 - September 2021)	7,566
6.1. HIV sero-positive (%)	0.94
6.1.1. Linked to ART	51
7. Tested for HIV (October 2021 - March 2022)	8,097
7.1. HIV sero-positive (%)	0.53
7.1.1. Linked to ART	30

#### E. Hijra/Transgender people

Indicator	2021-22
1. Estimated size	-
2. Coverage (%)	-
3. Condoms distributed	91,545
4. Tested for HIV (April 2021 - September 2021)	616
4.1. HIV sero-positive (%)	0.32
4.1.1. Linked to ART	1
5. Tested for HIV (October 2021 - March 2022)	595
5.1. HIV sero-positive (%)	0.50
5.1.1. Put on ART	3
6. Clinic Visits	2,326
7. STI / RTI treated	16
8. Presumptive treatment	16

#### F. Migrants

Indicator	2021-22
1. Estimated size	1,25,834
2. Coverage (%)	>=95
3. Tested for HIV	28,900
3.1. HIV sero-positive (%)	0.04
3.2. Linked to ART	8

#### G. Truckers

Indicator	2021-22
1. Estimated size	85,000
2. Coverage (%)	67
3. Tested for HIV	21,155
3.1. HIV sero-positive (%)	0.09
3.2. On ART	13

#### H. Prison Inmates

Indicator	2021-22
1. Total prisons	131
2. Prisons covered under programme	130
3. Total inmates admitted	1,58,793
4. Inmates Covered(%)	89
5. Tested for HIV	1,38,035
5.1. HIV sero-positive (%)	0.17
5.2. On ART (%)	90

#### I. Link Worker Scheme

Indicator	2021-22
1. Districts covered under scheme	9
2. Vulnerable population covered	1,24,243
3. Tested for HIV	59,858
3.1. HIV sero-positive (%)	0.10
3.2. Linked to ART (%)	91.53

## J. Opioid Substitution Therapy

Indicator	2021-22
1. OST Centres	17
1.1. OSTC in Public Health Settings	17
1.2. OSTC in NGO Settings	-
1.3 No. of Satellite OST Centres	-
2. IDU on OST	1,591

## 5. Early detection of HIV infected people

### A. HIV Counselling and Testing Services (HCTS)

Indicator	2021-22
1. ICTC facilities	1,845
1.1. Stand-alone	199
1.2. Facility integrated (Govt)	1,436
1.3. Facility integrated (PPP)	55
1.4. CBS	155

### B. HIV Testing among Vulnerable Population (Excluding Pregnant Women)

Indicator	2021-22			
	Male	Female	TG	Total
1. Tested for HIV	6,37,175	5,40,719	3,500	11,81,394
2. Found HIV Positive among tested	2,786	1,173	15	3,974
3. HIV sero-positivity (%) among tested	0.44	0.22	0.43	0.34
4. Spouse/sexual partner testing of HIV positive people identified	826	863	5	1,694

## 6. Initiation and retention on ART of HIV infected people

### A. Treatment Facilities

Indicator	2021-22
1. ART Centres	19
2. Centre of Excellence	
2.1. Centre of Excellence (Adult)	-
2.2. Centre of Excellence (Paediatric)	-
3. Link ART Centres	36
4. Care Support Centres	11

### B. Treatment Uptake

Indicator	2021-22			
	Male	Female	TG	Total
1. HIV positive cases diagnosed (At ICTC)	2,786	1,448	15	4,249
2. New PLHIV Registered at ART center	2,693	1,411	13	4,117
2.1 Initiated on ART	2,535	1,359	12	3,906
3. PLHIV alive and on ART	19,663	15,348	96	35,107
4. 12 months retention on ART (%)				80.01
5. Lost to follow-up cases	3,489	2,186	30	5,705

## 7. Viral Suppression and laboratories

### A. Laboratory facilities and service uptake

Indicator	2021-22
1. Viral load laboratories	1
1.1 Accredited Viral load laboratories	-
2. Viral load testing conducted	22,716
2.1. Virally suppressed (%)	77
3. National reference laboratories (NRL)	-
3.1 Accredited NRL	-
4. State reference laboratories (SRL)	4
4.1 Accredited SRL	1
5. CD4 testing conducted	19,868
6. External Quality Assessment of ICTC	
6.1 Average Participation (%)	70.67
6.2. Average Discordance (%)	0.00
7. Quality Assurance Scheme for Basic Composite Medical Laboratories (Entry Level)- M(EL)T	
7.1 No. of ICTCs certified for M(EL)T certification	-

## 8. Elimination of mother to child transmission of HIV & Syphilis

### A. HIV

Indicator	2021-22
1. Estimated pregnant women (PW)	22,23,030
2. HIV testing among PW	15,77,818
3. HIV sero-positivity (%) among tested	0.02
4. HIV Positive PW (old + new detections)	508
4.1 On life-long ART	503
5. Live births among HIV positive PW	468
5.1 Babies given ARV Prophylaxis (%)	99.79
6. Babies tested HIV (6 week- 6 month)	621
6.1 Babies confirmed HIV Positive (6 week- 6 month)	5
7. HIV exposed babies at 18 months	
7.1 HIV exposed babies tested at 18 month	438
7.2 Babies confirmed HIV positive at 18 months	19
8. HIV positive babies initiated on ART	25

### B. Syphilis

Indicator	2021-22
1. Estimated pregnant women (PW)	22,23,030
2. Syphilis testing among PW	12,71,529
3. Sero-positivity (%) among tested	0.04
4. Put on treatment	546

## 9. Elimination of HIV/AIDS related Stigma and Discrimination

### A. HIV/AIDS Prevention & Control Act (2017)

Indicator	2021-22
1. State rules notified for HIV/AIDS Prevention and Control Act (2017)	Yes
2. State designated/appointed ombudsman for HIV/AIDS Prevention and Control Act (2017)	Yes

## 10. HIV-TB Co-morbidities

## A. HRG and Bridge Population

Indicator								2021-22
	Quarter	FSW	MSW	IDU	TG	Migrants	Truckers	Total
Screened for TB	Quarter 1	28,248	9,559	6,368	556	9,891	6,932	61,554
	Quarter 2	34,822	12,734	8,261	620	24,389	14,052	94,878
	Quarter 3	35,437	12,166	7,699	348	22,770	21,019	99,439
	Quarter 4	37,738	14,500	7,919	648	30,110	22,621	1,13,536
Tested for TB	Quarter 1	105	50	33	-	70	8	266
	Quarter 2	262	92	221	4	4	8	591
	Quarter 3	326	110	161	5	30	16	648
	Quarter 4	190	77	180	1	38	29	515
Diagnosed with TB	Quarter 1	3	2	1	-	-	-	6
	Quarter 2	7	4	7	-	1	1	20
	Quarter 3	4	2	2	-	4	-	12
	Quarter 4	3	4	2	-	1	-	10
Initiated on TB treatment	Quarter 1	3	2	1	-	-	-	6
	Quarter 2	7	4	7	-	1	1	20
	Quarter 3	3	2	2	-	4	-	11
	Quarter 4	3	4	2	-	1	-	10

## B. HIV-TB Cross-Referral

Indicator	2021-22
1. In referral from TB program	37,914
1.1. HIV sero-positive (%)	1.92
1.2. ICTC clients referred to NTEP	19,319

## C. HIV-TB Coinfected at ART Centre

Indicator							2021-22	
	PLHIV attending ART Centre	PLHIV underwent 4S screening	PLHIV with presumptive TB	PLHIV tested for TB	PLHIV diagnosed with TB	PLHIV initiated on IPT	Co-infected enrolled at ARTc	Co-infected initiated on ART
Apr-21	11,602	11,234	774	681	33	136		
May-21	10,042	9,915	683	597	39	198		
Jun-21	11,356	10,860	544	455	84	263		
Jul-21	13,658	13,263	884	781	134	439		
Aug-21	14,379	14,162	929	830	119	216		
Sep-21	13,524	12,898	1,058	942	107	202		
Oct-21	13,321	12,662	974	879	78	203		
Nov-21	12,832	11,786	1,049	923	88	219		
Dec-21	14,531	13,399	1,190	993	89	229		
Jan-22	13,884	13,771	1,209	1,123	114	433		
Feb-22	12,328	12,002	881	776	85	392		
Mar-22	13,351	13,351	903	841	99	317		
April 2021-March 2022							1,334	1,273



## 11. Scorecard

State/UT Name		Madhya Pradesh
Overall Rank		8
IEC & MS	Frequency of Social Media updates (G= ≥60, Y=40-59, R=<40)	
	Status of AEP integration in state School curriculum (G=Yes, R=No)	
	Status of SCA (G= At least one meeting held since 2017, R= other than G)	
	Status of State Rules (G= Notified, R= Not notified)	
	Status of Ombudsman (G= Appointed, R=Not appointed)	
	Rank	5
TI	Facilities onboarded (G=≥95%, Y= 90-94%, R=<90%)	
	Coverage against target in contract (G=≥95%, Y= 90-94%, R=<90%)	
	HRG & BP living with HIV on ART (G=≥95%, Y= 90-94%, R=<90%)	
	IDU on OST (G=≥95%, Y= 90-94%, R=<90%)	
	Rank	11
BSD	Percentage of PLHIV who know their status (G=≥95%, Y= 80-94%, R=<80%)	
	HIV testing against target-GC ((G=≥95%, Y= 80-94%, R=<80%)	
	HIV testing against target-PW (G=≥95%, Y= 80-94%, R=<80%)	
	Percentage of Pregnant women who initiated ART (G=≥95%, Y= 80-94%, R=<80%)	
	Percentage of TB suspected cases referred to NTEP (G=≥95%, Y= 80-94%, R=<80%)	
	Clients managed at DSRC against the target (G=≥95%, Y= 80-94%, R=<80%)	
	Percentage of pregnant women tested for Syphilis (G=≥95%, Y= 80-94%, R=<80%)	
	Rank	2
CST	ART Initiation (Current FY) (G=≥95%, Y= 80-94%, R=<80%)	
	LFU rate among new ART initiation (G=<2%, Y= 2-4%, R=≥5%)	
	PLHIV put on ART during the FY against target (G=≥95%, Y= 80-94%, R=<80%)	
	Status on establishment of CSC (G=≥95%, Y= 80-94%, R=<80%)	NA
	Rank	17
LS	VL Suppression Rate (Current FY) (G=≥95%, Y= 85-94%, R=<85%)	
	% of SRL accredited (G=100%, Y= 80-99%, R=<80%)	
	% Participation of ICTCs in Re-testing (G=≥95%, Y= 85-94, R=<85%)	
	Rank	31
SI	% of NACP facilities active in SOCH (G=≥90%, Y= 75-89%, R=<75%)	
	Status of State Data Management Committee (G=one meeting held, Y= no meeting held, R= not constituted)	
	Status of finalized Priority Areas for Operational Research and Evaluation (G= 4, Y= 3, R= <3)	
	Rank	14
Finance	Expenditure with respect to funds released during FY 2021-22 (G=≥90%, Y= 85-89%, R=<85%)	
	Submission of Audit Report after approval of EC/GB for the preceding year (G= by 30th June, Y= 30th Sept, R= beyond 30th Sept 2021)	
	Submission of Utilization Certificate (in prescribed format GFR 12A) for the previous financial year (G= by 30th June, Y= 30th Sept, R= beyond 30th Sept 2021)	
	Rank	5
SCM	Report Submission (BSD-SCM Report) (G=≥90%, Y= 75-89%, R=<75%)	

Green=3 Marks

Yellow=2Marks

Red=1 Mark

No Colour=Not Applicable

A thick red ribbon is draped across the page, starting from the bottom left, looping upwards and to the right, and then looping back down and to the left. The background is a gradient of yellow and orange with faint, concentric circular lines.

# FACT SHEET

## MAHARASHTRA

# MAHARASHTRA

## 1. Status of HIV/AIDS Epidemic

### A. Epidemic Estimates (2021)

Indicator	Male	Female	Total
1. IPR	-	-	1.37
2. IMR	-	-	0.59
3. Adult (15-49 yrs) HIV Prevalence (%)	0.34	0.32	0.33
4. Estimated people living with HIV	2,13,995	1,80,083	3,94,078
5. ART coverage (%)	63.7	78	70
6. Estimated children living with HIV	5,377	4,718	10,095
7. Annual new HIV infections	2,837	2,573	5,410
8. Annual AIDS-related deaths (ARD)	4,865	969	5,834
9. Change in annual new HIV infections since 2010 (%)	-58.0	-53.12	-55.81
10. Change in annual ARD since 2010(%)	-80.5	-92.80	-84.83
11. EMTCT need	-	2,667	2,667


### B. High risk population size (2009), safe practices (2015) and prevalence (2021)

Population Group	Estimates Size	Condom Use (%)	New Needle/ Syringe use (%)	HIV Prevalence (%)
1. Female Sex Workers	81,320	80.1	11.3	2.54
2. Men who have sex with men	33,441	67.7	20.1	4.18
3. Injecting Drug Users	964	48.2	70.4	18.41
4. Hijra/Transgender People	7,114	-	-	6
5. Migrants	13,74,914	-	-	0.13
6. Truckers	2,05,000	-	-	0.4
7. Prison inmates	1,47,481	55.1	8.3	1.13

### C. HIV/AIDS related knowledge, stigma and high-risk behaviour in general population (2019-21)

Indicator	Male	Female	Total
1. Adults (15-49 yrs) with comprehensive knowledge about HIV/AIDS (%)	42.6	34.4	-
2. Youth (15-24 yrs) with comprehensive knowledge about HIV/AIDS (%)	37.2	35.2	-
3. Adults willing to care for a relative with HIV/AIDS in own home (%)	78.8	75.4	-
4. Adults willing to buy fresh vegetables from a shopkeeper or vendor who has HIV/AIDS (%)	74.1	71.2	-
5. Adults (15-49 yrs) who have had higher-risk sexual behaviour in the past 12 months (%)	4.4	0.4	-
5.1 Condom use during last higher-risk intercourse (%)	86.3	88.7	-
6. Youth (15-24 yrs) who have had higher-risk sexual behaviour in the past 12 months (%)	6.1	0.1	-
6.1 Condom use during last higher-risk intercourse (%)	91.2	100.0	-

## 2. Progress on 95-95-95 (2021-22)



Indicator	Male	Female	Total
1. Estimated PLHIV size (2021)	2,13,995	1,80,083	3,94,078
2. PLHIV who know their HIV Status	1,77,128	1,70,281	3,47,409
3. PLHIV who know their HIV status and are on ART	1,26,999	1,31,427	2,58,426
4. PLHIV who are on ART and tested for their viral load	1,03,320	1,05,461	2,08,781
5. PLHIV who are virally suppressed	90,626	93,829	1,84,455

### 3. Prevention of new HIV infections among general population

#### A. Information, Education, Communication, Youth and Mainstreaming

Indicator	2021-22
1. Schools with operational Adolescent Education Program (AEP)	183
2. Colleges with operational Red Ribbon Clubs (RRC)	1,170
3. Persons trained under mainstreaming	20,092

#### B. Sexually Transmitted Infections (STI)/Reproductive Tract Infections (RTI) Management at DSRCs

Indicator	2021-22			
1. NACO Supported Designated STI/RTI Clinics (DSRC)	80			
	Male	Female	TG	Total
2. Clients managed	-	-	-	5,81,118
3. RPR Tests conducted	1,75,304	2,92,766	1,401	4,69,471
4. Syphilis seropositivity (%)	0.79	0.20	7.21	0.44

### 4. Prevention of new HIV infections among high-risk group and bridge population

#### A. Targeted Interventions (TI) and Opioid Substitution Therapy (OST)

Indicator	2021-22
1. Targeted Interventions	172
2. OST centres	2
3. Employer Led Model Interventions	126

#### B. Female Sex Workers

Indicator	2021-22
1. Estimated size	81,320
2. Coverage (%)	>=95
3. Condoms distributed	2,12,57,199
4. Tested for HIV (April 2021 - September 2021)	64,603
4.1. HIV sero-positive (%)	0.15
4.1.1. Linked to ART	98
5. Tested for HIV (October 2021 - March 2022)	60,870
5.1. HIV sero-positive (%)	0.12
5.1.1. Linked to ART	75
6. Clinic Visits	2,62,756
7. STI/RTI treated	3,830
8. Presumptive treatment	9,370

#### C. Men who have Sex with Men

Indicator	2021-22
1. Estimated size	33,441
2. Coverage (%)	84
3. Condoms distributed	61,83,091
4. Tested for HIV (April 2021 - September 2021)	22,765
4.1. HIV sero-positive (%)	0.32
4.1.1. Linked to ART	71
5. Tested for HIV (October 2021 - March 2022)	21,067
5.1. HIV sero-positive (%)	0.28
5.1.1. Linked to ART	59
6. Clinic Visits	93,682
7. STI/RTI treated	1,056
8. Presumptive treatment	3,923

### D. Injecting Drug Users

Indicator	2021-22
1. Estimated size	964
2. Coverage (%)	87
3. Needles distributed	40,330
4. Syringes distributed	21,673
5. On OST	150
6. Tested for HIV (April 2021 - September 2021)	489
6.1. HIV sero-positive (%)	0.41
6.1.1. Linked to ART	2
7. Tested for HIV (October 2021 - March 2022)	727
7.1. HIV sero-positive (%)	0.00
7.1.1. Linked to ART	-

### E. Hijra/Transgender people

Indicator	2021-22
1. Estimated size	7,114
2. Coverage (%)	>=95
3. Condoms distributed	34,89,549
4. Tested for HIV (April 2021 - September 2021)	6,289
4.1. HIV sero-positive (%)	0.57
4.1.1. Linked to ART	34
5. Tested for HIV (October 2021 - March 2022)	6,925
5.1. HIV sero-positive (%)	0.42
5.1.1. Put on ART	27
6. Clinic Visits	31,115
7. STI / RTI treated	546
8. Presumptive treatment	1,046

### F. Migrants

Indicator	2021-22
1. Estimated size	13,74,914
2. Coverage (%)	>=95
3. Tested for HIV	2,44,537
3.1. HIV sero-positive (%)	0.15
3.2. Linked to ART	356

### G. Truckers

Indicator	2021-22
1. Estimated size	2,05,000
2. Coverage (%)	80
3. Tested for HIV	41,132
3.1. HIV sero-positive (%)	0.10
3.2. On ART	41

### H. Prison Inmates

Indicator	2021-22
1. Total prisons	64
2. Prisons covered under programme	62
3. Total inmates admitted	1,03,688
4. Inmates Covered(%)	44
5. Tested for HIV	41,693
5.1. HIV sero-positive (%)	0.40
5.2. On ART (%)	80

### I. Link Worker Scheme

Indicator	2021-22
1. Districts covered under scheme	21
2. Vulnerable population covered	4,07,017
3. Tested for HIV	2,89,034
3.1. HIV sero-positive (%)	0.02
3.2. Linked to ART (%)	96.97

## J. Opioid Substitution Therapy

Indicator	2021-22
1. OST Centres	2
1.1. OSTC in Public Health Settings	-
1.2. OSTC in NGO Settings	2
1.3 No. of Satellite OST Centres	-
2. IDU on OST	150

## 5. Early detection of HIV infected people

### A. HIV Counselling and Testing Services (HCTS)

Indicator	2021-22
1. ICTC facilities	4,660
1.1. Stand-alone	565
1.2. Facility integrated (Govt)	2,598
1.3. Facility integrated (PPP)	1,344
1.4. CBS	153

### B. HIV Testing among Vulnerable Population (Excluding Pregnant Women)

Indicator	2021-22			
	Male	Female	TG	Total
1. Tested for HIV	19,34,114	14,41,653	21,284	33,97,052
2. Found HIV Positive among tested	8,468	5,476	138	14,082
3. HIV sero-positivity (%) among tested	0.44	0.38	0.65	0.41
4. Spouse/sexual partner testing of HIV positive people identified	4,424	2,954	48	7,426

## 6. Initiation and retention on ART of HIV infected people

### A. Treatment Facilities

Indicator	2021-22
1. ART Centres	95
2. Centre of Excellence	
2.1. Centre of Excellence (Adult)	1
2.2. Centre of Excellence (Paediatric)	1
3. Link ART Centres	182
4. Care Support Centres	44

### B. Treatment Uptake

Indicator	2021-22			
	Male	Female	TG	Total
1. HIV positive cases diagnosed (At ICTC)	8,468	6,192	138	14,798
2. New PLHIV Registered at ART center	8,412	6,128	142	14,682
2.1 Initiated on ART	7,983	5,912	134	14,029
3. PLHIV alive and on ART	1,36,272	1,39,986	909	2,77,168
4. 12 months retention on ART (%)				80.71
5. Lost to follow-up cases	27,858	20,161	331	48,350

## 7. Viral Suppression and laboratories

### A. Laboratory facilities and service uptake

Indicator	2021-22
1. Viral load laboratories	13
1.1 Accredited Viral load laboratories	6
2. Viral load testing conducted	2,09,602
2.1. Virally suppressed (%)	88
3. National reference laboratories (NRL)	2
3.1 Accredited NRL	2
4. State reference laboratories (SRL)	16
4.1 Accredited SRL	16
5. CD4 testing conducted	1,95,977
6. External Quality Assessment of ICTC	
6.1 Average Participation (%)	99.44
6.2. Average Discordance (%)	0.05
7. Quality Assurance Scheme for Basic Composite Medical Laboratories (Entry Level)- M(EL)T	
7.1 No. of ICTCs certified for M(EL)T certification	15.00

## 8. Elimination of mother to child transmission of HIV & Syphilis

### A. HIV

Indicator	2021-22
1. Estimated pregnant women (PW)	20,86,620
2. HIV testing among PW	23,53,557
3. HIV sero-positivity (%) among tested	0.03
4. HIV Positive PW (old + new detections)	1,733
4.1 On life-long ART	1,607
5. Live births among HIV positive PW	1,631
5.1 Babies given ARV Prophylaxis (%)	95.22
6. Babies tested HIV (6 week- 6 month)	2,237
6.1 Babies confirmed HIV Positive (6 week- 6 month)	36
7. HIV exposed babies at 18 months	
7.1 HIV exposed babies tested at 18 month	1,272
7.2 Babies confirmed HIV positive at 18 months	32
8. HIV positive babies initiated on ART	66

### B. Syphilis

Indicator	2021-22
1. Estimated pregnant women (PW)	20,86,620
2. Syphilis testing among PW	11,03,775
3. Sero-positivity (%) among tested	0.02
4. Put on treatment	181

## 9. Elimination of HIV/AIDS related Stigma and Discrimination

### A. HIV/AIDS Prevention & Control Act (2017)

Indicator	2021-22
1. State rules notified for HIV/AIDS Prevention and Control Act (2017)	No
2. State designated/appointed ombudsman for HIV/AIDS Prevention and Control Act (2017)	No

## 10. HIV-TB Co-morbidities

### A. HRG and Bridge Population

Indicator								2021-22
	Quarter	FSW	MSW	IDU	TG	Migrants	Truckers	Total
Screened for TB	Quarter 1	56,517	17,572	351	6,540	62,647	31,581	1,75,208
	Quarter 2	65,852	22,296	439	7,710	96,753	40,290	2,33,340
	Quarter 3	67,052	22,849	562	8,012	98,930	38,645	2,36,050
	Quarter 4	67,878	21,932	658	7,949	85,535	37,607	2,21,559
Tested for TB	Quarter 1	601	248	10	38	724	163	1,784
	Quarter 2	903	393	4	284	1,082	166	2,832
	Quarter 3	854	638	7	514	732	262	3,007
	Quarter 4	988	298	7	33	551	245	2,122
Diagnosed with TB	Quarter 1	8	1	1	1	8	4	23
	Quarter 2	15	3	4	-	20	-	42
	Quarter 3	4	2	1	1	16	2	26
	Quarter 4	8	1	1	-	22	12	44
Initiated on TB treatment	Quarter 1	8	1	1	1	7	4	22
	Quarter 2	15	3	4	-	21	-	43
	Quarter 3	4	1	1	1	16	2	25
	Quarter 4	5	2	1	-	22	2	32

### B. HIV-TB Cross-Referral

Indicator		2021-22
1. In referral from TB program		76,767
1.1. HIV sero-positive (%)		0.80
1.2. ICTC clients referred to NTEP		2,05,820

### C. HIV-TB Coinfected at ART Centre

Indicator								2021-22
	PLHIV attending ART Centre	PLHIV underwent 4S screening	PLHIV with presumptive TB	PLHIV tested for TB	PLHIV diagnosed with TB	PLHIV initiated on IPT	Co-infected enrolled at ARTc	Co-infected initiated on ART
Apr-21	1,52,874	1,47,164	7,110	6,842	264	3,282		
May-21	1,49,170	1,44,530	6,920	6,696	270	3,299		
Jun-21	1,83,774	1,72,814	8,038	7,837	384	4,160		
Jul-21	1,92,804	1,86,238	9,417	9,086	414	3,843		
Aug-21	1,84,218	1,78,530	9,407	9,116	446	4,350		
Sep-21	1,87,791	1,81,510	9,909	9,513	435	4,684		
Oct-21	1,82,995	1,77,471	10,023	9,796	460	4,024		
Nov-21	1,62,502	1,56,860	9,267	8,998	377	2,249		
Dec-21	1,73,304	1,67,604	12,406	9,767	459	2,622		
Jan-22	1,64,356	1,58,640	10,779	8,812	428	3,212		
Feb-22	1,51,866	1,47,675	14,816	8,179	419	2,707		
Mar-22	1,62,590	1,56,585	16,124	8,681	452	3,034		
April 2021-March 2022							5,712	5,514

## 11. Scorecard

State/UT Name		Maharashtra
Overall Rank		14
IEC & MS	Frequency of Social Media updates (G= ≥60, Y=40-59, R=<40)	
	Status of AEP integration in state School curriculum (G=Yes, R=No)	
	Status of SCA (G= At least one meeting held since 2017, R= other than G)	
	Status of State Rules (G= Notified, R= Not notified)	
	Status of Ombudsman (G= Appointed, R=Not appointed)	
	Rank	34
TI	Facilities onboarded (G=≥95%, Y= 90-94%, R=<90%)	
	Coverage against target in contract (G=≥95%, Y= 90-94%, R=<90%)	
	HRG & BP living with HIV on ART (G=≥95%, Y= 90-94%, R=<90%)	
	IDU on OST (G=≥95%, Y= 90-94%, R=<90%)	
	Rank	3
BSD	Percentage of PLHIV who know their status (G=≥95%, Y= 80-94%, R=<80%)	
	HIV testing against target-GC ((G=≥95%, Y= 80-94%, R=<80%)	
	HIV testing against target-PW (G=≥95%, Y= 80-94%, R=<80%)	
	Percentage of Pregnant women who initiated ART (G=≥95%, Y= 80-94%, R=<80%)	
	Percentage of TB suspected cases referred to NTEP (G=≥95%, Y= 80-94%, R=<80%)	
	Clients managed at DSRC against the target (G=≥95%, Y= 80-94%, R=<80%)	
	Percentage of pregnant women tested for Syphilis (G=≥95%, Y= 80-94%, R=<80%)	
	Rank	11
CST	ART Initiation (Current FY) (G=≥95%, Y= 80-94%, R=<80%)	
	LFU rate among new ART initiation (G=<2%, Y= 2-4%, R=≥5%)	
	PLHIV put on ART during the FY against target (G=≥95%, Y= 80-94%, R=<80%)	
	Status on establishment of CSC (G=≥95%, Y= 80-94%, R=<80%)	NA
	Rank	1
LS	VL Suppression Rate (Current FY) (G=≥95%, Y= 85-94%, R=<85%)	
	% of SRL accredited (G=100%, Y= 80-99%, R=<80%)	
	% Participation of ICTCs in Re-testing (G=≥95%, Y= 85-94, R=<85%)	
	Rank	2
SI	% of NACP facilities active in SOCH (G=≥90%, Y= 75-89%, R=<75%)	
	Status of State Data Management Committee (G=one meeting held, Y= no meeting held, R= not constituted)	
	Status of finalized Priority Areas for Operational Research and Evaluation (G= 4, Y= 3, R= <3)	
	Rank	4
Finance	Expenditure with respect to funds released during FY 2021-22 (G=≥90%, Y= 85-89%, R=<85%)	
	Submission of Audit Report after approval of EC/GB for the preceding year (G= by 30th June, Y= 30th Sept, R= beyond 30th Sept 2021)	
	Submission of Utilization Certificate (in prescribed format GFR 12A) for the previous financial year (G= by 30th June, Y= 30th Sept, R= beyond 30th Sept 2021)	
	Rank	5
SCM	Report Submission (BSD-SCM Report) (G=≥90%, Y= 75-89%, R=<75%)	

Green=3 Marks

Yellow=2Marks

Red=1 Mark

No Colour=Not Applicable



A thick red ribbon is draped across the page, starting from the bottom left, looping upwards and to the right, and then looping back down towards the right edge. The background is a gradient of yellow and orange with faint, concentric circular lines.

# FACT SHEET

## MANIPUR

## 1. Status of HIV/AIDS Epidemic

### A. Epidemic Estimates (2021)

Indicator	Male	Female	Total
1. IPR	-	-	3.49
2. IMR	-	-	0.94
3. Adult (15-49 yrs) HIV Prevalence (%)	1.07	1.04	1.05
4. Estimated people living with HIV	14,405	13,584	27,989
5. ART coverage (%)	49.4	55	52
6. Estimated children living with HIV	854	811	1,665
7. Annual new HIV infections	501	477	978
8. Annual AIDS-related deaths (ARD)	504	337	841
9. Change in annual new HIV infections since 2010 (%)	-36.8	-32.72	-34.89
10. Change in annual ARD since 2010(%)	-62.5	-66.30	-64.14
11. EMTCT need	-	366	366


### B. High risk population size (2009), safe practices (2015) and prevalence (2021)

Population Group	Estimates Size	Condom Use (%)	New Needle/ Syringe use (%)	HIV Prevalence (%)
1. Female Sex Workers	5,703	54.4	28.5	1.13
2. Men who have sex with men	1,257	-	-	9.43
3. Injecting Drug Users	20,392	53.2	82.8	8.84
4. Hijra/Transgender People	799	-	-	-
5. Migrants	16,000	-	-	-
6. Truckers	-	-	-	-
7. Prison inmates	2,392	50	25	2.26

### C. HIV/AIDS related knowledge, stigma and high-risk behaviour in general population (2019-21)

Indicator	Male	Female	Total
1. Adults (15-49 yrs) with comprehensive knowledge about HIV/AIDS (%)	55.9	50.6	-
2. Youth (15-24 yrs) with comprehensive knowledge about HIV/AIDS (%)	48.4	48.7	-
3. Adults willing to care for a relative with HIV/AIDS in own home (%)	87	82	-
4. Adults willing to buy fresh vegetables from a shopkeeper or vendor who has HIV/AIDS (%)	85.9	85.4	-
5. Adults (15-49 yrs) who have had higher-risk sexual behaviour in the past 12 months (%)	3	0.1	-
5.1 Condom use during last higher-risk intercourse (%)	24.8	0	-
6. Youth (15-24 yrs) who have had higher-risk sexual behaviour in the past 12 months (%)	4.5	0	-
6.1 Condom use during last higher-risk intercourse (%)	14.3	NA	-

## 2. Progress on 95-95-95 (2021-22)



Indicator	Male	Female	Total
1. Estimated PLHIV size (2021)	14,405	13,584	27,989
2. PLHIV who know their HIV Status	7,951	7,851	15,802
3. PLHIV who know their HIV status and are on ART	6,670	7,062	13,732
4. PLHIV who are on ART and tested for their viral load	5,204	5,860	11,064
5. PLHIV who are virally suppressed	4,926	5,608	10,534

### 3. Prevention of new HIV infections among general population

#### A. Information, Education, Communication, Youth and Mainstreaming

Indicator	2021-22
1. Schools with operational Adolescent Education Program (AEP)	75
2. Colleges with operational Red Ribbon Clubs (RRC)	45
3. Persons trained under mainstreaming	1,340

#### B. Sexually Transmitted Infections (STI)/Reproductive Tract Infections (RTI) Management at DSRCs

Indicator	2021-22			
1. NACO Supported Designated STI/RTI Clinics (DSRC)	10			
	Male	Female	TG	Total
2. Clients managed	-	-	-	4,905
3. RPR Tests conducted	773	2,057	57	2,887
4. Syphilis seropositivity (%)	2.33	0.15	5.26	0.83

### 4. Prevention of new HIV infections among high-risk group and bridge population

#### A. Targeted Interventions (TI) and Opioid Substitution Therapy (OST)

Indicator	2021-22
1. Targeted Interventions	54
2. OST centres	52
3. Employer Led Model Interventions	-

#### B. Female Sex Workers

Indicator	2021-22
1. Estimated size	5,703
2. Coverage (%)	>=95
3. Condoms distributed	12,29,649
4. Tested for HIV (April 2021 - September 2021)	3,399
4.1. HIV sero-positive (%)	0.21
4.1.1. Linked to ART	7
5. Tested for HIV (October 2021 - March 2022)	4,720
5.1. HIV sero-positive (%)	0.06
5.1.1. Linked to ART	1
6. Clinic Visits	16,547
7. STI/RTI treated	47
8. Presumptive treatment	543

#### C. Men who have Sex with Men

Indicator	2021-22
1. Estimated size	1,257
2. Coverage (%)	>=95
3. Condoms distributed	2,35,426
4. Tested for HIV (April 2021 - September 2021)	749
4.1. HIV sero-positive (%)	0.27
4.1.1. Linked to ART	2
5. Tested for HIV (October 2021 - March 2022)	1,121
5.1. HIV sero-positive (%)	0.27
5.1.1. Linked to ART	3
6. Clinic Visits	4,638
7. STI/RTI treated	8
8. Presumptive treatment	130

### D. Injecting Drug Users

Indicator	2021-22
1. Estimated size	20,392
2. Coverage (%)	>=95
3. Needles distributed	52,36,998
4. Syringes distributed	52,67,127
5. On OST	4,111
6. Tested for HIV (April 2021 - September 2021)	12,908
6.1. HIV sero-positive (%)	0.24
6.1.1. Linked to ART	22
7. Tested for HIV (October 2021 - March 2022)	17,552
7.1. HIV sero-positive (%)	0.18
7.1.1. Linked to ART	27

### E. Hijra/Transgender people

Indicator	2021-22
1. Estimated size	799
2. Coverage (%)	18
3. Condoms distributed	11,053
4. Tested for HIV (April 2021 - September 2021)	74
4.1. HIV sero-positive (%)	0.00
4.1.1. Linked to ART	-
5. Tested for HIV (October 2021 - March 2022)	51
5.1. HIV sero-positive (%)	-
5.1.1. Put on ART	-
6. Clinic Visits	373
7. STI / RTI treated	0
8. Presumptive treatment	2

### F. Migrants

Indicator	2021-22
1. Estimated size	16,000
2. Coverage (%)	57
3. Tested for HIV	1,467
3.1. HIV sero-positive (%)	0.48
3.2. Linked to ART	4

### G. Truckers

Indicator	2021-22
1. Estimated size	-
2. Coverage (%)	-
3. Tested for HIV	-
3.1. HIV sero-positive (%)	-
3.2. On ART	-

### H. Prison Inmates

Indicator	2021-22
1. Total prisons	5
2. Prisons covered under programme	2
3. Total inmates admitted	1,956
4. Inmates Covered(%)	56
5. Tested for HIV	409
5.1. HIV sero-positive (%)	0.73
5.2. On ART (%)	100

### I. Link Worker Scheme

Indicator	2021-22
1. Districts covered under scheme	9
2. Vulnerable population covered	2,65,220
3. Tested for HIV	13,931
3.1. HIV sero-positive (%)	0.14
3.2. Linked to ART (%)	80.00

## J. Opioid Substitution Therapy

Indicator	2021-22
1. OST Centres	52
1.1. OSTC in Public Health Settings	19
1.2. OSTC in NGO Settings	7
1.3 No. of Satellite OST Centres	26
2. IDU on OST	4,111

## 5. Early detection of HIV infected people

### A. HIV Counselling and Testing Services (HCTS)

Indicator	2021-22
1. ICTC facilities	226
1.1. Stand-alone	64
1.2. Facility integrated (Govt)	82
1.3. Facility integrated (PPP)	13
1.4. CBS	67

### B. HIV Testing among Vulnerable Population (Excluding Pregnant Women)

Indicator	2021-22			
	Male	Female	TG	Total
1. Tested for HIV	52,050	26,742	2,119	80,911
2. Found HIV Positive among tested	429	248	11	688
3. HIV sero-positivity (%) among tested	0.82	0.93	0.52	0.85
4. Spouse/sexual partner testing of HIV positive people identified	107	127	7	241

## 6. Initiation and retention on ART of HIV infected people

### A. Treatment Facilities

Indicator	2021-22
1. ART Centres	13
2. Centre of Excellence	
2.1. Centre of Excellence (Adult)	1
2.2. Centre of Excellence (Paediatric)	1
3. Link ART Centres	15
4. Care Support Centres	4

### B. Treatment Uptake

Indicator	2021-22			
	Male	Female	TG	Total
1. HIV positive cases diagnosed (At ICTC)	429	286	11	726
2. New PLHIV Registered at ART center	461	307	11	779
2.1 Initiated on ART	437	295	10	742
3. PLHIV alive and on ART	7,119	7,424	102	14,645
4. 12 months retention on ART (%)				84.72
5. Lost to follow-up cases	986	636	9	1,631

## 7. Viral Suppression and laboratories

### A. Laboratory facilities and service uptake

Indicator	2021-22
1. Viral load laboratories	1
1.1 Accredited Viral load laboratories	1
2. Viral load testing conducted	9,373
2.1. Virally suppressed (%)	95
3. National reference laboratories (NRL)	1
3.1 Accredited NRL	1
4. State reference laboratories (SRL)	1
4.1 Accredited SRL	1
5. CD4 testing conducted	4,178
6. External Quality Assessment of ICTC	
6.1 Average Participation (%)	98.15
6.2. Average Discordance (%)	0.00
7. Quality Assurance Scheme for Basic Composite Medical Laboratories (Entry Level)- M(EL)T	
7.1 No. of ICTCs certified for M(EL)T certification	-

## 8. Elimination of mother to child transmission of HIV & Syphilis

### A. HIV

Indicator	2021-22
1. Estimated pregnant women (PW)	52,390
2. HIV testing among PW	31,571
3. HIV sero-positivity (%) among tested	0.12
4. HIV Positive PW (old + new detections)	104
4.1 On life-long ART	87
5. Live births among HIV positive PW	85
5.1 Babies given ARV Prophylaxis (%)	96.47
6. Babies tested HIV (6 week- 6 month)	106
6.1 Babies confirmed HIV Positive (6 week- 6 month)	-
7. HIV exposed babies at 18 months	
7.1 HIV exposed babies tested at 18 month	41
7.2 Babies confirmed HIV positive at 18 months	-
8. HIV positive babies initiated on ART	-

### B. Syphilis

Indicator	2021-22
1. Estimated pregnant women (PW)	52,390
2. Syphilis testing among PW	25,017
3. Sero-positivity (%) among tested	0.00
4. Put on treatment	-

## 9. Elimination of HIV/AIDS related Stigma and Discrimination

### A. HIV/AIDS Prevention & Control Act (2017)

Indicator	2021-22
1. State rules notified for HIV/AIDS Prevention and Control Act (2017)	Yes
2. State designated/appointed ombudsman for HIV/AIDS Prevention and Control Act (2017)	Yes

## 10. HIV-TB Co-morbidities

### A. HRG and Bridge Population

Indicator								2021-22
	Quarter	FSW	MSW	IDU	TG	Migrants	Truckers	Total
Screened for TB	Quarter 1	1,391	371	4,014	-	533	-	6,309
	Quarter 2	1,722	521	5,732	12	407	-	8,394
	Quarter 3	2,252	743	6,844	7	1,121	-	10,967
	Quarter 4	2,207	759	7,014	7	1,131	-	11,118
Tested for TB	Quarter 1	5	-	24	-	-	-	29
	Quarter 2	8	-	9	-	2	-	19
	Quarter 3	14	10	26	-	1	-	51
	Quarter 4	38	34	71	-	4	-	147
Diagnosed with TB	Quarter 1	-	-	2	-	-	-	2
	Quarter 2	-	-	-	-	1	-	1
	Quarter 3	-	-	2	-	-	-	2
	Quarter 4	-	-	1	-	-	-	1
Initiated on TB treatment	Quarter 1	-	-	2	-	-	-	2
	Quarter 2	-	-	-	-	1	-	1
	Quarter 3	-	-	2	-	-	-	2
	Quarter 4	-	-	1	-	-	-	1

### B. HIV-TB Cross-Referral

Indicator		2021-22
1. In referral from TB program		1,917
1.1. HIV sero-positive (%)		0.21
1.2. ICTC clients referred to NTEP		346

### C. HIV-TB Coinfected at ART Centre

Indicator								2021-22
	PLHIV attending ART Centre	PLHIV underwent 4S screening	PLHIV with presumptive TB	PLHIV tested for TB	PLHIV diagnosed with TB	PLHIV initiated on IPT	Co-infected enrolled at ARTc	Co-infected initiated on ART
Apr-21	10,777	10,777	61	61	9	777		
May-21	9,401	9,401	19	19	6	101		
Jun-21	6,190	6,190	23	23	5	79		
Jul-21	8,001	8,001	25	25	5	115		
Aug-21	7,402	7,398	31	31	6	134		
Sep-21	8,668	8,667	38	38	7	149		
Oct-21	9,345	9,345	52	52	9	118		
Nov-21	9,373	9,373	59	58	6	239		
Dec-21	9,565	9,565	49	48	6	212		
Jan-22	8,371	8,371	51	49	8	126		
Feb-22	8,377	8,377	48	48	3	190		
Mar-22	8,152	8,152	47	46	8	423		
April 2021-March 2022							112	106

## 11. Scorecard

State/UT Name		Manipur
Overall Rank		4
IEC & MS	Frequency of Social Media updates (G= ≥60, Y=40-59, R=<40)	
	Status of AEP integration in state School curriculum (G=Yes, R=No)	
	Status of SCA (G= At least one meeting held since 2017, R= other than G)	
	Status of State Rules (G= Notified, R= Not notified)	
	Status of Ombudsman (G= Appointed, R=Not appointed)	
	Rank	1
TI	Facilities onboarded (G=≥95%, Y= 90-94%, R=<90%)	
	Coverage against target in contract (G=≥95%, Y= 90-94%, R=<90%)	
	HRG & BP living with HIV on ART (G=≥95%, Y= 90-94%, R=<90%)	
	IDU on OST (G=≥95%, Y= 90-94%, R=<90%)	
	Rank	11
BSD	Percentage of PLHIV who know their status (G=≥95%, Y= 80-94%, R=<80%)	
	HIV testing against target-GC ((G=≥95%, Y= 80-94%, R=<80%)	
	HIV testing against target-PW (G=≥95%, Y= 80-94%, R=<80%)	
	Percentage of Pregnant women who initiated ART (G=≥95%, Y= 80-94%, R=<80%)	
	Percentage of TB suspected cases referred to NTEP (G=≥95%, Y= 80-94%, R=<80%)	
	Clients managed at DSRC against the target (G=≥95%, Y= 80-94%, R=<80%)	
	Percentage of pregnant women tested for Syphilis (G=≥95%, Y= 80-94%, R=<80%)	
	Rank	26
CST	ART Initiation (Current FY) (G=≥95%, Y= 80-94%, R=<80%)	
	LFU rate among new ART initiation (G=<2%, Y= 2-4%, R=≥5%)	
	PLHIV put on ART during the FY against target (G=≥95%, Y= 80-94%, R=<80%)	
	Status on establishment of CSC (G=≥95%, Y= 80-94%, R=<80%)	NA
	Rank	6
LS	VL Suppression Rate (Current FY) (G=≥95%, Y= 85-94%, R=<85%)	
	% of SRL accredited (G=100%, Y= 80-99%, R=<80%)	
	% Participation of ICTCs in Re-testing (G=≥95%, Y= 85-94, R=<85%)	
	Rank	1
SI	% of NACP facilities active in SOCH (G=≥90%, Y= 75-89%, R=<75%)	
	Status of State Data Management Committee (G=one meeting held, Y= no meeting held, R= not constituted)	
	Status of finalized Priority Areas for Operational Research and Evaluation (G= 4, Y= 3, R= <3)	
	Rank	4
Finance	Expenditure with respect to funds released during FY 2021-22 (G=≥90%, Y= 85-89%, R=<85%)	
	Submission of Audit Report after approval of EC/GB for the preceding year (G= by 30th June, Y= 30th Sept, R= beyond 30th Sept 2021)	
	Submission of Utilization Certificate (in prescribed format GFR 12A) for the previous financial year (G= by 30th June, Y= 30th Sept, R= beyond 30th Sept 2021)	
	Rank	23
SCM	Report Submission (BSD-SCM Report) (G=≥90%, Y= 75-89%, R=<75%)	

Green=3 Marks

Yellow=2Marks

Red=1 Mark

No Colour=Not Applicable

A thick red ribbon is draped across the page, starting from the bottom left, looping upwards and to the right, and then looping back down towards the bottom right. The background is a gradient of yellow and orange with faint, concentric circular lines.

# FACT SHEET

## MEGHALAYA



## 1. Status of HIV/AIDS Epidemic

### A. Epidemic Estimates (2021)

Indicator	Male	Female	Total
1. IPR	-	-	13.70
2. IMR	-	-	11.24
3. Adult (15-49 yrs) HIV Prevalence (%)	0.43	0.40	0.42
4. Estimated people living with HIV	4,499	4,193	8,692
5. ART coverage (%)	37.6	51	44
6. Estimated children living with HIV	176	171	347
7. Annual new HIV infections	613	578	1,191
8. Annual AIDS-related deaths (ARD)	47	26	73
9. Change in annual new HIV infections since 2010 (%)	200.5	244.05	221.02
10. Change in annual ARD since 2010(%)	42.4	8.33	30.36
11. EMTCT need	-	234	234


### B. High risk population size (2009), safe practices (2015) and prevalence (2021)

Population Group	Estimates Size	Condom Use (%)	New Needle/ Syringe use (%)	HIV Prevalence (%)
1. Female Sex Workers	1,357	51.5	40.2	10.92
2. Men who have sex with men	225	-	-	9.09
3. Injecting Drug Users	1,892	19.7	76.9	11.48
4. Hijra/Transgender People	-	-	-	-
5. Migrants	50,300	-	-	-
6. Truckers	4,150	-	-	-
7. Prison inmates	2,910	-	-	-

### C. HIV/AIDS related knowledge, stigma and high-risk behaviour in general population (2019-21)

Indicator	Male	Female	Total
1. Adults (15-49 yrs) with comprehensive knowledge about HIV/AIDS (%)	15.9	14.5	-
2. Youth (15-24 yrs) with comprehensive knowledge about HIV/AIDS (%)	14.3	13.4	-
3. Adults willing to care for a relative with HIV/AIDS in own home (%)	67.2	64.5	-
4. Adults willing to buy fresh vegetables from a shopkeeper or vendor who has HIV/AIDS (%)	37.5	27.3	-
5. Adults (15-49 yrs) who have had higher-risk sexual behaviour in the past 12 months (%)	2.6	1.1	-
5.1 Condom use during last higher-risk intercourse (%)	40.2	45.3	-
6. Youth (15-24 yrs) who have had higher-risk sexual behaviour in the past 12 months (%)	5.0	1.9	-
6.1 Condom use during last higher-risk intercourse (%)	40.7	46.2	-

## 2. Progress on 95-95-95 (2021-22)



### 3. Prevention of new HIV infections among general population

#### A. Information, Education, Communication, Youth and Mainstreaming

Indicator	2021-22
1. Schools with operational Adolescent Education Program (AEP)	200
2. Colleges with operational Red Ribbon Clubs (RRC)	67
3. Persons trained under mainstreaming	241

#### B. Sexually Transmitted Infections (STI)/Reproductive Tract Infections (RTI) Management at DSRCs

Indicator	2021-22			
1. NACO Supported Designated STI/RTI Clinics (DSRC)	10			
	Male	Female	TG	Total
2. Clients managed	-	-	-	10,447
3. RPR Tests conducted	4,864	5,435	3	10,302
4. Syphilis seropositivity (%)	7.18	5.59	100.00	6.37

### 4. Prevention of new HIV infections among high-risk group and bridge population

#### A. Targeted Interventions (TI) and Opioid Substitution Therapy (OST)

Indicator	2021-22
1. Targeted Interventions	11
2. OST centres	7
3. Employer Led Model Interventions	-

#### B. Female Sex Workers

Indicator	2020-21
1. Estimated size	1,357
2. Coverage (%)	>=95
3. Condoms distributed	2,45,714
4. Tested for HIV (April 2021 - September 2021)	1,009
4.1. HIV sero-positive (%)	0.99
4.1.1. Linked to ART	5
5. Tested for HIV (October 2021 - March 2022)	1,282
5.1. HIV sero-positive (%)	0.70
5.1.1. Linked to ART	4
6. Clinic Visits	4,886
7. STI/RTI treated	17
8. Presumptive treatment	496

#### C. Men who have Sex with Men

Indicator	2021-22
1. Estimated size	225
2. Coverage (%)	92
3. Condoms distributed	21,393
4. Tested for HIV (April 2021 - September 2021)	93
4.1. HIV sero-positive (%)	1.08
4.1.1. Linked to ART	0
5. Tested for HIV (October 2021 - March 2022)	190
5.1. HIV sero-positive (%)	0.53
5.1.1. Linked to ART	0
6. Clinic Visits	539
7. STI/RTI treated	0
8. Presumptive treatment	9

#### D. Injecting Drug Users

Indicator	2021-22
1. Estimated size	1,892
2. Coverage (%)	66
3. Needles distributed	1,84,836
4. Syringes distributed	1,85,126
5. On OST	1,708
6. Tested for HIV (April 2021 - September 2021)	549
6.1. HIV sero-positive (%)	1.82
6.1.1. Linked to ART	5
7. Tested for HIV (October 2021 - March 2022)	776
7.1. HIV sero-positive (%)	1.68
7.1.1. Linked to ART	3

#### E. Hijra/Transgender people

Indicator	2021-22
1. Estimated size	-
2. Coverage (%)	-
3. Condoms distributed	-
4. Tested for HIV (April 2021 - September 2021)	-
4.1. HIV sero-positive (%)	-
4.1.1. Linked to ART	-
5. Tested for HIV (October 2021 - March 2022)	-
5.1. HIV sero-positive (%)	-
5.1.1. Put on ART	-
6. Clinic Visits	-
7. STI / RTI treated	-
8. Presumptive treatment	-

#### F. Migrants

Indicator	2021-22
1. Estimated size	50,300
2. Coverage (%)	-
3. Tested for HIV	-
3.1. HIV sero-positive (%)	-
3.2. Linked to ART	-

#### G. Truckers

Indicator	2021-22
1. Estimated size	4,150
2. Coverage (%)	-
3. Tested for HIV	-
3.1. HIV sero-positive (%)	-
3.2. On ART	-

#### H. Prison Inmates

Indicator	2021-22
1. Total prisons	5
2. Prisons covered under programme	5
3. Total inmates admitted	2,843
4. Inmates Covered(%)	9
5. Tested for HIV	254
5.1. HIV sero-positive (%)	3.15
5.2. On ART (%)	100

#### I. Link Worker Scheme

Indicator	2021-22
1. Districts covered under scheme	-
2. Vulnerable population covered	-
3. Tested for HIV	-
3.1. HIV sero-positive (%)	-
3.2. Linked to ART (%)	-

## J. Opioid Substitution Therapy

Indicator	2021-22
1. OST Centres	7
1.1. OSTC in Public Health Settings	3
1.2. OSTC in NGO Settings	4
1.3 No. of Satellite OST Centres	-
2. IDU on OST	1,708

## 5. Early detection of HIV infected people

### A. HIV Counselling and Testing Services (HCTS)

Indicator	2021-22
1. ICTC facilities	222
1.1. Stand-alone	34
1.2. Facility integrated (Govt)	170
1.3. Facility integrated (PPP)	6
1.4. CBS	12

### B. HIV Testing among Vulnerable Population (Excluding Pregnant Women)

Indicator	2021-22			
	Male	Female	TG	Total
1. Tested for HIV	23,969	25,232	130	49,331
2. Found HIV Positive among tested	485	251	1	737
3. HIV sero-positivity (%) among tested	2.02	0.99	0.77	1.49
4. Spouse/sexual partner testing of HIV positive people identified	74	107	-	181

## 6. Initiation and retention on ART of HIV infected people

### A. Treatment Facilities

Indicator	2021-22
1. ART Centres	4
2. Centre of Excellence	
2.1. Centre of Excellence (Adult)	-
2.2. Centre of Excellence (Paediatric)	-
3. Link ART Centres	2
4. Care Support Centres	1

### B. Treatment Uptake

Indicator	2021-22			
	Male	Female	TG	Total
1. HIV positive cases diagnosed (At ICTC)	485	403	1	889
2. New PLHIV Registered at ART center	405	389	-	794
2.1 Initiated on ART	360	361	-	721
3. PLHIV alive and on ART	1,693	2,151	1	3,845
4. 12 months retention on ART (%)				85.20
5. Lost to follow-up cases	684	612	1	1,297

## 7. Viral Suppression and laboratories

### A. Laboratory facilities and service uptake

Indicator	2021-22
1. Viral load laboratories	-
1.1 Accredited Viral load laboratories	-
2. Viral load testing conducted	2,496
2.1. Virally suppressed (%)	88
3. National reference laboratories (NRL)	-
3.1 Accredited NRL	-
4. State reference laboratories (SRL)	1
4.1 Accredited SRL	1
5. CD4 testing conducted	1,673
6. External Quality Assessment of ICTC	
6.1 Average Participation (%)	93.08
6.2. Average Discordance (%)	0.00
7. Quality Assurance Scheme for Basic Composite Medical Laboratories (Entry Level)- M(EL)T	
7.1 No. of ICTCs certified for M(EL)T certification	-

## 8. Elimination of mother to child transmission of HIV & Syphilis

### A. HIV

Indicator	2021-22
1. Estimated pregnant women (PW)	80,690
2. HIV testing among PW	67,289
3. HIV sero-positivity (%) among tested	0.23
4. HIV Positive PW (old + new detections)	242
4.1 On life-long ART	219
5. Live births among HIV positive PW	205
5.1 Babies given ARV Prophylaxis (%)	97.07
6. Babies tested HIV (6 week- 6 month)	201
6.1 Babies confirmed HIV Positive (6 week- 6 month)	3
7. HIV exposed babies at 18 months	
7.1 HIV exposed babies tested at 18 month	153
7.2 Babies confirmed HIV positive at 18 months	7
8. HIV positive babies initiated on ART	10

### B. Syphilis

Indicator	2021-22
1. Estimated pregnant women (PW)	80,690
2. Syphilis testing among PW	51,013
3. Sero-positivity (%) among tested	0.95
4. Put on treatment	330

## 9. Elimination of HIV/AIDS related Stigma and Discrimination

### A. HIV/AIDS Prevention & Control Act (2017)

Indicator	2021-22
1. State rules notified for HIV/AIDS Prevention and Control Act (2017)	No
2. State designated/appointed ombudsman for HIV/AIDS Prevention and Control Act (2017)	No

## 10. HIV-TB Co-morbidities

### A. HRG and Bridge Population

Indicator								2021-22
	Quarter	FSW	MSW	IDU	TG	Migrants	Truckers	Total
Screened for TB	Quarter 1	842	88	782	-	-	-	1,712
	Quarter 2	1,289	150	1,121	-	-	-	2,560
	Quarter 3	1,132	185	1,106	-	-	-	2,423
	Quarter 4	1,120	163	1,003	-	-	-	2,286
Tested for TB	Quarter 1	-	-	-	-	-	-	-
	Quarter 2	21	-	-	-	-	-	21
	Quarter 3	27	-	2	-	-	-	29
	Quarter 4	16	-	-	-	-	-	16
Diagnosed with TB	Quarter 1	-	-	-	-	-	-	-
	Quarter 2	-	-	-	-	-	-	-
	Quarter 3	-	-	-	-	-	-	-
	Quarter 4	-	-	-	-	-	-	-
Initiated on TB treatment	Quarter 1	-	-	-	-	-	-	-
	Quarter 2	-	-	-	-	-	-	-
	Quarter 3	-	-	-	-	-	-	-
	Quarter 4	-	-	-	-	-	-	-

### B. HIV-TB Cross-Referral

Indicator		2021-22
1. In referral from TB program		1,737
1.1. HIV sero-positive (%)		2.53
1.2. ICTC clients referred to NTEP		185

### C. HIV-TB Coinfected at ART Centre

Indicator								2021-22
	PLHIV attending ART Centre	PLHIV underwent 4S screening	PLHIV with presumptive TB	PLHIV tested for TB	PLHIV diagnosed with TB	PLHIV initiated on IPT	Co-infected enrolled at ARTc	Co-infected initiated on ART
Apr-21	2,667	2,492	19	7	2	46		
May-21	1,392	1,363	5	2	2	4		
Jun-21	1,547	1,232	10	3	1	36		
Jul-21	1,478	1,264	5	5	5	102		
Aug-21	2,032	1,830	13	6	2	169		
Sep-21	1,921	1,837	13	4	1	90		
Oct-21	2,101	1,990	18	10	2	35		
Nov-21	2,365	2,329	17	11	4	3		
Dec-21	2,170	1,954	11	6	1	3		
Jan-22	2,226	2,041	8	2	-	30		
Feb-22	2,128	2,096	17	5	-	20		
Mar-22	2,316	2,296	34	10	3	22		
April 2021-March 2022							122	111

## 11. Scorecard

State/UT Name		Meghalaya
Overall Rank		12
IEC & MS	Frequency of Social Media updates (G= ≥60, Y=40-59, R=<40)	
	Status of AEP integration in state School curriculum (G=Yes, R=No)	
	Status of SCA (G= At least one meeting held since 2017, R= other than G)	
	Status of State Rules (G= Notified, R= Not notified)	
	Status of Ombudsman (G= Appointed, R=Not appointed)	
	Rank	5
TI	Facilities onboarded (G=≥95%, Y= 90-94%, R=<90%)	
	Coverage against target in contract (G=≥95%, Y= 90-94%, R=<90%)	
	HRG & BP living with HIV on ART (G=≥95%, Y= 90-94%, R=<90%)	
	IDU on OST (G=≥95%, Y= 90-94%, R=<90%)	
	Rank	19
BSD	Percentage of PLHIV who know their status (G=≥95%, Y= 80-94%, R=<80%)	
	HIV testing against target-GC ((G=≥95%, Y= 80-94%, R=<80%)	
	HIV testing against target-PW (G=≥95%, Y= 80-94%, R=<80%)	
	Percentage of Pregnant women who initiated ART (G=≥95%, Y= 80-94%, R=<80%)	
	Percentage of TB suspected cases referred to NTEP (G=≥95%, Y= 80-94%, R=<80%)	
	Clients managed at DSRC against the target (G=≥95%, Y= 80-94%, R=<80%)	
	Percentage of pregnant women tested for Syphilis (G=≥95%, Y= 80-94%, R=<80%)	
	Rank	22
CST	ART Initiation (Current FY) (G=≥95%, Y= 80-94%, R=<80%)	
	LFU rate among new ART initiation (G=<2%, Y= 2-4%, R=≥5%)	
	PLHIV put on ART during the FY against target (G=≥95%, Y= 80-94%, R=<80%)	
	Status on establishment of CSC (G=≥95%, Y= 80-94%, R=<80%)	NA
	Rank	29
LS	VL Suppression Rate (Current FY) (G=≥95%, Y= 85-94%, R=<85%)	
	% of SRL accredited (G=100%, Y= 80-99%, R=<80%)	
	% Participation of ICTCs in Re-testing (G=≥95%, Y= 85-94%, R=<85%)	
	Rank	6
SI	% of NACP facilities active in SOCH (G=≥90%, Y= 75-89%, R=<75%)	
	Status of State Data Management Committee (G=one meeting held, Y= no meeting held, R= not constituted)	
	Status of finalized Priority Areas for Operational Research and Evaluation (G= 4, Y= 3, R= <3)	
	Rank	4
Finance	Expenditure with respect to funds released during FY 2021-22 (G=≥90%, Y= 85-89%, R=<85%)	
	Submission of Audit Report after approval of EC/GB for the preceding year (G= by 30th June, Y= 30th Sept, R= beyond 30th Sept 2021)	
	Submission of Utilization Certificate (in prescribed format GFR 12A) for the previous financial year (G= by 30th June, Y= 30th Sept, R= beyond 30th Sept 2021)	
	Rank	5
SCM	Report Submission (BSD-SCM Report) (G=≥90%, Y= 75-89%, R=<75%)	

Green=3 Marks

Yellow=2Marks

Red=1 Mark

No Colour=Not Applicable

A thick red ribbon is tied in a loop, with the ends trailing off to the right. It is set against a yellow background with faint, concentric circles radiating from the center.

# FACT SHEET

## MIZORAM

## 1. Status of HIV/AIDS Epidemic

### A. Epidemic Estimates (2021)

Indicator	Male	Female	Total
1. IPR	-	-	6.50
2. IMR	-	-	4.61
3. Adult (15-49 yrs) HIV Prevalence (%)	3.02	2.38	2.70
4. Estimated people living with HIV	13,357	10,445	23,802
5. ART coverage (%)	59.2	53	56
6. Estimated children living with HIV	441	426	867
7. Annual new HIV infections	886	663	1,549
8. Annual AIDS-related deaths (ARD)	89	103	192
9. Change in annual new HIV infections since 2010 (%)	3.1	4.25	3.48
10. Change in annual ARD since 2010(%)	-76.8	-58.30	-69.52
11. EMTCT need	-	328	328


### B. High risk population size (2009), safe practices (2015) and prevalence (2021)

Population Group	Estimates Size	Condom Use (%)	New Needle/ Syringe use (%)	HIV Prevalence (%)
1. Female Sex Workers	1,465	37.7	43	56.15
2. Men who have sex with men	532	-	-	12.8
3. Injecting Drug Users	12,800	53.1	79.5	32.08
4. Hijra/Transgender People	-	-	-	-
5. Migrants	50,300	-	-	4.8
6. Truckers	15,000	-	-	-
7. Prison inmates	6,606	33.3	45.9	26.00

### C. HIV/AIDS related knowledge, stigma and high-risk behaviour in general population (2019-21)

Indicator	Male	Female	Total
1. Adults (15-49 yrs) with comprehensive knowledge about HIV/AIDS (%)	65.6	64.1	-
2. Youth (15-24 yrs) with comprehensive knowledge about HIV/AIDS (%)	60	68.9	-
3. Adults willing to care for a relative with HIV/AIDS in own home (%)	95.7	86.7	-
4. Adults willing to buy fresh vegetables from a shopkeeper or vendor who has HIV/AIDS (%)	89.4	88.4	-
5. Adults (15-49 yrs) who have had higher-risk sexual behaviour in the past 12 months (%)	3.3	0.7	-
5.1 Condom use during last higher-risk intercourse (%)	29	7.1	-
6. Youth (15-24 yrs) who have had higher-risk sexual behaviour in the past 12 months (%)	2.4	0.7	-
6.1 Condom use during last higher-risk intercourse (%)	57.1	33.3	-

## 2. Progress on 95-95-95 (2021-22)



Indicator	Male	Female	Total
1. Estimated PLHIV size (2021)	13,357	10,445	23,802
2. PLHIV who know their HIV Status	9,096	6,139	15,235
3. PLHIV who know their HIV status and are on ART	18,062	13,477	31,539
4. PLHIV who are on ART and tested for their viral load	5,279	3,724	9,003
5. PLHIV who are virally suppressed	4,771	3,449	8,220



### 3. Prevention of new HIV infections among general population

#### A. Information, Education, Communication, Youth and Mainstreaming

Indicator	2021-22
1. Schools with operational Adolescent Education Program (AEP)	-
2. Colleges with operational Red Ribbon Clubs (RRC)	43
3. Persons trained under mainstreaming	-

#### B. Sexually Transmitted Infections (STI)/Reproductive Tract Infections (RTI) Management at DSRCs

Indicator	2021-22			
1. NACO Supported Designated STI/RTI Clinics (DSRC)	10			
	Male	Female	TG	Total
2. Clients managed	-	-	-	19,706
3. RPR Tests conducted	3,073	15,097	0	18,170
4. Syphilis seropositivity (%)	0.49	0.19	-	0.24

### 4. Prevention of new HIV infections among high-risk group and bridge population

#### A. Targeted Interventions (TI) and Opioid Substitution Therapy (OST)

Indicator	2021-22
1. Targeted Interventions	36
2. OST centres	81
3. Employer Led Model Interventions	-

#### B. Female Sex Workers

Indicator	2021-22
1. Estimated size	1,465
2. Coverage (%)	61
3. Condoms distributed	77,798
4. Tested for HIV (April 2021 - September 2021)	401
4.1. HIV sero-positive (%)	1.00
4.1.1. Linked to ART	5
5. Tested for HIV (October 2021 - March 2022)	477
5.1. HIV sero-positive (%)	1.68
5.1.1. Linked to ART	8
6. Clinic Visits	2,550
7. STI/RTI treated	28
8. Presumptive treatment	113

#### C. Men who have Sex with Men

Indicator	2021-22
1. Estimated size	532
2. Coverage (%)	>=95
3. Condoms distributed	48,279
4. Tested for HIV (April 2021 - September 2021)	271
4.1. HIV sero-positive (%)	1.11
4.1.1. Linked to ART	1
5. Tested for HIV (October 2021 - March 2022)	502
5.1. HIV sero-positive (%)	0.60
5.1.1. Linked to ART	2
6. Clinic Visits	1,806
7. STI/RTI treated	3
8. Presumptive treatment	44

### D. Injecting Drug Users

Indicator	2021-22
1. Estimated size	12,800
2. Coverage (%)	>=95
3. Needles distributed	14,12,697
4. Syringes distributed	14,15,697
5. On OST	3,199
6. Tested for HIV (April 2021 - September 2021)	4,949
6.1. HIV sero-positive (%)	2.57
6.1.1. Linked to ART	88
7. Tested for HIV (October 2021 - March 2022)	5,548
7.1. HIV sero-positive (%)	2.02
7.1.1. Linked to ART	62

### E. Hijra/Transgender people

Indicator	2021-22
1. Estimated size	-
2. Coverage (%)	-
3. Condoms distributed	-
4. Tested for HIV (April 2021 - September 2021)	-
4.1. HIV sero-positive (%)	-
4.1.1. Linked to ART	-
5. Tested for HIV (October 2021 - March 2022)	-
5.1. HIV sero-positive (%)	-
5.1.1. Put on ART	-
6. Clinic Visits	-
7. STI / RTI treated	-
8. Presumptive treatment	-

### F. Migrants

Indicator	2021-22
1. Estimated size	50,300
2. Coverage (%)	58
3. Tested for HIV	4,306
3.1. HIV sero-positive (%)	0.23
3.2. Linked to ART	7

### G. Truckers

Indicator	2021-22
1. Estimated size	15,000
2. Coverage (%)	-
3. Tested for HIV	-
3.1. HIV sero-positive (%)	-
3.2. On ART	-

### H. Prison Inmates

Indicator	2021-22
1. Total prisons	10
2. Prisons covered under programme	10
3. Total inmates admitted	5,301
4. Inmates Covered(%)	5
5. Tested for HIV	693
5.1. HIV sero-positive (%)	7.07
5.2. On ART (%)	65

### I. Link Worker Scheme

Indicator	2021-22
1. Districts covered under scheme	8
2. Vulnerable population covered	11,817
3. Tested for HIV	7,745
3.1. HIV sero-positive (%)	0.87
3.2. Linked to ART (%)	92.54

## J. Opioid Substitution Therapy

Indicator	2021-22
1. OST Centres	81
1.1. OSTC in Public Health Settings	14
1.2. OSTC in NGO Settings	4
1.3 No. of Satellite OST Centres	63
2. IDU on OST	3,199

## 5. Early detection of HIV infected people

### A. HIV Counselling and Testing Services (HCTS)

Indicator	2021-22
1. ICTC facilities	161
1.1. Stand-alone	41
1.2. Facility integrated (Govt)	64
1.3. Facility integrated (PPP)	12
1.4. CBS	44

### B. HIV Testing among Vulnerable Population (Excluding Pregnant Women)

Indicator	2021-22			
	Male	Female	TG	Total
1. Tested for HIV	36,960	18,618	28	55,606
2. Found HIV Positive among tested	1,104	460	-	1,564
3. HIV sero-positivity (%) among tested	2.99	2.47	0.00	2.81
4. Spouse/sexual partner testing of HIV positive people identified	387	390	-	777

## 6. Initiation and retention on ART of HIV infected people

### A. Treatment Facilities

Indicator	2021-22
1. ART Centres	14
2. Centre of Excellence	
2.1. Centre of Excellence (Adult)	-
2.2. Centre of Excellence (Paediatric)	-
3. Link ART Centres	4
4. Care Support Centres	3

### B. Treatment Uptake

Indicator	2021-22			
	Male	Female	TG	Total
1. HIV positive cases diagnosed (At ICTC)	1,104	634	-	1,738
2. New PLHIV Registered at ART center	1,124	702	-	1,826
2.1 Initiated on ART	1,104	691	-	1,795
3. PLHIV alive and on ART	7,906	5,522	-	13,428
4. 12 months retention on ART (%)				88.99
5. Lost to follow-up cases	1,098	567	-	1,665

## 7. Viral Suppression and laboratories

### A. Laboratory facilities and service uptake

Indicator	2021-22
1. Viral load laboratories	-
1.1 Accredited Viral load laboratories	-
2. Viral load testing conducted	8,343
2.1. Virally suppressed (%)	91
3. National reference laboratories (NRL)	-
3.1 Accredited NRL	-
4. State reference laboratories (SRL)	1
4.1 Accredited SRL	1
5. CD4 testing conducted	2,299
6. External Quality Assessment of ICTC	
6.1 Average Participation (%)	69.51
6.2. Average Discordance (%)	0.00
7. Quality Assurance Scheme for Basic Composite Medical Laboratories (Entry Level)- M(EL)T	
7.1 No. of ICTCs certified for M(EL)T certification	4.00

## 8. Elimination of mother to child transmission of HIV & Syphilis

### A. HIV

Indicator	2021-22
1. Estimated pregnant women (PW)	18,760
2. HIV testing among PW	25,201
3. HIV sero-positivity (%) among tested	0.69
4. HIV Positive PW (old + new detections)	231
4.1 On life-long ART	230
5. Live births among HIV positive PW	220
5.1 Babies given ARV Prophylaxis (%)	98.64
6. Babies tested HIV (6 week- 6 month)	237
6.1 Babies confirmed HIV Positive (6 week- 6 month)	4
7. HIV exposed babies at 18 months	
7.1 HIV exposed babies tested at 18 month	168
7.2 Babies confirmed HIV positive at 18 months	5
8. HIV positive babies initiated on ART	7

### B. Syphilis

Indicator	2021-22
1. Estimated pregnant women (PW)	18,760
2. Syphilis testing among PW	18,490
3. Sero-positivity (%) among tested	0.05
4. Put on treatment	9

## 9. Elimination of HIV/AIDS related Stigma and Discrimination

### A. HIV/AIDS Prevention & Control Act (2017)

Indicator	2021-22
1. State rules notified for HIV/AIDS Prevention and Control Act (2017)	No
2. State designated/appointed ombudsman for HIV/AIDS Prevention and Control Act (2017)	No

## 10. HIV-TB Co-morbidities

### A. HRG and Bridge Population

Indicator								2021-22
	Quarter	FSW	MSW	IDU	TG	Migrants	Truckers	Total
Screened for TB	Quarter 1	8 557	319	7,917	-	413	-	9,206
	Quarter 2	670	393	9,474	-	2,200	-	12,737
	Quarter 3	689	537	8,819	-	3,815	-	13,860
	Quarter 4	762	556	8,793	-	2,326	-	12,437
Tested for TB	Quarter 1	-	-	12	-	1	-	13
	Quarter 2	-	-	27	-	1	-	29
	Quarter 3	-	-	15	-	-	-	15
	Quarter 4	-	-	13	-	-	-	13
Diagnosed with TB	Quarter 1	-	-	49	-	-	-	49
	Quarter 2	-	-	53	-	-	-	53
	Quarter 3	-	-	3	-	-	-	3
	Quarter 4	-	-	-	-	-	-	-
Initiated on TB treatment	Quarter 1	-	6	-	-	-	-	6
	Quarter 2	-	4	4	-	-	-	8
	Quarter 3	-	-	1	-	-	-	1
	Quarter 4	-	-	-	-	-	-	-

### B. HIV-TB Cross-Referral

Indicator		2021-22
1. In referral from TB program		1,575
1.1. HIV sero-positive (%)		5.02
1.2. ICTC clients referred to NTEP		1,177

### C. HIV-TB Coinfected at ART Centre

Indicator								2021-22
	PLHIV attending ART Centre	PLHIV underwent 4S screening	PLHIV with presumptive TB	PLHIV tested for TB	PLHIV diagnosed with TB	PLHIV initiated on IPT	Co-infected enrolled at ARTc	Co-infected initiated on ART
Apr-21	6,572	6,551	60	59	11	192		
May-21	5,113	5,113	8	7	2	146		
Jun-21	6,680	6,639	26	24	8	66		
Jul-21	4,521	4,501	22	22	7	78		
Aug-21	4,088	4,024	31	27	9	74		
Sep-21	5,539	5,513	28	28	9	63		
Oct-21	4,347	4,313	14	14	7	94		
Nov-21	4,668	4,668	22	22	10	165		
Dec-21	4,698	4,698	12	12	5	354		
Jan-22	4,760	4,760	10	10	6	196		
Feb-22	4,759	4,759	35	35	14	139		
Mar-22	5,397	5,397	44	44	18	207		
April 2021- March 2022							229	224

## 11. Scorecard

State/UT Name		Mizoram
Overall Rank		8
IEC & MS	Frequency of Social Media updates (G= ≥60, Y=40-59, R=<40)	
	Status of AEP integration in state School curriculum (G=Yes, R=No)	
	Status of SCA (G= At least one meeting held since 2017, R= other than G)	
	Status of State Rules (G= Notified, R= Not notified)	
	Status of Ombudsman (G= Appointed, R=Not appointed)	
	Rank	26
TI	Facilities onboarded (G=≥95%, Y= 90-94%, R=<90%)	
	Coverage against target in contract (G=≥95%, Y= 90-94%, R=<90%)	
	HRG & BP living with HIV on ART (G=≥95%, Y= 90-94%, R=<90%)	
	IDU on OST (G=≥95%, Y= 90-94%, R=<90%)	
	Rank	11
BSD	Percentage of PLHIV who know their status (G=≥95%, Y= 80-94%, R=<80%)	
	HIV testing against target-GC ((G=≥95%, Y= 80-94%, R=<80%)	
	HIV testing against target-PW (G=≥95%, Y= 80-94%, R=<80%)	
	Percentage of Pregnant women who initiated ART (G=≥95%, Y= 80-94%, R=<80%)	
	Percentage of TB suspected cases referred to NTEP (G=≥95%, Y= 80-94%, R=<80%)	
	Clients managed at DSRC against the target (G=≥95%, Y= 80-94%, R=<80%)	
	Percentage of pregnant women tested for Syphilis (G=≥95%, Y= 80-94%, R=<80%)	
	Rank	5
CST	ART Initiation (Current FY) (G=≥95%, Y= 80-94%, R=<80%)	
	LFU rate among new ART initiation (G=<2%, Y= 2-4%, R=≥5%)	
	PLHIV put on ART during the FY against target (G=≥95%, Y= 80-94%, R=<80%)	
	Status on establishment of CSC (G=≥95%, Y= 80-94%, R=<80%)	NA
	Rank	6
LS	VL Suppression Rate (Current FY) (G=≥95%, Y= 85-94%, R=<85%)	
	% of SRL accredited (G=100%, Y= 80-99%, R=<80%)	
	% Participation of ICTCs in Re-testing (G=≥95%, Y= 85-94%, R=<85%)	
	Rank	12
SI	% of NACP facilities active in SOCH (G=≥90%, Y= 75-89%, R=<75%)	
	Status of State Data Management Committee (G=one meeting held, Y= no meeting held, R= not constituted)	
	Status of finalized Priority Areas for Operational Research and Evaluation (G= 4, Y= 3, R= <3)	
	Rank	4
Finance	Expenditure with respect to funds released during FY 2021-22 (G=≥90%, Y= 85-89%, R=<85%)	
	Submission of Audit Report after approval of EC/GB for the preceding year (G= by 30th June, Y= 30th Sept, R= beyond 30th Sept 2021)	
	Submission of Utilization Certificate (in prescribed format GFR 12A) for the previous financial year (G= by 30th June, Y= 30th Sept, R= beyond 30th Sept 2021)	
	Rank	5
SCM	Report Submission (BSD-SCM Report) (G=≥90%, Y= 75-89%, R=<75%)	

Green=3 Marks

Yellow=2Marks

Red=1 Mark

No Colour=Not Applicable

A thick red ribbon is wrapped around the right side of the page, forming a loop at the top and extending downwards. The background is a gradient of yellow and orange with faint concentric circles.

# FACT SHEET

## NAGALAND

## 1. Status of HIV/AIDS Epidemic

### A. Epidemic Estimates (2021)

Indicator	Male	Female	Total
1. IPR	-	-	5.04
2. IMR	-	-	2.53
3. Adult (15-49 yrs) HIV Prevalence (%)	1.39	1.32	1.36
4. Estimated people living with HIV	11,481	10,249	21,730
5. ART coverage (%)	48.7	57	52
6. Estimated children living with HIV	524	491	1,015
7. Annual new HIV infections	580	516	1,096
8. Annual AIDS-related deaths (ARD)	185	122	307
9. Change in annual new HIV infections since 2010 (%)	-35.1	-29.70	-32.68
10. Change in annual ARD since 2010(%)	-66.1	-63.25	-65.07
11. EMTCT need	-	386	386


### B. High risk population size (2009), safe practices (2015) and prevalence (2021)

Population Group	Estimates Size	Condom Use (%)	New Needle/ Syringe use (%)	HIV Prevalence (%)
1. Female Sex Workers	2,893	80.2	0	2
2. Men who have sex with men	1,270	69.9	0	3.06
3. Injecting Drug Users	16,264	53	87.9	2.53
4. Hijra/Transgender People	20	-	-	-
5. Migrants	5,000	-	-	-
6. Truckers	5,000	-	-	1.2
7. Prison inmates	2,137	50	31.8	4.59

### C. HIV/AIDS related knowledge, stigma and high-risk behaviour in general population (2019-21)

Indicator	Male	Female	Total
1. Adults (15-49 yrs) with comprehensive knowledge about HIV/AIDS (%)	40.1	25.6	-
2. Youth (15-24 yrs) with comprehensive knowledge about HIV/AIDS (%)	31.9	21.1	-
3. Adults willing to care for a relative with HIV/AIDS in own home (%)	64.8	63.4	-
4. Adults willing to buy fresh vegetables from a shopkeeper or vendor who has HIV/AIDS (%)	63.7	56.8	-
5. Adults (15-49 yrs) who have had higher-risk sexual behaviour in the past 12 months (%)	8.8	2.3	-
5.1 Condom use during last higher-risk intercourse (%)	59.5	11.6	-
6. Youth (15-24 yrs) who have had higher-risk sexual behaviour in the past 12 months (%)	7.5	3.4	-
6.1 Condom use during last higher-risk intercourse (%)	66.7	6.3	-

## 2. Progress on 95-95-95 (2021-22)



Indicator	Male	Female	Total
1. Estimated PLHIV size (2021)	11,481	10,249	21,730
2. PLHIV who know their HIV Status	7,164	7,337	14,501
3. PLHIV who know their HIV status and are on ART	5,386	5,596	10,982
4. PLHIV who are on ART and tested for their viral load	5,231	5,797	11,028
5. PLHIV who are virally suppressed	4,394	5,093	9,487

### 3. Prevention of new HIV infections among general population

#### A. Information, Education, Communication, Youth and Mainstreaming

Indicator	2021-22
1. Schools with operational Adolescent Education Program (AEP)	724
2. Colleges with operational Red Ribbon Clubs (RRC)	83
3. Persons trained under mainstreaming	4,839

#### B. Sexually Transmitted Infections (STI)/Reproductive Tract Infections (RTI) Management at DSRCs

Indicator	2021-22			
1. NACO Supported Designated STI/RTI Clinics (DSRC)	12			
	Male	Female	TG	Total
2. Clients managed	-	-	-	5,494
3. RPR Tests conducted	2,749	2,694	9	5,452
4. Syphilis seropositivity (%)	1.05	1.60	0.00	1.32

### 4. Prevention of new HIV infections among high-risk group and bridge population

#### A. Targeted Interventions (TI) and Opioid Substitution Therapy (OST)

Indicator	2021-22
1. Targeted Interventions	46
2. OST centres	50
3. Employer Led Model Interventions	-

#### B. Female Sex Workers

Indicator	2021-22
1. Estimated size	2,893
2. Coverage (%)	>=95
3. Condoms distributed	5,89,670
4. Tested for HIV (April 2021 - September 2021)	2,471
4.1. HIV sero-positive (%)	0.04
4.1.1. Linked to ART	0
5. Tested for HIV (October 2021 - March 2022)	2,461
5.1. HIV sero-positive (%)	0.20
5.1.1. Linked to ART	6
6. Clinic Visits	10,037
7. STI/RTI treated	151
8. Presumptive treatment	909

#### C. Men who have Sex with Men

Indicator	2021-22
1. Estimated size	1,270
2. Coverage (%)	>=95
3. Condoms distributed	3,91,167
4. Tested for HIV (April 2021 - September 2021)	1,385
4.1. HIV sero-positive (%)	0.22
4.1.1. Linked to ART	3
5. Tested for HIV (October 2021 - March 2022)	1,002
5.1. HIV sero-positive (%)	0.00
5.1.1. Linked to ART	-
6. Clinic Visits	5,113
7. STI/RTI treated	10
8. Presumptive treatment	161

### D. Injecting Drug Users

Indicator	2021-22
1. Estimated size	16,264
2. Coverage (%)	>=95
3. Needles distributed	16,89,710
4. Syringes distributed	17,34,817
5. On OST	6,950
6. Tested for HIV (April 2021 - September 2021)	13,275
6.1. HIV sero-positive (%)	0.44
6.1.1. Linked to ART	51
7. Tested for HIV (October 2021 - March 2022)	12,967
7.1. HIV sero-positive (%)	0.37
7.1.1. Linked to ART	41

### E. Hijra/Transgender people

Indicator	2021-22
1. Estimated size	20
2. Coverage (%)	>=95
3. Condoms distributed	22,744
4. Tested for HIV (April 2021 - September 2021)	15
4.1. HIV sero-positive (%)	0.00
4.1.1. Linked to ART	-
5. Tested for HIV (October 2021 - March 2022)	34
5.1. HIV sero-positive (%)	-
5.1.1. Put on ART	-
6. Clinic Visits	132
7. STI / RTI treated	0
8. Presumptive treatment	20

### F. Migrants

Indicator	2021-22
1. Estimated size	5,000
2. Coverage (%)	>=95
3. Tested for HIV	1,754
3.1. HIV sero-positive (%)	0.11
3.2. Linked to ART	2

### G. Truckers

Indicator	2021-22
1. Estimated size	5,000
2. Coverage (%)	>=95
3. Tested for HIV	1,514
3.1. HIV sero-positive (%)	0.40
3.2. On ART	4

### H. Prison Inmates

Indicator	2021-22
1. Total prisons	11
2. Prisons covered under programme	11
3. Total inmates admitted	1,685
4. Inmates Covered(%)	10
5. Tested for HIV	86
5.1. HIV sero-positive (%)	2.33
5.2. On ART (%)	150

### I. Link Worker Scheme

Indicator	2021-22
1. Districts covered under scheme	-
2. Vulnerable population covered	-
3. Tested for HIV	-
3.1. HIV sero-positive (%)	-
3.2. Linked to ART (%)	-



## J. Opioid Substitution Therapy

Indicator	2021-22
1. OST Centres	50
1.1. OSTC in Public Health Settings	26
1.2. OSTC in NGO Settings	5
1.3 No. of Satellite OST Centres	19
2. IDU on OST	6,950

## 5. Early detection of HIV infected people

### A. HIV Counselling and Testing Services (HCTS)

Indicator	2021-22
1. ICTC facilities	269
1.1. Stand-alone	73
1.2. Facility integrated (Govt)	125
1.3. Facility integrated (PPP)	14
1.4. CBS	57

### B. HIV Testing among Vulnerable Population (Excluding Pregnant Women)

Indicator	2021-22			
	Male	Female	TG	Total
1. Tested for HIV	55,283	36,982	32	92,297
2. Found HIV Positive among tested	758	513	-	1,271
3. HIV sero-positivity (%) among tested	1.37	1.39	0.00	1.38
4. Spouse/sexual partner testing of HIV positive people identified	410	316	-	726

## 6. Initiation and retention on ART of HIV infected people

### A. Treatment Facilities

Indicator	2021-22
1. ART Centres	12
2. Centre of Excellence	
2.1. Centre of Excellence (Adult)	-
2.2. Centre of Excellence (Paediatric)	-
3. Link ART Centres	8
4. Care Support Centres	3

### B. Treatment Uptake

Indicator	2021-22			
	Male	Female	TG	Total
1. HIV positive cases diagnosed (At ICTC)	758	624	-	1,382
2. New PLHIV Registered at ART center	783	680	1	1,464
2.1 Initiated on ART	705	631	1	1,337
3. PLHIV alive and on ART	5,593	5,785	7	11,385
4. 12 months retention on ART (%)				76.77
5. Lost to follow-up cases	1,497	1,409	1	2,907

## 7. Viral Suppression and laboratories

### A. Laboratory facilities and service uptake

Indicator	2021-22
1. Viral load laboratories	-
1.1 Accredited Viral load laboratories	-
2. Viral load testing conducted	9,435
2.1. Virally suppressed (%)	86
3. National reference laboratories (NRL)	-
3.1 Accredited NRL	-
4. State reference laboratories (SRL)	2
4.1 Accredited SRL	2
5. CD4 testing conducted	5,375
6. External Quality Assessment of ICTC	
6.1 Average Participation (%)	94.17
6.2. Average Discordance (%)	0.00
7. Quality Assurance Scheme for Basic Composite Medical Laboratories (Entry Level)- M(EL)T	
7.1 No. of ICTCs certified for M(EL)T certification	10.00

## 8. Elimination of mother to child transmission of HIV & Syphilis

### A. HIV

Indicator	2021-22
1. Estimated pregnant women (PW)	29,830
2. HIV testing among PW	22,104
3. HIV sero-positivity (%) among tested	0.50
4. HIV Positive PW (old + new detections)	154
4.1 On life-long ART	126
5. Live births among HIV positive PW	206
5.1 Babies given ARV Prophylaxis (%)	99.03
6. Babies tested HIV (6 week- 6 month)	181
6.1 Babies confirmed HIV Positive (6 week- 6 month)	4
7. HIV exposed babies at 18 months	
7.1 HIV exposed babies tested at 18 month	150
7.2 Babies confirmed HIV positive at 18 months	3
8. HIV positive babies initiated on ART	5

### B. Syphilis

Indicator	2021-22
1. Estimated pregnant women (PW)	29,830
2. Syphilis testing among PW	16,578
3. Sero-positivity (%) among tested	0.45
4. Put on treatment	74

## 9. Elimination of HIV/AIDS related Stigma and Discrimination

### A. HIV/AIDS Prevention & Control Act (2017)

Indicator	2021-22
1. State rules notified for HIV/AIDS Prevention and Control Act (2017)	Yes
2. State designated/appointed ombudsman for HIV/AIDS Prevention and Control Act (2017)	Yes

## 10. HIV-TB Co-morbidities

### A. HRG and Bridge Population

Indicator								2021-22
	Quarter	FSW	MSW	IDU	TG	Migrants	Truckers	Total
Screened for TB	Quarter 1	627	627	4,482	11	40	-	5,787
	Quarter 2	961	639	5,465	20	99	-	7,184
	Quarter 3	1,049	679	6,193	36	39	-	7,996
	Quarter 4	987	732	5,610	54	89	-	7,472
Tested for TB	Quarter 1	2	1	7	-	-	-	10
	Quarter 2	3	-	29	-	2	-	34
	Quarter 3	6	-	12	-	-	-	18
	Quarter 4	2	-	17	-	3	-	22
Diagnosed with TB	Quarter 1	-	-	1	-	-	-	1
	Quarter 2	-	-	6	-	-	-	6
	Quarter 3	-	-	1	-	-	-	1
	Quarter 4	-	-	1	-	-	-	1
Initiated on TB treatment	Quarter 1	-	-	1	-	-	-	1
	Quarter 2	-	-	6	-	-	-	6
	Quarter 3	-	-	1	-	-	-	1
	Quarter 4	-	-	1	-	-	-	1

### B. HIV-TB Cross-Referral

Indicator	2021-22
1. In referral from TB program	1,749
1.1. HIV sero-positive (%)	5.32
1.2. ICTC clients referred to NTEP	2,875

### C. HIV-TB Coinfected at ART Centre

Indicator								2021-22
	PLHIV attending ART Centre	PLHIV underwent 4S screening	PLHIV with presumptive TB	PLHIV tested for TB	PLHIV diagnosed with TB	PLHIV initiated on IPT	Co-infected enrolled at ARTc	Co-infected initiated on ART
Apr-21	6,976	6,705	54	54	27	155		
May-21	4,460	4,263	9	9	3	112		
Jun-21	5,094	4,212	30	29	18	52		
Jul-21	5,297	5,264	55	54	27	63		
Aug-21	4,465	4,465	39	37	19	159		
Sep-21	5,276	5,276	49	46	23	169		
Oct-21	5,240	5,240	62	57	22	212		
Nov-21	5,727	5,648	84	62	20	476		
Dec-21	4,695	4,690	55	39	10	149		
Jan-22	4,666	4,536	80	57	12	103		
Feb-22	5,371	4,064	65	44	14	154		
Mar-22	6,030	4,922	61	46	24	395		
April 2021-March 2022							301	266

## 11. Scorecard

State/UT Name		Mizoram
Overall Rank		12
IEC & MS	Frequency of Social Media updates (G= ≥60, Y=40-59, R=<40)	
	Status of AEP integration in state School curriculum (G=Yes, R=No)	
	Status of SCA (G= At least one meeting held since 2017, R= other than G)	
	Status of State Rules (G= Notified, R= Not notified)	
	Status of Ombudsman (G= Appointed, R=Not appointed)	
	Rank	12
TI	Facilities onboarded (G=≥95%, Y= 90-94%, R=<90%)	
	Coverage against target in contract (G=≥95%, Y= 90-94%, R=<90%)	
	HRG & BP living with HIV on ART (G=≥95%, Y= 90-94%, R=<90%)	
	IDU on OST (G=≥95%, Y= 90-94%, R=<90%)	
	Rank	11
BSD	Percentage of PLHIV who know their status (G=≥95%, Y= 80-94%, R=<80%)	
	HIV testing against target-GC ((G=≥95%, Y= 80-94%, R=<80%)	
	HIV testing against target-PW (G=≥95%, Y= 80-94%, R=<80%)	
	Percentage of Pregnant women who initiated ART (G=≥95%, Y= 80-94%, R=<80%)	
	Percentage of TB suspected cases referred to NTEP (G=≥95%, Y= 80-94%, R=<80%)	
	Clients managed at DSRC against the target (G=≥95%, Y= 80-94%, R=<80%)	
	Percentage of pregnant women tested for Syphilis (G=≥95%, Y= 80-94%, R=<80%)	
	Rank	11
CST	ART Initiation (Current FY) (G=≥95%, Y= 80-94%, R=<80%)	
	LFU rate among new ART initiation (G=<2%, Y= 2-4%, R=≥5%)	
	PLHIV put on ART during the FY against target (G=≥95%, Y= 80-94%, R=<80%)	
	Status on establishment of CSC (G=≥95%, Y= 80-94%, R=<80%)	NA
	Rank	17
LS	VL Suppression Rate (Current FY) (G=≥95%, Y= 85-94%, R=<85%)	
	% of SRL accredited (G=100%, Y= 80-99%, R=<80%)	
	% Participation of ICTCs in Re-testing (G=≥95%, Y= 85-94%, R=<85%)	
	Rank	6
SI	% of NACP facilities active in SOCH (G=≥90%, Y= 75-89%, R=<75%)	
	Status of State Data Management Committee (G=one meeting held, Y= no meeting held, R= not constituted)	
	Status of finalized Priority Areas for Operational Research and Evaluation (G= 4, Y= 3, R= <3)	
	Rank	14
Finance	Expenditure with respect to funds released during FY 2021-22 (G=≥90%, Y= 85-89%, R=<85%)	
	Submission of Audit Report after approval of EC/GB for the preceding year (G= by 30th June, Y= 30th Sept, R= beyond 30th Sept 2021)	
	Submission of Utilization Certificate (in prescribed format GFR 12A) for the previous financial year (G= by 30th June, Y= 30th Sept, R= beyond 30th Sept 2021)	
	Rank	5
SCM	Report Submission (BSD-SCM Report) (G=≥90%, Y= 75-89%, R=<75%)	

Green=3 Marks

Yellow=2Marks

Red=1 Mark

No Colour=Not Applicable

A thick red ribbon is tied in a loop on the right side of the page, with the tail extending downwards and then curving back towards the left. The background is a gradient of yellow and orange with faint concentric circles.

# FACT SHEET

## ODISHA

## 1. Status of HIV/AIDS Epidemic

### A. Epidemic Estimates (2021)

Indicator	Male	Female	Total
1. IPR	-	-	4.18
2. IMR	-	-	1.04
3. Adult (15-49 yrs) HIV Prevalence (%)	0.15	0.13	0.14
4. Estimated people living with HIV	27,684	24,424	52,108
5. ART coverage (%)	47.6	45	47
6. Estimated children living with HIV	1,037	976	2,013
7. Annual new HIV infections	1,094	1,085	2,179
8. Annual AIDS-related deaths (ARD)	849	778	1,627
9. Change in annual new HIV infections since 2010 (%)	-48.6	-42.13	-45.57
10. Change in annual ARD since 2010(%)	-49.2	-40.79	-45.51
11. EMTCT need	-	534	534


### B. High risk population size (2009), safe practices (2015) and prevalence (2021)

Population Group	Estimates Size	Condom Use (%)	New Needle/ Syringe use (%)	HIV Prevalence (%)
1. Female Sex Workers	12,031	60.6	72	0.65
2. Men who have sex with men	4,230	31.5	67.8	1.2
3. Injecting Drug Users	2,564	63.9	87.3	1.9
4. Hijra/Transgender People	7,854	70.7	-	1.49
5. Migrants	92,000	-	-	1.6
6. Truckers	15,607	-	-	2
7. Prison inmates	82,440	34.4	0	0.00

### C. HIV/AIDS related knowledge, stigma and high-risk behaviour in general population (2019-21)

Indicator	Male	Female	Total
1. Adults (15-49 yrs) with comprehensive knowledge about HIV/AIDS (%)	24.6	21.4	-
2. Youth (15-24 yrs) with comprehensive knowledge about HIV/AIDS (%)	22.1	18.1	-
3. Adults willing to care for a relative with HIV/AIDS in own home (%)	77.5	71.3	-
4. Adults willing to buy fresh vegetables from a shopkeeper or vendor who has HIV/AIDS (%)	56.9	63.4	-
5. Adults (15-49 yrs) who have had higher-risk sexual behaviour in the past 12 months (%)	1.1	0.2	-
5.1 Condom use during last higher-risk intercourse (%)	39.3	2.7	-
6. Youth (15-24 yrs) who have had higher-risk sexual behaviour in the past 12 months (%)	1.8	0.4	-
6.1 Condom use during last higher-risk intercourse (%)	35.0	0.0	-

## 2. Progress on 95-95-95 (2021-22)



Indicator	Male	Female	Total
1. Estimated PLHIV size (2021)	27,684	24,424	52,108
2. PLHIV who know their HIV Status	15,105	12,235	27,340
3. PLHIV who know their HIV status and are on ART	12,322	10,363	22,685
4. PLHIV who are on ART and tested for their viral load	5,313	4,455	9,768
5. PLHIV who are virally suppressed	4,456	3,799	8,255

### 3. Prevention of new HIV infections among general population

#### A. Information, Education, Communication, Youth and Mainstreaming

Indicator	2021-22
1. Schools with operational Adolescent Education Program (AEP)	166
2. Colleges with operational Red Ribbon Clubs (RRC)	640
3. Persons trained under mainstreaming	1,660

#### B. Sexually Transmitted Infections (STI)/Reproductive Tract Infections (RTI) Management at DSRCs

Indicator	2021-22			
1. NACO Supported Designated STI/RTI Clinics (DSRC)	40			
	Male	Female	TG	Total
2. Clients managed	-	-	-	2,23,821
3. RPR Tests conducted	52,317	50,879	3,121	1,06,317
4. Syphilis seropositivity (%)	0.68	0.25	1.12	0.49

### 4. Prevention of new HIV infections among high-risk group and bridge population

#### A. Targeted Interventions (TI) and Opioid Substitution Therapy (OST)

Indicator	2021-22
1. Targeted Interventions	48
2. OST centres	4
3. Employer Led Model Interventions	25

#### B. Female Sex Workers

Indicator	2020-21
1. Estimated size	12,031
2. Coverage (%)	>=95
3. Condoms distributed	30,54,750
4. Tested for HIV (April 2021 - September 2021)	10,916
4.1. HIV sero-positive (%)	0.06
4.1.1. Linked to ART	6
5. Tested for HIV (October 2021 - March 2022)	10,970
5.1. HIV sero-positive (%)	0.04
5.1.1. Linked to ART	3
6. Clinic Visits	42,333
7. STI/RTI treated	1,296
8. Presumptive treatment	1,967

#### C. Men who have Sex with Men

Indicator	2021-22
1. Estimated size	4,230
2. Coverage (%)	87
3. Condoms distributed	6,98,937
4. Tested for HIV (April 2021 - September 2021)	2,536
4.1. HIV sero-positive (%)	0.24
4.1.1. Linked to ART	6
5. Tested for HIV (October 2021 - March 2022)	2,493
5.1. HIV sero-positive (%)	0.08
5.1.1. Linked to ART	1
6. Clinic Visits	9,904
7. STI/RTI treated	282
8. Presumptive treatment	474

### D. Injecting Drug Users

Indicator	2021-22
1. Estimated size	2,564
2. Coverage (%)	>=95
3. Needles distributed	3,37,357
4. Syringes distributed	5,64,543
5. On OST	289
6. Tested for HIV (April 2021 - September 2021)	2,706
6.1. HIV sero-positive (%)	0.07
6.1.1. Linked to ART	2
7. Tested for HIV (October 2021 - March 2022)	2,490
7.1. HIV sero-positive (%)	0.00
7.1.1. Linked to ART	-

### E. Hijra/Transgender people

Indicator	2021-22
1. Estimated size	7,854
2. Coverage (%)	49
3. Condoms distributed	9,86,805
4. Tested for HIV (April 2021 - September 2021)	2,451
4.1. HIV sero-positive (%)	1.06
4.1.1. Linked to ART	24
5. Tested for HIV (October 2021 - March 2022)	2,778
5.1. HIV sero-positive (%)	0.72
5.1.1. Put on ART	21
6. Clinic Visits	10,508
7. STI / RTI treated	325
8. Presumptive treatment	440

### F. Migrants

Indicator	2021-22
1. Estimated size	92,000
2. Coverage (%)	45
3. Tested for HIV	44,896
3.1. HIV sero-positive (%)	0.07
3.2. Linked to ART	32

### G. Truckers

Indicator	2021-22
1. Estimated size	15,607
2. Coverage (%)	>=95
3. Tested for HIV	8,451
3.1. HIV sero-positive (%)	0.07
3.2. On ART	4

### H. Prison Inmates

Indicator	2021-22
1. Total prisons	90
2. Prisons covered under programme	35
3. Total inmates admitted	77,834
4. Inmates Covered(%)	5
5. Tested for HIV	6,810
5.1. HIV sero-positive (%)	0.29
5.2. On ART (%)	75

### I. Link Worker Scheme

Indicator	2021-22
1. Districts covered under scheme	6
2. Vulnerable population covered	1,21,138
3. Tested for HIV	58,625
3.1. HIV sero-positive (%)	0.12
3.2. Linked to ART (%)	98.61

## J. Opioid Substitution Therapy

Indicator	2021-22
1. OST Centres	4
1.1. OSTC in Public Health Settings	3
1.2. OSTC in NGO Settings	1
1.3 No. of Satellite OST Centres	-
2. IDU on OST	289

## 5. Early detection of HIV infected people

### A. HIV Counselling and Testing Services (HCTS)

Indicator	2021-22
1. ICTC facilities	660
1.1. Stand-alone	214
1.2. Facility integrated (Govt)	217
1.3. Facility integrated (PPP)	83
1.4. CBS	146

### B. HIV Testing among Vulnerable Population (Excluding Pregnant Women)

Indicator	2021-22			
	Male	Female	TG	Total
1. Tested for HIV	7,11,698	3,61,035	7,128	10,79,861
2. Found HIV Positive among tested	1,446	630	119	2,195
3. HIV sero-positivity (%) among tested	0.20	0.17	1.67	0.20
4. Spouse/sexual partner testing of HIV positive people identified	294	274	19	587

## 6. Initiation and retention on ART of HIV infected people

### A. Treatment Facilities

Indicator	2021-22
1. ART Centres	16
2. Centre of Excellence	
2.1. Centre of Excellence (Adult)	-
2.2. Centre of Excellence (Paediatric)	-
3. Link ART Centres	19
4. Care Support Centres	12

### B. Treatment Uptake

Indicator	2021-22			
	Male	Female	TG	Total
1. HIV positive cases diagnosed (At ICTC)	1,446	837	119	2,402
2. New PLHIV Registered at ART center	1,320	670	84	2,074
2.1 Initiated on ART	1,239	639	80	1,958
3. PLHIV alive and on ART	13,181	10,728	365	24,274
4. 12 months retention on ART (%)				78.74
5. Lost to follow-up cases	2,212	1,280	94	3,586

## 7. Viral Suppression and laboratories

### A. Laboratory facilities and service uptake

Indicator	2021-22
1. Viral load laboratories	-
1.1 Accredited Viral load laboratories	-
2. Viral load testing conducted	11,309
2.1. Virally suppressed (%)	85
3. National reference laboratories (NRL)	-
3.1 Accredited NRL	-
4. State reference laboratories (SRL)	3
4.1 Accredited SRL	-
5. CD4 testing conducted	11,932
6. External Quality Assessment of ICTC	
6.1 Average Participation (%)	97.07
6.2. Average Discordance (%)	0.00
7. Quality Assurance Scheme for Basic Composite Medical Laboratories (Entry Level)- M(EL)T	
7.1 No. of ICTCs certified for M(EL)T certification	1.00

## 8. Elimination of mother to child transmission of HIV & Syphilis

### A. HIV

Indicator	2021-22
1. Estimated pregnant women (PW)	9,27,940
2. HIV testing among PW	7,92,116
3. HIV sero-positivity (%) among tested	0.03
4. HIV Positive PW (old + new detections)	290
4.1 On life-long ART	230
5. Live births among HIV positive PW	203
5.1 Babies given ARV Prophylaxis (%)	89.66
6. Babies tested HIV (6 week- 6 month)	86
6.1 Babies confirmed HIV Positive (6 week- 6 month)	1
7. HIV exposed babies at 18 months	
7.1 HIV exposed babies tested at 18 month	49
7.2 Babies confirmed HIV positive at 18 months	7
8. HIV positive babies initiated on ART	8

### B. Syphilis

Indicator	2021-22
1. Estimated pregnant women (PW)	9,27,940
2. Syphilis testing among PW	7,41,889
3. Sero-positivity (%) among tested	0.06
4. Put on treatment	398

## 9. Elimination of HIV/AIDS related Stigma and Discrimination

### A. HIV/AIDS Prevention & Control Act (2017)

Indicator	2021-22
1. State rules notified for HIV/AIDS Prevention and Control Act (2017)	No
2. State designated/appointed ombudsman for HIV/AIDS Prevention and Control Act (2017)	Yes



## 10. HIV-TB Co-morbidities

### A. HRG and Bridge Population

Indicator								2021-22
	Quarter	FSW	MSW	IDU	TG	Migrants	Truckers	Total
Screened for TB	Quarter 1	9,605	2,456	1,854	2,147	11,402	2,190	29,654
	Quarter 2	11,338	2,630	2,786	2,876	16,959	3,453	40,042
	Quarter 3	10,885	2,377	2,592	2,714	15,866	3,889	38,323
	Quarter 4	11,544	2,535	2,714	2,810	17,005	3,922	40,530
Tested for TB	Quarter 1	639	178	156	108	268	36	1,385
	Quarter 2	1,254	205	397	191	537	74	2,658
	Quarter 3	840	193	303	187	605	66	2,194
	Quarter 4	1,023	245	469	249	647	44	2,677
Diagnosed with TB	Quarter 1	3	1	-	1	-	-	5
	Quarter 2	4	3	1	1	7	1	17
	Quarter 3	-	1	-	1	8	1	11
	Quarter 4	1	3	-	1	6	1	12
Initiated on TB treatment	Quarter 1	3	1	-	1	-	-	5
	Quarter 2	4	3	1	1	7	1	17
	Quarter 3	-	1	-	1	8	1	11
	Quarter 4	1	2	-	1	6	1	11

### B. HIV-TB Cross-Referral

Indicator	2021-22
1. In referral from TB program	7,065
1.1. HIV sero-positive (%)	1.39
1.2. ICTC clients referred to NTEP	59,624

### C. HIV-TB Coinfected at ART Centre

Indicator								2021-22
	PLHIV attending ART Centre	PLHIV underwent 4S screening	PLHIV with presumptive TB	PLHIV tested for TB	PLHIV diagnosed with TB	PLHIV initiated on IPT	Co-infected enrolled at ARTc	Co-infected initiated on ART
Apr-21	12,321	11,263	262	259	18	282		
May-21	8,228	6,885	152	146	13	178		
Jun-21	6,252	5,818	184	184	16	134		
Jul-21	12,321	11,263	262	259	18	282		
Aug-21	9,563	8,733	337	337	29	244		
Sep-21	8,126	7,439	387	387	31	379		
Oct-21	9,198	8,613	360	355	20	305		
Nov-21	9,522	8,963	358	350	22	328		
Dec-21	10,615	9,903	362	362	31	266		
Jan-22	9,681	9,145	327	324	25	210		
Feb-22	9,375	8,939	364	362	30	294		
Mar-22	9,866	9,390	407	407	29	304		
April 2021-March 2022							547	513

## 11. Scorecard

State/UT Name		Odisha
Overall Rank		34
IEC & MS	Frequency of Social Media updates (G= ≥60, Y=40-59, R=<40)	
	Status of AEP integration in state School curriculum (G=Yes, R=No)	
	Status of SCA (G= At least one meeting held since 2017, R= other than G)	
	Status of State Rules (G= Notified, R= Not notified)	
	Status of Ombudsman (G= Appointed, R=Not appointed)	
	Rank	26
TI	Facilities onboarded (G=≥95%, Y= 90-94%, R=<90%)	
	Coverage against target in contract (G=≥95%, Y= 90-94%, R=<90%)	
	HRG & BP living with HIV on ART (G=≥95%, Y= 90-94%, R=<90%)	
	IDU on OST (G=≥95%, Y= 90-94%, R=<90%)	
	Rank	32
BSD	Percentage of PLHIV who know their status (G=≥95%, Y= 80-94%, R=<80%)	
	HIV testing against target-GC ((G=≥95%, Y= 80-94%, R=<80%)	
	HIV testing against target-PW (G=≥95%, Y= 80-94%, R=<80%)	
	Percentage of Pregnant women who initiated ART (G=≥95%, Y= 80-94%, R=<80%)	
	Percentage of TB suspected cases referred to NTEP (G=≥95%, Y= 80-94%, R=<80%)	
	Clients managed at DSRC against the target (G=≥95%, Y= 80-94%, R=<80%)	
	Percentage of pregnant women tested for Syphilis (G=≥95%, Y= 80-94%, R=<80%)	
	Rank	17
CST	ART Initiation (Current FY) (G=≥95%, Y= 80-94%, R=<80%)	
	LFU rate among new ART initiation (G=<2%, Y= 2-4%, R=≥5%)	
	PLHIV put on ART during the FY against target (G=≥95%, Y= 80-94%, R=<80%)	
	Status on establishment of CSC (G=≥95%, Y= 80-94%, R=<80%)	
	Rank	34
LS	VL Suppression Rate (Current FY) (G=≥95%, Y= 85-94%, R=<85%)	
	% of SRL accredited (G=100%, Y= 80-99%, R=<80%)	
	% Participation of ICTCs in Re-testing (G=≥95%, Y= 85-94, R=<85%)	
	Rank	12
SI	% of NACP facilities active in SOCH (G=≥90%, Y= 75-89%, R=<75%)	
	Status of State Data Management Committee (G=one meeting held, Y= no meeting held, R= not constituted)	
	Status of finalized Priority Areas for Operational Research and Evaluation (G= 4, Y= 3, R= <3)	
	Rank	25
Finance	Expenditure with respect to funds released during FY 2021-22 (G=≥90%, Y= 85-89%, R=<85%)	
	Submission of Audit Report after approval of EC/GB for the preceding year (G= by 30th June, Y= 30th Sept, R= beyond 30th Sept 2021)	
	Submission of Utilization Certificate (in prescribed format GFR 12A) for the previous financial year (G= by 30th June, Y= 30th Sept, R= beyond 30th Sept 2021)	
	Rank	5
SCM	Report Submission (BSD-SCM Report) (G=≥90%, Y= 75-89%, R=<75%)	

Green=3 Marks

Yellow=2Marks

Red=1 Mark

No Colour=Not Applicable

A thick red ribbon is draped across the page, starting from the bottom left, looping up to the top right, and then coming back down towards the bottom right. The background is a gradient of yellow and orange with faint concentric circles.

# FACT SHEET

## PUDUCHERRY

## 1. Status of HIV/AIDS Epidemic

### A. Epidemic Estimates (2021)

Indicator	Male	Female	Total
1. IPR	-	-	4.57
2. IMR	-	-	0.95
3. Adult (15-49 yrs) HIV Prevalence (%)	0.33	0.28	0.31
4. Estimated people living with HIV	2,055	1,906	3,961
5. ART coverage (%)	33.0	36	34
6. Estimated children living with HIV	68	69	137
7. Annual new HIV infections	95	86	181
8. Annual AIDS-related deaths (ARD)	88	75	163
9. Change in annual new HIV infections since 2010 (%)	-55.4	-52.75	-54.29
10. Change in annual ARD since 2010(%)	125.6	120.59	123.29
11. EMTCT need	-	30	30


### B. High risk population size (2009), safe practices (2015) and prevalence (2021)

Population Group	Estimates Size	Condom Use (%)	New Needle/ Syringe use (%)	HIV Prevalence (%)
1. Female Sex Workers	2,238	68.8	0	0.5
2. Men who have sex with men	2,353	85.9	0	0
3. Injecting Drug Users	-	-	-	-
4. Hijra/Transgender People	103	-	-	-
5. Migrants	15,000	-	-	0
6. Truckers	-	-	-	-
7. Prison inmates	2,378	-	-	-

### C. HIV/AIDS related knowledge, stigma and high-risk behaviour in general population (2019-21)

Indicator	Male	Female	Total
1. Adults (15-49 yrs) with comprehensive knowledge about HIV/AIDS (%)	32.5	30.2	-
2. Youth (15-24 yrs) with comprehensive knowledge about HIV/AIDS (%)	32.3	25.4	-
3. Adults willing to care for a relative with HIV/AIDS in own home (%)	76.4	67.4	-
4. Adults willing to buy fresh vegetables from a shopkeeper or vendor who has HIV/AIDS (%)	63.4	54.2	-
5. Adults (15-49 yrs) who have had higher-risk sexual behaviour in the past 12 months (%)	2.4	0.1	-
5.1 Condom use during last higher-risk intercourse (%)	60.5	0	-
6. Youth (15-24 yrs) who have had higher-risk sexual behaviour in the past 12 months (%)	0.0	0	-
6.1 Condom use during last higher-risk intercourse (%)	NA	NA	-

## 2. Progress on 95-95-95 (2021-22)



Indicator	Male	Female	Total
1. Estimated PLHIV size (2021)	2,055	1,906	3,961
2. PLHIV who know their HIV Status	853	792	1,645
3. PLHIV who know their HIV status and are on ART	629	636	1,265
4. PLHIV who are on ART and tested for their viral load	403	466	869
5. PLHIV who are virally suppressed	336	387	723

### 3. Prevention of new HIV infections among general population

#### A. Information, Education, Communication, Youth and Mainstreaming

Indicator	2021-22
1. Schools with operational Adolescent Education Program (AEP)	250
2. Colleges with operational Red Ribbon Clubs (RRC)	70
3. Persons trained under mainstreaming	395

#### B. Sexually Transmitted Infections (STI)/Reproductive Tract Infections (RTI) Management at DSRCs

Indicator	2021-22			
1. NACO Supported Designated STI/RTI Clinics (DSRC)	5			
	Male	Female	TG	Total
2. Clients managed	-	-	-	10,753
3. RPR Tests conducted	2,875	4,216	132	7,223
4. Syphilis seropositivity (%)	2.61	0.95	10.61	1.79

### 4. Prevention of new HIV infections among high-risk group and bridge population

#### A. Targeted Interventions (TI) and Opioid Substitution Therapy (OST)

Indicator	2021-22
1. Targeted Interventions	5
2. OST centres	-
3. Employer Led Model Interventions	6

#### B. Female Sex Workers

Indicator	2021-22
1. Estimated size	2,238
2. Coverage (%)	>=95
3. Condoms distributed	6,37,529
4. Tested for HIV (April 2021 - September 2021)	2,512
4.1. HIV sero-positive (%)	0.04
4.1.1. Linked to ART	1
5. Tested for HIV (October 2021 - March 2022)	2,300
5.1. HIV sero-positive (%)	0.00
5.1.1. Linked to ART	-
6. Clinic Visits	7,638
7. STI/RTI treated	54
8. Presumptive treatment	513

#### C. Men who have Sex with Men

Indicator	2021-22
1. Estimated size	2,353
2. Coverage (%)	>=95
3. Condoms distributed	5,45,065
4. Tested for HIV (April 2021 - September 2021)	2,439
4.1. HIV sero-positive (%)	0.00
4.1.1. Linked to ART	-
5. Tested for HIV (October 2021 - March 2022)	2,381
5.1. HIV sero-positive (%)	0.00
5.1.1. Linked to ART	-
6. Clinic Visits	8,075
7. STI/RTI treated	21
8. Presumptive treatment	441

#### D. Injecting Drug Users

Indicator	2021-22
1. Estimated size	-
2. Coverage (%)	-
3. Needles distributed	-
4. Syringes distributed	-
5. On OST	-
6. Tested for HIV (April 2021 - September 2021)	-
6.1. HIV sero-positive (%)	-
6.1.1. Linked to ART	-
7. Tested for HIV (October 2021 - March 2022)	-
7.1. HIV sero-positive (%)	-
7.1.1. Linked to ART	-

#### E. Hijra/Transgender people

Indicator	2021-22
1. Estimated size	103
2. Coverage (%)	>=95
3. Condoms distributed	62,570
4. Tested for HIV (April 2021 - September 2021)	163
4.1. HIV sero-positive (%)	0.61
4.1.1. Linked to ART	1
5. Tested for HIV (October 2021 - March 2022)	154
5.1. HIV sero-positive (%)	-
5.1.1. Put on ART	-
6. Clinic Visits	549
7. STI / RTI treated	1
8. Presumptive treatment	25

#### F. Migrants

Indicator	2021-22
1. Estimated size	15,000
2. Coverage (%)	>=95
3. Tested for HIV	6,670
3.1. HIV sero-positive (%)	0.00
3.2. Linked to ART	-

#### G. Truckers

Indicator	2021-22
1. Estimated size	-
2. Coverage (%)	-
3. Tested for HIV	-
3.1. HIV sero-positive (%)	-
3.2. On ART	-

#### H. Prison Inmates

Indicator	2021-22
1. Total prisons	4
2. Prisons covered under programme	1
3. Total inmates admitted	1,047
4. Inmates Covered(%)	65
5. Tested for HIV	679
5.1. HIV sero-positive (%)	0.44
5.2. On ART (%)	100

#### I. Link Worker Scheme

Indicator	2021-22
1. Districts covered under scheme	-
2. Vulnerable population covered	-
3. Tested for HIV	-
3.1. HIV sero-positive (%)	-
3.2. Linked to ART (%)	-

## J. Opioid Substitution Therapy

Indicator	2021-22
1. OST Centres	-
1.1. OSTC in Public Health Settings	-
1.2. OSTC in NGO Settings	-
1.3 No. of Satellite OST Centres	-
2. IDU on OST	-

## 5. Early detection of HIV infected people

### A. HIV Counselling and Testing Services (HCTS)

Indicator	2021-22
1. ICTC facilities	81
1.1. Stand-alone	12
1.2. Facility integrated (Govt)	48
1.3. Facility integrated (PPP)	16
1.4. CBS	5

### B. HIV Testing among Vulnerable Population (Excluding Pregnant Women)

Indicator	2021-22			
	Male	Female	TG	Total
1. Tested for HIV	55,280	36,620	378	92,278
2. Found HIV Positive among tested	88	58	1	147
3. HIV sero-positivity (%) among tested	0.16	0.16	0.26	0.16
4. Spouse/sexual partner testing of HIV positive people identified	45	62	-	107

## 6. Initiation and retention on ART of HIV infected people

### A. Treatment Facilities

Indicator	2021-22
1. ART Centres	1
2. Centre of Excellence	
2.1. Centre of Excellence (Adult)	-
2.2. Centre of Excellence (Paediatric)	-
3. Link ART Centres	1
4. Care Support Centres	1

### B. Treatment Uptake

Indicator	2021-22			
	Male	Female	TG	Total
1. HIV positive cases diagnosed (At ICTC)	88	59	1	148
2. New PLHIV Registered at ART center	51	31	1	83
2.1 Initiated on ART	50	31	1	82
3. PLHIV alive and on ART	677	679	4	1,360
4. 12 months retention on ART (%)				78.26
5. Lost to follow-up cases	54	40	2	96

## 7. Viral Suppression and laboratories

### A. Laboratory facilities and service uptake

Indicator	2021-22
1. Viral load laboratories	-
1.1 Accredited Viral load laboratories	-
2. Viral load testing conducted	859
2.1. Virally suppressed (%)	83
3. National reference laboratories (NRL)	-
3.1 Accredited NRL	-
4. State reference laboratories (SRL)	1
4.1 Accredited SRL	1
5. CD4 testing conducted	1,196
6. External Quality Assessment of ICTC	
6.1 Average Participation (%)	100
6.2. Average Discordance (%)	0.00
7. Quality Assurance Scheme for Basic Composite Medical Laboratories (Entry Level)- M(EL)T	
7.1 No. of ICTCs certified for M(EL)T certification	5.00

## 8. Elimination of mother to child transmission of HIV & Syphilis

### A. HIV

Indicator	2021-22
1. Estimated pregnant women (PW)	22,670
2. HIV testing among PW	26,607
3. HIV sero-positivity (%) among tested	0.00
4. HIV Positive PW (old + new detections)	10
4.1 On life-long ART	10
5. Live births among HIV positive PW	12
5.1 Babies given ARV Prophylaxis (%)	91.67
6. Babies tested HIV (6 week- 6 month)	13
6.1 Babies confirmed HIV Positive (6 week- 6 month)	1
7. HIV exposed babies at 18 months	
7.1 HIV exposed babies tested at 18 month	8
7.2 Babies confirmed HIV positive at 18 months	-
8. HIV positive babies initiated on ART	1

### B. Syphilis

Indicator	2021-22
1. Estimated pregnant women (PW)	22,670
2. Syphilis testing among PW	25,473
3. Sero-positivity (%) among tested	0.03
4. Put on treatment	7

## 9. Elimination of HIV/AIDS related Stigma and Discrimination

### A. HIV/AIDS Prevention & Control Act (2017)

Indicator	2021-22
1. State rules notified for HIV/AIDS Prevention and Control Act (2017)	No
2. State designated/appointed ombudsman for HIV/AIDS Prevention and Control Act (2017)	Yes

## 10. HIV-TB Co-morbidities

### A. HRG and Bridge Population

Indicator								2021-22
	Quarter	FSW	MSW	IDU	TG	Migrants	Truckers	Total
Screened for TB	Quarter 1	2,115	2,158	-	165	1,505	-	5,943
	Quarter 2	2,394	2,592	-	186	2,884	-	8,056
	Quarter 3	2,527	2,616	-	184	4,027	-	9,354
	Quarter 4	2,548	2,545	-	178	3,230	-	8,501
Tested for TB	Quarter 1	5	3	-	-	-	-	8
	Quarter 2	15	34	-	10	-	-	59
	Quarter 3	-	2	-	-	-	-	2
	Quarter 4	12	19	-	9	-	-	40
Diagnosed with TB	Quarter 1	-	-	-	-	-	-	-
	Quarter 2	-	-	-	-	-	-	-
	Quarter 3	-	-	-	-	-	-	-
	Quarter 4	-	-	-	-	-	-	-
Initiated on TB treatment	Quarter 1	-	-	-	-	-	-	-
	Quarter 2	-	-	-	-	-	-	-
	Quarter 3	-	-	-	-	-	-	-
	Quarter 4	-	-	-	-	-	-	-

### B. HIV-TB Cross-Referral

Indicator	2021-22
1. In referral from TB program	846
1.1. HIV sero-positive (%)	-
1.2. ICTC clients referred to NTEP	274

### C. HIV-TB Coinfected at ART Centre

Indicator								2021-22
	PLHIV attending ART Centre	PLHIV underwent 4S screening	PLHIV with presumptive TB	PLHIV tested for TB	PLHIV diagnosed with TB	PLHIV initiated on IPT	Co-infected enrolled at ARTc	Co-infected initiated on ART
Apr-21	1,074	810	31	31	4	6		
May-21	791	574	17	17	2	5		
Jun-21	547	406	10	10	4	8		
Jul-21	547	406	10	10	4	8		
Aug-21	1,085	1,037	27	27	2	4		
Sep-21	1,110	1,019	32	32	1	3		
Oct-21	1,084	1,003	23	23	2	4		
Nov-21	1,048	939	34	34	2	4		
Dec-21	1,136	1,094	30	30	2	3		
Jan-22	1,120	1,009	29	29	2	7		
Feb-22	953	805	32	32	-	9		
Mar-22	1,095	991	39	39	2	8		
April 2021-March 2022							26	26



## 11. Scorecard

State/UT Name		Puducherry
Overall Rank		24
IEC & MS	Frequency of Social Media updates (G= ≥60, Y=40-59, R=<40)	
	Status of AEP integration in state School curriculum (G=Yes, R=No)	
	Status of SCA (G= At least one meeting held since 2017, R= other than G)	
	Status of State Rules (G= Notified, R= Not notified)	
	Status of Ombudsman (G= Appointed, R=Not appointed)	
	Rank	15
TI	Facilities onboarded (G=≥95%, Y= 90-94%, R=<90%)	
	Coverage against target in contract (G=≥95%, Y= 90-94%, R=<90%)	
	HRG & BP living with HIV on ART (G=≥95%, Y= 90-94%, R=<90%)	
	IDU on OST (G=≥95%, Y= 90-94%, R=<90%)	NA
	Rank	10
BSD	Percentage of PLHIV who know their status (G=≥95%, Y= 80-94%, R=<80%)	
	HIV testing against target-GC ((G=≥95%, Y= 80-94%, R=<80%)	
	HIV testing against target-PW (G=≥95%, Y= 80-94%, R=<80%)	
	Percentage of Pregnant women who initiated ART (G=≥95%, Y= 80-94%, R=<80%)	
	Percentage of TB suspected cases referred to NTEP (G=≥95%, Y= 80-94%, R=<80%)	
	Clients managed at DSRC against the target (G=≥95%, Y= 80-94%, R=<80%)	
	Percentage of pregnant women tested for Syphilis (G=≥95%, Y= 80-94%, R=<80%)	
	Rank	33
CST	ART Initiation (Current FY) (G=≥95%, Y= 80-94%, R=<80%)	
	LFU rate among new ART initiation (G=<2%, Y= 2-4%, R=≥5%)	
	PLHIV put on ART during the FY against target (G=≥95%, Y= 80-94%, R=<80%)	
	Status on establishment of CSC (G=≥95%, Y= 80-94%, R=<80%)	
	Rank	4
LS	VL Suppression Rate (Current FY) (G=≥95%, Y= 85-94%, R=<85%)	
	% of SRL accredited (G=100%, Y= 80-99%, R=<80%)	
	% Participation of ICTCs in Re-testing (G=≥95%, Y= 85-94, R=<85%)	
	Rank	6
SI	% of NACP facilities active in SOCH (G=≥90%, Y= 75-89%, R=<75%)	
	Status of State Data Management Committee (G=one meeting held, Y= no meeting held, R= not constituted)	
	Status of finalized Priority Areas for Operational Research and Evaluation (G= 4, Y= 3, R= <3)	
	Rank	14
Finance	Expenditure with respect to funds released during FY 2021-22 (G=≥90%, Y= 85-89%, R=<85%)	
	Submission of Audit Report after approval of EC/GB for the preceding year (G= by 30th June, Y= 30th Sept, R= beyond 30th Sept 2021)	
	Submission of Utilization Certificate (in prescribed format GFR 12A) for the previous financial year (G= by 30th June, Y= 30th Sept, R= beyond 30th Sept 2021)	
	Rank	23
SCM	Report Submission (BSD-SCM Report) (G=≥90%, Y= 75-89%, R=<75%)	

Green=3 Marks

Yellow=2Marks

Red=1 Mark

No Colour=Not Applicable

A thick red ribbon is tied in a loop, with the tail extending diagonally across the bottom right of the page. The background is a gradient of yellow and orange, featuring faint, concentric circular lines that create a ripple effect.

# FACT SHEET

## PUNJAB

## 1. Status of HIV/AIDS Epidemic

### A. Epidemic Estimates (2021)

Indicator	Male	Female	Total
1. IPR	-	-	1.89
2. IMR	-	-	1.20
3. Adult (15-49 yrs) HIV Prevalence (%)	0.32	0.23	0.28
4. Estimated people living with HIV	44,135	28,818	72,953
5. ART coverage (%)	75.6	58	69
6. Estimated children living with HIV	822	701	1,523
7. Annual new HIV infections	817	565	1,382
8. Annual AIDS-related deaths (ARD)	244	336	580
9. Change in annual new HIV infections since 2010 (%)	-71.6	-68.87	-70.52
10. Change in annual ARD since 2010(%)	-91.1	-73.97	-85.60
11. EMTCT need	-	520	520


### B. High risk population size (2009), safe practices (2015) and prevalence (2021)

Population Group	Estimates Size	Condom Use (%)	New Needle/ Syringe use (%)	HIV Prevalence (%)
1. Female Sex Workers	25,645	71.9	56.5	3.38
2. Men who have sex with men	5,862	55.1	14.6	11.62
3. Injecting Drug Users	22,961	64.6	86.7	19.57
4. Hijra/Transgender People	4,182	-	-	-
5. Migrants	1,31,850	-	-	3.01
6. Truckers	-	-	-	2.33
7. Prison inmates	75,276	60	44.8	7.49

### C. HIV/AIDS related knowledge, stigma and high-risk behaviour in general population (2019-21)

Indicator	Male	Female	Total
1. Adults (15-49 yrs) with comprehensive knowledge about HIV/AIDS (%)	37.5	20.6	-
2. Youth (15-24 yrs) with comprehensive knowledge about HIV/AIDS (%)	33.3	17.5	-
3. Adults willing to care for a relative with HIV/AIDS in own home (%)	79.8	77.2	-
4. Adults willing to buy fresh vegetables from a shopkeeper or vendor who has HIV/AIDS (%)	67.5	66.4	-
5. Adults (15-49 yrs) who have had higher-risk sexual behaviour in the past 12 months (%)	5.9	0.3	-
5.1 Condom use during last higher-risk intercourse (%)	56.9	30.1	-
6. Youth (15-24 yrs) who have had higher-risk sexual behaviour in the past 12 months (%)	8.5	0.6	-
6.1 Condom use during last higher-risk intercourse (%)	61.4	33.3	-

## 2. Progress on 95-95-95 (2021-22)



Indicator	Male	Female	Total
1. Estimated PLHIV size (2021)	44,135	28,818	72,953
2. PLHIV who know their HIV Status	42,191	19,032	61,223
3. PLHIV who know their HIV status and are on ART	33,929	16,943	50,872
4. PLHIV who are on ART and tested for their viral load	11,089	7,051	18,140
5. PLHIV who are virally suppressed	8,605	5,667	14,272

### 3. Prevention of new HIV infections among general population

#### A. Information, Education, Communication, Youth and Mainstreaming

Indicator	2021-22
1. Schools with operational Adolescent Education Program (AEP)	6,057
2. Colleges with operational Red Ribbon Clubs (RRC)	700
3. Persons trained under mainstreaming	5,806

#### B. Sexually Transmitted Infections (STI)/Reproductive Tract Infections (RTI) Management at DSRCs

Indicator	2021-22			
1. NACO Supported Designated STI/RTI Clinics (DSRC)	31			
	Male	Female	TG	Total
2. Clients managed	-	-	-	1,63,487
3. RPR Tests conducted	63,241	91,363	474	1,55,078
4. Syphilis seropositivity (%)	0.95	0.18	0.84	0.49

### 4. Prevention of new HIV infections among high-risk group and bridge population

#### A. Targeted Interventions (TI) and Opioid Substitution Therapy (OST)

Indicator	2021-22
1. Targeted Interventions	66
2. OST centres	40
3. Employer Led Model Interventions	60

#### B. Female Sex Workers

Indicator	2021-22
1. Estimated size	25,645
2. Coverage (%)	81
3. Condoms distributed	44,32,834
4. Tested for HIV (April 2021 - September 2021)	13,258
4.1. HIV sero-positive (%)	0.21
4.1.1. Linked to ART	26
5. Tested for HIV (October 2021 - March 2022)	13,712
5.1. HIV sero-positive (%)	0.18
5.1.1. Linked to ART	18
6. Clinic Visits	52,353
7. STI/RTI treated	990
8. Presumptive treatment	1,798

#### C. Men who have Sex with Men

Indicator	2021-22
1. Estimated size	5,862
2. Coverage (%)	81
3. Condoms distributed	11,27,774
4. Tested for HIV (April 2021 - September 2021)	3,775
4.1. HIV sero-positive (%)	0.90
4.1.1. Linked to ART	31
5. Tested for HIV (October 2021 - March 2022)	4,061
5.1. HIV sero-positive (%)	0.79
5.1.1. Linked to ART	25
6. Clinic Visits	15,733
7. STI/RTI treated	140
8. Presumptive treatment	737

### D. Injecting Drug Users

Indicator	2021-22
1. Estimated size	22,961
2. Coverage (%)	90
3. Needles distributed	35,53,647
4. Syringes distributed	24,17,153
5. On OST	10,733
6. Tested for HIV (April 2021 - September 2021)	15,645
6.1. HIV sero-positive (%)	2.04
6.1.1. Linked to ART	258
7. Tested for HIV (October 2021 - March 2022)	15,447
7.1. HIV sero-positive (%)	1.50
7.1.1. Linked to ART	176

### E. Hijra/Transgender people

Indicator	2021-22
1. Estimated size	4,182
2. Coverage (%)	20
3. Condoms distributed	2,56,468
4. Tested for HIV (April 2021 - September 2021)	685
4.1. HIV sero-positive (%)	0.44
4.1.1. Linked to ART	3
5. Tested for HIV (October 2021 - March 2022)	749
5.1. HIV sero-positive (%)	0.40
5.1.1. Put on ART	3
6. Clinic Visits	2,878
7. STI / RTI treated	47
8. Presumptive treatment	132

### F. Migrants

Indicator	2021-22
1. Estimated size	1,31,850
2. Coverage (%)	>=95
3. Tested for HIV	24,947
3.1. HIV sero-positive (%)	0.09
3.2. Linked to ART	21

### G. Truckers

Indicator	2021-22
1. Estimated size	-
2. Coverage (%)	-
3. Tested for HIV	10,090
3.1. HIV sero-positive (%)	0.24
3.2. On ART	22

### H. Prison Inmates

Indicator	2021-22
1. Total prisons	24
2. Prisons covered under programme	24
3. Total inmates admitted	62,987
4. Inmates Covered(%)	41
5. Tested for HIV	25,371
5.1. HIV sero-positive (%)	2.24
5.2. On ART (%)	95

### I. Link Worker Scheme

Indicator	2021-22
1. Districts covered under scheme	7
2. Vulnerable population covered	17,008
3. Tested for HIV	15,074
3.1. HIV sero-positive (%)	4.32
3.2. Linked to ART (%)	94.32

## J. Opioid Substitution Therapy

Indicator	2021-22
1. OST Centres	40
1.1. OSTC in Public Health Settings	25
1.2. OSTC in NGO Settings	9
1.3 No. of Satellite OST Centres	6
2. IDU on OST	10,733

## 5. Early detection of HIV infected people

### A. HIV Counselling and Testing Services (HCTS)

Indicator	2021-22
1. ICTC facilities	845
1.1. Stand-alone	116
1.2. Facility integrated (Govt)	372
1.3. Facility integrated (PPP)	266
1.4. CBS	91

### B. HIV Testing among Vulnerable Population (Excluding Pregnant Women)

Indicator	2021-22			
	Male	Female	TG	Total
1. Tested for HIV	5,26,699	2,34,197	539	7,61,435
2. Found HIV Positive among tested	6,355	1,289	365	8,009
3. HIV sero-positivity (%) among tested	1.21	0.55	67.72	1.05
4. Spouse/sexual partner testing of HIV positive people identified	902	1,021	80	2,003

## 6. Initiation and retention on ART of HIV infected people

### A. Treatment Facilities

Indicator	2021-22
1. ART Centres	19
2. Centre of Excellence	
2.1. Centre of Excellence (Adult)	-
2.2. Centre of Excellence (Paediatric)	-
3. Link ART Centres	12
4. Care Support Centres	8

### B. Treatment Uptake

Indicator	2021-22			
	Male	Female	TG	Total
1. HIV positive cases diagnosed (At ICTC)	6,355	1,735	365	8,455
2. New PLHIV Registered at ART center	7,142	1,889	33	9,064
2.1 Initiated on ART	7,032	1,877	33	8,942
3. PLHIV alive and on ART	33,365	16,636	147	50,148
4. 12 months retention on ART (%)				75.59
5. Lost to follow-up cases	6,551	1,515	28	8,094

## 7. Viral Suppression and laboratories

### A. Laboratory facilities and service uptake

Indicator	2021-22
1. Viral load laboratories	1
1.1 Accredited Viral load laboratories	-
2. Viral load testing conducted	23,341
2.1. Virally suppressed (%)	79
3. National reference laboratories (NRL)	-
3.1 Accredited NRL	-
4. State reference laboratories (SRL)	2
4.1 Accredited SRL	2
5. CD4 testing conducted	38,290
6. External Quality Assessment of ICTC	
6.1 Average Participation (%)	69.74
6.2. Average Discordance (%)	0.00
7. Quality Assurance Scheme for Basic Composite Medical Laboratories (Entry Level)- M(EL)T	
7.1 No. of ICTCs certified for M(EL)T certification	-

## 8. Elimination of mother to child transmission of HIV & Syphilis

### A. HIV

Indicator	2021-22
1. Estimated pregnant women (PW)	4,83,520
2. HIV testing among PW	4,14,443
3. HIV sero-positivity (%) among tested	0.11
4. HIV Positive PW (old + new detections)	647
4.1 On life-long ART	593
5. Live births among HIV positive PW	367
5.1 Babies given ARV Prophylaxis (%)	92.10
6. Babies tested HIV (6 week- 6 month)	411
6.1 Babies confirmed HIV Positive (6 week- 6 month)	5
7. HIV exposed babies at 18 months	
7.1 HIV exposed babies tested at 18 month	191
7.2 Babies confirmed HIV positive at 18 months	2
8. HIV positive babies initiated on ART	8

### B. Syphilis

Indicator	2021-22
1. Estimated pregnant women (PW)	4,83,520
2. Syphilis testing among PW	3,09,599
3. Sero-positivity (%) among tested	0.02
4. Put on treatment	70

## 9. Elimination of HIV/AIDS related Stigma and Discrimination

### A. HIV/AIDS Prevention & Control Act (2017)

Indicator	2021-22
1. State rules notified for HIV/AIDS Prevention and Control Act (2017)	Yes
2. State designated/appointed ombudsman for HIV/AIDS Prevention and Control Act (2017)	Yes

## 10. HIV-TB Co-morbidities

### A. HRG and Bridge Population

Indicator								2021-22
	Quarter	FSW	MSW	IDU	TG	Migrants	Truckers	Total
Screened for TB	Quarter 1	12,757	3,656	14,438	684	5,747	3,088	40,370
	Quarter 2	13,147	3,868	17,288	738	6,691	4,825	46,557
	Quarter 3	12,578	3,926	17,418	578	6,099	5,206	45,805
	Quarter 4	12,848	4,264	18,244	852	8,213	5,867	50,288
Tested for TB	Quarter 1	14	12	350	-	26	2	404
	Quarter 2	4	16	326	1	30	6	383
	Quarter 3	4	8	160	-	14	9	195
	Quarter 4	12	12	76	-	19	3	122
Diagnosed with TB	Quarter 1	-	1	7	-	6	1	15
	Quarter 2	-	1	16	1	3	-	21
	Quarter 3	1	-	3	-	1	1	6
	Quarter 4	1	1	3	-	4	1	10
Initiated on TB treatment	Quarter 1	-	1	4	-	6	1	12
	Quarter 2	-	1	16	1	3	-	21
	Quarter 3	1	-	3	-	1	1	6
	Quarter 4	1	-	3	-	4	1	9

### B. HIV-TB Cross-Referral

Indicator	2021-22
1. In referral from TB program	23,953
1.1. HIV sero-positive (%)	3.31
1.2. ICTC clients referred to NTEP	15,904

### C. HIV-TB Coinfected at ART Centre

Indicator							2021-22	
	PLHIV attending ART Centre	PLHIV underwent 4S screening	PLHIV with presumptive TB	PLHIV tested for TB	PLHIV diagnosed with TB	PLHIV initiated on IPT	Co-infected enrolled at ARTc	Co-infected initiated on ART
Apr-21	26,084	25,985	430	364	59	708		
May-21	23,572	21,937	244	164	40	879		
Jun-21	21,604	21,574	327	286	68	973		
Jul-21	24,902	24,876	318	262	54	870		
Aug-21	24,396	24,384	336	272	60	981		
Sep-21	24,735	24,717	419	335	68	972		
Oct-21	24,186	24,159	414	299	62	906		
Nov-21	22,484	22,471	240	184	37	587		
Dec-21	22,467	22,452	282	251	26	590		
Jan-22	23,507	23,495	303	260	47	537		
Feb-22	21,697	21,680	335	282	51	574		
Mar-22	25,184	25,160	370	326	83	562		
April 2021- March 2022							972	936

## 11. Scorecard

State/UT Name		Andaman & Nicobar Islands
Overall Rank		15
IEC & MS	Frequency of Social Media updates (G= ≥60, Y=40-59, R=<40)	
	Status of AEP integration in state School curriculum (G=Yes, R=No)	
	Status of SCA (G= At least one meeting held since 2017, R= other than G)	
	Status of State Rules (G= Notified, R= Not notified)	
	Status of Ombudsman (G= Appointed, R=Not appointed)	
	Rank	15
TI	Facilities onboarded (G=≥95%, Y= 90-94%, R=<90%)	
	Coverage against target in contract (G=≥95%, Y= 90-94%, R=<90%)	
	HRG & BP living with HIV on ART (G=≥95%, Y= 90-94%, R=<90%)	
	IDU on OST (G=≥95%, Y= 90-94%, R=<90%)	
	Rank	1
BSD	Percentage of PLHIV who know their status (G=≥95%, Y= 80-94%, R=<80%)	
	HIV testing against target-GC ((G=≥95%, Y= 80-94%, R=<80%)	
	HIV testing against target-PW (G=≥95%, Y= 80-94%, R=<80%)	
	Percentage of Pregnant women who initiated ART (G=≥95%, Y= 80-94%, R=<80%)	
	Percentage of TB suspected cases referred to NTEP (G=≥95%, Y= 80-94%, R=<80%)	
	Clients managed at DSRC against the target (G=≥95%, Y= 80-94%, R=<80%)	
	Percentage of pregnant women tested for Syphilis (G=≥95%, Y= 80-94%, R=<80%)	
	Rank	22
CST	ART Initiation (Current FY) (G=≥95%, Y= 80-94%, R=<80%)	
	LFU rate among new ART initiation (G=<2%, Y= 2-4%, R=≥5%)	
	PLHIV put on ART during the FY against target (G=≥95%, Y= 80-94%, R=<80%)	
	Status on establishment of CSC (G=≥95%, Y= 80-94%, R=<80%)	NA
	Rank	6
LS	VL Suppression Rate (Current FY) (G=≥95%, Y= 85-94%, R=<85%)	
	% of SRL accredited (G=100%, Y= 80-99%, R=<80%)	
	% Participation of ICTCs in Re-testing (G=≥95%, Y= 85-94, R=<85%)	
	Rank	19
SI	% of NACP facilities active in SOCH (G=≥90%, Y= 75-89%, R=<75%)	
	Status of State Data Management Committee (G=one meeting held, Y= no meeting held, R= not constituted)	
	Status of finalized Priority Areas for Operational Research and Evaluation (G= 4, Y= 3, R= <3)	
	Rank	25
Finance	Expenditure with respect to funds released during FY 2021-22 (G=≥90%, Y= 85-89%, R=<85%)	
	Submission of Audit Report after approval of EC/GB for the preceding year (G= by 30th June, Y= 30th Sept, R= beyond 30th Sept 2021)	
	Submission of Utilization Certificate (in prescribed format GFR 12A) for the previous financial year (G= by 30th June, Y= 30th Sept, R= beyond 30th Sept 2021)	
	Rank	5
SCM	Report Submission (BSD-SCM Report) (G=≥90%, Y= 75-89%, R=<75%)	

Green=3 Marks

Yellow=2Marks

Red=1 Mark

No Colour=Not Applicable





# FACT SHEET

## RAJASTHAN

# RAJASTHAN

## 1. Status of HIV/AIDS Epidemic

### A. Epidemic Estimates (2021)

Indicator	Male	Female	Total
1. IPR	-	-	3.40
2. IMR	-	-	2.30
3. Adult (15-49 yrs) HIV Prevalence (%)	0.12	0.08	0.10
4. Estimated people living with HIV	40,473	26,713	67,186
5. ART coverage (%)	70.3	94	80
6. Estimated children living with HIV	1,257	1,103	2,360
7. Annual new HIV infections	1,382	902	2,284
8. Annual AIDS-related deaths (ARD)	341	81	422
9. Change in annual new HIV infections since 2010 (%)	-42.7	-36.52	-40.43
10. Change in annual ARD since 2010(%)	-77.0	-87.73	-80.29
11. EMTCT need	-	788	788


### B. High risk population size (2009), safe practices (2015) and prevalence (2021)

Population Group	Estimates Size	Condom Use (%)	New Needle/ Syringe use (%)	HIV Prevalence (%)
1. Female Sex Workers	27,530	62.6	40.7	2.75
2. Men who have sex with men	12,088	32.7	18.6	6.4
3. Injecting Drug Users	1,954	38.7	92.2	-
4. Hijra/Transgender People	1,847	-	-	3.6
5. Migrants	1,10,000	-	-	0.39
6. Truckers	38,340	-	-	0
7. Prison inmates	1,18,516	50	7.7	0.67

### C. HIV/AIDS related knowledge, stigma and high-risk behaviour in general population (2019-21)

Indicator	Male	Female	Total
1. Adults (15-49 yrs) with comprehensive knowledge about HIV/AIDS (%)	36	26.8	-
2. Youth (15-24 yrs) with comprehensive knowledge about HIV/AIDS (%)	34.3	27.6	-
3. Adults willing to care for a relative with HIV/AIDS in own home (%)	76	76	-
4. Adults willing to buy fresh vegetables from a shopkeeper or vendor who has HIV/AIDS (%)	78.2	72.4	-
5. Adults (15-49 yrs) who have had higher-risk sexual behaviour in the past 12 months (%)	6.4	0.9	-
5.1 Condom use during last higher-risk intercourse (%)	73.8	74.6	-
6. Youth (15-24 yrs) who have had higher-risk sexual behaviour in the past 12 months (%)	11.6	2.1	-
6.1 Condom use during last higher-risk intercourse (%)	74.2	76.5	-

## 2. Progress on 95-95-95 (2021-22)



Indicator	Male	Female	Total
1. Estimated PLHIV size (2021)	40,473	26,713	67,186
2. PLHIV who know their HIV Status	32,128	27,886	60,014
3. PLHIV who know their HIV status and are on ART	27,477	24,229	51,706
4. PLHIV who are on ART and tested for their viral load	14,615	13,080	27,695
5. PLHIV who are virally suppressed	12,170	11,272	23,442

### 3. Prevention of new HIV infections among general population

#### A. Information, Education, Communication, Youth and Mainstreaming

Indicator	2021-22
1. Schools with operational Adolescent Education Program (AEP)	300
2. Colleges with operational Red Ribbon Clubs (RRC)	715
3. Persons trained under mainstreaming	6,439

#### B. Sexually Transmitted Infections (STI)/Reproductive Tract Infections (RTI) Management at DSRCs

Indicator	2021-22			
1. NACO Supported Designated STI/RTI Clinics (DSRC)	53			
	Male	Female	TG	Total
2. Clients managed	-	-	-	1,93,566
3. RPR Tests conducted	35,174	99,111	21	1,34,306
4. Syphilis seropositivity (%)	1.63	0.44	0.00	0.75

### 4. Prevention of new HIV infections among high-risk group and bridge population

#### A. Targeted Interventions (TI) and Opioid Substitution Therapy (OST)

Indicator	2021-22
1. Targeted Interventions	42
2. OST centres	2
3. Employer Led Model Interventions	36

#### B. Female Sex Workers

Indicator	2021-22
1. Estimated size	27,530
2. Coverage (%)	57
3. Condoms distributed	45,39,009
4. Tested for HIV (April 2021 - September 2021)	11,481
4.1. HIV sero-positive (%)	0.10
4.1.1. Linked to ART	11
5. Tested for HIV (October 2021 - March 2022)	11,895
5.1. HIV sero-positive (%)	0.15
5.1.1. Linked to ART	18
6. Clinic Visits	42,038
7. STI/RTI treated	849
8. Presumptive treatment	778

#### C. Men who have Sex with Men

Indicator	2021-22
1. Estimated size	12,088
2. Coverage (%)	46
3. Condoms distributed	12,26,783
4. Tested for HIV (April 2021 - September 2021)	4,125
4.1. HIV sero-positive (%)	0.29
4.1.1. Linked to ART	12
5. Tested for HIV (October 2021 - March 2022)	4,257
5.1. HIV sero-positive (%)	0.19
5.1.1. Linked to ART	7
6. Clinic Visits	15,477
7. STI/RTI treated	211
8. Presumptive treatment	249

#### D. Injecting Drug Users

Indicator	2021-22
1. Estimated size	1,954
2. Coverage (%)	87
3. Needles distributed	5,64,423
4. Syringes distributed	3,14,806
5. On OST	236
6. Tested for HIV (April 2021 - September 2021)	1,360
6.1. HIV sero-positive (%)	0.88
6.1.1. Linked to ART	1
7. Tested for HIV (October 2021 - March 2022)	1,592
7.1. HIV sero-positive (%)	1.44
7.1.1. Linked to ART	33

#### E. Hijra/Transgender people

Indicator	2021-22
1. Estimated size	1,847
2. Coverage (%)	52
3. Condoms distributed	1,59,110
4. Tested for HIV (April 2021 - September 2021)	629
4.1. HIV sero-positive (%)	0.16
4.1.1. Linked to ART	1
5. Tested for HIV (October 2021 - March 2022)	756
5.1. HIV sero-positive (%)	0.13
5.1.1. Put on ART	1
6. Clinic Visits	2,479
7. STI / RTI treated	34
8. Presumptive treatment	83

#### F. Migrants

Indicator	2021-22
1. Estimated size	1,10,000
2. Coverage (%)	>=95
3. Tested for HIV	15,922
3.1. HIV sero-positive (%)	0.06
3.2. Linked to ART	9

#### G. Truckers

Indicator	2021-22
1. Estimated size	38,340
2. Coverage (%)	52
3. Tested for HIV	3,696
3.1. HIV sero-positive (%)	0.14
3.2. On ART	6

#### H. Prison Inmates

Indicator	2021-22
1. Total prisons	144
2. Prisons covered under programme	144
3. Total inmates admitted	1,14,424
4. Inmates Covered(%)	52
5. Tested for HIV	58,635
5.1. HIV sero-positive (%)	0.34
5.2. On ART (%)	87

#### I. Link Worker Scheme

Indicator	2021-22
1. Districts covered under scheme	-
2. Vulnerable population covered	-
3. Tested for HIV	-
3.1. HIV sero-positive (%)	-
3.2. Linked to ART (%)	-

## J. Opioid Substitution Therapy

Indicator	2021-22
1. OST Centres	2
1.1. OSTC in Public Health Settings	2
1.2. OSTC in NGO Settings	-
1.3 No. of Satellite OST Centres	-
2. IDU on OST	236

## 5. Early detection of HIV infected people

### A. HIV Counselling and Testing Services (HCTS)

Indicator	2021-22
1. ICTC facilities	2,705
1.1. Stand-alone	184
1.2. Facility integrated (Govt)	2,280
1.3. Facility integrated (PPP)	149
1.4. CBS	92

### B. HIV Testing among Vulnerable Population (Excluding Pregnant Women)

Indicator	2021-22			
	Male	Female	TG	Total
1. Tested for HIV	6,80,463	5,64,737	1,356	12,46,556
2. Found HIV Positive among tested	3,511	1,725	6	5,242
3. HIV sero-positivity (%) among tested	0.52	0.31	0.44	0.42
4. Spouse/sexual partner testing of HIV positive people identified	1,276	1,372	15	2,663

## 6. Initiation and retention on ART of HIV infected people

### A. Treatment Facilities

Indicator	2021-22
1. ART Centres	35
2. Centre of Excellence	
2.1. Centre of Excellence (Adult)	-
2.2. Centre of Excellence (Paediatric)	-
3. Link ART Centres	25
4. Care Support Centres	17

### B. Treatment Uptake

Indicator	2021-22			
	Male	Female	TG	Total
1. HIV positive cases diagnosed (At ICTC)	3,511	2,019	6	5,536
2. New PLHIV Registered at ART center	3,389	2,027	6	5,422
2.1 Initiated on ART	3,275	1,982	6	5,263
3. PLHIV alive and on ART	28,472	25,043	73	53,587
4. 12 months retention on ART (%)				77.67
5. Lost to follow-up cases	2,770	2,016	12	4,798

## 7. Viral Suppression and laboratories

### A. Laboratory facilities and service uptake

Indicator	2021-22
1. Viral load laboratories	3
1.1 Accredited Viral load laboratories	-
2. Viral load testing conducted	31,276
2.1. Virally suppressed (%)	85
3. National reference laboratories (NRL)	-
3.1 Accredited NRL	-
4. State reference laboratories (SRL)	6
4.1 Accredited SRL	1
5. CD4 testing conducted	53,810
6. External Quality Assessment of ICTC	
6.1 Average Participation (%)	85.66
6.2. Average Discordance (%)	0.00
7. Quality Assurance Scheme for Basic Composite Medical Laboratories (Entry Level)- M(EL)T	
7.1 No. of ICTCs certified for M(EL)T certification	-

## 8. Elimination of mother to child transmission of HIV & Syphilis

### A. HIV

Indicator	2021-22
1. Estimated pregnant women (PW)	20,64,990
2. HIV testing among PW	11,40,211
3. HIV sero-positivity (%) among tested	0.03
4. HIV Positive PW (old + new detections)	682
4.1 On life-long ART	688
5. Live births among HIV positive PW	570
5.1 Babies given ARV Prophylaxis (%)	99.47
6. Babies tested HIV (6 week- 6 month)	599
6.1 Babies confirmed HIV Positive (6 week- 6 month)	5
7. HIV exposed babies at 18 months	
7.1 HIV exposed babies tested at 18 month	465
7.2 Babies confirmed HIV positive at 18 months	25
8. HIV positive babies initiated on ART	23

### B. Syphilis

Indicator	2021-22
1. Estimated pregnant women (PW)	20,64,990
2. Syphilis testing among PW	9,94,417
3. Sero-positivity (%) among tested	0.07
4. Put on treatment	631

## 9. Elimination of HIV/AIDS related Stigma and Discrimination

### A. HIV/AIDS Prevention & Control Act (2017)

Indicator	2021-22
1. State rules notified for HIV/AIDS Prevention and Control Act (2017)	Yes
2. State designated/appointed ombudsman for HIV/AIDS Prevention and Control Act (2017)	Yes

## 10. HIV-TB Co-morbidities

## A. HRG and Bridge Population

Indicator								2021-22
	Quarter	FSW	MSW	IDU	TG	Migrants	Truckers	Total
Screened for TB	Quarter 1	16,460	7,061	847	694	31,231	7,789	64,082
	Quarter 2	20,788	8,091	1,976	1,060	37,751	14,252	83,918
	Quarter 3	20,462	8,095	2,014	1,118	40,169	13,883	85,741
	Quarter 4	21,208	8,191	2,340	1,454	38,226	13,868	85,287
Tested for TB	Quarter 1	6	9	-	-	3	1	19
	Quarter 2	20	12	-	-	11	7	50
	Quarter 3	41	5	-	-	40	9	95
	Quarter 4	15	19	-	-	14	8	56
Diagnosed with TB	Quarter 1	-	-	-	-	-	-	-
	Quarter 2	3	-	-	-	-	1	4
	Quarter 3	-	1	-	-	1	3	5
	Quarter 4	2	-	-	-	1	2	5
Initiated on TB treatment	Quarter 1	-	-	-	-	-	-	-
	Quarter 2	3	-	-	-	-	-	3
	Quarter 3	-	1	-	-	1	3	5
	Quarter 4	2	-	-	-	1	2	5

## B. HIV-TB Cross-Referral

Indicator	2021-22
1. In referral from TB program	40,989
1.1. HIV sero-positive (%)	1.83
1.2. ICTC clients referred to NTEP	37,346

## C. HIV-TB Coinfected at ART Centre

Indicator								2021-22
	PLHIV attending ART Centre	PLHIV underwent 4S screening	PLHIV with presumptive TB	PLHIV tested for TB	PLHIV diagnosed with TB	PLHIV initiated on IPT	Co-infected enrolled at ARTc	Co-infected initiated on ART
Apr-21	35,768	34,175	1,190	1,186	78	1,209		
May-21	24,715	23,009	982	976	43	552		
Jun-21	22,127	21,172	1,192	1,184	86	840		
Jul-21	31,705	30,745	1,321	1,318	145	1,150		
Aug-21	29,025	27,818	1,292	1,274	135	930		
Sep-21	31,414	30,403	1,439	1,414	126	785		
Oct-21	30,941	30,175	1,417	1,384	115	724		
Nov-21	27,883	27,282	1,377	1,351	106	779		
Dec-21	28,847	27,992	1,522	1,478	139	1,188		
Jan-22	28,513	28,078	1,543	1,500	124	988		
Feb-22	26,264	25,922	1,667	1,598	137	919		
Mar-22	30,463	30,289	1,699	909	130	1,035		
April 2021-March 2022							1,490	1,435

# 11. Scorecard

State/UT Name		Rajasthan
Overall Rank		11
IEC & MS	Frequency of Social Media updates (G= ≥60, Y=40-59, R=<40)	
	Status of AEP integration in state School curriculum (G=Yes, R=No)	
	Status of SCA (G= At least one meeting held since 2017, R= other than G)	
	Status of State Rules (G= Notified, R= Not notified)	
	Status of Ombudsman (G= Appointed, R=Not appointed)	
	Rank	1
TI	Facilities onboarded (G=≥95%, Y= 90-94%, R=<90%)	
	Coverage against target in contract (G=≥95%, Y= 90-94%, R=<90%)	
	HRG & BP living with HIV on ART (G=≥95%, Y= 90-94%, R=<90%)	
	IDU on OST (G=≥95%, Y= 90-94%, R=<90%)	
	Rank	11
BSD	Percentage of PLHIV who know their status (G=≥95%, Y= 80-94%, R=<80%)	
	HIV testing against target-GC ((G=≥95%, Y= 80-94%, R=<80%)	
	HIV testing against target-PW (G=≥95%, Y= 80-94%, R=<80%)	
	Percentage of Pregnant women who initiated ART (G=≥95%, Y= 80-94%, R=<80%)	
	Percentage of TB suspected cases referred to NTEP (G=≥95%, Y= 80-94%, R=<80%)	
	Clients managed at DSRC against the target (G=≥95%, Y= 80-94%, R=<80%)	
	Percentage of pregnant women tested for Syphilis (G=≥95%, Y= 80-94%, R=<80%)	
	Rank	11
CST	ART Initiation (Current FY) (G=≥95%, Y= 80-94%, R=<80%)	
	LFU rate among new ART initiation (G=<2%, Y= 2-4%, R=≥5%)	
	PLHIV put on ART during the FY against target (G=≥95%, Y= 80-94%, R=<80%)	
	Status on establishment of CSC (G=≥95%, Y= 80-94%, R=<80%)	
	Rank	11
LS	VL Suppression Rate (Current FY) (G=≥95%, Y= 85-94%, R=<85%)	
	% of SRL accredited (G=100%, Y= 80-99%, R=<80%)	
	% Participation of ICTCs in Re-testing (G=≥95%, Y= 85-94%, R=<85%)	
	Rank	19
SI	% of NACP facilities active in SOCH (G=≥90%, Y= 75-89%, R=<75%)	
	Status of State Data Management Committee (G=one meeting held, Y= no meeting held, R= not constituted)	
	Status of finalized Priority Areas for Operational Research and Evaluation (G= 4, Y= 3, R= <3)	
	Rank	4
Finance	Expenditure with respect to funds released during FY 2021-22 (G=≥90%, Y= 85-89%, R=<85%)	
	Submission of Audit Report after approval of EC/GB for the preceding year (G= by 30th June, Y= 30th Sept, R= beyond 30th Sept 2021)	
	Submission of Utilization Certificate (in prescribed format GFR 12A) for the previous financial year (G= by 30th June, Y= 30th Sept, R= beyond 30th Sept 2021)	
	Rank	23
SCM	Report Submission (BSD-SCM Report) (G=≥90%, Y= 75-89%, R=<75%)	

Green=3 Marks

Yellow=2Marks

Red=1 Mark

No Colour=Not Applicable

A thick red ribbon is tied in a loop on the right side of the page, with the tail extending downwards and then curving back towards the left. The background is a gradient of yellow and orange with faint concentric circles.

# FACT SHEET

## SIKKIM



## 1. Status of HIV/AIDS Epidemic

### A. Epidemic Estimates (2021)

Indicator	Male	Female	Total
1. IPR	-	-	7.26
2. IMR	-	-	5.67
3. Adult (15-49 yrs) HIV Prevalence (%)	0.10	0.07	0.09
4. Estimated people living with HIV	283	185	468
5. ART coverage (%)	53.4	62	57
6. Estimated children living with HIV	9	9	18
7. Annual new HIV infections	21	13	34
8. Annual AIDS-related deaths (ARD)	2	1	3
9. Change in annual new HIV infections since 2010 (%)	16.7	8.33	13.33
10. Change in annual ARD since 2010(%)	-50.0	0.00	-40.00
11. EMTCT need	-	5	5


### B. High risk population size (2009), safe practices (2015) and prevalence (2021)

Population Group	Estimates Size	Condom Use (%)	New Needle/ Syringe use (%)	HIV Prevalence (%)
1. Female Sex Workers	850	-	-	0
2. Men who have sex with men	128	-	-	-
3. Injecting Drug Users	1,450	28.6	89.7	0.2
4. Hijra/Transgender People	-	-	-	-
5. Migrants	-	-	-	-
6. Truckers	-	-	-	-
7. Prison inmates	944	-	-	-

### C. HIV/AIDS related knowledge, stigma and high-risk behaviour in general population (2019-21)

Indicator	Male	Female	Total
1. Adults (15-49 yrs) with comprehensive knowledge about HIV/AIDS (%)	18.5	23.9	-
2. Youth (15-24 yrs) with comprehensive knowledge about HIV/AIDS (%)	15.1	29.3	-
3. Adults willing to care for a relative with HIV/AIDS in own home (%)	64.1	74.4	-
4. Adults willing to buy fresh vegetables from a shopkeeper or vendor who has HIV/AIDS (%)	67.4	73.1	-
5. Adults (15-49 yrs) who have had higher-risk sexual behaviour in the past 12 months (%)	12.8	3.6	-
5.1 Condom use during last higher-risk intercourse (%)	71.8	52.3	-
6. Youth (15-24 yrs) who have had higher-risk sexual behaviour in the past 12 months (%)	6.9	7.9	-
6.1 Condom use during last higher-risk intercourse (%)	42.9	58.3	-

## 2. Progress on 95-95-95 (2021-22)



Indicator	Male	Female	Total
1. Estimated PLHIV size (2021)	283	185	468
2. PLHIV who know their HIV Status	174	132	306
3. PLHIV who know their HIV status and are on ART	147	111	258
4. PLHIV who are on ART and tested for their viral load	191	153	344
5. PLHIV who are virally suppressed	171	141	312

### 3. Prevention of new HIV infections among general population

#### A. Information, Education, Communication, Youth and Mainstreaming

Indicator	2021-22
1. Schools with operational Adolescent Education Program (AEP)	80
2. Colleges with operational Red Ribbon Clubs (RRC)	123
3. Persons trained under mainstreaming	1,100

#### B. Sexually Transmitted Infections (STI)/Reproductive Tract Infections (RTI) Management at DSRCs

Indicator	2021-22			
1. NACO Supported Designated STI/RTI Clinics (DSRC)	6			
	Male	Female	TG	Total
2. Clients managed	-	-	-	1,309
3. RPR Tests conducted	341	968	0	1,309
4. Syphilis seropositivity (%)	7.92	2.07	-	3.59

### 4. Prevention of new HIV infections among high-risk group and bridge population

#### A. Targeted Interventions (TI) and Opioid Substitution Therapy (OST)

Indicator	2021-22
1. Targeted Interventions	6
2. OST centres	4
3. Employer Led Model Interventions	-

#### B. Female Sex Workers

Indicator	2021-22
1. Estimated size	850
2. Coverage (%)	>=95
3. Condoms distributed	1,94,595
4. Tested for HIV (April 2021 - September 2021)	729
4.1. HIV sero-positive (%)	0.00
4.1.1. Linked to ART	-
5. Tested for HIV (October 2021 - March 2022)	875
5.1. HIV sero-positive (%)	0.00
5.1.1. Linked to ART	-
6. Clinic Visits	2,626
7. STI/RTI treated	65
8. Presumptive treatment	169

#### C. Men who have Sex with Men

Indicator	2021-22
1. Estimated size	128
2. Coverage (%)	-
3. Condoms distributed	-
4. Tested for HIV (April 2021 - September 2021)	-
4.1. HIV sero-positive (%)	-
4.1.1. Linked to ART	-
5. Tested for HIV (October 2021 - March 2022)	-
5.1. HIV sero-positive (%)	-
5.1.1. Linked to ART	-
6. Clinic Visits	-
7. STI/RTI treated	-
8. Presumptive treatment	-

#### D. Injecting Drug Users

Indicator	2021-22
1. Estimated size	1,450
2. Coverage (%)	>=95
3. Needles distributed	4,02,932
4. Syringes distributed	4,03,229
5. On OST	1,325
6. Tested for HIV (April 2021 - September 2021)	1,153
6.1. HIV sero-positive (%)	0.00
6.1.1. Linked to ART	0
7. Tested for HIV (October 2021 - March 2022)	1,081
7.1. HIV sero-positive (%)	0.00
7.1.1. Linked to ART	0

#### E. Hijra/Transgender people

Indicator	2021-22
1. Estimated size	-
2. Coverage (%)	-
3. Condoms distributed	-
4. Tested for HIV (April 2021 - September 2021)	-
4.1. HIV sero-positive (%)	-
4.1.1. Linked to ART	-
5. Tested for HIV (October 2021 - March 2022)	-
5.1. HIV sero-positive (%)	-
5.1.1. Put on ART	-
6. Clinic Visits	-
7. STI / RTI treated	-
8. Presumptive treatment	-

#### F. Migrants

Indicator	2021-22
1. Estimated size	-
2. Coverage (%)	-
3. Tested for HIV	-
3.1. HIV sero-positive (%)	-
3.2. Linked to ART	-

#### G. Truckers

Indicator	2021-22
1. Estimated size	-
2. Coverage (%)	-
3. Tested for HIV	-
3.1. HIV sero-positive (%)	-
3.2. On ART	-

#### H. Prison Inmates

Indicator	2021-22
1. Total prisons	2
2. Prisons covered under programme	1
3. Total inmates admitted	737
4. Inmates Covered(%)	44
5. Tested for HIV	324
5.1. HIV sero-positive (%)	0.00
5.2. On ART (%)	-

#### I. Link Worker Scheme

Indicator	2021-22
1. Districts covered under scheme	-
2. Vulnerable population covered	-
3. Tested for HIV	-
3.1. HIV sero-positive (%)	-
3.2. Linked to ART (%)	-

## J. Opioid Substitution Therapy

Indicator	2021-22
1. OST Centres	4
1.1. OSTC in Public Health Settings	4
1.2. OSTC in NGO Settings	-
1.3 No. of Satellite OST Centres	-
2. IDU on OST	1,325

## 5. Early detection of HIV infected people

### A. HIV Counselling and Testing Services (HCTS)

Indicator	2021-22
1. ICTC facilities	45
1.1. Stand-alone	13
1.2. Facility integrated (Govt)	26
1.3. Facility integrated (PPP)	-
1.4. CBS	6

### B. HIV Testing among Vulnerable Population (Excluding Pregnant Women)

Indicator	2021-22			
	Male	Female	TG	Total
1. Tested for HIV	11,946	6,676	-	18,622
2. Found HIV Positive among tested	44	9	-	53
3. HIV sero-positivity (%) among tested	0.37	0.13	-	0.28
4. Spouse/sexual partner testing of HIV positive people identified	1	2	-	3

## 6. Initiation and retention on ART of HIV infected people

### A. Treatment Facilities

Indicator	2021-22
1. ART Centres	1
2. Centre of Excellence	
2.1. Centre of Excellence (Adult)	-
2.2. Centre of Excellence (Paediatric)	-
3. Link ART Centres	1
4. Care Support Centres	-

### B. Treatment Uptake

Indicator	2021-22			
	Male	Female	TG	Total
1. HIV positive cases diagnosed (At ICTC)	44	10	-	54
2. New PLHIV Registered at ART center	28	10	-	38
2.1 Initiated on ART	25	10	-	35
3. PLHIV alive and on ART	151	115	-	267
4. 12 months retention on ART (%)				75.00
5. Lost to follow-up cases	12	6	-	18

## 7. Viral Suppression and laboratories

### A. Laboratory facilities and service uptake

Indicator	2021-22
1. Viral load laboratories	-
1.1 Accredited Viral load laboratories	-
2. Viral load testing conducted	325
2.1. Virally suppressed (%)	91
3. National reference laboratories (NRL)	-
3.1 Accredited NRL	-
4. State reference laboratories (SRL)	1
4.1 Accredited SRL	1
5. CD4 testing conducted	222
6. External Quality Assessment of ICTC	
6.1 Average Participation (%)	75.00
6.2. Average Discordance (%)	0.00
7. Quality Assurance Scheme for Basic Composite Medical Laboratories (Entry Level)- M(EL)T	
7.1 No. of ICTCs certified for M(EL)T certification	-

## 8. Elimination of mother to child transmission of HIV & Syphilis

### A. HIV

Indicator	2021-22
1. Estimated pregnant women (PW)	11,970
2. HIV testing among PW	7,682
3. HIV sero-positivity (%) among tested	0.01
4. HIV Positive PW (old + new detections)	3
4.1 On life-long ART	1
5. Live births among HIV positive PW	3
5.1 Babies given ARV Prophylaxis (%)	100.00
6. Babies tested HIV (6 week- 6 month)	-
6.1 Babies confirmed HIV Positive (6 week- 6 month)	-
7. HIV exposed babies at 18 months	
7.1 HIV exposed babies tested at 18 month	3
7.2 Babies confirmed HIV positive at 18 months	-
8. HIV positive babies initiated on ART	-

### B. Syphilis

Indicator	2021-22
1. Estimated pregnant women (PW)	11,970
2. Syphilis testing among PW	6,957
3. Sero-positivity (%) among tested	0.09
4. Put on treatment	6

## 9. Elimination of HIV/AIDS related Stigma and Discrimination

### A. HIV/AIDS Prevention & Control Act (2017)

Indicator	2021-22
1. State rules notified for HIV/AIDS Prevention and Control Act (2017)	No
2. State designated/appointed ombudsman for HIV/AIDS Prevention and Control Act (2017)	Yes

## 10. HIV-TB Co-morbidities

### A. HRG and Bridge Population

Indicator								2021-22
	Quarter	FSW	MSW	IDU	TG	Migrants	Truckers	Total
Screened for TB	Quarter 1	408	-	314	-	-	-	722
	Quarter 2	350	-	434	-	-	-	784
	Quarter 3	353	-	420	-	-	-	773
	Quarter 4	459	-	468	-	-	-	927
Tested for TB	Quarter 1	6	-	3	-	-	-	9
	Quarter 2	8	-	8	-	-	-	16
	Quarter 3	5	-	7	-	-	-	12
	Quarter 4	6	-	6	-	-	-	12
Diagnosed with TB	Quarter 1	-	-	-	-	-	-	-
	Quarter 2	1	-	-	-	-	-	1
	Quarter 3	-	-	-	-	-	-	-
	Quarter 4	-	-	-	-	-	-	-
Initiated on TB treatment	Quarter 1	-	-	-	-	-	-	-
	Quarter 2	1	-	-	-	-	-	1
	Quarter 3	-	-	-	-	-	-	-
	Quarter 4	-	-	-	-	-	-	-

### B. HIV-TB Cross-Referral

Indicator	2021-22
1. In referral from TB program	307
1.1. HIV sero-positive (%)	2.28
1.2. ICTC clients referred to NTEP	33

### C. HIV-TB Coinfected at ART Centre

Indicator							2021-22	
	PLHIV attending ART Centre	PLHIV underwent 4S screening	PLHIV with presumptive TB	PLHIV tested for TB	PLHIV diagnosed with TB	PLHIV initiated on IPT	Co-infected enrolled at ARTc	Co-infected initiated on ART
Apr-21	146	146	3	3	-	-		
May-21	155	155	-	-	-	-		
Jun-21	173	173	-	-	-	-		
Jul-21	216	216	2	2	-	10		
Aug-21	203	203	3	3	1	2		
Sep-21	277	277	-	-	-	-		
Oct-21	208	208	1	1	-	-		
Nov-21	136	136	1	1	-	-		
Dec-21	178	178	2	2	-	4		
Jan-22	191	191	1	1	-	1		
Feb-22	134	134	3	3	-	3		
Mar-22	148	148	3	3	1	1		
April 2021- March 2022							9	8

## 11. Scorecard

State/UT Name		Sikkim
Overall Rank		30
IEC & MS	Frequency of Social Media updates (G= ≥60, Y=40-59, R=<40)	
	Status of AEP integration in state School curriculum (G=Yes, R=No)	
	Status of SCA (G= At least one meeting held since 2017, R= other than G)	
	Status of State Rules (G= Notified, R= Not notified)	
	Status of Ombudsman (G= Appointed, R=Not appointed)	
	Rank	15
TI	Facilities onboarded (G=≥95%, Y= 90-94%, R=<90%)	
	Coverage against target in contract (G=≥95%, Y= 90-94%, R=<90%)	
	HRG & BP living with HIV on ART (G=≥95%, Y= 90-94%, R=<90%)	
	IDU on OST (G=≥95%, Y= 90-94%, R=<90%)	
	Rank	19
BSD	Percentage of PLHIV who know their status (G=≥95%, Y= 80-94%, R=<80%)	
	HIV testing against target-GC ((G=≥95%, Y= 80-94%, R=<80%)	
	HIV testing against target-PW (G=≥95%, Y= 80-94%, R=<80%)	
	Percentage of Pregnant women who initiated ART (G=≥95%, Y= 80-94%, R=<80%)	
	Percentage of TB suspected cases referred to NTEP (G=≥95%, Y= 80-94%, R=<80%)	
	Clients managed at DSRC against the target (G=≥95%, Y= 80-94%, R=<80%)	
	Percentage of pregnant women tested for Syphilis (G=≥95%, Y= 80-94%, R=<80%)	
	Rank	31
CST	ART Initiation (Current FY) (G=≥95%, Y= 80-94%, R=<80%)	
	LFU rate among new ART initiation (G=<2%, Y= 2-4%, R=≥5%)	
	PLHIV put on ART during the FY against target (G=≥95%, Y= 80-94%, R=<80%)	
	Status on establishment of CSC (G=≥95%, Y= 80-94%, R=<80%)	NA
	Rank	29
LS	VL Suppression Rate (Current FY) (G=≥95%, Y= 85-94%, R=<85%)	
	% of SRL accredited (G=100%, Y= 80-99%, R=<80%)	
	% Participation of ICTCs in Re-testing (G=≥95%, Y= 85-94%, R=<85%)	
	Rank	12
SI	% of NACP facilities active in SOCH (G=≥90%, Y= 75-89%, R=<75%)	
	Status of State Data Management Committee (G=one meeting held, Y= no meeting held, R= not constituted)	
	Status of finalized Priority Areas for Operational Research and Evaluation (G= 4, Y= 3, R= <3)	
	Rank	32
Finance	Expenditure with respect to funds released during FY 2021-22 (G=≥90%, Y= 85-89%, R=<85%)	
	Submission of Audit Report after approval of EC/GB for the preceding year (G= by 30th June, Y= 30th Sept, R= beyond 30th Sept 2021)	
	Submission of Utilization Certificate (in prescribed format GFR 12A) for the previous financial year (G= by 30th June, Y= 30th Sept, R= beyond 30th Sept 2021)	
	Rank	2
SCM	Report Submission (BSD-SCM Report) (G=≥90%, Y= 75-89%, R=<75%)	

Green=3 Marks

Yellow=2Marks

Red=1 Mark

No Colour=Not Applicable

A thick red ribbon is draped across the page, starting from the bottom left, looping upwards and to the right, and then looping back down towards the right edge. The background is a gradient of yellow and orange with faint, concentric circular lines.

# FACT SHEET

## TAMIL NADU

## 1. Status of HIV/AIDS Epidemic

### A. Epidemic Estimates (2021)

Indicator	Male	Female	Total
1. IPR	-	-	0.92
2. IMR	-	-	0.41
3. Adult (15-49 yrs) HIV Prevalence (%)	0.22	0.21	0.22
4. Estimated people living with HIV	84,733	78,124	1,62,857
5. ART coverage (%)	74.2	88	81
6. Estimated children living with HIV	1,383	1,281	2,664
7. Annual new HIV infections	817	681	1,498
8. Annual AIDS-related deaths (ARD)	1,599	480	2,079
9. Change in annual new HIV infections since 2010 (%)	-72.5	-72.56	-72.53
10. Change in annual ARD since 2010(%)	-75.5	-89.27	-81.11
11. EMTCT need	-	774	774


### B. High risk population size (2009), safe practices (2015) and prevalence (2021)

Population Group	Estimates Size	Condom Use (%)	New Needle/ Syringe use (%)	HIV Prevalence (%)
1. Female Sex Workers	70,892	88.8	17.3	1.52
2. Men who have sex with men	40,883	59.5	21.2	2.07
3. Injecting Drug Users	2,777	-	-	-
4. Hijra/Transgender People	5,147	52.3	-	4.8
5. Migrants	1,95,127	-	-	0
6. Truckers	47,000	-	-	0.6
7. Prison inmates	63,039	84.6	16.7	0.50

### C. HIV/AIDS related knowledge, stigma and high-risk behaviour in general population (2019-21)

Indicator	Male	Female	Total
1. Adults (15-49 yrs) with comprehensive knowledge about HIV/AIDS (%)	26.6	23.6	-
2. Youth (15-24 yrs) with comprehensive knowledge about HIV/AIDS (%)	23.2	23.9	-
3. Adults willing to care for a relative with HIV/AIDS in own home (%)	65.7	56.4	-
4. Adults willing to buy fresh vegetables from a shopkeeper or vendor who has HIV/AIDS (%)	52.2	41.5	-
5. Adults (15-49 yrs) who have had higher-risk sexual behaviour in the past 12 months (%)	0.8	0	-
5.1 Condom use during last higher-risk intercourse (%)	49.8	NA	-
6. Youth (15-24 yrs) who have had higher-risk sexual behaviour in the past 12 months (%)	0.7	0	-
6.1 Condom use during last higher-risk intercourse (%)	16.7	NA	-

## 2. Progress on 95-95-95 (2021-22)



Indicator	Male	Female	Total
1. Estimated PLHIV size (2021)	84,733	78,124	1,62,857
2. PLHIV who know their HIV Status	73,128	74,580	1,47,708
3. PLHIV who know their HIV status and are on ART	60,193	65,491	1,25,684
4. PLHIV who are on ART and tested for their viral load	40,036	44,704	84,740
5. PLHIV who are virally suppressed	33,885	39,170	73,055



### 3. Prevention of new HIV infections among general population

#### A. Information, Education, Communication, Youth and Mainstreaming

Indicator	2021-22
1. Schools with operational Adolescent Education Program (AEP)	9,830
2. Colleges with operational Red Ribbon Clubs (RRC)	2,279
3. Persons trained under mainstreaming	5,060

#### B. Sexually Transmitted Infections (STI)/Reproductive Tract Infections (RTI) Management at DSRCs

Indicator	2021-22			
1. NACO Supported Designated STI/RTI Clinics (DSRC)	157			
	Male	Female	TG	Total
2. Clients managed	-	-	-	6,16,566
3. RPR Tests conducted	2,21,209	2,33,896	6,004	4,61,109
4. Syphilis seropositivity (%)	0.57	0.14	27.75	0.71

### 4. Prevention of new HIV infections among high-risk group and bridge population

#### A. Targeted Interventions (TI) and Opioid Substitution Therapy (OST)

Indicator	2021-22
1. Targeted Interventions	86
2. OST centres	1
3. Employer Led Model Interventions	97

#### B. Female Sex Workers

Indicator	2021-22
1. Estimated size	70,892
2. Coverage (%)	91
3. Condoms distributed	84,56,731
4. Tested for HIV (April 2021 - September 2021)	42,347
4.1. HIV sero-positive (%)	0.03
4.1.1. Linked to ART	12
5. Tested for HIV (October 2021 - March 2022)	38,224
5.1. HIV sero-positive (%)	0.04
5.1.1. Linked to ART	14
6. Clinic Visits	89,144
7. STI/RTI treated	647
8. Presumptive treatment	10,873

#### C. Men who have Sex with Men

Indicator	2021-22
1. Estimated size	40,883
2. Coverage (%)	>=95
3. Condoms distributed	61,33,760
4. Tested for HIV (April 2021 - September 2021)	29,130
4.1. HIV sero-positive (%)	0.09
4.1.1. Linked to ART	24
5. Tested for HIV (October 2021 - March 2022)	26,941
5.1. HIV sero-positive (%)	0.14
5.1.1. Linked to ART	40
6. Clinic Visits	60,655
7. STI/RTI treated	104
8. Presumptive treatment	7,282

#### D. Injecting Drug Users

Indicator	2021-22
1. Estimated size	2,777
2. Coverage (%)	15
3. Needles distributed	12,553
4. Syringes distributed	12,553
5. On OST	40
6. Tested for HIV (April 2021 - September 2021)	385
6.1. HIV sero-positive (%)	0.00
6.1.1. Linked to ART	-
7. Tested for HIV (October 2021 - March 2022)	118
7.1. HIV sero-positive (%)	0.00
7.1.1. Linked to ART	-

#### E. Hijra/Transgender people

Indicator	2021-22
1. Estimated size	5,147
2. Coverage (%)	>=95
3. Condoms distributed	14,44,567
4. Tested for HIV (April 2021 - September 2021)	5,673
4.1. HIV sero-positive (%)	0.16
4.1.1. Linked to ART	9
5. Tested for HIV (October 2021 - March 2022)	5,020
5.1. HIV sero-positive (%)	0.14
5.1.1. Put on ART	7
6. Clinic Visits	10,908
7. STI / RTI treated	10
8. Presumptive treatment	1,193

#### F. Migrants

Indicator	2021-22
1. Estimated size	1,95,127
2. Coverage (%)	99
3. Tested for HIV	26,399
3.1. HIV sero-positive (%)	0.07
3.2. Linked to ART	18

#### G. Truckers

Indicator	2021-22
1. Estimated size	47,000
2. Coverage (%)	85
3. Tested for HIV	10,877
3.1. HIV sero-positive (%)	0.08
3.2. On ART	8

#### H. Prison Inmates

Indicator	2021-22
1. Total prisons	141
2. Prisons covered under programme	128
3. Total inmates admitted	84,951
4. Inmates Covered (%)	66
5. Tested for HIV	56,386
5.1. HIV sero-positive (%)	0.14
5.2. On ART (%)	89

#### I. Link Worker Scheme

Indicator	2021-22
1. Districts covered under scheme	17
2. Vulnerable population covered	1,81,619
3. Tested for HIV	1,02,572
3.1. HIV sero-positive (%)	0.04
3.2. Linked to ART (%)	100.00

## J. Opioid Substitution Therapy

Indicator	2021-22
1. OST Centres	1
1.1. OSTC in Public Health Settings	1
1.2. OSTC in NGO Settings	-
1.3 No. of Satellite OST Centres	-
2. IDU on OST	40

## 5. Early detection of HIV infected people

### A. HIV Counselling and Testing Services (HCTS)

Indicator	2021-22
1. ICTC facilities	2,987
1.1. Stand-alone	807
1.2. Facility integrated (Govt)	1,876
1.3. Facility integrated (PPP)	199
1.4. CBS	105

### B. HIV Testing among Vulnerable Population (Excluding Pregnant Women)

Indicator	2021-22			
	Male	Female	TG	Total
1. Tested for HIV	17,85,846	11,82,585	10,355	29,78,786
2. Found HIV Positive among tested	3,733	2,152	36	5,921
3. HIV sero-positivity (%) among tested	0.21	0.18	0.35	0.20
4. Spouse/sexual partner testing of HIV positive people identified	1,168	1,489	4	2,661

## 6. Initiation and retention on ART of HIV infected people

### A. Treatment Facilities

Indicator	2021-22
1. ART Centres	55
2. Centre of Excellence	
2.1. Centre of Excellence (Adult)	1
2.2. Centre of Excellence (Paediatric)	1
3. Link ART Centres	174
4. Care Support Centres	31

### B. Treatment Uptake

Indicator	2021-22			
	Male	Female	TG	Total
1. HIV positive cases diagnosed (At ICTC)	3,733	2,386	36	6,155
2. New PLHIV Registered at ART center	3,638	2,422	38	6,098
2.1 Initiated on ART	3,344	2,257	37	5,638
3. PLHIV alive and on ART	62,843	67,914	409	1,31,166
4. 12 months retention on ART (%)				79.91
5. Lost to follow-up cases	3,357	2,190	43	5,590

## 7. Viral Suppression and laboratories

### A. Laboratory facilities and service uptake

Indicator	2021-22
1. Viral load laboratories	7
1.1 Accredited Viral load laboratories	3
2. Viral load testing conducted	85,980
2.1. Virally suppressed (%)	86
3. National reference laboratories (NRL)	2
3.1 Accredited NRL	2
4. State reference laboratories (SRL)	12
4.1 Accredited SRL	8
5. CD4 testing conducted	1,31,901
6. External Quality Assessment of ICTC	
6.1 Average Participation (%)	99.03
6.2. Average Discordance (%)	0.00
7. Quality Assurance Scheme for Basic Composite Medical Laboratories (Entry Level)- M(EL)T	
7.1 No. of ICTCs certified for M(EL)T certification	-

## 8. Elimination of mother to child transmission of HIV & Syphilis

### A. HIV

Indicator	2021-22
1. Estimated pregnant women (PW)	11,70,490
2. HIV testing among PW	12,75,399
3. HIV sero-positivity (%) among tested	0.02
4. HIV Positive PW (old + new detections)	812
4.1 On life-long ART	823
5. Live births among HIV positive PW	488
5.1 Babies given ARV Prophylaxis (%)	96.31
6. Babies tested HIV (6 week- 6 month)	696
6.1 Babies confirmed HIV Positive (6 week- 6 month)	11
7. HIV exposed babies at 18 months	
7.1 HIV exposed babies tested at 18 month	448
7.2 Babies confirmed HIV positive at 18 months	16
8. HIV positive babies initiated on ART	29

### B. Syphilis

Indicator	2021-22
1. Estimated pregnant women (PW)	11,70,490
2. Syphilis testing among PW	12,32,598
3. Sero-positivity (%) among tested	0.01
4. Put on treatment	66

## 9. Elimination of HIV/AIDS related Stigma and Discrimination

### A. HIV/AIDS Prevention & Control Act (2017)

Indicator	2021-22
1. State rules notified for HIV/AIDS Prevention and Control Act (2017)	No
2. State designated/appointed ombudsman for HIV/AIDS Prevention and Control Act (2017)	Yes

## 10. HIV-TB Co-morbidities

## A. HRG and Bridge Population

Indicator								2021-22
	Quarter	FSW	MSW	IDU	TG	Migrants	Truckers	Total
Screened for TB	Quarter 1	33,318	23,742	340	5,025	14,242	5,634	82,301
	Quarter 2	42,996	29,396	375	6,017	24,762	10,264	1,13,810
	Quarter 3	44,376	30,926	243	6,210	34,814	10,968	1,27,537
	Quarter 4	44,313	31,574	106	6,568	56,192	12,923	1,51,676
Tested for TB	Quarter 1	100	47	-	4	6	-	157
	Quarter 2	322	423	-	132	24	31	932
	Quarter 3	221	173	-	37	3	90	524
	Quarter 4	381	478	-	81	6	46	992
Diagnosed with TB	Quarter 1	-	1	-	-	-	-	1
	Quarter 2	1	4	-	-	2	-	7
	Quarter 3	-	3	-	-	-	-	3
	Quarter 4	38	59	-	-	-	-	97
Initiated on TB treatment	Quarter 1	-	1	-	-	-	-	1
	Quarter 2	1	4	-	-	-	-	5
	Quarter 3	-	1	-	-	2	-	3
	Quarter 4	-	3	-	-	-	-	3

## B. HIV-TB Cross-Referral

Indicator		2021-22
1. In referral from TB program		2,02,879
1.1. HIV sero-positive (%)		0.43
1.2. ICTC clients referred to NTEP		1,66,127

## C. HIV-TB Coinfected at ART Centre

Indicator								2021-22
	PLHIV attending ART Centre	PLHIV underwent 4S screening	PLHIV with presumptive TB	PLHIV tested for TB	PLHIV diagnosed with TB	PLHIV initiated on IPT	Co-infected enrolled at ARTc	Co-infected initiated on ART
Apr-21	87,089	83,918	3,538	3,464	232	578		
May-21	65,078	63,084	1,831	1,770	78	392		
Jun-21	64,309	62,036	2,247	2,183	132	602		
Jul-21	81,548	79,114	3,967	3,876	241	1,566		
Aug-21	90,692	89,061	4,388	4,316	240	1,851		
Sep-21	1,00,115	97,544	5,288	5,215	286	1,785		
Oct-21	97,912	95,516	4,871	4,776	252	1,243		
Nov-21	90,375	88,222	4,503	4,398	206	1,227		
Dec-21	93,400	91,251	4,464	4,411	245	1,410		
Jan-22	88,946	86,854	4,380	4,324	215	1,434		
Feb-22	80,993	79,151	4,091	3,988	223	1,276		
Mar-22	90,189	87,781	5,132	5,017	253	1,290		
April 2021-March 2022							2,956	2,827

## 11. Scorecard

State/UT Name		Tamil Nadu
Overall Rank		5
IEC & MS	Frequency of Social Media updates (G= ≥60, Y=40-59, R=<40)	
	Status of AEP integration in state School curriculum (G=Yes, R=No)	
	Status of SCA (G= At least one meeting held since 2017, R= other than G)	
	Status of State Rules (G= Notified, R= Not notified)	
	Status of Ombudsman (G= Appointed, R=Not appointed)	
	Rank	15
TI	Facilities onboarded (G=≥95%, Y= 90-94%, R=<90%)	
	Coverage against target in contract (G=≥95%, Y= 90-94%, R=<90%)	
	HRG & BP living with HIV on ART (G=≥95%, Y= 90-94%, R=<90%)	
	IDU on OST (G=≥95%, Y= 90-94%, R=<90%)	
	Rank	3
BSD	Percentage of PLHIV who know their status (G=≥95%, Y= 80-94%, R=<80%)	
	HIV testing against target-GC ((G=≥95%, Y= 80-94%, R=<80%)	
	HIV testing against target-PW (G=≥95%, Y= 80-94%, R=<80%)	
	Percentage of Pregnant women who initiated ART (G=≥95%, Y= 80-94%, R=<80%)	
	Percentage of TB suspected cases referred to NTEP (G=≥95%, Y= 80-94%, R=<80%)	
	Clients managed at DSRC against the target (G=≥95%, Y= 80-94%, R=<80%)	
	Percentage of pregnant women tested for Syphilis (G=≥95%, Y= 80-94%, R=<80%)	
	Rank	11
CST	ART Initiation (Current FY) (G=≥95%, Y= 80-94%, R=<80%)	
	LFU rate among new ART initiation (G=<2%, Y= 2-4%, R=≥5%)	
	PLHIV put on ART during the FY against target (G=≥95%, Y= 80-94%, R=<80%)	
	Status on establishment of CSC (G=≥95%, Y= 80-94%, R=<80%)	
	Rank	4
LS	VL Suppression Rate (Current FY) (G=≥95%, Y= 85-94%, R=<85%)	
	% of SRL accredited (G=100%, Y= 80-99%, R=<80%)	
	% Participation of ICTCs in Re-testing (G=≥95%, Y= 85-94, R=<85%)	
	Rank	12
SI	% of NACP facilities active in SOCH (G=≥90%, Y= 75-89%, R=<75%)	
	Status of State Data Management Committee (G=one meeting held, Y= no meeting held, R= not constituted)	
	Status of finalized Priority Areas for Operational Research and Evaluation (G= 4, Y= 3, R= <3)	
	Rank	14
Finance	Expenditure with respect to funds released during FY 2021-22 (G=≥90%, Y= 85-89%, R=<85%)	
	Submission of Audit Report after approval of EC/GB for the preceding year (G= by 30th June, Y= 30th Sept, R= beyond 30th Sept 2021)	
	Submission of Utilization Certificate (in prescribed format GFR 12A) for the previous financial year (G= by 30th June, Y= 30th Sept, R= beyond 30th Sept 2021)	
	Rank	5
SCM	Report Submission (BSD-SCM Report) (G=≥90%, Y= 75-89%, R=<75%)	

Green=3 Marks

Yellow=2Marks

Red=1 Mark

No Colour=Not Applicable

A thick red ribbon is tied in a loop on the right side of the page, with the tail extending downwards and then curving back towards the left. The background is a gradient of yellow and orange with faint concentric circles.

# FACT SHEET

## TELANGANA

## 1. Status of HIV/AIDS Epidemic

### A. Epidemic Estimates (2021)

Indicator	Male	Female	Total
1. IPR	-	-	1.29
2. IMR	-	-	0.64
3. Adult (15-49 yrs) HIV Prevalence (%)	0.49	0.43	0.47
4. Estimated people living with HIV	82,849	73,142	1,55,991
5. ART coverage (%)	51.9	69	60
6. Estimated children living with HIV	1,813	1,662	3,475
7. Annual new HIV infections	1,133	874	2,007
8. Annual AIDS-related deaths (ARD)	1,410	345	1,755
9. Change in annual new HIV infections since 2010 (%)	-70.9	-71.00	-70.95
10. Change in annual ARD since 2010(%)	-83.8	-93.89	-87.76
11. EMTCT need	-	1,073	1,073


### B. High risk population size (2009), safe practices (2015) and prevalence (2021)

Population Group	Estimates Size	Condom Use (%)	New Needle/ Syringe use (%)	HIV Prevalence (%)
1. Female Sex Workers	1,01,696	-	-	1.81
2. Men who have sex with men	14,215	-	-	2.67
3. Injecting Drug Users	1,035	-	-	0.4
4. Hijra/Transgender People	2,124	80.7	-	4
5. Migrants	75,601	-	-	0.8
6. Truckers	47,000	-	-	0.8
7. Prison inmates	82,917	88.2	0	2.50

### C. HIV/AIDS related knowledge, stigma and high-risk behaviour in general population (2019-21)

Indicator	Male	Female	Total
1. Adults (15-49 yrs) with comprehensive knowledge about HIV/AIDS (%)	30.5	30.7	-
2. Youth (15-24 yrs) with comprehensive knowledge about HIV/AIDS (%)	30.3	32.9	-
3. Adults willing to care for a relative with HIV/AIDS in own home (%)	65.4	61.9	-
4. Adults willing to buy fresh vegetables from a shopkeeper or vendor who has HIV/AIDS (%)	70.4	58.9	-
5. Adults (15-49 yrs) who have had higher-risk sexual behaviour in the past 12 months (%)	4.4	0.4	-
5.1 Condom use during last higher-risk intercourse (%)	47.6	36.8	-
6. Youth (15-24 yrs) who have had higher-risk sexual behaviour in the past 12 months (%)	6.0	0.2	-
6.1 Condom use during last higher-risk intercourse (%)	32.3	50.0	-

## 2. Progress on 95-95-95 (2021-22)



### 3. Prevention of new HIV infections among general population

#### A. Information, Education, Communication, Youth and Mainstreaming

Indicator	2021-22
1. Schools with operational Adolescent Education Program (AEP)	1,000
2. Colleges with operational Red Ribbon Clubs (RRC)	770
3. Persons trained under mainstreaming	3,126

#### B. Sexually Transmitted Infections (STI)/Reproductive Tract Infections (RTI) Management at DSRCs

Indicator	2021-22			
1. NACO Supported Designated STI/RTI Clinics (DSRC)	50			
	Male	Female	TG	Total
2. Clients managed	-	-	-	4,55,351
3. RPR Tests conducted	28,741	68,929	224	97,894
4. Syphilis seropositivity (%)	1.57	0.61	7.14	0.91

### 4. Prevention of new HIV infections among high-risk group and bridge population

#### A. Targeted Interventions (TI) and Opioid Substitution Therapy (OST)

Indicator	2021-22
1. Targeted Interventions	52
2. OST centres	-
3. Employer Led Model Interventions	19

#### B. Female Sex Workers

Indicator	2021-22
1. Estimated size	1,01,696
2. Coverage (%)	>=95
3. Condoms distributed	2,28,47,957
4. Tested for HIV (April 2021 - September 2021)	58,737
4.1. HIV sero-positive (%)	0.08
4.1.1. Linked to ART	42
5. Tested for HIV (October 2021 - March 2022)	74,344
5.1. HIV sero-positive (%)	0.05
5.1.1. Linked to ART	38
6. Clinic Visits	2,41,833
7. STI/RTI treated	1,417
8. Presumptive treatment	7,920

#### C. Men who have Sex with Men

Indicator	2021-22
1. Estimated size	14,215
2. Coverage (%)	>=95
3. Condoms distributed	49,99,170
4. Tested for HIV (April 2021 - September 2021)	12,525
4.1. HIV sero-positive (%)	0.18
4.1.1. Linked to ART	17
5. Tested for HIV (October 2021 - March 2022)	14,267
5.1. HIV sero-positive (%)	0.13
5.1.1. Linked to ART	19
6. Clinic Visits	49,314
7. STI/RTI treated	55
8. Presumptive treatment	1,126

### D. Injecting Drug Users

Indicator	2021-22
1. Estimated size	1,035
2. Coverage (%)	>=95
3. Needles distributed	3,59,052
4. Syringes distributed	3,59,052
5. On OST	-
6. Tested for HIV (April 2021 - September 2021)	540
6.1. HIV sero-positive (%)	0.00
6.1.1. Linked to ART	-
7. Tested for HIV (October 2021 - March 2022)	964
7.1. HIV sero-positive (%)	0.10
7.1.1. Linked to ART	0

### E. Hijra/Transgender people

Indicator	2021-22
1. Estimated size	2,124
2. Coverage (%)	>=95
3. Condoms distributed	5,87,038
4. Tested for HIV (April 2021 - September 2021)	996
4.1. HIV sero-positive (%)	1.10
4.1.1. Linked to ART	12
5. Tested for HIV (October 2021 - March 2022)	1,614
5.1. HIV sero-positive (%)	0.43
5.1.1. Put on ART	9
6. Clinic Visits	4,032
7. STI / RTI treated	6
8. Presumptive treatment	90

### F. Migrants

Indicator	2021-22
1. Estimated size	75,601
2. Coverage (%)	>=95
3. Tested for HIV	26,206
3.1. HIV sero-positive (%)	0.05
3.2. Linked to ART	10

### G. Truckers

Indicator	2021-22
1. Estimated size	47,000
2. Coverage (%)	>=95
3. Tested for HIV	3,434
3.1. HIV sero-positive (%)	0.03
3.2. On ART	2

### H. Prison Inmates

Indicator	2021-22
1. Total prisons	37
2. Prisons covered under programme	36
3. Total inmates admitted	44,420
4. Inmates Covered(%)	47
5. Tested for HIV	18,461
5.1. HIV sero-positive (%)	0.23
5.2. On ART (%)	93

### I. Link Worker Scheme

Indicator	2021-22
1. Districts covered under scheme	9
2. Vulnerable population covered	76,376
3. Tested for HIV	56,103
3.1. HIV sero-positive (%)	0.14
3.2. Linked to ART (%)	100.00



## J. Opioid Substitution Therapy

Indicator	2021-22
1. OST Centres	-
1.1. OSTC in Public Health Settings	-
1.2. OSTC in NGO Settings	-
1.3 No. of Satellite OST Centres	-
2. IDU on OST	-

## 5. Early detection of HIV infected people

### A. HIV Counselling and Testing Services (HCTS)

Indicator	2021-22
1. ICTC facilities	1,184
1.1. Stand-alone	164
1.2. Facility integrated (Govt)	824
1.3. Facility integrated (PPP)	149
1.4. CBS	47

### B. HIV Testing among Vulnerable Population (Excluding Pregnant Women)

Indicator	2021-22			
	Male	Female	TG	Total
1. Tested for HIV	2,83,694	2,70,221	1,827	5,55,742
2. Found HIV Positive among tested	4,886	4,117	99	9,102
3. HIV sero-positivity (%) among tested	1.72	1.52	5.42	1.64
4. Spouse/sexual partner testing of HIV positive people identified	1,837	1,632	20	3,489

## 6. Initiation and retention on ART of HIV infected people

### A. Treatment Facilities

Indicator	2021-22
1. ART Centres	23
2. Centre of Excellence	
2.1. Centre of Excellence (Adult)	1
2.2. Centre of Excellence (Paediatric)	1
3. Link ART Centres	74
4. Care Support Centres	13

### B. Treatment Uptake

Indicator	2021-22			
	Male	Female	TG	Total
1. HIV positive cases diagnosed (At ICTC)	4,886	4,532	99	9,517
2. New PLHIV Registered at ART center	4,157	3,758	90	8,005
2.1 Initiated on ART	3,995	3,661	83	7,739
3. PLHIV alive and on ART	43,009	50,121	447	93,577
4. 12 months retention on ART (%)				77.36
5. Lost to follow-up cases	10,359	9,345	64	19,768

## 7. Viral Suppression and laboratories

### A. Laboratory facilities and service uptake

Indicator	2021-22
1. Viral load laboratories	3
1.1 Accredited Viral load laboratories	-
2. Viral load testing conducted	63,121
2.1. Virally suppressed (%)	77
3. National reference laboratories (NRL)	1
3.1 Accredited NRL	1
4. State reference laboratories (SRL)	3
4.1 Accredited SRL	2
5. CD4 testing conducted	67,666
6. External Quality Assessment of ICTC	
6.1 Average Participation (%)	94.59
6.2. Average Discordance (%)	0.00
7. Quality Assurance Scheme for Basic Composite Medical Laboratories (Entry Level)- M(EL)T	
7.1 No. of ICTCs certified for M(EL)T certification	-

## 8. Elimination of mother to child transmission of HIV & Syphilis

### A. HIV

Indicator	2021-22
1. Estimated pregnant women (PW)	6,80,790
2. HIV testing among PW	7,91,512
3. HIV sero-positivity (%) among tested	0.05
4. HIV Positive PW (old + new detections)	801
4.1 On life-long ART	813
5. Live births among HIV positive PW	599
5.1 Babies given ARV Prophylaxis (%)	91.65
6. Babies tested HIV (6 week- 6 month)	560
6.1 Babies confirmed HIV Positive (6 week- 6 month)	19
7. HIV exposed babies at 18 months	
7.1 HIV exposed babies tested at 18 month	460
7.2 Babies confirmed HIV positive at 18 months	7
8. HIV positive babies initiated on ART	15

### B. Syphilis

Indicator	2021-22
1. Estimated pregnant women (PW)	6,80,790
2. Syphilis testing among PW	5,18,643
3. Sero-positivity (%) among tested	0.01
4. Put on treatment	39

## 9. Elimination of HIV/AIDS related Stigma and Discrimination

### A. HIV/AIDS Prevention & Control Act (2017)

Indicator	2021-22
1. State rules notified for HIV/AIDS Prevention and Control Act (2017)	No
2. State designated/appointed ombudsman for HIV/AIDS Prevention and Control Act (2017)	No

## 10. HIV-TB Co-morbidities

### A. HRG and Bridge Population

Indicator								2021-22
	Quarter	FSW	MSW	IDU	TG	Migrants	Truckers	Total
Screened for TB	Quarter 1	1,53,520	32,203	2,567	3,676	43,068	-	2,35,034
	Quarter 2	1,78,777	35,058	2,607	4,263	42,227	155	2,63,087
	Quarter 3	1,86,960	36,125	2,762	4,744	51,790	250	2,82,631
	Quarter 4	1,93,366	36,755	2,759	4,847	67,464	827	3,06,018
Tested for TB	Quarter 1	370	97	-	1	-	-	468
	Quarter 2	681	82	-	11	-	-	774
	Quarter 3	638	93	1	2	4	1	739
	Quarter 4	737	82	-	10	3	3	835
Diagnosed with TB	Quarter 1	7	4	-	-	-	-	11
	Quarter 2	21	5	-	-	-	-	26
	Quarter 3	23	12	1	1	-	-	37
	Quarter 4	22	2	-	-	1	-	25
Initiated on TB treatment	Quarter 1	4	4	-	-	-	-	8
	Quarter 2	5	1	-	-	-	-	6
	Quarter 3	6	1	1	1	-	-	9
	Quarter 4	8	2	-	-	1	-	11

### B. HIV-TB Cross-Referral

Indicator	2021-22
1. In referral from TB program	17,622
1.1. HIV sero-positive (%)	5.54
1.2. ICTC clients referred to NTEP	23,581

### C. HIV-TB Coinfected at ART Centre

Indicator								2021-22
	PLHIV attending ART Centre	PLHIV underwent 4S screening	PLHIV with presumptive TB	PLHIV tested for TB	PLHIV diagnosed with TB	PLHIV initiated on IPT	Co-infected enrolled at ARTc	Co-infected initiated on ART
Apr-21	60,640	55,373	7,348	2,611	107	1,225		
May-21	50,967	43,828	5,008	1,279	55	424		
Jun-21	62,261	55,104	6,887	1,878	122	526		
Jul-21	69,145	61,542	7,322	2,307	109	1,129		
Aug-21	65,102	59,038	7,217	2,328	107	411		
Sep-21	64,496	59,565	7,443	2,456	114	321		
Oct-21	65,832	61,223	5,930	1,368	149	204		
Nov-21	65,946	61,877	1,521	1,431	165	193		
Dec-21	67,391	61,780	1,543	1,466	190	418		
Jan-22	73,788	60,740	1,148	1,088	122	2,517		
Feb-22	58,209	54,721	3,909	940	139	2,108		
Mar-22	50,652	48,237	1,148	1,090	197	1,025		
April 2021- March 2022							1,717	1,555

# 11. Scorecard

State/UT Name		Telangana
Overall Rank		32
IEC & MS	Frequency of Social Media updates (G= ≥60, Y=40-59, R=<40)	
	Status of AEP integration in state School curriculum (G=Yes, R=No)	
	Status of SCA (G= At least one meeting held since 2017, R= other than G)	
	Status of State Rules (G= Notified, R= Not notified)	
	Status of Ombudsman (G= Appointed, R=Not appointed)	
	Rank	32
TI	Facilities onboarded (G=≥95%, Y= 90-94%, R=<90%)	
	Coverage against target in contract (G=≥95%, Y= 90-94%, R=<90%)	
	HRG & BP living with HIV on ART (G=≥95%, Y= 90-94%, R=<90%)	
	IDU on OST (G=≥95%, Y= 90-94%, R=<90%)	
	Rank	3
BSD	Percentage of PLHIV who know their status (G=≥95%, Y= 80-94%, R=<80%)	
	HIV testing against target-GC ((G=≥95%, Y= 80-94%, R=<80%)	
	HIV testing against target-PW (G=≥95%, Y= 80-94%, R=<80%)	
	Percentage of Pregnant women who initiated ART (G=≥95%, Y= 80-94%, R=<80%)	
	Percentage of TB suspected cases referred to NTEP (G=≥95%, Y= 80-94%, R=<80%)	
	Clients managed at DSRC against the target (G=≥95%, Y= 80-94%, R=<80%)	
	Percentage of pregnant women tested for Syphilis (G=≥95%, Y= 80-94%, R=<80%)	
	Rank	26
CST	ART Initiation (Current FY) (G=≥95%, Y= 80-94%, R=<80%)	
	LFU rate among new ART initiation (G=<2%, Y= 2-4%, R=≥5%)	
	PLHIV put on ART during the FY against target (G=≥95%, Y= 80-94%, R=<80%)	
	Status on establishment of CSC (G=≥95%, Y= 80-94%, R=<80%)	
	Rank	29
LS	VL Suppression Rate (Current FY) (G=≥95%, Y= 85-94%, R=<85%)	
	% of SRL accredited (G=100%, Y= 80-99%, R=<80%)	
	% Participation of ICTCs in Re-testing (G=≥95%, Y= 85-94%, R=<85%)	
	Rank	25
SI	% of NACP facilities active in SOCH (G=≥90%, Y= 75-89%, R=<75%)	
	Status of State Data Management Committee (G=one meeting held, Y= no meeting held, R= not constituted)	
	Status of finalized Priority Areas for Operational Research and Evaluation (G= 4, Y= 3, R= <3)	
	Rank	14
Finance	Expenditure with respect to funds released during FY 2021-22 (G=≥90%, Y= 85-89%, R=<85%)	
	Submission of Audit Report after approval of EC/GB for the preceding year (G= by 30th June, Y= 30th Sept, R= beyond 30th Sept 2021)	
	Submission of Utilization Certificate (in prescribed format GFR 12A) for the previous financial year (G= by 30th June, Y= 30th Sept, R= beyond 30th Sept 2021)	
	Rank	23
SCM	Report Submission (BSD-SCM Report) (G=≥90%, Y= 75-89%, R=<75%)	

Green=3 Marks

Yellow=2Marks

Red=1 Mark

No Colour=Not Applicable

A thick red ribbon is draped across the page, starting from the bottom left, looping upwards and to the right, and then looping back down towards the bottom right. The background is a gradient of yellow and orange with faint, concentric circular lines.

# FACT SHEET

## TRIPURA

## 1. Status of HIV/AIDS Epidemic

### A. Epidemic Estimates (2021)

Indicator	Male	Female	Total
1. IPR	-	-	14.44
2. IMR	-	-	17.37
3. Adult (15-49 yrs) HIV Prevalence (%)	0.14	0.10	0.12
4. Estimated people living with HIV	2,138	1,470	3,608
5. ART coverage (%)	99.3	57	82
6. Estimated children living with HIV	46	44	90
7. Annual new HIV infections	308	214	522
8. Annual AIDS-related deaths (ARD)	4	4	8
9. Change in annual new HIV infections since 2010 (%)	327.8	328.00	330.58
10. Change in annual ARD since 2010(%)	33.3	-20.00	0.00
11. EMTCT need	-	47	47


### B. High risk population size (2009), safe practices (2015) and prevalence (2021)

Population Group	Estimates Size	Condom Use (%)	New Needle/ Syringe use (%)	HIV Prevalence (%)
1. Female Sex Workers	5,473	54.7	0	2.9
2. Men who have sex with men	205	36	100	-
3. Injecting Drug Users	573	60.9	84.2	18
4. Hijra/Transgender People	-	-	-	-
5. Migrants	35,800	-	-	-
6. Truckers	1,000	-	-	-
7. Prison inmates	4,558	13.3	0	1.00

### C. HIV/AIDS related knowledge, stigma and high-risk behaviour in general population (2019-21)

Indicator	Male	Female	Total
1. Adults (15-49 yrs) with comprehensive knowledge about HIV/AIDS (%)	29.9	15.4	-
2. Youth (15-24 yrs) with comprehensive knowledge about HIV/AIDS (%)	31.9	11.6	-
3. Adults willing to care for a relative with HIV/AIDS in own home (%)	49.7	47.8	-
4. Adults willing to buy fresh vegetables from a shopkeeper or vendor who has HIV/AIDS (%)	59.4	53.1	-
5. Adults (15-49 yrs) who have had higher-risk sexual behaviour in the past 12 months (%)	0.4	0.1	-
5.1 Condom use during last higher-risk intercourse (%)	7.6	0	-
6. Youth (15-24 yrs) who have had higher-risk sexual behaviour in the past 12 months (%)	0.5	0.3	-
6.1 Condom use during last higher-risk intercourse (%)	0.0	0.0	-

## 2. Progress on 95-95-95 (2021-22)



Indicator	Male	Female	Total
1. Estimated PLHIV size (2021)	2,138	1,470	3,608
2. PLHIV who know their HIV Status	2,440	884	3,324
3. PLHIV who know their HIV status and are on ART	2,066	798	2,864
4. PLHIV who are on ART and tested for their viral load	804	479	1,283
5. PLHIV who are virally suppressed	627	378	1,005

### 3. Prevention of new HIV infections among general population

#### A. Information, Education, Communication, Youth and Mainstreaming

Indicator	2021-22
1. Schools with operational Adolescent Education Program (AEP)	400
2. Colleges with operational Red Ribbon Clubs (RRC)	30
3. Persons trained under mainstreaming	2,345

#### B. Sexually Transmitted Infections (STI)/Reproductive Tract Infections (RTI) Management at DSRCs

Indicator	2021-22			
1. NACO Supported Designated STI/RTI Clinics (DSRC)	18			
	Male	Female	TG	Total
2. Clients managed	-	-	-	43,359
3. RPR Tests conducted	16,061	27,292	2	43,355
4. Syphilis seropositivity (%)	0.32	0.14	0.00	0.21

### 4. Prevention of new HIV infections among high-risk group and bridge population

#### A. Targeted Interventions (TI) and Opioid Substitution Therapy (OST)

Indicator	2021-22
1. Targeted Interventions	15
2. OST centres	6
3. Employer Led Model Interventions	-

#### B. Female Sex Workers

Indicator	2021-22
1. Estimated size	5,473
2. Coverage (%)	83
3. Condoms distributed	5,33,630
4. Tested for HIV (April 2021 - September 2021)	2,432
4.1. HIV sero-positive (%)	0.16
4.1.1. Linked to ART	4
5. Tested for HIV (October 2021 - March 2022)	2,466
5.1. HIV sero-positive (%)	0.16
5.1.1. Linked to ART	4
6. Clinic Visits	9,845
7. STI/RTI treated	156
8. Presumptive treatment	232

#### C. Men who have Sex with Men

Indicator	2021-22
1. Estimated size	205
2. Coverage (%)	>=95
3. Condoms distributed	63,695
4. Tested for HIV (April 2021 - September 2021)	380
4.1. HIV sero-positive (%)	0.00
4.1.1. Linked to ART	-
5. Tested for HIV (October 2021 - March 2022)	369
5.1. HIV sero-positive (%)	1.63
5.1.1. Linked to ART	5
6. Clinic Visits	1,599
7. STI/RTI treated	9
8. Presumptive treatment	55

#### D. Injecting Drug Users

Indicator	2021-22
1. Estimated size	573
2. Coverage (%)	>=95
3. Needles distributed	7,21,438
4. Syringes distributed	7,33,449
5. On OST	799
6. Tested for HIV (April 2021 - September 2021)	2,659
6.1. HIV sero-positive (%)	9.36
6.1.1. Linked to ART	178
7. Tested for HIV (October 2021 - March 2022)	2,748
7.1. HIV sero-positive (%)	9.46
7.1.1. Linked to ART	217

#### E. Hijra/Transgender people

Indicator	2021-22
1. Estimated size	-
2. Coverage (%)	-
3. Condoms distributed	-
4. Tested for HIV (April 2021 - September 2021)	-
4.1. HIV sero-positive (%)	-
4.1.1. Linked to ART	-
5. Tested for HIV (October 2021 - March 2022)	-
5.1. HIV sero-positive (%)	-
5.1.1. Put on ART	-
6. Clinic Visits	-
7. STI / RTI treated	-
8. Presumptive treatment	-

#### F. Migrants

Indicator	2021-22
1. Estimated size	35,800
2. Coverage (%)	20
3. Tested for HIV	5,418
3.1. HIV sero-positive (%)	0.33
3.2. Linked to ART	17

#### G. Truckers

Indicator	2021-22
1. Estimated size	1,000
2. Coverage (%)	>=95
3. Tested for HIV	1,469
3.1. HIV sero-positive (%)	0.34
3.2. On ART	2

#### H. Prison Inmates

Indicator	2021-22
1. Total prisons	13
2. Prisons covered under programme	13
3. Total inmates admitted	4,087
4. Inmates Covered (%)	24
5. Tested for HIV	879
5.1. HIV sero-positive (%)	3.30
5.2. On ART (%)	100

#### I. Link Worker Scheme

Indicator	2021-22
1. Districts covered under scheme	2
2. Vulnerable population covered	19,430
3. Tested for HIV	16,604
3.1. HIV sero-positive (%)	0.56
3.2. Linked to ART (%)	91.40

## J. Opioid Substitution Therapy

Indicator	2021-22
1. OST Centres	6
1.1. OSTC in Public Health Settings	6
1.2. OSTC in NGO Settings	-
1.3 No. of Satellite OST Centres	-
2. IDU on OST	799

## 5. Early detection of HIV infected people

### A. HIV Counselling and Testing Services (HCTS)

Indicator	2021-22
1. ICTC facilities	187
1.1. Stand-alone	24
1.2. Facility integrated (Govt)	136
1.3. Facility integrated (PPP)	9
1.4. CBS	18

### B. HIV Testing among Vulnerable Population (Excluding Pregnant Women)

Indicator	2021-22			
	Male	Female	TG	Total
1. Tested for HIV	68,262	35,557	-	1,03,819
2. Found HIV Positive among tested	972	119	-	1091
3. HIV sero-positivity (%) among tested	1.42	0.33	-	1.05
4. Spouse/sexual partner testing of HIV positive people identified	29	73	-	102

## 6. Initiation and retention on ART of HIV infected people

### A. Treatment Facilities

Indicator	2021-22
1. ART Centres	3
2. Centre of Excellence	
2.1. Centre of Excellence (Adult)	-
2.2. Centre of Excellence (Paediatric)	-
3. Link ART Centres	3
4. Care Support Centres	1

### B. Treatment Uptake

Indicator	2021-22			
	Male	Female	TG	Total
1. HIV positive cases diagnosed (At ICTC)	972	142	1	1,115
2. New PLHIV Registered at ART center	899	109	-	1,008
2.1 Initiated on ART	894	108	-	1,002
3. PLHIV alive and on ART	2,123	834	-	2,957
4. 12 months retention on ART (%)				80.52
5. Lost to follow-up cases	410	97	-	507

## 7. Viral Suppression and laboratories

### A. Laboratory facilities and service uptake

Indicator	2021-22
1. Viral load laboratories	-
1.1 Accredited Viral load laboratories	-
2. Viral load testing conducted	1,395
2.1. Virally suppressed (%)	78
3. National reference laboratories (NRL)	-
3.1 Accredited NRL	-
4. State reference laboratories (SRL)	1
4.1 Accredited SRL	1
5. CD4 testing conducted	1,584
6. External Quality Assessment of ICTC	
6.1 Average Participation (%)	100.00
6.2. Average Discordance (%)	0.00
7. Quality Assurance Scheme for Basic Composite Medical Laboratories (Entry Level)- M(EL)T	
7.1 No. of ICTCs certified for M(EL)T certification	-

## 8. Elimination of mother to child transmission of HIV & Syphilis

### A. HIV

Indicator	2021-22
1. Estimated pregnant women (PW)	59,310
2. HIV testing among PW	53,242
3. HIV sero-positivity (%) among tested	0.04
4. HIV Positive PW (old + new detections)	77
4.1 On life-long ART	79
5. Live births among HIV positive PW	18
5.1 Babies given ARV Prophylaxis (%)	72.22
6. Babies tested HIV (6 week- 6 month)	1
6.1 Babies confirmed HIV Positive (6 week- 6 month)	-
7. HIV exposed babies at 18 months	
7.1 HIV exposed babies tested at 18 month	-
7.2 Babies confirmed HIV positive at 18 months	-
8. HIV positive babies initiated on ART	-

### B. Syphilis

Indicator	2021-22
1. Estimated pregnant women (PW)	59,310
2. Syphilis testing among PW	47,457
3. Sero-positivity (%) among tested	0.05
4. Put on treatment	28

## 9. Elimination of HIV/AIDS related Stigma and Discrimination

### A. HIV/AIDS Prevention & Control Act (2017)

Indicator	2021-22
1. State rules notified for HIV/AIDS Prevention and Control Act (2017)	No
2. State designated/appointed ombudsman for HIV/AIDS Prevention and Control Act (2017)	No



## 10. HIV-TB Co-morbidities

### A. HRG and Bridge Population

Indicator								2021-22
	Quarter	FSW	MSW	IDU	TG	Migrants	Truckers	Total
Screened for TB	Quarter 1	2,315	314	2,298	-	1,431	1,226	7,584
	Quarter 2	2,236	296	2,592	-	1,209	739	7,072
	Quarter 3	1,981	286	2,804	-	1,473	442	6,986
	Quarter 4	1,844	264	2,623	-	1,269	384	6,384
Tested for TB	Quarter 1	20	1	28	-	3	-	52
	Quarter 2	34	2	31	-	6	-	73
	Quarter 3	31	-	28	-	4	1	64
	Quarter 4	33	-	71	-	-	1	105
Diagnosed with TB	Quarter 1	-	-	2	-	1	-	3
	Quarter 2	-	-	1	-	-	-	1
	Quarter 3	1	-	1	-	-	-	2
	Quarter 4	1	-	2	-	-	-	3
Initiated on TB treatment	Quarter 1	-	-	1	-	1	-	2
	Quarter 2	-	-	1	-	-	-	1
	Quarter 3	1	-	1	-	-	-	2
	Quarter 4	1	-	2	-	-	-	3

### B. HIV-TB Cross-Referral

Indicator	2021-22
1. In referral from TB program	868
1.1. HIV sero-positive (%)	7.14
1.2. ICTC clients referred to NTEP	1,507

### C. HIV-TB Coinfected at ART Centre

Indicator								2021-22
	PLHIV attending ART Centre	PLHIV underwent 4S screening	PLHIV with presumptive TB	PLHIV tested for TB	PLHIV diagnosed with TB	PLHIV initiated on IPT	Co-infected enrolled at ARTc	Co-infected initiated on ART
Apr-21	1,164	1,164	21	15	-	32		
May-21	1,068	1,061	22	22	1	53		
Jun-21	1,100	1,097	5	4	1	60		
Jul-21	982	980	11	9	1	19		
Aug-21	1,011	1,008	15	14	-	16		
Sep-21	1,125	1,121	33	31	3	34		
Oct-21	923	915	13	13	1	23		
Nov-21	1,022	1,015	22	20	1	116		
Dec-21	1,001	999	21	20	4	56		
Jan-22	823	821	36	34	2	48		
Feb-22	830	825	13	13	2	54		
Mar-22	1,271	1,266	31	29	1	85		
April 2021-March 2022							40	38

## 11. Scorecard

State/UT Name		Tripura
Overall Rank		20
IEC & MS	Frequency of Social Media updates (G= ≥60, Y=40-59, R=<40)	
	Status of AEP integration in state School curriculum (G=Yes, R=No)	
	Status of SCA (G= At least one meeting held since 2017, R= other than G)	
	Status of State Rules (G= Notified, R= Not notified)	
	Status of Ombudsman (G= Appointed, R=Not appointed)	
	Rank	26
TI	Facilities onboarded (G=≥95%, Y= 90-94%, R=<90%)	
	Coverage against target in contract (G=≥95%, Y= 90-94%, R=<90%)	
	HRG & BP living with HIV on ART (G=≥95%, Y= 90-94%, R=<90%)	
	IDU on OST (G=≥95%, Y= 90-94%, R=<90%)	
	Rank	19
BSD	Percentage of PLHIV who know their status (G=≥95%, Y= 80-94%, R=<80%)	
	HIV testing against target-GC ((G=≥95%, Y= 80-94%, R=<80%)	
	HIV testing against target-PW (G=≥95%, Y= 80-94%, R=<80%)	
	Percentage of Pregnant women who initiated ART (G=≥95%, Y= 80-94%, R=<80%)	
	Percentage of TB suspected cases referred to NTEP (G=≥95%, Y= 80-94%, R=<80%)	
	Clients managed at DSRC against the target (G=≥95%, Y= 80-94%, R=<80%)	
	Percentage of pregnant women tested for Syphilis (G=≥95%, Y= 80-94%, R=<80%)	
	Rank	22
CST	ART Initiation (Current FY) (G=≥95%, Y= 80-94%, R=<80%)	
	LFU rate among new ART initiation (G=<2%, Y= 2-4%, R=≥5%)	
	PLHIV put on ART during the FY against target (G=≥95%, Y= 80-94%, R=<80%)	
	Status on establishment of CSC (G=≥95%, Y= 80-94%, R=<80%)	NA
	Rank	17
LS	VL Suppression Rate (Current FY) (G=≥95%, Y= 85-94%, R=<85%)	
	% of SRL accredited (G=100%, Y= 80-99%, R=<80%)	
	% Participation of ICTCs in Re-testing (G=≥95%, Y= 85-94, R=<85%)	
	Rank	6
SI	% of NACP facilities active in SOCH (G=≥90%, Y= 75-89%, R=<75%)	
	Status of State Data Management Committee (G=one meeting held, Y= no meeting held, R= not constituted)	
	Status of finalized Priority Areas for Operational Research and Evaluation (G= 4, Y= 3, R= <3)	
	Rank	14
Finance	Expenditure with respect to funds released during FY 2021-22 (G=≥90%, Y= 85-89%, R=<85%)	
	Submission of Audit Report after approval of EC/GB for the preceding year (G= by 30th June, Y= 30th Sept, R= beyond 30th Sept 2021)	
	Submission of Utilization Certificate (in prescribed format GFR 12A) for the previous financial year (G= by 30th June, Y= 30th Sept, R= beyond 30th Sept 2021)	
	Rank	2
SCM	Report Submission (BSD-SCM Report) (G=≥90%, Y= 75-89%, R=<75%)	

Green=3 Marks

Yellow=2Marks

Red=1 Mark

No Colour=Not Applicable

A thick red ribbon is draped across the page, starting from the bottom left, looping up to the right, and then looping back down to the right. The background is a gradient of yellow and orange with faint concentric circles.

# FACT SHEET

## UTTAR PRADESH

# UTTAR PRADESH

## 1. Status of HIV/AIDS Epidemic

### A. Epidemic Estimates (2021)

Indicator	Male	Female	Total
1. IPR	-	-	4.74
2. IMR	-	-	2.08
3. Adult (15-49 yrs) HIV Prevalence (%)	0.12	0.08	0.10
4. Estimated people living with HIV	1,10,878	67,256	1,78,134
5. ART coverage (%)	50.3	70	58
6. Estimated children living with HIV	3,720	3,290	7,010
7. Annual new HIV infections	5,557	2,888	8,445
8. Annual AIDS-related deaths (ARD)	2,031	397	2,428
9. Change in annual new HIV infections since 2010 (%)	-25.2	-26.02	-25.51
10. Change in annual ARD since 2010(%)	-59.3	-83.19	-66.98
11. EMTCT need	-	2,186	2,186


### B. High risk population size (2009), safe practices (2015) and prevalence (2021)

Population Group	Estimates Size	Condom Use (%)	New Needle/ Syringe use (%)	HIV Prevalence (%)
1. Female Sex Workers	22,414	79.8	54.4	1.04
2. Men who have sex with men	10,922	40.8	28.6	1.1
3. Injecting Drug Users	14,259	18.7	82.6	5.45
4. Hijra/Transgender People	8,001	-	-	3.6
5. Migrants	3,27,000	-	-	0.67
6. Truckers	72,000	-	-	0.7
7. Prison inmates	4,09,046	0	0	0.13

### C. HIV/AIDS related knowledge, stigma and high-risk behaviour in general population (2019-21)

Indicator	Male	Female	Total
1. Adults (15-49 yrs) with comprehensive knowledge about HIV/AIDS (%)	22.1	13.1	-
2. Youth (15-24 yrs) with comprehensive knowledge about HIV/AIDS (%)	19.8	11.6	-
3. Adults willing to care for a relative with HIV/AIDS in own home (%)	70	64.1	-
4. Adults willing to buy fresh vegetables from a shopkeeper or vendor who has HIV/AIDS (%)	67.4	57.6	-
5. Adults (15-49 yrs) who have had higher-risk sexual behaviour in the past 12 months (%)	5.3	0.7	-
5.1 Condom use during last higher-risk intercourse (%)	58.5	70.5	-
6. Youth (15-24 yrs) who have had higher-risk sexual behaviour in the past 12 months (%)	8.7	1.3	-
6.1 Condom use during last higher-risk intercourse (%)	60.4	79.2	-

## 2. Progress on 95-95-95 (2021-22)



Indicator	Male	Female	Total
1. Estimated PLHIV size (2021)	1,10,878	67,256	1,78,134
2. PLHIV who know their HIV Status	63,809	51,780	1,15,589
3. PLHIV who know their HIV status and are on ART	52,686	44,630	97,316
4. PLHIV who are on ART and tested for their viral load	32,626	28,427	61,053
5. PLHIV who are virally suppressed	27,172	24,760	51,932

### 3. Prevention of new HIV infections among general population

#### A. Information, Education, Communication, Youth and Mainstreaming

Indicator	2021-22
1. Schools with operational Adolescent Education Program (AEP)	-
2. Colleges with operational Red Ribbon Clubs (RRC)	373
3. Persons trained under mainstreaming	4,162
4. No. of calls received at helpline	-

#### B. Sexually Transmitted Infections (STI)/Reproductive Tract Infections (RTI) Management at DSRCs

Indicator	2021-22			
1. NACO Supported Designated STI/RTI Clinics (DSRC)	115			
	Male	Female	TG	Total
2. Clients managed	-	-	-	8,14,777
3. RPR Tests conducted	1,14,597	1,80,157	2,254	2,97,008
4. Syphilis seropositivity (%)	0.37	0.19	4.26	0.29

### 4. Prevention of new HIV infections among high-risk group and bridge population

#### A. Targeted Interventions (TI) and Opioid Substitution Therapy (OST)

Indicator	2021-22
1. Targeted Interventions	81
2. OST centres	20
3. Employer Led Model Interventions	44

#### B. Female Sex Workers

Indicator	2021-22
1. Estimated size	22,414
2. Coverage (%)	>=95
3. Condoms distributed	64,56,684
4. Tested for HIV (April 2021 - September 2021)	16,779
4.1. HIV sero-positive (%)	0.13
4.1.1. Linked to ART	18
5. Tested for HIV (October 2021 - March 2022)	18,053
5.1. HIV sero-positive (%)	0.10
5.1.1. Linked to ART	17
6. Clinic Visits	62,937
7. STI/RTI treated	1,449
8. Presumptive treatment	3,339

#### C. Men who have Sex with Men

Indicator	2021-22
1. Estimated size	10,922
2. Coverage (%)	>=95
3. Condoms distributed	24,39,300
4. Tested for HIV (April 2021 - September 2021)	8,101
4.1. HIV sero-positive (%)	0.36
4.1.1. Linked to ART	26
5. Tested for HIV (October 2021 - March 2022)	9,084
5.1. HIV sero-positive (%)	0.43
5.1.1. Linked to ART	39
6. Clinic Visits	31,020
7. STI/RTI treated	439
8. Presumptive treatment	1,629

### D. Injecting Drug Users

Indicator	2021-22
1. Estimated size	14,259
2. Coverage (%)	>=95
3. Needles distributed	96,56,497
4. Syringes distributed	49,16,962
5. On OST	2,060
6. Tested for HIV (April 2021 - September 2021)	15,318
6.1. HIV sero-positive (%)	0.86
6.1.1. Linked to ART	93
7. Tested for HIV (October 2021 - March 2022)	16,060
7.1. HIV sero-positive (%)	0.61
7.1.1. Linked to ART	76

### E. Hijra/Transgender people

Indicator	2021-22
1. Estimated size	8,001
2. Coverage (%)	62
3. Condoms distributed	10,70,652
4. Tested for HIV (April 2021 - September 2021)	3,450
4.1. HIV sero-positive (%)	0.35
4.1.1. Linked to ART	11
5. Tested for HIV (October 2021 - March 2022)	3,741
5.1. HIV sero-positive (%)	0.19
5.1.1. Put on ART	6
6. Clinic Visits	13,606
7. STI / RTI treated	160
8. Presumptive treatment	586

### F. Migrants

Indicator	2021-22
1. Estimated size	3,27,000
2. Coverage (%)	42
3. Tested for HIV	19,224
3.1. HIV sero-positive (%)	0.14
3.2. Linked to ART	23

### G. Truckers

Indicator	2021-22
1. Estimated size	72,000
2. Coverage (%)	90
3. Tested for HIV	18,778
3.1. HIV sero-positive (%)	0.09
3.2. On ART	17

### H. Prison Inmates

Indicator	2021-22
1. Total prisons	72
2. Prisons covered under programme	75
3. Total inmates admitted	4,15,548
4. Inmates Covered(%)	13
5. Tested for HIV	53,617
5.1. HIV sero-positive (%)	0.49
5.2. On ART (%)	94

### I. Link Worker Scheme

Indicator	2021-22
1. Districts covered under scheme	7
2. Vulnerable population covered	1,18,191
3. Tested for HIV	52,603
3.1. HIV sero-positive (%)	0.15
3.2. Linked to ART (%)	97.47

## J. Opioid Substitution Therapy

Indicator	2021-22
1. OST Centres	20
1.1. OSTC in Public Health Settings	16
1.2. OSTC in NGO Settings	-
1.3 No. of Satellite OST Centres	4
2. IDU on OST	2,060

## 5. Early detection of HIV infected people

### A. HIV Counselling and Testing Services (HCTS)

Indicator	2021-22
1. ICTC facilities	3,288
1.1. Stand-alone	456
1.2. Facility integrated (Govt)	1,800
1.3. Facility integrated (PPP)	99
1.4. CBS	933

### B. HIV Testing among Vulnerable Population (Excluding Pregnant Women)

Indicator	2021-22			
	Male	Female	TG	Total
1. Tested for HIV	6,68,586	5,29,268	8,022	12,05,876
2. Found HIV Positive among tested	7,344	3,486	59	10,889
3. HIV sero-positivity (%) among tested	1.10	0.66	0.74	0.90
4. Spouse/sexual partner testing of HIV positive people identified	3,050	1,930	54	5,034

## 6. Initiation and retention on ART of HIV infected people

### A. Treatment Facilities

Indicator	2021-22
1. ART Centres	51
2. Centre of Excellence	
2.1. Centre of Excellence (Adult)	1
2.2. Centre of Excellence (Paediatric)	-
3. Link ART Centres	32
4. Care Support Centres	27

### B. Treatment Uptake

Indicator	2021-22			
	Male	Female	TG	Total
1. HIV positive cases diagnosed (At ICTC)	7,344	3,978	59	11,381
2. New PLHIV Registered at ART center	6,986	3,888	40	10,914
2.1 Initiated on ART	6,636	3,783	38	10,457
3. PLHIV alive and on ART	55,820	47,023	284	1,03,127
4. 12 months retention on ART (%)				79.45
5. Lost to follow-up cases	3,920	2,031	14	5,965

## 7. Viral Suppression and laboratories

### A. Laboratory facilities and service uptake

Indicator	2021-22
1. Viral load laboratories	3
1.1 Accredited Viral load laboratories	-
2. Viral load testing conducted	62,073
2.1. Virally suppressed (%)	85
3. National reference laboratories (NRL)	1
3.1 Accredited NRL	1
4. State reference laboratories (SRL)	9
4.1 Accredited SRL	9
5. CD4 testing conducted	56,663
6. External Quality Assessment of ICTC	
6.1 Average Participation (%)	85.54
6.2. Average Discordance (%)	0.00
7. Quality Assurance Scheme for Basic Composite Medical Laboratories (Entry Level)- M(EL)T	
7.1 No. of ICTCs certified for M(EL)T certification	2.00

## 8. Elimination of mother to child transmission of HIV & Syphilis

### A. HIV

Indicator	2021-22
1. Estimated pregnant women (PW)	67,91,420
2. HIV testing among PW	55,00,861
3. HIV sero-positivity (%) among tested	0.01
4. HIV Positive PW (old + new detections)	1,060
4.1 On life-long ART	1,110
5. Live births among HIV positive PW	674
5.1 Babies given ARV Prophylaxis (%)	85.01
6. Babies tested HIV (6 week- 6 month)	765
6.1 Babies confirmed HIV Positive (6 week- 6 month)	17
7. HIV exposed babies at 18 months	
7.1 HIV exposed babies tested at 18 month	3
7.2 Babies confirmed HIV positive at 18 months	1
8. HIV positive babies initiated on ART	10

### B. Syphilis

Indicator	2021-22
1. Estimated pregnant women (PW)	67,91,420
2. Syphilis testing among PW	36,88,156
3. Sero-positivity (%) among tested	0.01
4. Put on treatment	292

## 9. Elimination of HIV/AIDS related Stigma and Discrimination

### A. HIV/AIDS Prevention & Control Act (2017)

Indicator	2021-22
1. State rules notified for HIV/AIDS Prevention and Control Act (2017)	Yes
2. State designated/appointed ombudsman for HIV/AIDS Prevention and Control Act (2017)	Yes

## 10. HIV-TB Co-morbidities

## A. HRG and Bridge Population

Indicator								2021-22
	Quarter	FSW	MSW	IDU	TG	Migrants	Truckers	Total
Screened for TB	Quarter 1	10,445	5,385	9,971	2,515	1,938	2,287	32,541
	Quarter 2	11,525	5,883	11,951	2,395	3,149	4,334	39,237
	Quarter 3	11,796	6,326	11,472	2,552	4,937	5,446	42,529
	Quarter 4	13,947	7,581	12,500	3,260	5,387	8,283	50,958
Tested for TB	Quarter 1	130	59	123	30	16	19	377
	Quarter 2	195	66	183	31	27	44	546
	Quarter 3	288	92	175	31	94	31	711
	Quarter 4	332	89	210	37	72	16	756
Diagnosed with TB	Quarter 1	2	-	10	-	-	1	13
	Quarter 2	8	-	11	-	1	3	23
	Quarter 3	2	1	5	1	1	1	11
	Quarter 4	3	2	8	1	1	-	15
Initiated on TB treatment	Quarter 1	3	-	10	-	-	1	14
	Quarter 2	8	-	11	-	1	3	23
	Quarter 3	2	1	5	1	1	1	11
	Quarter 4	2	2	8	1	1	-	14

## B. HIV-TB Cross-Referral

Indicator	2021-22
1. In referral from TB program	1,02,194
1.1. HIV sero-positive (%)	4.84
1.2. ICTC clients referred to NTEP	44,542

## C. HIV-TB Coinfected at ART Centre

Indicator								2021-22
	PLHIV attending ART Centre	PLHIV underwent 4S screening	PLHIV with presumptive TB	PLHIV tested for TB	PLHIV diagnosed with TB	PLHIV initiated on IPT	Co-infected enrolled at ARTc	Co-infected initiated on ART
Apr-21	59,318	59,130	755	734	86	964		
May-21	53,248	53,082	556	513	41	553		
Jun-21	57,865	57,683	1,397	759	127	1,108		
Jul-21	62,881	62,728	996	961	156	799		
Aug-21	63,058	62,774	1,045	1,018	161	565		
Sep-21	65,265	65,054	1,225	1,208	151	879		
Oct-21	64,568	64,459	1,217	1,187	164	1,292		
Nov-21	68,170	67,995	1,238	1,202	149	1,445		
Dec-21	61,176	61,062	1,319	1,276	181	1,604		
Jan-22	58,124	58,019	1,190	1,127	126	1,785		
Feb-22	59,623	59,474	1,236	1,133	139	1,689		
Mar-22	64,098	63,904	1,470	1,442	189	1,480		
April 2021-March 2022							2,447	2,304



## 11. Scorecard

State/UT Name		Uttar Pradesh
Overall Rank		20
IEC & MS	Frequency of Social Media updates (G= ≥60, Y=40-59, R=<40)	
	Status of AEP integration in state School curriculum (G=Yes, R=No)	
	Status of SCA (G= At least one meeting held since 2017, R= other than G)	
	Status of State Rules (G= Notified, R= Not notified)	
	Status of Ombudsman (G= Appointed, R=Not appointed)	
	Rank	26
TI	Facilities onboarded (G=≥95%, Y= 90-94%, R=<90%)	
	Coverage against target in contract (G=≥95%, Y= 90-94%, R=<90%)	
	HRG & BP living with HIV on ART (G=≥95%, Y= 90-94%, R=<90%)	
	IDU on OST (G=≥95%, Y= 90-94%, R=<90%)	
	Rank	19
BSD	Percentage of PLHIV who know their status (G=≥95%, Y= 80-94%, R=<80%)	
	HIV testing against target-GC ((G=≥95%, Y= 80-94%, R=<80%)	
	HIV testing against target-PW (G=≥95%, Y= 80-94%, R=<80%)	
	Percentage of Pregnant women who initiated ART (G=≥95%, Y= 80-94%, R=<80%)	
	Percentage of TB suspected cases referred to NTEP (G=≥95%, Y= 80-94%, R=<80%)	
	Clients managed at DSRC against the target (G=≥95%, Y= 80-94%, R=<80%)	
	Percentage of pregnant women tested for Syphilis (G=≥95%, Y= 80-94%, R=<80%)	
	Rank	22
CST	ART Initiation (Current FY) (G=≥95%, Y= 80-94%, R=<80%)	
	LFU rate among new ART initiation (G=<2%, Y= 2-4%, R=≥5%)	
	PLHIV put on ART during the FY against target (G=≥95%, Y= 80-94%, R=<80%)	
	Status on establishment of CSC (G=≥95%, Y= 80-94%, R=<80%)	NA
	Rank	17
LS	VL Suppression Rate (Current FY) (G=≥95%, Y= 85-94%, R=<85%)	
	% of SRL accredited (G=100%, Y= 80-99%, R=<80%)	
	% Participation of ICTCs in Re-testing (G=≥95%, Y= 85-94, R=<85%)	
	Rank	6
SI	% of NACP facilities active in SOCH (G=≥90%, Y= 75-89%, R=<75%)	
	Status of State Data Management Committee (G=one meeting held, Y= no meeting held, R= not constituted)	
	Status of finalized Priority Areas for Operational Research and Evaluation (G= 4, Y= 3, R= <3)	
	Rank	14
Finance	Expenditure with respect to funds released during FY 2021-22 (G=≥90%, Y= 85-89%, R=<85%)	
	Submission of Audit Report after approval of EC/GB for the preceding year (G= by 30th June, Y= 30th Sept, R= beyond 30th Sept 2021)	
	Submission of Utilization Certificate (in prescribed format GFR 12A) for the previous financial year (G= by 30th June, Y= 30th Sept, R= beyond 30th Sept 2021)	
	Rank	2
SCM	Report Submission (BSD-SCM Report) (G=≥90%, Y= 75-89%, R=<75%)	

Green=3 Marks

Yellow=2Marks

Red=1 Mark

No Colour=Not Applicable

A thick red ribbon is draped across the page, starting from the bottom left, looping upwards and to the right, and then looping back down towards the bottom right. The background is a gradient of yellow and orange with faint, concentric circular lines.

# FACT SHEET

## UTTARAKHAND

# UTTARAKHAND

## 1. Status of HIV/AIDS Epidemic

### A. Epidemic Estimates (2021)

Indicator	Male	Female	Total
1. IPR	-	-	4.29
2. IMR	-	-	1.03
3. Adult (15-49 yrs) HIV Prevalence (%)	0.14	0.10	0.12
4. Estimated people living with HIV	6,663	4,664	11,327
5. ART coverage (%)	40.4	47	43
6. Estimated children living with HIV	196	167	363
7. Annual new HIV infections	291	194	485
8. Annual AIDS-related deaths (ARD)	268	122	390
9. Change in annual new HIV infections since 2010 (%)	-39.2	-34.90	-37.45
10. Change in annual ARD since 2010(%)	-44.2	-47.19	-45.37
11. EMTCT need	-	97	97


### B. High risk population size (2009), safe practices (2015) and prevalence (2021)

Population Group	Estimates Size	Condom Use (%)	New Needle/ Syringe use (%)	HIV Prevalence (%)
1. Female Sex Workers	5,800	61	43.3	0.42
2. Men who have sex with men	1,770	65.7	20.3	2.68
3. Injecting Drug Users	1,950	28	93.2	9.77
4. Hijra/Transgender People	160	-	-	-
5. Migrants	90,000	-	-	-
6. Truckers	40,000	-	-	2.1
7. Prison inmates	20,582	0	0	0.00

### C. HIV/AIDS related knowledge, stigma and high-risk behaviour in general population (2019-21)

Indicator	Male	Female	Total
1. Adults (15-49 yrs) with comprehensive knowledge about HIV/AIDS (%)	35.9	24.5	-
2. Youth (15-24 yrs) with comprehensive knowledge about HIV/AIDS (%)	27.1	21.5	-
3. Adults willing to care for a relative with HIV/AIDS in own home (%)	80.7	70.3	-
4. Adults willing to buy fresh vegetables from a shopkeeper or vendor who has HIV/AIDS (%)	72.4	65.8	-
5. Adults (15-49 yrs) who have had higher-risk sexual behaviour in the past 12 months (%)	6.3	0	-
5.1 Condom use during last higher-risk intercourse (%)	61	NA	-
6. Youth (15-24 yrs) who have had higher-risk sexual behaviour in the past 12 months (%)	13.2	0	-
6.1 Condom use during last higher-risk intercourse (%)	59.7	NA	-

## 2. Progress on 95-95-95 (2021-22)



Indicator	Male	Female	Total
1. Estimated PLHIV size (2021)	6,663	4,664	11,327
2. PLHIV who know their HIV Status	3,961	2,854	6,815
3. PLHIV who know their HIV status and are on ART	2,506	2,035	4,541
4. PLHIV who are on ART and tested for their viral load	2,350	1,958	4,308
5. PLHIV who are virally suppressed	1,994	1,731	3,725

### 3. Prevention of new HIV infections among general population

#### A. Information, Education, Communication, Youth and Mainstreaming

Indicator	2021-22
1. Schools with operational Adolescent Education Program (AEP)	100
2. Colleges with operational Red Ribbon Clubs (RRC)	100
3. Persons trained under mainstreaming	10,417

#### B. Sexually Transmitted Infections (STI)/Reproductive Tract Infections (RTI) Management at DSRCs

Indicator	2021-22			
1. NACO Supported Designated STI/RTI Clinics (DSRC)	27			
	Male	Female	TG	Total
2. Clients managed	-	-	-	54,161
3. RPR Tests conducted	6,660	21,613	0	28,273
4. Syphilis seropositivity (%)	1.01	0.06	-	0.29

### 4. Prevention of new HIV infections among high-risk group and bridge population

#### A. Targeted Interventions (TI) and Opioid Substitution Therapy (OST)

Indicator	2021-22
1. Targeted Interventions	27
2. OST centres	5
3. Employer Led Model Interventions	66

#### B. Female Sex Workers

Indicator	2021-22
1. Estimated size	5,800
2. Coverage (%)	87
3. Condoms distributed	11,62,314
4. Tested for HIV (April 2021 - September 2021)	4,234
4.1. HIV sero-positive (%)	0.02
4.1.1. Linked to ART	1
5. Tested for HIV (October 2021 - March 2022)	4,327
5.1. HIV sero-positive (%)	0.07
5.1.1. Linked to ART	3
6. Clinic Visits	15,872
7. STI/RTI treated	676
8. Presumptive treatment	670

#### C. Men who have Sex with Men

Indicator	2021-22
1. Estimated size	1,770
2. Coverage (%)	>=95
3. Condoms distributed	4,67,933
4. Tested for HIV (April 2021 - September 2021)	1,920
4.1. HIV sero-positive (%)	0.57
4.1.1. Linked to ART	9
5. Tested for HIV (October 2021 - March 2022)	1,988
5.1. HIV sero-positive (%)	0.40
5.1.1. Linked to ART	9
6. Clinic Visits	7,655
7. STI/RTI treated	189
8. Presumptive treatment	336

### D. Injecting Drug Users

Indicator	2021-22
1. Estimated size	1,950
2. Coverage (%)	>=95
3. Needles distributed	10,73,150
4. Syringes distributed	5,36,653
5. On OST	482
6. Tested for HIV (April 2021 - September 2021)	2,307
6.1. HIV sero-positive (%)	0.91
6.1.1. Linked to ART	10
7. Tested for HIV (October 2021 - March 2022)	2,169
7.1. HIV sero-positive (%)	0.55
7.1.1. Linked to ART	14

### E. Hijra/Transgender people

Indicator	2021-22
1. Estimated size	160
2. Coverage (%)	>=95
3. Condoms distributed	31,328
4. Tested for HIV (April 2021 - September 2021)	126
4.1. HIV sero-positive (%)	2.38
4.1.1. Linked to ART	3
5. Tested for HIV (October 2021 - March 2022)	118
5.1. HIV sero-positive (%)	1.69
5.1.1. Put on ART	2
6. Clinic Visits	517
7. STI / RTI treated	18
8. Presumptive treatment	25

### F. Migrants

Indicator	2021-22
1. Estimated size	90,000
2. Coverage (%)	>=95
3. Tested for HIV	23,395
3.1. HIV sero-positive (%)	0.06
3.2. Linked to ART	15

### G. Truckers

Indicator	2021-22
1. Estimated size	40,000
2. Coverage (%)	>=95
3. Tested for HIV	8,495
3.1. HIV sero-positive (%)	0.12
3.2. On ART	10

### H. Prison Inmates

Indicator	2021-22
1. Total prisons	11
2. Prisons covered under programme	10
3. Total inmates admitted	15,801
4. Inmates Covered(%)	71
5. Tested for HIV	8,064
5.1. HIV sero-positive (%)	0.92
5.2. On ART (%)	54

### I. Link Worker Scheme

Indicator	2021-22
1. Districts covered under scheme	-
2. Vulnerable population covered	-
3. Tested for HIV	-
3.1. HIV sero-positive (%)	-
3.2. Linked to ART (%)	-

## J. Opioid Substitution Therapy

Indicator	2021-22
1. OST Centres	5
1.1. OSTC in Public Health Settings	5
1.2. OSTC in NGO Settings	-
1.3 No. of Satellite OST Centres	-
2. IDU on OST	482

## 5. Early detection of HIV infected people

### A. HIV Counselling and Testing Services (HCTS)

Indicator	2021-22
1. ICTC facilities	183
1.1. Stand-alone	51
1.2. Facility integrated (Govt)	91
1.3. Facility integrated (PPP)	14
1.4. CBS	27

### B. HIV Testing among Vulnerable Population (Excluding Pregnant Women)

Indicator	2021-22			
	Male	Female	TG	Total
1. Tested for HIV	92,116	55,864	239	1,48,219
2. Found HIV Positive among tested	579	240	3	822
3. HIV sero-positivity (%) among tested	0.63	0.43	1.26	0.55
4. Spouse/sexual partner testing of HIV positive people identified	69	135	-	204

## 6. Initiation and retention on ART of HIV infected people

### A. Treatment Facilities

Indicator	2021-22
1. ART Centres	6
2. Centre of Excellence	
2.1. Centre of Excellence (Adult)	-
2.2. Centre of Excellence (Paediatric)	-
3. Link ART Centres	32
4. Care Support Centres	2

### B. Treatment Uptake

Indicator	2021-22			
	Male	Female	TG	Total
1. HIV positive cases diagnosed (At ICTC)	579	272	3	854
2. New PLHIV Registered at ART center	700	336	8	1,044
2.1 Initiated on ART	526	259	3	788
3. PLHIV alive and on ART	2,690	2,169	21	4,881
4. 12 months retention on ART (%)				69.85
5. Lost to follow-up cases	1,020	597	5	1,622

## 7. Viral Suppression and laboratories

### A. Laboratory facilities and service uptake

Indicator	2021-22
1. Viral load laboratories	-
1.1 Accredited Viral load laboratories	-
2. Viral load testing conducted	4,374
2.1. Virally suppressed (%)	86
3. National reference laboratories (NRL)	-
3.1 Accredited NRL	-
4. State reference laboratories (SRL)	1
4.1 Accredited SRL	1
5. CD4 testing conducted	3,364
6. External Quality Assessment of ICTC	
6.1 Average Participation (%)	73.00
6.2. Average Discordance (%)	0.00
7. Quality Assurance Scheme for Basic Composite Medical Laboratories (Entry Level)- M(EL)T	
7.1 No. of ICTCs certified for M(EL)T certification	-

## 8. Elimination of mother to child transmission of HIV & Syphilis

### A. HIV

Indicator	2021-22
1. Estimated pregnant women (PW)	2,18,460
2. HIV testing among PW	1,70,977
3. HIV sero-positivity (%) among tested	0.02
4. HIV Positive PW (old + new detections)	55
4.1 On life-long ART	40
5. Live births among HIV positive PW	42
5.1 Babies given ARV Prophylaxis (%)	78.57
6. Babies tested HIV (6 week- 6 month)	54
6.1 Babies confirmed HIV Positive (6 week- 6 month)	1
7. HIV exposed babies at 18 months	
7.1 HIV exposed babies tested at 18 month	17
7.2 Babies confirmed HIV positive at 18 months	1
8. HIV positive babies initiated on ART	2

### B. Syphilis

Indicator	2021-22
1. Estimated pregnant women (PW)	2,18,460
2. Syphilis testing among PW	1,24,175
3. Sero-positivity (%) among tested	0.01
4. Put on treatment	5

## 9. Elimination of HIV/AIDS related Stigma and Discrimination

### A. HIV/AIDS Prevention & Control Act (2017)

Indicator	2021-22
1. State rules notified for HIV/AIDS Prevention and Control Act (2017)	No
2. State designated/appointed ombudsman for HIV/AIDS Prevention and Control Act (2017)	Yes

## 10. HIV-TB Co-morbidities

## A. HRG and Bridge Population

Indicator								2021-22
	Quarter	FSW	MSW	IDU	TG	Migrants	Truckers	Total
Screened for TB	Quarter 1	4,025	1,731	1,565	96	5,902	3,964	17,283
	Quarter 2	4,855	2,084	1,646	122	9,397	4,210	22,314
	Quarter 3	4,850	2,358	1,503	123	8,033	4,129	20,996
	Quarter 4	4,644	2,225	1,766	169	8,462	4,357	21,623
Tested for TB	Quarter 1	6	4	9	-	26	29	74
	Quarter 2	18	19	37	6	51	29	160
	Quarter 3	2	5	29	4	30	4	74
	Quarter 4	2	12	28	5	10	-	57
Diagnosed with TB	Quarter 1	-	-	2	-	9	1	12
	Quarter 2	-	2	2	-	6	25	35
	Quarter 3	-	-	1	-	1	1	3
	Quarter 4	-	-	4	1	1	-	6
Initiated on TB treatment	Quarter 1	-	-	2	-	9	1	12
	Quarter 2	-	2	2	-	6	6	16
	Quarter 3	-	-	1	-	1	-	2
	Quarter 4	-	-	4	1	1	-	6

## B. HIV-TB Cross-Referral

Indicator	2021-22
1. In referral from TB program	7,620
1.1. HIV sero-positive (%)	1.25
1.2. ICTC clients referred to NTEP	1,384

## C. HIV-TB Coinfected at ART Centre

Indicator								2021-22
	PLHIV attending ART Centre	PLHIV underwent 4S screening	PLHIV with presumptive TB	PLHIV tested for TB	PLHIV diagnosed with TB	PLHIV initiated on IPT	Co-infected enrolled at ARTc	Co-infected initiated on ART
Apr-21	2,274	1,881	41	25	11	4		
May-21	2,021	1,767	34	17	7	1		
Jun-21	3,142	2,630	44	24	11	2		
Jul-21	3,501	2,852	70	38	15	-		
Aug-21	3,383	3,041	80	41	16	-		
Sep-21	3,708	3,264	75	44	19	-		
Oct-21	3,576	3,009	88	65	17	58		
Nov-21	3,291	3,214	77	60	21	106		
Dec-21	3,269	3,232	69	52	15	44		
Jan-22	3,129	3,066	68	52	15	-		
Feb-22	2,551	2,414	58	40	11	7		
Mar-22	3,149	2,957	65	44	6	7		
April 2021-March 2022							141	79

## 11. Scorecard

State/UT Name		Uttarakhand
Overall Rank		21
IEC & MS	Frequency of Social Media updates (G= ≥60, Y=40-59, R=<40)	
	Status of AEP integration in state School curriculum (G=Yes, R=No)	
	Status of SCA (G= At least one meeting held since 2017, R= other than G)	
	Status of State Rules (G= Notified, R= Not notified)	
	Status of Ombudsman (G= Appointed, R=Not appointed)	
	Rank	15
TI	Facilities onboarded (G=≥95%, Y= 90-94%, R=<90%)	
	Coverage against target in contract (G=≥95%, Y= 90-94%, R=<90%)	
	HRG & BP living with HIV on ART (G=≥95%, Y= 90-94%, R=<90%)	
	IDU on OST (G=≥95%, Y= 90-94%, R=<90%)	
	Rank	28
BSD	Percentage of PLHIV who know their status (G=≥95%, Y= 80-94%, R=<80%)	
	HIV testing against target-GC ((G=≥95%, Y= 80-94%, R=<80%)	
	HIV testing against target-PW (G=≥95%, Y= 80-94%, R=<80%)	
	Percentage of Pregnant women who initiated ART (G=≥95%, Y= 80-94%, R=<80%)	
	Percentage of TB suspected cases referred to NTEP (G=≥95%, Y= 80-94%, R=<80%)	
	Clients managed at DSRC against the target (G=≥95%, Y= 80-94%, R=<80%)	
	Percentage of pregnant women tested for Syphilis (G=≥95%, Y= 80-94%, R=<80%)	
	Rank	2
CST	ART Initiation (Current FY) (G=≥95%, Y= 80-94%, R=<80%)	
	LFU rate among new ART initiation (G=<2%, Y= 2-4%, R=≥5%)	
	PLHIV put on ART during the FY against target (G=≥95%, Y= 80-94%, R=<80%)	
	Status on establishment of CSC (G=≥95%, Y= 80-94%, R=<80%)	NA
	Rank	29
LS	VL Suppression Rate (Current FY) (G=≥95%, Y= 85-94%, R=<85%)	
	% of SRL accredited (G=100%, Y= 80-99%, R=<80%)	
	% Participation of ICTCs in Re-testing (G=≥95%, Y= 85-94%, R=<85%)	
	Rank	12
SI	% of NACP facilities active in SOCH (G=≥90%, Y= 75-89%, R=<75%)	
	Status of State Data Management Committee (G=one meeting held, Y= no meeting held, R= not constituted)	
	Status of finalized Priority Areas for Operational Research and Evaluation (G= 4, Y= 3, R= <3)	
	Rank	25
Finance	Expenditure with respect to funds released during FY 2021-22 (G=≥90%, Y= 85-89%, R=<85%)	
	Submission of Audit Report after approval of EC/GB for the preceding year (G= by 30th June, Y= 30th Sept, R= beyond 30th Sept 2021)	
	Submission of Utilization Certificate (in prescribed format GFR 12A) for the previous financial year (G= by 30th June, Y= 30th Sept, R= beyond 30th Sept 2021)	
	Rank	18
SCM	Report Submission (BSD-SCM Report) (G=≥90%, Y= 75-89%, R=<75%)	
Green=3 Marks		Yellow=2Marks
Red=1 Mark		No Colour=Not Applicable



A thick red ribbon is draped across the page, starting from the bottom left, looping upwards and to the right, and then looping back down towards the right edge. The background is a gradient of yellow and orange with faint, concentric circular lines.

# FACT SHEET

## WEST BENGAL

# WEST BENGAL

## 1. Status of HIV/AIDS Epidemic

### A. Epidemic Estimates (2021)

Indicator	Male	Female	Total
1. IPR	-	-	2.20
2. IMR	-	-	1.22
3. Adult (15-49 yrs) HIV Prevalence (%)	0.08	0.07	0.08
4. Estimated people living with HIV	38,627	30,573	69,200
5. ART coverage (%)	72.9	69	71
6. Estimated children living with HIV	1,087	1,033	2,120
7. Annual new HIV infections	805	720	1,525
8. Annual AIDS-related deaths (ARD)	371	345	716
9. Change in annual new HIV infections since 2010 (%)	-57.7	-57.17	-57.47
10. Change in annual ARD since 2010(%)	-89.1	-85.17	-87.49
11. EMTCT need	-	517	517


### B. High risk population size (2009), safe practices (2015) and prevalence (2021)

Population Group	Estimates Size	Condom Use (%)	New Needle/ Syringe use (%)	HIV Prevalence (%)
1. Female Sex Workers	21,562	95.7	0	1.27
2. Men who have sex with men	2,627	42.4	24	4.36
3. Injecting Drug Users	1,713	62	94.6	7.4
4. Hijra/Transgender People	1,562	-	-	9.15
5. Migrants	30,000	-	-	3.2
6. Truckers	60,000	-	-	2.01
7. Prison inmates	1,13,242	26.1	26.7	0.84

### C. HIV/AIDS related knowledge, stigma and high-risk behaviour in general population (2019-21)

Indicator	Male	Female	Total
1. Adults (15-49 yrs) with comprehensive knowledge about HIV/AIDS (%)	15.5	18.5	-
2. Youth (15-24 yrs) with comprehensive knowledge about HIV/AIDS (%)	14.3	17.4	-
3. Adults willing to care for a relative with HIV/AIDS in own home (%)	59.3	66.5	-
4. Adults willing to buy fresh vegetables from a shopkeeper or vendor who has HIV/AIDS (%)	56.7	64.2	-
5. Adults (15-49 yrs) who have had higher-risk sexual behaviour in the past 12 months (%)	1.7	1	-
5.1 Condom use during last higher-risk intercourse (%)	63.6	52.4	-
6. Youth (15-24 yrs) who have had higher-risk sexual behaviour in the past 12 months (%)	3.5	1.5	-
6.1 Condom use during last higher-risk intercourse (%)	67.9	62.5	-

## 2. Progress on 95-95-95 (2021-22)



Indicator	Male	Female	Total
1. Estimated PLHIV size (2021)	38,627	30,573	69,200
2. PLHIV who know their HIV Status	33,853	24,725	58,578
3. PLHIV who know their HIV status and are on ART	27,906	21,035	48,941
4. PLHIV who are on ART and tested for their viral load	13,921	10,910	24,831
5. PLHIV who are virally suppressed	11,998	9,555	21,553

### 3. Prevention of new HIV infections among general population

#### A. Information, Education, Communication, Youth and Mainstreaming

Indicator	2021-22
1. Schools with operational Adolescent Education Program (AEP)	2,500
2. Colleges with operational Red Ribbon Clubs (RRC)	480
3. Persons trained under mainstreaming	6,765

#### B. Sexually Transmitted Infections (STI)/Reproductive Tract Infections (RTI) Management at DSRCs

Indicator	2021-22			
1. NACO Supported Designated STI/RTI Clinics (DSRC)	48			
	Male	Female	TG	Total
2. Clients managed	-	-	-	1,24,871
3. RPR Tests conducted	21,523	48,964	89	70,576
4. Syphilis seropositivity (%)	2.00	0.66	21.35	1.10

### 4. Prevention of new HIV infections among high-risk group and bridge population

#### A. Targeted Interventions (TI) and Opioid Substitution Therapy (OST)

Indicator	2021-22
1. Targeted Interventions	44
2. OST centres	11
3. Employer Led Model Interventions	37

#### B. Female Sex Workers

Indicator	2021-22
1. Estimated size	21,562
2. Coverage (%)	85
3. Condoms distributed	50,86,143
4. Tested for HIV (April 2021 - September 2021)	12,458
4.1. HIV sero-positive (%)	0.10
4.1.1. Linked to ART	11
5. Tested for HIV (October 2021 - March 2022)	13,869
5.1. HIV sero-positive (%)	0.16
5.1.1. Linked to ART	23
6. Clinic Visits	48,727
7. STI/RTI treated	417
8. Presumptive treatment	1,867

#### C. Men who have Sex with Men

Indicator	2021-22
1. Estimated size	2,627
2. Coverage (%)	69
3. Condoms distributed	3,56,390
4. Tested for HIV (April 2021 - September 2021)	1,492
4.1. HIV sero-positive (%)	0.94
4.1.1. Linked to ART	13
5. Tested for HIV (October 2021 - March 2022)	1,601
5.1. HIV sero-positive (%)	0.69
5.1.1. Linked to ART	10
6. Clinic Visits	5,923
7. STI/RTI treated	15
8. Presumptive treatment	83

### D. Injecting Drug Users

Indicator	2021-22
1. Estimated size	1,713
2. Coverage (%)	98
3. Needles distributed	9,59,652
4. Syringes distributed	4,79,898
5. On OST	808
6. Tested for HIV (April 2021 - September 2021)	1,539
6.1. HIV sero-positive (%)	0.19
6.1.1. Linked to ART	0
7. Tested for HIV (October 2021 - March 2022)	1,577
7.1. HIV sero-positive (%)	0.13
7.1.1. Linked to ART	1

### E. Hijra/Transgender people

Indicator	2021-22
1. Estimated size	1,562
2. Coverage (%)	>=95
3. Condoms distributed	4,09,450
4. Tested for HIV (April 2021 - September 2021)	1,238
4.1. HIV sero-positive (%)	0.89
4.1.1. Linked to ART	13
5. Tested for HIV (October 2021 - March 2022)	1,553
5.1. HIV sero-positive (%)	1.35
5.1.1. Put on ART	21
6. Clinic Visits	4,876
7. STI / RTI treated	34
8. Presumptive treatment	208

### F. Migrants

Indicator	2021-22
1. Estimated size	30,000
2. Coverage (%)	>=95
3. Tested for HIV	11,726
3.1. HIV sero-positive (%)	0.03
3.2. Linked to ART	4

### G. Truckers

Indicator	2021-22
1. Estimated size	60,000
2. Coverage (%)	92
3. Tested for HIV	11,444
3.1. HIV sero-positive (%)	0.06
3.2. On ART	7

### H. Prison Inmates

Indicator	2021-22
1. Total prisons	59
2. Prisons covered under programme	27
3. Total inmates admitted	1,11,962
4. Inmates Covered(%)	12
5. Tested for HIV	1,699
5.1. HIV sero-positive (%)	1.71
5.2. On ART (%)	86

### I. Link Worker Scheme

Indicator	2021-22
1. Districts covered under scheme	11
2. Vulnerable population covered	1,01,870
3. Tested for HIV	77,022
3.1. HIV sero-positive (%)	0.18
3.2. Linked to ART (%)	95.04

## J. Opioid Substitution Therapy

Indicator	2021-22
1. OST Centres	11
1.1. OSTC in Public Health Settings	7
1.2. OSTC in NGO Settings	1
1.3 No. of Satellite OST Centres	3
2. IDU on OST	808

## 5. Early detection of HIV infected people

### A. HIV Counselling and Testing Services (HCTS)

Indicator	2021-22
1. ICTC facilities	1,015
1.1. Stand-alone	314
1.2. Facility integrated (Govt)	583
1.3. Facility integrated (PPP)	35
1.4. CBS	83

### B. HIV Testing among Vulnerable Population (Excluding Pregnant Women)

Indicator	2021-22			
	Male	Female	TG	Total
1. Tested for HIV	9,64,132	6,98,453	3,471	16,66,056
2. Found HIV Positive among tested	2,920	1,194	55	4,169
3. HIV sero-positivity (%) among tested	0.30	0.17	1.58	0.25
4. Spouse/sexual partner testing of HIV positive people identified	1,597	881	19	2,497

## 6. Initiation and retention on ART of HIV infected people

### A. Treatment Facilities

Indicator	2021-22
1. ART Centres	20
2. Centre of Excellence	
2.1. Centre of Excellence (Adult)	1
2.2. Centre of Excellence (Paediatric)	1
3. Link ART Centres	52
4. Care Support Centres	13

### B. Treatment Uptake

Indicator	2021-22			
	Male	Female	TG	Total
1. HIV positive cases diagnosed (At ICTC)	2,920	1,431	55	4,406
2. New PLHIV Registered at ART center	2,905	1,430	55	4,390
2.1 Initiated on ART	2,652	1,350	48	4,050
3. PLHIV alive and on ART	28,167	20,997	225	49,389
4. 12 months retention on ART (%)				79.90
5. Lost to follow-up cases	6,561	4,020	68	10,649

## 7. Viral Suppression and laboratories

### A. Laboratory facilities and service uptake

Indicator	2021-22
1. Viral load laboratories	2
1.1 Accredited Viral load laboratories	1
2. Viral load testing conducted	19,813
2.1. Virally suppressed (%)	87
3. National reference laboratories (NRL)	2
3.1 Accredited NRL	2
4. State reference laboratories (SRL)	5
4.1 Accredited SRL	4
5. CD4 testing conducted	33,300
6. External Quality Assessment of ICTC	
6.1 Average Participation (%)	63.93
6.2. Average Discordance (%)	0.26
7. Quality Assurance Scheme for Basic Composite Medical Laboratories (Entry Level)- M(EL)T	
7.1 No. of ICTCs certified for M(EL)T certification	-

## 8. Elimination of mother to child transmission of HIV & Syphilis

### A. HIV

Indicator	2021-22
1. Estimated pregnant women (PW)	16,24,570
2. HIV testing among PW	15,56,286
3. HIV sero-positivity (%) among tested	0.02
4. HIV Positive PW (old + new detections)	465
4.1 On life-long ART	440
5. Live births among HIV positive PW	362
5.1 Babies given ARV Prophylaxis (%)	98.34
6. Babies tested HIV (6 week- 6 month)	352
6.1 Babies confirmed HIV Positive (6 week- 6 month)	4
7. HIV exposed babies at 18 months	
7.1 HIV exposed babies tested at 18 month	241
7.2 Babies confirmed HIV positive at 18 months	12
8. HIV positive babies initiated on ART	25

### B. Syphilis

Indicator	2021-22
1. Estimated pregnant women (PW)	16,24,570
2. Syphilis testing among PW	10,33,524
3. Sero-positivity (%) among tested	0.06
4. Put on treatment	381

## 9. Elimination of HIV/AIDS related Stigma and Discrimination

### A. HIV/AIDS Prevention & Control Act (2017)

Indicator	2021-22
1. State rules notified for HIV/AIDS Prevention and Control Act (2017)	Yes
2. State designated/appointed ombudsman for HIV/AIDS Prevention and Control Act (2017)	Yes

## 10. HIV-TB Co-morbidities

## A. HRG and Bridge Population

Indicator								2021-22
	Quarter	FSW	MSW	IDU	TG	Migrants	Truckers	Total
Screened for TB	Quarter 1	8,166	549	399	723	2,517	4,353	16,707
	Quarter 2	11,658	946	340	1,227	3,474	5,015	22,660
	Quarter 3	11,995	1,261	80	1,308	3,077	4,375	22,096
	Quarter 4	12,177	1,157	113	1,355	3,397	5,203	23,402
Tested for TB	Quarter 1	4	2	-	-	-	-	6
	Quarter 2	94	7	36	-	-	-	137
	Quarter 3	42	14	-	-	1	-	57
	Quarter 4	82	23	-	1	-	593	699
Diagnosed with TB	Quarter 1	-	-	-	-	-	-	-
	Quarter 2	1	-	-	-	-	-	1
	Quarter 3	-	-	-	-	-	-	-
	Quarter 4	-	1	-	1	-	10	12
Initiated on TB treatment	Quarter 1	-	-	-	-	-	-	-
	Quarter 2	1	-	-	-	-	-	1
	Quarter 3	-	-	-	-	-	-	-
	Quarter 4	-	1	-	1	-	10	12

## B. HIV-TB Cross-Referral

Indicator	2021-22
1. In referral from TB program	5,31,540
1.1. HIV sero-positive (%)	0.08
1.2. ICTC clients referred to NTEP	29,307

## C. HIV-TB Coinfected at ART Centre

Indicator								2021-22
	PLHIV attending ART Centre	PLHIV underwent 4S screening	PLHIV with presumptive TB	PLHIV tested for TB	PLHIV diagnosed with TB	PLHIV initiated on IPT	Co-infected enrolled at ARTc	Co-infected initiated on ART
Apr-21	32,013	31,710	239	237	32	236		
May-21	22,806	22,444	154	151	27	188		
Jun-21	22,383	21,984	174	172	26	202		
Jul-21	27,654	27,220	302	295	35	355		
Aug-21	26,196	25,488	294	291	30	239		
Sep-21	24,940	24,520	304	295	26	423		
Oct-21	18,713	18,307	1,680	189	31	303		
Nov-21	20,547	20,453	297	290	31	501		
Dec-21	23,297	23,189	303	292	41	514		
Jan-22	20,149	20,050	246	240	24	389		
Feb-22	19,305	19,237	253	247	34	398		
Mar-22	22,517	22,411	356	350	50	371		
April 2021-March 2022							1,021	942

## 11. Scorecard

State/UT Name		West Bengal
Overall Rank		3
IEC & MS	Frequency of Social Media updates (G= ≥60, Y=40-59, R=<40)	
	Status of AEP integration in state School curriculum (G=Yes, R=No)	
	Status of SCA (G= At least one meeting held since 2017, R= other than G)	
	Status of State Rules (G= Notified, R= Not notified)	
	Status of Ombudsman (G= Appointed, R=Not appointed)	
	Rank	5
TI	Facilities onboarded (G=≥95%, Y= 90-94%, R=<90%)	
	Coverage against target in contract (G=≥95%, Y= 90-94%, R=<90%)	
	HRG & BP living with HIV on ART (G=≥95%, Y= 90-94%, R=<90%)	
	IDU on OST (G=≥95%, Y= 90-94%, R=<90%)	
	Rank	1
BSD	Percentage of PLHIV who know their status (G=≥95%, Y= 80-94%, R=<80%)	
	HIV testing against target-GC ((G=≥95%, Y= 80-94%, R=<80%)	
	HIV testing against target-PW (G=≥95%, Y= 80-94%, R=<80%)	
	Percentage of Pregnant women who initiated ART (G=≥95%, Y= 80-94%, R=<80%)	
	Percentage of TB suspected cases referred to NTEP (G=≥95%, Y= 80-94%, R=<80%)	
	Clients managed at DSRC against the target (G=≥95%, Y= 80-94%, R=<80%)	
	Percentage of pregnant women tested for Syphilis (G=≥95%, Y= 80-94%, R=<80%)	
	Rank	5
CST	ART Initiation (Current FY) (G=≥95%, Y= 80-94%, R=<80%)	
	LFU rate among new ART initiation (G=<2%, Y= 2-4%, R=≥5%)	
	PLHIV put on ART during the FY against target (G=≥95%, Y= 80-94%, R=<80%)	
	Status on establishment of CSC (G=≥95%, Y= 80-94%, R=<80%)	
	Rank	11
LS	VL Suppression Rate (Current FY) (G=≥95%, Y= 85-94%, R=<85%)	
	% of SRL accredited (G=100%, Y= 80-99%, R=<80%)	
	% Participation of ICTCs in Re-testing (G=≥95%, Y= 85-94%, R=<85%)	
	Rank	19
SI	% of NACP facilities active in SOCH (G=≥90%, Y= 75-89%, R=<75%)	
	Status of State Data Management Committee (G=one meeting held, Y= no meeting held, R= not constituted)	
	Status of finalized Priority Areas for Operational Research and Evaluation (G= 4, Y= 3, R= <3)	
	Rank	25
Finance	Expenditure with respect to funds released during FY 2021-22 (G=≥90%, Y= 85-89%, R=<85%)	
	Submission of Audit Report after approval of EC/GB for the preceding year (G= by 30th June, Y= 30th Sept, R= beyond 30th Sept 2021)	
	Submission of Utilization Certificate (in prescribed format GFR 12A) for the previous financial year (G= by 30th June, Y= 30th Sept, R= beyond 30th Sept 2021)	
	Rank	18
SCM	Report Submission (BSD-SCM Report) (G=≥90%, Y= 75-89%, R=<75%)	

Green=3 Marks

Yellow=2Marks

Red=1 Mark

No Colour=Not Applicable

A large, thick red ribbon is draped across the page, starting from the bottom left, looping upwards and to the right, and then looping back down towards the bottom right. The background is a gradient of yellow and orange, with faint, concentric circular lines radiating from the center.

# **INDICATOR GLOSSARY**



THE HIV Epidemic		
IPR	Numerator: Estimated number of newly infected people with HIV in a calendar year	HIV Estimations 2021, NACO /NIMS( Biennial measurement)
	Denominator: Estimated number of total people living with HIV (PLHIV)	
IMR	Numerator: Estimated number of newly infected people with HIV in a calendar year	HIV Estimations 2021, NACO/ NIMS( Biennial measurement)
	Denominator: Number of Deaths to PLHIV population in the Calender year	
Adult prevalence (%)	Numerator: Estimated number of adult people (15-49 years) living with HIV (PLHIV)	HIV Estimations 2021, NACO/ NIMS( Biennial measurement)
	Denominator: Total adult (15-49 years) population	
ART Coverage (%)	Numerator: Number of diagnosed PLHIV who are on ART	HIV Estimations 2021, NACO/ NIMS(Biennial measurement)
	Denominator: Estimated number of total people living with HIV (PLHIV)	
PLHIV size	Estimated number of total people living with HIV (PLHIV)	HIV Estimations 2021, NACO/NIMS(Biennial measurement)
CLHIV (<15)	Estimated number of children (<15 years) living with HIV (CLHIV)	HIV Estimations 2021, NACO /NIMS (Biennial measurement)
Annual New HIV infections	Estimated number of newly infected people with HIV in a calendar year	HIV Estimations 2021, NACO/ NIMS(Biennial measurement)
Annual AIDS-related deaths	Estimated number of people who have died of AIDS-related illness in a calendar year	HIV Estimations 2021, NACO/NIMS( Biennial measurement)
HIV/AIDS RELATED KNOWLEDGE		
Adults (15-49 yrs) with comprehensive knowledge about HIV/AIDS (%)	Numerator: Males/females (15-49 years) with comprehensive knowledge of HIV/AIDS	National Family Health Survey 5 (2019-21)
	Denominator: Number of male/female (15-49 years)	
Youth (15-24 yrs) with comprehensive knowledge about HIV/AIDS (%)	Numerator: Males/females (15-24 years) with comprehensive knowledge of HIV/AIDS	National Family Health Survey 5 (2019-21)
	Denominator: Number of male/female (15-24 years)	
Adults (15-49 yrs) willing to care for a relative with HIV/AIDS in own home (%)	Numerator: Male/female (15-49 years) willing to care for a relative with HIV/AIDS in own home	National Family Health Survey 5 (2019-21)
	Denominator: Number of male/ female (15-49 years) who have heard of HIV or AIDS	
Adults (15-49 yrs) willing to buy fresh vegetables from a shopkeeper or vendor who has HIV/AIDS (%)	Numerator: Male/female (15-49 years) willing to buy fresh vegetables from a shopkeeper or vendor who has HIV/AIDS	National Family Health Survey 5 (2019-21)
	Denominator: Number of male/ female (15-49 years) who have heard of HIV or AIDS	

Adults (15-49 yrs) who have had higher-risk sexual behaviour in the past 12 months (%)	Numerator: Male/female (15-49 years) who had sexual intercourse in the 12 months preceding the survey with a person who was neither their spouse nor lived with them	National Family Health Survey 5 (2019-21)
	Denominator: Number of male/female (15-49 years)	
Out of the above, condom used during last higher-risk intercourse (%)	Numerator: Male/female (15-49 years) who used a condom the last time they had sexual intercourse with a person who was neither their spouse nor lived with them	National Family Health Survey 5 (2019-21)
	Denominator: Number of male/female (15-49 years) who had sexual intercourse in the 12 months preceding the survey with a person who was neither their spouse nor lived with them	
Youth (15-24 yrs) who have had higher-risk sexual behaviour in the past 12 months (%)	Numerator: Male/female (15-24 years) who had sexual intercourse in the 12 months preceding the survey with a person who was neither their spouse nor lived with them	National Family Health Survey 5 (2019-21)
	Denominator: Number of male/female (15-24 years)	
Out of the above, condom used during last higher-risk intercourse (%)	Numerator: Male/female (15-24 years) who used a condom the last time they had sexual intercourse with a person who was neither their spouse nor lived with them	National Family Health Survey 5 (2019-21)
	Denominator: Number of male/female (15-24 years) who had sexual intercourse in the 12 months preceding the survey with a person who was neither their spouse nor lived with them	

### 95-95-95 PROGRESS

PLHIV who know their status (1st 95)	Numerator: Number of PLHIV who know their HIV status	Based on facility data.
	Denominator: Number of PLHIV	PLHIV size estimate through Spectrum modelling using surveillance, national survey and demographic data, and programme monitoring data. (Annual measurement)
PLHIV who know their status and are active on treatment (2nd 95)	Numerator: Number of diagnosed PLHIV who are on ART	Based on facility data (Annual measurement)
	Denominator: Number of PLHIV who know their HIV status	
PLHIV who have suppressed viral load (3rd 95)	Numerator: Number of people on ART who have suppressed viral load (VL)	Based on facility data (Annual measurement)
	Denominator: Number of diagnosed PLHIV who are on ART	

### TARGETED INTERVENTIONS: KEY POPULATIONS (FSW, MSM, IDU, H/TG, Migrants and Truckers)

Targeted Interventions (Tis)	Number of Targeted intervention functional on 31 March for the reference year	Based on facility data
OST centres	Number of OST centres functional on 31 March for the reference year	Based on facility data
Employer Led Model Interventions	Number of ELM intervention functional on 31 March for the reference year	Based on facility data
Estimated size of Population	Estimate of the size of the Key Population	Periodic size estimation/ Validation Under the Program

HIV Prevalence	Numerator: Number of key population who tested HIV positive in reference year	Based on facility data
	Denominator: Number of key population included in the survey in reference year	HIV Sentinel Surveillance 2020-21
Programme coverage (%)	Numerator: Number of key population reached by the programme in the reference year (Including dynamic Population),	Based on facility data
	Denominator: Estimated size of key population	Periodic size estimation/ Validation Under the Program
Condoms distributed	Number of free condoms distributed to key population in the reference year	Based on facility data
Tested for HIV	Number of key population (FSW/MSM/IDU/H/TG/inmate), Bridge population (Migrant/Trucker) and Vulnerable Population who tested for HIV in the reference year	Based on facility data
Linked to ART	Number of key population (FSW/MSM/IDU/H/TG), Bridge population (Migrant/Trucker) and Vulnerable Population who tested for HIV in the reference year	Based on facility data
Condom use (%)	Numerator: Number of key population (FSW/MSM) who reported using a condom consistently during every sex act with a client in the reference year	Bio Behavioural Surveillance Survey 2014-15
	Denominator: Number of key population (FSW/MSM) recruited under survey	
HIV sero-positive (%)	Numerator: Number of key population(FSW/MSM/IDU/H/TG/Migrants/Truckers) who detected HIV positive in the reference year	Based on facility data
	Denominator: Number of key population(FSW/MSM/IDU/H/TG/Migrants/Truckers) tested for HIV in the reference year	
Clinic Visits	Number of key population (FSW/MSM/IDU/H/TG) and Bridge population (Migrant/Trucker) visited clinic in the reference year	Based on facility data
STI/RTI treated	Number of key population (FSW/MSM/IDU/H/TG) Diagnosed & Treated for STI in the reference year	Based on facility data
Presumptive treatment	Number of key population (FSW/MSM/H/TG) provided Presumptive treatment in the reference year	Based on facility data
Total prisons	Number of prisons as on December 2020	Prison Statistics India 2020
Prisons covered under programme	Number of Prison covered by TI services in the reference year	Based on facility data
Inmates Coverage	Numerator: Number of inmates covered through any of the eligible service in the reference year	Based on facility data
	Denominator: Number of Inmates as on 31 Dec and released in the reference year	
Districts covered under scheme LWS	Number of Link Worker Schemes functional on 31 March for the reference year	Based on facility data

Vulnerable population covered	Vulnerable Population covered under the Link Worker Schemes in the reference year	Based on facility data
OSTC in Public Health Settings	Number of main OST centres in public health settings in the reference year	Based on facility data
OSTC in NGO Settings	Number of main OST centres in NGO settings in the reference year	Based on facility data
No. of Satellite OST Centres	Number of satellite OST centers (linked with either public health or NGO main OST centres) in the reference year	Based on facility data
IDU on OST	Number of active OST clients out of total active IDU population in the reference year	Based on facility data
<b>HIV counselling and testing services (HCTS)</b>		
ICTC facilities	Number of HCTS Facilities functional on 31 March for the reference year	Based on facility data
Stand-alone	Number of SA-ICTC Facilities functional on 31 March for the reference year	Based on facility data
Facility integrated (Govt)	Number of F-ICTC Govt. Facilities functional on 31 March for the reference year	Based on facility data
Facility integrated (PPP)	Number of PPP-ICTC Facilities functional on 31 March for the reference year	Based on facility data
CBS	Number of Community Based Screening site functional on 31 March for the reference year	Based on facility data
<b>HIV testing among vulnerable population (excluding pregnant women)</b>		
Tested for HIV (Total)	Number of At-Risk Clients excluding pregnant women) who have tested for HIV in the reference year	Based on facility data (SIMS April-Nov-21) Physical Data (Dec-21-March-22)
Found HIV Positive among At-Risk Clients (excluding pregnant women)	Number of confirmed positive at SA-ICTC (Confirmatory site) Out of total tested for HIV in the reference year	Based on facility data (SIMS April-Nov-21) Physical Data (Dec-21-March-22)
HIV sero-positivity (%) among At-Risk Clients (excluding pregnant women)	Numerator : Number of At-Risk clients (excluding pregnant women) confirmed HIV positive in the reference year.	Based on facility data (SIMS April-Nov-21) Physical Data (Dec-21-March-22)
	Denominator: Number of At-Risk Clients (Excl.pregnant women) who have tested for HIV in the reference year	
Spouse/sexual partner testing of HIV positive people identified	Number of Spouse or Sexual partner of HIV positive At-Risk ' Clients tested for HIV in the reference year	Based on facility data Physical Data (April- 21 - March 22)
<b>Elimination of the Vertical Transmission of HIV and Syphilis</b>		
Estimated Pregnant Women (PW)	Estimated number of pregnant women in the reference year	National Health Mission (NHM)

Estimated PPTCT need	Estimated number of HIV-positive women giving birth in calendar year and, therefore, in need of prophylaxis to prevent HIV transmission to the baby	HIV Estimations 2021, NACO/NIMS(Biennial measurement)
HIV testing among PW	Number of HIV test performed for pregnant women in the reference year	Based on facility data (SIMS April-Nov-21) Physical Data (Dec-21-March-22)
Pregnant Women tested for HIV	Number of pregnant women attending antenatal care (ANC) clinic who were tested for HIV in the reference year	Based on facility data (SIMS April-Nov-21) Physical Data (Dec-21-March-22)
HIV Positive among Pregnant Women (%)	Numerator: Number of pregnant women attending antenatal care (ANC) clinic who were confirmed positive for HIV in the reference year	Based on facility data (Monthly measurement) (SIMS April-Nov-21) Physical Data (Dec-21-March-22)
	Denominator: Total Number of HIV test performed among pregnant women	
Coverage for HIV testing of Pregnant Women (%)	Numerator: Number of pregnant women attending ANC clinic who were tested for HIV during pregnancy or already knew their HIV positive status in the reference year	Based on facility data; to be triangulated periodically with National Family Health Survey (NHFS) and surveillance data
	Denominator: Estimated number of Pregnant women in the reference year	National Health Mission (NHM)
HIV positive PW initiated on ART for EVTHS (%) (Facility level)	Numerator: Number of Positive PW Initiated On ART treatment during the FY (Known+New)	Based on facility data (Monthly measurement) (SIMS April-Nov-21) Physical Data (Dec-21-March-22)
	Denominator: Number of Positive PW newly confirmed and registered at ICTC+ART (Known+New)	
HIV positive PW initiated on ART for EVTHS(%) (Population level)	Numerator: Number of Positive PW Initiated On ART treatment during the FY (Known+New)	Based on facility data (Monthly measurement) (SIMS April-Nov-21) Physical Data (Dec-21-March-22)
	Denominator: Estimated positive pregnant women	HIV Estimations 2021, NACO/NIMS (Biennial measurement)
Babies given ARV Drug (%)	Numerator: Number of HIV Exposed babies initiated on ARV prophylaxis in the reference year	Based on facility data (SIMS April-Nov-21) Physical Data (Dec-21-March-22)
	Denominator: Number of Live Birth to HIV positive pregnant women in the reference year	
Babies tested for HIV (6 week- 6 month)	Number of HIV exposed babies who have tested for DNA PCR test in between the age of 6 weeks to 6 months in the reference year	Based on facility data Physical Data (April- 21 - March 22)
Babies confirmed HIV positive (6week - 6month)	Numerator: Number of HIV exposed babies who have found HIV positive in DNA PCR test in the reference year	Based on facility data Physical Data ( April- 21 - March 22)
	Denominator: Number of HIV exposed babies who have tested for DNA PCR test in between the age of 6 weeks to 6 months in the reference year	
HIV positive babies initiated on ART (6 week- 6 month))	Numerator: Number of babies initiated on ART who have found HIV positive in DNA PCR test in the reference year	Based on facility data
	Denominator: Number of babies who have found HIV positive in DNA PCR test in the reference year	Physical Data ( April- 21 - March 22)

HIV exposed babies tested at 18 month	Number of HIV exposed babies who have tested for Antibody test at 18 month for HIV confirmation in the reference year	Based on facility data Physical Data (April- 21 - March 22)
HIV positive babies at 18 month	Numerator: Number of HIV exposed babies who have confirmed HIV positive in Antibody test at 18 month in the reference year	Based on facility data Physical Data ( April- 21 - March 22)
	Denominator: Number of HIV exposed babies who have tested for Antibody test at 18 month for HIV confirmation in the reference year	
HIV positive babies initiated on ART	Numerator: Number of babies initiated on ART who have Confirmed HIV positive in 18 Months test in the reference year	Based on facility data Physical Data ( April- 21 - March 22)
	Denominator: Number of babies confirmed HIV Positive babies at 18 Months	
Syphilis testing among PW	Numerator: Number of pregnant women tested for syphilis in the reference year	Based on facility data (SIMS April-Nov-21) Physical Data (Dec-21-March-22)
	Denominator: Estimated number of pregnant women in the reference year	
Syphilis Sero-positivity (%) among tested	Numerator: Number of pregnant women attending antenatal care (ANC) clinic who were confirmed positive for Syphilis in the reference year	Based on facility data (SIMS April-Nov-21) Physical Data (Dec-21-March-22)
	Denominator: Total Number of pregnant women attending antenatal care (ANC) clinic who were tested for Syphilis in the reference year	
Put on treatment	Numerator: Number of Syphilis Reactive PW women receiving Syphilis treatment in the reference year	Based on facility data (SIMS April-Nov-21) Physical Data (Dec-21-March-22)
	Denominator: Number of PW found Syphilis Reactive	
STI/RTI Services at DSRCs		
STI/RTI Facilities	Number of NACO Supported designated Sexually Transmitted Infections (STI)/Reproductive Tract Infections (RTI) clinics (DSRC) functional on 31 March for the reference year	Based on facilities approved under AAP [2021-2022]
Patients managed for STI/RTI	Number of patients managed for Sexually Transmitted Infections (STI)/Reproductive Tract Infections (RTI) at DSRC in the reference year	Based on Physical Data [April 2021 - March 2022]
RPR tests conducted	Number of RPR Tests conducted for syphilis screening among clients including pregnant women at DSRCs in the reference year	Based on Physical Data [April 2021 - March 2022]
Syphilis sero-positivity (%)	Numerator: Number of clients (including pregnant women) who have tested Syphilis seropositive at DSRCs in the reference year	Based on Physical Data [April 2021 - March 2022]
	Denominator: Number of RPR Test conducted for syphilis among clients including pregnant women at DSRCs in the reference year	

## CARE, SUPPORT AND TREATMENT

HIV positive cases diagnosed (At ICTC)	Number of patients who have been detected HIV positive in a reference year	Based on facility data
ART Centres	Number of ART centers functional on 31st March for the reference year	Based on facility data
Link ART Centres	Number of Link ART Centers functional on 31st March for the reference year	Based on facility data
Care Support Centres	Number of functional on 31st March for the reference year	Based on facility data
Centre of Excellence (Adult)	Number of Centre of Excellence (Adult) functional on 31st March for the reference year	Based on facility data
Centre of Excellence (Paediatric)	Number of Centre of Excellence (Paediatric) functional on 31st March for the reference year	Based on facility data
New PLHIV Registered at ART center	Number of PLHIV who have been registered at ART centers in a reference year	Based on facility data
Initiated on ART	Number of PLHIV who have been initiated on ART in the reference year	Based on facility data
PLHIV alive and on ART	Cumulative number of PLHIV who are Alive and on ART as on 31st March of reference year	Based on facility data
Lost to follow-up cases	Proportion of PLHIV on ART with no clinical contact or ARV pick-up for 90 days or more since last due date (missed appointment) + PLHIV not initiated on ART and with no clinical contact or visit to health facility for more than or equal to 28 days from the date of registration at ART center in reference year	Based on facility data
12 months retention on ART (%)	Numerator: Number of PLHIV retained on ART after completion of 12 month from the date of ART initiation in the reference year	Based on facility data
	Denominator: Number of patients who were initiated on ART during the study cohort	

## LABORATORIES SERVICES

National Reference Laboratories	Number of National Reference laboratories under NACP functional on 31 March for the reference year	Based on facility data
State Reference Laboratories	Number of State Reference laboratories under NACP functional on 31 March for the reference year	Based on facility data
Viral Load testing Lab	Number of Viral load testing laboratories under NACP functional on 31 March for the reference year	Based on facility data
Viral Load (% Suppression)	Numerator: Number of Valid viral load tests conducted in the reference year	Monthly report from Viral load testing laboratories
	Denominator: Number of Viral Load tests conducted in the reference year	



Panel Testing (% Participation)	Numerator: Numerator of HIV reference laboratories/ICTC participated in panel testing	Bi-annual reporting by ICMR-NARI
	Denominator: Number of HIV reference laboratories/ICTC in the reference year	
Panel Testing (% Performance )	Numerator: Number of HIV reference laboratories/ICTC with discordant result in panel testing	Bi-annual reporting by ICMR-NARI
	Denominator: Number of HIV reference laboratories/ICTC participated in panel testing in the reference year	
Re-testing (% Participation)	Numerator: Number of ICTCs participated in Retesting in the reference year	Quarterly reporting by SACS
	Denominator: Number of ICTCs in the state in the reference year	
Re-testing (% Performance)	Numerator: Number of ICTCs with discordant result in Retesting in the reference year	Quarterly reporting by SACS
	Denominator: Number of ICTCs participated in Retesting in the reference year	
Viral Load External Quality Assurance	Auto calculated through NACO PRAYOG SHALA" tool	
No. of ICTCs certified for M(EL)T certification under Quality Assurance Scheme for Basic Composite Medical Laboratories (Entry Level)- M(EL)T	Numerator: Number of ICTCs who have achieved M(EL)T certificate	Quarterly reporting by SACS
	Denominator: Target given to States in Annual Action Plan	
HIV-TB Co-morbidities		
HRG and Bridge Population: Screened for TB	Number of HRGs (core and bridge population) screened for 4S in the reference year	Based on facility data
	Denominator: Number of HRGs and Bridge population availed clinical services	Based on facility data
HRG and Bridge Population: Tested for TB	Number of HRGs (core and bridge population) tested for TB in the reference year	Based on facility data
	Denominator: Number of HRGs and Bridge population referred for TB test	Based on facility data
HRG and Bridge Population: Diagnosed with TB	Number of HRGs (core and bridge population) tested and diagnosed with TB in the reference year	Based on facility data
	Denominator: Number of HRGs and Bridge population tested for TB test	Based on facility data
HRG and Bridge Population: Initiated on TB treatment	Number of HRGs (core and bridge population) diagnosed with TB and linked with DOTS in the reference year	Based on facility data
	Denominator: Number of HRGs and Bridge population diagnosed with TB	Based on facility data

HIV-TB cross-referral	Number of HIV Positive Cases and TB symptomatic cases referred from SAICTC to NTEP for TB screening	The number of HIV Positive Cases and TB symptomatic cases reported at SAICTC in HIV Programme and referred to NTEP for know their TB status mentioned in the SAICTC monthly report. Data Source: Physical Data collection report from April-2021 to March-2022
In referral from TB program	Number of Confirmed TB cases and HIV symptomatic cases referred from NTEP to SAICTC	Data Source: Physical Data collection report from April-2021 to March 2022
ICTC client clients referred to NTEP	Number of HIV Positive and HIV Negative cases referred to NTEP	Data Source: Physical Data collection report from April-2021 to March 2022
HIV sero-positive (%) (NTEP-ICTC)	Numerator: Number of referred TB cases tested HIV positive in the reference year	Data Source: Physical Data collection report from April-2021 to March 2022
	Denominator: Number of TB cases referred from NTEP and tested for HIV at confirmatory facility in reference year	Data Source: Physical Data collection report from April-2021 to March 2023
PLHIV attending ART Centre	Number of PLHIV attended ART Centre (Pre ART and ART) during the reference year	Based on facility data
PLHIV underwent 4S screening	Number of PLHIV who underwent (4S) screening during the reference year	Based on facility data
PLHIV with presumptive TB	Number of PLHIV with presumptive TB (those with one or more symptom(s) present) during the reference year	Based on facility data
PLHIV tested for TB	Number of PLHIV with presumptive TB, tested for TB during the reference year	Based on facility data
PLHIV diagnosed with TB	Number of PLHIV diagnosed with TB during the reference year	Based on facility data
PLHIV initiated on IPT	Number of PLHIV newly initiated on IPT during the reference year	Based on facility data
Co-infected enrolled at ARTc/psum	Number of Co-infected patients enrolled in HIV/TB register during the reference year	Based on facility data
Co-infected initiated on ART	Number of Co-infected patients initiated on ART during the reference year	Based on facility data
Number of PLHIV in Private has been distributed in suitable age/gender category following the same pattern as observed in NACO supported ARTc. The Number reflecting in the Section 2 of Factsheet (progress on 95-95-95), it is to be noted that the indicators (female) are sum of TG & Females both.		

A thick red ribbon is tied in a loop, with the tail extending diagonally across the bottom right of the page. The background is a solid yellow color with a subtle pattern of concentric circles in a lighter shade of yellow.


# REFERENCES

# References

- <sup>1</sup>Reddy DC. Evidence generation to strategize India's response to HIV: Journey so far and challenges ahead. *Indian Journal of Public Health*. 2020 Apr 1;64(5):1.
- <sup>2</sup>National AIDS Control Organization (2022). Strategy Document: National AIDS and STD Control Programme Phase-V (2021-26). New Delhi: NACO, Ministry of Health and Family Welfare, Government of India.
- <sup>3</sup>National AIDS Control Organization & ICMR-National Institute of Medical Statistics (2022). India HIV Estimates 2021: Fact Sheet. New Delhi: NACO, Ministry of Health and Family Welfare, Government of India
- <sup>4</sup>Kumar P, Das C, Kumar A, Sahu D, Rai SK, Godbole S, Arumugam E, PVM L, Dutta S, Devi HS, Vardhana Rao Mendu V. Diversity in HIV epidemic transitions in India: An application of HIV epidemiological metrics and benchmarks. *PloS one*. 2022 Jul 18;17(7): e0270886.
- <sup>5</sup>World Health Organization. Global health sector strategy on sexually transmitted infections 2016–2021. Towards ending STIs. Report No. WHO/RHR/16.09, (Geneva, 2016)
- <sup>6</sup>Stover J, Bollinger L, Izazola JA, Loures L, DeLay P, Ghys PD, Fast Track modeling working Group. What is required to end the AIDS epidemic as a public health threat by 2030? The cost and impact of the fast-track approach. *PloS one*. 2016 May 9;11(5):e0154893.
- <sup>7</sup>National AIDS Control Organization (2020). Sankalak: Status of National AIDS Response (Second edition, 2020). New Delhi: NACO, Ministry of Health and Family Welfare, Government of India.
- <sup>8</sup>IN DANGER: UNAIDS Global AIDS Update 2022. Geneva: Joint United Nations Programme on HIV/AIDS; 2022. Licence: CC BY-NC-SA 3.0 IGO
- <sup>9</sup>Diclemente RJ, Wingood GM, Sionean C, Crosby R, Harrington K, Davies S, HOOK III EW, Oh MK. Association of adolescents' history of sexually transmitted disease (STD) and their current high-risk behavior and STD status: a case for intensifying clinic-based prevention efforts. *Sexually transmitted diseases*. 2002 Sep 1:503-9.
- <sup>10</sup>World Health Organization. Global health sector strategy on sexually transmitted infections 2016–2021. Towards ending STIs. Report No. WHO/RHR/16.09, (Geneva, 2016)
- <sup>11</sup>Global AIDS Monitoring 2022. Geneva: Joint United Nations Programme on HIV/AIDS; [2022]. Licence: CC BY-NC-SA 3.0 IGO
- <sup>12</sup>Central TB Division, M. o. (March 2022). India TB Report 2022. New Delhi: Central TB Division, Ministry of Health, and Family Welfare.
- <sup>13</sup>World Health Organization. Global monitoring framework and strategy for the Global Plan towards the elimination of new HIV infections among children by 2015 and keeping their mothers alive. Available from: [http://www.who.int/hiv/pub/me/monitoring\\_framework/en/](http://www.who.int/hiv/pub/me/monitoring_framework/en/).
- <sup>14</sup>UNAIDS. [cited 2022 March 20]. Available from: [https://www.unaids.org/en/topics/2025\\_target\\_setting](https://www.unaids.org/en/topics/2025_target_setting)
- <sup>15</sup>De Cock KM, Fowler MG, Mercier E, de Vincenzi I, Saba J, Hoff E et al. Prevention of mother-to-child HIV transmission in resource-poor countries: translating research into policy and practice. *JAMA*. 2000;283:1175-82. doi: 10.1001/jama.283.9.1175
- <sup>16</sup>Gomez GB, Kamb ML, Newman LM, Mark J, Broutet N, Hawkes SJ. Untreated maternal syphilis and adverse outcomes of pregnancy: a systematic review and meta-analysis. *Bull World Health Organ*. 2013;91:217-26. doi: 10.2471/blt.12.107623.
- <sup>17</sup>United Nations. Sustainable Development Goals. Goal 3: Ensure healthy lives and promote well-being for all at all ages. Available from: <http://www.un.org/sustainabledevelopment/health/>.
- <sup>18</sup>Global guidance on criteria and processes for validation: elimination of mother-to-child transmission of HIV, syphilis and hepatitis B virus. Geneva: World Health Organization; 2021. Licence: CC BY-NC-SA 3.0 IGO.
- <sup>19</sup>Mofenson, L, Updating PMTCT Transmission Probabilities for Use in the Spectrum Model, Report to UNAIDS, October 24, 2018.







“Sankalak - Status of National AIDS Response” is the evidence driven flagship report of NACP, detailing the National AIDS response toward the 2030 goal to end the epidemic of HIV/ AIDS. 'Sankalak' reports the robust programmatic and epidemic data Nationally and by State/Union Territories (UT) under NACP. In this fourth edition of Sankalak, the progress across HIV care continuum for the financial year 2021-22 is summarized”.



**National AIDS Control Organisation**

India's response to HIV & Sexually Transmitted Infections

Ministry of Health & Family Welfare, Government of India  
[www.naco.gov.in](http://www.naco.gov.in)